Clustering O 0 0.00013247292372398078
of O 0 1.709024036244955e-05
missense O 0 9.985448559746146e-05
mutations O 0 1.0658304745447822e-05
in O 0 2.8653534172917716e-05
the O 0 0.00037244753912091255
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 5.2570041589206085e-05
in O 0 1.0918382940872107e-05
a O 0 1.0055262464447878e-05
sporadic B-Disease 1 0.9231569170951843
T I-Disease 1 0.999997615814209
- I-Disease 1 0.9191234111785889
cell I-Disease 1 0.5367549061775208
leukaemia I-Disease 1 0.9867521524429321
. O 0 2.113644086421118e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.611248295484984e-07
is O 0 1.0567606523181894e-07
a O 0 4.6098185180198925e-07
recessive B-Disease 0 0.00022504397202283144
multi I-Disease 1 0.9968031644821167
- I-Disease 1 0.9986048340797424
system I-Disease 0 0.00011121721036033705
disorder I-Disease 0 0.00035579592804424465
caused O 0 6.925542948010843e-07
by O 0 1.380245784332601e-08
mutations O 0 1.3864700498800175e-08
in O 0 2.0457882499158586e-07
the O 0 8.378292477573268e-07
ATM O 0 2.4128990844474174e-05
gene O 0 3.3386538689228473e-06
at O 0 5.30742690898478e-05
11q22 O 0 4.002263813163154e-05
- O 0 1.572035762364976e-05
q23 O 0 2.8819717044825666e-05
( O 0 2.2850060759083135e-06
ref O 0 2.151328226318583e-05
. O 0 1.455646696513213e-07
3 O 0 3.84209079129505e-06
) O 0 5.137741823091346e-07
. O 0 5.784378913631372e-07

The O 0 1.5266954505932517e-05
risk O 0 1.9297265680506825e-05
of O 0 3.43147294188384e-05
cancer B-Disease 1 0.936205267906189
, O 0 2.5260549136874033e-06
especially O 0 3.013276455021696e-06
lymphoid B-Disease 0 0.0003485969500616193
neoplasias I-Disease 0 0.00035087051219306886
, O 0 7.866414648560749e-07
is O 0 2.192858232774597e-07
substantially O 0 2.216055918324855e-06
elevated O 0 0.0008924318244680762
in O 0 0.00027709442656487226
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.226283171097748e-06
and O 0 1.6980526140741858e-07
has O 0 7.865111939509006e-08
long O 0 4.2373212494339896e-08
been O 0 7.864196760465347e-08
associated O 0 9.131226619274457e-08
with O 0 3.185855632636958e-07
chromosomal O 1 1.0
instability O 1 0.9999992847442627
. O 0 1.8399447071715258e-05

By O 0 2.6857417196879396e-06
analysing O 0 7.814305718056858e-05
tumour B-Disease 1 1.0
DNA O 0 2.4233231670223176e-06
from O 0 2.825102569659066e-07
patients O 0 6.458678569742915e-08
with O 0 3.564264261513017e-08
sporadic B-Disease 0 0.00041072300518862903
T I-Disease 1 0.9796528816223145
- I-Disease 0 0.0013954518362879753
cell I-Disease 0 0.005427450407296419
prolymphocytic I-Disease 0 0.0022264134604483843
leukaemia I-Disease 1 0.9996870756149292
( O 0 5.256638178252615e-05
T B-Disease 0 0.0006536273285746574
- I-Disease 0 3.954740532208234e-05
PLL I-Disease 0 0.00015400024130940437
) O 0 1.4013937743584393e-07
, O 0 1.8146794289464196e-08
a O 0 8.283432606503993e-08
rare O 0 1.8416138800603221e-06
clonal B-Disease 0 8.105979941319674e-05
malignancy I-Disease 0 5.560583667829633e-05
with O 0 4.845934142849728e-08
similarities O 0 7.068874765536748e-07
to O 0 4.19023621134329e-07
a O 0 9.990551916416734e-06
mature B-Disease 0 7.614937203470618e-05
T I-Disease 0 0.0004088321584276855
- I-Disease 0 6.353660864988342e-05
cell I-Disease 0 0.00015455573156941682
leukaemia I-Disease 0 0.000587905349675566
seen O 0 1.783777042874135e-05
in O 0 2.487108031345997e-05
A B-Disease 1 0.9999914169311523
- I-Disease 1 0.9587642550468445
T I-Disease 1 0.9998124241828918
, O 0 7.963866011095888e-08
we O 0 4.401998765501958e-09
demonstrate O 0 4.618222604335642e-08
a O 0 5.759103061109272e-08
high O 0 5.070616566626995e-07
frequency O 0 2.917375923061627e-07
of O 0 1.9709600564965513e-06
ATM O 0 8.756743773119524e-05
mutations O 0 5.354915174393682e-06
in O 0 5.331807187758386e-05
T B-Disease 0 0.0013138051144778728
- I-Disease 0 0.00011860811355290934
PLL I-Disease 0 0.0005684548523277044
. O 0 2.8273602765693795e-06

In O 0 1.807898843253497e-05
marked O 0 1.6660824257996865e-05
contrast O 0 9.293781317865069e-07
to O 0 1.0916959780615798e-07
the O 0 9.697525911178673e-07
ATM O 0 2.919423241110053e-05
mutation O 0 1.0551046898399363e-06
pattern O 0 2.7961377782048658e-05
in O 0 0.00010886078234761953
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 4.2490245277804206e-07
the O 0 5.330141306103542e-08
most O 0 1.2640699154076174e-08
frequent O 0 5.563886418258335e-08
nucleotide O 0 2.260663904962712e-07
changes O 0 2.2048945780284157e-08
in O 0 7.710662686122305e-08
this O 0 7.82721869541092e-08
leukaemia B-Disease 0 5.8838017139350995e-05
were O 0 7.542057005593961e-07
missense O 0 8.874552804627456e-06
mutations O 0 1.528389475424774e-06
. O 0 9.657784403316327e-07

These O 0 6.79014783599996e-06
clustered O 0 2.2522106519318186e-05
in O 0 4.678837740357267e-06
the O 0 3.4831941775337327e-06
region O 0 4.117426215088926e-06
corresponding O 0 1.2603219147422351e-05
to O 0 3.7866677757847356e-06
the O 0 2.5086137611651793e-05
kinase O 0 2.322332511539571e-05
domain O 0 1.0996086530212779e-05
, O 0 3.3441685332036286e-07
which O 0 8.581970689647278e-08
is O 0 1.0248826498582275e-07
highly O 0 1.754184779656498e-07
conserved O 0 4.778026436724758e-07
in O 0 1.9203043848392554e-06
ATM O 0 2.7746091291191988e-05
- O 0 1.6989254163490841e-06
related O 0 2.655951050201111e-07
proteins O 0 6.425821652555896e-08
in O 0 4.6710704282304505e-07
mouse O 0 6.383170898516255e-07
, O 0 6.000501429070937e-08
yeast O 0 5.837523531226907e-07
and O 0 5.662218427460175e-07
Drosophila O 0 3.128677053609863e-05
. O 0 1.113853727474634e-06

The O 0 0.00029141452978365123
resulting O 0 0.00026731888647191226
amino O 0 5.716681698686443e-05
- O 0 3.749765892280266e-05
acid O 0 3.7444087865878828e-06
substitutions O 0 2.3370391772914445e-06
are O 0 3.6950825688109035e-07
predicted O 0 3.0647968287667027e-06
to O 0 1.8522440825563535e-07
interfere O 0 2.9218520012364024e-06
with O 0 1.4644343764302903e-06
ATP O 0 0.0039016366936266422
binding O 0 4.254954546922818e-06
or O 0 1.7190911876241444e-06
substrate O 0 4.746072590933181e-06
recognition O 0 3.2324460335075855e-06
. O 0 2.169400431739632e-06

Two O 0 1.1954672118008602e-05
of O 0 5.0387996452627704e-05
seventeen O 0 0.0004284036112949252
mutated O 0 0.0001929935096995905
T B-Disease 0 0.0004725579346995801
- I-Disease 0 2.0952360500814393e-05
PLL I-Disease 0 5.501928535522893e-05
samples O 0 2.3911917423902196e-07
had O 0 2.3636917489966436e-07
a O 0 4.356720353371202e-07
previously O 0 2.162208375011687e-06
reported O 0 3.3370401069987565e-05
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999855756759644
T I-Disease 1 0.9999995231628418
allele O 0 2.3434455215465277e-05
. O 0 2.0505653992586304e-06

In O 0 0.00010048654803540558
contrast O 0 2.052731542789843e-05
, O 0 1.5194921161310049e-06
no O 0 3.1848560411162907e-07
mutations O 0 1.9785863969445927e-07
were O 0 9.200454655911017e-07
detected O 0 1.5480671891054953e-06
in O 0 8.120170491565659e-07
the O 0 9.972465022656252e-07
p53 O 0 2.4714554456295446e-06
gene O 0 9.826952691582846e-07
, O 0 1.1701158086907526e-07
suggesting O 0 2.6642032935342286e-07
that O 0 4.003498688120999e-08
this O 0 1.4743640122105717e-06
tumour B-Disease 1 1.0
suppressor O 0 0.0014141363790258765
is O 0 3.663345751192537e-07
not O 0 2.96404039090703e-08
frequently O 0 1.1398336852153079e-07
altered O 0 3.496329554764088e-07
in O 0 3.1603124739376653e-07
this O 0 3.1344717399406363e-07
leukaemia B-Disease 0 0.001901359879411757
. O 0 3.025453679583734e-06

Occasional O 0 0.00038725751801393926
missense O 0 0.0003512098628561944
mutations O 0 1.1325914783810731e-05
in O 0 2.0214141841279343e-05
ATM O 0 6.214406312210485e-05
were O 0 9.567487495587557e-07
also O 0 8.658044237108697e-08
found O 0 7.777291699540001e-08
in O 0 6.702589416818228e-07
tumour B-Disease 1 1.0
DNA O 0 7.852945032027492e-07
from O 0 4.795217591890832e-07
patients O 0 2.9234948328848986e-07
with O 0 2.835913619492203e-07
B B-Disease 0 0.0006405742024071515
- I-Disease 0 0.000862878980115056
cell I-Disease 1 0.991188645362854
non I-Disease 1 0.9561460614204407
- I-Disease 0 0.17703324556350708
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 0.040677908807992935
( O 0 5.939190486969892e-06
B B-Disease 0 1.8737409845925868e-05
- I-Disease 0 1.3241638043837156e-06
NHL I-Disease 0 3.3519763746880926e-06
) O 0 5.508575995349929e-08
and O 0 1.1012639333785046e-07
a O 0 2.1858979835087666e-06
B B-Disease 0 4.823930430575274e-05
- I-Disease 0 1.0611649486236274e-05
NHL I-Disease 0 2.386772212048527e-05
cell O 0 1.886012432805728e-05
line O 0 1.268588221137179e-05
. O 0 6.518783379760862e-07

The O 0 9.499747648078483e-06
evidence O 0 1.1118883094241028e-06
of O 0 1.9909057300537825e-06
a O 0 9.178212394544971e-07
significant O 0 7.905551910880604e-07
proportion O 0 7.663335964025464e-06
of O 0 0.00012104144116165116
loss O 0 0.007942917756736279
- O 0 3.988132448284887e-05
of O 0 4.348115180619061e-05
- O 0 1.4168199413688853e-05
function O 0 1.7967037138078013e-06
mutations O 0 4.5295891482055595e-08
and O 0 4.457612590158533e-08
a O 0 1.3901167505991907e-07
complete O 0 6.674376891169231e-07
absence O 0 3.2848715818545315e-06
of O 0 1.2297836065044976e-06
the O 0 4.884062718701898e-07
normal O 0 7.57993461775186e-07
copy O 0 2.770462685930397e-07
of O 0 5.913244649491389e-07
ATM O 0 3.1640804536436917e-06
in O 0 7.030030957366762e-08
the O 0 9.031715109131255e-08
majority O 0 5.738642272490324e-08
of O 0 2.8716194719891064e-06
mutated O 0 0.0001358665176667273
tumours B-Disease 1 1.0
establishes O 0 1.5530798918916844e-05
somatic O 0 5.8291179811931215e-06
inactivation O 0 1.742305357765872e-05
of O 0 1.0258111160510452e-06
this O 0 4.149534404973565e-08
gene O 0 9.151766278137075e-08
in O 0 2.8306445187809004e-07
the O 0 1.0987646419380326e-06
pathogenesis O 0 5.897631490370259e-05
of O 0 4.642770727514289e-05
sporadic B-Disease 0 0.005213706288486719
T I-Disease 1 0.6373587846755981
- I-Disease 0 0.0004083374806214124
PLL I-Disease 0 0.0001804621279006824
and O 0 1.550768189417795e-07
suggests O 0 3.9930508677343823e-08
that O 0 9.202243411721156e-09
ATM O 0 3.31650949192408e-06
acts O 0 1.0403459782537539e-06
as O 0 1.932440454766038e-06
a O 0 1.8657527107279748e-05
tumour B-Disease 1 1.0
suppressor O 0 0.006671056617051363
. O 0 1.883255777102022e-06

As O 0 2.5570658181095496e-05
constitutional O 0 3.150323391309939e-05
DNA O 0 1.036817934618739e-06
was O 0 1.576999125063594e-06
not O 0 4.104947848304619e-08
available O 0 9.256201138896358e-08
, O 0 1.3412360999609518e-07
a O 0 3.3290200462943176e-06
putative O 0 0.00031644749105907977
hereditary O 1 0.9999982118606567
predisposition O 1 0.9998397827148438
to O 0 0.0008449829183518887
T B-Disease 1 0.9079661965370178
- I-Disease 0 0.00019408875959925354
PLL I-Disease 0 0.00017625321925152093
will O 0 6.682230235810493e-08
require O 0 1.9409567286743368e-08
further O 0 4.1114670779052176e-08
investigation O 0 4.2497416075093497e-07
. O 0 1.4816737348155584e-07
. O 0 5.009927122046065e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0010649255709722638
kinase O 0 3.421102155698463e-05
is O 0 1.1177532144301949e-07
involved O 0 1.3723835401435736e-08
in O 0 1.498988666526202e-08
the O 0 1.3915646412954175e-08
modulation O 0 8.918324567730451e-08
of O 0 9.156830316214837e-08
the O 0 2.629563482514641e-07
Ca2 O 0 5.816989414597629e-06
+ O 0 6.318483792711049e-05
homeostasis O 0 8.799367060419172e-05
in O 0 3.723827103385702e-05
skeletal O 1 0.923285186290741
muscle O 0 0.0006867899792268872
cells O 0 7.2399532655254e-05
. O 0 1.8337765368414694e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.367755264043808
DM B-Disease 1 1.0
) O 0 2.4384691641898826e-05
, O 0 3.8251639011832594e-07
the O 0 5.601003749688971e-07
most O 0 1.0815647328854539e-06
prevalent O 0 0.0012106811627745628
muscular B-Disease 1 0.999996542930603
disorder I-Disease 1 0.9996757507324219
in O 0 3.6306530546426075e-06
adults O 0 7.265316526172683e-07
, O 0 1.1196544136282682e-07
is O 0 1.1825083134908709e-07
caused O 0 1.7107927305914927e-06
by O 0 3.256237732784939e-07
( O 0 1.2328342791079194e-06
CTG O 0 3.8837701140437275e-05
) O 0 4.911597102363885e-07
n O 0 3.615729383454891e-06
- O 0 3.121188854038337e-07
repeat O 0 1.6873256925009628e-07
expansion O 0 1.9977667875537009e-07
in O 0 6.91953587761418e-08
a O 0 1.595677900922965e-07
gene O 0 8.787480965111172e-08
encoding O 0 3.0179387522366596e-07
a O 0 2.447766746627167e-06
protein O 0 6.045907866791822e-06
kinase O 0 2.367259185120929e-05
( O 0 1.0160855708818417e-05
DM B-Disease 1 0.9990828037261963
protein O 0 3.893567554769106e-05
kinase O 0 1.5788116797921248e-05
; O 0 4.2404181499478e-07
DMPK O 0 1.1600250218180008e-05
) O 0 2.3690011730082006e-08
and O 0 4.8504440464114396e-09
involves O 0 1.1839421887316348e-08
changes O 0 3.269056136900872e-08
in O 0 8.826247608340054e-07
cytoarchitecture O 0 1.5890969734755345e-05
and O 0 1.934203055498074e-06
ion O 0 0.00013020863116253167
homeostasis O 0 0.0004633928765542805
. O 0 5.166217306395993e-06

To O 0 3.036845782844466e-06
obtain O 0 2.3805889668437885e-06
clues O 0 2.421038516331464e-06
to O 0 5.9036093347231144e-08
the O 0 4.0706930803935393e-07
normal O 0 4.584251655614935e-06
biological O 0 3.627351134127821e-06
role O 0 4.812126917386195e-06
of O 0 3.6617813748307526e-05
DMPK O 0 0.0006907843053340912
in O 0 7.151865429477766e-05
cellular O 0 0.0003888889623340219
ion O 0 0.0003903094620909542
homeostasis O 0 0.0007318199495784938
, O 0 1.6327923049175297e-06
we O 0 9.934829847679794e-08
have O 0 4.6257689234607824e-08
compared O 0 4.7642578238082933e-07
the O 0 1.857072646771485e-07
resting O 0 1.9763469936151523e-06
[ O 0 2.8992255352022767e-07
Ca2 O 0 9.43549309795344e-07
+ O 0 6.908326213306282e-06
] O 0 2.7137227789353346e-06
i O 0 6.943417929505813e-07
, O 0 5.902955990677583e-08
the O 0 9.319514049366262e-08
amplitude O 0 1.0691313718780293e-06
and O 0 3.890328628131101e-07
shape O 0 2.490941596988705e-06
of O 0 7.230966730276123e-06
depolarization O 0 2.909317845478654e-05
- O 0 1.0096745427290443e-05
induced O 0 1.3025239240960218e-05
Ca2 O 0 6.521179329865845e-06
+ O 0 1.2987122318008915e-05
transients O 0 9.864541425486095e-06
, O 0 1.556765027999063e-07
and O 0 8.968012821242155e-08
the O 0 3.221261408725695e-07
content O 0 3.1672246336711396e-07
of O 0 1.0644723261066247e-05
ATP O 0 0.0003122768539469689
- O 0 8.13661881693406e-06
driven O 0 7.3770092967606615e-06
ion O 0 6.024255526426714e-06
pumps O 0 1.0590408237476368e-05
in O 0 1.0851843398995697e-05
cultured O 0 0.0006205390673130751
skeletal O 0 0.027105767279863358
muscle O 0 7.22437325748615e-05
cells O 0 8.539427653886378e-06
of O 0 1.1088291103078518e-05
wild O 0 3.1846420824876986e-06
- O 0 8.321832751789771e-07
type O 0 7.74641534917464e-07
and O 0 4.527330474957125e-07
DMPK O 0 6.615603342652321e-05
[ O 0 5.009486358176218e-06
- O 0 5.264123501547147e-06
/ O 0 1.8688157069846056e-05
- O 0 1.1562685358512681e-05
] O 0 7.237175395857776e-06
knockout O 0 0.0002034021308645606
mice O 0 3.200963692506775e-05
. O 0 1.2988159596716287e-06

In O 0 0.00042996645788662136
vitro O 0 0.0015370212495326996
- O 0 0.00016026300727389753
differentiated O 0 5.972065628156997e-05
DMPK O 0 0.0008017538930289447
[ O 0 4.474712841329165e-05
- O 0 3.621441646828316e-05
/ O 0 6.16516699665226e-05
- O 0 1.2100468666176312e-05
] O 0 3.963688413932687e-06
myotubes O 0 5.345256795408204e-06
exhibit O 0 1.783141442501801e-06
a O 0 9.795737696549622e-07
higher O 0 2.8309973458817694e-06
resting O 0 8.30861881695455e-06
[ O 0 1.593396859789209e-06
Ca2 O 0 2.8770552944479277e-06
+ O 0 1.6223946659010835e-05
] O 0 9.970714927476365e-06
i O 0 2.4755008780630305e-06
than O 0 3.468631177838688e-07
do O 0 2.9360930398070195e-07
wild O 0 1.4299200756795472e-06
- O 0 1.5524817627010634e-06
type O 0 1.3360966022446519e-06
myotubes O 0 3.2973632642097073e-06
because O 0 2.9510376364783042e-08
of O 0 2.0626595187422936e-07
an O 0 7.901604703874909e-08
altered O 0 5.888258556296933e-07
open O 0 5.617963779513957e-06
probability O 0 1.7042611943907104e-06
of O 0 9.424113159184344e-06
voltage O 0 0.00013759480498265475
- O 0 7.068382728903089e-06
dependent O 0 3.461593223619275e-06
l O 0 3.399065008125035e-06
- O 0 1.1451813719531856e-07
type O 0 7.103827925902806e-08
Ca2 O 0 1.7160022025564103e-07
+ O 0 3.7455049550771946e-07
and O 0 8.325756084559544e-08
Na O 0 5.948237230768427e-06
+ O 0 1.147920897892618e-06
channels O 0 1.0019424507845542e-06
. O 0 6.517092856483941e-07

The O 0 0.0001072442828444764
mutant O 0 0.0001539958466310054
myotubes O 0 0.00020283063349779695
exhibit O 0 1.1356610229995567e-05
smaller O 0 3.4321985253882303e-07
and O 0 9.807742884504478e-08
slower O 0 1.4016064824318164e-06
Ca2 O 0 1.8723998209679849e-06
+ O 0 1.703221187199233e-06
responses O 0 1.271206571118455e-07
upon O 0 3.657659135569702e-07
triggering O 0 1.7154635543192853e-06
by O 0 4.878103609939899e-08
acetylcholine O 0 2.9424438707792433e-06
or O 0 6.258413236537308e-07
high O 0 2.878979103115853e-06
external O 0 6.071383268135833e-06
K O 0 2.8818285500165075e-05
+ O 0 9.351811058877502e-06
. O 0 8.645294542475312e-07

In O 0 7.100828952388838e-05
addition O 0 3.0234518817451317e-06
, O 0 3.577191307613248e-07
we O 0 1.7476915914471647e-08
observed O 0 2.6698467436858664e-08
that O 0 4.618925242283467e-09
these O 0 1.2208537292224264e-08
Ca2 O 0 2.893264309022925e-06
+ O 0 1.779247759259306e-05
transients O 0 2.0671232050517574e-05
partially O 0 3.93450090996339e-06
result O 0 2.5771592504497676e-07
from O 0 5.167135697092817e-08
an O 0 7.1441541571459766e-09
influx O 0 3.8738015462058684e-08
of O 0 5.37402570444101e-07
extracellular O 0 8.158539799296705e-07
Ca2 O 0 3.078412191825919e-06
+ O 0 4.729544798465213e-06
through O 0 2.9217943620096776e-07
the O 0 1.0782855497382116e-06
l O 0 2.904402435888187e-06
- O 0 1.8849577543278428e-07
type O 0 1.5825371235678176e-07
Ca2 O 0 7.093186127349327e-07
+ O 0 1.8432762090014876e-06
channel O 0 1.9382616756047355e-06
. O 0 6.190688850438164e-07

Neither O 0 5.992173828417435e-05
the O 0 9.985084034269676e-06
content O 0 7.920772873148962e-07
nor O 0 4.2869999106187606e-07
the O 0 1.1834210766892284e-07
activity O 0 3.6061828723177314e-07
of O 0 7.107269652806281e-07
Na O 0 1.3549692994274665e-05
+ O 0 5.3222447604639456e-06
/ O 0 6.626607955695363e-06
K O 0 9.14310021471465e-06
+ O 0 4.554080533125671e-06
ATPase O 0 1.1889514098584186e-05
and O 0 1.6208322222155402e-06
sarcoplasmic O 0 2.6740552129922435e-05
reticulum O 0 2.1031377400504425e-05
Ca2 O 0 3.169235060340725e-05
+ O 0 8.167673513526097e-05
- O 0 2.1783896954730153e-05
ATPase O 0 2.2418349544750527e-05
are O 0 9.391909827627387e-08
affected O 0 1.5274976306045573e-07
by O 0 1.5939333763981267e-07
DMPK O 0 0.00015333210467360914
absence O 0 3.675639527500607e-05
. O 0 3.3521332625241484e-06

In O 0 7.81643102527596e-05
conclusion O 0 2.521815440559294e-05
, O 0 2.8156021016911836e-06
our O 0 9.362449304717302e-07
data O 0 8.160500328813214e-07
suggest O 0 2.434122734484845e-07
that O 0 9.629112440734389e-08
DMPK O 0 3.24027641909197e-05
is O 0 9.968921688141563e-08
involved O 0 3.8236784405398794e-08
in O 0 9.673421175193653e-08
modulating O 0 1.157317001343472e-06
the O 0 1.1063335136896058e-07
initial O 0 1.346213167607857e-07
events O 0 3.6339258713269373e-07
of O 0 4.526550583250355e-06
excitation O 0 0.0001025223100441508
- O 0 0.0005342108779586852
contraction O 0 0.0005352708394639194
coupling O 0 3.345059303683229e-05
in O 0 2.6106679797521792e-05
skeletal O 0 0.022222314029932022
muscle O 0 5.2868268539896235e-05
. O 0 9.282213682126894e-07
. O 0 5.178758897272928e-07

Constitutional O 0 0.013342172838747501
RB1 O 1 0.940480649471283
- O 0 0.0004473789012990892
gene O 0 3.687039225042099e-06
mutations O 0 2.9690374958590837e-07
in O 0 3.0686177865391073e-07
patients O 0 2.890030259550258e-07
with O 0 4.233120876051544e-08
isolated O 0 6.688939265586669e-06
unilateral B-Disease 0 0.0001910802529891953
retinoblastoma I-Disease 1 0.9999246597290039
. O 0 3.2263542379951105e-05

In O 0 2.6029516448033974e-05
most O 0 1.8162985497838235e-06
patients O 0 1.325570110566332e-06
with O 0 7.299264126459093e-08
isolated O 0 6.105331976868911e-06
unilateral B-Disease 0 0.00019392077228985727
retinoblastoma I-Disease 1 0.9999822378158569
, O 0 5.691796104656532e-06
tumor B-Disease 0 0.0002801119117066264
development O 0 3.1995602967072045e-07
is O 0 1.1567808932966273e-08
initiated O 0 7.239312083129334e-08
by O 0 1.3169893620101902e-08
somatic O 0 3.2843814778971137e-07
inactivation O 0 3.165607722621644e-06
of O 0 4.871051828558848e-07
both O 0 9.567618519668031e-08
alleles O 0 1.5756896232232975e-07
of O 0 6.797596938667994e-07
the O 0 2.2917802198207937e-06
RB1 O 0 0.00017612570081837475
gene O 0 4.869230906479061e-06
. O 0 1.478004605814931e-06

However O 0 7.683438525418751e-06
, O 0 1.6372769096051343e-07
some O 0 4.3589283293954395e-09
of O 0 1.1229202101503688e-07
these O 0 8.220162328598235e-08
patients O 0 2.360867256356869e-06
can O 0 5.338596338333446e-07
transmit O 0 1.935283034981694e-05
retinoblastoma B-Disease 0 0.011612271890044212
predisposition O 0 0.00011099386756541207
to O 0 4.5230800083118083e-07
their O 0 4.398262376525963e-07
offspring O 0 3.1437064080819255e-06
. O 0 7.573099196633848e-07

To O 0 5.672271186085709e-07
determine O 0 1.029117768780452e-07
the O 0 2.428194250114757e-07
frequency O 0 1.2116103107473464e-06
and O 0 1.1989477854967845e-07
nature O 0 8.285057901957771e-07
of O 0 4.2657784433686174e-06
constitutional O 0 0.00023274206614587456
RB1 O 0 0.0021535083651542664
- O 0 3.861714503727853e-05
gene O 0 5.356803285394562e-07
mutations O 0 6.290822796017892e-08
in O 0 1.1867936677845137e-07
patients O 0 1.1014403611397938e-07
with O 0 1.9787554705885668e-08
isolated O 0 1.8859229840018088e-06
unilateral B-Disease 0 1.509805861132918e-05
retinoblastoma I-Disease 0 0.0008584668394178152
, O 0 2.5081661192416504e-07
we O 0 1.6317519779818213e-08
analyzed O 0 3.2493314705561716e-08
DNA O 0 1.1256564391715074e-07
from O 0 4.850492700825271e-07
peripheral O 0 3.439420834183693e-05
blood O 0 7.494194051105296e-06
and O 0 2.6752941266749986e-06
from O 0 1.1269843525951728e-05
tumor B-Disease 1 0.7814329266548157
tissue O 0 0.00026838891790248454
. O 0 2.4200389816542156e-06

The O 0 5.215996134211309e-05
analysis O 0 1.0013760402216576e-05
of O 0 0.00010926918912446126
tumors B-Disease 1 1.0
from O 0 3.4737062378553674e-05
54 O 0 1.2732798495562747e-05
( O 0 3.472678997695766e-07
71 O 0 1.9905980934709078e-06
% O 0 9.876072937231584e-08
) O 0 2.0323833282986925e-08
of O 0 3.0743061074645084e-07
76 O 0 2.0436955310287885e-05
informative O 0 1.098218831430131e-06
patients O 0 7.867315048315504e-07
showed O 0 1.8415736349197687e-06
loss O 0 4.3629670472000726e-06
of O 0 5.242025963525521e-06
constitutional O 0 0.00010527505946811289
heterozygosity O 0 0.0008304124930873513
( O 0 3.419728818698786e-05
LOH O 0 0.4626109004020691
) O 0 4.6823952288832515e-06
at O 0 3.50651316693984e-05
intragenic O 0 0.00015704732504673302
loci O 0 4.9276757636107504e-05
. O 0 4.008146788692102e-06

Three O 0 2.1756697606178932e-05
of O 0 2.457228401908651e-05
13 O 0 0.00016662623966112733
uninformative O 0 0.0012815307127311826
patients O 0 9.433825653104577e-06
had O 0 5.983991286484525e-06
constitutional O 0 4.9547837988939136e-05
deletions O 0 7.994897168828174e-05
. O 0 6.305740043899277e-06

For O 0 1.7045233107637614e-05
39 O 0 0.00010059354099212214
randomly O 0 7.052471573842922e-06
selected O 0 0.00013977274647913873
tumors B-Disease 1 1.0
, O 0 4.054718010593206e-05
SSCP O 0 0.0014946921728551388
, O 0 1.6684180081938393e-05
hetero O 0 0.00010993504110956565
- O 0 1.109617187466938e-05
duplex O 0 5.463896377477795e-05
analysis O 0 7.130495305318618e-07
, O 0 1.3177060509406147e-07
sequencing O 0 3.4311543117837573e-07
, O 0 8.376360227657642e-08
and O 0 7.221342457341962e-08
Southern O 0 8.915796456676617e-07
blot O 0 5.428676104202168e-06
analysis O 0 1.0199606492733437e-07
were O 0 1.0115986981418246e-07
used O 0 5.0826425734840086e-08
to O 0 3.161137840379524e-08
identify O 0 2.4693886757631844e-07
mutations O 0 2.9547434223786695e-06
. O 0 3.06316928799788e-06

Mutations O 0 2.1341429601307027e-05
were O 0 4.339136921771569e-06
detected O 0 3.8110317746031797e-06
in O 0 1.0733537010310101e-06
21 O 0 5.152204721525777e-06
( O 0 2.53199743838195e-07
91 O 0 2.9506491046049632e-06
% O 0 2.3004946569926688e-07
) O 0 1.617257936459282e-07
of O 0 1.4925194591342006e-05
23 O 1 0.9997844099998474
tumors B-Disease 1 1.0
with O 0 0.0017344712978228927
LOH O 1 1.0
. O 0 2.899305400205776e-05

In O 0 5.0231883506057784e-05
6 O 0 5.5276403145398945e-05
( O 0 8.756909437579452e-07
38 O 0 4.6833688429614995e-06
% O 0 2.8858107725682203e-07
) O 0 1.754629863626178e-07
of O 0 2.4612108973087743e-05
16 O 1 0.9976664781570435
tumors B-Disease 1 1.0
without O 0 0.0010999228106811643
LOH O 1 0.9999943971633911
, O 0 2.625051138238632e-06
one O 0 2.7259869739282294e-07
mutation O 0 1.5199978520286095e-07
was O 0 2.4550981834181584e-06
detected O 0 8.450537620774412e-07
, O 0 2.2719454761954694e-08
and O 0 2.4761657613225907e-08
in O 0 1.2714502872768207e-07
9 O 0 2.5079439183173236e-06
( O 0 1.5920375062705716e-07
56 O 0 2.635674491102691e-06
% O 0 8.951212180363655e-07
) O 0 6.531596454806277e-07
of O 0 3.070585444220342e-05
the O 0 0.08596326410770416
tumors B-Disease 1 1.0
without O 0 0.0023233680985867977
LOH O 1 0.9999946355819702
, O 0 8.523697943019215e-07
both O 0 9.493994923559512e-08
mutations O 0 2.6278087261744076e-07
were O 0 5.756652967647824e-07
found O 0 4.470030887659959e-07
. O 0 2.984047853260563e-07

Thus O 0 2.6706684366217814e-05
, O 0 5.36123934580246e-07
a O 0 2.341824227869438e-07
total O 0 8.407811264987686e-07
of O 0 2.5096260287682526e-06
45 O 0 4.663988875108771e-06
mutations O 0 5.354259542400541e-07
were O 0 1.6804842744022608e-06
identified O 0 7.590365385112818e-07
in O 0 5.0321154958510306e-06
tumors B-Disease 1 1.0
of O 0 2.991005385410972e-05
36 O 0 0.00016321675502695143
patients O 0 7.202488632174209e-06
. O 0 2.337306796107441e-06

Thirty O 0 0.00046671993914060295
- O 0 4.2214269342366606e-05
nine O 0 1.543820690130815e-05
of O 0 1.213782343256753e-05
the O 0 3.853264388453681e-06
mutations O 0 4.757905571750598e-07
- O 0 1.4925969935575267e-06
including O 0 4.4922916231371346e-07
34 O 0 5.05159869135241e-06
small O 0 4.3719703057831794e-07
mutations O 0 3.3218893236153235e-07
, O 0 4.1696597463669605e-07
2 O 0 4.6732234295632225e-06
large O 0 2.573870460764738e-06
structural O 0 0.00011927080777240917
alterations O 0 0.00014950401964597404
, O 0 1.2725394299195614e-05
and O 0 6.85886789142387e-06
hypermethylation O 0 0.0009683577809482813
in O 0 0.00024156560539267957
3 O 0 0.019749347120523453
tumors O 1 1.0
- O 0 8.986187822301872e-06
were O 0 1.7145153208275588e-07
not O 0 5.314890305641029e-09
detected O 0 3.8179795325277155e-08
in O 0 1.1554225132215379e-08
the O 0 5.420029935976345e-08
corresponding O 0 2.8761965040757786e-06
peripheral O 0 0.00022955397434998304
blood O 0 3.687474600155838e-05
DNA O 0 1.0857381312234793e-05
. O 0 3.2627174277877202e-06

In O 0 0.00012238387716934085
6 O 0 0.0001359878369839862
( O 0 2.250850911877933e-06
17 O 0 5.272564521874301e-06
% O 0 2.407766146461654e-07
) O 0 3.041886742494171e-08
of O 0 5.208814286561392e-07
the O 0 2.678850478332606e-06
36 O 0 4.59401635453105e-05
patients O 0 2.019359499172424e-06
, O 0 2.1145221751339704e-07
a O 0 5.429025691228162e-07
mutation O 0 3.328310924644029e-07
was O 0 7.789339178998489e-06
detected O 0 1.8996887547473307e-06
in O 0 4.4965392476115085e-07
constitutional O 0 4.043352873850381e-06
DNA O 0 2.488307870862627e-07
, O 0 5.874830932839359e-08
and O 0 7.509953547923942e-08
1 O 0 2.1927526177023537e-06
of O 0 1.2270422757865163e-06
these O 0 1.554136304093845e-07
mutations O 0 1.520689465905889e-06
is O 0 5.762535693065729e-07
known O 0 2.802898393383657e-07
to O 0 1.964233220519418e-08
be O 0 2.9183318872583186e-08
associated O 0 4.495694483352963e-08
with O 0 1.4839399931076969e-08
reduced O 0 3.159822881571017e-06
expressivity O 0 7.644935976713896e-05
. O 0 4.353548320068512e-06

The O 0 2.9815251764375716e-05
presence O 0 9.863411833066493e-06
of O 0 2.037361446127761e-05
a O 0 1.3056554053036962e-05
constitutional O 0 5.447622243082151e-05
mutation O 0 1.4896322682034224e-06
was O 0 6.145709448901471e-06
not O 0 2.8904841187227248e-08
associated O 0 2.1780099501711447e-08
with O 0 3.7209229031276436e-09
an O 0 1.573694596856967e-08
early O 0 1.756295660015894e-07
age O 0 1.072666009349632e-06
at O 0 5.21943366038613e-06
treatment O 0 3.888743776769843e-06
. O 0 7.779515271977289e-07

In O 0 2.2657741283182986e-05
1 O 0 9.225822577718645e-05
patient O 0 1.6366870113415644e-05
, O 0 9.745272109284997e-07
somatic O 0 2.038455568253994e-05
mosaicism O 0 0.00013356510316953063
was O 0 1.3121260735715623e-06
demonstrated O 0 2.1688303775135864e-07
by O 0 4.482412219175558e-09
molecular O 0 1.1706325864224709e-07
analysis O 0 5.1559099212283854e-09
of O 0 6.096855997839157e-08
DNA O 0 9.847482118630069e-08
and O 0 2.4126134690050094e-07
RNA O 0 3.43081137543777e-06
from O 0 4.13175575886271e-06
peripheral O 0 0.0005046246806159616
blood O 0 6.592792487936094e-05
. O 0 3.792471943597775e-06

In O 0 1.953186438186094e-05
2 O 0 8.74804682098329e-05
patients O 0 9.254335395780799e-07
without O 0 6.857560919115713e-08
a O 0 5.731629357796919e-07
detectable O 0 1.912253355840221e-05
mutation O 0 6.8456932922345e-07
in O 0 5.180337211641017e-06
peripheral O 0 0.00032678761635906994
blood O 0 2.7186391889699735e-05
, O 0 4.719902335637016e-07
mosaicism O 0 1.1674951565510128e-05
was O 0 7.550109444309783e-07
suggested O 0 1.8769961585007877e-08
because O 0 5.089682897363446e-09
1 O 0 2.147339728253428e-07
of O 0 1.0369993930225974e-07
the O 0 9.255703616872779e-07
patients O 0 8.178378266165964e-06
showed O 0 0.00020728673553094268
multifocal O 1 0.999998927116394
tumors B-Disease 1 1.0
and O 0 2.801914206429501e-06
the O 0 1.112664563152066e-06
other O 0 3.4327310771686825e-08
later O 0 3.5776994877778634e-07
developed O 0 1.440331402591255e-06
bilateral B-Disease 0 6.224275421118364e-05
retinoblastoma I-Disease 0 0.017721060663461685
. O 0 8.47599767439533e-06

In O 0 5.256051372271031e-05
conclusion O 0 1.444382178306114e-05
, O 0 1.0570677204668755e-06
our O 0 2.276357378150351e-07
results O 0 3.593706594529067e-07
emphasize O 0 4.224473926228711e-08
that O 0 2.3365210211068188e-08
the O 0 3.046863525923982e-07
manifestation O 0 8.90437513589859e-06
and O 0 9.351651897304691e-07
transmissibility O 0 8.20193745312281e-05
of O 0 9.233414857590105e-06
retinoblastoma B-Disease 0 8.44280730234459e-05
depend O 0 1.1943673143832712e-06
on O 0 3.853179805446416e-06
the O 0 7.778350550324831e-07
nature O 0 9.490172487858217e-07
of O 0 2.132766667273245e-06
the O 0 7.756128184155386e-07
first O 0 1.1922403473363374e-06
mutation O 0 2.2598943871798838e-07
, O 0 1.1430013557856e-07
its O 0 1.0520646753775509e-07
time O 0 1.7375765537508414e-07
in O 0 7.603116500831675e-07
development O 0 1.4680140338896308e-06
, O 0 1.5616943471741251e-07
and O 0 1.1934650956391124e-07
the O 0 3.8794991041868343e-07
number O 0 1.0553401352808578e-06
and O 0 1.623308776288468e-06
types O 0 4.824321877094917e-06
of O 0 1.7219579603988677e-05
cells O 0 4.4870603232993744e-06
that O 0 1.0402342809356924e-07
are O 0 4.928691055283707e-08
affected O 0 1.6568026239838218e-07
. O 0 3.729052622247764e-08
. O 0 3.195108320142026e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9922379851341248
the I-Disease 0 0.0005705432267859578
fifth I-Disease 0 0.0011284383945167065
component I-Disease 0 1.622714989935048e-05
of I-Disease 0 8.510641237080563e-06
complement I-Disease 0 1.6293099179165438e-05
in O 0 3.8443493394879624e-05
man O 0 0.00017734018911141902
. O 0 2.4017601845116587e-06

I O 0 0.005292176268994808
. O 0 5.370200233301148e-05

Clinical O 0 0.034345854073762894
, O 0 5.0799451855709776e-05
immunochemical O 0 0.0007507466361857951
, O 0 1.399133111590345e-06
and O 0 4.7318454221567663e-07
family O 0 6.575495490324101e-07
studies O 0 2.3466782295145094e-06
. O 0 1.30916873786191e-06

The O 0 3.2355333132727537e-06
first O 0 1.7918370076586143e-06
recognized O 0 2.938189936685376e-06
human O 0 2.5832991013885476e-05
kindred O 0 0.00012527310173027217
with O 0 1.2116564676034614e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999713897705078
the I-Disease 0 0.008893498219549656
fifth I-Disease 0 0.262105792760849
component I-Disease 0 5.9513717133086175e-05
of I-Disease 0 4.055298268212937e-05
complement I-Disease 0 3.00013562082313e-05
( O 0 2.0559053155011497e-05
C5 O 0 0.0009710694430395961
) O 0 5.636363198391336e-07
is O 0 2.5228695221812814e-07
described O 0 1.1865745364048053e-06
. O 0 1.0328319604013814e-06

The O 0 0.000809833116363734
proband O 0 0.0021634558215737343
, O 0 1.3297712030180264e-05
a O 0 1.2182564205431845e-05
20 O 0 3.475339326541871e-05
- O 0 7.809055205143522e-06
year O 0 4.651041308534332e-06
- O 0 4.255896328686504e-06
old O 0 1.3955271924714907e-06
black O 0 1.9360786041033862e-07
female O 0 6.718524900861667e-07
with O 0 1.713275992187846e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9999997615814209
age O 0 0.16320335865020752
11 O 0 0.0001526786363683641
, O 0 9.566821290718508e-07
lacked O 0 2.9894827093812637e-05
serum O 0 0.00013887019304092973
hemolytic O 0 0.0026342784985899925
complement O 0 2.438210231048288e-06
activity O 0 3.1546383070235606e-06
, O 0 6.944657826579714e-08
even O 0 1.3131717935266352e-08
during O 0 7.993325539246143e-07
remission O 0 9.120934919337742e-06
. O 0 7.097442562553624e-07

C5 O 0 0.03704944625496864
was O 0 0.0002664743224158883
undetectable O 0 0.0001533069444121793
in O 0 6.377287036229973e-07
her O 0 2.491913164703874e-07
serum O 0 4.078727670275839e-06
by O 0 1.3958636202460184e-07
both O 0 7.811155455783592e-07
immunodiffusion O 0 8.501208503730595e-05
and O 0 4.065927441843087e-06
hemolytic O 1 0.999921441078186
assays O 0 0.00015116643044166267
. O 0 7.768574505462311e-06

Other O 0 9.759484100868576e-07
complement O 0 1.7604219237910002e-06
components O 0 3.41232316714013e-06
were O 0 3.0983173360255023e-07
normal O 0 1.59766807428241e-06
during O 0 2.824188641170622e-06
remission O 0 1.392511239828309e-05
of O 0 1.2279469956411049e-05
lupus O 0 0.0012411453062668443
, O 0 4.58931253888295e-06
but O 0 1.3011839428145322e-06
C1 O 0 9.809959010453895e-05
, O 0 2.0165189198451117e-06
C4 O 0 9.773766942089424e-05
, O 0 1.325795096818183e-06
C2 O 0 1.1422659554227721e-05
, O 0 1.969589220607304e-07
and O 0 4.7270239633689926e-07
C3 O 0 0.000523155729752034
levels O 0 4.995652852812782e-05
fell O 0 0.0017938576638698578
during O 0 3.108886812697165e-05
exacerbations O 0 0.0027289597783237696
. O 0 6.84920814819634e-06

A O 0 0.0031201669480651617
younger O 0 8.414073818130419e-05
half O 0 2.7688893169397488e-05
- O 0 2.634577867866028e-05
sister O 0 1.08853946585441e-05
, O 0 4.142813736507378e-07
who O 0 3.0509286830238125e-07
had O 0 3.523866325849667e-06
no O 0 1.3090665561321657e-05
underlying O 1 0.6490112543106079
disease O 1 0.9874917268753052
, O 0 6.906507792336924e-07
was O 0 2.463974169586436e-06
also O 0 1.2873287857928517e-07
found O 0 8.64995612914754e-08
to O 0 4.2242806586045845e-08
lack O 0 1.4224261576600838e-05
immunochemically O 0 0.0015671036671847105
detectable O 0 0.036153484135866165
C5 O 0 0.1409921795129776
. O 0 1.2054904800606892e-05

By O 0 0.00018131434626411647
hemolytic O 1 0.9999626874923706
assay O 0 0.001635732944123447
, O 0 6.310583103186218e-06
she O 0 7.344077062043652e-07
exhibited O 0 9.352336746815126e-06
1 O 0 4.9762456910684705e-06
- O 0 2.9281378033374494e-07
2 O 0 6.729734423061018e-07
% O 0 6.12658155318968e-08
of O 0 3.595904161102226e-07
the O 0 2.1988653315929696e-06
normal O 0 3.035863846889697e-05
serum O 0 3.6370787711348385e-05
C5 O 0 8.36713079479523e-05
level O 0 5.362888259696774e-06
and O 0 1.5629339600309322e-07
normal O 0 8.421622510468296e-07
concentrations O 0 1.0087929922519834e-06
of O 0 5.96307927480666e-07
other O 0 8.841279708349248e-08
complement O 0 2.7241362658969592e-06
components O 0 2.070775008178316e-05
. O 0 1.8096386611432536e-06

C5 O 0 0.016866691410541534
levels O 0 0.00027060965658165514
of O 0 5.129838245920837e-05
other O 0 1.264908746634319e-06
family O 0 1.0243076076221769e-06
members O 0 2.1048425935532578e-07
were O 0 1.220080662278633e-06
either O 0 8.336241990036797e-07
normal O 0 5.046421847509919e-06
or O 0 5.683544941348373e-07
approximately O 0 1.011866629596625e-06
half O 0 1.2846272738897824e-06
- O 0 2.0705540464405203e-06
normal O 0 6.64092283386708e-07
, O 0 1.9968938502756828e-08
consistent O 0 7.109033361984984e-08
with O 0 1.40539500037562e-08
autosomal O 0 7.948939128255006e-06
codominant O 0 5.030249667470343e-06
inheritance O 0 1.0638085257141938e-07
of O 0 1.5490358862280118e-07
the O 0 4.799935027222091e-07
gene O 0 8.238169357355218e-06
determining O 0 0.00018082177848555148
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.498583464534022e-05

Normal O 0 0.011687462218105793
hemolytic O 1 0.9992895126342773
titers O 0 0.0018630009144544601
were O 0 7.148039912863169e-06
restored O 0 9.006974323710892e-06
to O 0 2.024568601655119e-07
both O 0 2.251568048450281e-06
homozygous O 0 0.00036859579267911613
C5 B-Disease 1 1.0
- I-Disease 1 0.999974250793457
deficient I-Disease 1 1.0
( O 0 7.850373367546126e-05
C5D B-Disease 1 0.9999997615814209
) O 0 1.058290195032896e-06
sera O 0 4.979412096872693e-06
by O 0 5.557191151694951e-09
addition O 0 2.730846659915187e-08
of O 0 7.59126294269663e-07
highly O 0 7.165061106206849e-06
purified O 0 2.8582710001501255e-05
human O 0 7.029568223515525e-05
C5 O 0 0.001052290783263743
. O 0 3.344932110849186e-06

In O 0 0.00027509205392561853
specific O 0 5.4895077482797205e-05
C5 O 0 0.006200730800628662
titrations O 0 0.0009541151812300086
, O 0 8.782377335592173e-06
however O 0 1.0389330782345496e-06
, O 0 2.611686511500011e-07
it O 0 3.7512315032017796e-08
was O 0 1.7402991261405987e-06
noted O 0 2.1578277653588884e-07
that O 0 1.4003939341478144e-08
when O 0 3.582092844567342e-08
limited O 0 6.437721111751671e-08
amounts O 0 1.6720105122658424e-07
of O 0 5.183362191019114e-06
C5 O 0 7.59455215302296e-05
were O 0 2.254219225505949e-06
assayed O 0 3.2874884254852077e-06
in O 0 1.7493552206815366e-07
the O 0 7.842267280011583e-08
presence O 0 9.763843422661012e-08
of O 0 1.0990664804921835e-06
low O 0 1.330336817773059e-05
dilutions O 0 9.794517245609313e-05
of O 0 4.332085882197134e-05
either O 0 0.0001024592638714239
C5D B-Disease 1 0.9999997615814209
serum O 0 0.0003287412109784782
, O 0 6.805200428061653e-06
curving O 0 2.106152351188939e-05
rather O 0 5.666875040333252e-07
than O 0 2.1938747352123755e-07
linear O 0 2.8455708616093034e-06
dose O 0 7.870640729379375e-06
- O 0 5.232112016528845e-06
response O 0 5.267093570182624e-07
plots O 0 1.9211545350117376e-06
were O 0 5.642585847454029e-07
consistently O 0 7.342592311943008e-07
obtained O 0 5.923426442677737e-07
, O 0 1.1517177966879899e-07
suggesting O 0 8.53841015668877e-08
some O 0 1.4027625283574707e-08
inhibitory O 0 6.264209332584869e-06
effect O 0 1.0939552339550573e-05
. O 0 2.3681577658862807e-06

Further O 0 3.805834239756223e-06
studies O 0 2.5691642804304138e-06
suggested O 0 5.807040110994421e-07
that O 0 1.319564688628816e-07
low O 0 1.4042211660125758e-05
dilutions O 0 0.00013619988749269396
of O 0 0.00011007623834302649
C5D B-Disease 1 0.9999961853027344
serum O 0 6.201500946190208e-05
contain O 0 3.1698341445007827e-06
a O 0 3.8032655993447406e-06
factor O 0 2.2262534002948087e-06
( O 0 5.507084210876201e-07
or O 0 3.865922906243213e-07
factors O 0 2.9839537774023484e-07
) O 0 1.0052705334828715e-07
interfering O 0 3.952173130983283e-07
at O 0 1.4594402273360174e-06
some O 0 2.1763321811363312e-08
step O 0 3.310077829610236e-07
in O 0 9.455887948206509e-07
the O 0 5.606825197901344e-06
hemolytic O 0 0.005323330871760845
assay O 0 9.464674076298252e-05
of O 0 0.00010237040260108188
C5 O 0 0.000690051238052547
, O 0 2.953234741198685e-07
rather O 0 5.639477507202173e-08
than O 0 1.7062234292097855e-08
a O 0 2.7897294785361737e-07
true O 0 3.372906121512642e-06
C5 O 0 0.0002490550687070936
inhibitor O 0 9.005185711430386e-05
or O 0 8.22171841718955e-06
inactivator O 0 8.368359704036266e-05
. O 0 2.1841747184225824e-06

Of O 0 0.00017697717703413218
clinical O 0 0.0006068939110264182
interest O 0 1.1435248779889662e-05
are O 0 7.03571743088105e-07
( O 0 1.5999690106127673e-07
a O 0 5.924997381612229e-08
) O 0 1.03057482547797e-08
the O 0 1.7372725480413465e-08
documentation O 0 5.449728064377268e-07
of O 0 1.7468291844124906e-05
membranous O 1 0.9999977350234985
glomerulonephritis B-Disease 1 1.0
, O 0 0.06036382168531418
vasculitis B-Disease 1 1.0
, O 0 9.340235556010157e-05
and O 0 5.3110416047275066e-05
arthritis B-Disease 1 1.0
in O 0 3.4473945561330765e-05
an O 0 1.9079243429587223e-06
individual O 0 2.6036468625534326e-06
lacking O 0 0.00019292192882858217
C5 O 0 0.000802710943389684
( O 0 1.5343903214670718e-06
and O 0 1.6733488905629201e-07
its O 0 3.267068393597583e-07
biologic O 0 8.02224712970201e-06
functions O 0 2.7067958399129566e-06
) O 0 1.4785430835217994e-07
, O 0 1.787595316216084e-08
and O 0 3.7946968234336964e-08
( O 0 1.0738118305653188e-07
b O 0 5.87956094477704e-07
) O 0 2.027435286322543e-08
a O 0 4.402302877792863e-08
remarkable O 0 7.3967021307908e-07
propensity O 0 5.522469109564554e-06
to O 0 2.0383677110658027e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.5356817786814645e-05
the O 0 4.129294211452361e-06
proband O 0 2.4941957235569134e-05
, O 0 1.5427995947447926e-07
even O 0 2.7953776182698675e-08
during O 0 2.491019586159382e-07
periods O 0 9.988408464778331e-07
of O 0 2.9026302854617825e-06
low O 0 1.9316745238029398e-05
- O 0 1.7854692941909889e-06
dose O 0 1.4952970559534151e-06
or O 0 4.600630632012326e-07
alternate O 0 6.827646075180382e-07
- O 0 2.3042061911837664e-06
day O 0 2.159805490009603e-06
corticosteroid O 0 0.000339763006195426
therapy O 0 5.2242106903577223e-05
. O 0 4.932664410262078e-07

Other O 0 6.102299266785849e-06
observations O 0 8.281762347905897e-06
indicate O 0 4.176642050879309e-06
that O 0 2.5138655246337294e-07
the O 0 4.7332268877653405e-06
C5D B-Disease 1 0.9996709823608398
state O 0 1.659133204157115e-06
is O 0 4.825402584174299e-07
compatible O 0 5.887046086172631e-07
with O 0 7.228163667605259e-08
normal O 0 1.2813952707801946e-05
coagulation O 0 9.206280992657412e-06
function O 0 6.278826731431764e-06
and O 0 2.4341832727259316e-07
the O 0 2.2821654965810012e-07
capacity O 0 5.335430728337087e-07
to O 0 7.270834601058596e-08
mount O 0 1.1908668966498226e-05
a O 0 3.927378202206455e-06
neutrophilic O 0 0.001174953649751842
leukocytosis O 0 0.0021720747463405132
during O 0 9.307915752287954e-05
pyogenic B-Disease 0 0.004461504053324461
infection I-Disease 0 0.0001913759915623814
. O 0 2.817410234001727e-07
. O 0 5.744938675888989e-07

Susceptibility O 1 0.9890601634979248
to O 0 0.004703483544290066
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9966404438018799
twins O 0 0.0004557642387226224
: O 0 1.623751870738488e-07
the O 0 6.692026488508418e-08
role O 0 2.7336460561855347e-07
of O 0 2.4024475351325236e-06
genes O 0 1.4862820307826041e-06
, O 0 2.132425152012729e-06
HLA O 0 2.6062549295602366e-05
, O 0 3.590904213979229e-07
and O 0 3.606076006690273e-07
the O 0 1.5673314237574232e-06
environment O 0 8.028055162867531e-06
. O 0 2.1770913463114994e-06

OBJECTIVE O 0 2.4394043066422455e-05
To O 0 1.2444360208974103e-07
determine O 0 1.075367492830992e-07
the O 0 7.213921549009683e-08
relative O 0 1.0388458804300171e-06
effects O 0 1.5616362816217588e-06
of O 0 1.6198558228097681e-07
genetic O 0 3.00684689591435e-07
and O 0 6.305393895900124e-08
environmental O 0 1.4125669167697197e-07
factors O 0 7.143312785728995e-08
in O 0 4.009918654901412e-07
susceptibility O 0 0.0001938730856636539
to O 0 7.817176083335653e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.09625119715929031
AS B-Disease 1 1.0
) O 0 1.5301701523640077e-06
. O 0 3.3929399023691076e-07

METHODS O 0 0.001235352479852736
Twins O 0 0.00026680249720811844
with O 0 1.4891564887875575e-06
AS B-Disease 0 0.014416354708373547
were O 0 1.8589383898870437e-07
identified O 0 1.016615769344753e-08
from O 0 5.182549500659661e-09
the O 0 9.821704338719428e-09
Royal O 0 4.649564743886003e-06
National O 0 2.353874151594937e-05
Hospital O 0 0.006429567467421293
for O 0 6.924017270648619e-06
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.0002845540293492377
. O 0 6.014807240717346e-06

Clinical O 0 0.0010637356899678707
and O 0 7.3306396188854706e-06
radiographic O 0 0.00012494206021074206
examinations O 0 3.536026270012371e-05
were O 0 5.988565021652903e-07
performed O 0 8.251577696682943e-07
to O 0 2.220348882531198e-08
establish O 0 5.381441496865591e-07
diagnoses O 0 0.00014576510875485837
, O 0 1.136373953158909e-06
and O 0 3.9518895391665865e-06
disease O 1 0.9986081719398499
severity O 0 0.00018706131959334016
was O 0 1.4919859495421406e-05
assessed O 0 1.0313701750419568e-06
using O 0 7.2291420849524e-08
a O 0 1.125610253893683e-07
combination O 0 1.2784160219325713e-07
of O 0 3.61077354682493e-07
validated O 0 4.270394583727466e-06
scoring O 0 7.092583018675214e-06
systems O 0 2.1817617380293086e-05
. O 0 1.1173721077284426e-06

HLA O 0 0.007583701517432928
typing O 0 0.0004964285180903971
for O 0 7.763584289932624e-05
HLA O 0 0.0004810317186638713
- O 0 0.00010631891200318933
B27 O 0 0.0001350617822026834
, O 0 6.261515409278218e-06
HLA O 0 2.4008142645470798e-05
- O 0 9.313273039879277e-06
B60 O 0 2.7566011340240948e-05
, O 0 8.923835252971912e-07
and O 0 7.279367650880886e-07
HLA O 0 2.398349533905275e-05
- O 0 1.4178849596646614e-05
DR1 O 0 0.0005366217810660601
was O 0 4.8431847972096875e-06
performed O 0 8.863894436217379e-07
by O 0 6.705313637667132e-08
polymerase O 0 9.73526039160788e-06
chain O 0 2.19764729081362e-06
reaction O 0 3.7191725255070196e-07
with O 0 6.380194150779062e-08
sequence O 0 1.4476216847469914e-06
- O 0 1.4787124200665858e-06
specific O 0 9.795721922500888e-08
primers O 0 3.0769037948630285e-06
, O 0 1.8452814742886403e-07
and O 0 1.907171593984458e-07
zygosity O 0 1.5516867279075086e-05
was O 0 2.883075921999989e-06
assessed O 0 2.3348072772932937e-06
using O 0 8.31222791930486e-07
microsatellite O 0 2.371453410887625e-05
markers O 0 2.5415405616513453e-05
. O 0 3.439988176978659e-06

Genetic O 0 0.0003025309124495834
and O 0 1.4213210306479596e-05
environmental O 0 1.050381706590997e-05
variance O 0 4.754236215376295e-06
components O 0 1.6320420400006697e-05
were O 0 3.056140258195228e-06
assessed O 0 1.9713172605406726e-06
with O 0 8.031488363258177e-08
the O 0 1.1397503385524033e-06
program O 0 1.473149723096867e-06
Mx O 0 5.115403109812178e-05
, O 0 1.4061542685794848e-07
using O 0 5.917306111768994e-08
data O 0 8.38320133311754e-08
from O 0 1.4455141972291585e-08
this O 0 2.902094342616124e-09
and O 0 1.0472713363185449e-08
previous O 0 1.0622027701856496e-07
studies O 0 1.9487249858229916e-07
of O 0 1.4348158856591908e-06
twins O 0 1.7108912288676947e-05
with O 0 1.3275183619043673e-06
AS B-Disease 1 0.9994827508926392
. O 0 4.57227088190848e-06

RESULTS O 0 0.00044170930050313473
Six O 0 2.4369723178097047e-05
of O 0 5.588907879428007e-05
8 O 0 0.00041412521386519074
monozygotic O 0 0.0006332789198495448
( O 0 2.867810871975962e-05
MZ O 0 0.0016601375536993146
) O 0 3.468360773695167e-06
twin O 0 2.995852628373541e-05
pairs O 0 2.215962922491599e-06
were O 0 3.528880142766866e-06
disease O 0 3.9610171370441094e-05
concordant O 0 1.0975101758958772e-05
, O 0 1.2696048656835046e-07
compared O 0 5.034074774812325e-07
with O 0 2.7595136842251122e-08
4 O 0 7.567961802124046e-06
of O 0 8.760955097386613e-06
15 O 0 4.5182347093941644e-05
B27 O 0 6.036819831933826e-05
- O 0 2.170890729757957e-05
positive O 0 2.6017303298431216e-06
dizygotic O 0 5.2990108088124543e-05
( O 0 4.413575425132876e-06
DZ O 0 0.00013369023508857936
) O 0 8.246008178502962e-07
twin O 0 6.981943442951888e-06
pairs O 0 3.4978469898305775e-07
( O 0 1.6849475059643737e-07
27 O 0 2.133914222213207e-06
% O 0 1.557367852456082e-07
) O 0 1.7781756511681124e-08
and O 0 1.2526267312296113e-07
4 O 0 1.1115087545476854e-05
of O 0 5.567290281760506e-05
32 O 0 0.0007702175644226372
DZ O 0 0.009207394905388355
twin O 0 0.00026986998273059726
pairs O 0 2.8393715183483437e-06
overall O 0 1.3900778867537156e-05
( O 0 4.259857462329819e-07
12 O 0 1.0706884268074646e-06
. O 0 1.6840630223668995e-08
5 O 0 6.248942554520909e-07
% O 0 3.3239524555028765e-07
) O 0 2.185086174222306e-07
. O 0 5.139515337759804e-07

Nonsignificant O 0 0.0019017144804820418
increases O 0 6.007257525197929e-06
in O 0 4.568521205783327e-07
similarity O 0 4.363806169749296e-07
with O 0 6.403721997116918e-09
regard O 0 1.1869294525013174e-07
to O 0 1.5320823720799126e-08
age O 0 1.1411577816033969e-06
at O 0 1.39138828672003e-05
disease O 0 4.371902468847111e-05
onset O 0 1.817333759390749e-05
and O 0 5.3116401943498204e-08
all O 0 1.5362315863853837e-08
of O 0 1.8909408083800372e-07
the O 0 1.9555254766601138e-06
disease O 0 6.000746361678466e-05
severity O 0 4.6936706894484814e-06
scores O 0 1.2274084610908176e-06
assessed O 0 5.513936685019871e-07
were O 0 2.7515361011865025e-07
noted O 0 7.413227649522014e-07
in O 0 3.90442937714397e-06
disease O 0 0.005150193348526955
- O 0 5.0518239731900394e-05
concordant O 0 0.0004188014136161655
MZ O 0 0.024194782599806786
twins O 0 4.853207428823225e-05
compared O 0 3.6446401736611733e-06
with O 0 4.732770548798726e-07
concordant O 0 0.0014482613187283278
DZ O 1 0.9976853132247925
twins O 0 0.0013133040629327297
. O 0 1.1238206752750557e-05

HLA O 0 0.13527056574821472
- O 0 0.0017700670287013054
B27 O 0 0.0004964044201187789
and O 0 3.6253591133572627e-06
B60 O 0 1.9149176296195947e-05
were O 0 6.498331686088932e-07
associated O 0 1.564279017429726e-07
with O 0 3.47661526234333e-08
the O 0 3.2207806270889705e-06
disease O 0 0.0011135113891214132
in O 0 4.954912128596334e-06
probands O 0 0.00010167063737753779
, O 0 1.4344627174978086e-07
and O 0 2.9608987262008668e-08
the O 0 6.322350287746303e-08
rate O 0 5.727919187847874e-07
of O 0 6.957948812669201e-07
disease O 0 2.3273301849258132e-05
concordance O 0 9.918261639541015e-06
was O 0 6.393280273186974e-06
significantly O 0 9.18738123800722e-07
increased O 0 6.491086878668284e-06
among O 0 4.538532721198862e-06
DZ O 0 0.0006674146861769259
twin O 0 0.00011498577077873051
pairs O 0 2.629036998769152e-06
in O 0 3.798415491473861e-06
which O 0 1.3813565828968422e-06
the O 0 4.0832037484506145e-06
co O 0 1.4339104382088408e-05
- O 0 5.623146989819361e-06
twin O 0 7.175208793341881e-06
was O 0 1.2960715594090289e-06
positive O 0 8.740342138935375e-08
for O 0 1.4834763817361818e-07
both O 0 8.528478474545409e-07
B27 O 0 5.4832609748700634e-05
and O 0 6.743727681168821e-06
DR1 O 0 0.00811370275914669
. O 0 6.42971053821384e-06

Additive O 0 0.0029149623587727547
genetic O 0 4.387732406030409e-05
effects O 0 3.3445554436184466e-05
were O 0 8.97117558906757e-07
estimated O 0 8.655056404904826e-08
to O 0 3.3418707801047276e-09
contribute O 0 3.588329633430476e-08
97 O 0 1.3050514553469839e-06
% O 0 2.9832047943045836e-08
of O 0 5.145852099985859e-08
the O 0 8.013738295176154e-08
population O 0 3.211641441680513e-08
variance O 0 8.839573979457782e-07
. O 0 1.4375813179867691e-06

CONCLUSION O 0 0.00035018339985981584
Susceptibility O 0 0.0009696308989077806
to O 0 2.3036192942527123e-05
AS B-Disease 1 0.9998272061347961
is O 0 1.2688111610259512e-06
largely O 0 5.635750994770206e-07
genetically O 0 5.613410536398078e-08
determined O 0 8.981262311635874e-08
, O 0 2.3159072881639986e-08
and O 0 3.0454454957862254e-08
the O 0 3.0532891059920075e-07
environmental O 0 1.8567711776995566e-06
trigger O 0 1.946688826137688e-06
for O 0 8.222456813200552e-07
the O 0 1.0512595508771483e-05
disease O 0 0.0019071745919063687
is O 0 2.3279280867427588e-06
probably O 0 5.964051069895504e-06
ubiquitous O 0 1.984560913115274e-05
. O 0 7.403752420032106e-07

HLA O 0 0.16092664003372192
- O 0 0.00018812628695741296
B27 O 0 2.9618267944897525e-05
accounts O 0 4.607101899978261e-08
for O 0 1.386726555807627e-08
a O 0 2.8214586222929938e-08
minority O 0 7.498227816427061e-09
of O 0 9.499810005308973e-08
the O 0 3.126059198166331e-07
overall O 0 1.0452802598592825e-05
genetic O 0 6.6328170760243665e-06
susceptibility O 0 0.00010022500646300614
to O 0 1.1018718396371696e-05
AS B-Disease 1 0.9999995231628418
. O 0 6.891657903906889e-06

Cell O 0 0.0359518900513649
cycle O 0 0.000271207100013271
- O 0 1.8063339666696265e-05
dependent O 0 2.9942441415187204e-06
colocalization O 0 1.7776721506379545e-05
of O 0 8.828942554828245e-06
BARD1 O 0 0.00012443294690456241
and O 0 9.561321121509536e-07
BRCA1 O 0 1.0190617558691883e-06
proteins O 0 1.2003492599887977e-07
in O 0 3.2816200246088556e-07
discrete O 0 7.85990687290905e-06
nuclear O 0 2.4952592866611667e-05
domains O 0 3.444331377977505e-05
. O 0 2.7357295948604587e-06

Germ O 0 0.08520543575286865
- O 0 0.00015785206051077694
line O 0 6.756164111720864e-06
mutations O 0 2.7204083608012297e-07
of O 0 8.340329600287077e-07
the O 0 2.8948927592864493e-06
BRCA1 O 0 2.3307837182073854e-05
gene O 0 2.8599383767868858e-06
predispose O 0 3.5106036193610635e-06
women O 0 5.2043056086858996e-08
to O 0 9.56724921508112e-09
early O 0 1.8825554661816568e-06
- O 0 0.0004148858424741775
onset O 1 0.9999890327453613
breast B-Disease 1 1.0
and I-Disease 1 0.9999747276306152
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 4.846395995627972e-07
compromising O 0 2.1486744117282797e-06
the O 0 6.941478432054282e-07
genes O 0 1.5661510133213596e-06
presumptive O 0 1.293710829486372e-05
function O 0 3.4470128866814775e-06
as O 0 9.015396358336147e-07
a O 0 2.776310338958865e-06
tumor B-Disease 0 0.0008811787120066583
suppressor O 0 0.0008536771056242287
. O 0 1.870564915407158e-06

Although O 0 1.0723749255703297e-05
the O 0 1.2270947991055436e-05
biochemical O 0 0.00018791436741594225
properties O 0 0.0003257869102526456
of O 0 0.0001578526571393013
BRCA1 O 0 8.678634185343981e-05
polypeptides O 0 9.214168130711187e-06
are O 0 5.855186913095167e-08
not O 0 1.501251922775282e-08
understood O 0 4.910393514023781e-08
, O 0 1.1281965583975762e-08
their O 0 4.9386446043797605e-09
expression O 0 5.558306384045864e-07
pattern O 0 1.2665697113334318e-06
and O 0 4.078666790974239e-07
subcellular O 0 7.137469219742343e-05
localization O 0 2.8698928872472607e-05
suggest O 0 3.90701558217188e-07
a O 0 3.8945381675148383e-07
role O 0 1.1873804623974138e-06
in O 0 5.717114618164487e-06
cell O 0 6.632134318351746e-05
- O 0 1.613062522665132e-05
cycle O 0 4.171073214820353e-06
regulation O 0 3.513567889967817e-06
. O 0 9.67114942795888e-07

When O 0 0.00034969273838214576
resting O 0 0.0021635303273797035
cells O 0 3.288462175987661e-05
are O 0 6.999110837568878e-07
induced O 0 7.857966011215467e-06
to O 0 2.587578933344048e-07
proliferate O 0 1.2262993323020055e-06
, O 0 1.9877305135196366e-07
the O 0 2.6700232069742924e-07
steady O 0 4.351481493358733e-06
- O 0 1.4410592541480582e-07
state O 0 2.6357088955819563e-08
levels O 0 3.6264756886339455e-07
of O 0 6.771999778720783e-07
BRCA1 O 0 1.0601690973999212e-06
increase O 0 9.629054602555698e-07
in O 0 5.77491482545156e-06
late O 0 2.0366136595839635e-05
G1 O 0 1.4076576007937547e-05
and O 0 5.469504316124585e-08
reach O 0 9.716988103036783e-08
a O 0 6.302700938931594e-08
maximum O 0 1.2308935311011737e-06
during O 0 1.1724893738573883e-05
S O 0 0.00011572628864087164
phase O 0 2.040565959759988e-05
. O 0 3.2644011298543774e-06

Moreover O 0 4.1494600736768916e-05
, O 0 2.4170728920580586e-06
in O 0 1.1385855941625778e-05
S O 0 0.0007206833688542247
phase O 0 0.0001776399149093777
cells O 0 3.3198801247635856e-05
, O 0 2.8182992082292913e-06
BRCA1 O 0 8.609753422206268e-06
polypeptides O 0 3.893501343554817e-06
are O 0 9.285872692998964e-08
hyperphosphorylated O 0 2.1330474737624172e-06
and O 0 5.378015188739482e-08
accumulate O 0 1.4085675559272204e-07
into O 0 1.1190886084477825e-07
discrete O 0 7.718143933743704e-06
subnuclear O 0 9.099169983528554e-05
foci O 0 0.00014932749036233872
termed O 0 5.954368316452019e-05
" O 0 1.8708200514083728e-05
BRCA1 O 0 1.9626548237283714e-05
nuclear O 0 4.637801248463802e-05
dots O 0 4.302697197999805e-05
. O 0 1.7374866274622036e-06

" O 0 0.00028531302814371884
BRCA1 O 0 0.00022406615607906133
associates O 0 4.2807110730791464e-05
in O 0 8.30835233500693e-07
vivo O 0 1.528920438431669e-05
with O 0 5.709176065238353e-08
a O 0 2.006784598052036e-06
structurally O 0 7.826813089195639e-05
related O 0 1.095550487661967e-05
protein O 0 0.00013651311746798456
termed O 0 0.0005178081919439137
BARD1 O 0 0.004054178483784199
. O 0 1.1521452506713104e-05

Here O 0 0.0001628933532629162
we O 0 1.4427550922846422e-06
show O 0 6.910803449500236e-07
that O 0 9.200947914678181e-08
the O 0 6.123170805949485e-07
steady O 0 1.1375742360542063e-05
- O 0 4.718336299447401e-07
state O 0 1.1786488585130428e-07
levels O 0 2.339703996767639e-06
of O 0 6.0334891713864636e-06
BARD1 O 0 0.00021331098105292767
, O 0 5.876438535779016e-07
unlike O 0 2.1678275174963346e-07
those O 0 4.1558234187277776e-08
of O 0 5.955105848443054e-07
BRCA1 O 0 2.5100760012719547e-06
, O 0 3.053856190149418e-08
remain O 0 4.4280046296307773e-08
relatively O 0 7.509535215888263e-09
constant O 0 1.2396824899951753e-07
during O 0 1.839458491303958e-06
cell O 0 2.377091186644975e-05
cycle O 0 8.858165529090911e-06
progression O 0 3.627324986155145e-05
. O 0 2.0952704744559014e-06

However O 0 7.363612530753016e-05
, O 0 1.6971418517641723e-05
immunostaining O 0 0.0001242730941157788
revealed O 0 2.0382243747008033e-05
that O 0 8.903832622308983e-07
BARD1 O 0 0.00021038918930571526
resides O 0 3.247670247219503e-05
within O 0 2.5676897621451644e-06
BRCA1 O 0 3.219447535229847e-06
nuclear O 0 1.2376119229884353e-05
dots O 0 5.162449724593898e-06
during O 0 1.7500420653959736e-05
S O 0 4.0954011637950316e-05
phase O 0 5.834290277562104e-06
of O 0 7.3692672231118195e-06
the O 0 1.0414923053758685e-05
cell O 0 3.361768904142082e-05
cycle O 0 2.4330395262950333e-06
, O 0 3.5057141190009133e-08
but O 0 8.11420086677117e-09
not O 0 1.0480347256702771e-08
during O 0 4.733289529212925e-07
the O 0 7.044419021440262e-07
G1 O 0 1.9156921553076245e-05
phase O 0 1.2193710972496774e-05
. O 0 2.5986976197600598e-06

Nevertheless O 0 0.0029630146455019712
, O 0 0.0001361927279504016
BARD1 O 0 0.0013027286622673273
polypeptides O 0 2.602179483801592e-05
are O 0 3.62056653102627e-07
found O 0 1.6584071715897153e-07
exclusively O 0 1.0818334317264089e-07
in O 0 4.1011060147866374e-07
the O 0 6.8641156758531e-07
nuclear O 0 2.8470883535192115e-06
fractions O 0 1.4234491345632705e-06
of O 0 9.091279025597032e-06
both O 0 2.97786664305022e-06
G1 O 0 4.280996654415503e-05
- O 0 4.392319624457741e-06
and O 0 1.323203150604968e-06
S O 0 7.797416765242815e-05
- O 0 4.4323833208181895e-06
phase O 0 1.005136982712429e-05
cells O 0 5.697900178347481e-06
. O 0 9.145081207861949e-07

Therefore O 0 0.0001149094823631458
, O 0 5.8805703702091705e-06
progression O 0 6.941326864762232e-05
to O 0 1.2767800399160478e-06
S O 0 6.988210225244984e-05
phase O 0 4.136277766519925e-06
is O 0 1.3097215401103313e-07
accompanied O 0 2.4642977791700105e-07
by O 0 1.4716366791844848e-08
the O 0 6.511296390954158e-08
aggregation O 0 7.028609161352506e-07
of O 0 2.743583536357619e-06
nuclear O 0 2.47050411417149e-05
BARD1 O 0 0.0001486866967752576
polypeptides O 0 1.0370579730079044e-05
into O 0 5.638193215418141e-06
BRCA1 O 0 1.7875081539386883e-05
nuclear O 0 6.11978248343803e-05
dots O 0 6.413353548850864e-05
. O 0 5.202685770200333e-06

This O 0 4.356005592853762e-05
cell O 0 0.0004166654252912849
cycle O 0 3.410990029806271e-05
- O 0 3.7641289054590743e-06
dependent O 0 1.2037106671414222e-06
colocalization O 0 1.9122806406812742e-05
of O 0 8.370740943064447e-06
BARD1 O 0 0.0002368603163631633
and O 0 1.2205181292301859e-06
BRCA1 O 0 3.76043317373842e-06
indicates O 0 7.143393077058136e-07
a O 0 1.62611044629557e-07
role O 0 8.274840865851729e-07
for O 0 2.016015287154005e-06
BARD1 O 0 0.00019977139891125262
in O 0 1.1860953236464411e-05
BRCA1 O 0 7.029159314697608e-05
- O 0 4.5468401367543265e-05
mediated O 0 0.00023731013061478734
tumor B-Disease 1 0.7654641270637512
suppression O 0 0.0014253419358283281
. O 0 3.143613412248669e-06

Ethnic O 0 3.931803803425282e-06
differences O 0 7.182712124631507e-06
in O 0 1.1014442861778662e-05
the O 0 1.6766467524576e-05
HFE O 0 0.0018668860429897904
codon O 0 0.00016909361875150353
282 O 0 0.00014274523709900677
( O 0 2.002070141315926e-05
Cys O 0 0.007904143072664738
/ O 0 0.0006571189151145518
Tyr O 0 0.00037281319964677095
) O 0 1.8430441741656978e-06
polymorphism O 0 1.0558813301031478e-05
. O 0 4.203743174002739e-06

Recent O 0 2.717524694162421e-06
studies O 0 1.2958120123585104e-06
have O 0 2.6843540013032907e-07
shown O 0 3.2076397928904044e-06
that O 0 9.895615221466869e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9519976377487183
HH B-Disease 1 0.9999998807907104
) O 0 5.771699761680793e-06
is O 0 3.381078670372517e-07
likely O 0 1.634316220133769e-07
to O 0 6.537216989954686e-08
be O 0 4.91567902827228e-07
caused O 0 2.3185295958683128e-06
by O 0 9.560211822190468e-08
homozygosity O 0 8.591831829107832e-06
for O 0 2.995081160861446e-07
a O 0 1.3921149957241141e-06
Cys282Tyr O 0 2.6302197511540726e-05
mutation O 0 4.308710970235552e-07
in O 0 1.0513903134778957e-06
the O 0 2.63760557572823e-06
HFE O 0 0.00014051950711291283
gene O 0 1.8075515981763601e-06
located O 0 7.977357199706603e-06
4 O 0 2.258484710182529e-05
. O 0 1.4300278508017072e-06

5 O 0 0.0010583633556962013
Mb O 0 0.006249960511922836
telomeric O 0 0.0015630355337634683
to O 0 8.623979374533519e-05
HLA O 0 0.004731976892799139
- O 0 0.00028384142206050456
A O 0 6.0479749663500115e-05
. O 0 2.5173012545565143e-06

Population O 0 2.6654411158233415e-06
studies O 0 2.715493792493362e-06
of O 0 1.4640238532592775e-06
this O 0 8.019579667006838e-08
polymorphism O 0 5.539742460314301e-07
are O 0 3.576290197315757e-08
facilitated O 0 2.0633697772609594e-07
by O 0 8.436500387176693e-09
the O 0 2.7275360636735968e-08
fact O 0 1.2633612378465386e-08
that O 0 1.318779130343728e-08
the O 0 6.416250357688114e-07
Cys282Tyr O 0 7.228866161312908e-05
mutation O 0 2.405065515631577e-06
creates O 0 4.008796622656519e-06
a O 0 5.561420493904734e-06
Rsal O 0 0.00017353073053527623
restriction O 0 2.481360934325494e-05
site O 0 1.0778520845633466e-05
. O 0 1.2811356100428384e-06

We O 0 7.643277967872564e-06
have O 0 3.9905845028442855e-07
studied O 0 9.70303426583996e-06
the O 0 4.54908877145499e-06
codon O 0 3.472603202681057e-05
282 O 0 6.0155627579661086e-05
( O 0 2.432138535368722e-05
Cys O 0 0.01239066757261753
/ O 0 0.0007694224477745593
Tyr O 0 0.0001812745613278821
) O 0 2.0537071065973578e-07
polymorphism O 0 2.8129375095886644e-07
in O 0 7.656291955981942e-08
different O 0 1.1732127269681314e-08
ethnic O 0 1.0164804109535908e-07
groups O 0 1.623928511662598e-07
. O 0 7.047657959446951e-07

In O 0 3.164650115650147e-05
agreement O 0 4.149510004936019e-06
with O 0 1.2555919965961948e-06
previous O 0 2.0567365936585702e-05
observations O 0 5.0670561904553324e-05
the O 0 2.7853622668772005e-05
Tyr O 0 0.0001511631126049906
allele O 0 8.048453310038894e-06
appeared O 0 1.1033028386009391e-05
to O 0 2.0442902837203292e-07
be O 0 3.8175798522388504e-07
rare O 0 1.4294661241365247e-06
or O 0 1.372443307445792e-06
absent O 0 2.2541805719811236e-06
in O 0 5.156974793862901e-07
Asiatic O 0 2.8355182166706072e-06
( O 0 1.737127490741841e-07
Indian O 0 2.493163151484623e-07
, O 0 9.310986115451669e-08
Chinese O 0 4.7507688805126236e-07
) O 0 1.5958056565068546e-07
populations O 0 2.40440670040698e-07
. O 0 3.98757890707202e-07

The O 0 3.9135542465373874e-05
highest O 0 0.00011640449520200491
allele O 0 5.085865723231109e-06
frequency O 0 6.71077805236564e-06
( O 0 6.992125918259262e-07
7 O 0 2.1703729089495027e-06
. O 0 1.715857322892589e-08
5 O 0 3.203138305707398e-07
% O 0 9.781812337905649e-08
) O 0 4.641465167765091e-08
was O 0 8.78470473253401e-07
found O 0 1.689739548282887e-07
in O 0 4.134194000471325e-07
Swedes O 0 1.5459776477655396e-05
. O 0 2.982809292007005e-06

Saamis O 0 0.0020850731525570154
( O 0 1.5169326616160106e-05
2 O 0 2.379772013227921e-05
% O 0 1.7156681906271842e-06
) O 0 1.8740024643193465e-07
and O 0 5.64862148166867e-07
Mordvinians O 0 2.496858905942645e-05
( O 0 7.074918357830029e-07
1 O 0 1.0800958989420906e-06
. O 0 1.0528994565106586e-08
8 O 0 7.37419213692192e-07
% O 0 5.537123115573195e-08
) O 0 1.6517549994432557e-08
had O 0 1.455841101005717e-07
significantly O 0 1.7000181173898454e-07
lower O 0 1.1235526926611783e-06
frequencies O 0 5.924222818975977e-07
of O 0 2.5948172606149456e-06
the O 0 1.0523349374125246e-05
Tyr O 0 0.00015827736933715641
allele O 0 1.6535428585484624e-05
. O 0 3.2646375984768383e-06

Comparisons O 0 3.597937757149339e-05
with O 0 2.348756197534385e-06
allele O 0 9.465962648391724e-06
frequencies O 0 9.04779153643176e-06
based O 0 7.709646183684526e-07
on O 0 3.2323505365638994e-06
prevalence O 0 3.954699059249833e-05
estimates O 0 3.50339951182832e-06
of O 0 1.0682450920285191e-05
HH B-Disease 1 0.9952419996261597
showed O 0 8.619063009973615e-05
some O 0 5.48227149010927e-07
disagreements O 0 5.453437552205287e-06
with O 0 8.647644449411018e-07
the O 0 7.666932106076274e-06
RFLP O 0 3.6407640436664224e-05
data O 0 1.618553937987599e-06
, O 0 1.5098702021987265e-07
particularly O 0 1.2475396715672105e-07
in O 0 6.614843073293741e-07
Finns O 0 9.887370651995298e-06
. O 0 1.5208460126814316e-06

The O 0 7.130979065550491e-05
newly O 0 0.00015512312529608607
described O 0 6.344047142192721e-05
HFE O 0 0.005872802808880806
marker O 0 4.879795233136974e-05
provides O 0 8.228975616475509e-07
a O 0 6.654623234680912e-07
new O 0 2.1493639223990613e-07
approach O 0 5.537951892620185e-07
to O 0 9.147368729145455e-08
the O 0 4.92076310365519e-07
screening O 0 1.065985316017759e-06
of O 0 1.1699383321683854e-05
HH B-Disease 0 0.0063330125994980335
as O 0 1.0211514336333494e-06
well O 0 7.232024756831379e-08
as O 0 3.06321368270801e-08
studies O 0 4.110338025498095e-08
of O 0 1.0239975978265647e-07
the O 0 1.6050903184350318e-07
relationship O 0 9.830479541506065e-08
between O 0 9.317680564890907e-07
the O 0 4.119963705306873e-06
HFE O 0 0.0013931029243394732
Tyr O 0 6.0463949921540916e-05
allele O 0 2.8985089102206985e-06
and O 0 2.7920214051846415e-07
different O 0 1.0278647550876485e-06
disorders O 1 0.9999995231628418
including O 0 0.00012598336616065353
cancer B-Disease 1 0.9999983310699463

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999985694885254
associated O 0 9.056519047589973e-06
with O 0 3.627475280154613e-07
a O 0 5.406181571743218e-06
missense O 0 3.334934081067331e-05
mutation O 0 7.644947800145019e-06
encoding O 0 2.2066225938033313e-05
Gly23 O 0 0.00028116448083892465
- O 0 3.8674934330629185e-05
- O 0 2.6084257115144283e-05
> O 0 1.0316788575437386e-05
Val O 0 2.843462243617978e-05
in O 0 4.843328042625217e-06
neurophysin O 0 0.00031487023807130754
II O 1 0.9932706952095032
. O 0 1.2631929166673217e-05

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 9.285123815061525e-05
ADNDI B-Disease 1 0.9907187819480896
) O 0 7.632044685124129e-07
is O 0 1.626088845796403e-07
an O 0 1.5390023690997623e-06
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9971734285354614
by O 0 2.2188708044268424e-06
progressive O 1 0.8638393878936768
degeneration O 1 0.9999299049377441
of O 0 3.7742149288533255e-05
the O 0 2.1890020434511825e-05
magnocellular O 0 0.00015959766460582614
neurons O 0 1.0172461770707741e-05
of O 0 1.4558867405867204e-05
the O 0 1.6059559129644185e-05
hypothalamus O 0 3.818131153821014e-05
leading O 0 6.2820672610541806e-06
to O 0 7.98075987518132e-08
decreased O 0 9.382110874867067e-06
ability O 0 5.408401193562895e-07
to O 0 4.335962273671612e-07
produce O 0 1.3659093838214176e-06
the O 0 2.8156075131846592e-05
hormone O 0 0.00013970612781122327
arginine O 0 6.847960321465507e-05
vasopressin O 0 6.421866419259459e-05
( O 0 1.0511494110687636e-05
AVP O 0 0.0002669699606485665
) O 0 8.270122862086282e-07
. O 0 9.70380824583117e-07

Affected O 0 4.129371518502012e-05
individuals O 0 2.841582329438097e-07
are O 0 9.816183421662572e-08
not O 0 5.233481559230313e-08
symptomatic O 0 1.0600482710287906e-05
at O 0 3.325364787087892e-06
birth O 0 2.230597146990476e-06
, O 0 4.381628926353187e-08
but O 0 1.1155845136556763e-08
usually O 0 3.534100017077435e-07
develop O 0 5.467216396937147e-06
diabetes B-Disease 1 0.9982967972755432
insipidus I-Disease 0 0.0021116803400218487
at O 0 0.00018529656517785043
1 O 0 4.0928483940660954e-05
- O 0 1.0327617019356694e-05
6 O 0 7.029213884379715e-05
yr O 0 0.00014817039482295513
of O 0 4.339740826253546e-06
age O 0 1.6512893125764094e-05
. O 0 2.750155999819981e-06

The O 0 3.4653685361263342e-06
genetic O 0 2.0260183646314545e-06
locus O 0 1.2998745660297573e-05
of O 0 9.913778740155976e-06
the O 0 7.672483479836956e-05
disease O 1 0.9340516924858093
is O 0 1.2558108210214414e-05
the O 0 3.612749424064532e-05
AVP O 0 0.0009638484916649759
- O 0 5.605668411590159e-05
neurophysin O 0 0.00016068227705545723
II O 0 0.053305093199014664
( O 0 9.34003674046835e-06
NPII O 0 0.00019196924404241145
) O 0 1.236199068443966e-06
gene O 0 8.791636219029897e-07
, O 0 4.097642261058354e-07
and O 0 8.236286248575198e-07
mutations O 0 2.499124320820556e-06
that O 0 1.4069150893192273e-06
cause O 0 2.894031786127016e-05
ADNDI B-Disease 0 0.00015087940846569836
have O 0 6.259290898924519e-07
been O 0 3.1180294968180533e-07
found O 0 3.266968207071841e-08
in O 0 3.988582264469187e-08
both O 0 3.0985891186219305e-08
the O 0 2.1321535825791216e-07
signal O 0 4.9619866331340745e-06
peptide O 0 2.0274856069590896e-06
of O 0 1.5670619177399203e-05
the O 0 7.746560004306957e-05
prepro O 0 0.00241802167147398
- O 0 0.0026194890961050987
AVP O 0 0.005291609559208155
- O 0 9.195442544296384e-05
NPII O 0 0.00019833826809190214
precursor O 0 1.2210410204716027e-05
and O 0 6.119609565757855e-07
within O 0 2.6597124360705493e-06
NPII O 0 0.0003494450938887894
itself O 0 3.866349743475439e-06
. O 0 1.9589001567510422e-06

An O 0 0.00011711069237207994
affected O 0 5.785079702036455e-05
girl O 0 4.010451812064275e-05
who O 0 1.7643263845457113e-06
presented O 0 4.0486620491719805e-06
at O 0 1.741619416861795e-05
9 O 0 1.227284246851923e-05
months O 0 7.943474997773592e-07
of O 0 1.0398707672720775e-06
age O 0 8.007235919649247e-06
and O 0 2.1661421669705305e-06
her O 0 6.9712787080788985e-06
similarly O 0 3.752606426132843e-05
affected O 0 3.514882700983435e-05
younger O 0 3.355440276209265e-05
brother O 0 9.069577208720148e-05
and O 0 3.850373559544096e-06
father O 0 6.6428119680495e-06
were O 0 6.980200168982265e-07
all O 0 4.128031250161257e-08
found O 0 4.252769869594886e-08
to O 0 6.931183627045812e-09
have O 0 3.532616688062262e-08
a O 0 2.4317563429576694e-07
novel O 0 2.735379894147627e-06
missense O 0 1.7059301171684638e-05
mutation O 0 2.852213810911053e-06
( O 0 2.1068501609988743e-06
G1758 O 0 2.0634655811591074e-05
- O 0 7.675894266867545e-06
- O 0 9.759327440406196e-06
> O 0 6.16425859334413e-06
T O 0 3.0582100407627877e-06
) O 0 3.747641130757984e-08
encoding O 0 1.8855942585105367e-07
the O 0 2.3375516775558935e-06
amino O 0 1.9811061520158546e-06
acid O 0 1.0925036804110277e-06
substitution O 0 2.504683607185143e-06
Gly23 O 0 4.391420225147158e-05
- O 0 1.5177342902461533e-05
- O 0 1.0536574336583726e-05
> O 0 7.503991582780145e-06
Val O 0 2.9291837563505396e-05
within O 0 5.4996808103169315e-06
NPII O 0 0.00048223682097159326
. O 0 4.617906142811989e-06

The O 0 3.1225845305016264e-05
mutation O 0 5.299938948155614e-06
was O 0 3.790837581618689e-06
confirmed O 0 3.2139215022652934e-07
by O 0 1.5146115472930433e-08
restriction O 0 1.030701582749316e-06
endonuclease O 0 2.3904280169517733e-05
analysis O 0 1.1834679298772244e-06
. O 0 1.1470738172647543e-06

A O 0 0.0013193406630307436
T1 O 0 0.00512640830129385
- O 0 1.1802234439528547e-05
weighted O 0 6.373775704560103e-06
magnetic O 0 2.292492808919633e-06
resonance O 0 2.388856046309229e-06
imaging O 0 2.9042945243418217e-05
of O 0 9.348064850200899e-06
the O 0 7.289637869689614e-05
fathers O 0 0.0005616120179183781
pituitary O 0 0.05886407569050789
gland O 0 0.0009836287936195731
demonstrates O 0 8.163628081092611e-06
an O 0 4.287108367861947e-06
attenuated O 0 0.0015561420004814863
posterior O 0 0.025077199563384056
pituitary O 1 0.9999978542327881
bright O 0 0.4521995484828949
spot O 0 0.0003777859383262694
. O 0 2.7527380552783143e-06

This O 0 1.5336237993324175e-05
mutation O 0 1.032448562909849e-05
may O 0 3.5365010262466967e-06
be O 0 2.1038050590505009e-07
valuable O 0 2.731894710450433e-07
for O 0 5.738959885093209e-08
developing O 0 3.0655695582026965e-07
models O 0 8.679719485371606e-07
of O 0 6.746126928192098e-06
dominantly B-Disease 1 0.9420587420463562
inherited I-Disease 1 0.9999946355819702
neurodegeneration I-Disease 1 1.0
, O 0 4.6322583102664794e-07
as O 0 1.7647282746224846e-08
the O 0 6.251086315245402e-09
early O 0 1.6045829553945623e-08
age O 0 1.1859813042747192e-07
of O 0 3.108551993591391e-07
onset O 0 0.0018384308787062764
of O 0 0.00010429634130559862
symptoms O 1 0.999670147895813
suggests O 0 3.633680535131134e-06
that O 0 1.3300612522471056e-07
this O 0 2.0684765900114144e-07
mutation O 0 1.1060271845053649e-06
may O 0 8.847307526593795e-07
be O 0 1.9047740806854563e-07
particularly O 0 1.973276084754616e-07
deleterious O 0 2.982015757879708e-06
to O 0 3.3003036037371203e-07
the O 0 3.6392671063367743e-06
magnocellular O 0 0.00019849777163472027
neuron O 0 7.640256808372214e-05
. O 0 7.634235998921213e-07
. O 0 1.3833234788762638e-06

Frequent O 0 3.261736128479242e-05
inactivation O 0 0.0008963241125456989
of O 0 0.0007063372759148479
PTEN O 1 0.999977707862854
/ O 0 0.005179383791983128
MMAC1 O 0 0.006353782489895821
in O 0 6.872248195577413e-05
primary O 1 0.9999998807907104
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7936590666067787e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 0.03004070371389389
the O 0 2.0851122826570645e-05
most O 0 1.5508126125496347e-06
common O 0 8.877490472514182e-06
male B-Disease 0 8.147361950250342e-05
cancer I-Disease 0 0.0002170918887713924
in O 0 5.1699830692086834e-06
the O 0 3.977328105975175e-06
Western O 0 9.252242307411507e-06
world O 0 1.838921889429912e-06
, O 0 2.4359170680554598e-08
yet O 0 6.915574335408792e-09
many O 0 4.3642425784362615e-10
of O 0 7.076737418287848e-09
the O 0 1.9980443966005623e-08
major O 0 2.4262959641419e-07
genetic O 0 7.96357753074517e-08
events O 0 4.103311468384163e-08
involved O 0 1.1986660553020556e-08
in O 0 3.2827525586753836e-08
the O 0 1.0452981058506339e-07
progression O 0 4.953660209139343e-06
of O 0 5.538263394555543e-07
this O 0 7.714154435234377e-07
often O 0 1.4567312064173166e-05
fatal O 1 0.8184105753898621
cancer B-Disease 0 0.001962624490261078
remain O 0 4.0004060792853124e-06
to O 0 8.045517319033024e-08
be O 0 3.7359691873462e-07
elucidated O 0 3.7866564525756985e-05
. O 0 1.5701768916187575e-06

Numerous O 0 0.00012016602704534307
cytogenetic O 1 0.5988244414329529
and O 0 2.231328107882291e-05
allelotype O 0 0.0004631449410226196
studies O 0 2.2646956949756714e-06
have O 0 1.2618842504252825e-07
reported O 0 2.635938187722786e-07
frequent O 0 3.5743099147111934e-07
loss O 0 6.4885493884503376e-06
of O 0 7.008434749877779e-06
heterozygosity O 0 0.006383238360285759
on O 0 0.00017681121244095266
chromosomal O 1 0.9447388052940369
arm O 0 0.0008256483706645668
10q O 0 9.23874686122872e-05
in O 0 9.194181075145025e-06
sporadic B-Disease 1 0.9999994039535522
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.1664417191641405e-06

Deletion O 0 0.0006633558659814298
mapping O 0 0.0001412241836078465
studies O 0 1.3428731108433567e-05
have O 0 2.7073119781562127e-06
unambiguously O 0 1.3193688573664986e-05
identified O 0 1.7381712495989632e-06
a O 0 1.6538219824724365e-06
region O 0 2.9333439215406543e-06
of O 0 2.2768901544623077e-05
chromosome O 0 0.0002426683495286852
10q23 O 0 0.00013478002802003175
to O 0 1.0329490578442346e-06
be O 0 4.1581319010219886e-07
the O 0 2.5190948349518294e-07
minimal O 0 4.501264356804313e-06
area O 0 2.733653673203662e-06
of O 0 3.1515799037151737e-06
loss O 0 7.916121103335172e-05
. O 0 3.403362825338263e-06

A O 0 7.764132169540972e-05
new O 0 1.0430698239360936e-05
tumor B-Disease 0 0.0015311817405745387
suppressor O 0 0.001078684814274311
gene O 0 1.0492252840776928e-05
, O 0 5.045137640991015e-06
PTEN O 0 0.0011791852302849293
/ O 0 0.0001599016977706924
MMAC1 O 0 0.0006585716037079692
, O 0 3.945163825846976e-06
was O 0 4.775340494234115e-05
isolated O 0 1.1890340829268098e-05
recently O 0 5.839845925947884e-06
at O 0 1.1228725270484574e-05
this O 0 1.0483249468506983e-07
region O 0 1.2876176924692118e-06
of O 0 1.845783117460087e-05
chromosome O 0 0.0002520857669878751
10q23 O 0 8.715582225704566e-05
and O 0 7.794307634867437e-07
found O 0 8.106329829615788e-08
to O 0 2.1765054203370937e-09
be O 0 3.614595511791663e-09
inactivated O 0 6.377469219387422e-08
by O 0 1.0468375055694423e-09
mutation O 0 1.0154219687308341e-08
in O 0 1.2876050448085152e-07
three O 0 1.6753823729231954e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.0005556128453463316
lines O 0 1.0445917723700404e-05
. O 0 1.2125384500905056e-06

We O 0 6.604753707506461e-06
screened O 0 9.52184054767713e-05
80 O 0 0.0014486503787338734
prostate B-Disease 1 0.9999996423721313
tumors I-Disease 1 1.0
by O 0 8.520836445313762e-07
microsatellite O 0 2.4514050892321393e-05
analysis O 0 5.276309025248338e-07
and O 0 5.213953500060597e-07
found O 0 1.5601789300490054e-06
chromosome O 0 2.6021323719760403e-05
10q23 O 0 2.8225191272213124e-05
to O 0 3.918545701253606e-07
be O 0 5.436761512100929e-07
deleted O 0 4.328211673509941e-07
in O 0 2.472386313456809e-07
23 O 0 7.831772563804407e-06
cases O 0 3.469841942660423e-07
. O 0 7.867629392421804e-07

We O 0 2.56395810538379e-06
then O 0 1.1799253485378358e-07
proceeded O 0 7.528411316570782e-08
with O 0 1.2902822144056358e-09
sequence O 0 3.742712451071384e-08
analysis O 0 3.467370390808355e-08
of O 0 3.394720238247828e-07
the O 0 2.271946641485556e-06
entire O 0 6.0375048633432016e-05
PTEN O 0 0.0034627981949597597
/ O 0 0.0003055026463698596
MMAC1 O 0 0.0002598203136585653
coding O 0 3.893489338224754e-05
region O 0 8.423578947258648e-06
and O 0 2.5386518700543093e-06
tested O 0 3.551301006154972e-06
for O 0 3.3059640713872795e-07
homozygous O 0 1.3110466170473956e-06
deletion O 0 1.7582390228199074e-06
with O 0 3.4526998149431165e-08
new O 0 3.93116721397746e-07
intragenic O 0 7.650928637303878e-06
markers O 0 4.579465837650787e-07
in O 0 8.288031239089833e-08
these O 0 1.0660017757402329e-08
23 O 0 1.0763396858237684e-06
cases O 0 3.412337790109632e-08
with O 0 6.35663042203305e-08
10q23 O 0 3.896732232533395e-05
loss O 0 6.172742723720148e-05
of O 0 7.87062817835249e-05
heterozygosity O 0 0.0025619466323405504
. O 0 1.95457450899994e-05

The O 0 3.3464125408499967e-06
identification O 0 5.665248750119645e-07
of O 0 3.315620915600448e-06
the O 0 1.8197054032498272e-06
second O 0 2.3351678919425467e-06
mutational O 0 1.1670921594486572e-05
event O 0 2.9427496883727144e-06
in O 0 4.629352758911409e-07
10 O 0 5.246644150247448e-07
( O 0 1.808908933753628e-07
43 O 0 8.477194569422863e-06
% O 0 1.288396833842853e-05
) O 0 4.646752495318651e-05
tumors B-Disease 1 1.0
establishes O 0 0.28939759731292725
PTEN O 1 0.999991774559021
/ O 0 0.0026807726826518774
MMAC1 O 0 0.0004993467591702938
as O 0 7.11679319920222e-07
a O 0 2.801791652018437e-07
main O 0 9.699080010250327e-07
inactivation O 0 6.150001354399137e-06
target O 0 1.2717012509710912e-07
of O 0 1.9506158821513964e-07
10q O 0 1.4569091035809834e-05
loss O 0 4.904112756776158e-06
in O 0 4.778208676725626e-06
sporadic B-Disease 1 0.9999871253967285
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.723202899484022e-06
. O 0 6.298332664300688e-07

Risk O 0 2.2296604583971202e-05
reversals O 0 2.1022235159762204e-05
in O 0 2.8805834517697804e-07
predictive O 0 1.1716934750438668e-05
testing O 0 6.28409861747059e-06
for O 0 3.195821409462951e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.275145784049528e-06

The O 0 2.244379629701143e-06
first O 0 9.681557457952294e-07
predictive O 0 1.4021202332514804e-05
testing O 0 9.305673302151263e-06
for O 0 3.79155644623097e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.2739885733026313e-06
HD B-Disease 0 1.4581058167095762e-05
) O 0 6.145798892021048e-08
was O 0 2.5292365535278805e-07
based O 0 1.95742639874652e-08
on O 0 2.5702277639538806e-07
analysis O 0 7.45061541351788e-08
of O 0 8.957983936852543e-07
linked O 0 4.8179631448874716e-06
polymorphic O 0 2.9121376883267658e-06
DNA O 0 4.6276178977677773e-07
markers O 0 1.0681917501642602e-06
to O 0 3.240295853856878e-08
estimate O 0 1.7194471979564696e-07
the O 0 9.151382585059764e-08
likelihood O 0 3.020464021119551e-07
of O 0 2.5643516892159823e-06
inheriting O 0 1.2673704986809753e-05
the O 0 1.79112817022542e-06
mutation O 0 3.938754957744095e-07
for O 0 8.346694926331111e-07
HD B-Disease 0 0.00011985487799393013
. O 0 3.3927242384379497e-06

Limits O 0 4.634468950825976e-06
to O 0 7.080332409259427e-08
accuracy O 0 9.140860015577346e-07
included O 0 1.1145556300107273e-07
recombination O 0 5.7974013145667413e-08
between O 0 3.545328013387916e-07
the O 0 6.40313885469368e-07
DNA O 0 3.172312403876276e-07
markers O 0 1.1586179198275204e-06
and O 0 1.1592588862185949e-06
the O 0 2.6516738671489293e-06
mutation O 0 2.283827370774816e-06
, O 0 1.2186235380795551e-06
pedigree O 0 3.738025725397165e-06
structure O 0 6.380787908710772e-06
, O 0 2.7338623453943e-07
and O 0 6.631708515669743e-08
whether O 0 3.849921270671075e-08
DNA O 0 1.4077780008392438e-07
samples O 0 1.2399378590544075e-07
were O 0 2.3819465866381506e-07
available O 0 1.0229668845340711e-07
from O 0 2.0691750535206666e-07
family O 0 2.510348622308811e-07
members O 0 2.2933228649435478e-07
. O 0 9.661524700277369e-07

With O 0 2.2984340830589645e-06
direct O 0 7.117687346180901e-06
tests O 0 4.72047895527794e-06
for O 0 2.421758836135268e-06
the O 0 9.996651897381525e-06
HD B-Disease 0 0.00031905301148071885
mutation O 0 1.8057253328152e-06
, O 0 1.1936243993204698e-07
we O 0 1.3547684751813449e-08
have O 0 7.760277753732225e-09
assessed O 0 6.727578494292175e-08
the O 0 5.344087483649673e-08
accuracy O 0 4.784970997206983e-07
of O 0 1.0906309171332396e-06
results O 0 1.990184273381601e-06
obtained O 0 2.18032869270246e-06
by O 0 6.195396053954028e-07
linkage O 0 8.981398423202336e-06
approaches O 0 7.118074336176505e-06
when O 0 1.4984818790253485e-06
requested O 0 1.338184233645734e-06
to O 0 3.000181436618732e-07
do O 0 1.3912254814840708e-07
so O 0 2.5454676588765324e-08
by O 0 1.0940572892081946e-08
the O 0 9.550297619398407e-08
test O 0 9.993175353883998e-08
individuals O 0 8.311793209259122e-08
. O 0 9.257345254809479e-07

For O 0 2.711149318201933e-05
six O 0 2.845994458766654e-06
such O 0 6.874755342778371e-08
individuals O 0 2.9429211068077166e-08
, O 0 1.7571846200326036e-08
there O 0 1.0834602548470684e-08
was O 0 1.5592701174682588e-07
significant O 0 6.64053061427694e-08
disparity O 0 5.951829393779917e-07
between O 0 6.392003797373036e-07
the O 0 1.4920932471795822e-06
tests O 0 1.5770229992995155e-06
. O 0 1.3305032098287484e-06

Three O 0 6.777309317840263e-05
went O 0 4.006583185400814e-05
from O 0 2.0114791823289124e-06
a O 0 2.7753337690228363e-06
decreased O 0 9.736613719724119e-05
risk O 0 1.2605362371687079e-06
to O 0 5.935030245041162e-08
an O 0 1.5646534734514717e-07
increased O 0 2.0771399249497335e-06
risk O 0 9.855784810497425e-07
, O 0 7.748521824169075e-08
while O 0 4.673213283012956e-08
in O 0 7.21386683721903e-08
another O 0 9.929185296186915e-08
three O 0 1.5939288289246178e-07
the O 0 3.043744527531089e-07
risk O 0 1.4131774150882848e-06
was O 0 7.032141638774192e-06
decreased O 0 0.00015353561320807785
. O 0 2.2809063011663966e-06

Knowledge O 0 6.210472201928496e-05
of O 0 2.1401940102805384e-05
the O 0 7.787296453898307e-06
potential O 0 1.573713234392926e-06
reasons O 0 6.785465984648908e-07
for O 0 6.196506063815832e-08
these O 0 1.0637431380189355e-08
changes O 0 8.477459090272532e-08
in O 0 3.440505906837643e-07
results O 0 6.01010015088832e-07
and O 0 1.1501197150209919e-07
impact O 0 3.52505225009736e-07
of O 0 4.821272341359872e-07
these O 0 1.740925483773026e-07
risk O 0 1.3639672715726192e-06
reversals O 0 9.58428699959768e-06
on O 0 3.2297775760525838e-06
both O 0 5.213600502429472e-07
patients O 0 5.589807869910146e-07
and O 0 2.3166390406004211e-07
the O 0 7.535852546425303e-07
counseling O 0 8.380865210710908e-07
team O 0 1.575779720042192e-07
can O 0 2.3348368571873834e-08
assist O 0 6.870101998401879e-08
in O 0 2.3472999544082995e-07
the O 0 6.928779612280778e-07
development O 0 7.064878104756644e-07
of O 0 1.3674604133484536e-06
strategies O 0 9.252420340999379e-07
for O 0 5.504994078364689e-07
the O 0 1.0958104894598364e-06
prevention O 0 3.4830447930289665e-06
and O 0 2.843952131570404e-07
, O 0 5.87016018016584e-08
where O 0 6.953909092999311e-08
necessary O 0 1.8161290427087806e-07
, O 0 1.4815735482898162e-07
management O 0 4.98073404742172e-07
of O 0 3.858338857298804e-07
a O 0 1.6396191995227127e-06
risk O 0 2.0100715119042434e-06
reversal O 0 4.969023393641692e-06
in O 0 2.2149458800413413e-07
any O 0 3.9985916799878396e-08
predictive O 0 2.707260364331887e-06
testing O 0 4.534300330760743e-07
program O 0 4.586970590025885e-07
. O 0 8.292253284025719e-08
. O 0 3.096199634455843e-07

A O 0 6.393465446308255e-05
novel O 0 9.18511886993656e-06
common O 0 5.888904070161516e-06
missense O 0 4.66311103082262e-05
mutation O 0 6.270341600611573e-06
G301C O 0 6.311167089734226e-05
in O 0 2.2586482373299077e-05
the O 0 4.485367389861494e-05
N O 0 0.00019740380230359733
- O 0 2.8660915631917305e-05
acetylgalactosamine O 0 6.506141653517261e-05
- O 0 1.106383751903195e-05
6 O 0 4.00079479732085e-05
- O 0 6.7255205067340285e-06
sulfate O 0 2.2809455913375132e-05
sulfatase O 0 0.00017190445214509964
gene O 0 1.7152198097392102e-06
in O 0 3.671001650218386e-06
mucopolysaccharidosis B-Disease 0 0.00027572643011808395
IVA I-Disease 0 0.13251154124736786
. O 0 1.0150841262657195e-05

Mucopolysaccharidosis B-Disease 0 0.11835790425539017
IVA I-Disease 1 0.99998939037323
( O 0 0.004206022713333368
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.898479917552322e-06
is O 0 1.2759531387018797e-07
an O 0 2.728317269884428e-07
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999823570251465
by O 0 5.271941063256236e-06
a O 1 0.5157151222229004
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 0.013598603196442127
N O 0 0.000948570144828409
- O 0 3.758763341465965e-05
acetylgalactosamine O 0 0.00013735282118432224
- O 0 1.1567803085199557e-05
6 O 0 7.66773009672761e-05
- O 0 1.1631720553850755e-05
sulfate O 0 3.734317942871712e-05
sulfatase O 0 0.00042846237192861736
( O 0 6.0914499044884e-06
GALNS O 0 0.0003167441755067557
) O 0 1.7391843130099005e-06
. O 0 8.9667531710802e-07

In O 0 0.0003832528891507536
previous O 0 0.00017355837917421013
studies O 0 2.7579579182201996e-05
, O 0 2.124650336554623e-06
we O 0 2.426823755286023e-07
have O 0 1.0702355979219647e-07
found O 0 5.321019358461854e-08
two O 0 2.6889498627724606e-08
common O 0 1.5899344418812689e-07
mutations O 0 1.936170974659035e-07
in O 0 7.344658570218598e-07
Caucasians O 0 1.213704649671854e-06
and O 0 3.3328086601613904e-07
Japanese O 0 6.357409347401699e-06
, O 0 5.107769425194419e-07
respectively O 0 7.663620635867119e-06
. O 0 9.001839771372033e-07

To O 0 5.189959665585775e-06
characterize O 0 2.102163307426963e-05
the O 0 5.10818153998116e-06
mutational O 0 9.723660332383588e-05
spectrum O 0 2.1126666069903877e-06
in O 0 6.081292980297803e-08
various O 0 2.4176616264526274e-08
ethnic O 0 2.9508125720667522e-08
groups O 0 1.1651688502922752e-08
, O 0 1.13486118280548e-08
mutations O 0 4.018156118945626e-08
in O 0 2.4440996071461996e-07
the O 0 1.3455115777105675e-06
GALNS O 0 4.1424300434300676e-05
gene O 0 1.3205457207732252e-06
in O 0 8.73012777447002e-06
Colombian O 0 0.0002642741601448506
MPS B-Disease 1 0.9999325275421143
IVA I-Disease 1 1.0
patients O 0 4.9391124775866047e-05
were O 0 9.478572792431805e-06
investigated O 0 6.2172935031412635e-06
, O 0 1.9529278461050126e-07
and O 0 6.934121188351128e-08
genetic O 0 2.9977732651786937e-07
backgrounds O 0 1.459320486674187e-07
were O 0 6.240652794531343e-08
extensively O 0 5.1441841009136624e-08
analyzed O 0 4.9148908942697744e-08
to O 0 5.186584495220359e-09
identify O 0 1.1167980318305126e-08
racial O 0 5.752603726705274e-08
origin O 0 9.380917020962443e-08
, O 0 2.3982202890238113e-08
based O 0 1.921757153411363e-08
on O 0 5.775019076281751e-07
mitochondrial O 0 2.1936896246188553e-06
DNA O 0 3.5110312524011533e-07
( O 0 2.733088138029416e-07
mtDNA O 0 4.3195933585593593e-07
) O 0 4.843743681703927e-07
lineages O 0 2.2335111680149566e-06
. O 0 9.515148349237279e-07

Three O 0 3.996874875156209e-05
novel O 0 6.166107050376013e-05
missense O 0 0.00018395007646176964
mutations O 0 1.7512109479866922e-05
never O 0 1.3945299542683642e-05
identified O 0 2.024811010414851e-06
previously O 0 2.295323611178901e-06
in O 0 8.539595910406206e-07
other O 0 5.600982788678266e-08
populations O 0 3.931354441988333e-08
and O 0 5.0351118829894403e-08
found O 0 6.518901329854998e-08
in O 0 2.9941216439510754e-07
16 O 0 3.2603470572212245e-06
out O 0 8.421664432489706e-08
of O 0 3.0433895972237224e-06
19 O 0 0.000186356293852441
Colombian O 0 0.0003151086566504091
MPS B-Disease 1 0.8033218383789062
IVA I-Disease 1 0.9998077750205994
unrelated O 0 1.1481089131848421e-05
alleles O 0 9.446432045479014e-07
account O 0 1.2336323607087252e-07
for O 0 5.319528213476588e-07
84 O 0 4.1948365833377466e-05
. O 0 2.0662500901380554e-06

2 O 0 3.7419857108034194e-05
% O 0 1.346573185401212e-06
of O 0 8.266511599686055e-07
the O 0 1.0031423016698682e-06
alleles O 0 5.140535108694166e-07
in O 0 3.336860459057789e-07
this O 0 7.066300611313636e-08
study O 0 6.284088840402546e-07
. O 0 7.496564649045467e-07

The O 0 7.343900506384671e-05
G301C O 0 0.0002093785733450204
and O 0 2.2702292881149333e-06
S162F O 0 3.4573466109577566e-05
mutations O 0 6.184887979543419e-07
account O 0 1.8768750464914774e-07
for O 0 1.1311936987112858e-06
68 O 0 8.434389746980742e-05
. O 0 4.090000402356964e-06

4 O 0 0.00027423808933235705
% O 0 7.631194421264809e-06
and O 0 2.0933709947712487e-06
10 O 0 1.3750433026871178e-05
. O 0 2.9562797863036394e-06

5 O 0 5.8136600273428485e-05
% O 0 4.545034244074486e-06
of O 0 6.842555194452871e-06
mutations O 0 2.3431853151123505e-06
, O 0 2.8449983346945373e-06
respectively O 0 2.8263521016924642e-05
, O 0 7.551578846687335e-07
whereas O 0 1.2927310990562546e-06
the O 0 1.8228196267955354e-06
remaining O 0 6.863539965706877e-06
F69V O 0 7.859407924115658e-05
is O 0 2.5343723564219545e-07
limited O 0 1.2243893365848635e-07
to O 0 6.865281676482482e-08
a O 0 6.985160894146247e-07
single O 0 1.275441263715038e-06
allele O 0 4.104042545804987e-06
. O 0 1.8773865804178058e-06

The O 0 1.4531028682540637e-05
skewed O 0 1.5224847629724536e-05
prevalence O 0 2.65394937741803e-05
of O 0 7.235415523609845e-06
G301C O 0 4.256705506122671e-05
in O 0 6.079837930883514e-07
only O 0 2.828153924383514e-07
Colombian O 0 6.272662176343147e-06
patients O 0 4.5492959088733187e-07
and O 0 1.574255179548345e-07
haplotype O 0 4.041733518533874e-06
analysis O 0 1.2749239886034047e-07
by O 0 1.401585691951368e-08
restriction O 0 2.2365776430888218e-07
fragment O 0 5.72319606817473e-07
length O 0 5.000537726118637e-07
polymorphisms O 0 3.251869657105999e-06
in O 0 4.368296231405111e-06
the O 0 1.1784935850300826e-05
GALNS O 0 0.0002738205948844552
gene O 0 1.9633437204902293e-06
suggest O 0 1.9788542715559743e-07
that O 0 3.604174381166558e-08
G301C O 0 4.34076355304569e-06
originated O 0 5.683078825313714e-07
from O 0 2.0883929607862228e-07
a O 0 3.2378991932091594e-07
common O 0 9.385227599523205e-07
ancestor O 0 1.4477996046480257e-05
. O 0 1.2712432635453297e-06

Investigation O 0 1.0230765838059597e-05
of O 0 2.760662027867511e-06
the O 0 1.5042434142742422e-06
genetic O 0 1.3448124036585796e-06
background O 0 5.286422606332053e-07
by O 0 1.1148532053084637e-07
means O 0 6.774874350412574e-07
of O 0 5.9937806327070575e-06
mtDNA O 0 4.8428846639581025e-06
lineages O 0 2.3643665372219402e-06
indicate O 0 6.280776005951338e-07
that O 0 3.916564850214854e-08
all O 0 8.483007007953347e-08
our O 0 1.9462973455119936e-07
patients O 0 1.737573285254257e-07
are O 0 1.447301922752331e-08
probably O 0 5.868324137736636e-08
of O 0 3.963738208767609e-07
native O 0 1.5883674677752424e-06
American O 0 8.01632722868817e-06
descent O 0 0.00021103530889376998

Low O 0 2.278595457028132e-05
frequency O 0 1.566645437378611e-06
of O 0 1.0536094805502216e-06
BRCA1 O 0 8.844836884236429e-06
germline O 0 1.498457550042076e-06
mutations O 0 1.2850810193754114e-08
in O 0 1.798302662336937e-08
45 O 0 9.455102372157853e-07
German O 1 0.9475882053375244
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.8057086183252977e-06
. O 0 1.0948734825433348e-06

In O 0 1.308774244535016e-06
this O 0 1.048674569403829e-08
study O 0 1.08899405049101e-08
we O 0 2.229157081146127e-09
investigated O 0 3.0718261712081585e-08
45 O 0 1.0263023568768403e-06
German O 0 0.17620901763439178
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0209610223910204e-07
for O 0 1.7423171527752856e-07
germline O 0 4.37975086242659e-06
mutations O 0 6.706452637672555e-08
in O 0 3.3344360872433754e-07
the O 0 1.411744278811966e-06
BRCA1 O 0 1.3404307537712157e-05
gene O 0 5.361001058190595e-06
. O 0 9.434080538994749e-07

We O 0 9.288791261496954e-06
identified O 0 2.8815998120990116e-06
four O 0 1.322398247793899e-06
germline O 0 1.7061203834600747e-05
mutations O 0 3.487733977181051e-07
in O 0 3.74133520608666e-07
three O 0 1.8185291992267594e-06
breast B-Disease 1 0.6811138987541199
cancer I-Disease 0 5.555129610002041e-05
families O 0 9.269395029321004e-09
and O 0 2.7984023986959983e-08
in O 0 1.9437670744082425e-06
one O 0 0.0008570831851102412
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 3.1379013307741843e-06
. O 0 1.6409122949312405e-08
among O 0 4.624610916437177e-09
these O 0 3.6994947105739584e-09
were O 0 1.1377267838952321e-07
one O 0 1.2491646828038938e-07
frameshift O 0 4.098058525414672e-06
mutation O 0 3.580713610062958e-07
, O 0 1.9747182022911147e-07
one O 0 1.6676153791195247e-07
nonsense O 0 2.5694314444990596e-06
mutation O 0 2.91332753477036e-07
, O 0 6.440275512886728e-08
one O 0 3.4590474484730294e-08
novel O 0 3.2453681342303753e-07
splice O 0 2.0670206595241325e-06
site O 0 6.975481596782629e-07
mutation O 0 9.863573069424092e-08
, O 0 7.66459109513562e-08
and O 0 1.0188212229422788e-07
one O 0 3.784080035984516e-07
missense O 0 2.8601607482414693e-05
mutation O 0 1.825995605031494e-05
. O 0 5.194465757085709e-06

The O 0 0.00011652355169644579
missense O 0 0.00014068227028474212
mutation O 0 7.2173052103607915e-06
was O 0 3.253441900596954e-05
also O 0 6.600501478715159e-07
found O 0 1.3867085613128438e-07
in O 0 5.156423981134139e-07
2 O 0 1.2799173418898135e-05
. O 0 1.7440906958654523e-06

8 O 0 0.0003366127784829587
% O 0 9.15247801458463e-06
of O 0 1.1314395123918075e-05
the O 0 4.898895895166788e-06
general O 0 1.1863191502925474e-05
population O 0 4.7073334030756087e-07
, O 0 1.6886941978100367e-07
suggesting O 0 1.2415719652381085e-07
that O 0 8.492392566950002e-09
it O 0 1.0210015943812323e-08
is O 0 7.702475102178141e-08
not O 0 1.7830465992574318e-07
disease O 0 3.568468673620373e-05
associated O 0 2.6676304969441844e-06
. O 0 2.1707912765123183e-06

The O 0 3.8989301174297e-06
average O 0 4.077459834661568e-06
age O 0 2.2720118977304082e-06
of O 0 6.841021331638331e-06
disease O 1 0.8820674419403076
onset O 0 0.05719372257590294
in O 0 5.536179742193781e-06
those O 0 3.488668767204217e-07
families O 0 2.937319720786036e-07
harbouring O 0 3.880378426401876e-05
causative O 0 9.571809641784057e-06
mutations O 0 1.0802515362229315e-06
was O 0 4.598849955073092e-06
between O 0 1.885356482489442e-06
32 O 0 2.736365240707528e-05
. O 0 1.3731829540120088e-06

3 O 0 0.0002892788907047361
and O 0 1.1628525498963427e-05
37 O 0 0.0001346816134173423
. O 0 4.424207418196602e-06

4 O 0 0.0002559261629357934
years O 0 5.6374833548034076e-06
, O 0 9.12787186280184e-07
whereas O 0 1.2743907973344903e-06
the O 0 7.537490773756872e-07
family O 0 1.0454970151840826e-06
harbouring O 0 7.512338197557256e-05
the O 0 1.8750945400825003e-06
missense O 0 1.1435783562774304e-05
mutation O 0 2.9283359026521794e-07
had O 0 3.57540784534649e-07
an O 0 1.840941088460113e-08
average O 0 2.119108728493302e-07
age O 0 2.290070852950521e-07
of O 0 1.3715457498619799e-06
onset O 0 0.002124346327036619
of O 0 0.0005981391295790672
51 O 0 0.0021334895864129066
. O 0 2.8673679480561987e-05

2 O 0 0.0004928180715069175
years O 0 2.5615760023356415e-05
. O 0 7.678873771510553e-06

These O 0 3.1251283871824853e-06
findings O 0 2.2014271507941885e-06
show O 0 2.667694388946984e-06
that O 0 2.3748832234105066e-07
BRCA1 O 0 8.83325446920935e-06
is O 0 1.6034914551710244e-07
implicated O 0 2.555206890519912e-07
in O 0 1.946391492424482e-08
a O 0 1.1193357352112798e-08
small O 0 5.602625474665501e-09
fraction O 0 1.0836880193210163e-07
of O 0 1.5074335351528134e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.1723120009228296e-08
suggesting O 0 4.433819000837502e-08
the O 0 1.3624803507639172e-08
involvement O 0 1.1453550285978054e-07
of O 0 2.7542824909687624e-07
another O 0 3.6546956039273937e-07
susceptibility O 0 1.2808894098270684e-05
gene O 0 7.826389264664613e-06
( O 0 6.7528603722166736e-06
s O 0 0.00017525511793792248
) O 0 9.113266969507094e-06

Paternal O 0 0.013545209541916847
transmission O 1 0.999950647354126
of O 1 0.9999994039535522
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00019375295960344374

We O 0 1.9939611775043886e-06
report O 0 1.2627509704543627e-07
a O 0 5.293909666193031e-08
rare O 0 2.0387473398386646e-07
case O 0 1.8770361975839478e-07
of O 0 3.4285872061445843e-06
paternally O 1 0.9993007183074951
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.012440645135939121
DM B-Disease 1 1.0
) O 0 1.2790949767804705e-05
. O 0 1.5785833511472447e-06

The O 0 0.0001984171540243551
proband O 0 0.00039704973460175097
is O 0 1.5327392475228407e-06
a O 0 7.416367111545696e-07
23 O 0 8.487184459227137e-06
year O 0 6.163278953863482e-07
old O 0 1.6138596038217656e-05
, O 0 5.227194378676359e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.0007496364414691925
who O 0 4.8669167881598696e-05
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.000915253534913063

He O 0 1.2885972864751238e-05
presented O 0 1.482944207964465e-05
with O 0 6.385377673723269e-06
respiratory O 1 1.0
and O 0 1.0292909792042337e-05
feeding O 0 3.6757341149495915e-05
difficulties O 0 5.028196392231621e-05
at O 0 0.0004806787765119225
birth O 0 0.00016875505389180034
. O 0 2.171062533307122e-06

His O 0 7.634430949110538e-05
two O 0 5.580786455539055e-05
sibs O 1 0.9994831085205078
suffer O 0 0.00117356120608747
from O 0 7.947991434775759e-06
childhood O 0 0.08229096978902817
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.00016836513532325625

Their O 0 4.094656105735339e-05
late O 0 0.00013883018982596695
father O 0 1.8251668734592386e-05
had O 0 2.058382733594044e-06
the O 0 4.2532610677881166e-07
adult O 0 7.545560833932541e-07
type O 0 5.520657850865973e-06
of O 0 0.0001650102058192715
DM B-Disease 1 1.0
, O 0 9.073238288692664e-06
with O 0 5.002507919016352e-07
onset O 0 0.002715755021199584
around O 0 7.905417987785768e-06
30 O 0 1.1337575415382162e-05
years O 0 1.8769461576084723e-06
. O 0 5.949809747107793e-07

Only O 0 1.1237530088692438e-06
six O 0 3.847902689813054e-07
other O 0 1.2084913514343043e-08
cases O 0 4.9089702969240534e-08
of O 0 1.0714228437791462e-06
paternal O 0 0.006106399931013584
transmission O 1 0.9999969005584717
of O 1 0.999997615814209
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.000526020594406873
been O 0 1.4934322280168999e-05
reported O 0 4.286094736016821e-06
recently O 0 3.158840854666778e-06
. O 0 6.529603524541017e-07

We O 0 1.0169463848797022e-06
review O 0 1.2539139504497143e-07
the O 0 4.884192250642627e-08
sex O 0 2.0029098379836796e-07
related O 0 2.6208658709947485e-07
effects O 0 1.3876176581106847e-06
on O 0 3.2383361485699425e-06
transmission O 0 0.0003109788231085986
of O 0 0.0005538521218113601
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00036475935485213995

Decreased O 0 0.002308763563632965
fertility O 0 4.6829456550767645e-05
of O 0 3.457194850398082e-07
males O 0 6.526888540747677e-08
with O 0 2.6530846852779177e-08
adult O 0 1.5088976397237275e-05
onset O 1 0.9998810291290283
DM B-Disease 1 1.0
and O 0 5.222621257416904e-05
contraction O 0 0.0004124334955122322
of O 0 3.783639385801507e-06
the O 0 1.251395019608026e-06
repeat O 0 1.869703623924579e-06
upon O 0 6.285395670602156e-07
male O 0 1.3325386589713162e-06
transmission O 0 7.227818059618585e-07
contribute O 0 7.500802645665772e-09
to O 0 5.890368193206541e-09
the O 0 6.830160259596596e-08
almost O 0 2.1951807127607026e-07
absent O 0 4.7340481046376226e-07
occurrence O 0 9.79004397549943e-08
of O 0 1.6446855966023577e-07
paternal O 0 4.396142321638763e-05
transmission O 0 0.0006340203108265996
of O 0 0.0017808547709137201
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0005778749473392963

Also O 0 6.021531953592785e-05
the O 0 9.694793334347196e-06
fathers O 0 3.9582296267326456e-06
of O 0 4.32487104262691e-06
the O 0 7.548175744886976e-06
reported O 0 3.844693492283113e-05
congenitally O 0 0.000400763499783352
affected O 0 1.809017362575105e-06
children O 0 8.870854344422696e-07
showed O 0 3.5410469081398332e-06
, O 0 1.56841835519117e-07
on O 0 1.330225245510519e-06
average O 0 6.490703526651487e-06
, O 0 4.435397045199352e-07
shorter O 0 5.044892077421537e-06
CTG O 0 0.0001206689776154235
repeat O 0 1.5310430399040342e-06
lengths O 0 3.4108850286429515e-06
and O 0 1.1223549023497981e-07
hence O 0 1.467843276259373e-06
less O 0 1.244711825165723e-06
severe O 0 0.13255062699317932
clinical O 1 0.5692791938781738
symptoms O 0 0.0017627797788009048
than O 0 8.143880592115238e-08
the O 0 4.6716269963553714e-08
mothers O 0 4.989110280462228e-08
of O 0 3.6093751987209544e-08
children O 0 3.8127916468511103e-07
with O 0 3.938269856007537e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00021990659297443926

We O 0 8.574908179070917e-07
conclude O 0 8.881587518771994e-07
that O 0 4.950964438421579e-08
paternal O 0 6.81124729453586e-05
transmission O 0 0.002689467277377844
of O 1 0.7008004188537598
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.0007626604055985808
rare O 0 6.5534241002751514e-06
and O 0 3.4240414947817044e-07
preferentially O 0 2.474162386079115e-07
occurs O 0 9.265686884418756e-08
with O 0 2.6861100010933114e-08
onset O 0 0.00014899297093506902
of O 0 0.00019337977573741227
DM B-Disease 1 1.0
past O 0 2.6819980121217668e-05
30 O 0 8.926584087021183e-06
years O 0 7.920493771962356e-07
in O 0 5.158765361557016e-07
the O 0 1.0372510814704583e-06
father O 0 5.441650046122959e-06
. O 0 1.3960966782633477e-07
. O 0 4.385772172099678e-07

The O 0 7.613426714669913e-05
RB1 O 0 0.0027522079180926085
gene O 0 4.657606041291729e-06
mutation O 0 3.9316583411164174e-07
in O 0 2.654563218129624e-07
a O 0 6.957583309485926e-07
child O 0 4.25063126385794e-06
with O 0 1.6097470734166563e-06
ectopic B-Disease 1 0.9999960660934448
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 5.1698727475013584e-05

The O 0 0.00020234673866070807
RB1 O 0 0.004840105772018433
gene O 0 1.7996249880525284e-05
mutation O 0 1.9182652977178805e-06
was O 0 6.062883130653063e-06
investigated O 0 1.013056248666544e-06
in O 0 5.28442683389585e-07
a O 0 1.5787475149409147e-06
child O 0 8.18612716102507e-06
with O 0 2.331140649403096e-06
ectopic B-Disease 1 0.999796450138092
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9812623858451843
using O 0 8.391430128540378e-07
DNA O 0 2.5232736788893817e-07
obtained O 0 3.07588379655499e-07
from O 0 4.582034591749107e-07
both O 0 5.040012069912336e-07
the O 0 4.785623787029181e-06
pineal B-Disease 0 0.0015404644655063748
and I-Disease 0 2.084981133521069e-05
retinal I-Disease 1 0.9997804760932922
tumours I-Disease 1 1.0
of O 0 4.0015347622102126e-05
the O 0 1.1859233381983358e-05
patient O 0 4.870872726314701e-05
. O 0 3.6028732210979797e-06

A O 0 0.0003408284392207861
nonsense O 0 0.00013503397349268198
mutation O 0 2.6923837594949873e-06
in O 0 3.3554179026396014e-06
exon O 0 6.219908300408861e-06
17 O 0 2.5279074179707095e-05
( O 0 1.5148792726904503e-06
codon O 0 6.630634743487462e-06
556 O 0 1.2900628462375607e-05
) O 0 3.434690256653994e-07
of O 0 4.277021616871934e-06
the O 0 1.6284726370940916e-05
RB1 O 0 0.00048083774163387716
gene O 0 4.6473210204567295e-06
was O 0 2.4040422431426123e-05
found O 0 3.013130367435224e-07
to O 0 2.7582244044310755e-08
be O 0 4.678047105244332e-08
present O 0 1.0032363917389375e-07
homozygously O 0 4.911432824883377e-06
in O 0 5.634670401377662e-07
both O 0 5.119503043715667e-07
the O 0 3.539483714121161e-06
retinal B-Disease 0 0.0002766986726783216
and I-Disease 0 7.918101800896693e-06
the I-Disease 0 8.823953976389021e-05
pineal I-Disease 1 0.9998618364334106
tumours I-Disease 1 1.0
. O 0 2.2260825062403455e-05

The O 0 4.14799214922823e-05
same O 0 3.884736997861182e-06
mutation O 0 1.6801189985926612e-06
was O 0 6.174166173877893e-06
present O 0 5.608208653029578e-07
heterozygously O 0 8.4043686001678e-06
in O 0 1.135818138209288e-06
the O 0 8.269838644991978e-07
DNA O 0 2.4148553734448797e-07
from O 0 7.296152375602105e-07
the O 0 1.1179540706507396e-06
constitutional O 0 1.2590892765729222e-05
cells O 0 2.4974995085358387e-06
of O 0 4.207669917377643e-06
the O 0 7.91093862062553e-06
patient O 0 1.9364386389497668e-05
, O 0 6.285779363679467e-07
proving O 0 1.615047608538589e-06
it O 0 6.959160803177156e-09
to O 0 6.6786345342961795e-09
be O 0 4.210220083677996e-08
of O 0 7.470086984540103e-07
germline O 0 3.500532329780981e-05
origin O 0 1.9646606688183965e-06
. O 0 1.8201168359155417e-06

The O 0 2.2108331904746592e-05
initial O 0 4.6604895942437e-06
mutation O 0 1.9152309960190905e-06
was O 0 4.304482445149915e-06
shown O 0 3.0629192337983113e-07
to O 0 2.3143970295791405e-08
have O 0 2.7212276876298347e-08
occurred O 0 4.532942909918347e-07
in O 0 1.382104812819307e-07
the O 0 5.248435854809941e-07
paternally O 0 1.6257044990197755e-05
derived O 0 1.3626640793518163e-05
RB1 O 0 0.00027753436006605625
allele O 0 1.0614321581670083e-05
. O 0 2.0324123397585936e-06

The O 0 8.407192945014685e-05
mutation O 0 2.737499016802758e-06
is O 0 7.290566941264842e-07
in O 0 4.276432150618348e-07
an O 0 9.34730337576184e-08
area O 0 3.1546755963063333e-07
of O 0 1.3187486729293596e-06
the O 0 2.3007937670627143e-06
gene O 0 4.547538878796331e-07
that O 0 4.885553153144429e-07
encodes O 0 3.411822035559453e-06
the O 0 2.0229010260663927e-05
protein O 0 9.05170054465998e-06
- O 0 4.1174735088134184e-06
binding O 0 3.16508248943137e-06
region O 0 1.0351469427405391e-05
known O 0 1.7565835150890052e-05
as O 0 6.7211026362201665e-06
the O 0 1.0573939107416663e-05
pocket O 0 0.00010325846233172342
region O 0 1.2958890692971181e-05
and O 0 3.168398507114034e-06
has O 0 7.608832106598129e-07
been O 0 5.710231789635145e-07
detected O 0 4.3816791617246054e-07
in O 0 5.827311611028563e-08
other O 0 8.714352794925162e-09
cases O 0 5.2148383389294395e-08
of O 0 1.1086038966823253e-06
retinoblastoma B-Disease 0 0.00021108744840603322
. O 0 1.2395446447044378e-06
. O 0 2.0015056634292705e-06

Low O 0 0.00016795337432995439
levels O 0 1.0263914191455115e-05
of O 0 3.844520961138187e-06
beta O 0 3.6948877095710486e-05
hexosaminidase O 0 2.8462973205023445e-05
A O 0 1.6035601220210083e-06
in O 0 2.6699595423451683e-07
healthy O 0 3.0999430578049214e-07
individuals O 0 2.6390023499800463e-09
with O 0 2.730846659915187e-08
apparent O 0 4.047176844323985e-05
deficiency O 1 0.9932599663734436
of O 0 6.459195719799027e-05
this O 0 2.9184379854996223e-06
enzyme O 0 2.7656275051413104e-05
. O 0 2.8800475320167607e-06

Appreciable O 0 0.0025515651796013117
beta O 0 0.001355262123979628
hexosaminidase O 0 0.002453467808663845
A O 0 0.00039872454362921417
( O 0 1.2470389265217818e-05
hex O 0 6.855924584669992e-05
A O 0 1.0220361218671314e-05
) O 0 1.3723003178256477e-07
activity O 0 3.141867352951522e-07
has O 0 9.927953925625843e-08
been O 0 5.402936835707806e-07
detected O 0 4.614534191205166e-06
in O 0 1.8052216546493582e-05
cultured O 0 0.008605379611253738
skin O 1 0.9966204166412354
fibroblasts O 0 0.001512160524725914
and O 0 4.6552908315788954e-05
melanoma B-Disease 1 0.9999363422393799
tissue O 0 0.00030216711456887424
from O 0 1.0988568419634248e-06
healthy O 0 3.9162259213298967e-07
individuals O 0 5.122064106188873e-09
previously O 0 3.96379903122579e-07
reported O 0 9.325512451141549e-07
as O 0 1.5982227523636539e-06
having O 0 2.212857907579746e-05
deficiency B-Disease 1 0.9856239557266235
of I-Disease 0 6.607709656236693e-05
hex I-Disease 0 0.00015390277258120477
A I-Disease 0 2.7677240268531023e-06
activity O 0 5.944704639659903e-07
indistinguishable O 0 8.335973689099774e-08
from O 0 2.561216350116524e-09
that O 0 1.741175120750782e-10
of O 0 2.025077705525291e-08
patients O 0 3.312686658318853e-07
with O 0 2.3053271434037015e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.00011120712588308379
TSD B-Disease 1 0.8674577474594116
) O 0 8.496254849887919e-06
. O 0 1.973595090021263e-06

Identification O 0 3.236524207750335e-05
and O 0 1.382942900818307e-05
quantitation O 0 0.002059913706034422
of O 0 0.0009413320804014802
hex O 0 0.0009090170497074723
A O 0 4.754606561618857e-05
, O 0 4.974619400854863e-07
amounting O 0 2.0679926819866523e-06
to O 0 2.0643342679704801e-07
3 O 0 1.3102306184009649e-05
. O 0 2.2999206521490123e-06

5 O 0 0.00019912519201170653
% O 0 1.9620316379587166e-05
- O 0 2.574040445324499e-05
6 O 0 0.00010126618872163817
. O 0 5.109005087433616e-06

9 O 0 0.0001164577915915288
% O 0 2.428139396215556e-06
of O 0 5.3166695579420775e-06
total O 0 7.808034570189193e-05
beta O 0 0.00017452020256314427
hexosaminidase O 0 0.00022978743072599173
activity O 0 1.6011128536774777e-05
, O 0 2.8812650043619215e-07
has O 0 6.857337808696684e-08
been O 0 9.99256499767398e-08
obtained O 0 3.0770397074775246e-07
by O 0 5.219316108195926e-07
cellulose O 0 2.488244354026392e-05
acetate O 0 1.2502828212745953e-05
gel O 0 1.4049298442841973e-05
electrophoresis O 0 1.8327820725971833e-05
, O 0 4.4774592424801085e-06
DEAE O 0 0.00010605977877276018
- O 0 1.3761045920546167e-05
cellulose O 0 1.3613560440717265e-05
ion O 0 1.240904657606734e-05
- O 0 7.274999916262459e-06
exchange O 0 2.2919395632925443e-05
chromatography O 0 6.815950473537669e-05
, O 0 8.119372978399042e-07
radial O 0 2.0953340936102904e-05
immunodiffusion O 0 6.078231308492832e-05
, O 0 1.0518766657696688e-06
and O 0 1.1939060868826346e-06
radioimmunoassay O 0 0.00010725030733738095
. O 0 3.209304168194649e-06

Previous O 0 0.0006294078775681555
family O 0 1.0657755410647951e-05
studies O 0 5.214900738792494e-06
suggested O 0 8.478031077174819e-07
that O 0 3.656075264757419e-08
these O 0 2.416223310319765e-08
individuals O 0 3.840826323653346e-08
may O 0 7.221190116979415e-07
be O 0 3.0260341077337216e-07
compound O 0 2.8648028091993183e-06
heterozygotes O 0 1.4035567801329307e-06
for O 0 3.731258146899563e-08
the O 0 2.666974410203693e-07
common O 0 1.088202907340019e-06
mutant O 0 2.0794292140635662e-05
TSD B-Disease 0 0.00026915769558399916
gene O 0 1.1691581676132046e-06
and O 0 1.2310057684317144e-07
a O 0 3.6854325458079984e-07
rare O 0 8.327183422807138e-07
( O 0 2.8093609216739424e-07
allelic O 0 3.589354037103476e-06
) O 0 4.255516898865608e-07
mutant O 0 6.8334516072354745e-06
gene O 0 3.811740498349536e-06
. O 0 1.106328909372678e-06

Thus O 0 3.810372072621249e-05
, O 0 1.6057867924246239e-06
the O 0 9.586841542841285e-07
postulated O 0 8.149159839376807e-06
rate O 0 4.776559762831312e-06
mutant O 0 3.8795533328084275e-06
gene O 0 5.311599693413882e-07
appears O 0 1.6111373213334446e-07
to O 0 8.20533951895186e-09
code O 0 3.5960372457566336e-08
for O 0 2.8792921824560835e-08
the O 0 1.5193892011211574e-07
expression O 0 4.933148716190772e-07
of O 0 1.0241592462989502e-06
low O 0 5.988209977658698e-06
amounts O 0 4.217743594381318e-07
of O 0 1.3013715943088755e-05
hex O 0 0.00019549569697119296
A O 0 5.81797503400594e-05
. O 0 4.846086085308343e-06

Heterozygotes O 0 0.0034328321926295757
for O 0 2.8708951504086144e-05
the O 0 9.299676094087772e-06
rare O 0 2.7995934942737222e-05
mutant O 0 3.200646460754797e-05
may O 0 1.8929448515336844e-06
be O 0 1.417465540498597e-07
indistinguishable O 0 7.03434920978907e-07
from O 0 3.222170263939006e-08
heterozygotes O 0 5.740897108807985e-07
for O 0 2.474843796562709e-08
the O 0 2.696490071230073e-07
common O 0 2.571684262875351e-06
TSD B-Disease 0 0.000641652091871947
mutant O 0 5.288057218422182e-05
. O 0 2.9635823466378497e-06

However O 0 7.503962933697039e-06
, O 0 4.4507910956781416e-07
direct O 0 6.770159757252259e-07
visualization O 0 3.882229430018924e-05
and O 0 2.7899395718122832e-06
quantitation O 0 0.00032141568954102695
of O 0 8.172432717401534e-05
hex O 0 0.0001491651200922206
A O 0 3.445717766226153e-06
by O 0 6.816963349365324e-08
the O 0 2.3710043706159922e-07
methods O 0 7.403646691273025e-07
described O 0 7.676015911783907e-07
may O 0 1.1070148957514903e-06
prevent O 0 3.9814841557017644e-07
false O 0 7.53925974095182e-07
- O 0 2.1315893263817998e-06
positive O 0 3.49068898231053e-07
prenatal O 0 0.0002196545246988535
diagnosis O 0 0.00026564154541119933
of O 0 4.147604340687394e-05
TSD B-Disease 0 0.4434833824634552
in O 0 4.554130646283738e-05
fetuses O 0 3.492556425044313e-05
having O 0 6.636061016251915e-07
the O 0 1.110995867747988e-06
incomplete O 0 1.0370728887210134e-05
hex B-Disease 0 8.663320477353409e-05
A I-Disease 0 2.712413333938457e-05
deficiency I-Disease 0 0.0015117703005671501
of O 0 1.6205654901568778e-05
the O 0 6.95431981512229e-06
type O 0 3.771926640183665e-05
described O 0 3.6242772694095038e-06
in O 0 1.5683540368627291e-06
the O 0 1.996895662159659e-06
four O 0 1.933841531354119e-06
healthy O 0 8.217838512791786e-06
individuals O 0 1.0318178738089046e-06

The O 0 0.0003449981741141528
tumor B-Disease 1 0.9689126014709473
suppressor O 0 0.059845276176929474
gene O 0 0.00011753044236684218
Smad4 O 0 0.0023200667928904295
/ O 0 0.0004403889470268041
Dpc4 O 0 0.00028040155302733183
is O 0 1.0067747098219115e-06
required O 0 2.951827013930597e-07
for O 0 4.972238230038784e-07
gastrulation O 0 1.3085560567560606e-05
and O 0 2.941322634342214e-07
later O 0 1.5158650512603344e-06
for O 0 6.272533141782333e-07
anterior O 0 3.28352689393796e-05
development O 0 4.0271934267366305e-06
of O 0 1.0463863873155788e-05
the O 0 1.4072523299546447e-05
mouse O 0 4.759896546602249e-05
embryo O 0 1.742554741213098e-05
. O 0 1.4844318911855225e-06

Mutations O 0 4.2526644392637536e-05
in O 0 2.1360569007811137e-05
the O 0 3.578139512683265e-05
SMAD4 O 0 0.011347872205078602
/ O 0 0.002442173659801483
DPC4 O 0 0.003943922929465771
tumor B-Disease 0 0.003959945403039455
suppressor O 0 0.0004917035694234073
gene O 0 1.516460656603158e-06
, O 0 2.6476965331312385e-07
a O 0 1.135168417931709e-06
key O 0 9.806723937799688e-06
signal O 0 4.040131898364052e-05
transducer O 0 8.850743324728683e-05
in O 0 3.206181645509787e-05
most O 0 1.6278127077384852e-05
TGFbeta O 0 0.001063029165379703
- O 0 8.289238758152351e-05
related O 0 6.244419637368992e-06
pathways O 0 2.2091855953476625e-06
, O 0 1.0338943035037573e-08
are O 0 5.936722224930691e-10
involved O 0 9.454664828822956e-10
in O 0 1.1004907207734504e-08
50 O 0 2.8068546953363693e-07
% O 0 9.560191074342583e-07
of O 0 2.4918230337789282e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 4.756724592880346e-05

Homozygous O 0 0.00303591787815094
Smad4 O 0 0.01168210431933403
mutant O 0 0.0009531289106234908
mice O 0 0.00018741747771855444
die O 0 3.496278804959729e-05
before O 0 1.3473567150867893e-06
day O 0 2.647757128215744e-06
7 O 0 1.5178934518189635e-05
. O 0 1.1243125754845096e-06

5 O 0 0.00012889879872091115
of O 0 3.9456957892980427e-05
embryogenesis O 0 0.00035375930019654334
. O 0 1.3809159099764656e-05

Mutant O 0 0.000606842921115458
embryos O 0 2.4710225261515006e-05
have O 0 1.11771953470452e-06
reduced O 0 2.7527853490028065e-06
size O 0 2.175105464630178e-06
, O 0 9.09439279439539e-07
fail O 0 1.6075781559266034e-06
to O 0 2.5199548758791934e-07
gastrulate O 0 3.7458346923813224e-05
or O 0 1.888460587906593e-06
express O 0 2.621060843921441e-07
a O 0 4.761028549182811e-07
mesodermal O 0 1.4684993402624968e-05
marker O 0 4.39575615018839e-06
, O 0 5.7063779479449295e-08
and O 0 5.9537942576071146e-08
show O 0 2.688173481146805e-06
abnormal O 0 0.00042839953675866127
visceral O 0 0.0008916418300941586
endoderm O 0 0.0017807555850595236
development O 0 5.694134597433731e-05
. O 0 5.400883765105391e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 0.29055726528167725
the O 0 0.0015748986043035984
Smad4 O 1 0.6706891655921936
- O 0 0.006133750546723604
deficient O 0 0.000316772551741451
embryos O 0 1.4200959412846714e-06
results O 0 1.0067400353364064e-06
from O 0 1.7627844783874025e-07
reduced O 0 3.0642884212284116e-06
cell O 0 1.2835746019845828e-05
proliferation O 0 2.8517160899355076e-06
rather O 0 6.335194058237903e-08
than O 0 3.476203858099325e-08
increased O 0 1.9846954728564015e-06
apoptosis O 0 6.745193968527019e-05
. O 0 1.267850734620879e-06

Aggregation O 0 9.519379818812013e-05
of O 0 6.029276846675202e-05
mutant O 0 0.00021764732082374394
Smad4 O 0 0.003073436440899968
ES O 0 0.0055599212646484375
cells O 0 3.5896896406484302e-06
with O 0 1.0288214014053665e-07
wild O 0 2.2761801119486336e-06
- O 0 2.5797705802688142e-06
type O 0 3.970362286054296e-06
tetraploid O 0 8.469078602502123e-05
morulae O 0 0.000280043255770579
rescues O 0 6.816523091401905e-05
the O 0 3.470193041721359e-05
gastrulation B-Disease 0 0.002710726810619235
defect I-Disease 0 0.0002604947367217392
. O 0 3.1464776384382276e-06

These O 0 3.216931872884743e-05
results O 0 9.713364852359518e-05
indicate O 0 1.2017552762699779e-05
that O 0 5.822095658913895e-07
Smad4 O 0 3.0358116418938152e-05
is O 0 1.716563673426208e-07
initially O 0 1.0777247183568761e-07
required O 0 3.5921367214086786e-08
for O 0 6.981365174851817e-08
the O 0 1.7624500969759538e-07
differentiation O 0 1.34976426124922e-06
of O 0 6.872506673971657e-06
the O 0 6.1660452956857625e-06
visceral O 0 8.414363401243463e-05
endoderm O 0 9.18517034733668e-05
and O 0 8.786179250819259e-07
that O 0 1.816136006027591e-07
the O 0 3.30498505718424e-06
gastrulation B-Disease 0 0.00018884749442804605
defect I-Disease 0 2.531120480853133e-05
in O 0 5.028618488722714e-06
the O 0 1.4725676010129973e-05
epiblast O 0 0.0003959577588830143
is O 0 4.206394351058407e-06
secondary O 0 4.745021942653693e-05
and O 0 2.2113144950708374e-06
non O 0 0.00016346330812666565
- O 0 7.594870839966461e-05
cell O 0 8.952254574978724e-05
autonomous O 0 3.553655915311538e-05
. O 0 1.848160650297359e-06

Rescued O 0 0.001235704985447228
embryos O 0 0.00012409004557412118
show O 0 0.00019487649842631072
severe O 1 0.985066294670105
anterior O 1 0.9985849857330322
truncations O 1 0.9993858337402344
, O 0 1.0967505659209564e-05
indicating O 0 2.92682416329626e-05
a O 0 1.008325511975272e-06
second O 0 1.5140243476707838e-06
important O 0 2.746198788372567e-07
role O 0 2.5750662189238938e-06
for O 0 1.3070542763671256e-06
Smad4 O 0 0.00019001196778845042
in O 0 2.4083699827315286e-05
anterior O 0 0.0029097285587340593
patterning O 0 0.0007926705293357372
during O 0 0.0007719523855485022
embryogenesis O 0 0.0004421807243488729
. O 0 4.298062776797451e-06

Prevalence O 0 0.0010987939313054085
of O 0 0.00010742349695647135
p16 O 0 0.00021188434038776904
and O 0 2.303891596966423e-05
CDK4 O 0 0.004179174546152353
germline O 0 0.0003405348106753081
mutations O 0 8.88979047886096e-06
in O 0 5.4766660468885675e-05
48 O 0 0.003295376431196928
melanoma B-Disease 1 0.9999152421951294
- O 0 0.0005252498085610569
prone O 0 3.222262239432894e-05
families O 0 6.857155199213594e-08
in O 0 7.731308073744003e-07
France O 0 3.8891001167939976e-05
. O 0 6.741528522979934e-06

The O 0 2.109861270582769e-05
French O 0 0.006595708429813385
Familial B-Disease 1 0.9999992847442627
Melanoma I-Disease 1 1.0
Study O 0 8.913479541661218e-05
Group O 0 3.494620159472106e-06
. O 0 8.156625881383661e-07

Germline O 0 0.007234886754304171
mutations O 0 4.976813215762377e-05
in O 0 3.680567169794813e-05
the O 0 4.2835003114305437e-05
p16 O 0 8.223333134083077e-05
and O 0 1.8886528778239153e-05
CDK4 O 0 0.00033311263541691005
genes O 0 1.1919357802980812e-06
have O 0 2.2940491817280417e-07
been O 0 2.183232368224708e-07
reported O 0 1.5605763792336802e-07
in O 0 1.58102409386629e-07
a O 0 1.2386536809572135e-06
subset O 0 2.485889126546681e-05
of O 0 6.980782927712426e-05
melanoma B-Disease 1 0.9993540644645691
pedigrees O 0 0.0002493858337402344
, O 0 1.579723402755917e-06
but O 0 5.8561813176538635e-08
their O 0 3.9115555239277455e-08
prevalence O 0 7.012988135102205e-06
is O 0 2.0881738294065144e-07
not O 0 1.0372921366297305e-07
well O 0 4.7328927621492767e-07
known O 0 4.793644620804116e-06
. O 0 1.2088369203411276e-06

We O 0 3.718470679814345e-06
searched O 0 2.378120143475826e-06
for O 0 1.8765420861655002e-07
such O 0 3.219363406969933e-07
germline O 0 1.9546992916730233e-05
mutations O 0 8.168200906766288e-07
in O 0 7.729723620286677e-06
48 O 0 0.00038949301233515143
French O 1 0.9996974468231201
melanoma B-Disease 1 1.0
- O 0 0.03199688345193863
prone O 0 5.4313233704306185e-05
families O 0 1.9177463173036813e-07
selected O 0 1.7259235107758286e-07
according O 0 8.119684480334399e-08
to O 0 2.4636252149434767e-08
two O 0 1.0831961816393232e-07
major O 0 2.992799409184954e-06
criteria O 0 2.2200010789674707e-06
families O 0 8.607330670429292e-08
with O 0 8.80664288160915e-08
at O 0 9.535247045278084e-06
least O 0 2.0174718429188943e-07
three O 0 2.407825832051458e-07
affected O 0 5.029003204981564e-07
members O 0 1.5107704598449345e-07
( O 0 5.79384163756913e-07
n O 0 9.32950570131652e-06
= O 0 1.0121299965248909e-05
20 O 0 7.463453584932722e-06
) O 0 3.8818566849840863e-07
or O 0 3.7546965359069873e-07
families O 0 1.4020669958370036e-08
with O 0 2.1687904805389735e-08
two O 0 3.43731159091476e-07
affected O 0 1.0082754897666746e-06
members O 0 1.9967363584783016e-07
, O 0 1.505318181216353e-07
one O 0 5.784180601153821e-08
of O 0 2.1618195944483887e-07
them O 0 1.4795735303607671e-08
affected O 0 1.3108811458550917e-07
before O 0 1.6716182926757028e-07
the O 0 1.6146073278378026e-07
age O 0 5.320441118783492e-07
of O 0 1.458051883673761e-06
50 O 0 1.661322926338471e-06
( O 0 2.4138952881003206e-07
n O 0 4.6010832193132956e-06
= O 0 5.804404736409197e-06
28 O 0 1.0823038792295847e-05
) O 0 1.2708005669992417e-07
, O 0 1.8642053234430023e-08
and O 0 1.4376642099023229e-08
one O 0 1.2793070602867829e-08
additional O 0 1.0220287549600471e-07
minor O 0 3.664261748781428e-05
criterion O 0 0.0005799099453724921
. O 0 1.104865350498585e-05

Sixteen O 0 0.0002542169822845608
different O 0 8.726184205443133e-06
p16 O 0 0.00033923867158591747
germline O 0 9.770048927748576e-05
mutations O 0 9.065384460882342e-07
were O 0 5.521224579752015e-07
found O 0 6.789583295585544e-08
in O 0 1.0084661994369526e-07
21 O 0 1.8985168708240963e-06
families O 0 1.7219358383613326e-08
, O 0 6.325220880398774e-08
while O 0 1.8969609527630382e-07
one O 0 8.361976142623462e-07
germline O 0 1.846953819040209e-05
mutation O 0 1.2724659654850257e-06
, O 0 6.782360628676543e-07
Arg24His O 0 1.8345133867114782e-05
, O 0 3.5153166777490696e-07
was O 0 2.3507077457907144e-06
detected O 0 1.2471119816837017e-06
in O 0 9.554621556162601e-07
the O 0 3.9898641261970624e-06
CDK4 O 0 0.0005616492708213627
gene O 0 1.6697584214853123e-05
. O 0 4.9040659177990165e-06

The O 0 1.0838697562576272e-05
frequency O 0 1.119008993555326e-05
of O 0 1.622554009372834e-05
p16 O 0 5.7935369113693014e-05
gene O 0 1.9291665012133308e-06
mutation O 0 2.9036556270511937e-07
in O 0 7.741651870674104e-07
our O 0 1.8753310371266707e-07
sample O 0 1.272421883413699e-07
( O 0 2.7822238735097926e-07
44 O 0 2.3203501768875867e-06
% O 0 6.928145239726291e-07
) O 0 1.4565284800482914e-07
is O 0 7.763834020124705e-08
among O 0 2.8009868202616417e-08
the O 0 2.67414890231521e-07
highest O 0 6.292818397923838e-06
rates O 0 4.825099040317582e-07
yet O 0 5.2921329540822626e-08
reported O 0 3.7920744944131e-07
and O 0 1.7730592105635878e-07
the O 0 7.215056712084333e-07
CDK4 O 0 4.0051389078143984e-05
mutation O 0 2.858281504813931e-07
is O 0 6.451020340136893e-08
the O 0 8.091423353562277e-08
second O 0 4.0146707647181756e-07
mutation O 0 1.455388485283038e-07
detected O 0 7.413941602862906e-07
in O 0 9.831660463532899e-08
this O 0 4.7858790708232846e-08
gene O 0 1.029973418553709e-06
worldwide O 0 1.8797137499859673e-06
. O 0 9.442325108466321e-07

In O 0 9.546970250084996e-05
summary O 0 0.00030179633176885545
, O 0 1.2264969200259657e-06
our O 0 2.5898256694745214e-07
results O 0 2.0712757020646677e-07
show O 0 6.049674539099215e-08
frequent O 0 6.694285303865399e-08
involvement O 0 4.188150626305287e-07
of O 0 4.7437691819141037e-07
the O 0 1.5924899798847036e-06
p16 O 0 3.211329021723941e-05
gene O 0 2.865125225071097e-06
in O 0 1.9862668523273896e-06
familial B-Disease 0 0.00036907679168507457
melanoma I-Disease 0 0.4463482201099396
and O 0 4.468385554901033e-07
confirm O 0 3.1192962524073664e-07
the O 0 7.023691068752669e-07
role O 0 2.5205417841789313e-06
of O 0 1.0385742825747002e-05
the O 0 1.592996522958856e-05
CDK4 O 0 0.0013511040015146136
gene O 0 1.2748751942126546e-05
as O 0 6.781921911169775e-06
a O 0 1.4460250895353965e-05
melanoma B-Disease 0 0.01506543718278408
- O 0 7.699118577875197e-05
predisposing O 0 4.6687706344528124e-05
gene O 0 2.2787799025536515e-06
. O 0 1.966145362075622e-07
. O 0 6.534748990816297e-07

Progression O 0 0.003778730519115925
of O 0 0.0001392433186993003
somatic O 0 0.0003422379377298057
CTG O 0 0.0003355634107720107
repeat O 0 7.780242299304518e-07
length O 0 2.4648642238389584e-07
heterogeneity O 0 8.210335522562673e-07
in O 0 1.441891015474539e-07
the O 0 2.3624275513611792e-07
blood O 0 3.6283477129472885e-06
cells O 0 1.2628521290025674e-05
of O 0 9.735165076563135e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00020484002016019076
. O 0 1.909307684400119e-06

The O 0 1.1761128462239867e-06
genetic O 0 1.3511501038010465e-06
basis O 0 7.4216768553014845e-06
of O 0 0.0005989906494505703
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0004851012781728059
DM B-Disease 1 1.0
) O 0 1.987585847018636e-06
is O 0 2.159767120701872e-07
the O 0 2.712419018280343e-07
expansion O 0 2.5843680759862764e-06
of O 0 5.4738420658395626e-06
an O 0 6.77313209962449e-06
unstable O 0 6.442469748435542e-05
CTG O 0 8.113643707474694e-05
repeat O 0 1.075942464012769e-06
in O 0 5.384952714848623e-07
the O 0 7.432311690536153e-07
34 O 0 4.435698883753503e-06
UTR O 0 4.8705569497542456e-05
of O 0 1.2705906556220725e-05
the O 0 4.947923662257381e-05
DM B-Disease 1 0.9999545812606812
protein O 0 5.77129285375122e-05
kinase O 0 2.959680750791449e-05
gene O 0 1.506655394223344e-06
on O 0 6.418193152057938e-06
chromosome O 0 4.127182546653785e-05
19 O 0 8.463401900371537e-05
. O 0 3.392543248992297e-06

One O 0 7.865125553507823e-06
of O 0 5.33202955921297e-06
the O 0 1.958784196176566e-06
principal O 0 1.2282913303351961e-05
features O 0 4.778974016517168e-07
of O 0 6.754972673661541e-06
the O 0 7.440387707902119e-05
DM B-Disease 1 1.0
mutation O 0 1.5080128832778428e-05
is O 0 1.4870419136059354e-06
an O 0 3.0075034374021925e-07
extraordinarily O 0 8.269214049505536e-06
high O 0 4.550132143776864e-05
level O 0 0.00014120667765382677
of O 0 6.276069325394928e-05
somatic O 0 0.0008087495807558298
mosaicism O 0 0.002373727038502693
, O 0 6.624211437156191e-07
due O 0 1.2544082892418373e-06
to O 0 2.8209313995830598e-08
an O 0 5.98233143023208e-08
extremely O 0 2.56799836506616e-07
high O 0 1.4340840834847768e-06
degree O 0 1.1391633961466141e-05
of O 0 1.2923766917083412e-05
somatic O 0 3.7060282920720056e-05
instability O 0 1.4613311577704735e-05
both O 0 4.3892575263271283e-07
within O 0 1.9345152679761668e-07
and O 0 7.884531783020066e-08
between O 0 4.372178636913304e-07
different O 0 4.882595021626912e-07
tissues O 0 2.1469177227118053e-05
. O 0 1.3732104662267375e-06

This O 0 7.748082134639844e-05
instability O 0 0.0003927393991034478
appears O 0 1.1350904060236644e-05
to O 0 1.5733020575225964e-07
be O 0 1.683566068777509e-07
biased O 0 2.575451674147189e-07
towards O 0 1.8741491203400074e-07
further O 0 1.749666367345526e-08
expansion O 0 1.3964029221824603e-07
and O 0 2.7495469012706053e-08
continuous O 0 8.445542221124924e-07
throughout O 0 5.069011308478366e-07
the O 0 1.852005198088591e-06
life O 0 3.0295477699837647e-06
of O 0 7.284699222509516e-06
an O 0 2.6184875423496123e-06
individual O 0 4.119623895348923e-07
, O 0 2.0199901484829752e-07
features O 0 1.0765044322624817e-07
that O 0 8.054281686042941e-09
could O 0 1.1125374399512111e-08
be O 0 9.932097810860796e-09
associated O 0 1.5422971344491998e-08
with O 0 9.263668054870777e-09
the O 0 2.1717154652378667e-07
progressive O 0 5.807959951198427e-06
nature O 0 5.473051487570046e-07
of O 0 1.49964841966721e-06
the O 0 9.7028496384155e-06
disease O 0 0.0010413695126771927
. O 0 4.5400306589726824e-06

Although O 0 5.533889179787366e-06
increasing O 0 4.109714154765243e-06
measured O 0 9.378102731716353e-06
allele O 0 9.870645953924395e-07
size O 0 4.2594800220285833e-07
between O 0 1.2932094932693872e-06
patients O 0 1.3880862752557732e-06
clearly O 0 1.283369357452102e-07
correlates O 0 1.6309778061440738e-07
with O 0 2.1559092289180626e-09
an O 0 6.339168301394693e-09
increased O 0 1.4057575015158363e-07
severity O 0 3.120324663541396e-06
of O 0 6.822915111115435e-06
symptoms O 0 0.00014743499923497438
and O 0 7.33938577468507e-07
an O 0 1.2429237017386185e-07
earlier O 0 3.0455620958491636e-07
age O 0 5.633800128634903e-07
of O 0 2.117406893376028e-06
onset O 0 0.0002765591780189425
, O 0 6.22200502675696e-07
this O 0 5.994244389739833e-08
correlation O 0 1.3071103239781223e-06
is O 0 4.786280669577536e-07
not O 0 1.0051708443370444e-07
precise O 0 1.1216823168069823e-06
and O 0 1.8445070963934995e-06
measured O 0 2.6666091798688285e-05
allele O 0 5.650131242873613e-06
length O 0 6.171104814711725e-06
cannot O 0 1.970298626474687e-06
be O 0 1.6698258775704744e-07
used O 0 8.324835221173998e-08
as O 0 2.2074907235491992e-08
an O 0 5.272423386770697e-09
accurate O 0 1.0460938426604116e-07
predictor O 0 2.9405475743260467e-06
of O 0 5.6540488913015e-07
age O 0 5.5649593377893325e-06
of O 0 1.89211787073873e-05
onset O 0 0.40922555327415466
. O 0 2.5864717827062123e-05

In O 0 4.907537459075684e-06
order O 0 2.3620445688266045e-07
to O 0 3.161174078059048e-08
further O 0 7.414436709041183e-08
characterize O 0 7.002716415627219e-07
the O 0 1.7212352076967363e-06
dynamics O 0 2.2861828256282024e-05
of O 0 0.00014983696746639907
DM B-Disease 1 1.0
CTG O 1 0.9647943377494812
repeat O 0 0.0010033384896814823
somatic O 0 0.0005458834348246455
instability O 0 5.994952152832411e-05
, O 0 4.991318292013602e-07
we O 0 3.724531438820122e-08
have O 0 1.3255426978275864e-08
studied O 0 2.632037308103463e-07
repeat O 0 1.46146945212422e-07
length O 0 4.1056679833673115e-08
changes O 0 6.2679084145145225e-09
over O 0 1.2379075542412465e-08
time O 0 3.405991222393823e-08
in O 0 5.116623356116179e-07
111 O 0 0.0027764826081693172
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 6.483691095127142e-07
with O 0 6.409685671115994e-09
varying O 0 9.457853593630716e-07
clinical O 0 0.00024834112264215946
severity O 0 0.00033551466185599566
and O 0 3.529022797010839e-05
CTG O 0 0.0003100811445619911
repeat O 0 3.7689280816266546e-06
size O 0 5.074307978247816e-07
over O 0 3.4009548244284815e-07
time O 0 1.4446079887875385e-07
intervals O 0 5.497575443769165e-07
of O 0 1.4930711813576636e-06
1 O 0 6.423153081414057e-06
- O 0 1.4759044688616996e-06
7 O 0 5.449699528981e-06
years O 0 8.471323553749244e-07
. O 0 7.383868023680407e-07

We O 0 1.534810508019291e-05
have O 0 3.1652410825699917e-07
found O 0 1.4908529522017488e-07
a O 0 1.181607700573295e-07
direct O 0 8.293485507238074e-07
progression O 0 3.2629028282826766e-05
of O 0 3.6750122944795294e-06
the O 0 1.6700740843589301e-06
size O 0 4.1203938394573925e-07
heterogeneity O 0 2.3605048227182124e-06
over O 0 1.684280505287461e-06
time O 0 6.031966108821507e-07
related O 0 1.6202696997424937e-06
to O 0 3.999423654477141e-07
initial O 0 6.299014330579666e-06
CTG O 0 0.0001643876894377172
repeat O 0 4.477348284126492e-06
size O 0 1.6952288888205658e-06
and O 0 3.9403107621183153e-07
the O 0 3.207234442470508e-07
time O 0 1.620501706156574e-07
interval O 0 6.861484962428221e-07
and O 0 1.1343789907414248e-07
always O 0 5.652658430221891e-08
biased O 0 1.656113823855776e-07
towards O 0 9.913988918697214e-08
further O 0 1.0413182138790944e-07
expansion O 0 4.265652478352422e-06
. O 0 2.2386313958122628e-06

Attempts O 0 6.272586324485019e-05
to O 0 4.539303063211264e-06
mathematically O 0 2.8300497433519922e-05
model O 0 1.8662794900592417e-05
the O 0 5.4719630497857e-06
dynamics O 0 1.6272430002572946e-05
have O 0 5.743991096096579e-07
proved O 0 1.995943648580578e-06
only O 0 9.236642739551826e-08
partially O 0 1.2723749023280106e-06
successful O 0 1.3274446075683954e-07
suggesting O 0 5.993581453367369e-08
that O 0 2.7099864574609e-09
individual O 0 6.068475499887427e-09
specific O 0 5.967493166281201e-08
genetic O 0 3.485450406515156e-06
and O 0 9.963244337996002e-06
/ O 0 0.0008184450562112033
or O 0 4.448700565262698e-06
environmental O 0 1.5481202808587113e-06
factors O 0 1.8163299841944536e-07
also O 0 9.747654416969453e-08
play O 0 1.7347667835565517e-07
a O 0 2.2574560887278494e-07
role O 0 5.226787607170991e-07
in O 0 1.2278393342057825e-06
somatic O 0 1.1214759069844149e-05
mosaicism O 0 0.00010078297782456502
. O 0 3.298324315892387e-07
. O 0 4.941229008181836e-07

Aspartylglucosaminuria B-Disease 1 0.999997615814209
among O 0 2.420065902697388e-05
Palestinian O 0 0.00010116851626662537
Arabs O 0 2.4379391106776893e-05
. O 0 2.8832655516453087e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9968087077140808
AGU B-Disease 1 1.0
) O 0 3.4004590361291775e-06
is O 0 1.547599168816305e-07
a O 0 2.6897353677668434e-07
rare O 0 1.0992636816808954e-05
disorder B-Disease 1 0.9999946355819702
of I-Disease 0 0.27217093110084534
glycoprotein I-Disease 1 0.9999932050704956
metabolism I-Disease 1 0.9822672009468079
caused O 0 7.799299964972306e-06
by O 0 5.4114565273266635e-08
the O 0 8.144484127114993e-07
deficiency B-Disease 0 0.0015743528492748737
of I-Disease 0 2.538720946176909e-05
the I-Disease 0 5.898531890125014e-05
lysosomal I-Disease 0 0.01614053174853325
enzyme I-Disease 0 3.671964077511802e-05
aspartylglucosaminidase I-Disease 0 0.0001706085604382679
( O 0 6.340141680993838e-06
AGA O 0 0.0002507867175154388
) O 0 1.5702906921433168e-06
. O 0 6.641379286520532e-07

AGU B-Disease 1 1.0
is O 0 7.412343984469771e-05
inherited O 0 0.00251665897667408
as O 0 6.4574001044093166e-06
an O 0 2.5324541184090776e-06
autosomal O 1 0.9999849796295166
recessive O 1 0.9999890327453613
trait O 0 0.0015918866265565157
and O 0 2.4509854483767413e-06
occurs O 0 3.4217009670101106e-07
with O 0 3.129319026129451e-08
a O 0 4.375891364816198e-07
high O 0 6.649201168329455e-06
frequency O 0 1.440183154954866e-06
in O 0 8.264020721071574e-07
Finland O 0 1.414627035956073e-06
because O 0 1.6546235315217928e-07
of O 0 2.2987890133663313e-06
a O 0 6.2601066019851714e-06
founder O 0 5.548073022509925e-05
effect O 0 6.5590634221734945e-06
. O 0 1.8072723833029158e-06

While O 0 0.00010364240006310865
very O 0 6.610721356992144e-06
few O 0 3.939366706617875e-06
patients O 0 1.0864652722375467e-05
with O 0 3.4993793178728083e-06
AGU B-Disease 1 0.9999998807907104
have O 0 2.995692057083943e-06
been O 0 1.6697730416126433e-06
reported O 0 1.4543356883223169e-06
from O 0 6.078835212974809e-07
non O 0 5.8890614127449226e-06
- O 0 1.1389615792722907e-06
Finnish O 0 7.191856639110483e-06
origin O 0 1.0283765732310712e-06
, O 0 6.91698858190648e-07
we O 0 8.85530994310102e-07
diagnosed O 0 0.002375559415668249
the O 0 5.815064923808677e-06
disorder O 0 0.001005134778097272
in O 0 3.3295439152425388e-06
8 O 0 1.9407110812608153e-05
patients O 0 4.459913327536924e-07
originating O 0 4.219095330881828e-07
from O 0 3.424861176881677e-07
3 O 0 5.607113962469157e-06
unrelated O 0 7.955134151416132e-07
families O 0 1.0206709788462831e-07
, O 0 1.556580855321954e-07
all O 0 2.0006801548788644e-07
Palestinian O 0 4.555996383714955e-06
Arabs O 0 1.0113225243912893e-06
from O 0 2.634940585721779e-07
the O 0 1.203150219453164e-07
region O 0 2.2475488492545992e-07
of O 0 1.7724821645970223e-06
Jerusalem O 0 0.00012006363976979628
. O 0 5.394619165599579e-06

The O 0 3.648737401817925e-05
clinical O 1 0.963567852973938
diagnosis O 1 0.9999996423721313
of O 1 0.9999961853027344
AGU B-Disease 1 1.0
is O 0 7.991277379915118e-05
often O 0 1.099806695492589e-06
difficult O 0 1.570972187892039e-07
, O 0 2.118639486070606e-08
in O 0 2.825918166138308e-08
particular O 0 5.454180040942447e-08
early O 0 3.2294832408297225e-07
in O 0 2.8951308195246384e-07
the O 0 6.333031592475891e-07
course O 0 1.4042301472727559e-06
of O 0 2.5103583993768552e-06
the O 0 1.0085995199915487e-05
disease O 0 0.0002594705147203058
, O 0 3.024536852080928e-07
and O 0 8.887198532647744e-08
most O 0 6.577489841674833e-08
of O 0 4.1934384853448137e-07
the O 0 2.161064230676857e-06
patients O 0 3.0348107884492492e-06
are O 0 3.925382827674184e-07
diagnosed O 0 5.1600567530840635e-05
after O 0 8.601026593169081e-07
the O 0 1.3303200319114694e-07
age O 0 3.472487151157111e-07
of O 0 7.500547667405044e-07
5 O 0 7.362952146650059e-06
years O 0 3.2396767437603557e-06
. O 0 3.0726398563274415e-06

However O 0 4.222892312100157e-05
, O 0 2.266899855385418e-06
since O 0 1.5421112493640976e-06
these O 0 2.6991445523094626e-08
patients O 0 1.6017705206650135e-07
excrete O 0 6.027084396009741e-07
early O 0 1.2926729198170506e-07
large O 0 9.866018757520578e-08
amounts O 0 2.2162494417443668e-07
of O 0 6.6243901528650895e-06
aspartylglucosamine O 0 7.048337283777073e-05
in O 0 1.3380410564423073e-05
urine O 0 9.907683306664694e-06
, O 0 2.9634080078722036e-07
biochemical O 0 2.868663386834669e-06
screening O 0 7.708073326284648e-07
is O 0 3.408208328892215e-07
easy O 0 1.4133497927559802e-07
by O 0 7.977624960631147e-08
urine O 0 2.0781940293090884e-06
chromatography O 0 2.1792540792375803e-05
. O 0 2.2357268392170226e-07
. O 0 8.619427944722702e-07

Detection O 0 3.263484904891811e-05
of O 0 8.026501745916903e-06
heterozygous O 0 2.888447852456011e-06
carriers O 0 9.461670060773031e-07
of O 0 1.0822212971106637e-05
the O 0 0.00017830751312430948
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00027458398835733533
ATM O 0 0.00045835398486815393
) O 0 3.01783245504339e-07
gene O 0 1.1877152417127945e-07
by O 0 5.4977018493218566e-08
G2 O 0 7.564714906038716e-05
phase O 0 1.2924605471198447e-05
chromosomal O 0 0.00011383392848074436
radiosensitivity O 0 0.00017107427993323654
of O 0 0.00011479383101686835
peripheral O 1 0.9586760401725769
blood O 0 0.0007727963384240866
lymphocytes O 0 0.0002750894345808774
. O 0 3.2602506507828366e-06

In O 0 0.08564476668834686
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.140980753523763e-06
patients O 0 4.863453000325535e-07
, O 0 2.3515026370546366e-08
mutations O 0 1.4083198607295344e-08
in O 0 3.050037733487443e-08
a O 0 4.9852197037125734e-08
single O 0 3.445785168310067e-08
gene O 0 3.7988606038652506e-08
, O 0 1.2198294818688282e-08
ATM O 0 1.0270151733493549e-06
, O 0 2.662319253943224e-09
result O 0 1.5980315737351702e-08
in O 0 1.5816348764019494e-07
an O 0 1.92995103134308e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.4934704470069846e-06
embraces O 0 9.834761840465944e-07
a O 0 5.933683056014161e-08
variety O 0 4.140316178791181e-08
of O 0 7.090264375619881e-07
clinical O 0 3.167911199852824e-05
features O 0 3.353773536218796e-06
and O 0 2.5817053028731607e-06
manifests O 0 1.233390412380686e-05
extreme O 0 9.915783448377624e-05
radiosensitivity O 0 0.00040913894190452993
and O 0 4.256488864484709e-06
a O 0 6.42886425339384e-06
strong O 0 7.745234142930713e-06
pre O 0 0.00046547100646421313
- O 0 3.976310836151242e-05
disposition O 0 5.18292908964213e-05
to O 0 1.6924568626563996e-06
malignancy B-Disease 0 0.000976544339209795
. O 0 2.22027006202552e-06

Heterozygotes O 0 0.0009580753976479173
for O 0 9.41051712288754e-06
the O 0 4.880495453107869e-06
ATM O 0 3.5691497032530606e-05
gene O 0 3.4130906101381697e-07
have O 0 5.479162368260404e-08
no O 0 1.6361234145279013e-07
clinical O 0 1.2361081644485239e-05
expression O 0 3.18072852678597e-05
of O 0 0.0005917010712437332
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 2.5865970201266464e-06
may O 0 7.888088475738186e-06
be O 0 3.5454058888717555e-06
cancer B-Disease 0 3.613352237152867e-05
prone O 0 9.146074830823636e-07
with O 0 1.277583017156303e-08
a O 0 1.433143239637502e-07
moderate O 0 5.38012272954802e-07
increase O 0 1.7739098723268398e-07
in O 0 6.221565627129166e-07
in O 0 4.451942913874518e-06
vitro O 0 0.0002668923116289079
radiosensitivity O 0 0.00033282945514656603
. O 0 3.4870497529482236e-06

We O 0 5.778165359515697e-06
performed O 0 1.849508043960668e-05
a O 0 6.350997864501551e-06
blind O 0 6.638587365159765e-05
chromosomal O 0 6.191832653712481e-05
analysis O 0 3.4943634545925306e-06
on O 0 2.7437916287453845e-05
G2 O 0 0.00022236609947867692
- O 0 2.2970712052483577e-06
phase O 0 4.6953405217209365e-06
lymphocytes O 0 2.0304885310906684e-06
from O 0 5.908498224016512e-07
7 O 0 1.3904596926295199e-05
unrelated O 0 1.5082199752214365e-05
A B-Disease 1 0.999961256980896
- I-Disease 1 0.9999375343322754
T I-Disease 1 0.9999998807907104
patients O 0 3.7634902128047543e-06
, O 0 2.823920226546761e-07
13 O 0 5.6443368521286175e-06
obligate O 0 9.33899536903482e-06
A B-Disease 1 0.9999910593032837
- I-Disease 1 0.9987177848815918
T I-Disease 1 0.9999792575836182
heterozygotes O 0 1.643310497456696e-05
( O 0 2.328957720010294e-07
parents O 0 1.3917770047555678e-08
of O 0 3.2781917980173603e-07
the O 0 5.30077045368671e-07
patients O 0 1.3605578885744762e-07
) O 0 3.9579582278292946e-08
, O 0 4.1504687686710895e-08
and O 0 1.3377078289522615e-07
14 O 0 8.26765153760789e-06
normal O 0 8.492058441333938e-06
controls O 0 5.999339464324294e-06
following O 0 4.399136287247529e-06
X O 0 7.544334948761389e-05
- O 0 1.5819863392607658e-06
irradiation O 0 1.7508734799775993e-06
with O 0 1.0908946279641896e-07
1 O 0 1.2096178579668049e-05
Gy O 0 4.102445745957084e-05
in O 0 1.0608866318762011e-07
order O 0 5.906999334115426e-08
to O 0 3.087191302597603e-08
evaluate O 0 1.1319690429445473e-07
this O 0 9.596018202273626e-08
cytogenetic O 0 3.352350177010521e-05
method O 0 1.4930982388250413e-06
as O 0 4.601850491781079e-07
a O 0 3.0475288781417476e-07
tool O 0 6.042249651727616e-07
for O 0 3.8153881831703984e-08
detection O 0 8.249153893302719e-07
of O 0 6.608679541386664e-06
ATM O 0 0.0001731385273160413
carriers O 0 8.023363989195786e-06
. O 0 3.110959369223565e-06

Both O 0 0.0020147734321653843
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.00013905887317378074
and O 0 4.161607023434044e-07
heterozygotes O 0 4.823769813810941e-06
showed O 0 6.158566634439921e-07
significantly O 0 1.552139679006359e-07
increased O 0 8.187207072296587e-07
levels O 0 3.83933638659073e-06
of O 0 1.1077457202190999e-05
radiation O 1 0.7663646936416626
- O 0 0.0003932249383069575
induced O 0 0.00035591889172792435
chromatid O 0 0.0010071664582937956
damage O 0 7.130441372282803e-05
relative O 0 6.685444532195106e-06
to O 0 7.314664429713957e-08
that O 0 2.3456211195593824e-08
of O 0 8.151330348482588e-07
normal O 0 2.253493403259199e-05
controls O 0 1.7854108591564e-05
. O 0 3.223736712243408e-06

These O 0 1.489393525844207e-06
results O 0 5.5599889492441434e-06
show O 0 2.5150816327368375e-06
that O 0 4.898849965684349e-07
the O 0 8.620294465799816e-06
G2 O 0 0.0006640832871198654
- O 0 5.2010262152180076e-05
phase O 0 0.00012986059300601482
chromosomal O 0 0.000628182606305927
radiosensitivity O 0 0.0005328363622538745
assay O 0 3.865365943056531e-05
can O 0 1.09837955619696e-07
be O 0 4.202454206847506e-08
used O 0 2.773195184602173e-08
for O 0 2.3012356464846562e-08
the O 0 9.59764818730946e-08
detection O 0 2.232084625575226e-06
of O 0 2.5898581952787936e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 0.0003395475505385548
. O 0 2.514853576940368e-06

In O 0 1.2215861715958454e-05
combination O 0 1.5454677850357257e-05
with O 0 1.489241640229011e-06
molecular O 0 0.0005361278890632093
genetic O 0 1.7147067410405725e-05
analyses O 0 6.553511411766522e-06
, O 0 6.520568263113091e-07
this O 0 5.005227521337474e-08
test O 0 2.5065088493647636e-07
may O 0 7.017170133849504e-08
be O 0 4.922750651559227e-09
of O 0 7.3527504085291184e-09
value O 0 2.4019835009880808e-08
in O 0 2.5224814237390092e-08
studies O 0 7.61204148602701e-08
of O 0 3.307096392290987e-07
familial B-Disease 0 8.939858162193559e-06
and I-Disease 0 2.5336184990010224e-06
sporadic I-Disease 0 0.00020673347171396017
cancers I-Disease 0 0.01886090263724327
aimed O 0 3.394138730072882e-06
at O 0 1.2259088180144317e-06
determination O 0 3.4688124372905804e-08
of O 0 1.3397455234098743e-07
the O 0 3.309591534161882e-08
potential O 0 3.97196409096523e-08
involvement O 0 4.793699872607249e-07
of O 0 3.4613192383403657e-06
ATM O 0 0.00021041970467194915
mutations O 0 4.00306225856184e-06
in O 0 1.2729326044791378e-05
tumor B-Disease 1 0.9979920387268066
risk O 0 9.630234671931248e-06
or O 0 8.752151074986614e-07
development O 0 5.928173436586803e-07
. O 0 8.731428380315265e-08
. O 0 4.463121570097428e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 3.730213938979432e-05
identification O 0 1.0125385188075597e-06
and O 0 5.722088189941132e-07
detection O 0 2.32800048252102e-05
of O 0 0.00021861339337192476
founder O 0 0.0009936165297403932
- O 0 7.038583134999499e-06
effect O 0 6.959474490031425e-07
mutations O 0 5.2433431818599274e-08
in O 0 1.7007251074119267e-07
the O 0 4.211987345570378e-07
ATM O 0 6.20933542450075e-06
gene O 0 8.985922761439724e-08
in O 0 7.29835960555647e-08
ethnic O 0 1.011658454785902e-07
populations O 0 3.33986577061296e-07
. O 0 3.626447835358704e-07

To O 0 9.34586580569885e-07
facilitate O 0 1.2139536238464643e-06
the O 0 4.6903721795388265e-07
evaluation O 0 2.1331409243430244e-06
of O 0 3.7360371152317384e-06
ATM O 0 0.00025593905593268573
heterozygotes O 0 4.232217543176375e-05
for O 0 1.0486604651305242e-06
susceptibility O 0 3.388160985196009e-05
to O 0 8.662931350045255e-07
other O 0 2.2602034732699394e-06
diseases O 0 0.03687482327222824
, O 0 3.48771408198445e-07
such O 0 2.3237683421939437e-07
as O 0 2.29087545449147e-05
breast B-Disease 1 0.9992732405662537
cancer I-Disease 0 0.017414338886737823
, O 0 4.1486771351628704e-07
we O 0 2.9512291277455915e-08
have O 0 2.7518868961351473e-08
attempted O 0 1.7252766326691926e-07
to O 0 1.8216567809759e-08
define O 0 2.581407159141236e-07
the O 0 1.3461311709761503e-07
most O 0 5.406215564107697e-08
common O 0 6.933949237009074e-08
mutations O 0 3.262453773800189e-08
and O 0 1.7347693059832636e-08
their O 0 1.8626593600856722e-08
frequencies O 0 1.9699227777891792e-06
in O 0 1.705959402897861e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9996151924133301
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.2978464383195387e-06
homozygotes O 0 5.784759650850901e-06
from O 0 2.822834801463614e-07
10 O 0 2.2560054446785216e-07
ethnic O 0 3.474520227086941e-08
populations O 0 1.777993361429253e-07
. O 0 2.8782960725948215e-07

Both O 0 1.4731042028870434e-05
genomic O 0 4.13571615354158e-05
mutations O 0 2.9027160053374246e-06
and O 0 2.621078465381288e-07
their O 0 5.597052776806777e-08
effects O 0 2.082709670503391e-06
on O 0 2.078475517919287e-06
cDNA O 0 5.606055310636293e-06
were O 0 6.597731498914072e-07
characterized O 0 2.3172499368229182e-06
. O 0 7.362899054896843e-07

Protein O 0 0.0001919904607348144
- O 0 1.7751835912349634e-05
truncation O 0 2.505276097508613e-05
testing O 0 7.514530580010614e-07
of O 0 1.0502758414077107e-06
the O 0 3.848559799735085e-07
entire O 0 1.492190108365321e-06
ATM O 0 5.631637122860411e-06
cDNA O 0 1.3951664641354e-06
detected O 0 1.2806859785996494e-06
92 O 0 7.561223810625961e-06
( O 0 3.1713321391180216e-07
66 O 0 2.1722862584283575e-06
% O 0 2.198587480961578e-07
) O 0 5.9291693332852446e-08
truncating O 0 1.4354523045767564e-06
mutations O 0 2.02526962311822e-07
in O 0 8.282372050416598e-07
140 O 0 3.7639817946910625e-06
mutant O 0 2.6412253646412864e-06
alleles O 0 7.064480769258807e-07
screened O 0 5.879016953258542e-06
. O 0 8.398924364882987e-07

The O 0 0.00017967866733670235
haplotyping O 0 0.001475003082305193
of O 0 4.6458353608613834e-05
patients O 0 1.9049870388698764e-05
with O 0 6.736078717040073e-07
identical O 0 3.1703351851319894e-05
mutations O 0 5.954310381639516e-06
indicates O 0 3.4117113045795122e-06
that O 0 3.528091951920942e-08
almost O 0 1.3709700397157576e-07
all O 0 9.152094193609628e-09
of O 0 3.4292629180754375e-08
these O 0 7.591276052210105e-09
represent O 0 6.651749373531857e-08
common O 0 1.8383958888534835e-07
ancestry O 0 1.0824671647924333e-07
and O 0 3.257715164295405e-08
that O 0 8.405372398101463e-09
very O 0 3.6260875191374e-08
few O 0 6.229200977259097e-08
spontaneously O 0 5.86629255394655e-07
recurring O 0 1.5002926375018433e-05
ATM O 0 6.97702998877503e-05
mutations O 0 1.2098702200091793e-06
exist O 0 9.806692560232477e-07
. O 0 7.415737854898907e-07

Assays O 0 9.868994675343856e-05
requiring O 0 5.949088063061936e-06
minimal O 0 2.0621770090656355e-05
amounts O 0 1.8329162685404299e-06
of O 0 6.5861672737810295e-06
genomic O 0 5.9046446949651e-06
DNA O 0 4.0246993648906937e-07
were O 0 1.6210319131459983e-07
designed O 0 2.968572054840024e-08
to O 0 2.5487214561081828e-09
allow O 0 5.906997113669377e-09
rapid O 0 3.9371175830638094e-07
screening O 0 1.6487780385432416e-07
for O 0 1.0729642241358306e-07
common O 0 5.177129196454189e-07
ethnic O 0 2.2216670458874432e-07
mutations O 0 1.979119588213507e-06
. O 0 9.415402928425465e-07

These O 0 1.167926711787004e-06
rapid O 0 1.3895662050344981e-05
assays O 0 6.124074843683047e-06
detected O 0 3.0779133339819964e-06
mutations O 0 8.906833670607739e-08
in O 0 3.3209329330929904e-07
76 O 0 7.149342309276108e-06
% O 0 3.060714561797795e-07
of O 0 3.0927576517569833e-06
Costa O 0 4.0399314457317814e-05
Rican O 0 9.028125350596383e-05
patients O 0 3.0462756512861233e-06
( O 0 2.699783863135963e-07
3 O 0 1.054839003700181e-06
) O 0 2.294403067537587e-08
, O 0 2.354711803320697e-08
50 O 0 1.6584324669111083e-07
% O 0 5.0950468732935406e-08
of O 0 4.6439535594799963e-07
Norwegian O 0 2.9427492336253636e-05
patients O 0 1.5906351791272755e-06
( O 0 4.164862730249297e-07
1 O 0 1.95816028281115e-06
) O 0 3.021099814759509e-08
, O 0 1.1920269216147972e-08
25 O 0 1.5698684308063093e-07
% O 0 5.16421927443389e-08
of O 0 4.824022425964358e-07
Polish O 0 0.0001135971033363603
patients O 0 9.060994671017397e-06
( O 0 8.694631219441362e-07
4 O 0 4.614595582097536e-06
) O 0 5.143820658304321e-08
, O 0 2.4728903369464206e-08
and O 0 3.097678913377422e-08
14 O 0 9.58425403041474e-07
% O 0 1.7086586012737826e-07
of O 0 7.154130798880942e-07
Italian O 0 5.93953336647246e-05
patients O 0 8.30050885269884e-06
( O 0 2.1181035663175862e-06
1 O 0 1.513364986749366e-05
) O 0 3.261629899498075e-07
, O 0 5.7573238620989287e-08
as O 0 4.630924621551458e-08
well O 0 2.6672610786704354e-08
as O 0 2.6754388926519823e-08
in O 0 7.002529400779167e-08
patients O 0 9.330203454283037e-08
of O 0 7.444761536135047e-07
Amish O 0 9.968528502213303e-06
/ O 0 1.586625694471877e-05
Mennonite O 0 5.273388978821458e-06
and O 0 2.686438733690011e-07
Irish O 0 3.029946583410492e-06
English O 0 6.048883733456023e-06
backgrounds O 0 1.7158170066977618e-06
. O 0 8.599747047810524e-07

Additional O 0 1.1423607247706968e-05
mutations O 0 7.759533218631987e-06
were O 0 4.604959030984901e-06
observed O 0 2.7228272756474325e-06
in O 0 1.0898822893068427e-06
Japanese O 0 5.284146936901379e-06
, O 0 3.500957461710641e-07
Utah O 0 1.057859321917931e-06
Mormon O 0 1.8219370190308837e-07
, O 0 9.081547958089686e-09
and O 0 1.6701992677781163e-08
African O 0 5.026428198107169e-07
American O 0 2.6332777451898437e-06
patients O 0 2.9567534056695877e-06
. O 0 1.0564216381681035e-06

These O 0 7.764142537780572e-07
assays O 0 1.855413529483485e-06
should O 0 1.0845896269984223e-07
facilitate O 0 1.2794843939900602e-07
screening O 0 1.5077823718456784e-06
for O 0 1.0124523214471992e-05
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999920129776001
T I-Disease 1 0.9999959468841553
heterozygotes O 0 5.3255294005793985e-06
in O 0 1.66450746519331e-07
the O 0 9.496168473788202e-08
populations O 0 5.5819779021248905e-08
studied O 0 1.3918122476752615e-06
. O 0 1.6641408251416578e-07
. O 0 3.6325675978332583e-07

The O 0 0.0002913252974394709
von B-Disease 1 0.9999397993087769
Hippel I-Disease 1 0.9999997615814209
- I-Disease 1 0.9999992847442627
Lindau I-Disease 1 0.9999991655349731
tumor I-Disease 1 0.9999864101409912
suppressor O 0 0.0006448632921092212
gene O 0 1.382538528105215e-07
is O 0 5.990881568607165e-09
required O 0 5.926836799119428e-09
for O 0 5.1460286698556956e-08
cell O 0 4.084999090991914e-06
cycle O 0 1.5907580745988525e-06
exit O 0 7.006731266301358e-07
upon O 0 4.3055277387793467e-07
serum O 0 9.000021236715838e-06
withdrawal O 0 1.2172878086857963e-05
. O 0 4.433186859387206e-06

The O 0 6.0235083765292075e-06
inactivation O 0 0.0001211185590364039
of O 0 2.243610106233973e-05
the O 0 1.7211406884598546e-05
von B-Disease 1 0.9998557567596436
Hippel I-Disease 1 0.9999998807907104
- I-Disease 1 0.9999995231628418
Lindau I-Disease 1 0.9999992847442627
( I-Disease 0 0.0007355892448686063
VHL I-Disease 1 0.9998847246170044
) I-Disease 0 1.7696529539534822e-05
tumor I-Disease 1 0.9761661887168884
suppressor O 0 0.01500016264617443
gene O 0 1.423225171492959e-06
predisposes O 0 1.3950932498119073e-06
affected O 0 3.7175620803964193e-08
individuals O 0 1.656657366844172e-09
to O 0 4.8902957239249645e-09
the O 0 8.919045058064512e-07
human O 1 0.9998552799224854
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 9.055501948296296e-08
is O 0 1.4671524439791028e-08
associated O 0 1.5542573450488817e-08
with O 0 1.1750423745127136e-08
sporadic B-Disease 0 0.11673276126384735
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.0005759828491136432
RCC B-Disease 1 0.999909520149231
) O 0 5.157829036761541e-06
and O 0 8.42798181110993e-06
brain B-Disease 1 0.9999790191650391
hemangioblastomas I-Disease 0 0.007716357242316008
. O 0 9.042864803632256e-06

VHL O 1 0.9381745457649231
- O 0 0.0011720629408955574
negative O 0 8.767831604927778e-05
786 O 0 0.0016918819164857268
- O 0 0.0004335322882980108
0 O 0 0.000524354400113225
RCC B-Disease 0 0.00468079186975956
cells O 0 1.5462490409845486e-05
are O 0 1.0626298490024055e-06
tumorigenic O 0 6.407844921341166e-05
in O 0 1.7008456779876724e-05
nude O 0 0.0006523870979435742
mice O 0 3.6296835332905175e-06
which O 0 2.8871230739468956e-08
is O 0 6.435827870632238e-09
suppressed O 0 5.143349568470512e-08
by O 0 2.161739676154184e-09
the O 0 3.017483507505858e-08
reintroduction O 0 9.301717796006415e-07
of O 0 3.916359219147125e-06
VHL B-Disease 0 0.0010570501908659935
. O 0 4.9915697672986425e-06

Remarkably O 0 0.001323249191045761
, O 0 1.0403073247289285e-06
this O 0 3.879938859085996e-08
occurs O 0 1.8028312354090303e-07
without O 0 5.0063160728086586e-08
affecting O 0 1.8209505014965544e-07
the O 0 1.1406427091742444e-07
growth O 0 4.878443746747507e-07
rate O 0 5.046654223406222e-07
and O 0 2.4946641019596427e-07
cell O 0 5.805904947919771e-06
cycle O 0 7.393380769826763e-07
profile O 0 7.795231482532472e-08
of O 0 3.6389616298038163e-07
these O 0 6.28977900873906e-08
cells O 0 9.128872875407978e-07
in O 0 6.615568395318405e-07
culture O 0 1.6284520825138316e-06
. O 0 8.113722174130089e-07

The O 0 0.00025355108664371073
786 O 0 0.0013914400478824973
- O 0 0.00010067366383736953
0 O 0 0.00010282866423949599
cell O 0 2.747174585238099e-05
line O 0 1.0274775377183687e-05
, O 0 1.7937179563887184e-07
like O 0 1.1811761169155943e-07
many O 0 9.147193935632458e-08
cancer B-Disease 0 1.5438075934071094e-05
cells O 0 1.0069455811390071e-06
, O 0 3.8115260281301744e-08
fails O 0 5.4212605959946814e-08
to O 0 1.4585086027807392e-08
exit O 0 7.360638392128749e-07
the O 0 2.451179170748219e-07
cell O 0 1.8797065877151908e-06
cycle O 0 4.0461043226969196e-07
upon O 0 1.5106249406926509e-07
serum O 0 5.652632353303488e-06
withdrawal O 0 7.922285476524848e-06
. O 0 3.6013891531183617e-06

Here O 0 0.00039503141306340694
, O 0 1.5853497643547598e-06
it O 0 2.463456105772366e-08
is O 0 1.3421964872861736e-08
shown O 0 1.897029200392808e-08
that O 0 4.863747626870918e-09
reintroduction O 0 3.807199391303584e-07
of O 0 3.532071559675387e-07
the O 0 8.457382705273631e-07
wild O 0 4.46090598416049e-06
- O 0 7.44640601624269e-06
type O 0 5.309403150022263e-06
VHL B-Disease 0 0.0002580167492851615
gene O 0 7.669898423046106e-07
restores O 0 4.930439899908379e-06
the O 0 1.2875942729806411e-06
ability O 0 1.5344679695772356e-06
of O 0 6.291121826507151e-05
VHL O 1 0.9965749382972717
- O 0 0.004905698820948601
negative O 0 9.320901881437749e-05
RCC B-Disease 0 0.3076958656311035
cancer I-Disease 0 1.2750540008710232e-05
cells O 0 1.0411712736413392e-07
to O 0 1.6042891459733255e-08
exit O 0 4.975587444278062e-07
the O 0 3.6607826814361033e-07
cell O 0 4.851746325584827e-06
cycle O 0 1.0592483477012138e-06
and O 0 3.3550998068676563e-07
enter O 0 5.592929483100306e-06
G0 O 0 0.0005253044073469937
/ O 0 3.749386814888567e-05
quiescence O 0 3.712894977070391e-05
in O 0 4.414412615005858e-06
low O 0 4.519795038504526e-05
serum O 0 4.06923281843774e-05
. O 0 3.1769975521456217e-06

Both O 0 0.000738349393941462
VHL O 1 0.8924116492271423
- O 0 0.00030762574169784784
positive O 0 9.695393600850366e-06
and O 0 1.0710237802413758e-05
VHL O 0 0.006851619109511375
- O 0 2.586614755273331e-05
negative O 0 3.7669478842872195e-06
RCC B-Disease 0 0.00021518542780540884
cells O 0 6.523080742226739e-07
exit O 0 7.952653504617047e-07
the O 0 3.2945612815638015e-07
cell O 0 4.134136815991951e-06
cycle O 0 7.666929491279006e-07
by O 0 3.0812266516022646e-08
contact O 0 1.1671772881527431e-06
inhibition O 0 3.084996933466755e-05
. O 0 3.970218585891416e-06

The O 0 0.0003831898211501539
cyclin O 0 0.00039930519415065646
- O 0 6.265484262257814e-05
dependent O 0 9.165501069219317e-06
kinase O 0 2.049324211839121e-05
inhibitor O 0 2.035926081589423e-05
, O 0 4.515821672157472e-07
p27 O 0 7.548996563855326e-06
, O 0 2.1339009492749028e-07
accumulates O 0 4.897747771792638e-07
upon O 0 3.69540657629841e-07
serum O 0 2.5743295282154577e-06
withdrawal O 0 2.3167128802015213e-06
, O 0 2.710394255700521e-07
only O 0 1.0445307907502865e-07
in O 0 4.7393604063472594e-07
the O 0 1.032613226925605e-06
presence O 0 2.2062083644414088e-06
of O 0 5.2833394875051454e-05
VHL B-Disease 0 0.0022409993689507246
, O 0 1.056991095538251e-06
as O 0 1.8640280075032933e-07
a O 0 6.897714399656252e-08
result O 0 7.866431417369313e-08
of O 0 3.61088382305752e-07
the O 0 2.603867699235707e-07
stabilization O 0 4.403102593641961e-06
of O 0 3.7201482427917654e-06
the O 0 7.677812391193584e-06
protein O 0 2.7100582883576863e-05
. O 0 3.742816488738754e-06

We O 0 5.63918274565367e-06
propose O 0 5.271571694720478e-07
that O 0 4.340057557783439e-08
the O 0 4.6715115331608104e-07
loss O 0 2.7094765755464323e-06
of O 0 7.676436325709801e-06
wild O 0 2.0600460629793815e-05
- O 0 6.602771463803947e-05
type O 0 4.022797293146141e-05
VHL B-Disease 0 0.0009444610914215446
gene O 0 9.097073530028865e-07
results O 0 4.11034250191733e-07
in O 0 2.3661884540615574e-07
a O 0 9.63710249379801e-07
specific O 0 2.2605158846999984e-06
cellular O 0 0.0029644323512911797
defect O 0 0.00011306907254038379
in O 0 3.664604082587175e-05
serum O 0 0.00041157371015287936
- O 0 6.218982161954045e-05
dependent O 0 9.47412718232954e-06
growth O 0 5.246281943982467e-06
control O 0 1.943070174093009e-06
, O 0 8.526480854698093e-08
which O 0 6.872238600408309e-08
may O 0 1.1722585213647108e-06
initiate O 0 2.7854014206241118e-06
tumor B-Disease 0 0.0002222823677584529
formation O 0 1.1015787094947882e-05
. O 0 2.071925109703443e-06

This O 0 1.1643473044387065e-05
is O 0 3.1920853871270083e-06
corrected O 0 4.192441338091157e-06
by O 0 5.759828169971115e-08
the O 0 3.0827644081909966e-07
reintroduction O 0 1.4194474715623073e-06
of O 0 2.7792905257228995e-06
wild O 0 1.5759640518808737e-05
- O 0 8.569831697968766e-05
type O 0 0.00026451313169673085
VHL B-Disease 0 0.2963371276855469
, O 0 1.536463969387114e-05
implicating O 0 0.0003482889733277261
VHL B-Disease 0 0.00716337189078331
as O 0 6.412514721887419e-06
the O 0 1.8665591596800368e-06
first O 0 7.616885795869166e-06
tumor B-Disease 0 0.00019460298062767833
suppressor O 0 7.924549572635442e-05
involved O 0 3.8911301203370385e-07
in O 0 9.091288006857212e-07
the O 0 1.0980282922901097e-06
regulation O 0 2.6314703518437454e-06
of O 0 1.675484782026615e-05
cell O 0 0.00011103472934337333
cycle O 0 7.366147656284738e-06
exit O 0 4.1184825931850355e-06
, O 0 7.511314237262923e-08
which O 0 2.3519826086726425e-08
is O 0 2.5285219251713897e-08
consistent O 0 4.437042377958278e-08
with O 0 4.386786045529334e-09
its O 0 6.528270546368731e-08
gatekeeper O 0 1.1660718882922083e-05
function O 0 3.2270158953906503e-06
in O 0 8.870549095263414e-07
the O 0 2.6495251859159907e-06
kidney O 0 0.0005755992024205625
. O 0 2.4661787279001146e-07
. O 0 6.700909125356702e-07

Piebaldism B-Disease 1 1.0
with O 0 0.0012224020902067423
deafness B-Disease 1 1.0
: O 0 7.475734946638113e-06
molecular O 0 2.6605396215018118e-06
evidence O 0 9.093632513668126e-08
for O 0 1.384178318630802e-07
an O 0 6.364564342220547e-07
expanded O 0 0.0009041739976964891
syndrome O 1 1.0
. O 0 1.908327431010548e-05

In O 0 1.2746065294777509e-05
a O 0 1.6251474335149396e-06
South O 0 1.1051140518247848e-06
African O 0 3.163490589486173e-07
girl O 0 2.5713308104968746e-07
of O 0 1.2151357964285125e-07
Xhosa O 0 1.711320146569051e-05
stock O 0 9.020866968967312e-07
with O 0 1.240429448046143e-08
severe O 0 0.00895001832395792
piebaldism B-Disease 1 0.9578801989555359
and O 0 3.8171045162016526e-05
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 2.161891279683914e-05
identified O 0 4.985515147382102e-07
a O 0 1.164135312592407e-07
novel O 0 2.4115806240843085e-07
missense O 0 2.441628339511226e-06
substitution O 0 2.4797186597425025e-06
at O 0 7.91470392869087e-06
a O 0 2.854560250398208e-07
highly O 0 7.1762576681067e-07
conserved O 0 1.805561623768881e-06
residue O 0 2.814503886838793e-06
in O 0 1.254953986062901e-06
the O 0 1.0759312090158346e-06
intracellular O 0 6.277270131249679e-06
kinase O 0 2.2069654733058996e-05
domain O 0 1.354163123323815e-05
of O 0 4.734070898848586e-05
the O 0 6.733350164722651e-05
KIT O 0 0.00017116776143666357
proto O 0 0.0011109387269243598
- O 0 9.162522474071011e-05
oncogene O 0 0.0002739600313361734
, O 0 1.1083078561568982e-06
R796G O 0 2.0940215108566917e-05
. O 0 7.862544180170516e-07

Though O 0 0.00025469445972703397
auditory B-Disease 1 0.961385190486908
anomalies I-Disease 0 0.013124308548867702
have O 0 2.444850451865932e-06
been O 0 2.132292820533621e-06
observed O 0 2.176294401579071e-06
in O 0 2.4211053641920444e-06
mice O 0 5.398298981162952e-06
with O 0 3.9732148593429883e-07
dominant O 0 1.811205584090203e-05
white O 0 1.135190018430876e-06
spotting O 0 7.932785592856817e-06
( O 0 4.864093170908745e-06
W O 0 0.0006684321560896933
) O 0 4.776099444825377e-07
due O 0 7.654673026991077e-06
to O 0 2.2691967842547456e-06
KIT O 0 0.00045775662874802947
mutations O 0 0.00022015122522134334
, O 0 7.37122172722593e-05
deafness B-Disease 1 1.0
is O 0 2.82661926576111e-06
not O 0 9.089314545462912e-08
typical O 0 7.374051733677334e-07
in O 0 6.686966571578523e-07
human O 0 8.580989742767997e-06
piebaldism B-Disease 0 8.595613326178864e-05
. O 0 2.4893884074117523e-06

Thus O 0 1.8993263211086742e-06
, O 0 1.178225161879709e-07
the O 0 1.1551475864735039e-07
occurrence O 0 1.7938473320100456e-05
of O 0 0.0009738619555719197
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 1 0.7974902987480164
this O 0 4.734265075967414e-06
patient O 0 9.479585060034879e-06
extends O 0 1.9919502847187687e-06
considerably O 0 6.358224595715001e-07
the O 0 2.3797758785804035e-07
phenotypic O 0 6.277300144574838e-06
range O 0 3.77592550648842e-06
of O 0 4.512090526986867e-06
piebaldism B-Disease 0 4.461801654542796e-05
due O 0 6.114550615166081e-06
to O 0 4.878308459410619e-07
KIT O 0 8.93957621883601e-06
gene O 0 9.011236556943913e-07
mutation O 0 1.8993050332483108e-07
in O 0 3.4825225725398923e-07
humans O 0 2.6461944457878417e-07
and O 0 6.711225353228656e-08
tightens O 0 5.530599764824728e-07
the O 0 5.7986952128885605e-08
clinical O 0 5.968654477328528e-07
similarity O 0 9.043563977684244e-07
between O 0 2.139554680979927e-06
piebaldism B-Disease 0 1.8708808056544513e-05
and O 0 4.790829422063325e-08
the O 0 2.703091084299558e-08
various O 0 2.488755868057524e-08
forms O 0 1.4546408237947617e-06
of O 0 0.0002465062716510147
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.895484951499384e-06
. O 0 2.22179096454056e-06

Cycloheximide O 0 0.004088148940354586
facilitates O 0 4.314114630687982e-05
the O 0 2.1820283109263983e-06
identification O 0 7.007953968241054e-07
of O 0 4.729016836790834e-06
aberrant O 0 4.337368591222912e-05
transcripts O 0 1.972833342733793e-05
resulting O 0 6.3003599279909395e-06
from O 0 2.019463636315777e-06
a O 0 2.2264953258854803e-06
novel O 0 3.0775199775234796e-06
splice O 0 1.965481169463601e-05
- O 0 1.5925111256365199e-06
site O 0 1.1549558109891223e-07
mutation O 0 2.156284395482544e-08
in O 0 3.5527598640783253e-08
COL17A1 O 0 1.6265015801764093e-05
in O 0 1.5643043127511191e-07
a O 0 5.956060249445727e-07
patient O 0 5.644498287438182e-06
with O 0 8.874475838638318e-07
generalized O 1 0.999919056892395
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999953508377075
. O 0 3.787581226788461e-05

Patients O 0 0.00035488788853399456
with O 0 3.349985718159587e-06
generalized O 1 0.9999831914901733
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9998860359191895
often O 0 1.9742483345908113e-06
show O 0 6.999351853664848e-07
decreased O 0 4.737760900752619e-05
expression O 0 4.503969648794737e-06
of O 0 5.828406301588984e-06
type O 0 0.00010600226232782006
XVII O 0 0.019145622849464417
collagen O 0 9.841571591095999e-05
, O 0 1.4247461876948364e-06
a O 0 1.5238252899507643e-06
transmembrane O 0 9.649706044001505e-06
hemidesmosomal O 0 4.0329414332518354e-05
protein O 0 3.825462499662535e-06
encoded O 0 8.975557079793361e-07
by O 0 4.774910848936997e-07
COL17A1 O 0 0.00022912517306394875
. O 0 2.7894020604435354e-06

This O 0 1.154133406089386e-05
report O 0 3.602028073146357e-06
documents O 0 1.0404779686723487e-06
a O 0 2.4372152438445482e-06
novel O 0 5.24382630828768e-06
splice O 0 2.38177217397606e-05
- O 0 3.887149432557635e-06
site O 0 2.266942118467341e-07
mutation O 0 4.806553732805696e-08
in O 0 1.8010457836226124e-07
COL17A1 O 0 4.33111927122809e-05
in O 0 2.6477067649466335e-07
a O 0 1.0587373253656551e-06
patient O 0 1.1830382391053718e-05
with O 0 1.6529515960428398e-06
generalized O 1 0.9999980926513672
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999974966049194
, O 0 3.219214249838842e-06
and O 0 1.240969424998184e-07
applies O 0 2.737548925324518e-07
a O 0 1.7907558458318817e-07
new O 0 8.274574270217272e-08
methodology O 0 3.1959800139702566e-07
to O 0 1.7177631761455814e-08
define O 0 1.9936614137350261e-07
and O 0 9.003971257470766e-08
characterize O 0 2.970612058561528e-07
the O 0 1.6124116086757567e-07
resulting O 0 2.3910160962259397e-07
mRNA O 0 1.3295505141286412e-06
splice O 0 5.761262400483247e-06
variants O 0 5.162691195437219e-06
. O 0 2.5341139462398132e-06

Mutational O 0 0.0067528910003602505
analysis O 0 5.9126225096406415e-05
of O 0 0.00025070010451599956
COL17A1 O 0 0.027485467493534088
identified O 0 0.0001311050436925143
a O 0 7.841508340789005e-05
maternally O 0 0.0001450593554181978
inherited O 0 0.0011861782986670732
G O 0 0.0009473946411162615
- O 0 4.158777301199734e-05
to O 0 1.0798212315421551e-05
- O 0 8.798696217127144e-05
T O 0 0.000137364084366709
transversion O 0 4.907051697955467e-05
at O 0 2.776859219011385e-05
the O 0 8.899477847990056e-07
- O 0 4.311008581225906e-07
1 O 0 1.4205918432708131e-06
position O 0 7.617959454364609e-07
of O 0 2.0430034055607393e-06
exon O 0 7.178980013122782e-06
32 O 0 2.87858765659621e-05
. O 0 2.6105240067408886e-06

This O 0 1.780194725142792e-05
acceptor O 0 8.788636478129774e-06
splice O 0 6.823339208494872e-05
- O 0 1.0297003427695017e-05
site O 0 1.2144237189204432e-06
mutation O 0 1.851802409191805e-07
led O 0 4.949869207848678e-07
to O 0 3.142070426065402e-08
the O 0 3.3621660122662433e-07
formation O 0 1.6754404441599036e-06
of O 0 7.621383701916784e-06
aberrant O 0 2.259223401779309e-05
transcripts O 0 9.913637768477201e-06
present O 0 2.4178243620553985e-06
at O 0 6.0698443121509627e-05
extremely O 0 5.4330002967617474e-06
low O 0 3.344781725900248e-05
levels O 0 1.7355989257339388e-05
. O 0 9.106803986469458e-07

Based O 0 1.4106061826169025e-05
on O 0 7.54116035750485e-06
our O 0 5.273064971333952e-07
recent O 0 2.439711863644334e-07
finding O 0 1.3756600480974157e-07
that O 0 1.378191711864929e-07
cycloheximide O 0 0.00016889977268874645
stabilized O 0 0.000370420137187466
mutant O 0 5.210036033531651e-05
COL17A1 O 0 0.00020937218505423516
transcripts O 0 1.4042332622921094e-05
in O 0 1.1809412399088615e-06
keratinocytes O 0 6.003449016134255e-06
homozygous O 0 1.5603337715219823e-06
for O 0 3.9337399471151e-07
a O 0 2.6050524866150226e-06
frameshift O 0 2.4944454708020203e-05
mutation O 0 1.186460281132895e-06
, O 0 5.383556072047213e-07
the O 0 1.474175633120467e-06
effects O 0 4.447777973837219e-05
of O 0 8.569015335524455e-05
the O 0 4.424903090693988e-05
splice O 0 3.8129677705001086e-05
- O 0 6.4431533246533945e-06
site O 0 7.356568403338315e-07
mutation O 0 6.015031317474495e-08
on O 0 8.904911510398961e-07
splicing O 0 5.680044523614924e-07
of O 0 4.203262051305501e-06
COL17A1 O 0 6.215010216692463e-05
transcripts O 0 3.7977779356879182e-06
were O 0 3.4819711913769424e-07
determined O 0 1.026956937266732e-07
using O 0 3.5604458048510423e-08
reverse O 0 1.0028056749433745e-06
transcriptase O 0 5.498380232893396e-06
polymerase O 0 1.0441435733810067e-05
chain O 0 1.9437577520875493e-06
reaction O 0 2.812736283885897e-07
of O 0 1.0177728881899384e-06
total O 0 4.76881268696161e-06
RNA O 0 2.722801355048432e-06
from O 0 1.3463574077832163e-06
keratinocytes O 0 2.316452082595788e-06
incubated O 0 3.2942170946625993e-06
for O 0 3.02317005207442e-07
2 O 0 8.782737495494075e-06
. O 0 7.170230560404889e-07

5 O 0 0.0004411303380038589
h O 0 0.0002898105594795197
in O 0 6.796671641495777e-06
the O 0 2.535815838200506e-06
presence O 0 2.82444170807139e-06
or O 0 5.20793764735572e-06
absence O 0 1.111468554881867e-05
of O 0 1.103424892789917e-05
10 O 0 2.091708483931143e-05
microg O 0 0.00017393544840160757
cycloheximide O 0 0.00012187567335786298
per O 0 6.153190770419315e-05
ml O 0 9.718451474327594e-05
. O 0 3.4005174711637665e-06

Using O 0 2.255972685816232e-05
this O 0 1.8845366867026314e-06
approach O 0 1.3024257896177005e-05
, O 0 1.6885634295249474e-06
an O 0 1.155585437118134e-06
abnormally O 0 0.00013874760770704597
spliced O 0 3.1198163924273103e-05
transcript O 0 5.6543427490396425e-05
was O 0 3.8035286706872284e-05
identified O 0 3.2766413937679317e-07
that O 0 3.190333686120539e-08
contains O 0 8.24519190700812e-08
an O 0 6.425330667525486e-08
extra O 0 3.2156688689610746e-07
264 O 0 5.959422651358182e-06
bases O 0 3.717615982168354e-06
upstream O 0 1.5927442291285843e-05
from O 0 1.936776243383065e-06
exon O 0 2.0817210497625638e-06
32 O 0 5.186866928852396e-06
, O 0 1.2691981510215555e-07
resulting O 0 2.967316561353073e-07
in O 0 9.64264472713694e-07
a O 0 4.960490969097009e-06
premature O 0 1.4797937183175236e-05
termination O 0 1.5726956917205825e-05
codon O 0 4.48963837698102e-05
27 O 0 0.00017257682338822633
bp O 0 2.8839896913268603e-05
downstream O 0 1.7673964975983836e-05
from O 0 2.796220542222727e-06
the O 0 3.6739190818479983e-06
cryptic O 0 2.1036030375398695e-05
splice O 0 2.9277201974764466e-05
site O 0 8.923426321416628e-06
. O 0 1.9387480278965086e-06

Three O 0 7.569499575765803e-05
other O 0 2.2162505501910346e-06
splice O 0 1.4248495062929578e-05
variants O 0 3.3857716061902465e-06
, O 0 5.516314445230819e-07
including O 0 4.3175012365281873e-07
one O 0 2.9387038580352964e-07
derived O 0 6.524642230942845e-07
from O 0 5.813623147332692e-07
the O 0 9.209706490764802e-07
skipping O 0 1.3363592188397888e-06
of O 0 5.876898285350762e-06
exon O 0 4.355338660388952e-06
32 O 0 1.7699989257380366e-05
, O 0 3.371120271822292e-07
were O 0 6.285329732236278e-07
also O 0 3.917746198567329e-07
identified O 0 7.486326580874447e-07
. O 0 5.202866759645985e-07

These O 0 2.3350164610747015e-06
results O 0 5.703108399757184e-06
indicate O 0 1.1036312344003818e-06
the O 0 2.440961850425083e-07
usefulness O 0 8.079623512458056e-07
of O 0 1.0374311614214093e-06
cycloheximide O 0 1.5275154510163702e-05
treatment O 0 1.1803929282905301e-06
in O 0 3.4688065397858736e-07
evaluating O 0 4.6058809743954043e-07
the O 0 3.782513886108063e-06
abnormal O 0 4.8659050662536174e-05
processing O 0 2.689892062335275e-05
of O 0 2.6733365302789025e-05
mRNA O 0 2.3275853891391307e-05
due O 0 4.6995301090646535e-05
to O 0 4.1261446313001215e-06
splice O 0 2.545996721892152e-05
- O 0 1.1793570592999458e-05
site O 0 1.9073221437793109e-06
mutations O 0 4.52013892981995e-07
, O 0 3.0706812026437547e-07
because O 0 1.735203625230497e-07
( O 0 6.585266305592086e-07
i O 0 1.3506307823263342e-06
) O 0 2.5446382778682164e-07
aberrant O 0 2.2645638182439143e-06
splicing O 0 8.058876801442239e-07
often O 0 1.412185781646258e-07
generates O 0 6.566377237504639e-07
a O 0 1.9006927232112503e-06
premature O 0 9.048559149960056e-06
termination O 0 1.1429536243667826e-05
codon O 0 1.4484968232864048e-05
, O 0 8.603405490248406e-07
( O 0 2.1426224350307166e-07
ii O 0 8.595232429797761e-06
) O 0 1.5361092664534226e-07
transcripts O 0 8.510945690431981e-07
with O 0 1.2457849152269773e-07
premature O 0 1.204628551931819e-05
termination O 0 8.545888704247773e-06
codons O 0 4.012805675301934e-06
can O 0 1.9812978280242532e-07
occur O 0 1.0656793847374502e-06
at O 0 2.7176229195902124e-05
low O 0 3.4474534913897514e-05
or O 0 6.35025890005636e-06
undetectable O 0 7.769523654133081e-05
levels O 0 7.969524631334934e-06
due O 0 8.198878276743926e-06
to O 0 7.9766567750994e-07
nonsense O 0 8.886942850949708e-06
- O 0 9.659921715865494e-07
mediated O 0 2.0338568447186844e-06
mRNA O 0 1.534817783976905e-06
decay O 0 2.9032505608483916e-06
, O 0 1.2007419059045787e-07
and O 0 1.6814240666462865e-07
( O 0 1.7273872288114944e-07
iii O 0 1.3971536645840388e-05
) O 0 4.502516617321817e-07
the O 0 1.3303039168022224e-06
levels O 0 3.4960235097969417e-06
of O 0 1.4287900285125943e-06
these O 0 1.0872449252019578e-07
transcripts O 0 1.7945220633919234e-06
can O 0 3.1668712097143725e-08
be O 0 1.6163847149641697e-08
increased O 0 1.7895403914280905e-07
by O 0 2.0181010995656834e-07
cycloheximide O 0 3.736298458534293e-05
. O 0 1.4197588598108268e-06

A O 0 4.134158371016383e-05
deletion O 0 1.8910246581071988e-05
mutation O 0 1.1841881359941908e-06
in O 0 1.0508188097446691e-06
COL17A1 O 0 2.884924651880283e-05
in O 0 8.895237613160134e-08
five O 0 7.581511596299606e-08
Austrian O 0 4.4311577767075505e-06
families O 0 1.1990803727712773e-07
with O 0 4.0982754967444635e-07
generalized O 1 0.9999206066131592
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999988317489624
represents O 0 2.2368183635990135e-05
propagation O 0 1.5299414371838793e-05
of O 0 3.3127350889117224e-06
an O 0 8.432688787252118e-07
ancestral O 0 3.494908378343098e-05
allele O 0 1.9171104213455692e-05
. O 0 1.85462090485089e-06

Patients O 0 0.0002782303490675986
with O 0 3.549926077539567e-06
generalized O 1 0.999974250793457
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999992847442627
, O 0 3.0814201181783574e-06
a O 0 4.5597550979437074e-07
usually O 0 2.5351772592330235e-07
nonlethal O 0 6.012639005348319e-06
form O 0 9.139117196355073e-07
of O 0 2.3205502657219768e-05
junctional B-Disease 1 0.9999806880950928
epidermolysis I-Disease 1 0.9999948740005493
bullosa I-Disease 1 0.9942268133163452
, O 0 1.0497831226530252e-06
have O 0 1.8816099611740356e-07
generalized O 0 3.7690901081077754e-05
blistering B-Disease 0 0.0005910088657401502
, O 0 3.3544863981660455e-05
nail B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 1.0
, O 0 7.29109297026298e-06
patchy B-Disease 1 0.9988207221031189
alopecia I-Disease 1 1.0
, O 0 2.8929169275215827e-05
and O 0 0.0001950341247720644
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.00045422627590596676

Skin B-Disease 1 0.9999998807907104
fragility I-Disease 1 0.9978649020195007
in O 0 3.303206176497042e-05
most O 0 3.578784628643916e-07
cases O 0 8.734559031609024e-08
is O 0 2.2454550219208613e-08
due O 0 1.5013469578661898e-07
to O 0 1.181927355986545e-08
mutations O 0 3.133320802817252e-08
in O 0 8.900838111003395e-08
the O 0 2.388306370448845e-07
gene O 0 5.727509915232076e-07
encoding O 0 3.850689154205611e-06
type O 0 9.366038284497336e-05
XVII O 0 0.011692491360008717
collagen O 0 0.0003557605086825788
( O 0 2.2254647774389014e-05
COL17A1 O 0 0.00042653968557715416
) O 0 1.7570255295140669e-06
. O 0 8.470087209389021e-07

Recently O 0 0.00015107392391655594
, O 0 6.614180847464013e-07
we O 0 4.1992734622908756e-08
reported O 0 3.731521402983162e-08
five O 0 1.981622155255991e-08
Austrian O 0 3.5877183108823374e-06
families O 0 7.092793907759187e-08
with O 0 4.1628376834523806e-07
generalized O 1 0.9997369647026062
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999990463256836
who O 0 1.301627344219014e-05
share O 0 1.338131937700382e-06
the O 0 1.0347436045776703e-06
same O 0 2.2469666873803362e-06
COL17A1 O 0 0.0005519791739061475
mutation O 0 6.408046374417609e-06
. O 0 1.6756849845478428e-06

Affected O 0 0.00013763231982011348
individuals O 0 9.775728813110618e-07
in O 0 2.616101482999511e-06
three O 0 6.508465730803437e-07
families O 0 3.83432663397798e-08
are O 0 3.65348924447062e-08
homozygous O 0 3.042183038814983e-07
for O 0 3.573911442344979e-07
4003delTC O 0 7.5806519816978835e-06
, O 0 4.809470510735991e-07
whereas O 0 3.121617737633642e-07
those O 0 2.965210832428511e-08
in O 0 2.0952315082922723e-07
two O 0 2.3140886185046838e-07
others O 0 1.6796658997009217e-07
are O 0 1.2298886531425524e-07
compound O 0 9.367055099573918e-06
heterozygotes O 0 3.0237575629143976e-05
. O 0 2.0573309029714437e-06

To O 0 4.677418928622501e-06
determine O 0 1.3274220691528171e-06
if O 0 2.233725666656028e-07
the O 0 2.6070455305671203e-07
occurrence O 0 1.3259088973427424e-06
of O 0 1.197084770865331e-06
4003delTC O 0 5.840675385115901e-06
in O 0 2.8154065034868836e-07
these O 0 3.810558979466805e-08
unrelated O 0 5.80771029490279e-07
families O 0 3.0044471799328676e-08
signifies O 0 2.6662926302378764e-06
propagation O 0 6.339887477224693e-06
of O 0 4.134034043090651e-06
an O 0 3.6308331345935585e-06
ancestral O 0 5.253450945019722e-05
allele O 0 1.8304675904801115e-05
or O 0 6.8698000177391805e-06
a O 0 7.835589713067748e-06
mutational O 0 0.00043573728180490434
hot O 0 0.00033364372211508453
spot O 0 3.8715599657734856e-05
, O 0 2.7308004746373626e-07
haplotypes O 0 2.1329130959202303e-06
were O 0 4.3392466864133894e-07
determined O 0 2.2331015259169362e-07
for O 0 1.1605548877469118e-07
polymorphisms O 0 1.6316886330969282e-06
both O 0 4.339573536071839e-07
within O 0 1.2699503031399217e-06
and O 0 3.7989989323250484e-06
flanking O 0 0.0012479312717914581
COL17A1 O 0 0.010744797997176647
. O 0 1.1582352271943819e-05

Five O 0 0.0003830603964161128
intragenic O 0 0.0011018885998055339
polymorphisms O 0 7.613448542542756e-05
were O 0 5.32444255441078e-06
chosen O 0 1.050931132340338e-06
based O 0 1.6444033690277138e-07
on O 0 1.4185853842718643e-06
their O 0 7.02177544553706e-07
informativeness O 0 0.0001742927124723792
. O 0 3.417667585381423e-06

One O 0 4.3758984247688204e-05
of O 0 2.1726926206611097e-05
these O 0 6.734889552717505e-07
, O 0 5.419920512395038e-07
not O 0 2.0325525440512138e-07
previously O 0 1.7174754702864448e-06
reported O 0 3.5416683203948196e-06
, O 0 5.325568395164737e-07
was O 0 1.5175316548265982e-05
2988 O 0 4.5458433305611834e-05
A O 0 5.2122279157629237e-05
or O 0 1.1913984053535387e-05
C O 0 3.5806282539851964e-05
that O 0 7.861466855274557e-08
introduces O 0 4.592857862917299e-07
a O 0 4.950950369675411e-07
new O 0 1.5243426787492353e-07
restriction O 0 1.1935019301745342e-06
site O 0 1.030128601087199e-06
for O 0 7.505212806790951e-07
Eco0109 O 0 6.306017166934907e-05
I O 0 5.954141670372337e-05
. O 0 3.768784154090099e-06

All O 0 2.4121121896314435e-05
the O 0 1.0063321497000288e-05
4003delTC O 0 4.0562419599154964e-05
alleles O 0 4.718165655503981e-06
showed O 0 2.715923756113625e-06
the O 0 2.555355536060233e-07
same O 0 2.405615191491961e-07
haplotype O 0 5.523817890207283e-06
for O 0 2.079465701854133e-07
these O 0 6.57628547173772e-08
five O 0 9.527543625154067e-07
polymorphic O 0 8.368466296815313e-06
markers O 0 2.0222068997099996e-05
. O 0 1.982185267479508e-06

Fourteen O 0 0.0005086302408017218
microsatellite O 0 0.0005331345601007342
polymorphisms O 0 9.514498378848657e-05
were O 0 8.09950415714411e-06
selected O 0 2.2591216293221805e-06
based O 0 3.0173401910360553e-07
on O 0 1.6022470390453236e-06
their O 0 4.2285009271836316e-07
high O 0 2.6127203454962e-05
heterozygosity O 0 4.0283481212100014e-05
and O 0 7.710484624112723e-07
their O 0 2.1898718216561974e-07
location O 0 6.698961897200206e-06
within O 0 3.126067440462066e-06
10q23 O 0 7.430306141031906e-05
- O 0 4.767818973050453e-05
q25 O 0 0.0001252243819180876
near O 0 0.0005603175959549844
COL17A1 O 0 0.0010863024508580565
. O 0 4.346790774434339e-06

Three O 0 8.12043344922131e-06
families O 0 4.4581443603419757e-07
shared O 0 1.984324399018078e-06
microsatellite O 0 2.08605906664161e-05
polymorphisms O 0 3.09301249217242e-05
covering O 0 0.00022190267918631434
at O 0 0.0014706035144627094
most O 0 2.272059418828576e-06
19 O 0 2.537738146202173e-05
cM O 0 2.0908490114379674e-05
, O 0 8.178294592653401e-07
whereas O 0 1.5647624422854278e-06
the O 0 3.711229282998829e-06
others O 0 9.524509323455277e-07
shared O 0 1.1156907930853777e-06
smaller O 0 2.2475819605460856e-06
regions O 0 2.9569760044978466e-06
consistent O 0 9.607355423213448e-06
with O 0 3.6923137258781935e-07
cross O 0 3.713484375111875e-06
- O 0 3.94222013255785e-07
over O 0 3.831548767152526e-08
events O 0 4.103397799326558e-08
during O 0 1.224457122361855e-07
passage O 0 4.5982353924500785e-08
of O 0 2.4493255423863047e-08
this O 0 7.098705623320711e-09
mutation O 0 1.9465177913957632e-08
through O 0 3.492905875646102e-08
several O 0 6.446592237807636e-08
generations O 0 5.465848289532005e-07
. O 0 5.84722954499739e-07

These O 0 9.970515748136677e-06
results O 0 2.691862937354017e-05
indicate O 0 9.990056241804268e-06
that O 0 4.023214330572955e-07
4003delTC O 0 1.7273099729209207e-05
occurs O 0 1.0931426004390232e-06
on O 0 2.5449833174207015e-06
a O 0 2.0501956896623597e-06
single O 0 1.6875571873242734e-06
ancestral O 0 1.6146232155733742e-05
allele O 0 3.4670542845560703e-06
. O 0 2.6805116704053944e-07
. O 0 6.88153704686556e-07

The O 0 0.00017609246424399316
haptoglobin O 0 0.0022200834937393665
- O 0 8.654073462821543e-05
gene O 0 3.320978521514917e-06
deletion O 0 4.859020918956958e-06
responsible O 0 1.2877231938546174e-06
for O 0 1.71955196037743e-06
anhaptoglobinemia B-Disease 0 0.0004578947846312076
. O 0 1.3392831533565186e-05

We O 0 2.001879329327494e-05
have O 0 9.432559977540222e-07
found O 0 2.1255490878502314e-07
an O 0 4.3949203387683156e-08
allelic O 0 2.94839037451311e-06
deletion O 0 4.88875002702116e-06
of O 0 2.9723865736741573e-05
the O 0 3.833355731330812e-05
haptoglobin O 0 0.0005947054596617818
( O 0 1.6238760508713312e-05
Hp O 0 7.917268521850929e-05
) O 0 4.820849426323548e-07
gene O 0 2.9444296956171456e-07
from O 0 3.231821779081656e-07
an O 0 4.920143581443881e-08
individual O 0 6.869001367704186e-08
with O 0 2.802248673106078e-07
anhaptoglobinemia B-Disease 0 0.0004719619173556566
. O 0 4.871465080213966e-06

The O 0 0.0002561013970989734
Hp O 0 0.00029603810980916023
gene O 0 2.0595236946974183e-06
cluster O 0 3.3148999136756174e-06
consists O 0 4.456150861642527e-07
of O 0 1.8550224467617227e-06
coding O 0 6.600660981348483e-06
regions O 0 1.7111369743361138e-06
of O 0 2.714602669584565e-05
the O 0 2.011276774283033e-05
alpha O 0 2.29155266424641e-05
chain O 0 9.4296370889424e-07
and O 0 1.5764682359531434e-07
beta O 0 1.4105814898357494e-06
chain O 0 6.510153980343603e-07
of O 0 7.755825208732858e-07
the O 0 1.9597632672230247e-06
haptoglobin O 0 3.8885660615051165e-05
gene O 0 1.3068149655737216e-06
( O 0 9.114736485571484e-07
Hp O 0 8.869552402757108e-06
) O 0 5.0641311588606186e-08
and O 0 8.383505445408446e-08
of O 0 1.4777932619836065e-06
the O 0 5.42768202649313e-06
alpha O 0 1.888377300929278e-05
chain O 0 1.6800597677502083e-06
and O 0 3.248573250402842e-07
beta O 0 5.8966033975593746e-06
chain O 0 2.5072981770790648e-06
of O 0 1.8580483356345212e-06
the O 0 2.9156449272704776e-06
haptoglobin O 0 4.069143324159086e-05
- O 0 5.5918467296578456e-06
related O 0 1.5582696732963086e-06
gene O 0 6.117934958638216e-07
( O 0 5.743349902331829e-07
Hpr O 0 7.582054877275368e-06
) O 0 3.6510513723442273e-07
, O 0 2.688004769879626e-07
in O 0 1.2721127404802246e-06
tandem O 0 2.8221529646543786e-05
from O 0 1.0263571539326222e-06
the O 0 1.8469010001354036e-06
5 O 0 8.682221960043535e-06
side O 0 3.0972296372056007e-06
. O 0 1.6558499282837147e-06

Southern O 0 0.0012143909698352218
blot O 0 0.0009801517007872462
and O 0 3.806580571108498e-05
PCR O 0 4.312198143452406e-05
analyses O 0 2.7872163173014997e-06
have O 0 5.436880314846348e-07
indicated O 0 9.803270586417057e-07
that O 0 6.029826238318492e-08
the O 0 2.9766155762445123e-07
individual O 0 6.337357660868292e-08
with O 0 1.246059468940075e-07
anhaptoglobinemia B-Disease 0 1.7653748727752827e-05
was O 0 9.05909291759599e-06
homozygous O 0 9.358102488477016e-07
for O 0 2.715475773129583e-07
the O 0 8.759950560488505e-07
gene O 0 5.851536002410285e-07
deletion O 0 1.3113079830873176e-06
and O 0 2.8349697345220193e-07
that O 0 8.352477465223274e-08
the O 0 5.971126029180596e-07
gene O 0 1.5289420218778105e-07
deletion O 0 1.4935852732378407e-06
was O 0 1.1340300261508673e-05
included O 0 6.188699330778036e-07
at O 0 6.696164291497553e-06
least O 0 1.1421558099300455e-07
from O 0 4.224772283123457e-07
the O 0 1.9888316273863893e-06
promoter O 0 2.2612883185502142e-05
region O 0 1.1761984751501586e-05
of O 0 9.729912562761456e-05
Hp O 0 0.0003944496565964073
to O 0 6.592124009330291e-06
Hpr O 0 0.00040614488534629345
alpha O 0 3.725336500792764e-05
but O 0 7.502408294612906e-08
not O 0 2.4087826844265692e-08
to O 0 6.430872900864415e-08
Hpr O 0 2.318749830010347e-05
beta O 0 1.554959271743428e-05
( O 0 2.235721240140265e-06
Hpdel O 0 8.247568621300161e-05
) O 0 1.988689291465562e-06
. O 0 1.0077505976369139e-06

In O 0 0.00014473315968643874
addition O 0 1.9580185835366137e-05
, O 0 2.9344182621571235e-06
we O 0 4.865772780249245e-07
found O 0 3.5482503335515503e-07
seven O 0 4.564209916679829e-07
individuals O 0 1.667442894870419e-08
with O 0 1.0974434871968697e-07
hypohaptoglobinemia B-Disease 0 1.7452241081628017e-05
in O 0 3.4052493447234156e-06
three O 0 8.945494300860446e-07
families O 0 6.538564178981687e-08
, O 0 1.0463673305594057e-07
and O 0 1.379879108753812e-07
the O 0 6.428506367228692e-07
genotypes O 0 3.6868987081106752e-06
of O 0 5.748365310864756e-06
six O 0 9.226408110407647e-06
of O 0 1.3851973562850617e-05
the O 0 8.89761940925382e-06
seven O 0 2.774198264887673e-06
individuals O 0 3.7304541677940506e-08
were O 0 4.0337678797186527e-07
found O 0 9.896249508756227e-08
to O 0 6.108635375312588e-08
be O 0 1.1772518746511196e-06
Hp2 O 0 0.00037850657827220857
/ O 0 0.000344039814081043
Hpdel O 0 0.0007895307498984039
. O 0 1.5658668417017907e-05

The O 0 0.0001535199407953769
phenotypes O 0 0.00011599629942793399
and O 0 6.2192798395699356e-06
genotypes O 0 3.611674401327036e-05
in O 0 3.766405825444963e-06
one O 0 2.0871168260327977e-07
of O 0 4.149155472532584e-07
these O 0 3.0811559526000565e-08
three O 0 2.3122885295379092e-07
families O 0 4.686281229737688e-08
showed O 0 2.0302270513639087e-06
the O 0 1.985346671062871e-06
father O 0 5.579333901550854e-06
to O 0 5.604337047770969e-07
be O 0 1.929985273818602e-06
hypohaptoglobinemic B-Disease 0 2.3694887204328552e-05
( O 0 1.5816439145055483e-06
Hp2 O 0 3.606917744036764e-05
) O 0 9.610926099412609e-07
and O 0 1.8294340407010168e-06
Hp2 O 0 0.0005044320714659989
/ O 0 0.0004500877112150192
Hpdel O 0 0.0007730559445917606
, O 0 7.976246706675738e-06
the O 0 1.1006703971361276e-05
mother O 0 1.8530354282120243e-05
to O 0 1.497898892921512e-06
be O 0 2.9052528134343447e-06
Hp2 O 0 3.768011447391473e-05
- O 0 3.8277325984381605e-06
1 O 0 1.0229126928607002e-05
and O 0 1.4654793858426274e-06
Hp1 O 0 0.00012953901023138314
/ O 0 7.093385647749528e-05
Hp2 O 0 0.00015012412040960044
, O 0 1.8606053799885558e-06
one O 0 5.459278895614261e-07
of O 0 3.1826807571633253e-06
the O 0 2.150876298401272e-06
two O 0 8.470879038213752e-07
children O 0 7.466533133992925e-07
to O 0 2.527907838612009e-07
be O 0 1.7600577848497778e-06
hypohaptoglobinemic B-Disease 0 3.533070412231609e-05
( O 0 2.379703801125288e-06
Hp2 O 0 4.5647830120287836e-05
) O 0 6.312625941973238e-07
and O 0 1.3601586488221074e-06
Hp2 O 0 0.00025658629601821303
/ O 0 0.0002478148671798408
Hpdel O 0 0.00040428026113659143
, O 0 3.851901055895723e-06
and O 0 8.405326070715091e-07
the O 0 1.4093322988628643e-06
other O 0 2.821658711127384e-07
child O 0 1.291511125600664e-06
to O 0 1.5161381838879606e-07
be O 0 9.003617265079811e-07
Hp1 O 0 4.036754398839548e-05
and O 0 1.8075274965667631e-06
Hp1 O 0 0.00033459486439824104
/ O 0 0.00010983886022586375
Hpdel O 0 0.00010430081601953134
, O 0 6.077414695937478e-07
showing O 0 2.4688949906703783e-06
an O 0 7.124806415959029e-07
anomalous O 0 9.27339933696203e-05
inheritance O 0 3.0137161957100034e-05
of O 0 0.0004773951368406415
Hp O 0 0.0008958699181675911
phenotypes O 0 1.460198745917296e-05
in O 0 2.7121861876366893e-06
the O 0 1.246403371624183e-06
child O 0 2.6090306164405774e-06
with O 0 3.176526490733522e-07
Hp1 O 0 0.0004511297738645226
. O 0 9.005840183817782e-06

The O 0 0.0005633688997477293
Hp2 O 0 0.015801459550857544
/ O 0 0.0039606704376637936
Hpdel O 0 0.0008938534301705658
individuals O 0 1.8962151671075844e-06
had O 0 1.685496317804791e-05
an O 0 2.228810899396194e-06
extremely O 0 8.653347322251648e-06
low O 0 8.348275150638074e-05
level O 0 0.00040619439096190035
of O 0 0.0002567920892033726
Hp O 0 0.00026033062022179365
( O 0 1.1669736750263837e-06
mean O 0 3.587598484955379e-06
+ O 0 1.375923943669477e-06
/ O 0 7.424235946018598e-07
- O 0 4.605143146818591e-07
SD O 0 3.768054739339277e-06
= O 0 1.324185291196045e-06
0 O 0 2.5999543140642345e-07
. O 0 1.6776832367781935e-08
049 O 0 1.4026201142769423e-06
+ O 0 4.1038759945877246e-07
/ O 0 5.448055162560195e-07
- O 0 3.768011822558037e-07
0 O 0 2.672912273737893e-07
. O 0 1.2484187905670296e-08
043 O 0 2.3859849989094073e-06
mg O 0 3.270078195782844e-06
/ O 0 1.0972693189614802e-06
ml O 0 9.381191716784087e-07
; O 0 7.3831223801335e-08
n O 0 2.119877990480745e-06
= O 0 2.201744337071432e-06
6 O 0 3.4863048767874716e-06
) O 0 6.474737546113829e-08
, O 0 5.119595769542684e-08
compared O 0 2.0667494027293287e-07
with O 0 1.6155677684537295e-08
the O 0 5.147290380591585e-07
level O 0 7.768996511003934e-06
( O 0 1.5628296523573226e-07
1 O 0 6.387335815816186e-07
. O 0 1.9724362587680844e-08
64 O 0 7.619070174769149e-07
+ O 0 4.554196664230403e-07
/ O 0 5.713761765946401e-07
- O 0 2.466936166456435e-07
1 O 0 7.948612505970232e-07
. O 0 2.2471045468819284e-08
07 O 0 3.2840696349012433e-06
mg O 0 2.7268654321233043e-06
/ O 0 6.828511800449633e-07
ml O 0 1.5277657894330332e-07
) O 0 3.7314555889622625e-09
obtained O 0 2.823149003461367e-08
from O 0 1.4515032376039017e-07
52 O 0 6.361321538861375e-06
healthy O 0 8.844498324833694e-07
volunteers O 0 4.747720652176213e-07
having O 0 1.4534427918988513e-06
phenotype O 0 1.2059227628924418e-05
Hp2 O 0 3.6808865843340755e-05
, O 0 3.71162542478487e-07
whereas O 0 6.948803843442874e-07
the O 0 7.544625759692281e-07
serum O 0 6.400320216926048e-06
Hp O 0 4.482220901991241e-05
level O 0 1.1994125998171512e-05
of O 0 1.9151616470480803e-06
an O 0 4.548427909867314e-07
individual O 0 9.751187235451653e-08
with O 0 4.337649670560495e-07
Hp1 O 0 0.0005195252015255392
/ O 0 0.0001924336247611791
Hpdel O 0 0.00021405995357781649
was O 0 4.066044130013324e-05
0 O 0 2.252019476145506e-05
. O 0 4.821134211852041e-07

50 O 0 0.00039979731081984937
mg O 0 0.0003143207577522844
/ O 0 6.99245574651286e-05
ml O 0 1.8230444766231813e-05
, O 0 1.9694296327088523e-07
which O 0 3.864200692760278e-08
was O 0 8.552587473786843e-07
approximately O 0 1.0950138573662116e-07
half O 0 1.6471577168886142e-07
the O 0 5.279606511976453e-07
level O 0 1.4748416106158402e-05
of O 0 1.449596766178729e-05
Hp O 0 5.928758400841616e-05
in O 0 5.637827143800678e-06
control O 0 2.6491628887015395e-05
sera O 0 0.00011186664050910622
from O 0 2.072079041681718e-06
the O 0 1.450002287128882e-06
Hp1 O 0 3.155103695462458e-05
phenotype O 0 3.5323853353474988e-06
( O 0 2.976652524466772e-07
1 O 0 9.003986178868217e-07
. O 0 1.8728407269463787e-08
26 O 0 1.223012873197149e-06
+ O 0 4.96740426569886e-07
/ O 0 3.6175464401821955e-07
- O 0 1.9518124361184164e-07
0 O 0 2.8247495720279403e-07
. O 0 1.2230818136060861e-08
33 O 0 9.234966569238168e-07
mg O 0 2.1407895474112593e-06
/ O 0 1.3661933735420462e-06
ml O 0 1.2913461659991299e-06
; O 0 8.631267434111578e-08
n O 0 1.8306417359781335e-06
= O 0 2.76992363978934e-06
9 O 0 3.218124675186118e-06
) O 0 4.572418177417603e-08
, O 0 4.3641385616410844e-08
showing O 0 8.691829407325713e-07
a O 0 2.071950802928768e-06
gene O 0 2.2727203941030893e-06
- O 0 2.762626763797016e-06
dosage O 0 6.350477178784786e-06
effect O 0 4.356705176178366e-06
. O 0 1.1535913699844969e-06

The O 0 0.00013126013800501823
other O 0 4.992316917196149e-06
allele O 0 1.3212436897447333e-05
( O 0 3.1018289519124664e-06
Hp2 O 0 4.3229152652202174e-05
) O 0 3.447317737936828e-07
of O 0 1.5551935348412371e-06
individuals O 0 1.8036756443962076e-07
with O 0 1.463183593841677e-06
Hp2 O 0 0.18182052671909332
/ O 1 0.8547379970550537
Hpdel O 0 0.05773887783288956
was O 0 0.0013649830361828208
found O 0 3.775489858526271e-06
to O 0 2.3596376763634908e-07
have O 0 2.2367099461462203e-07
, O 0 4.619473870093316e-08
in O 0 7.336404905800009e-08
all O 0 6.16707680478612e-08
exons O 0 2.6111015358765144e-06
, O 0 6.24127167725419e-08
no O 0 3.3855375392022324e-08
mutation O 0 4.068530401468706e-08
, O 0 6.8511907258539395e-09
by O 0 3.775455059695787e-09
DNA O 0 1.0332618671782257e-07
sequencing O 0 1.9201561372028664e-06
. O 0 1.5041114238556474e-06

On O 0 3.334157736389898e-05
the O 0 1.2074865480826702e-06
basis O 0 5.569927452597767e-07
of O 0 1.187372618005611e-06
the O 0 3.256805882756453e-07
present O 0 2.0595126670741593e-07
study O 0 1.9392957995023608e-07
, O 0 5.270515401889497e-08
the O 0 1.4667892855868558e-07
mechanism O 0 1.2489997516240692e-06
of O 0 4.08367850468494e-06
anhaptoglobinemia B-Disease 0 5.1429167797323316e-05
and O 0 6.768887601538154e-07
the O 0 1.1514512152643874e-06
mechanism O 0 2.7547864647203824e-06
of O 0 5.364018761611078e-06
anomalous O 0 0.0002402989484835416
inheritance O 0 4.993990296497941e-05
of O 0 0.00021008809562772512
Hp O 0 0.000348205998307094
phenotypes O 0 1.7465043129050173e-05
were O 0 3.18446586788923e-06
well O 0 9.482970995122741e-07
explained O 0 2.465365469106473e-06
. O 0 8.865001746016787e-07

However O 0 2.1858020772924647e-05
, O 0 1.0181952347920742e-06
the O 0 5.902730890738894e-07
mechanism O 0 3.263000508013647e-06
of O 0 1.222003083967138e-05
hypohaptoglobinemia B-Disease 0 0.0012107215588912368
remains O 0 0.0003047530190087855
unknown O 0 0.0003346085431985557

ATM O 0 0.00210555293597281
mutations O 0 1.9265158698544838e-05
and O 0 6.299296728684567e-06
phenotypes O 0 0.0006535756983794272
in O 0 0.342698872089386
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.4763740182388574e-05
in O 0 4.198418537271209e-06
the O 0 2.5183144316542894e-06
British O 0 5.486709596880246e-06
Isles O 0 1.143981899076607e-05
: O 0 3.5317476942964277e-08
expression O 0 6.732533819331366e-08
of O 0 9.60913268954755e-08
mutant O 0 5.563636022998253e-07
ATM O 0 1.57494002905878e-06
and O 0 1.2580326114175477e-08
the O 0 1.904599145063912e-08
risk O 0 6.962748244632166e-08
of O 0 6.610756599911838e-07
leukemia B-Disease 1 0.9999995231628418
, O 0 0.00020024091645609587
lymphoma B-Disease 1 1.0
, O 0 9.285442502005026e-06
and O 0 1.0353770449000876e-05
breast B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9998340606689453
. O 0 7.401292805297999e-06

We O 0 2.623872205731459e-06
report O 0 2.2047689185455965e-07
the O 0 5.423008175853283e-08
spectrum O 0 1.6960068194293854e-07
of O 0 3.484170179035573e-07
59 O 0 1.2543936463771388e-05
ATM O 0 2.7656564270728268e-05
mutations O 0 6.855918286419183e-07
observed O 0 1.228422570420662e-05
in O 0 7.808213558746502e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9998773336410522
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.7119286894740071e-06
patients O 0 3.519019742270757e-07
in O 0 3.4908819657175627e-07
the O 0 1.3391262427830952e-06
British O 0 2.2019305106368847e-05
Isles O 0 5.87463473493699e-05
. O 0 4.067044301336864e-06

Of O 0 0.0005978664848953485
51 O 0 0.001116256695240736
ATM O 0 0.0007804500637575984
mutations O 0 5.291938578011468e-06
identified O 0 2.0543468508549267e-06
in O 0 1.406840056006331e-06
families O 0 1.6218282894442382e-07
native O 0 2.7154601411893964e-07
to O 0 1.577003558850265e-07
the O 0 1.515483404546103e-06
British O 0 1.4853600987407845e-05
Isles O 0 3.355382432346232e-05
, O 0 2.3679274363530567e-06
11 O 0 1.6918042092584074e-05
were O 0 6.931628831807757e-06
founder O 0 1.4037204891792499e-05
mutations O 0 1.751635494429138e-07
, O 0 3.9269774987360506e-08
and O 0 2.134580157076016e-08
2 O 0 2.938936347618437e-07
of O 0 5.152609361402938e-08
these O 0 2.1145861950344624e-08
11 O 0 1.52618417814665e-06
conferred O 0 8.571339094487485e-06
a O 0 1.1354499065419077e-06
milder O 0 7.150794317567488e-06
clinical O 0 9.903073078021407e-06
phenotype O 0 9.864830872174934e-07
with O 0 1.8812110980093166e-08
respect O 0 2.144942925497162e-07
to O 0 3.260305163621524e-07
both O 0 8.376602636417374e-06
cerebellar B-Disease 1 0.9996587038040161
degeneration I-Disease 1 0.9999992847442627
and O 0 8.974719094112515e-06
cellular O 0 7.743464811937883e-05
features O 0 2.8236579510121373e-06
. O 0 1.1299947573206737e-06

We O 0 4.9299549573333934e-05
report O 0 7.318296411540359e-06
, O 0 7.919398967715097e-07
in O 0 2.4863516046025325e-06
two O 0 7.116641882021213e-06
A B-Disease 1 0.9999780654907227
- I-Disease 1 0.9984661340713501
T I-Disease 1 0.9999995231628418
families O 0 6.357406050483405e-07
, O 0 2.3715402619473025e-07
an O 0 7.380883175756026e-07
ATM O 0 4.4301548768999055e-05
mutation O 0 2.408958607702516e-06
( O 0 3.1266279165720334e-06
7271T O 0 3.0058976335567422e-05
- O 0 2.9603806979139335e-05
- O 0 7.05361453583464e-05
> O 0 6.227278936421499e-05
G O 0 7.722147711319849e-05
) O 0 2.2686678846639552e-07
that O 0 1.4865207731418195e-08
may O 0 1.4429159023165994e-07
be O 0 1.8709627624957648e-08
associated O 0 7.281295566485824e-09
with O 0 6.161098298207435e-10
an O 0 2.271051791069567e-09
increased O 0 1.3269217902234232e-07
risk O 0 3.1622840879208525e-07
of O 0 3.890305379172787e-06
breast B-Disease 1 0.8663398623466492
cancer I-Disease 0 0.00024961851886473596
in O 0 2.954672936539282e-06
both O 0 1.4766492313356139e-06
homozygotes O 0 1.1257996447966434e-05
and O 0 6.863238581900077e-07
heterozygotes O 0 8.316997991641983e-06
( O 0 5.395964421950339e-07
relative O 0 2.9127932066330686e-06
risk O 0 5.262594982013979e-07
12 O 0 6.70732163143839e-07
. O 0 2.514473607106993e-08
7 O 0 2.2817982880951604e-06
; O 0 2.2708671565396799e-07
P O 0 8.069884643191472e-05
= O 0 1.1770288438128773e-05
. O 0 3.190909012573684e-07
0025 O 0 3.3285163226537406e-05
) O 0 6.908155114615511e-08
, O 0 6.843485333973831e-09
although O 0 5.647924350427047e-09
there O 0 1.4381359214610256e-08
is O 0 2.974336155148194e-08
a O 0 2.5259294034185586e-07
less O 0 2.072537654385087e-06
severe O 1 0.9996578693389893
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 0.9999996423721313
phenotype O 0 6.387689381881501e-07
in O 0 5.860804286328403e-09
terms O 0 4.938343067806272e-09
of O 0 1.746452227280315e-08
the O 0 3.8519193168440324e-08
degree O 0 1.2950144082424231e-05
of O 0 5.873329791938886e-05
cerebellar B-Disease 1 0.9999781847000122
degeneration I-Disease 1 0.9999998807907104
. O 0 1.3138517715560738e-05

This O 0 6.071488678571768e-05
mutation O 0 1.173188411485171e-05
( O 0 5.3902995205135085e-06
7271T O 0 1.6053983927122317e-05
- O 0 7.176386134233326e-06
- O 0 8.521312338416465e-06
> O 0 8.172967682185117e-06
G O 0 8.577675544074737e-06
) O 0 1.5262789077041816e-07
also O 0 1.6403575386902958e-07
allows O 0 5.385159340676182e-08
expression O 0 1.9081207938143052e-06
of O 0 3.6347755667520687e-06
full O 0 3.491259121801704e-06
- O 0 2.137017872883007e-06
length O 0 1.5659627479180926e-06
ATM O 0 3.0883496947353706e-05
protein O 0 4.455956968740793e-06
at O 0 4.579877440846758e-06
a O 0 2.568990282725281e-07
level O 0 1.4297987718236982e-06
comparable O 0 3.546555262801121e-07
with O 0 9.736464967602387e-09
that O 0 1.9945870732840376e-08
in O 0 6.842586230959569e-07
unaffected O 0 7.362123596976744e-06
individuals O 0 6.457434409412599e-08
. O 0 3.7570674749076716e-07

In O 0 9.127291559707373e-05
addition O 0 4.363337211543694e-06
, O 0 7.22710126410675e-07
we O 0 5.467335029152309e-08
have O 0 3.5491158456579797e-08
studied O 0 6.147502972453367e-06
18 O 0 0.000335437071043998
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 1.256988980458118e-06
, O 0 1.7670927832114103e-08
in O 0 2.8782379146718995e-08
15 O 0 2.0810846024232887e-07
families O 0 2.890427452939548e-09
, O 0 9.418132940197665e-09
who O 0 4.155522503879183e-08
developed O 0 2.809853640428628e-06
leukemia B-Disease 1 0.9999991655349731
, O 0 0.00013777439016848803
lymphoma B-Disease 1 1.0
, O 0 4.721518780570477e-05
preleukemic O 0 0.17694181203842163
T O 1 0.6030693650245667
- O 0 0.00015387695748358965
cell O 0 0.00013315019896253943
proliferation O 0 7.160784298321232e-05
, O 0 7.949606128931919e-07
or O 0 0.00014014188491273671
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.7779877907742048e-06
mostly O 0 1.8161516379677778e-07
in O 0 6.773750556021696e-07
childhood O 0 2.3887763745733537e-05
. O 0 1.7003420680339332e-06

A O 0 4.16349976148922e-05
wide O 0 5.7724428188521415e-06
variety O 0 9.373080729346839e-07
of O 0 1.3153762665751856e-05
ATM O 0 0.00013634956849273294
mutation O 0 1.2487496405810816e-06
types O 0 1.5909901094346424e-06
, O 0 7.217960842353932e-07
including O 0 1.154204255726654e-06
missense O 0 1.9506602257024497e-05
mutations O 0 3.9330002437054645e-06
and O 0 1.5113327208382543e-05
in O 0 6.251822924241424e-05
- O 0 5.944621443632059e-05
frame O 0 4.099289435544051e-05
deletions O 0 1.7507464917798643e-06
, O 0 2.559055189976789e-07
were O 0 1.5555183097148984e-07
seen O 0 2.357341202241514e-07
in O 0 6.8847285206175e-08
these O 0 4.869189140777053e-08
patients O 0 1.4561148873326601e-06
. O 0 1.0238564982500975e-06

We O 0 1.712049743218813e-05
also O 0 2.9839083026672597e-07
show O 0 1.3184275360345055e-07
that O 0 1.1264034149860436e-08
25 O 0 3.2555109896748036e-07
% O 0 1.4541551252023055e-07
of O 0 1.8095903442372219e-06
all O 0 5.884424354007933e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999982118606567
T I-Disease 1 1.0
patients O 0 5.735255854233401e-06
carried O 0 2.024863306360203e-06
in O 0 3.836917130684014e-06
- O 0 5.5507071010652e-06
frame O 0 7.272350103448844e-06
deletions O 0 2.805376880132826e-06
or O 0 3.200681931048166e-06
missense O 0 1.4202194506651722e-05
mutations O 0 1.2358783578747534e-06
, O 0 1.5954360321757122e-07
many O 0 1.0330742483688482e-08
of O 0 1.134173501782243e-07
which O 0 2.614843452874993e-08
were O 0 4.426349775599192e-08
also O 0 1.7590959799917982e-08
associated O 0 1.0763397284563325e-08
with O 0 7.118175826548168e-09
expression O 0 5.791648050035292e-07
of O 0 9.844549140325398e-07
mutant O 0 8.809296559775248e-06
ATM O 0 9.04380576685071e-05
protein O 0 1.6947124095167965e-05
. O 0 1.419521936441015e-06

The O 0 1.8781956896418706e-05
DMPK O 0 0.0007358788279816508
gene O 0 7.78408139012754e-06
of O 0 1.874829649750609e-05
severely O 1 0.9999905824661255
affected O 1 0.9999710321426392
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.8196990489959717
is O 0 7.248731435538502e-06
hypermethylated O 0 9.367949678562582e-05
proximal O 0 3.74803930753842e-05
to O 0 1.6526917079318082e-07
the O 0 1.0149242370971479e-06
largely O 0 2.0655190837715054e-06
expanded O 0 5.963646799500566e-06
CTG O 0 0.000264563801465556
repeat O 0 2.0788223991985433e-05
. O 0 2.9773441383440513e-06

Using O 0 0.00022400122543331236
methylation O 0 0.000304656830849126
- O 0 0.0001831825647968799
sensitive O 0 4.284586975700222e-05
restriction O 0 9.244145076081622e-06
enzymes O 0 2.153257128156838e-06
, O 0 2.6176536493949243e-07
we O 0 7.303483329224036e-08
characterized O 0 2.6281546183781757e-07
the O 0 3.473298590961349e-07
methylation O 0 1.6557884237045073e-06
pattern O 0 2.9659204301424325e-06
on O 0 3.706189090735279e-06
the O 0 1.6868782495294e-06
5 O 0 3.9219694372150116e-06
side O 0 8.204707455661264e-07
of O 0 2.6536824861977948e-06
the O 0 4.701824764197227e-06
CTG O 0 8.599647844675928e-05
repeat O 0 2.5215949790435843e-06
in O 0 6.399896506081859e-07
the O 0 6.211001277733885e-07
DMPK O 0 1.792089460650459e-05
gene O 0 1.2495961243530473e-07
of O 0 1.3112401120451977e-07
normal O 0 9.020935181069945e-07
individuals O 0 4.702018774338512e-09
and O 0 8.29416446634923e-09
of O 0 1.9160553677011194e-07
patients O 0 3.1688157378084725e-06
affected O 0 6.81884966979851e-06
with O 0 3.55488300556317e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.684772025280836e-07
showing O 0 3.38546357170344e-07
expansions O 0 3.6132743730377115e-07
of O 0 4.7475757014581177e-07
the O 0 8.240591000685527e-07
repetitive O 0 1.453984350519022e-05
sequence O 0 2.98806230603077e-06
. O 0 2.802317794703413e-06

The O 0 2.8063404897693545e-05
gene O 0 2.8847946396126645e-06
segment O 0 2.273893414894701e-06
analyzed O 0 2.5437213935219916e-07
corresponds O 0 4.0311681459570536e-07
to O 0 2.476419069807889e-07
the O 0 3.86114334105514e-06
genomic O 0 4.559692752081901e-05
SacI O 0 0.0010112831369042397
- O 0 2.665042848093435e-05
HindIII O 0 4.329335206421092e-05
fragment O 0 5.718303327739704e-06
carrying O 0 2.943782646980253e-06
exons O 0 1.0298073902959004e-05
11 O 0 1.846712621045299e-05
- O 0 5.25568657394615e-06
15 O 0 8.27302301331656e-06
. O 0 8.734923540032469e-07

There O 0 2.794957072183024e-05
is O 0 3.485344223008724e-06
constitutive O 0 3.0087196137174033e-05
methylation O 0 6.182061042636633e-06
in O 0 7.79343372414587e-06
intron O 0 2.672367736522574e-05
12 O 0 1.3702690921491012e-05
at O 0 5.833411250932841e-06
restriction O 0 3.9006229712867935e-07
sites O 0 2.0262548616756249e-07
of O 0 2.28856947614986e-06
SacII O 0 5.508848698809743e-05
and O 0 5.8025948419526685e-06
HhaI O 0 0.00012856244575232267
, O 0 1.6941492049227236e-06
localized O 0 1.2199806405988056e-05
1 O 0 1.594251807546243e-05
, O 0 4.3361274038034026e-07
159 O 0 1.5919433735689381e-06
- O 0 6.282381264099968e-07
1 O 0 4.249804078426678e-06
, O 0 2.3733096554678923e-07
232 O 0 2.0932411644025706e-06
bp O 0 4.13094039686257e-06
upstream O 0 8.088805770967156e-06
of O 0 2.184037111874204e-05
the O 0 4.6333672798937187e-05
CTG O 0 0.000536389066837728
repeat O 0 7.050816202536225e-05
, O 0 5.155438884685282e-06
whereas O 0 3.7663696730305674e-06
most O 0 6.404549708349805e-07
, O 0 1.9998522304831567e-07
if O 0 3.746204768617645e-08
not O 0 4.4717062053223344e-08
all O 0 6.920459583170668e-08
, O 0 3.6074553122489306e-08
of O 0 3.3824690603978524e-07
the O 0 2.1358880530897295e-07
other O 0 3.065592579787335e-08
sites O 0 2.8268192409086623e-07
of O 0 2.5929518869816093e-06
SacII O 0 7.637000817339867e-05
, O 0 5.670092832588125e-06
HhaI O 0 9.533841512165964e-05
, O 0 2.493957936167135e-06
and O 0 1.7438811710235314e-06
HpaII O 0 6.922248576302081e-05
in O 0 3.1294139262172394e-06
this O 0 3.87934761647557e-07
region O 0 1.880395075204433e-06
are O 0 3.4427674222570204e-07
unmethylated O 0 5.797915491712047e-06
, O 0 9.261163569362907e-08
in O 0 1.5111076834273263e-07
normal O 0 6.233307203729055e-07
individuals O 0 8.0510247357779e-09
and O 0 3.1714829873408235e-08
most O 0 2.5213751086994307e-08
of O 0 2.683883053578029e-07
the O 0 1.144508132711053e-06
patients O 0 3.916968125849962e-06
. O 0 1.3333115020941477e-06

In O 0 3.266339990659617e-05
a O 0 9.332638001069427e-06
number O 0 4.165337486483622e-06
of O 0 4.196925146970898e-05
young O 0 1.9096218238701113e-05
and O 0 1.504145075159613e-05
severely O 0 0.006241144146770239
affected O 0 1.1441237802500837e-05
patients O 0 2.3770001007505925e-06
, O 0 1.748315980876214e-07
however O 0 1.7417673348063545e-07
, O 0 8.882962987399878e-08
complete O 0 5.884615461582143e-07
methylation O 0 7.085552624630509e-07
of O 0 1.2950337122674682e-06
these O 0 3.6997224839296905e-08
restriction O 0 3.5627903116619564e-07
sites O 0 1.1806524469193391e-07
was O 0 5.230438091530232e-07
found O 0 4.6582805168782215e-08
in O 0 9.183397509104907e-08
the O 0 3.817004596839979e-07
mutated O 0 4.001283741672523e-06
allele O 0 1.0411178664071485e-05
. O 0 2.667399030542583e-06

In O 0 5.853768925589975e-06
most O 0 6.349056747012582e-08
of O 0 5.509711087370306e-08
these O 0 7.797369860895742e-09
patients O 0 5.3358167662054257e-08
, O 0 9.766554232015778e-10
the O 0 6.147227171737768e-09
onset O 0 4.289611297281226e-06
of O 0 1.302487589782686e-06
the O 0 4.5125165343051776e-05
disease O 1 0.9999991655349731
was O 1 0.9992777705192566
congenital O 1 1.0
. O 0 4.166045619058423e-05

Preliminary O 0 0.00012846772733610123
in O 0 0.00012203172082081437
vivo O 0 0.0017623669700697064
footprinting O 0 0.0005727591342292726
data O 0 4.4894832171848975e-06
gave O 0 9.018724540510448e-07
evidence O 0 5.1323252137081e-07
for O 0 8.922456800064538e-07
protein O 0 5.9037492974312045e-06
- O 0 2.5012202513607917e-06
DNA O 0 4.6419964405686187e-07
contact O 0 8.841538488013612e-07
in O 0 4.713101589004509e-06
normal O 0 4.131032983423211e-05
genes O 0 3.0049457109271316e-06
at O 0 2.339738784939982e-05
an O 0 7.664422128073056e-07
Sp1 O 0 2.6008274289779365e-05
consensus O 0 1.437270157111925e-06
binding O 0 9.904064199872664e-07
site O 0 2.45976457335928e-06
upstream O 0 5.535102900466882e-06
of O 0 4.6622767513326835e-06
the O 0 7.932717380754184e-06
CTG O 0 0.00013768640928901732
repeat O 0 3.1369379485113313e-06
and O 0 1.1402686084238667e-07
for O 0 3.144840476920763e-08
a O 0 3.91166032898127e-08
significant O 0 3.319320640571277e-08
reduction O 0 3.8811424474261e-07
of O 0 5.188160798752506e-07
this O 0 7.65598571206283e-08
interaction O 0 2.916769403782382e-07
in O 0 6.560011911460606e-07
cells O 0 2.1543280581681756e-07
with O 0 2.0693597946319642e-08
a O 0 1.2524777730504866e-06
hypermethylated O 0 5.184976544114761e-05
DMPK O 0 0.0001631601044209674
gene O 0 2.2077281300880713e-06
. O 0 2.2585240344596968e-07
. O 0 3.6848771856057283e-07

The O 0 0.0018349532037973404
hemochromatosis B-Disease 1 1.0
gene O 0 6.456812843680382e-05
product O 0 6.759967163816327e-06
complexes O 0 6.949745511519723e-06
with O 0 1.3939028065124148e-07
the O 0 5.3643207138520665e-06
transferrin O 0 7.70099795772694e-05
receptor O 0 1.9736309695872478e-05
and O 0 1.2876876098744106e-06
lowers O 0 5.2315926950541325e-06
its O 0 1.7473892910402355e-07
affinity O 0 5.274684440337296e-07
for O 0 4.957994974574831e-07
ligand O 0 1.4460223610512912e-05
binding O 0 9.918441719491966e-06
. O 0 2.705768565647304e-06

We O 0 6.943577318452299e-06
recently O 0 1.66854272265482e-06
reported O 0 1.9097687697922083e-07
the O 0 3.5978143131387696e-08
positional O 0 2.4060748273768695e-06
cloning O 0 4.0433269532513805e-07
of O 0 7.048210193261184e-08
a O 0 1.806464382525519e-07
candidate O 0 1.6959517097347998e-06
gene O 0 1.2479051292757504e-05
for O 0 4.533116225502454e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999908208847046
HFE O 1 0.9999741315841675
. O 0 2.038132879533805e-05

The O 0 4.078525671502575e-05
gene O 0 3.1190809295367217e-06
product O 0 1.8393006939732004e-06
, O 0 1.4219835975382011e-07
a O 0 3.100241769971035e-07
member O 0 8.101134767457552e-07
of O 0 8.260417416749988e-06
the O 0 3.4115073503926396e-05
major O 0 0.0009365148725919425
histocompatibility O 1 0.9956626296043396
complex O 1 0.9988672733306885
class O 0 0.00017479197413194925
I O 0 0.00010903926158789545
- O 0 7.422653197863838e-06
like O 0 3.8113626033009496e-07
family O 0 2.5803217340580886e-07
, O 0 1.2068011301380466e-07
was O 0 8.474353307974525e-07
found O 0 8.717865540575076e-08
to O 0 3.95917396645018e-08
have O 0 1.6805759628368833e-07
a O 0 1.6868137890924118e-06
mutation O 0 1.4618375416830531e-06
, O 0 1.784931441761728e-06
Cys O 0 8.695534052094445e-05
- O 0 1.542420250189025e-05
282 O 0 4.5757748011965305e-05
- O 0 2.2915812223800458e-05
- O 0 4.4188516767462716e-05
> O 0 1.6281837815768085e-05
Tyr O 0 3.313933848403394e-05
( O 0 1.0739937579273828e-06
C282Y O 0 3.732048980964464e-06
) O 0 6.555109166583861e-08
, O 0 8.372587956273492e-09
in O 0 3.603198450718992e-08
85 O 0 5.562092724176182e-07
% O 0 1.3066787118987122e-07
of O 0 7.544891786892549e-07
patient O 0 2.305889574927278e-05
chromosomes O 0 5.414186307461932e-05
. O 0 7.472377546946518e-06

This O 0 4.313485987950116e-06
mutation O 0 3.1618365028407425e-06
eliminates O 0 5.135751507623354e-06
the O 0 1.9273718407930573e-06
ability O 0 1.499625568612828e-06
of O 0 2.6355379304732196e-05
HFE O 0 0.0013899336336180568
to O 0 4.263871232979e-06
associate O 0 5.56658924324438e-05
with O 0 2.4464131911372533e-06
beta2 O 0 0.00037799772690050304
- O 0 0.00012649920245166868
microglobulin O 0 0.0002819337823893875
( O 0 4.98568442708347e-06
beta2m O 0 5.146880721440539e-05
) O 0 8.103182835839107e-07
and O 0 1.1413188758524484e-06
prevents O 0 5.190558567846892e-06
cell O 0 0.00039653797284699976
- O 0 3.372364881215617e-05
surface O 0 9.018556011142209e-05
expression O 0 4.563351103570312e-05
. O 0 1.839286596805323e-06

A O 0 0.000771481019910425
second O 0 4.5796561607858166e-05
mutation O 0 9.365136861561041e-07
that O 0 2.4549760269110266e-07
has O 0 5.898296535633563e-07
no O 0 4.3188597942389606e-07
effect O 0 8.318965228681918e-06
on O 0 8.077877282630652e-05
beta2m O 0 0.0004039562772959471
association O 0 2.69071533693932e-05
, O 0 2.0499630863923812e-06
H63D O 0 8.354811870958656e-05
, O 0 7.406831628031796e-07
was O 0 3.5161588129994925e-06
found O 0 1.5523026775099424e-07
in O 0 1.880601843140539e-07
eight O 0 3.126071135284292e-07
out O 0 2.8033330323751215e-08
of O 0 1.931217497030957e-07
nine O 0 1.9113153939542826e-06
patients O 0 5.238380254013464e-07
heterozygous O 0 4.2562271573842736e-07
for O 0 1.396931708086413e-07
the O 0 2.154310777768842e-06
C282Y O 0 4.72820975119248e-05
mutant O 0 3.907151040039025e-05
. O 0 3.4083550417562947e-06

In O 0 3.1129988201428205e-05
this O 0 5.447390094559523e-07
report O 0 5.127198505761044e-07
, O 0 5.99366174469651e-08
we O 0 2.0919605603353375e-08
demonstrate O 0 3.834627193555207e-07
in O 0 3.1031693197292043e-06
cultured O 0 5.704515933757648e-05
293 O 0 8.452191832475364e-05
cells O 0 3.5839693737216294e-05
overexpressing O 0 0.0001545395061839372
wild O 0 9.134192623605486e-06
- O 0 7.439733508363133e-06
type O 0 3.970581929024775e-06
or O 0 2.7230817067902535e-06
mutant O 0 7.44659064366715e-06
HFE O 0 6.33435629424639e-05
proteins O 0 1.307290773411296e-07
that O 0 2.8467896484585253e-08
both O 0 1.7135165819581744e-07
the O 0 6.619462737944559e-07
wild O 0 2.2831936803413555e-06
- O 0 2.3557643089588964e-06
type O 0 2.7381126983527793e-06
and O 0 2.9929021820862545e-06
H63D O 0 0.0010534243192523718
HFE O 0 0.0007867256063036621
proteins O 0 2.1719672531617107e-06
form O 0 3.038772547370172e-06
stable O 0 1.9662160411826335e-05
complexes O 0 4.122349309909623e-06
with O 0 1.1083125173172448e-07
the O 0 2.0694112663477426e-06
transferrin O 0 5.6096407206496224e-05
receptor O 0 1.553708170831669e-05
( O 0 3.1003089588921284e-06
TfR O 0 0.0005375171895138919
) O 0 1.6070124502221006e-06
. O 0 8.427142574873869e-07

The O 0 0.00013866866356693208
C282Y O 0 0.0004645565350074321
mutation O 0 9.667694939707872e-06
nearly O 0 7.431366157106822e-06
completely O 0 2.772344487311784e-06
prevents O 0 3.997547253220546e-07
the O 0 4.858724764744693e-07
association O 0 4.419921424414497e-07
of O 0 5.705686021428846e-07
the O 0 1.2154340538472752e-06
mutant O 0 2.2754444216843694e-05
HFE O 0 0.00032730025122873485
protein O 0 3.8541206777154e-06
with O 0 1.5931962593640492e-07
the O 0 2.7026917450712062e-06
TfR O 0 0.0046652136370539665
. O 0 5.773758857685607e-06

Studies O 0 0.00015694493777118623
on O 0 9.805824811337516e-05
cell O 0 7.297462434507906e-05
- O 0 5.7135443967126776e-06
associated O 0 1.0630859605953447e-06
transferrin O 0 2.27332093345467e-05
at O 0 1.781456739990972e-05
37 O 0 6.701179245283129e-06
degrees O 0 6.467208731919527e-05
C O 0 6.916575512150303e-05
suggest O 0 4.3424839191175124e-07
that O 0 1.4552664140410343e-07
the O 0 3.52830511474167e-06
overexpressed O 0 0.00011714454740285873
wild O 0 1.0787364772113506e-05
- O 0 5.109555786475539e-06
type O 0 2.3295849587157136e-06
HFE O 0 5.157857231097296e-05
protein O 0 6.380450372489577e-07
decreases O 0 2.733260373588564e-07
the O 0 1.1183205117504258e-07
affinity O 0 2.0610355022654403e-07
of O 0 1.022076958179241e-06
the O 0 2.020819920289796e-06
TfR O 0 0.000376598589355126
for O 0 4.277967946109129e-06
transferrin O 0 0.0001811439433367923
. O 0 4.146357241552323e-06

The O 0 0.0033366880379617214
overexpressed O 0 0.3698446750640869
H63D O 1 0.9943460822105408
protein O 0 0.00098231912124902
does O 0 2.0060347196704242e-06
not O 0 2.636677436385071e-07
have O 0 7.805780199987566e-08
this O 0 9.593361660620303e-09
effect O 0 1.7032198229571804e-07
, O 0 1.7345675118463078e-08
providing O 0 1.3155910139062144e-08
the O 0 1.3161255196791899e-08
first O 0 1.2708412100437272e-08
direct O 0 3.466497489057474e-08
evidence O 0 5.850732875956055e-08
for O 0 5.424714899504579e-08
a O 0 5.320715104062401e-07
functional O 0 1.5829862604732625e-05
consequence O 0 8.645733032608405e-06
of O 0 7.05023876435007e-06
the O 0 1.6545554899494164e-05
H63D O 0 0.0009996440494433045
mutation O 0 1.3483654583978932e-05
. O 0 4.363449534139363e-06

Addition O 0 5.430386227089912e-05
of O 0 0.00016805846826173365
soluble O 0 0.0010064106900244951
wild O 0 8.990298374556005e-05
- O 0 0.00016726697504054755
type O 0 0.0002595843398012221
HFE O 1 0.8017619848251343
/ O 0 0.0011370914289727807
beta2m O 0 0.0005078773247078061
heterodimers O 0 0.00011878093937411904
to O 0 4.9911936912394594e-06
cultured O 0 6.816808308940381e-05
cells O 0 2.8348908927000593e-06
also O 0 1.9584054200549872e-07
decreased O 0 4.718453510577092e-06
the O 0 2.2368955399088009e-07
apparent O 0 6.091834734434087e-07
affinity O 0 5.183941880204657e-07
of O 0 3.326468686282169e-06
the O 0 2.7430837690189946e-06
TfR O 0 0.00026954314671456814
for O 0 1.6225055787799647e-06
its O 0 8.734307357372018e-07
ligand O 0 5.790698196506128e-06
under O 0 3.877134531649062e-06
steady O 0 2.44846596615389e-05
- O 0 3.2747107070463244e-07
state O 0 4.220721194769794e-08
conditions O 0 5.694574838344124e-07
, O 0 2.746852878487971e-08
both O 0 4.1985604326555404e-08
in O 0 3.3439260960221873e-07
293 O 0 3.08354265143862e-06
cells O 0 5.685382689080143e-07
and O 0 2.0679539147749892e-07
in O 0 1.6113260699057719e-06
HeLa O 0 0.00010860198381124064
cells O 0 9.013479029817972e-06
. O 0 1.1645954600680852e-06

Furthermore O 0 5.7251163525506854e-05
, O 0 1.730536268951255e-06
at O 0 4.959582838637289e-06
4 O 0 7.94880270404974e-06
degrees O 0 9.421451250091195e-05
C O 0 0.00010323127935407683
, O 0 9.788267334442935e-07
the O 0 2.6761158551380504e-06
added O 0 1.0014715371653438e-05
soluble O 0 2.5342022127006203e-05
complex O 0 4.0790582715999335e-05
of O 0 4.0077029552776366e-05
HFE O 0 0.010322879999876022
/ O 0 0.00027474528178572655
beta2m O 0 7.828790694475174e-05
inhibited O 0 3.799321348196827e-06
binding O 0 9.463502124162915e-07
of O 0 6.347800535877468e-06
transferrin O 0 4.6104345528874546e-05
to O 0 1.6554347439523553e-06
HeLa O 0 0.0001118325162678957
cell O 0 2.6280287784175016e-05
TfR O 0 0.00024342842516489327
in O 0 2.4596213279437507e-06
a O 0 6.093187039368786e-06
concentration O 0 0.00022829500085208565
- O 0 3.1079202017281204e-05
dependent O 0 4.786724275618326e-06
manner O 0 7.017650659690844e-06
. O 0 1.3385683814703953e-06

Scatchard O 0 0.002438542665913701
plots O 0 5.2965562645113096e-05
of O 0 1.5091018212842755e-05
these O 0 9.38758205393242e-07
data O 0 4.383854047773639e-06
indicate O 0 1.347246211480524e-06
that O 0 2.0707227577076992e-07
the O 0 1.5093532965693157e-06
added O 0 1.806123123060388e-06
heterodimer O 0 7.4073936957574915e-06
substantially O 0 7.478740826627472e-07
reduced O 0 4.2589192617015215e-07
the O 0 1.5029772271191177e-07
affinity O 0 7.73190549807623e-07
of O 0 5.358169346436625e-06
TfR O 0 0.0013350739609450102
for O 0 7.84400890552206e-06
transferrin O 0 0.00039438268868252635
. O 0 5.931928171776235e-06

These O 0 1.3525630038202507e-06
results O 0 4.096526936336886e-06
establish O 0 1.4707857189932838e-06
a O 0 2.497644800314447e-06
molecular O 0 1.0079658750328235e-05
link O 0 6.770477284590015e-06
between O 0 1.244230861630058e-05
HFE O 0 0.0009238880593329668
and O 0 4.527345026872354e-06
a O 0 7.540793831140036e-06
key O 0 3.06635738525074e-05
protein O 0 5.493684057000792e-06
involved O 0 1.4652321169705829e-06
in O 0 7.613276920892531e-06
iron O 0 0.00037034170236438513
transport O 0 6.998300523264334e-05
, O 0 1.4736358480149647e-06
the O 0 2.1686164473067038e-06
TfR O 0 0.0004920521751046181
, O 0 8.765473467065021e-07
and O 0 1.2682677663633513e-07
raise O 0 7.70184342968605e-08
the O 0 2.02631099455175e-07
possibility O 0 1.591595690797476e-07
that O 0 6.785026585021114e-08
alterations O 0 1.937701654242119e-06
in O 0 8.092317216323863e-07
this O 0 8.564621367668224e-08
regulatory O 0 5.731662326979858e-07
mechanism O 0 1.100127633435477e-06
may O 0 2.8730966050716233e-07
play O 0 6.753136716497465e-08
a O 0 1.9794047290133676e-08
role O 0 2.234556006897037e-08
in O 0 6.052594869743189e-08
the O 0 4.806095716958225e-07
pathogenesis O 0 0.0004886770038865507
of O 0 0.001027795602567494
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 8.040143438847736e-05
. O 0 5.211912593949819e-06

Genomic O 0 0.00015086632629390806
organization O 0 9.710365702630952e-06
of O 0 1.2427793990354985e-05
the O 0 2.0869883883278817e-05
UBE3A O 0 0.0037106501404196024
/ O 0 0.0002611676463857293
E6 O 0 0.000356847420334816
- O 0 4.7384557547047734e-05
AP O 0 1.591620639374014e-05
gene O 0 3.600835611905495e-07
and O 0 1.597556860133409e-07
related O 0 3.5530622426449554e-06
pseudogenes O 0 8.08666372904554e-05
. O 0 2.3764471279719146e-06

The O 0 0.00016738232807256281
UBE3A O 0 0.00222072284668684
gene O 0 1.1061642908316571e-05
encodes O 0 1.7974603906623088e-05
the O 0 2.7751013476517983e-05
E6 O 0 0.0003281265962868929
- O 0 0.00020337695605121553
AP O 0 0.00026967396843247116
ubiquitin O 0 7.695044769207016e-05
- O 0 3.122095949947834e-05
protein O 0 1.1304924555588514e-05
ligase O 0 2.9768614240310853e-06
and O 0 2.3359199019523658e-07
has O 0 1.6891176812805497e-07
recently O 0 1.48435816527126e-07
been O 0 1.8596136186488366e-08
shown O 0 1.4163203942985092e-08
to O 0 3.5016560762102245e-09
be O 0 3.0304608600317806e-08
mutated O 0 3.06375659420155e-06
in O 0 5.869847518624738e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.790183424949646
who O 0 1.2552635780593846e-05
lack O 0 0.00012788752792403102
15q11 O 0 0.0008175462717190385
- O 0 0.00015618358156643808
q13 O 0 9.59980025072582e-05
deletions O 0 7.41010671845288e-06
or O 0 5.461692126118578e-06
chromosome O 0 0.0001045131721184589
15 O 0 7.451060082530603e-05
paternal O 0 0.019810153171420097
uniparental B-Disease 1 0.9998893737792969
disomy I-Disease 1 0.5271941423416138
. O 0 1.8795859432430007e-05

Previous O 0 0.0003144451475236565
UBE3A O 0 0.0035898208152502775
cDNA O 0 5.9614139900077134e-05
analysis O 0 7.036617262201617e-07
has O 0 2.0228316088832798e-07
shown O 0 1.887544556211651e-07
a O 0 3.877572112287453e-07
coding O 0 1.7752244048097054e-06
region O 0 3.34806799173748e-07
of O 0 1.7424980569558102e-06
approximately O 0 3.573672984202858e-06
2 O 0 3.868710336973891e-05
. O 0 2.0447205315576866e-06

6 O 0 0.0029606742318719625
kb O 0 0.0022105397656559944
and O 0 2.1611449483316392e-05
a O 0 2.147265877283644e-05
3 O 0 3.285803904873319e-05
- O 0 8.02693102741614e-06
untranslated O 0 8.399027137784287e-05
region O 0 3.470087904133834e-06
( O 0 7.859620154704317e-07
UTR O 0 3.056512650800869e-05
) O 0 2.825660487815185e-07
of O 0 7.093847216310678e-06
< O 0 4.687320324592292e-05
50 O 0 3.3137221180368215e-05
bp O 0 9.281477105105296e-06
, O 0 7.044089898045058e-07
whereas O 0 5.616161615762394e-07
Northern O 0 1.2732925824820995e-06
analysis O 0 1.7516204309231398e-07
has O 0 2.4422635647169955e-07
indicated O 0 3.0923544613870035e-07
mRNA O 0 3.215463664218987e-07
sizes O 0 3.1295166991185397e-07
of O 0 2.8558285976032494e-06
5 O 0 1.350338334304979e-05
- O 0 1.0924226444330998e-05
8 O 0 4.1343279008287936e-05
kb O 0 0.0002040371036855504
. O 0 3.8995399336272385e-06

We O 0 1.3310171198099852e-05
have O 0 3.644733794772037e-07
analyzed O 0 2.432342967040313e-07
additional O 0 7.945552482624407e-08
cDNA O 0 4.499779151956318e-06
clones O 0 2.2411647933040513e-06
and O 0 5.013281878518683e-08
provide O 0 1.862662735163667e-08
evidence O 0 6.341190328384982e-08
for O 0 7.000673463153362e-08
an O 0 6.319734069393235e-08
additional O 0 3.160848791594617e-07
0 O 0 2.3630642317584716e-05
. O 0 1.7064925259546726e-06

5 O 0 0.0004517774796113372
kb O 0 0.0005036878865212202
of O 0 0.00012577127199620008
5 O 0 4.379588790470734e-05
- O 0 1.2478098142310046e-05
UTR O 0 9.247630805475637e-05
and O 0 1.8543732949183322e-06
> O 0 6.437029696826357e-06
2 O 0 1.0989051588694565e-05
kb O 0 4.000111948698759e-05
of O 0 2.6941383111989126e-05
3 O 0 0.00014965161972213537
- O 0 6.37779085082002e-05
UTR O 0 0.00041262537706643343
. O 0 2.268154048579163e-06

We O 0 6.042714176146546e-06
have O 0 1.7641971794546407e-07
established O 0 2.445405016260338e-07
the O 0 1.5820768339835922e-07
genomic O 0 9.175236641567608e-07
organization O 0 3.67278033763796e-07
of O 0 1.4522705669151037e-06
UBE3A O 0 7.549963629571721e-05
and O 0 3.616397918904113e-07
the O 0 3.70258192106121e-07
sequence O 0 2.020175173811367e-07
of O 0 5.132744718139293e-06
intron O 0 9.165982191916555e-05
- O 0 2.8250235118321143e-05
exon O 0 9.138208952208515e-06
borders O 0 2.8954505069123115e-06
. O 0 2.067947434625239e-06

We O 0 7.054179877741262e-05
have O 0 3.2076000024972018e-06
also O 0 5.294359084473399e-07
mapped O 0 6.398254868145159e-07
two O 0 3.70302700503089e-07
highly O 0 1.0345580676585087e-06
homologous O 0 3.2487109820067417e-06
processed O 0 6.056433903722791e-06
pseudogenes O 0 2.4722412490518764e-05
, O 0 3.0341450383275514e-06
UBE3AP1 O 0 0.00014184959582053125
and O 0 1.0492413821339142e-05
UBE3AP2 O 0 0.00011438985529821366
, O 0 7.177687848525238e-07
to O 0 1.0413718598556443e-07
chromosomes O 0 8.254726253653644e-07
2 O 0 4.627243470167741e-06
and O 0 3.6868070196760527e-07
21 O 0 9.53401922743069e-06
, O 0 2.2368912766523863e-07
respectively O 0 6.117695647844812e-07
, O 0 1.691712370188725e-08
and O 0 7.634226584229964e-09
determined O 0 2.4276657129007617e-08
their O 0 2.8650486427750366e-08
genomic O 0 2.8650133572227787e-06
organization O 0 1.4206947298589512e-06
. O 0 7.708028988417936e-07

These O 0 5.954111202299828e-06
results O 0 3.725438091350952e-06
will O 0 2.6398495833745983e-08
form O 0 4.430182443115882e-09
the O 0 2.505792462415002e-09
basis O 0 5.1604351902767576e-09
for O 0 2.5969291161942465e-09
studies O 0 4.166037470554329e-08
of O 0 9.97772886535131e-08
mutation O 0 1.1124190280042967e-07
and O 0 1.5706426381711935e-07
imprinting O 0 1.4059940440347418e-05
of O 0 2.7378946469980292e-05
UBE3A O 0 0.0033996575511991978
. O 0 1.072849590855185e-05

Mutation O 0 0.00017519845278002322
spectrum O 0 7.643448770977557e-05
and O 0 2.561047949711792e-06
genotype O 0 4.266625546733849e-05
- O 0 1.4482165170193184e-05
phenotype O 0 3.6269086649554083e-06
analyses O 0 1.3767061091130017e-07
in O 0 6.099351139710052e-07
Cowden B-Disease 1 0.9904318451881409
disease I-Disease 1 0.7211154699325562
and O 0 1.1603424354689196e-05
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 4.3797490434371866e-07
two O 0 1.4833677823844482e-06
hamartoma B-Disease 1 0.9999958276748657
syndromes I-Disease 1 0.999988317489624
with O 0 1.030414568958804e-05
germline O 1 0.9995255470275879
PTEN O 1 0.9994832277297974
mutation O 0 2.9943103072582744e-05
. O 0 4.124838596908376e-06

The O 0 0.003924377728253603
tumour B-Disease 1 1.0
suppressor O 1 0.9999793767929077
gene O 0 0.00041660189162939787
PTEN O 0 0.0016115843318402767
, O 0 3.498647629385232e-07
which O 0 3.270247361797374e-08
maps O 0 1.948494485759511e-07
to O 0 3.18632658036222e-07
10q23 O 0 0.00010351301170885563
. O 0 7.128325250960188e-06

3 O 0 2.8079301046091132e-05
and O 0 2.212828178471682e-07
encodes O 0 1.3545225101552205e-06
a O 0 1.0209284937445773e-06
403 O 0 3.237940973122022e-06
amino O 0 1.3754359997619758e-06
acid O 0 1.6613435036560986e-06
dual O 0 2.162023156415671e-05
specificity O 0 4.9257443606620654e-05
phosphatase O 0 0.004148504696786404
( O 0 6.770294567104429e-05
protein O 0 0.00013898542965762317
tyrosine O 0 0.00011134093074360862
phosphatase O 0 0.00026005227118730545
; O 0 5.029841304349247e-06
PTPase O 0 4.189807441434823e-05
) O 0 5.121382855577394e-07
, O 0 1.0240405856620782e-07
was O 0 6.254207391975797e-07
shown O 0 1.5305043632451998e-07
recently O 0 1.1011589151621592e-07
to O 0 6.520951334465508e-09
play O 0 1.0568111008524284e-07
a O 0 6.676751951317783e-08
broad O 0 3.0401355388676166e-07
role O 0 4.384228873277607e-07
in O 0 2.434167527098907e-06
human O 0 3.899282819475047e-05
malignancy B-Disease 0 0.0006774310604669154
. O 0 2.5502044991299044e-06

Somatic O 0 0.0196621622890234
PTEN O 0 0.009051746688783169
deletions O 0 9.775116268428974e-06
and O 0 1.7079922542961867e-07
mutations O 0 6.106014183160369e-08
were O 0 2.101522689201829e-08
observed O 0 1.6139569680717614e-08
in O 0 1.6247177825334802e-08
sporadic B-Disease 0 6.068233687983593e-06
breast I-Disease 1 0.9999021291732788
, I-Disease 0 1.2869085367128719e-05
brain I-Disease 1 0.9999996423721313
, I-Disease 0 8.194196198019199e-06
prostate I-Disease 1 1.0
and I-Disease 0 0.008607430383563042
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9999961853027344
cell O 0 2.4793549528112635e-05
lines O 0 8.01300501507285e-08
and O 0 3.82591647252184e-09
in O 0 1.230468882340574e-08
several O 0 4.2101881092548865e-08
primary O 0 2.664615931280423e-05
tumours B-Disease 1 1.0
such O 0 2.3806884996702138e-07
as O 0 1.715222060738597e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9850800633430481
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999926090240479
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.00012264522956684232

In O 0 3.188004848198034e-05
addition O 0 5.105863237986341e-06
, O 0 4.005082246294478e-06
PTEN O 0 0.00021676631877198815
was O 0 1.0008097888203338e-06
identified O 0 5.991718410314206e-08
as O 0 2.0588206695038025e-08
the O 0 2.7699917026779985e-08
susceptibility O 0 2.771271283563692e-06
gene O 0 2.643745347086224e-07
for O 0 1.532024640482632e-07
two O 0 4.678628101828508e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 1.4619039575336501e-05
CD B-Disease 0 0.00017662215395830572
; O 0 2.9983275453560054e-06
MIM O 0 0.0005423568072728813
158350 O 0 5.767221227870323e-05
) O 0 9.903507134367828e-07
and O 0 1.4632882994192187e-06
Bannayan B-Disease 0 0.00039088085759431124
- I-Disease 0 0.00042120894067920744
Zonana I-Disease 0 0.0035583339631557465
( I-Disease 0 6.937852049304638e-06
BZS I-Disease 0 0.0004913939046673477
) I-Disease 0 2.563769839980523e-06
or I-Disease 0 3.2494363040314056e-06
Ruvalcaba I-Disease 0 0.00018077640561386943
- I-Disease 0 8.623732719570398e-05
Riley I-Disease 0 0.00012392151984386146
- I-Disease 0 0.038330480456352234
Smith I-Disease 0 0.0030875455122441053
syndrome I-Disease 1 0.9999998807907104
( O 0 2.0851619410677813e-05
MIM O 0 0.007780757267028093
153480 O 0 0.00028375702095218003
) O 0 2.507872295609559e-06
. O 0 1.4067568372411188e-06

Constitutive O 0 0.0007264818996191025
DNA O 0 2.6418389097671025e-05
from O 0 1.2393978977343068e-05
37 O 0 2.8358663257677108e-05
CD B-Disease 0 9.574256182531826e-06
families O 0 1.2639800672786805e-07
and O 0 2.46933950620587e-07
seven O 0 2.036902287727571e-06
BZS B-Disease 0 9.564127685735002e-05
families O 0 2.9331701512091968e-08
was O 0 5.230951387602545e-07
screened O 0 1.3995576182423974e-06
for O 0 1.8264025811731699e-06
germline O 0 0.0004459409392438829
PTEN O 0 0.0021645009983330965
mutations O 0 1.0784690857690293e-05
. O 0 2.826230911523453e-06

PTEN O 0 0.010735212825238705
mutations O 0 6.5147764871653635e-06
were O 0 3.46853926203039e-06
identified O 0 1.8126148404462583e-07
in O 0 3.7331020052988606e-07
30 O 0 1.6325509477610467e-06
of O 0 3.655040927696973e-06
37 O 0 1.1802639164670836e-05
( O 0 6.410898549802369e-07
81 O 0 8.81063169799745e-06
% O 0 2.6483229476070846e-07
) O 0 7.868997897730878e-08
CD B-Disease 0 1.2713305750366999e-06
families O 0 1.7877010094480283e-08
, O 0 2.928966225113072e-08
including O 0 1.4155364169710083e-07
missense O 0 1.047745445248438e-05
and O 0 6.864246643090155e-06
nonsense O 0 9.875839168671519e-05
point O 0 3.2917061616899446e-05
mutations O 0 1.193286834677565e-06
, O 0 3.737847293905361e-07
deletions O 0 6.226712230272824e-07
, O 0 1.7899994020353915e-07
insertions O 0 7.272116704371001e-07
, O 0 1.2316080244545446e-07
a O 0 5.478733555719373e-07
deletion O 0 6.794506589358207e-06
/ O 0 2.3095755750546232e-05
insertion O 0 3.041213403776055e-06
and O 0 3.887401362590026e-06
splice O 0 7.975266635185108e-05
site O 0 1.8319171431357972e-05
mutations O 0 4.032239303342067e-06
. O 0 2.4409555408055894e-06

These O 0 1.0849981663341168e-05
mutations O 0 5.4356692089641e-06
were O 0 2.9501763947337167e-06
scattered O 0 8.701275646672002e-07
over O 0 2.0341387596545246e-07
the O 0 5.950178092462011e-07
entire O 0 1.4544813211614382e-06
length O 0 1.9431329292274313e-06
of O 0 4.971714588464238e-05
PTEN O 0 0.0005120323621667922
, O 0 5.555699544856907e-07
with O 0 2.8864842960274473e-08
the O 0 3.911049191174243e-07
exception O 0 4.077348592090857e-07
of O 0 1.3858244756193017e-06
the O 0 1.3639880762639223e-06
first O 0 2.0261441022739746e-06
, O 0 4.5549043647952203e-07
fourth O 0 4.597315637511201e-06
and O 0 2.0196549144202436e-07
last O 0 1.798174366740568e-06
exons O 0 1.8526909116189927e-05
. O 0 2.6296788746549282e-06

A O 0 0.0009594112634658813
hot O 0 0.0005706006195396185
spot O 0 0.00010111334995599464
for O 0 8.488900675729383e-06
PTEN O 0 0.00040123105281963944
mutation O 0 1.06619484085968e-06
in O 0 3.8981861507636495e-06
CD B-Disease 0 2.291205237270333e-05
was O 0 2.177492388000246e-05
identified O 0 4.3207882072238135e-07
in O 0 7.409418003589963e-07
exon O 0 9.15718544547417e-07
5 O 0 1.6766296084824717e-06
that O 0 8.289121922189224e-08
contains O 0 6.440435527110822e-07
the O 0 8.271508704638109e-06
PTPase O 0 0.0002321177744306624
core O 0 0.00010450489207869396
motif O 0 6.0878378462803084e-06
, O 0 1.3537137988350878e-07
with O 0 2.6048779133702737e-08
13 O 0 1.7328003423244809e-06
of O 0 1.7544184629514348e-06
30 O 0 2.9663533496204764e-06
( O 0 1.853150308761542e-07
43 O 0 1.4990279169069254e-06
% O 0 3.7552621279246523e-07
) O 0 2.185142307098431e-07
CD B-Disease 0 4.486692432692507e-06
mutations O 0 2.8698295295725984e-07
identified O 0 3.20584916835287e-07
in O 0 3.756841806534794e-07
this O 0 2.2256324427871732e-07
exon O 0 7.005026873230236e-06
. O 0 1.1414473419790738e-06

Seven O 0 0.0001101552988984622
of O 0 9.831638453761116e-05
30 O 0 4.0456452552462e-05
( O 0 1.328944563283585e-06
23 O 0 1.1023227671103086e-05
% O 0 5.533142370950372e-07
) O 0 1.0021921070801909e-07
were O 0 4.5146157390263397e-07
within O 0 6.245594477150007e-07
the O 0 3.0360786240635207e-06
core O 0 1.7430766092729755e-05
motif O 0 5.241951384959975e-06
, O 0 4.0230455056189385e-07
the O 0 5.545408612306346e-07
majority O 0 8.752036251280515e-08
( O 0 2.674908898825379e-07
five O 0 6.885954917379422e-07
of O 0 3.143040885333903e-06
seven O 0 2.81213237940392e-06
) O 0 1.4880545506912313e-07
of O 0 3.520509892496193e-07
which O 0 7.591655304395317e-08
were O 0 8.386078320654633e-07
missense O 0 3.8944854168221354e-06
mutations O 0 6.369348852786061e-07
, O 0 2.9166079684728174e-07
possibly O 0 1.3915281726895046e-07
pointing O 0 4.67124408487507e-07
to O 0 1.681476113901681e-08
the O 0 1.3371300155995414e-07
functional O 0 2.320874500583159e-06
significance O 0 1.4336861795527511e-06
of O 0 3.0126816454867367e-06
this O 0 3.3537884291945375e-07
region O 0 4.314576472097542e-06
. O 0 3.3519318094477057e-06

Germline O 0 0.06378170102834702
PTEN O 0 0.013428614474833012
mutations O 0 1.1013434232154395e-05
were O 0 4.14563737649587e-06
identified O 0 2.5751299403964367e-07
in O 0 2.579775468802836e-07
four O 0 2.1640143188506045e-07
of O 0 1.341670099463954e-06
seven O 0 2.287742518092273e-06
( O 0 1.0274482065142365e-06
57 O 0 1.2874596905021463e-05
% O 0 2.391488806097186e-06
) O 0 1.5850791896809824e-06
BZS B-Disease 0 0.0003429905336815864
families O 0 5.340027655620361e-07
studied O 0 3.940480382880196e-05
. O 0 7.461631867045071e-06

Interestingly O 0 0.0001676950923865661
, O 0 1.1682096783260931e-06
none O 0 3.5053807323492947e-07
of O 0 3.579279734822194e-07
these O 0 4.077759996334862e-08
mutations O 0 5.47602724054741e-07
was O 0 3.9270935303648e-06
observed O 0 7.50047604469728e-07
in O 0 6.921191584297048e-07
the O 0 2.5070878564292798e-06
PTPase O 0 0.00016622505791019648
core O 0 0.00012146437802584842
motif O 0 4.853689461015165e-05
. O 0 4.369921043689828e-06

It O 0 5.925578534515807e-06
is O 0 1.0409692094981438e-06
also O 0 3.22102465588614e-07
worthy O 0 8.139693363773404e-07
of O 0 2.340523224120261e-06
note O 0 8.854609063746466e-07
that O 0 5.843929429261152e-08
a O 0 9.309172241955821e-07
single O 0 2.7252433483226923e-06
nonsense O 0 1.6217294614762068e-05
point O 0 1.1955402442254126e-05
mutation O 0 2.486227685949416e-07
, O 0 1.7516221362257056e-07
R233X O 0 1.646846612857189e-06
, O 0 1.213464742022552e-07
was O 0 8.432882054876245e-07
observed O 0 4.629423528967891e-07
in O 0 5.744039981436799e-07
the O 0 8.320309348164301e-07
germline O 0 4.857686690229457e-06
DNA O 0 1.7755549208686716e-07
from O 0 2.3217857858526258e-07
two O 0 1.2168381147148466e-07
unrelated O 0 1.0556824463492376e-06
CD B-Disease 0 6.279749413806712e-06
families O 0 1.4317402019514702e-07
and O 0 8.263650101980602e-07
one O 0 3.552777798176976e-06
BZS B-Disease 0 0.0016656367806717753
family O 0 5.563510512729408e-06
. O 0 4.131590230826987e-06

Genotype O 0 0.008539759553968906
- O 0 0.0012001615250483155
phenotype O 0 6.73648391966708e-05
studies O 0 3.3107487524830503e-06
were O 0 4.907308834845026e-07
not O 0 3.43847794681551e-08
performed O 0 5.896609422961774e-07
on O 0 1.0749117791419849e-06
this O 0 5.2762484159529777e-08
small O 0 3.042777905193361e-07
group O 0 1.2922427572448214e-07
of O 0 3.7922332012385596e-06
BZS B-Disease 0 0.0011605311883613467
families O 0 1.6592169913565158e-06
. O 0 2.9982588785060216e-06

However O 0 7.178595114964992e-05
, O 0 9.448880518903024e-06
genotype O 0 9.532678814139217e-05
- O 0 6.0598624259000644e-05
phenotype O 0 3.633639425970614e-05
analysis O 0 2.513928166081314e-06
inthe O 0 3.848718188237399e-05
group O 0 5.37737832928542e-07
of O 0 3.206902420060942e-06
CD B-Disease 0 3.4082688216585666e-05
families O 0 2.909196439304651e-07
revealed O 0 2.456288029861753e-06
two O 0 7.217919915092352e-07
possible O 0 1.417771159140102e-06
associations O 0 1.2786968000000343e-06
worthy O 0 3.554872364475159e-06
of O 0 6.005934210406849e-06
follow O 0 5.01115039241995e-07
- O 0 6.428310257433623e-07
up O 0 1.1283972156661548e-07
in O 0 7.678551128265099e-08
independent O 0 1.148984978271983e-07
analyses O 0 5.187279725760163e-07
. O 0 1.4335603282233933e-06

The O 0 0.00011704159987857565
first O 0 2.7946080081164837e-05
was O 0 5.635189518216066e-05
an O 0 1.767644221217779e-06
association O 0 1.592468606759212e-06
noted O 0 1.7024824217060086e-07
in O 0 1.248905050488247e-07
the O 0 1.3532580567243713e-07
group O 0 1.632857227207296e-08
of O 0 1.1828748824882496e-07
CD B-Disease 0 6.400149231922114e-06
families O 0 7.829653014823634e-08
with O 0 1.7828608633863041e-06
breast B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.733432145556435e-05

A O 0 5.921740739722736e-05
correlation O 0 1.0999578989867587e-05
was O 0 6.749930435034912e-06
observed O 0 5.751692242483841e-07
between O 0 2.712276625516097e-07
the O 0 3.3947850397453294e-07
presence O 0 1.3415332205113373e-06
/ O 0 1.8685446775634773e-05
absence O 0 2.150129830624792e-06
of O 0 2.949979489130783e-06
a O 0 6.173494966787985e-06
PTEN O 0 0.00020489883900154382
mutation O 0 3.6802127567625575e-08
and O 0 1.541556038375802e-08
the O 0 4.228972727560176e-08
type O 0 7.010140166130441e-07
of O 0 8.026846444408875e-06
breast O 1 0.9793380498886108
involvement O 0 0.0010105515830218792
( O 0 0.00026738562155514956
unaffected O 0 0.005868314299732447
versus O 0 0.1347847878932953
benign O 1 0.9816008806228638
versus O 0 0.0013056538300588727
malignant O 0 0.017255138605833054
) O 0 2.2030549189366866e-06
. O 0 6.156417384772794e-07

Specifically O 0 0.00010863885836442932
and O 0 1.5464835087186657e-05
more O 0 1.1757483662222512e-06
directly O 0 3.2943803489615675e-06
, O 0 4.72605506729451e-07
an O 0 3.775976153974625e-07
association O 0 1.077216666089953e-06
was O 0 5.645772489515366e-07
also O 0 2.9049093797084424e-08
observed O 0 1.8764305664831227e-08
between O 0 9.235547437924652e-09
the O 0 5.557764026775658e-09
presence O 0 1.2971601570654911e-08
of O 0 9.680398704858817e-08
a O 0 2.4563184979342623e-06
PTEN O 0 0.04755010828375816
mutation O 0 1.925924516399391e-05
and O 0 9.563552885083482e-05
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999994039535522
. O 0 5.672050519933691e-06

Secondly O 0 0.0033250623382627964
, O 0 2.710500302782748e-05
there O 0 2.860800350390491e-06
appeared O 0 5.294947641232284e-06
to O 0 2.0078631735032104e-07
be O 0 4.657561305521085e-07
an O 0 3.161837867082795e-07
interdependent O 0 1.5253303899953607e-05
association O 0 3.5801851936412277e-06
between O 0 2.6379175324109383e-06
mutations O 0 1.8038372218143195e-06
upstream O 0 1.582035474712029e-05
and O 0 6.312253049145511e-07
within O 0 1.670564643063699e-06
the O 0 7.728315722488333e-06
PTPase O 0 0.00029317682492546737
core O 0 0.0001836514420574531
motif O 0 2.6417785193189047e-05
, O 0 9.845253998719272e-07
the O 0 1.1812712727987673e-06
core O 0 4.3631998778437264e-06
motif O 0 9.418474178346514e-07
containing O 0 2.2290353740572755e-07
the O 0 9.006307521985946e-08
majority O 0 1.8208787366802426e-08
of O 0 8.913696660783899e-07
missense O 0 8.426535714534111e-06
mutations O 0 4.726938414023607e-07
, O 0 5.812237446889412e-08
and O 0 1.2381838665476153e-08
the O 0 2.7448049166878263e-08
involvement O 0 4.696249078506298e-08
of O 0 1.1376226893844432e-07
all O 0 4.3732960364195606e-08
major O 0 4.218470166961197e-06
organ O 1 0.9999462366104126
systems O 0 0.1971464902162552
( O 0 8.75391469890019e-06
central O 0 0.00010721657599788159
nervous O 0 0.0002747096586972475
system O 0 9.198187035508454e-05
, O 0 5.0148687478213105e-06
thyroid O 1 1.0
, O 0 6.470033258665353e-05
breast O 1 0.9999998807907104
, O 0 0.00022498560429085046
skin O 1 0.9999828338623047
and O 0 0.0009360646945424378
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 1.8951208403450437e-05
. O 0 1.3741982911597006e-06

However O 0 0.00035662230220623314
, O 0 6.957935056561837e-06
these O 0 4.4057389914087253e-07
observations O 0 8.677056030137464e-06
would O 0 5.488806209541508e-07
need O 0 2.0573983761096315e-07
to O 0 6.844219058166345e-08
be O 0 1.9738990886253305e-07
confirmed O 0 1.2432059293132625e-07
by O 0 7.106196964201672e-09
studying O 0 3.929405067992775e-08
a O 0 4.250467000588287e-08
larger O 0 1.4377272705701216e-08
number O 0 7.119535894162254e-08
of O 0 1.396122115693288e-06
CD B-Disease 0 1.7832107914728113e-05
families O 0 3.120917995147465e-07
. O 0 1.3503977243090048e-06

Molecular O 1 0.9783049821853638
defects O 0 0.39920303225517273
leading O 0 1.9343808162375353e-05
to O 0 1.3011178623401065e-07
human O 0 5.1098431868012995e-06
complement B-Disease 0 7.906238897703588e-05
component I-Disease 1 0.9999986886978149
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.7846821467392147e-05
an O 0 1.0368812581873499e-06
African O 0 1.8312808833798044e-06
- O 0 1.7277181996178115e-06
American O 0 4.897803478343121e-07
family O 0 2.1159462448849808e-07
. O 0 2.1785423598430498e-07

Complement B-Disease 0 0.004986168816685677
component I-Disease 1 0.9999961853027344
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.00018575739522930235
C6D B-Disease 0 0.005809457041323185
) O 0 4.7035514398885425e-06
was O 0 7.8896242484916e-05
diagnosed O 0 0.0031415231060236692
in O 0 1.5013661140983459e-05
a O 0 1.3533600395021494e-05
16 O 0 3.749712050193921e-05
- O 0 4.361444098321954e-06
year O 0 3.4019640224869363e-06
- O 0 1.245031171492883e-06
old O 0 5.272660018817987e-06
African O 0 1.186140138997871e-06
- O 0 8.796735073701711e-07
American O 0 2.1108269265823765e-07
male O 0 1.0015936595664243e-06
with O 0 8.997265013022115e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 6.1101554820197634e-06

The O 0 0.0002639528247527778
patients O 0 0.00016967295960057527
father O 0 0.00011412456660764292
and O 0 2.382633465458639e-05
two O 0 3.74334558728151e-05
brothers O 0 0.0002454298664815724
also O 0 1.873912515293341e-05
had O 0 4.465546953724697e-05
C6D B-Disease 0 0.0005383277893997729
, O 0 1.469349939497988e-07
but O 0 4.1219316848639664e-09
gave O 0 1.1501170682493012e-08
no O 0 2.309502278308173e-08
history O 0 3.167753277466545e-07
of O 0 4.61090940007125e-06
meningitis B-Disease 1 0.9999998807907104
or O 0 1.658346809563227e-05
other O 0 1.1526444723131135e-06
neisserial B-Disease 0 0.0009355579386465251
infection I-Disease 0 0.0020030091982334852
. O 0 7.411053502437426e-06

By O 0 3.582449608074967e-06
using O 0 7.752061037535896e-07
exon O 0 1.7060498294085846e-06
- O 0 6.438617674575653e-07
specific O 0 9.485705021461399e-08
polymerase O 0 2.4268072593258694e-05
chain O 0 1.933608109538909e-05
reaction O 0 3.7513823372137267e-06
( O 0 1.1616981510087498e-06
PCR O 0 5.896215498069068e-06
) O 0 8.552489703106403e-07
/ O 0 9.21335958992131e-06
single O 0 1.9105500541627407e-06
- O 0 2.3315230919251917e-06
strand O 0 2.9756581625406398e-06
conformation O 0 5.931962618888065e-07
polymorphism O 0 1.4316201202291268e-07
as O 0 3.5505582474115727e-08
a O 0 2.6388425666823423e-08
screening O 0 5.1763290542794493e-08
step O 0 1.7444587285808666e-07
and O 0 6.111304173828103e-08
nucleotide O 0 2.7841244332194037e-07
sequencing O 0 5.669382971973391e-07
of O 0 5.556194082600996e-06
target O 0 5.557084023166681e-06
exons O 0 1.1361127690179273e-05
, O 0 5.71702116758388e-07
we O 0 8.938385320789166e-08
determined O 0 1.421374804522202e-07
that O 0 6.692842902111806e-08
the O 0 5.299627900967607e-07
proband O 0 1.5844951121835038e-05
was O 0 4.926350356981857e-06
a O 0 7.027778110568761e-07
compound O 0 3.2446178011014126e-06
heterozygote O 0 2.141567620128626e-06
for O 0 1.9802229189735954e-07
two O 0 8.628738328297914e-07
C6 O 0 0.00137225107755512
gene O 0 1.5605402950313874e-05
mutations O 0 5.946512828813866e-06
. O 0 2.3507011519541265e-06

The O 0 0.00022433615231420845
first O 0 3.15768011205364e-05
, O 0 2.157248673029244e-06
1195delC O 0 5.078057711216388e-06
located O 0 7.391487997665536e-06
in O 0 1.3525450412998907e-06
exon O 0 4.170811280346243e-06
7 O 0 1.5392359273391776e-05
, O 0 1.6344954190117278e-07
is O 0 4.867248648565692e-08
a O 0 1.3062027903743e-07
novel O 0 3.870939906391868e-07
mutation O 0 1.749864111388888e-07
, O 0 1.7253606188205595e-07
while O 0 1.8771470422507264e-07
the O 0 6.773685754524195e-07
second O 0 7.109044418029953e-06
, O 0 1.1574097698030528e-06
1936delG O 0 3.386750222489354e-06
in O 0 7.236023066070629e-06
exon O 0 1.2680390682362486e-05
12 O 0 3.95592869608663e-05
, O 0 7.084107096488879e-07
has O 0 3.078260704114655e-07
been O 0 3.7503517091863614e-07
described O 0 6.559124017258e-07
before O 0 5.618679779217928e-07
to O 0 1.9589248267948278e-07
cause O 0 2.252994136142661e-06
C6D B-Disease 0 9.496640996076167e-05
in O 0 2.2752469703846145e-06
an O 0 6.993933538979036e-07
unrelated O 0 3.0150670227158116e-06
African O 0 3.4935537769342773e-06
- O 0 3.388559434824856e-06
American O 0 7.02071758951206e-07
individual O 0 2.2843711633413477e-07
. O 0 1.260583189832687e-06

Both O 0 4.298439762351336e-06
mutations O 0 2.504454187146621e-06
result O 0 1.455887058909866e-06
in O 0 1.3237382745501236e-06
premature O 0 7.4627992034947965e-06
termination O 0 4.238568180880975e-06
codons O 0 8.293466635223012e-06
and O 0 2.633488747960655e-06
C6 O 0 0.0018363283015787601
null O 0 0.0002671889087650925
alleles O 0 1.2997257726965472e-05
. O 0 2.8573431336553767e-06

Allele O 0 0.0002678234886843711
- O 0 3.2648731576045975e-05
specific O 0 3.790787275192997e-07
PCR O 0 9.181397217616905e-06
indicated O 0 1.1605343388509937e-06
that O 0 8.47162411332647e-08
the O 0 1.491720468038693e-06
probands O 0 7.488892151741311e-05
two O 0 5.870126642548712e-06
brothers O 0 3.3434746001148596e-05
also O 0 2.9662739962077467e-06
inherited O 0 2.8135807951912284e-05
the O 0 5.593724381469656e-06
1195delC O 0 1.0774092515930533e-05
mutation O 0 2.0245454379619332e-07
from O 0 1.7604091340217565e-07
their O 0 4.740797976410249e-08
heterozygous O 0 4.494665688525856e-07
mother O 0 8.96538494998822e-07
and O 0 1.6425677529241511e-07
the O 0 5.897031201129721e-07
1936delG O 0 2.88388173430576e-06
mutation O 0 1.6137899194745842e-07
from O 0 2.424871183848154e-07
their O 0 7.39511634151313e-08
homozygous O 0 3.4798904380295426e-06
father O 0 5.526989752979716e-06
. O 0 2.163463364013296e-07
. O 0 6.177342584123835e-07

PAX6 O 0 0.031057175248861313
mutations O 0 5.6855238653952256e-05
reviewed O 0 3.832288712146692e-05
. O 0 1.3446017874230165e-05

Mutations O 0 9.1194873675704e-05
in O 0 6.230058352230117e-05
PAX6 O 0 0.0032621193677186966
are O 0 2.864573389160796e-06
responsible O 0 1.0358313375036232e-05
for O 0 1.0484401173016522e-05
human O 0 0.002951584057882428
aniridia B-Disease 1 1.0
and O 0 1.3234302969067357e-05
have O 0 3.096128864399361e-07
also O 0 4.9539305990720095e-08
been O 0 2.218808070608702e-08
found O 0 3.109498880604633e-09
in O 0 6.807995056590244e-09
patients O 0 3.9297948006833394e-08
with O 0 5.718581519431609e-08
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 1.0
, O 0 6.634253168158466e-06
with O 0 0.0002711331471800804
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 2.1292273231665604e-05
with O 0 2.154939693355118e-06
autosomal B-Disease 1 0.9999996423721313
dominant I-Disease 1 0.9999997615814209
keratitis I-Disease 1 1.0
, O 0 3.9467745409638155e-06
and O 0 7.047826215966779e-07
with O 0 4.7062389967322815e-06
isolated B-Disease 1 0.9999773502349854
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.00048581944429315627

No O 0 0.0002767899713944644
locus O 0 0.0003317099472042173
other O 0 2.181322770411498e-06
than O 0 1.4839903315078118e-06
chromosome O 0 3.9779079088475555e-05
11p13 O 0 6.306883005890995e-05
has O 0 4.140260443818988e-06
been O 0 6.937097623449517e-06
implicated O 0 1.9920184058719315e-05
in O 0 5.5563010391779244e-05
aniridia B-Disease 1 0.9999996423721313
, O 0 5.791549028799636e-06
and O 0 3.513758883855189e-06
PAX6 O 0 0.0005217683501541615
is O 0 1.973111466213595e-06
clearly O 0 1.0906383067776915e-06
the O 0 2.005472424571053e-06
major O 0 9.055810551217292e-06
, O 0 2.1377830705660017e-07
if O 0 2.1195610599988868e-08
not O 0 1.1849067504954292e-08
only O 0 4.191135261066847e-08
, O 0 9.495317243590762e-08
gene O 0 1.1470037861727178e-06
responsible O 0 3.625462795753265e-06
. O 0 2.897022113756975e-06

Twenty O 0 0.00032177838147617877
- O 0 1.6470901755383238e-05
eight O 0 3.096012960668304e-06
percent O 0 5.178855644771829e-06
of O 0 2.488681275281124e-06
identified O 0 1.0788742656586692e-05
PAX6 O 0 0.0002896760415751487
mutations O 0 4.635923232854111e-06
are O 0 2.0427032723091543e-06
C O 0 0.00011887817527167499
- O 0 4.498587077250704e-05
T O 0 3.308250234113075e-05
changes O 0 4.6638191975034715e-07
at O 0 2.176338057324756e-05
CpG O 0 1.2546593097795267e-05
dinucleotides O 0 1.3048875189269893e-05
, O 0 4.0857679550754256e-07
20 O 0 8.892911296243255e-07
% O 0 2.8384192773955874e-07
are O 0 9.38390556370905e-08
splicing O 0 1.302751002185687e-06
errors O 0 4.7932026063790545e-05
, O 0 1.0807851822391967e-06
and O 0 3.743555225810269e-07
more O 0 3.768996137409886e-08
than O 0 5.829835103554615e-08
30 O 0 8.613708359916927e-07
% O 0 1.2456541753635975e-07
are O 0 2.0478859497075064e-08
deletion O 0 7.623140731993772e-07
or O 0 5.41740405424207e-07
insertion O 0 1.9275003069196828e-06
events O 0 2.580695991127868e-06
. O 0 2.1168759758438682e-06

There O 0 2.301844688190613e-05
is O 0 4.848152457270771e-06
a O 0 7.566951353510376e-06
noticeably O 0 6.99109659763053e-05
elevated O 0 0.0002779938222374767
level O 0 5.374709144234657e-05
of O 0 1.385346786264563e-05
mutation O 0 1.7716657794153434e-06
in O 0 3.970839316025376e-06
the O 0 2.115913048328366e-06
paired O 0 8.499492309965717e-07
domain O 0 6.479777994172764e-07
compared O 0 1.912240179535729e-07
with O 0 1.1191351845241115e-08
the O 0 1.6291683380131872e-07
rest O 0 1.2271200944269367e-07
of O 0 8.44602595861943e-07
the O 0 2.442879122099839e-06
gene O 0 4.660165359382518e-06
. O 0 2.5175413611577824e-06

Increased O 0 4.601066393661313e-05
mutation O 0 6.72967144055292e-06
in O 0 3.631473646237282e-06
the O 0 2.2021013137418777e-06
homeodomain O 0 1.3164316442271229e-05
is O 0 1.4962199657020392e-07
accounted O 0 6.420804652407242e-07
for O 0 7.856340289436048e-08
by O 0 1.711458850195413e-07
the O 0 3.323177224956453e-06
hypermutable O 0 0.00019018867169506848
CpG O 0 0.00019122406956739724
dinucleotide O 0 0.00012883046292699873
in O 0 1.8459833881934173e-05
codon O 0 6.50415604468435e-05
240 O 0 2.145329381164629e-05
. O 0 1.809557602427958e-06

Very O 0 1.0658243809302803e-05
nearly O 0 2.203197709604865e-06
all O 0 8.847200660966337e-08
mutations O 0 2.58125226082484e-07
appear O 0 2.1967221641716606e-07
to O 0 3.055330211054752e-08
cause O 0 5.6827701655493e-07
loss O 0 3.1899919576972025e-06
of O 0 5.952243100182386e-06
function O 0 1.429451094736578e-05
of O 0 1.4164267668093089e-05
the O 0 7.0426654019684065e-06
mutant O 0 7.868156899348833e-06
allele O 0 1.1769914181058994e-06
, O 0 9.989287974576655e-08
and O 0 2.8909472149507565e-08
more O 0 1.962651818843142e-09
than O 0 7.247100697327369e-09
80 O 0 2.1525332272176456e-07
% O 0 6.46683915306312e-08
of O 0 3.8062557905504946e-07
exonic O 0 2.2140548026072793e-05
substitutions O 0 2.379084207859705e-06
result O 0 2.2682122562400764e-06
in O 0 5.101998340251157e-06
nonsense O 0 5.4472737247124314e-05
codons O 0 4.087480920134112e-05
. O 0 3.136501163680805e-06

In O 0 5.21420624863822e-05
a O 0 1.1170131074322853e-05
gene O 0 1.5246030216076178e-06
with O 0 6.879135838744332e-08
such O 0 2.6466767621968756e-07
extraordinarily O 0 6.678129011561396e-06
high O 0 4.623547283699736e-06
sequence O 0 2.965217333894543e-07
conservation O 0 3.6763125876859704e-07
throughout O 0 1.5240257766890863e-07
evolution O 0 5.24187328210246e-07
, O 0 7.174677563170917e-08
there O 0 5.55387735801105e-08
are O 0 2.0713409298878105e-07
presumed O 0 2.3613476514583454e-05
undiscovered O 0 0.00010839341848623008
missense O 0 3.4884553315350786e-05
mutations O 0 4.862400146521395e-06
, O 0 4.77640014651115e-07
these O 0 5.229509980608782e-08
are O 0 7.523788525531927e-08
hypothesized O 0 6.81385586176475e-07
to O 0 1.3298964063324092e-07
exist O 0 4.1923070170923893e-07
in O 0 3.186094090779079e-06
as O 0 4.966947926732246e-06
- O 0 4.826447820960311e-06
yet O 0 2.9538372814386094e-07
unidentified O 0 3.540010084179812e-06
phenotypes O 0 2.0613983906514477e-06
. O 0 8.590094324745223e-08
. O 0 4.3201040966778237e-07

Genetic O 0 5.4544987506233156e-05
heterogeneity O 0 3.9100777939893305e-05
and O 0 5.220635443947685e-07
penetrance O 0 2.1719943106290884e-05
analysis O 0 9.720696425574715e-08
of O 0 2.6182229362348153e-07
the O 0 7.189923962869216e-07
BRCA1 O 0 7.030740562186111e-06
and O 0 6.62260674744175e-07
BRCA2 O 0 8.926677764975466e-06
genes O 0 1.4687492466691765e-06
in O 0 6.4103137447091285e-06
breast B-Disease 1 0.9985656142234802
cancer I-Disease 0 0.0006489107618108392
families O 0 3.586851846648642e-07
. O 0 8.130390938276832e-07

The O 0 0.0017085691215470433
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.002998184645548463
Consortium O 0 9.188114199787378e-05
. O 0 3.834199105767766e-06

The O 0 5.307068136062298e-07
contribution O 0 4.852732331528387e-07
of O 0 1.8341158920520684e-06
BRCA1 O 0 1.3394135748967528e-05
and O 0 1.8919251942861592e-06
BRCA2 O 0 0.0001870185078587383
to O 0 1.873760629678145e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.0017327236710116267
assessed O 0 3.834670678770635e-06
by O 0 1.0360641766737899e-07
linkage O 0 2.3417042029905133e-06
and O 0 3.4376262192381546e-07
mutation O 0 3.572602622625709e-07
analysis O 0 1.5785050777594734e-07
in O 0 7.558423362752364e-07
237 O 0 3.4812846934073605e-06
families O 0 6.651482920005947e-08
, O 0 5.37735864725164e-08
each O 0 8.22313772630423e-09
with O 0 2.0910627895887046e-08
at O 0 1.2765779047185788e-06
least O 0 2.0784062471079778e-08
four O 0 3.299261308598034e-08
cases O 0 4.734400249617465e-08
of O 0 1.6869038290678873e-06
breast B-Disease 1 0.8303986191749573
cancer I-Disease 0 2.4415967345703393e-05
, O 0 9.644953280485424e-09
collected O 0 1.0628671276435853e-08
by O 0 1.4825934258055895e-08
the O 0 2.8958536404388724e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.00022230675676837564
Consortium O 0 2.9227019695099443e-05
. O 0 2.4420544377790065e-06

Families O 0 1.8735250932877534e-06
were O 0 3.6753658605448436e-07
included O 0 5.191248675373572e-08
without O 0 2.4103222528992774e-08
regard O 0 5.836789185309499e-08
to O 0 8.349384295058826e-09
the O 0 8.64527223143341e-08
occurrence O 0 6.518605005112477e-06
of O 0 0.0001594210771145299
ovarian B-Disease 1 1.0
or I-Disease 0 0.00043665204429998994
other I-Disease 0 5.5982072808546945e-06
cancers I-Disease 1 0.9969117045402527
. O 0 5.727854841097724e-06

Overall O 0 0.009515122510492802
, O 0 0.00020728159870486706
disease O 1 0.9970811009407043
was O 0 0.001005208003334701
linked O 0 3.6751873267348856e-05
to O 0 3.3192389992109383e-07
BRCA1 O 0 2.0275995211704867e-06
in O 0 3.023481554009777e-07
an O 0 7.424625891871983e-08
estimated O 0 2.583172999948147e-07
52 O 0 1.3620123127111583e-06
% O 0 2.6960171339851513e-07
of O 0 1.910573701024987e-06
families O 0 2.596651427211327e-07
, O 0 2.886231982301979e-07
to O 0 2.2892935191975994e-07
BRCA2 O 0 1.895161290121905e-06
in O 0 1.7606100755074294e-06
32 O 0 4.203366188448854e-06
% O 0 4.4325511794340855e-07
of O 0 1.432021690561669e-06
families O 0 1.525260273638196e-07
, O 0 8.688914476806531e-08
and O 0 4.31334434836117e-08
to O 0 1.6045614614768056e-08
neither O 0 9.049941951388973e-08
gene O 0 3.841412876681716e-08
in O 0 1.978231551902354e-07
16 O 0 1.0247903219351429e-06
% O 0 1.0163407893060139e-07
( O 0 2.3659396219954942e-08
95 O 0 4.6033076728235756e-07
% O 0 2.8496125992205634e-07
confidence O 0 5.303792022459675e-06
interval O 0 1.562026227475144e-05
[ O 0 2.0721994587802328e-05
CI O 0 0.0012209695996716619
] O 0 4.858284228248522e-06
6 O 0 3.445126367296325e-06
% O 0 2.4981207502605685e-07
- O 0 3.017910046310135e-07
28 O 0 2.3263567072717706e-06
% O 0 2.684282378595526e-07
) O 0 4.314833645935323e-08
, O 0 2.178358826654403e-08
suggesting O 0 2.2702197099988553e-07
other O 0 1.6194803720281925e-07
predisposition O 0 7.452118734363467e-05
genes O 0 7.28958457330009e-06
. O 0 2.6900354441750096e-06

The O 0 6.205475528986426e-06
majority O 0 1.9404780005061184e-07
( O 0 2.2092477536261867e-07
81 O 0 2.8424653919500997e-06
% O 0 1.4518950308683998e-07
) O 0 4.462597757992626e-08
of O 0 1.3353628673939966e-06
the O 0 0.012340271845459938
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.137065954841091e-07
were O 0 5.935663125455903e-07
due O 0 3.260284756834153e-06
to O 0 5.038099857301859e-07
BRCA1 O 0 4.564228675008053e-06
, O 0 2.2090560491960787e-07
with O 0 2.962248579763127e-08
most O 0 8.731311140763864e-08
others O 0 6.967783150457763e-08
( O 0 7.949373070914589e-08
14 O 0 1.5918005829007598e-06
% O 0 3.524463920712151e-07
) O 0 1.9281240781765518e-07
due O 0 5.26380699739093e-06
to O 0 3.88576700061094e-06
BRCA2 O 0 0.00021937215933576226
. O 0 1.3297343684826046e-05

Conversely O 0 0.0003705705457832664
, O 0 1.4112529242993332e-06
the O 0 2.001038836851876e-07
majority O 0 2.154130562814771e-08
of O 0 2.1506824054995377e-07
families O 0 3.163043515996833e-08
with O 0 8.093336845149679e-08
male B-Disease 0 1.725354013615288e-05
and I-Disease 0 8.69314135343302e-06
female I-Disease 0 0.43656212091445923
breast I-Disease 1 0.9999967813491821
cancer I-Disease 0 0.0279498640447855
were O 0 1.9813462586171227e-06
due O 0 5.062256150267785e-06
to O 0 2.1282873774453037e-07
BRCA2 O 0 2.62753815150063e-06
( O 0 6.041805704626313e-07
76 O 0 1.232265367434593e-05
% O 0 1.062921683114837e-06
) O 0 5.784808649877959e-07
. O 0 9.445387831874541e-07

The O 0 4.647780951927416e-05
largest O 0 1.0675465091480874e-05
proportion O 0 3.0020098620298086e-06
( O 0 1.4226905022951541e-06
67 O 0 1.1746404197765514e-05
% O 0 1.2534636653072084e-06
) O 0 2.8053452183485206e-07
of O 0 6.869794106023619e-06
families O 0 1.3591707102023065e-06
due O 0 5.4085143347037956e-05
to O 0 1.4672917814095854e-06
other O 0 6.335526450129692e-07
genes O 0 9.369344411425118e-07
was O 0 6.450863111240324e-06
found O 0 9.068136819223582e-08
in O 0 5.191912322288772e-08
families O 0 5.088576671141709e-09
with O 0 4.004565568038743e-09
four O 0 5.700645289152817e-08
or O 0 6.165817723058353e-08
five O 0 2.7878753527943445e-08
cases O 0 2.8325016998564934e-08
of O 0 1.773339477040281e-06
female O 0 0.0021337394136935472
breast B-Disease 1 0.9999945163726807
cancer I-Disease 0 0.14599302411079407
only O 0 1.5030475424282486e-06
. O 0 1.663409307184338e-06

These O 0 1.1727511264325585e-05
estimates O 0 5.197310201765504e-06
were O 0 1.0325502444175072e-06
not O 0 4.266533082386559e-08
substantially O 0 3.864879261072929e-07
affected O 0 6.383590545055995e-08
either O 0 3.347020083310781e-08
by O 0 1.5309664647134014e-08
changing O 0 1.2927542059060215e-07
the O 0 1.6123085799790715e-07
assumed O 0 2.928848971350817e-06
penetrance O 0 1.9677243471960537e-05
model O 0 8.98036830676574e-07
for O 0 4.26151103738448e-07
BRCA1 O 0 1.1481507726784912e-06
or O 0 9.254718236206827e-08
by O 0 4.876547610166426e-09
including O 0 4.282725285520428e-08
or O 0 3.509381087951624e-07
excluding O 0 3.468754130153684e-06
BRCA1 O 0 1.0645189831848256e-05
mutation O 0 2.379687884968007e-06
data O 0 2.923451802416821e-06
. O 0 8.168683507392416e-07

Among O 0 5.7251240832556505e-06
those O 0 5.905534976591298e-07
families O 0 3.3580130320842727e-07
with O 0 7.747738095531531e-07
disease O 0 0.46981391310691833
due O 0 0.00031408501672558486
to O 0 4.193032964394661e-06
BRCA1 O 0 1.1925272701773793e-05
that O 0 2.977260180614394e-07
were O 0 7.631418270648282e-07
tested O 0 1.4426035477299592e-07
by O 0 1.0512198223011637e-08
one O 0 1.2250827907678286e-08
of O 0 7.700227655504932e-08
the O 0 9.722067773054732e-08
standard O 0 3.058622439766623e-07
screening O 0 1.694884730341073e-07
methods O 0 3.9809867757867323e-07
, O 0 1.1730185178748798e-07
mutations O 0 4.9979107075159845e-08
were O 0 5.68973291592556e-07
detected O 0 1.1429200412749196e-06
in O 0 4.229513024256448e-07
the O 0 9.064866048902331e-07
coding O 0 2.98921395369689e-06
sequence O 0 1.2362509096419672e-06
or O 0 1.986848701562849e-06
splice O 0 1.7129362959167338e-06
sites O 0 2.219760801835946e-07
in O 0 7.723777173396229e-08
an O 0 4.1259688998707134e-08
estimated O 0 1.6151447823631315e-07
63 O 0 1.8665947436602437e-06
% O 0 2.592178134364076e-07
( O 0 1.6316282369643886e-07
95 O 0 4.013509624201106e-06
% O 0 1.9260176031821175e-06
CI O 0 0.0011807908304035664
51 O 0 2.3351645722868852e-05
% O 0 2.4580597255408065e-06
- O 0 4.150305358052719e-06
77 O 0 1.508009881945327e-05
% O 0 1.4854119854135206e-06
) O 0 5.378670948630315e-07
. O 0 1.175571242129081e-06

The O 0 1.8560329408501275e-05
estimated O 0 2.2242074919631705e-06
sensitivity O 0 1.7934920606421656e-06
was O 0 2.8489162104960997e-06
identical O 0 6.939414021189805e-08
for O 0 3.5895752148462634e-08
direct O 0 1.505918447719523e-07
sequencing O 0 5.834190233144909e-07
and O 0 2.297659591476986e-07
other O 0 1.6005732561552577e-07
techniques O 0 8.506714038958307e-06
. O 0 2.1188511709624436e-06

The O 0 7.383646152447909e-05
penetrance O 0 0.0006152604473754764
of O 0 5.370917642721906e-05
BRCA2 O 0 2.929136280727107e-05
was O 0 7.5134585131308995e-06
estimated O 0 1.3769226825388614e-07
by O 0 1.5488742732827632e-08
maximizing O 0 2.487124447725364e-06
the O 0 3.227505203540204e-06
LOD O 0 0.0006807278259657323
score O 0 2.6486020942684263e-05
in O 0 2.3131555280997418e-05
BRCA2 O 0 0.00014591417857445776
- O 0 1.8864353478420526e-05
mutation O 0 2.7728495410883625e-07
families O 0 2.0534869804578193e-08
, O 0 6.498774851593225e-09
over O 0 6.164910359984788e-09
all O 0 7.783194533317328e-09
possible O 0 1.640581217543513e-07
penetrance O 0 5.950247941655107e-05
functions O 0 1.2199306183902081e-05
. O 0 3.1929869237501407e-06

The O 0 1.2251269936314202e-06
estimated O 0 5.062445893599943e-07
cumulative O 0 8.446214451396372e-06
risk O 0 2.4590303837612737e-06
of O 0 1.571669963595923e-05
breast B-Disease 1 0.9333084225654602
cancer I-Disease 0 0.0012993060518056154
reached O 0 6.538714660564438e-05
28 O 0 2.0829022105317563e-05
% O 0 4.5177341689850437e-07
( O 0 1.1609301253656668e-07
95 O 0 2.862847622964182e-06
% O 0 1.2865460803368478e-06
CI O 0 0.0006287156720645726
9 O 0 4.04826168960426e-05
% O 0 1.1865429314639186e-06
- O 0 6.401551218004897e-07
44 O 0 1.2601107073351159e-06
% O 0 1.9162563091867924e-07
) O 0 2.0138536171998567e-08
by O 0 2.113376496026831e-08
age O 0 4.265174595730059e-07
50 O 0 6.313300673355116e-07
years O 0 2.0837458691858046e-07
and O 0 1.314623290227246e-07
84 O 0 3.1727709028928075e-06
% O 0 1.953048780478639e-07
( O 0 6.95566058084296e-08
95 O 0 1.5761870599817485e-06
% O 0 1.2536489748526947e-06
CI O 0 0.0004914107848890126
43 O 0 1.9019846149603836e-05
% O 0 1.0188333590122056e-06
- O 0 7.49702905977756e-07
95 O 0 1.40538907089649e-06
% O 0 8.611731061591854e-08
) O 0 8.200990109230588e-09
by O 0 8.80771366951194e-09
age O 0 9.610889719624538e-07
70 O 0 2.4383659820159664e-06
years O 0 1.3867895631847205e-06
. O 0 1.0016576652560616e-06

The O 0 9.975760622182861e-05
corresponding O 1 0.9999984502792358
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 6.987976667005569e-05
were O 0 4.269412784196902e-06
0 O 0 1.2380523003230337e-05
. O 0 5.36235404524632e-07

4 O 0 0.00012227435945533216
% O 0 4.4954513214179315e-06
( O 0 7.714368166489294e-07
95 O 0 8.674358468852006e-06
% O 0 2.6640841497282963e-06
CI O 0 0.0008349183481186628
0 O 0 8.145470019371714e-06
% O 0 2.886614538510912e-07
- O 0 2.2116468301192072e-07
1 O 0 1.6073695405793842e-06
% O 0 8.783727167838151e-08
) O 0 1.438519969809704e-08
by O 0 1.6400642621761108e-08
age O 0 3.8560509096896567e-07
50 O 0 7.056131607896532e-07
years O 0 1.356154797349518e-07
and O 0 1.0146537476884987e-07
27 O 0 1.8623841242515482e-06
% O 0 1.0860655663691432e-07
( O 0 4.15989198643274e-08
95 O 0 6.751359364898235e-07
% O 0 7.508620569751656e-07
CI O 0 0.00018594559514895082
0 O 0 4.036410246044397e-06
% O 0 2.6187970547653094e-07
- O 0 4.383911118566175e-07
47 O 0 1.3124877114023548e-06
% O 0 1.0136923833670153e-07
) O 0 1.1801139621070433e-08
by O 0 1.260155624294157e-08
age O 0 9.793963045012788e-07
70 O 0 4.870331395068206e-06
years O 0 2.9763448310404783e-06
. O 0 1.4987534768806654e-06

The O 0 5.762119599239668e-06
lifetime O 0 4.850893674301915e-05
risk O 0 1.8731336240307428e-05
of O 0 5.6104061513906345e-05
breast B-Disease 1 0.999998927116394
cancer I-Disease 1 0.7717548608779907
appears O 0 4.4654434532276355e-06
similar O 0 2.785670005778229e-07
to O 0 2.781125658657402e-07
the O 0 5.727188636228675e-06
risk O 0 7.031625500530936e-06
in O 0 1.0451207344885916e-05
BRCA1 O 0 1.2672387128986884e-05
carriers O 0 9.55815835368412e-07
, O 0 3.101146717199299e-07
but O 0 2.792995168476864e-08
there O 0 3.648997193295145e-08
was O 0 4.702747560259013e-07
some O 0 1.2576464314406621e-08
suggestion O 0 1.451892330806004e-07
of O 0 7.561350230389507e-07
a O 0 5.633184173348127e-06
lower O 0 6.335902435239404e-05
risk O 0 4.852769052376971e-06
in O 0 3.523486611811677e-06
BRCA2 O 0 6.996761385380523e-06
carriers O 0 5.564941716329486e-07
< O 0 9.142158887698315e-06
50 O 0 7.202784786386474e-07
years O 0 2.212484275787574e-07
of O 0 8.533726827408827e-07
age O 0 1.0185653991356958e-05
. O 0 1.8721087826634175e-06

Eye B-Disease 1 0.9999985694885254
movement I-Disease 0 0.0032490163575857878
abnormalities I-Disease 1 0.5539687275886536
correlate O 0 2.4328401195816696e-06
with O 0 5.114851830967382e-08
genotype O 0 1.763959699019324e-05
in O 0 7.826314686099067e-06
autosomal O 1 0.9999996423721313
dominant O 1 0.9999998807907104
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 2.9749415261903778e-05

We O 0 8.680571772856638e-05
compared O 0 0.00043169959099031985
horizontal O 0 0.0033758629579097033
eye O 1 0.5912204384803772
movements O 0 0.0003713298647198826
( O 0 1.1298857316432986e-05
visually O 0 4.42781265519443e-06
guided O 0 4.623203039955115e-06
saccades O 0 3.739156818483025e-05
, O 0 7.760264679745887e-07
antisaccades O 0 7.40105224394938e-06
, O 0 2.3724565778593387e-07
and O 0 2.4103550799736695e-07
smooth O 0 1.2314229024923407e-05
pursuit O 0 9.586562555341516e-06
) O 0 2.4666937292749935e-07
in O 0 3.3847760505523183e-07
control O 0 1.773829922058212e-06
subjects O 0 8.161541700246744e-06
( O 0 1.2008454177703243e-06
n O 0 1.00779479907942e-05
= O 0 6.010437573422678e-06
14 O 0 1.3700372392122517e-06
) O 0 2.1034674446696044e-08
and O 0 9.145585622150065e-09
patients O 0 8.106249893558015e-09
with O 0 1.2931328230436634e-09
three O 0 5.7616631465862156e-08
forms O 0 7.379102839877305e-07
of O 0 1.214852454722859e-05
autosomal O 1 0.99996018409729
dominant O 1 0.9395107626914978
cerebellar B-Disease 1 0.9999333620071411
ataxias I-Disease 1 0.6638336181640625
type I-Disease 0 0.0013204921269789338
I I-Disease 0 0.0002816527849063277
spinocerebellar B-Disease 0 0.0010495604947209358
ataxias I-Disease 0 0.00014796822506468743
1 I-Disease 0 2.7342473913449794e-05
and I-Disease 0 1.0972285053867381e-06
2 I-Disease 0 8.792216249275953e-06
( O 0 4.5117926106286177e-07
SCA1 B-Disease 0 1.879499905044213e-05
, O 0 7.65150332426856e-07
n O 0 5.122758921061177e-06
= O 0 4.308741608838318e-06
11 O 0 3.168407602061052e-06
; O 0 1.2226928447489627e-07
SCA2 B-Disease 0 9.940562449628487e-06
, O 0 3.882871340010752e-07
n O 0 2.8037693482474424e-06
= O 0 2.7203250283491798e-06
10 O 0 7.517519975408504e-07
) O 0 2.503133771369903e-07
and O 0 2.686095285753254e-06
SCA3 B-Disease 1 0.9999945163726807
/ O 0 0.0002866531431209296
Machado B-Disease 0 7.054623711155728e-05
- I-Disease 0 4.7413039283128455e-05
Joseph I-Disease 0 0.0004698270931839943
disease I-Disease 0 0.0006790379993617535
( O 0 2.2473332137451507e-06
MJD B-Disease 1 0.9998935461044312
) O 0 4.6333099135154043e-07
( O 0 2.3591786657561897e-07
n O 0 4.642320618586382e-06
= O 0 6.270933681662427e-06
16 O 0 9.459826287638862e-06
) O 0 8.44569512992166e-07
. O 0 7.786417768329557e-07

In O 0 0.00037323389551602304
SCA1 B-Disease 0 0.002409004606306553
, O 0 4.172207354713464e-06
saccade O 0 6.030915756127797e-05
amplitude O 0 1.88897338375682e-05
was O 0 3.7251822959660785e-06
significantly O 0 2.6365341909695417e-07
increased O 0 8.989700290840119e-07
, O 0 1.5587184520882147e-07
resulting O 0 4.820049639420176e-07
in O 0 2.9278351121320156e-06
hypermetria B-Disease 0 0.00026723224436864257
. O 0 5.3375852075987495e-06

The O 0 9.086892532650381e-05
smooth O 0 0.00019876119040418416
pursuit O 0 6.940664752619341e-05
gain O 0 7.522044325014576e-05
was O 0 5.247873195912689e-05
decreased O 0 0.0011321709025651217
. O 0 5.204372882872121e-06

In O 0 0.00024515760014764965
SCA2 B-Disease 0 0.0024287260603159666
, O 0 4.0041427382675465e-06
saccade O 0 6.712213507853448e-05
velocity O 0 3.3684566005831584e-05
was O 0 2.1482181182364002e-05
markedly O 0 7.39253664505668e-05
decreased O 0 0.0002318333717994392
. O 0 2.1479634142451687e-06

The O 0 2.094273077091202e-05
percentage O 0 2.211672290286515e-05
of O 0 1.5657175026717596e-05
errors O 0 0.0009943348122760653
in O 0 9.016527474159375e-05
antisaccades O 0 0.0011931401677429676
was O 0 1.4008945981913712e-05
greatly O 0 9.321751122115529e-07
increased O 0 3.067962097702548e-07
and O 0 1.763456403125474e-08
was O 0 1.4022333516550134e-07
significantly O 0 1.9725078459487122e-08
correlated O 0 5.093540877965097e-08
with O 0 3.5030922607148796e-09
age O 0 1.3051161431576475e-06
at O 0 2.8335793103906326e-05
disease O 0 0.00013201843830756843
onset O 0 0.00035369087709113955
. O 0 4.766002803080482e-06

In O 0 1.1768638614739757e-05
addition O 0 1.400022142661328e-06
, O 0 2.4505763462912e-07
a O 0 1.8934707668449846e-07
correlation O 0 1.3667315670318203e-06
between O 0 2.819890823957394e-06
smooth O 0 3.0070215871091932e-05
pursuit O 0 1.0349614058213774e-05
gain O 0 2.7732726266549435e-06
and O 0 9.33741404196553e-08
the O 0 1.0823122664760376e-07
number O 0 7.730203321898443e-08
of O 0 1.4408080915018218e-06
trinucleotide O 0 5.545803651330061e-05
repeats O 0 7.928648301458452e-06
was O 0 1.3272678188513964e-05
found O 0 8.888832212505804e-07
. O 0 6.185725283103238e-07

In O 0 0.032400865107774734
SCA3 B-Disease 1 1.0
, O 0 0.0011009995359927416
gaze B-Disease 0 0.388462096452713
- I-Disease 0 0.0005261083715595305
evoked I-Disease 0 0.00012141202751081437
nystagmus I-Disease 0 0.0003081811300944537
was O 0 5.326357495505363e-06
often O 0 4.013399745872448e-08
present O 0 4.880197934653552e-08
as O 0 2.1227010904567578e-07
was O 0 1.984801428989158e-06
saccade O 0 2.1126983483554795e-05
hypometria O 0 2.66425540758064e-05
and O 0 1.19547610211157e-06
smooth O 0 2.5440527679165825e-05
pursuit O 0 2.4777571525191888e-05
gain O 0 4.077250196132809e-05
was O 0 3.357616515131667e-05
markedly O 0 6.123225466581061e-05
decreased O 0 0.00023579206026624888
. O 0 2.461921212670859e-06

Three O 0 3.763730637729168e-05
major O 0 2.074091389658861e-05
criteria O 0 8.077728125499561e-06
, O 0 9.529224485049781e-07
saccade O 0 2.595485420897603e-05
amplitude O 0 1.6575279005337507e-05
, O 0 1.278565036955115e-06
saccade O 0 1.7919765014084987e-05
velocity O 0 1.351252922177082e-05
, O 0 6.157192729006056e-07
and O 0 4.391903587475099e-07
presence O 0 5.247361968940822e-06
of O 0 0.00010944386303890496
gaze B-Disease 0 0.0282748993486166
- I-Disease 0 0.0001310526713496074
evoked I-Disease 0 3.425960676395334e-05
nystagmus I-Disease 0 2.9042475944152102e-05
, O 0 4.4301337709384825e-08
permitted O 0 5.80947769890372e-08
the O 0 1.4137070536435203e-07
correct O 0 2.167608244008079e-07
assignment O 0 4.100097044101858e-07
of O 0 1.2574816992128035e-06
90 O 0 3.361128392498358e-06
% O 0 6.87938495502749e-07
of O 0 4.145605998928659e-06
the O 0 9.48705474002054e-06
SCA1 B-Disease 0 6.694352487102151e-05
, O 0 4.827828661291278e-07
90 O 0 1.1186441497557098e-06
% O 0 3.3531424037391844e-07
of O 0 1.3679585890713497e-06
the O 0 4.913757038593758e-06
SCA2 B-Disease 0 4.197638190817088e-05
, O 0 2.225560393753767e-07
and O 0 1.357323213824202e-07
93 O 0 3.129539436486084e-06
% O 0 1.8074052832162124e-07
of O 0 8.029724654079473e-07
the O 0 2.7757889711210737e-06
patients O 0 3.8050650346121984e-06
with O 0 2.168386799894506e-06
SCA3 B-Disease 1 0.9999998807907104
to O 0 1.3184970839574817e-06
their O 0 4.628204806067515e-07
genetically O 0 1.0835470902748057e-06
confirmed O 0 2.3876057184679667e-06
patient O 0 8.70824351295596e-06
group O 0 5.361587227525888e-07
and O 0 2.756804917680711e-07
, O 0 2.0236284115071612e-07
therefore O 0 4.6013499854780093e-07
, O 0 1.5553018783975858e-07
may O 0 4.933322657052486e-07
help O 0 1.1809385114247561e-07
orient O 0 5.297576353768818e-05
diagnoses O 0 3.0283226806204766e-05
of O 0 4.851541598327458e-05
SCA1 B-Disease 0 0.0017079066019505262
, O 0 5.605055775959045e-06
SCA2 B-Disease 0 0.00012917022104375064
, O 0 3.611593228924903e-07
and O 0 3.543820241702633e-07
SCA3 B-Disease 1 0.9999827146530151
at O 0 1.7220053223354626e-06
early O 0 2.0500243635979132e-07
clinical O 0 2.433304189253249e-06
stages O 0 4.048650680488208e-06
of O 0 8.273788807855453e-06
the O 0 1.543354483146686e-05
diseases O 0 0.011521043255925179
. O 0 5.427684754977236e-07
. O 0 1.4846174281046842e-06

Genetic O 0 1.2046432402712526e-06
basis O 0 1.1827193446833917e-07
and O 0 6.425196374948428e-08
molecular O 0 4.330252977524651e-06
mechanism O 0 1.6109010175568983e-05
for O 0 7.499075582018122e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.00022724887821823359

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 0.0007265616441145539
more O 0 5.092496735414898e-07
than O 0 3.2075800504571816e-07
300 O 0 6.259822384890867e-07
, O 0 5.273612302403308e-08
000 O 0 2.79785854218062e-06
sudden O 0 2.3402417355100624e-06
deaths O 0 8.930535386753036e-07
each O 0 6.638555305471527e-08
year O 0 4.0371816112383385e-07
in O 0 1.0107055459229741e-06
the O 0 3.3344024359394098e-06
USA O 0 1.832998896134086e-05
alone O 0 2.3518671241617994e-06
. O 0 5.373503313421679e-07

In O 0 7.630209438502789e-05
approximately O 0 1.42633825817029e-05
5 O 0 2.3505723220296204e-05
- O 0 3.9861106415628456e-06
12 O 0 3.0599840101785958e-06
% O 0 1.619031166910645e-07
of O 0 1.5394839181226416e-07
these O 0 2.6006382825016772e-08
cases O 0 1.0536350458778543e-07
, O 0 2.024977341363865e-08
there O 0 1.135714278177602e-08
are O 0 8.178807853198578e-09
no O 0 1.2100740320875047e-07
demonstrable O 0 0.0007719385321252048
cardiac O 1 1.0
or O 0 0.00481270020827651
non O 1 0.9998427629470825
- O 1 0.9995298385620117
cardiac O 1 0.9999997615814209
causes O 0 2.045978590103914e-06
to O 0 3.685607907755184e-08
account O 0 2.291852929658944e-08
for O 0 4.7866461017065376e-08
the O 0 8.087195624284504e-08
episode O 0 2.3204532340059814e-07
, O 0 5.488081544768875e-09
which O 0 2.674799715052245e-09
is O 0 1.5587987567400319e-09
therefore O 0 2.0436717207417132e-08
classified O 0 2.56119875530203e-07
as O 0 9.209626114170533e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9248509407043457
IVF B-Disease 1 1.0
) O 0 4.509148311626632e-06
. O 0 1.201838699671498e-06

A O 0 0.0001783649786375463
distinct O 0 1.649702971917577e-05
group O 0 1.0640541404427495e-05
of O 0 0.0001282962184632197
IVF B-Disease 1 1.0
patients O 0 1.7224640032509342e-05
has O 0 8.661130550535745e-07
been O 0 2.8325729317657533e-07
found O 0 1.1662939058965094e-08
to O 0 2.503833806954958e-09
present O 0 1.6874906805242063e-08
with O 0 2.5440359152639758e-08
a O 0 1.7982223425860866e-06
characteristic O 0 9.10809394554235e-05
electrocardiographic O 0 0.0017033475451171398
pattern O 0 0.0002653982664924115
. O 0 8.538263500668108e-06

Because O 0 5.9735124523285776e-05
of O 0 8.210232044802979e-05
the O 0 7.897535397205502e-06
small O 0 4.494854408676474e-07
size O 0 3.3586792369533214e-07
of O 0 9.639179552323185e-07
most O 0 2.7470920826999645e-07
pedigrees O 0 6.203305815688509e-07
and O 0 8.32408915130145e-08
the O 0 1.1838613289683053e-07
high O 0 1.765511228768446e-06
incidence O 0 6.099523943703389e-06
of O 0 1.218456191054429e-06
sudden B-Disease 0 3.1479841709369794e-05
death I-Disease 0 1.4018594811204821e-05
, O 0 5.7530208152911655e-08
however O 0 4.7000124681062516e-08
, O 0 3.168061013525403e-08
molecular O 0 1.4172210285323672e-06
genetic O 0 4.7149265469670354e-07
studies O 0 4.783534222951857e-06
of O 0 5.357873305911198e-05
IVF B-Disease 1 0.9999920129776001
have O 0 1.6942785805440508e-06
not O 0 2.077721461546389e-07
yet O 0 2.79073560705001e-07
been O 0 5.596747882918862e-07
done O 0 8.607229915469361e-07
. O 0 1.0416573559268727e-06

Because O 0 9.788093302631751e-05
IVF B-Disease 1 1.0
causes O 1 0.7465018033981323
cardiac O 1 1.0
rhythm O 1 0.9999691247940063
disturbance O 1 0.6928806900978088
, O 0 1.7590809875400737e-06
we O 0 9.21677312248903e-08
investigated O 0 4.1913995119102765e-07
whether O 0 1.8702139925608208e-07
malfunction O 0 7.732080121058971e-05
of O 0 4.3150231476829504e-07
ion O 0 7.363204986177152e-06
channels O 0 2.650293254191638e-06
could O 0 4.18775130128779e-07
cause O 0 7.358203220064752e-07
the O 0 1.801430471459753e-07
disorder O 0 2.498373760317918e-06
by O 0 2.6795792251732564e-09
studying O 0 1.8969060988638375e-08
mutations O 0 9.200173067824835e-09
in O 0 5.098264921343798e-08
the O 0 2.5234155032194394e-07
cardiac O 0 9.413961379323155e-05
sodium O 0 3.6043027193954913e-06
channel O 0 1.3830194802721962e-05
gene O 0 2.5626024580560625e-05
SCN5A O 0 0.0007652477943338454
. O 0 7.239598289743299e-06

We O 0 1.7341382772428915e-05
have O 0 5.672741849593876e-07
now O 0 4.401182707169937e-07
identified O 0 3.121432996522344e-07
a O 0 6.558323093486251e-07
missense O 0 7.901204298832454e-06
mutation O 0 1.6183824982363149e-06
, O 0 5.003232672606828e-07
a O 0 1.504858914813667e-06
splice O 0 1.461230840504868e-05
- O 0 1.1110615560028236e-05
donor O 0 1.6212590026043472e-06
mutation O 0 8.615688784630038e-07
, O 0 3.6588767216017004e-07
and O 0 3.557276500032458e-07
a O 0 2.3240440896188375e-06
frameshift O 0 2.4206798116210848e-05
mutation O 0 1.1274048574705375e-06
in O 0 1.30049795643572e-06
the O 0 1.4025424661667785e-06
coding O 0 5.943326868873555e-06
region O 0 1.3168584018785623e-06
of O 0 6.6521506596473046e-06
SCN5A O 0 8.523856376996264e-05
in O 0 4.553663529804908e-06
three O 0 9.350570508104283e-06
IVF B-Disease 1 0.999360978603363
families O 0 4.653396672438248e-07
. O 0 6.50963215775846e-07

We O 0 2.571649929450359e-06
show O 0 2.749985696937074e-07
that O 0 9.836102599081187e-09
sodium O 0 1.0201941336163145e-07
channels O 0 3.151962246761286e-08
with O 0 9.861612859651814e-09
the O 0 3.922307030279626e-07
missense O 0 1.4881348761264235e-05
mutation O 0 1.4826139249635162e-06
recover O 0 4.4308535507298075e-06
from O 0 9.191771823680028e-07
inactivation O 0 2.6553116185823455e-05
more O 0 7.313283845178375e-08
rapidly O 0 2.856978653653641e-07
than O 0 2.7997531404366782e-08
normal O 0 2.809414638704766e-07
and O 0 2.8396637929972712e-08
that O 0 1.2705333674034591e-08
the O 0 3.901579077592032e-07
frameshift O 0 7.801501851645298e-06
mutation O 0 4.90857701151981e-07
causes O 0 8.019171104933775e-07
the O 0 1.0139839332623524e-06
sodium O 0 1.6748541611377732e-06
channel O 0 2.446184680593433e-06
to O 0 3.7938650621072156e-07
be O 0 2.0038357888552127e-06
non O 0 3.0384417186724022e-05
- O 0 1.2001736649835948e-05
functional O 0 2.6673489628592506e-05
. O 0 1.573566237311752e-06

Our O 0 2.6699170120991766e-05
results O 0 7.941392141219694e-06
indicate O 0 9.220622132488643e-07
that O 0 9.688174884558975e-08
mutations O 0 7.079953547872719e-07
in O 0 7.0719561335863546e-06
cardiac O 0 0.007439973298460245
ion O 0 3.495235068839975e-05
- O 0 6.3331194724014495e-06
channel O 0 7.745868515485199e-07
genes O 0 3.397186887355019e-08
contribute O 0 8.776387616649117e-09
to O 0 9.291804659028458e-09
the O 0 9.970138137305185e-08
risk O 0 3.70690656836814e-07
of O 0 2.0735340058308793e-06
developing O 0 1.4384548194357194e-05
IVF B-Disease 1 0.999710738658905
. O 0 3.7843074096599594e-07
. O 0 4.323199505051889e-07

Molecular O 0 0.0019995959009975195
heterogeneity O 0 0.0010651858756318688
in O 0 0.0002566198236308992
mucopolysaccharidosis B-Disease 0 0.0019760241266340017
IVA I-Disease 0 0.09766215085983276
in O 0 2.3704018531134352e-05
Australia O 0 7.828576258361863e-07
and O 0 1.5978295664353936e-07
Northern O 0 5.539097855944419e-07
Ireland O 0 3.599180899982457e-07
: O 0 5.6329625408579886e-08
nine O 0 9.07628674440275e-08
novel O 0 1.9136430751132139e-07
mutations O 0 1.7292958887082932e-07
including O 0 2.9625405773003877e-07
T312S O 0 1.0904648661380634e-05
, O 0 1.1045498382600272e-07
a O 0 1.318855140652886e-07
common O 0 1.7276525454690272e-07
allele O 0 4.1073647594203067e-07
that O 0 2.724816461352475e-08
confers O 0 1.918888301588595e-05
a O 0 1.62411142810015e-05
mild O 0 0.0013395189307630062
phenotype O 0 0.00023997861717361957
. O 0 4.574905233312165e-06

Mucopolysaccharidosis B-Disease 0 0.07667862623929977
IVA I-Disease 1 0.9999901056289673
( O 0 0.003646884113550186
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 2.878556415453204e-06
is O 0 1.336609898316965e-07
an O 0 3.516614413001662e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999289512634277
by O 0 3.1251045129465638e-06
a O 0 0.0029116799123585224
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 0.018398312851786613
N O 0 0.0019731074571609497
- O 0 7.106655539246276e-05
acetylgalactosamine O 0 0.00026296789292246103
- O 0 1.5913627066765912e-05
6 O 0 7.179156818892807e-05
- O 0 1.3872637282474898e-05
sulfate O 0 2.7975196644547395e-05
sulfatase O 0 0.00028619435033760965
( O 0 5.529784175450914e-06
GALNS O 0 0.0002608421491459012
) O 0 1.6573840184719302e-06
. O 0 7.205148335742706e-07

Previous O 0 5.621909804176539e-05
studies O 0 1.3701855095860083e-05
of O 0 2.4254632080555893e-05
patients O 0 1.067623816197738e-05
from O 0 4.765352969116066e-06
a O 0 4.1644839257060084e-06
British O 0 1.5652054571546614e-05
- O 0 4.183766122878296e-06
Irish O 0 1.1103380757049308e-06
population O 0 2.990759639942553e-08
showed O 0 1.7313669786744867e-07
that O 0 8.834161846493771e-09
the O 0 2.1834925689745432e-07
I113F O 0 6.214346740307519e-06
mutation O 0 1.4223388689060812e-07
is O 0 4.3316468634202465e-08
the O 0 3.921692837138835e-08
most O 0 1.840316166124012e-08
common O 0 9.58800541184246e-08
single O 0 1.7551955977523903e-07
mutation O 0 2.3658003556192853e-07
among O 0 3.096288310189266e-07
MPS B-Disease 1 0.9909104704856873
IVA I-Disease 1 1.0
patients O 0 7.531048595410539e-06
and O 0 1.0270979799997804e-07
produces O 0 1.0858528867174755e-06
a O 0 2.519722329452634e-06
severe O 1 0.5568196773529053
clinical O 0 0.34565961360931396
phenotype O 0 0.0008260213653557003
. O 0 6.539059086207999e-06

We O 0 4.3843474486493506e-06
studied O 0 6.878564818180166e-06
mutations O 0 8.683353485139378e-07
in O 0 1.917493591463426e-06
the O 0 3.106761141680181e-06
GALNS O 0 3.182002910762094e-05
gene O 0 6.553422053912072e-07
from O 0 5.169708856556099e-07
23 O 0 8.059252650127746e-06
additional O 0 3.6536885090754367e-06
MPS B-Disease 1 0.992021381855011
IVA I-Disease 1 1.0
patients O 0 5.685930955223739e-05
( O 0 2.026528591159149e-06
15 O 0 5.303478246787563e-06
from O 0 6.448800036196189e-07
Australia O 0 1.0560232510670176e-07
, O 0 5.46465521722439e-08
8 O 0 5.434200147647061e-07
from O 0 6.103010719016311e-08
Northern O 0 1.03462461709114e-07
Ireland O 0 3.253964564464695e-08
) O 0 1.6461315865967663e-08
, O 0 1.3500317530557027e-09
with O 0 1.0234850744694768e-09
various O 0 8.728813583047668e-08
clinical O 0 0.00012863481242675334
phenotypes O 0 0.0001965432456927374
( O 0 2.476641930115875e-05
severe O 0 0.03348691761493683
, O 0 9.914033398672473e-07
16 O 0 4.185362286079908e-06
cases O 0 2.8311467303865356e-07
; O 0 1.0865130661841249e-07
intermediate O 0 1.7313071793978452e-06
, O 0 7.333327545211432e-08
4 O 0 3.935686891054502e-06
cases O 0 3.763967697523185e-07
; O 0 6.097025107010268e-07
mild O 0 3.29045724356547e-05
, O 0 4.238113717747183e-07
3 O 0 4.135149993089726e-06
cases O 0 4.0335024209525727e-07
) O 0 8.434442406723974e-07
. O 0 8.948753702497925e-07

We O 0 5.090366175863892e-05
found O 0 4.025400357932085e-06
two O 0 4.518096261563187e-07
common O 0 2.4634098849674047e-07
mutations O 0 5.89640727355345e-08
that O 0 1.026455187513875e-08
together O 0 1.2579798536194176e-08
accounted O 0 4.515705143148807e-07
for O 0 7.818729130804059e-08
32 O 0 1.4915284509697813e-06
% O 0 2.1039615205609152e-07
of O 0 4.953373604621447e-07
the O 0 1.2198247532069217e-06
44 O 0 1.1263839041930623e-05
unrelated O 0 1.0719307965700864e-06
alleles O 0 3.372515777755325e-07
in O 0 1.59859467885326e-07
these O 0 7.385502698298296e-08
patients O 0 1.3090215134070604e-06
. O 0 7.495742124774551e-07

One O 0 2.8929307518410496e-05
is O 0 3.0816433991276426e-06
the O 0 2.210867478424916e-06
T312S O 0 4.3677562644006684e-05
mutation O 0 5.931962618888065e-07
, O 0 8.161202913470333e-08
a O 0 5.930480995175458e-08
novel O 0 1.6756469278789154e-07
mutation O 0 1.6825036652790004e-07
found O 0 5.031137462196966e-08
exclusively O 0 5.359930455028916e-08
in O 0 3.102960306478053e-07
milder O 0 1.3860642866347916e-05
patients O 0 4.442167664819863e-06
. O 0 1.5645236999262124e-06

The O 0 9.256356133846566e-05
other O 0 1.2661699884120026e-06
is O 0 4.325174529640208e-07
the O 0 3.50459856690577e-07
previously O 0 1.532733449494117e-06
described O 0 8.235193718064693e-07
I113F O 0 1.2835085726692341e-05
that O 0 9.121391997268802e-08
produces O 0 2.3507125206378987e-06
a O 0 7.572191407234641e-06
severe O 0 0.1471783071756363
phenotype O 0 0.0009989462560042739
. O 0 1.31077185869799e-05

The O 0 0.00027027420583181083
I113F O 0 0.0004900817875750363
and O 0 1.2142894775024615e-05
T312S O 0 7.412343984469771e-05
mutations O 0 2.3745531052554725e-06
accounted O 0 6.704502993670758e-06
for O 0 7.187729806901189e-07
8 O 0 8.408537723880727e-06
( O 0 3.2414337169939245e-07
18 O 0 3.051748080906691e-06
% O 0 2.570399146861746e-07
) O 0 2.4728054270894972e-08
and O 0 2.042534532620266e-07
6 O 0 6.546096756210318e-06
( O 0 1.6468514729695016e-07
14 O 0 9.258899353881134e-07
% O 0 9.067081663260979e-08
) O 0 1.1444777570090992e-08
of O 0 2.1394984628386737e-07
44 O 0 5.0743396968755405e-06
unrelated O 0 2.4321348064404447e-06
alleles O 0 9.971942063202732e-07
, O 0 7.36054005301412e-07
respectively O 0 1.3597044016933069e-05
. O 0 1.480095079386956e-06

The O 0 0.00012752367183566093
relatively O 0 4.192112828604877e-05
high O 0 0.00017565242887940258
residual O 0 0.0006628470728173852
GALNS O 0 0.005844308529049158
activity O 0 2.1710397049901076e-05
seen O 0 3.1087615752767306e-06
when O 0 1.5053858248847973e-07
the O 0 1.5831243160846498e-07
T312S O 0 4.015278591396054e-06
mutant O 0 1.1538630815266515e-06
cDNA O 0 3.1891918297333177e-06
is O 0 1.86652556521949e-07
overexpressed O 0 6.507846592285205e-06
in O 0 3.3609796901146183e-07
mutant O 0 1.46563593261817e-06
cells O 0 2.4360340944440395e-07
provides O 0 2.6115341000831904e-08
an O 0 7.378740729535593e-09
explanation O 0 4.192798286339894e-08
for O 0 5.889426901717343e-08
the O 0 1.1815598099929048e-06
mild O 0 0.00016077759210020304
phenotype O 0 7.01946464687353e-06
in O 0 5.069582016403729e-07
patients O 0 8.542905760577924e-08
with O 0 4.382897156318677e-09
this O 0 7.427317427755042e-08
mutation O 0 1.3295201597429696e-06
. O 0 1.0411567927803844e-06

The O 0 2.9696084311581217e-06
distribution O 0 8.061390417424263e-07
and O 0 2.5615113941057643e-07
relative O 0 3.4769182093441486e-06
frequencies O 0 2.5671681669336976e-06
of O 0 5.965063337498577e-06
the O 0 1.0189345630351454e-05
I113F O 0 7.297086995095015e-05
and O 0 1.0042000212706625e-05
T312S O 0 3.004974678333383e-05
mutations O 0 2.2488854938274017e-06
in O 0 3.3093879210355226e-06
Australia O 0 4.849576953347423e-07
corresponded O 0 4.3164470753254136e-07
to O 0 1.0979815101563872e-07
those O 0 1.0877738532144576e-07
observed O 0 1.4503854117720039e-06
in O 0 1.6152324633367243e-06
Northern O 0 2.722178123804042e-06
Ireland O 0 1.0886441259572166e-06
and O 0 4.1322704191770754e-07
are O 0 6.014985132196671e-08
unique O 0 5.553294712967727e-08
to O 0 5.746484887936276e-08
these O 0 5.353074783442935e-08
two O 0 2.629475659432501e-07
populations O 0 2.1365968905229238e-07
, O 0 1.8077879815336928e-07
suggesting O 0 4.88502166717808e-07
that O 0 1.514479208708508e-07
both O 0 5.850899924553232e-07
mutations O 0 4.635201662495092e-07
were O 0 1.7624125803195057e-06
probably O 0 3.849980600989511e-07
introduced O 0 4.465543668175087e-08
to O 0 7.369008514501729e-09
Australia O 0 1.2706061092160326e-08
by O 0 4.7666186553385614e-09
Irish O 0 3.311138812023273e-07
migrants O 0 1.3552147493101074e-07
during O 0 4.396974873088766e-07
the O 0 3.5767919825957506e-07
19th O 0 4.246571279509226e-06
century O 0 9.63646289164899e-06
. O 0 1.654219545343949e-06

Haplotype O 0 0.0005741439526900649
analysis O 0 5.921233878325438e-06
using O 0 1.2572071454997058e-06
6 O 0 2.2555897885467857e-05
RFLPs O 0 4.108278881176375e-05
provides O 0 1.8280670133208332e-07
additional O 0 7.556204906222774e-08
data O 0 7.035959583845397e-07
that O 0 5.050674545259426e-08
the O 0 7.962345307532814e-07
I113F O 0 1.8078229913953692e-05
mutation O 0 2.8601218104995496e-07
originated O 0 2.3678386185110867e-07
from O 0 8.260570893980912e-08
a O 0 1.456538285538045e-07
common O 0 5.425862923402747e-07
ancestor O 0 1.1756590538425371e-05
. O 0 1.0482384595889016e-06

The O 0 5.473032433656044e-05
other O 0 2.051224328170065e-06
9 O 0 3.895759073202498e-05
novel O 0 3.2271079817292048e-06
mutations O 0 1.35446964577568e-06
identified O 0 4.5121279867998965e-07
in O 0 4.1855196286633145e-07
these O 0 1.1343616534986722e-07
23 O 0 2.4892982764868066e-05
patients O 0 3.8080236208770657e-07
were O 0 1.3831029832545028e-07
each O 0 1.406701066741789e-08
limited O 0 1.0653415927208698e-07
to O 0 7.650366029565703e-08
a O 0 1.3983247981741442e-06
single O 0 3.470822548479191e-06
family O 0 1.7240313354704995e-06
. O 0 1.822190483835584e-06

These O 0 1.0545895747782197e-06
data O 0 5.669583060807781e-07
provide O 0 2.777599661385466e-08
further O 0 2.5487276289481997e-08
evidence O 0 8.424363073800123e-08
for O 0 1.4404368187115324e-07
extensive O 0 3.0299581794679398e-06
allelic O 0 5.07195400132332e-05
heterogeneity O 0 0.0001278084091609344
in O 0 0.00024229081464000046
MPS B-Disease 1 0.9999388456344604
IVA I-Disease 1 0.9999996423721313
in O 0 3.991877019871026e-05
British O 0 5.635318666463718e-05
- O 0 2.4291341105708852e-05
Irish O 0 3.2411046504421392e-06
patients O 0 2.640499872086366e-07
and O 0 1.7882602065810715e-08
provide O 0 1.7089723414187574e-08
evidence O 0 1.7451176859140105e-07
for O 0 2.4815540200506803e-07
their O 0 2.2251636266901187e-07
transmission O 0 6.538416528201196e-06
to O 0 2.020621963083613e-07
Australia O 0 3.6261988611840934e-07
by O 0 2.0196453931475844e-07
British O 0 2.5197150534950197e-06
- O 0 2.2792994514020393e-06
Irish O 0 8.064412213570904e-07
migrants O 0 1.517732357569912e-07
. O 0 2.7407558889080974e-08
. O 0 1.8766012033211155e-07

Identification O 0 6.8990625550213736e-06
of O 0 1.5675817849114537e-05
constitutional O 0 0.0005936447414569557
WT1 O 0 0.007504029665142298
mutations O 0 1.1979320788668701e-06
, O 0 4.510794227030601e-08
in O 0 5.3991467297009876e-08
patients O 0 9.482105411962038e-08
with O 0 2.9403851797837888e-08
isolated O 0 0.00018527112843003124
diffuse B-Disease 1 0.9999699592590332
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.9094016440467385e-07
and O 0 2.844341651098148e-08
analysis O 0 8.276798979522937e-08
of O 0 1.9973069811385358e-06
genotype O 0 0.00023857876658439636
/ O 0 0.00013734836829826236
phenotype O 0 1.5970754247973673e-06
correlations O 0 2.024923873022999e-07
by O 0 8.454364319732122e-09
use O 0 5.3792641452332646e-09
of O 0 7.24677207131208e-08
a O 0 4.746466402139049e-07
computerized O 0 2.76908995147096e-05
mutation O 0 3.320120413263794e-06
database O 0 4.36262189396075e-06
. O 0 1.3956895372757572e-06

Constitutional O 0 0.0002538851404096931
mutations O 0 6.050637693988392e-06
of O 0 2.353057061554864e-05
the O 0 1.6590698578511365e-05
WT1 O 0 0.00017297352314926684
gene O 0 9.491737955613644e-07
, O 0 3.21009849812981e-07
encoding O 0 1.7983321640713257e-06
a O 0 8.715986950846855e-06
zinc O 0 9.252518793800846e-05
- O 0 1.4910357094777282e-05
finger O 0 1.3864053471479565e-05
transcription O 0 9.916029739542864e-06
factor O 0 1.032907675835304e-06
involved O 0 1.0976146995744784e-06
in O 0 5.9996702475473285e-05
renal O 1 1.0
and O 0 0.002257566899061203
gonadal O 1 0.999998927116394
development O 0 7.249037298606709e-05
, O 0 1.4651088520167832e-07
are O 0 6.978753575026531e-09
found O 0 4.247944218604971e-09
in O 0 7.678620406181835e-09
most O 0 8.297027953574343e-09
patients O 0 5.0991790345733534e-08
with O 0 5.3662830623579794e-08
Denys B-Disease 1 0.999964714050293
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0001499108475400135
DDS B-Disease 1 1.0
) O 0 1.6322925375789055e-06
, O 0 3.5375936136006203e-07
or O 0 2.0867953935521655e-05
diffuse B-Disease 1 0.999723494052887
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.004947683308273554
DMS B-Disease 1 0.9999150037765503
) O 0 6.091323712098529e-07
associated O 0 5.214927796259872e-07
with O 0 4.187795354937407e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.00010201218537986279
/ O 0 0.19160249829292297
or O 0 7.152029138524085e-05
Wilms B-Disease 1 0.9999933242797852
tumor I-Disease 1 0.9999388456344604
( O 0 2.8886221116408706e-05
WT B-Disease 1 0.999984622001648
) O 0 1.182443497782515e-06
. O 0 7.502429753003526e-07

Most O 0 1.3796430721413344e-05
mutations O 0 2.2187601643963717e-05
in O 0 0.00011156368418596685
DDS B-Disease 1 1.0
patients O 0 8.511786290910095e-05
lie O 0 3.346741141285747e-05
in O 0 7.595683200634085e-06
exon O 0 7.884538717917167e-06
8 O 0 2.570748074504081e-05
or O 0 1.7757475916369003e-06
exon O 0 2.4526434572180733e-06
9 O 0 1.8234462913824245e-05
, O 0 9.301948580286989e-07
encoding O 0 4.792520485352725e-06
zinc O 0 0.00017977430252358317
finger O 0 0.0003001944860443473
2 O 0 0.0003568797546904534
or O 0 5.2567938837455586e-05
zinc O 0 0.00017680716700851917
finger O 0 8.088613685686141e-05
3 O 0 3.686961281346157e-05
, O 0 6.150924605208274e-07
respectively O 0 2.8117433430452365e-06
, O 0 7.579964744763856e-08
with O 0 4.7865547969649924e-08
a O 0 4.767766768054571e-06
hot O 0 7.101966912159696e-05
spot O 0 2.0882804165012203e-05
( O 0 7.242529136419762e-07
R394W O 0 2.295365220561507e-06
) O 0 7.469311924523936e-08
in O 0 3.562372228316235e-07
exon O 0 3.415123046579538e-06
9 O 0 2.1845142327947542e-05
. O 0 1.442517032046453e-06

We O 0 6.436434887291398e-06
analyzed O 0 1.2082214198017027e-06
a O 0 4.20469916662114e-07
series O 0 3.3250620390390395e-07
of O 0 1.2478210464905715e-06
24 O 0 1.8089544028043747e-05
patients O 0 1.3807954246658483e-06
, O 0 2.682401714082516e-07
10 O 0 1.4909326182532823e-06
with O 0 5.902730890738894e-07
isolated B-Disease 0 0.00013521048822440207
DMS I-Disease 0 0.15064756572246552
( O 0 2.585307629487943e-05
IDMS B-Disease 0 0.0005312106222845614
) O 0 7.885988679845468e-07
, O 0 3.010160583016841e-07
10 O 0 9.694483651401242e-07
with O 0 3.410110025470203e-07
DDS B-Disease 1 1.0
, O 0 3.960972492222936e-07
and O 0 1.9126012773540424e-07
4 O 0 7.171021934482269e-06
with O 0 4.3110745195917843e-07
urogenital B-Disease 1 0.9998716115951538
abnormalities I-Disease 1 0.9999946355819702
and O 0 9.506416972726583e-05
/ O 1 0.9561063051223755
or O 0 0.0003749562310986221
WT B-Disease 1 1.0
. O 0 6.008976015436929e-06

We O 0 5.120386049384251e-05
report O 0 2.3622891603736207e-05
WT1 O 0 0.0008445119601674378
heterozygous O 0 3.269401531724725e-06
mutations O 0 6.034244961483637e-07
in O 0 1.1759289009205531e-06
16 O 0 1.1219647603866179e-05
patients O 0 3.767627276829444e-07
, O 0 4.8834568389111155e-08
4 O 0 1.3749860272582737e-06
of O 0 6.515185191346973e-07
whom O 0 1.527966787762125e-06
presented O 0 8.49850766826421e-06
with O 0 7.728566743026022e-06
IDMS B-Disease 0 0.03205408528447151
. O 0 1.3361322999116965e-05

One O 0 2.028704693657346e-05
male O 0 5.1610027185233776e-06
and O 0 3.950756024551083e-07
two O 0 4.0869213080441114e-07
female O 0 1.8736767742666416e-05
IDMS B-Disease 1 0.9957044720649719
patients O 0 2.4661321731400676e-06
with O 0 5.663665660904371e-07
WT1 O 1 0.9998993873596191
mutations O 0 0.0004434115835465491
underwent O 1 0.9999983310699463
normal O 1 0.7943807244300842
puberty O 0 0.011395679786801338
. O 0 2.859014102796209e-06

Two O 0 0.00013523781672120094
mutations O 0 0.00010687552276067436
associated O 0 1.792739021766465e-05
with O 0 3.055452452827012e-06
IDMS B-Disease 0 0.002098815981298685
are O 0 8.454674826907649e-08
different O 0 6.207576230821132e-09
from O 0 6.421937115419496e-08
those O 0 1.1266956256861249e-08
described O 0 3.9055626643857977e-07
in O 0 8.19442266219994e-06
DDS B-Disease 1 1.0
patients O 0 2.2212774638319388e-05
. O 0 1.987430550798308e-06

No O 0 0.00040191086009144783
WT1 O 0 0.0033189936075359583
mutations O 0 2.523858711356297e-06
were O 0 9.005635206449369e-07
detected O 0 5.03151227349008e-07
in O 0 8.377016058602749e-08
the O 0 1.369358813008148e-07
six O 0 3.318878043501172e-07
other O 0 2.639701506268466e-07
IDMS B-Disease 1 0.9660448431968689
patients O 0 1.752774664964818e-06
, O 0 3.570837492361534e-08
suggesting O 0 1.5783787432610552e-07
genetic O 0 3.270622244144761e-07
heterogeneity O 0 3.2223135804088088e-06
of O 0 3.058703214264824e-06
this O 0 5.022919140174054e-06
disease O 0 0.3098909854888916
. O 0 3.3055589483410586e-06

We O 0 2.8145790565758944e-05
analyzed O 0 5.869494998478331e-05
genotype O 0 0.0003446162154432386
/ O 0 0.0002777869231067598
phenotype O 0 1.806302861950826e-05
correlations O 0 1.0630723409121856e-05
, O 0 2.610140370506997e-07
on O 0 2.411568971183442e-07
the O 0 3.11004022535144e-08
basis O 0 9.745647133740931e-08
of O 0 4.331737954998971e-07
the O 0 4.4690122535939736e-07
constitution O 0 1.061669536284171e-06
of O 0 1.2557417221614742e-06
a O 0 4.482219083001837e-06
WT1 O 0 0.00017224605835508555
mutation O 0 6.048452405593707e-07
database O 0 2.0368634068290703e-06
of O 0 1.420284479536349e-05
84 O 0 0.0007370087550953031
germ O 0 0.006353053729981184
- O 0 0.00032829336123541
line O 0 2.5162711608572863e-05
mutations O 0 3.06728935584033e-07
, O 0 1.77455703465057e-08
to O 0 2.775315754988128e-09
compare O 0 1.354587642055094e-08
the O 0 3.2384111392502746e-08
distribution O 0 8.023649655797271e-08
and O 0 7.365568421846547e-08
type O 0 5.934327305112674e-07
of O 0 1.133770524575084e-06
mutations O 0 2.4018100930334185e-07
, O 0 2.2976742286573426e-08
according O 0 3.867214548591846e-09
to O 0 4.243684514904089e-09
the O 0 7.805706303543047e-08
different O 0 2.289070692995665e-07
symptoms O 0 7.454606384271756e-05
. O 0 3.1876897992333397e-06

This O 0 1.1845047993119806e-05
demonstrated O 0 3.0002041967236437e-05
( O 0 1.9777496618189616e-06
1 O 0 7.571678906970192e-06
) O 0 1.9277747753676522e-07
the O 0 4.2186687210232776e-07
association O 0 2.2614358385908417e-07
between O 0 2.5446067297707486e-07
mutations O 0 7.770248089400411e-08
in O 0 1.5999917195586022e-06
exons O 0 4.960311343893409e-06
8 O 0 1.4439056030823849e-05
and O 0 1.0313278835383244e-06
9 O 0 4.309094947529957e-05
and O 0 4.575908860715572e-06
DMS B-Disease 0 0.0010256139794364572
; O 0 3.96761123511169e-07
( O 0 2.78448538892917e-07
2 O 0 1.980373326659901e-06
) O 0 5.940239589108387e-08
among O 0 2.2538522159720742e-08
patients O 0 2.310205502453755e-07
with O 0 3.172173137500067e-07
DMS B-Disease 0 0.2895828187465668
, O 0 2.1057400090285228e-07
a O 0 1.6089370546978898e-07
higher O 0 2.496936986062792e-07
frequency O 0 2.339281763852341e-07
of O 0 3.5176842061446223e-07
exon O 0 7.463827387255151e-07
8 O 0 2.930502887465991e-06
mutations O 0 1.3637847473546572e-07
among O 0 1.039149566395281e-07
46 O 0 9.071992280951235e-06
, O 0 1.9016209762412473e-06
XY O 0 0.000938002485781908
patients O 0 9.252111681234965e-07
with O 0 8.61071285385151e-08
female O 0 5.434912509372225e-06
phenotype O 0 3.564333383110352e-06
than O 0 7.184934247561614e-08
among O 0 5.7753830162710074e-08
46 O 0 5.232446255831746e-06
, O 0 9.986864597522072e-07
XY O 0 0.0004077552002854645
patients O 0 3.009798774655792e-07
with O 0 3.2543493233561094e-08
sexual O 0 2.497849436622346e-06
ambiguity O 0 1.3382823453866877e-05
or O 0 2.0586126993293874e-05
male O 0 9.311834219261073e-06
phenotype O 0 3.575415121304104e-06
; O 0 1.2429201490249397e-07
and O 0 1.846913448844134e-07
( O 0 2.5241953949262097e-07
3 O 0 1.0993893511113129e-06
) O 0 3.03816989344341e-08
statistically O 0 5.6692538663583036e-08
significant O 0 3.646728785611231e-08
evidence O 0 1.3939640552962373e-07
that O 0 4.2566650648723225e-08
mutations O 0 1.6802154334527586e-07
in O 0 8.988886293082032e-07
exons O 0 4.129171884414973e-06
8 O 0 7.74087766330922e-06
and O 0 3.2609767686153646e-07
9 O 0 6.826748631283408e-06
preferentially O 0 4.2293316937502823e-07
affect O 0 8.466226972814184e-07
amino O 0 8.79767469541548e-07
acids O 0 5.8662873669845794e-08
with O 0 3.4240323909529025e-09
different O 0 8.201506140892434e-09
functions O 0 1.7701983097140328e-06
. O 0 1.391241539749899e-07
. O 0 2.9596799322462175e-07

The O 0 0.00012513570254668593
185delAG O 0 0.0003544493520166725
BRCA1 O 0 4.3761821871157736e-05
mutation O 0 9.867615062830737e-07
originated O 0 2.17908973354497e-06
before O 0 6.470651214840473e-07
the O 0 2.741752780366369e-07
dispersion O 0 4.50771631221869e-06
of O 0 2.5291114980063867e-06
Jews O 0 2.1788632693642285e-06
in O 0 1.6674546259309864e-06
the O 0 9.318809475189482e-07
diaspora O 0 9.370524480800668e-07
and O 0 4.949463345838012e-07
is O 0 2.4411968979620724e-07
not O 0 4.0628695074929055e-08
limited O 0 3.5899557815355365e-07
to O 0 4.2013522261186154e-07
Ashkenazim O 0 8.199974399758503e-05
. O 0 2.0242146092641633e-06

The O 0 7.245015149237588e-05
185delAG O 0 0.00028917440795339644
mutation O 0 8.88530757947592e-06
in O 0 4.688807621278102e-06
BRCA1 O 0 1.1854574950120877e-05
is O 0 1.1333841598570871e-07
detected O 0 1.3728683256886143e-07
in O 0 1.6621843457187424e-08
Ashkenazi O 0 1.396934408148809e-07
Jews O 0 3.383949120916441e-08
both O 0 1.1785887821247343e-08
in O 0 2.6443049705449084e-07
familial B-Disease 1 0.9989197254180908
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.2437031955414568e-06
in O 0 5.119752017890278e-07
the O 0 5.880648927814036e-07
general O 0 1.966109493878321e-06
population O 0 3.901977265741152e-07
. O 0 3.895845850365731e-07

All O 0 1.534244256617967e-05
tested O 0 1.418591091351118e-05
Ashkenazi O 0 1.0956152436847333e-05
mutation O 0 3.260267646965076e-07
carriers O 0 6.018726850243183e-08
share O 0 5.4808555915997204e-08
the O 0 4.489233518256697e-08
same O 0 6.822869380584962e-08
allelic O 0 4.589290711010108e-06
pattern O 0 8.740825251152273e-06
at O 0 1.9177010472049005e-05
the O 0 2.3417510419676546e-06
BRCA1 O 0 1.4861946510791313e-05
locus O 0 8.018053631531075e-05
. O 0 4.94441974296933e-06

Our O 0 2.9404993256321177e-05
previous O 0 1.0792610737553332e-05
study O 0 1.2300298521950026e-06
showed O 0 2.705771066757734e-06
that O 0 7.365849796769908e-08
this O 0 1.2433908125331072e-07
Ashkenazi O 0 7.65381810197141e-06
mutation O 0 1.120678234656225e-06
also O 0 5.91669106597692e-07
occurs O 0 1.2518540870587458e-07
in O 0 8.898223313735798e-08
Iraqi O 0 1.3384075145950192e-06
Jews O 0 1.4096157485710137e-07
with O 0 8.829579734026538e-09
a O 0 9.264396538810615e-08
similar O 0 1.6924715851018846e-07
allelic O 0 3.554428622010164e-05
pattern O 0 4.307816561777145e-05
. O 0 4.683779934566701e-06

We O 0 2.667463559191674e-05
extended O 0 3.399410707061179e-05
our O 0 4.516460194281535e-06
analysis O 0 5.414650559032452e-07
to O 0 2.626067612254701e-07
other O 0 5.65492257464939e-07
non O 0 2.1429348635138012e-05
- O 0 5.430576493381523e-06
Ashkenazi O 0 5.252339178696275e-06
subsets O 0 1.0337037565477658e-05
354 O 0 7.812772309989668e-06
of O 0 3.2586715406068834e-06
Moroccan O 0 5.749474075855687e-05
origin O 0 1.5241638493534992e-06
, O 0 3.508276904540253e-07
200 O 0 8.207391601899872e-07
Yemenites O 0 4.702936621470144e-06
and O 0 2.543833090840053e-07
150 O 0 1.016413989418652e-06
Iranian O 0 4.019281732325908e-06
Jews O 0 2.6461818833922734e-06
. O 0 1.3479311746777967e-06

Heteroduplex O 0 0.0007358596194535494
analysis O 0 7.003143878137053e-07
complemented O 0 4.4968692236579955e-07
by O 0 8.242970750416134e-09
direct O 0 1.1029161584019676e-07
DNA O 0 3.703856918946258e-07
sequencing O 0 2.5227759579138365e-06
of O 0 7.877323696448002e-06
abnormally O 0 9.773683996172622e-05
migrating O 0 3.583969601095305e-07
bands O 0 5.601783641395741e-07
were O 0 4.521953940184176e-07
employed O 0 2.6227264697809005e-06
. O 0 5.239539291324036e-07

Four O 0 7.686075696256012e-05
of O 0 7.310411456273869e-05
Moroccan O 0 0.000516594504006207
origin O 0 2.5107462988671614e-06
( O 0 2.720091742958175e-07
1 O 0 8.1440646226838e-07
. O 0 1.02872093066253e-08
1 O 0 7.15527107786329e-07
% O 0 1.2887008438156045e-07
) O 0 4.350533444608118e-08
and O 0 1.0941661798824498e-07
none O 0 6.45301440727053e-07
of O 0 5.935238277743338e-06
the O 0 1.004283330985345e-05
Yemenites O 0 3.535527503117919e-05
or O 0 1.7094048416765872e-06
Iranians O 0 1.259155851585092e-06
was O 0 7.039435558908735e-07
a O 0 6.393009499561231e-08
carrier O 0 7.762397302712998e-08
of O 0 2.3173086560746015e-07
the O 0 9.056570320353785e-07
185delAG O 0 2.5251172701246105e-05
mutation O 0 3.289928372396389e-06
. O 0 3.820773599727545e-06

BRCA1 O 0 0.00111894600559026
allelic O 0 0.0002707090461626649
patterns O 0 3.948391167796217e-05
were O 0 3.4587812933750683e-06
determined O 0 3.5266293707536533e-07
for O 0 1.2263176074611692e-07
four O 0 2.1766255997590633e-07
of O 0 2.526456910345587e-07
these O 0 1.7596899937188937e-08
individuals O 0 1.1547879985585041e-08
and O 0 4.7588084584049284e-08
for O 0 1.3108362395541917e-07
12 O 0 3.06797846860718e-06
additional O 0 8.58978012274747e-07
non O 0 0.00012045742914779112
- O 0 1.3160425623937044e-05
Ashkenazi O 0 4.1434559534536675e-06
185delAG O 0 1.4116513966655475e-06
mutation O 0 6.56970442491911e-08
carriers O 0 3.405809678724836e-08
who O 0 4.3534551963375634e-08
had O 0 5.465621597977588e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.602030715730507e-05

Six O 0 0.0012032922822982073
non O 0 0.008734704926609993
- O 0 0.00018648339028004557
Ashkenazi O 0 1.696649815130513e-05
individuals O 0 1.640288616044927e-07
shared O 0 1.258279439753096e-06
the O 0 3.1179865800368134e-06
common O 0 5.723459253204055e-06
Ashkenazi O 0 0.0001205936205224134
haplotype O 0 0.0002527280303183943
, O 0 3.649224026958109e-06
four O 0 1.0204641966993222e-06
had O 0 2.346172777833999e-06
a O 0 1.3810035852657165e-06
closely O 0 6.067616027394251e-07
related O 0 3.86694000553689e-06
pattern O 0 2.4908013074309565e-05
, O 0 7.171954052864749e-07
and O 0 4.0245535615213157e-07
the O 0 1.5495782008656533e-06
rest O 0 8.916239266909542e-07
( O 0 4.2564383306853415e-07
n O 0 7.487649781978689e-06
= O 0 8.207781320379581e-06
6 O 0 3.838420980173396e-06
) O 0 5.48067795591578e-08
displayed O 0 7.288780352610047e-07
a O 0 4.5305051799005014e-07
distinct O 0 6.679987336610793e-07
BRCA1 O 0 1.3176851098251063e-05
allelic O 0 3.0235209123929963e-05
pattern O 0 3.7458168662851676e-05
. O 0 2.0013414996356005e-06

We O 0 6.302385372691788e-06
conclude O 0 4.968644134351052e-06
that O 0 1.9462233069589274e-07
the O 0 2.0447985207283637e-06
185delAG O 0 7.074160384945571e-05
BRCA1 O 0 2.8393924367264844e-05
mutation O 0 2.3573552425659727e-06
occurs O 0 1.9611020434240345e-06
in O 0 2.1109265162522206e-06
some O 0 6.014423661326873e-07
non O 0 0.00014551027561537921
- O 0 2.5179562726407312e-05
Ashkenazi O 0 4.545090632745996e-06
populations O 0 2.506011753666826e-07
at O 0 1.4011000075697666e-06
rates O 0 6.032092159102831e-08
comparable O 0 8.680698471152937e-08
with O 0 5.649863688006462e-09
that O 0 2.7132255553397044e-08
of O 0 3.2585346616542665e-06
Ashkenazim O 0 0.0001865063386503607
. O 0 3.1806443985260557e-06

The O 0 8.187962521333247e-06
majority O 0 4.6263645003818965e-07
of O 0 3.2328375709766988e-06
Jewish O 0 3.5035311157116666e-05
185delAG O 0 9.003432933241129e-05
mutation O 0 2.556955223553814e-06
carriers O 0 8.523649057678995e-07
have O 0 1.3737184190176777e-07
a O 0 2.4936412046372425e-07
common O 0 4.4583740077541734e-07
allelic O 0 7.424614523188211e-06
pattern O 0 1.0516808288230095e-05
, O 0 4.3885958689315885e-07
supporting O 0 2.100480287481332e-06
the O 0 5.833633622387424e-06
founder O 0 2.806238626362756e-05
effect O 0 4.028368948638672e-06
notion O 0 1.593200863680977e-06
, O 0 2.3875139731899253e-07
but O 0 2.7969081273226948e-08
dating O 0 5.031502610108873e-07
the O 0 4.6288715793707524e-07
mutations O 0 2.634553766256431e-07
origin O 0 5.607780622085556e-07
to O 0 9.780917054058591e-08
an O 0 1.8447852312419855e-07
earlier O 0 4.7048203555277723e-07
date O 0 1.7339872329102946e-06
than O 0 1.6142193715040776e-07
currently O 0 7.967722694957047e-07
estimated O 0 1.9378255728952354e-06
. O 0 1.25604481127084e-06

However O 0 5.041481927037239e-06
, O 0 1.8968739823321812e-07
the O 0 8.53582093895966e-08
different O 0 2.0901577357790302e-08
allelic O 0 5.6046601457637735e-06
pattern O 0 1.890016756078694e-05
at O 0 6.079541708459146e-05
the O 0 5.407873231888516e-06
BRCA1 O 0 9.486476301390212e-06
locus O 0 9.951584615919273e-06
even O 0 1.6691332405116555e-07
in O 0 1.413630172919511e-07
some O 0 6.161808840943195e-08
Jewish O 0 4.4520575102069415e-06
mutation O 0 7.681508122914238e-07
carriers O 0 6.495828301922302e-07
, O 0 7.95007011333837e-08
might O 0 2.1614068757003224e-08
suggest O 0 1.6156201709804918e-08
that O 0 2.8971280929823706e-09
the O 0 3.9202422641437806e-08
mutation O 0 1.1773670394177316e-07
arose O 0 9.538318579416227e-08
independently O 0 6.681987940737599e-08
. O 0 1.353283920479953e-07
. O 0 6.132883640930231e-07

Crystal O 0 0.007515387609601021
structure O 0 0.00013163404946681112
of O 0 0.00014592392835766077
the O 0 0.0006020863074809313
hemochromatosis B-Disease 1 1.0
protein O 0 0.0019206336000934243
HFE O 0 0.004952417220920324
and O 0 2.0041261450387537e-06
characterization O 0 3.712322950377711e-06
of O 0 2.238411525468109e-06
its O 0 3.523035729813273e-07
interaction O 0 8.954695545071445e-07
with O 0 3.495929377095308e-07
transferrin O 0 0.00010475293674971908
receptor O 0 3.434563768678345e-05
. O 0 1.0555314702287433e-06

HFE O 1 0.9978129863739014
is O 0 0.00029839540366083384
an O 0 3.317785740364343e-05
MHC O 0 0.00031576759647578
- O 0 2.483046228007879e-05
related O 0 1.6860017240105662e-06
protein O 0 3.442553975219198e-07
that O 0 4.275524378982709e-09
is O 0 9.651560439749574e-09
mutated O 0 1.952444783626106e-08
in O 0 6.635440996660691e-08
the O 0 2.192186002503149e-06
iron B-Disease 1 0.9999986886978149
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0013778886059299111

HFE O 0 0.012116093188524246
binds O 0 3.6221015761839226e-05
to O 0 9.854770723904949e-06
transferrin O 0 0.00011586054461076856
receptor O 0 2.455939829815179e-05
( O 0 1.998179641304887e-06
TfR O 0 0.00015961166354827583
) O 0 2.17028073734582e-07
and O 0 1.1228580376609898e-07
reduces O 0 3.5848412949235353e-07
its O 0 3.2349669254472246e-07
affinity O 0 1.6372191566915717e-06
for O 0 4.635034656530479e-06
iron O 0 0.00027660795603878796
- O 0 8.612102647020947e-06
loaded O 0 1.6131019719978212e-06
transferrin O 0 2.282255627505947e-05
, O 0 5.962203317722015e-07
implicating O 0 3.573437061277218e-05
HFE O 0 0.0029472566675394773
in O 0 0.0001741393789416179
iron O 1 0.9988234639167786
metabolism O 0 0.02219051867723465
. O 0 6.17300020167022e-06

The O 0 0.00017961152479983866
2 O 0 0.00034240703098475933
. O 0 9.6467792900512e-06

6 O 0 0.001560620148666203
A O 0 0.0001244078011950478
crystal O 0 0.0009143113857135177
structure O 0 3.411559737287462e-05
of O 0 2.967772525153123e-05
HFE O 0 0.0031897148583084345
reveals O 0 4.307172275730409e-06
the O 0 9.148727144747681e-07
locations O 0 3.7976838029862847e-06
of O 0 0.00012757063086610287
hemochromatosis B-Disease 1 1.0
mutations O 0 0.00019525294192135334
and O 0 6.596892490051687e-05
a O 0 0.00015885916945990175
patch O 0 0.0008629744406789541
of O 0 0.0018087089993059635
histidines O 0 0.0036116400733590126
that O 0 1.1070360415033065e-06
could O 0 7.386586844404519e-07
be O 0 4.655105385609204e-07
involved O 0 3.8641863397970155e-07
in O 0 2.0332847725512693e-06
pH O 0 0.0001361868780804798
- O 0 1.6635514839435928e-05
dependent O 0 2.3771112864778843e-06
interactions O 0 1.5085358882060973e-06
. O 0 8.626294061286899e-07

We O 0 2.8500107873696834e-05
also O 0 2.7352052711648867e-06
demonstrate O 0 3.1332244816439925e-06
that O 0 1.1058679092457169e-06
soluble O 0 8.21362336864695e-05
TfR O 0 0.002609462244436145
and O 0 1.0990876035066321e-05
HFE O 0 0.00043525404180400074
bind O 0 1.1977333542745328e-06
tightly O 0 3.395430439923075e-06
at O 0 1.3323428902367596e-05
the O 0 7.867044473641727e-07
basic O 0 6.328361905616475e-06
pH O 0 3.671841477626003e-05
of O 0 5.4851596360094845e-05
the O 0 4.7373407142004e-05
cell O 0 5.715172301279381e-05
surface O 0 2.4197197490138933e-05
, O 0 3.7004249975325365e-07
but O 0 4.6207603077164094e-08
not O 0 9.038832615715364e-08
at O 0 3.2586219731456367e-06
the O 0 6.473644589277683e-07
acidic O 0 6.518660484289285e-06
pH O 0 3.3471525966888294e-05
of O 0 2.3622484150109813e-05
intracellular O 0 0.00011442072718637064
vesicles O 0 0.00023705822241026908
. O 0 1.4274703062255867e-05

TfR O 1 0.976321816444397
HFE O 0 0.03558263182640076
stoichiometry O 0 0.0009167389944195747
( O 0 1.9096984033240005e-05
2 O 0 3.90080786019098e-05
1 O 0 1.657616303418763e-05
) O 0 3.7310593370420975e-07
differs O 0 3.90801403682417e-07
from O 0 9.448468745176797e-07
TfR O 0 0.0003073765547014773
transferrin O 0 2.56673083640635e-05
stoichiometry O 0 1.1428194738982711e-05
( O 0 7.436728992615826e-07
2 O 0 6.41680389890098e-06
2 O 0 3.3833671295724344e-06
) O 0 9.631096276052631e-08
, O 0 3.380788271556412e-08
implying O 0 2.052864971346935e-07
a O 0 8.525358907718328e-08
different O 0 8.019299890804632e-09
mode O 0 6.901635174472176e-07
of O 0 4.4511901364785444e-07
binding O 0 9.5467976279906e-07
for O 0 4.070415798196336e-06
HFE O 0 0.0004518838250078261
and O 0 4.383766281534918e-06
transferrin O 0 6.424114690162241e-05
to O 0 1.2252309034010977e-06
TfR O 0 0.00102699501439929
, O 0 6.647753707511583e-07
consistent O 0 1.0785303174998262e-06
with O 0 5.684076853640363e-08
our O 0 5.297667371451098e-07
demonstration O 0 9.912598216033075e-06
that O 0 2.3368178858618194e-07
HFE O 0 0.0001032648651744239
, O 0 4.913012503493519e-07
transferrin O 0 7.1481213126389775e-06
, O 0 9.372583065214712e-08
and O 0 9.910113618616379e-08
TfR O 0 0.0003486284986138344
form O 0 2.061337454506429e-06
a O 0 1.3631657566293143e-05
ternary O 0 0.0006204296951182187
complex O 0 0.00045071664499118924
. O 0 1.0275168278894853e-05

Identification O 0 4.631168394553242e-06
of O 0 7.999160516192205e-06
three O 0 1.557696123200003e-06
novel O 0 1.2667195505855489e-06
mutations O 0 1.2294007945001795e-07
and O 0 8.279705099312196e-08
a O 0 8.101785908820602e-08
high O 0 6.322549097603769e-07
frequency O 0 1.423302364855772e-07
of O 0 2.601318840333988e-07
the O 0 6.935701435395458e-07
Arg778Leu O 0 2.111723370035179e-05
mutation O 0 3.482924171294144e-07
in O 0 4.6866031766512606e-07
Korean O 0 8.44825990498066e-06
patients O 0 8.783489988672954e-07
with O 0 2.257417293094477e-07
Wilson B-Disease 0 0.0001909423735924065
disease I-Disease 0 0.0006990166148170829
. O 0 1.4500908491754672e-06

Four O 0 0.0003109518438577652
mutations O 0 1.5130719475564547e-05
- O 0 3.6891349736833945e-05
- O 0 2.5941886633518152e-05
R778L O 0 3.5937475331593305e-05
, O 0 2.1234675386949675e-06
A874V O 0 2.1485480829142034e-05
, O 0 3.3557637379999505e-06
L1083F O 0 2.503813993826043e-05
, O 0 2.031800022450625e-06
and O 0 1.3178661220081267e-06
2304delC O 0 5.967407560092397e-06
- O 0 1.5030776694402448e-06
- O 0 1.2764768371198443e-06
in O 0 2.518530664019636e-06
the O 0 6.0657921494566835e-06
copper O 0 5.146242619957775e-05
- O 0 2.480742750776699e-06
transporting O 0 4.861532943323255e-06
enzyme O 0 4.5750448407488875e-06
, O 0 2.123783360730158e-06
P O 0 0.0002628247893881053
- O 0 1.0855694199563004e-05
type O 0 2.7515214242157526e-05
ATPase O 0 0.0001035694804158993
( O 0 3.827655746135861e-06
ATP7B O 0 6.463201134465635e-05
) O 0 7.937797619206322e-08
, O 0 6.6713394808459725e-09
were O 0 8.735221435074436e-09
identified O 0 1.0887032608764002e-08
in O 0 5.347523668319809e-08
Korean O 0 2.3112861526897177e-06
Patients O 0 8.14924703718134e-07
with O 0 3.167843942719628e-07
Wilson B-Disease 0 0.00016220982070080936
disease I-Disease 0 0.0028852149844169617
. O 0 2.228105358881294e-06

Arg778Leu O 0 0.006669420748949051
, O 0 9.537229743727949e-06
the O 0 2.156347818527138e-06
most O 0 2.544388451042323e-07
frequently O 0 5.338861228665337e-07
reported O 0 1.1727751143553178e-06
mutation O 0 1.4115528301772429e-07
of O 0 4.772379725181963e-06
this O 0 7.114757067938626e-07
enzyme O 0 1.919441956488299e-06
, O 0 3.482342947336292e-07
was O 0 2.289848907821579e-06
found O 0 3.186076469319232e-08
in O 0 4.835251488088943e-08
six O 0 7.883088670723737e-08
of O 0 2.989262952723948e-07
eight O 0 9.216225862473948e-07
unrelated O 0 1.5696873560955282e-06
patients O 0 4.77723347103165e-07
studied O 0 2.050105649686884e-06
, O 0 4.808396880662258e-08
an O 0 1.4708004592023372e-08
allele O 0 1.0057635080329419e-07
frequency O 0 7.444477319040743e-07
of O 0 4.223312316753436e-06
37 O 0 7.278496195795015e-05
. O 0 2.866839167836588e-06

5 O 0 0.00028153599123470485
% O 0 1.0920538443315309e-05
, O 0 6.522465128000476e-07
which O 0 2.90856377205273e-07
is O 0 3.97754092773539e-07
considerably O 0 9.748339380166726e-07
higher O 0 1.057387294167711e-06
than O 0 2.1793729487740165e-08
those O 0 1.1384470255393353e-08
in O 0 1.9453121069545887e-07
other O 0 1.0409726058924207e-07
Asian O 0 9.287959983339533e-07
populations O 0 7.271597723956802e-08
. O 0 2.7365047117200447e-07

The O 0 2.175661393266637e-05
novel O 0 9.161105481325649e-06
single O 0 7.555608135589864e-06
nucleotide O 0 1.0863357601920143e-05
deletion O 0 2.1786867364426143e-05
, O 0 1.7213189948961372e-06
2304delC O 0 7.870948138588574e-06
, O 0 2.7060036700277124e-07
was O 0 1.8333970501771546e-06
found O 0 1.1208958738961883e-07
in O 0 2.7224328391639574e-07
one O 0 4.55653804465328e-07
patient O 0 1.0820211173268035e-05
. O 0 3.531859647409874e-06

Since O 0 2.8169368306407705e-05
a O 0 4.7031430767674465e-06
mutation O 0 1.3198986152929137e-06
at O 0 1.6296438843710348e-05
cDNA O 0 1.4112601093074773e-05
nucleotide O 0 3.962944174418226e-05
2302 O 0 0.0006763776182197034
( O 0 8.286707270599436e-06
2302insC O 0 3.06481342704501e-05
) O 0 1.1701877156156115e-06
had O 0 3.072434992645867e-06
been O 0 1.972626023416524e-06
previously O 0 4.244377123541199e-06
described O 0 6.131012355581333e-07
, O 0 2.37664981028729e-08
this O 0 7.68144747809174e-09
region O 0 2.8169776555841963e-07
of O 0 2.074270014418289e-06
the O 0 1.2785328181053046e-05
ATP7B O 0 0.0026087237056344748
gene O 0 7.936742804304231e-06
may O 0 1.9658077690110076e-06
be O 0 1.857136311400609e-07
susceptible O 0 8.723568498680834e-07
to O 0 4.243775819645634e-08
gene O 0 3.854091119137593e-06
rearrangements O 0 0.0001955018233275041
causing O 0 0.01885879412293434
Wilson B-Disease 0 0.00338205648586154
disease I-Disease 1 0.9785788655281067
. O 0 3.0495630198856816e-06

Disruption O 0 0.003675298299640417
of O 0 8.331437857123092e-05
splicing O 0 1.0063283298222814e-05
regulated O 0 7.649834515177645e-06
by O 0 2.072947467013364e-07
a O 0 1.7543683270559995e-06
CUG O 0 6.313086487352848e-05
- O 0 2.1840912722836947e-06
binding O 0 1.2975581284990767e-06
protein O 0 2.076803139061667e-05
in O 0 6.104417843744159e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.4603462659579236e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.04619365558028221
DM B-Disease 1 1.0
) O 0 8.824593533063307e-05
is O 0 7.14932821210823e-06
caused O 0 2.2764623281545937e-05
by O 0 6.184545782161877e-07
a O 0 3.346687208249932e-06
CTG O 0 4.864342190558091e-05
expansion O 0 1.3376942433751537e-06
in O 0 3.0473344736492436e-07
the O 0 3.4178034979959193e-07
3 O 0 1.7179620499518933e-06
untranslated O 0 6.692327133350773e-06
region O 0 6.51082473268616e-07
of O 0 5.0361772991891485e-06
the O 0 5.060831244918518e-05
DM B-Disease 1 1.0
gene O 0 4.9199512432096526e-05
. O 0 5.703326223738259e-06

One O 0 1.017130671243649e-05
model O 0 2.0203409803798422e-05
of O 0 0.0002841853129211813
DM B-Disease 1 1.0
pathogenesis O 1 0.9909641742706299
suggests O 0 8.955687007983215e-06
that O 0 5.096991344544222e-07
RNAs O 0 8.059437277552206e-06
from O 0 9.466037909078295e-07
the O 0 3.616725336996751e-07
expanded O 0 9.424674658475851e-07
allele O 0 1.5071641428221483e-06
create O 0 6.016672386977007e-07
a O 0 6.17208206676878e-06
gain O 0 2.361032420594711e-05
- O 0 6.754528385499725e-06
of O 0 1.758510734362062e-05
- O 0 1.0344690053898375e-05
function O 0 4.2255846892658155e-06
mutation O 0 1.0739940847770413e-07
by O 0 2.983102476150634e-08
the O 0 1.768587196693261e-07
inappropriate O 0 2.2067125371449947e-07
binding O 0 1.4620381705299224e-07
of O 0 7.124575063244265e-07
proteins O 0 9.553485824653762e-08
to O 0 1.303976091548975e-07
the O 0 2.346085466342629e-06
CUG O 0 0.0001991153258131817
repeats O 0 2.1300254957168363e-05
. O 0 2.6368461476522498e-06

Data O 0 7.951938459882513e-05
presented O 0 1.4814373571425676e-05
here O 0 3.615581135818502e-06
indicate O 0 1.111631718231365e-06
that O 0 7.166197946162356e-08
the O 0 9.264481377613265e-07
conserved O 0 1.2594664440257475e-05
heterogeneous O 0 9.979451715480536e-05
nuclear O 0 0.000253659876761958
ribonucleoprotein O 0 0.0013379837619140744
, O 0 1.0597197615425102e-05
CUG O 0 0.00018890657520387322
- O 0 7.117680524970638e-06
binding O 0 4.581384473567596e-06
protein O 0 1.1806151633209083e-05
( O 0 2.461738176862127e-06
CUG O 0 0.0001467108231736347
- O 0 3.0681301723234355e-05
BP O 0 3.4403721656417474e-05
) O 0 9.60761781243491e-07
, O 0 6.763015676369832e-07
may O 0 3.1799772841623053e-06
mediate O 0 6.240371476451401e-06
the O 0 2.2144729882711545e-05
trans O 0 2.024757668550592e-05
- O 0 5.9050948948424775e-06
dominant O 0 1.265388959836855e-06
effect O 0 2.6060016011797416e-07
of O 0 5.372796181291051e-07
the O 0 1.1054240758312517e-06
RNA O 0 3.030270136150648e-06
. O 0 1.17389970455406e-06

CUG O 1 0.7810490131378174
- O 0 0.008326827548444271
BP O 0 0.0006113772979006171
was O 0 1.089590568881249e-05
found O 0 7.504426235982464e-08
to O 0 3.4668661275105705e-09
bind O 0 1.0658675719810162e-08
to O 0 1.725598508528492e-08
the O 0 7.245652113851975e-07
human O 0 0.00010506305261515081
cardiac O 1 1.0
troponin O 1 0.9999228715896606
T O 0 0.005076587200164795
( O 0 5.914946996199433e-06
cTNT O 0 1.4914409803168382e-05
) O 0 3.2175216801988427e-07
pre O 0 1.0088362614624202e-05
- O 0 9.27907080949808e-07
messenger O 0 5.461711225507315e-07
RNA O 0 4.5531148629152085e-08
and O 0 1.4015162363989475e-08
regulate O 0 2.2629670581864048e-08
its O 0 2.6982798218000426e-08
alternative O 0 2.2776059438456286e-07
splicing O 0 8.303021559186163e-07
. O 0 8.640192845632555e-07

Splicing O 0 5.5414315283996984e-05
of O 0 7.626025762874633e-05
cTNT O 0 0.0003466102643869817
was O 0 0.00016014491848181933
disrupted O 0 0.0010503288358449936
in O 0 0.00016790855443105102
DM B-Disease 1 1.0
striated O 0 0.0040834457613527775
muscle O 0 0.00027199016767553985
and O 0 4.6723944251425564e-06
in O 0 5.86008627578849e-06
normal O 0 2.5368184651597403e-05
cells O 0 9.77198283180769e-07
expressing O 0 1.0174734654810891e-07
transcripts O 0 7.810872375557665e-07
that O 0 2.5508189338552256e-08
contain O 0 9.245787282452511e-07
CUG O 0 0.00014377567276824266
repeats O 0 1.7249953089049086e-05
. O 0 5.305672857502941e-06

Altered O 0 0.00013736513210460544
expression O 0 6.41375154373236e-05
of O 0 4.0827009797794744e-05
genes O 0 7.940127034089528e-06
regulated O 0 2.9953043849673122e-05
posttranscriptionally O 0 6.51148657198064e-05
by O 0 3.2446735076518962e-06
CUG O 0 0.0005687008961103857
- O 0 5.344161399989389e-05
BP O 0 1.84069576789625e-05
therefore O 0 2.9891830877204484e-07
may O 0 4.675625291383767e-07
contribute O 0 1.7252570216896856e-07
to O 0 1.613835934222152e-06
DM B-Disease 1 1.0
pathogenesis O 0 0.008077030070126057
. O 0 1.809196987778705e-06
. O 0 1.4572497093467973e-06

Identification O 0 4.334955065132817e-06
of O 0 2.696757292142138e-06
a O 0 2.3799534574209247e-06
novel O 0 3.5867672067979584e-06
nonsense O 0 2.2512656869366765e-05
mutation O 0 3.170939066876599e-07
and O 0 1.4935625358702964e-07
a O 0 4.5135655568628863e-07
missense O 0 3.0490484732581535e-06
substitution O 0 2.4558430595789105e-06
in O 0 3.6003589229949284e-06
the O 0 6.594016667804681e-06
vasopressin O 0 3.896108319167979e-05
- O 0 1.0858706446015276e-05
neurophysin O 0 1.8479404388926923e-05
II O 0 8.153518137987703e-05
gene O 0 1.1932442589568382e-07
in O 0 3.9958163000619606e-08
two O 0 2.112703434420382e-08
Spanish O 0 9.120154231823108e-07
kindreds O 0 4.490613719099201e-06
with O 0 1.261191187040822e-07
familial B-Disease 1 0.9993188381195068
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999982118606567
. O 0 2.0144883819739334e-05

Familial B-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.15291863679885864
FNDI B-Disease 1 1.0
) O 0 1.5106724049473996e-06
is O 0 5.654459300785675e-08
an O 0 1.6999695162667194e-07
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9790019989013672
by O 0 4.684869509219425e-06
deficiency O 1 1.0
in O 0 0.015805227681994438
the O 0 0.0018997390288859606
antidiuretic O 0 0.009145211428403854
hormone O 0 0.0001373532140860334
arginine O 0 1.571635584696196e-05
vasopressin O 0 1.1043828635592945e-05
( O 0 8.141711305142962e-07
AVP O 0 1.758815960783977e-05
) O 0 4.432584788105487e-08
encoded O 0 1.208768338756272e-07
by O 0 1.62535698677857e-07
the O 0 6.766849764971994e-06
AVP O 0 0.00031044971547089517
- O 0 6.020923319738358e-05
neurophysin O 0 0.00017994373047258705
II O 1 0.9972942471504211
( O 0 0.00011896458454430103
AVP O 0 0.0034444339107722044
- O 0 5.4765198001405224e-05
NPII O 0 0.0001266434119315818
) O 0 3.421563974370656e-07
gene O 0 5.060500711806526e-07
on O 0 6.087164365453646e-06
chromosome O 0 0.00011975628876825795
20p13 O 0 0.00029984809225425124
. O 0 6.198939900059486e-06

In O 0 6.932402902748436e-05
this O 0 1.491190005253884e-06
study O 0 1.034637989505427e-06
, O 0 2.4199226800192264e-07
we O 0 2.809569288331204e-08
analyzed O 0 8.734676271160424e-08
two O 0 8.365423553868823e-08
families O 0 3.889274680091148e-08
with O 0 2.1417277196178475e-07
FNDI B-Disease 1 0.9717881083488464
using O 0 1.4551833373843692e-06
direct O 0 7.209876002889359e-06
automated O 0 5.726918243453838e-05
fluorescent O 0 9.862621482170653e-06
, O 0 3.409690805256105e-07
solid O 0 2.8805445708712796e-06
phase O 0 3.9119804569054395e-06
, O 0 2.3733436194106616e-07
single O 0 3.40312197977255e-07
- O 0 4.114511682473676e-07
stranded O 0 2.2271994737366185e-07
DNA O 0 2.2359714080266713e-08
sequencing O 0 2.3073233990089648e-07
of O 0 5.235855496721342e-06
PCR O 0 5.0876435125246644e-05
- O 0 0.00013108454004395753
amplified O 0 0.0002032391057582572
AVP O 0 0.0016142843523994088
- O 0 2.7098618375021033e-05
NPII O 0 9.209754352923483e-05
DNA O 0 2.242751406811294e-06
. O 0 9.622766583561315e-07

In O 0 9.380929986946285e-05
one O 0 3.2121122330863727e-06
of O 0 4.169633484707447e-06
the O 0 2.0421384760993533e-06
families O 0 7.937827462001223e-08
, O 0 5.3721919357485604e-08
affected O 0 7.442462646167769e-08
individuals O 0 9.11651820700854e-09
presented O 0 6.311320248642005e-07
a O 0 1.0192522950092098e-06
novel O 0 3.06839410768589e-06
nonsense O 0 8.035707651288249e-06
mutation O 0 1.9525218419857993e-07
in O 0 7.77423451836512e-07
exon O 0 6.046445832907921e-07
3 O 0 2.5429455945413793e-06
of O 0 1.670392634878226e-06
the O 0 1.2700508023044677e-06
gene O 0 1.7496587645382533e-07
, O 0 6.658565609996003e-08
consisting O 0 5.4687738781922235e-08
in O 0 5.475301918522746e-07
a O 0 3.992025995103177e-06
G O 0 7.848218956496567e-05
to O 0 4.466414793569129e-06
T O 0 0.00023623039305675775
transition O 0 1.4866454876028001e-05
at O 0 4.320665539125912e-05
nucleotide O 0 9.969023267331067e-06
2101 O 0 6.634296732954681e-05
, O 0 1.767546820019561e-07
which O 0 8.67839702323181e-08
produces O 0 6.647982075946857e-08
a O 0 2.2997093651611067e-07
stop O 0 2.835316195159976e-07
signal O 0 3.461068445176352e-06
in O 0 2.014187657550792e-06
codon O 0 9.82627989287721e-06
82 O 0 2.8392219974193722e-05
( O 0 1.9506417174852686e-06
Glu O 0 0.00011145863390993327
) O 0 7.414132596750278e-07
of O 0 9.099789167521521e-06
NPII O 0 0.0015011049108579755
. O 0 1.2331105608609505e-05

The O 0 0.0001425065565854311
premature O 0 0.00014720420585945249
termination O 0 2.341252184123732e-05
eliminates O 0 3.5326818306202767e-06
part O 0 3.5475841286825016e-06
of O 0 4.182378324912861e-05
the O 0 3.757193189812824e-05
C O 0 0.0004169511084910482
- O 0 4.9103004130302e-05
terminal O 0 0.00012354268983472139
domain O 0 4.7946964514267165e-06
of O 0 1.7496382497483864e-05
NPII O 0 0.00020071497419849038
, O 0 1.5653879472665722e-06
including O 0 5.618251179839717e-07
a O 0 2.4119240151776467e-06
cysteine O 0 1.7139709029834194e-07
residue O 0 3.5508198834577342e-06
in O 0 5.071737177786417e-06
position O 0 1.8640668713487685e-05
85 O 0 1.651091042731423e-05
, O 0 3.100327603533515e-07
which O 0 6.161985055541663e-08
could O 0 2.7707949712407753e-08
be O 0 3.471168597002361e-08
involved O 0 3.062051234792307e-08
in O 0 2.190546410929528e-07
the O 0 5.111424457027169e-07
correct O 0 2.326002004338079e-06
folding O 0 9.167581993096974e-06
of O 0 4.553072812996106e-06
the O 0 1.5216486644931138e-05
prohormone O 0 0.0020303598139435053
. O 0 5.809981303173117e-06

In O 0 0.0001111869714804925
the O 0 2.4167446099454537e-05
second O 0 4.0359347622143105e-05
family O 0 2.8365998332446907e-06
, O 0 4.684225416440313e-07
a O 0 1.2238143654030864e-06
G279A O 0 1.4075636499910615e-05
substitution O 0 1.2267636520846281e-05
at O 0 7.395851571345702e-05
position O 0 6.1970545175427105e-06
- O 0 7.69658470289869e-07
1 O 0 1.9043613974645268e-06
of O 0 7.08583002051455e-07
the O 0 1.2655506225200952e-06
signal O 0 6.943014341231901e-06
peptide O 0 1.6207936823775526e-06
was O 0 1.2158919844296179e-06
observed O 0 3.5648767493512423e-07
in O 0 8.33982198855665e-08
all O 0 3.1835256208978535e-08
affected O 0 1.094176695914939e-07
individuals O 0 4.1682156393108016e-08
. O 0 5.27602253441728e-07

This O 0 1.3083988960715942e-05
missense O 0 0.00011231579264858738
mutation O 0 1.962697751878295e-05
, O 0 3.46932665706845e-06
which O 0 3.3692640499793924e-06
replaces O 0 0.00011489172902656719
Ala O 0 0.00021725216356571764
with O 0 8.300416425299773e-07
Thr O 0 0.0008174813119694591
, O 0 6.838802733000193e-07
is O 0 1.3244880392448977e-07
frequent O 0 1.5928940229059663e-06
among O 0 5.752911874878919e-06
FNDI B-Disease 1 1.0
patients O 0 6.373546784743667e-05
and O 0 1.0746330190158915e-06
is O 0 4.316496813316917e-07
thought O 0 6.418349585146643e-08
to O 0 8.166462173164746e-09
reduce O 0 3.3331509996514797e-08
the O 0 3.1921723575578653e-07
efficiency O 0 1.6655791341690929e-06
of O 0 1.497998937338707e-06
cleavage O 0 5.523233085114043e-06
by O 0 6.321421892607759e-07
signal O 0 2.3060852981870994e-05
peptidases O 0 4.389532114146277e-05
. O 0 4.4704015067509317e-07
. O 0 1.0296090522388113e-06

Genetic O 0 9.855452663032338e-05
heterogeneity O 0 0.00031465626670978963
of O 0 0.000944164174143225
Saethre B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.778053385554813e-06
due O 0 2.2136367988423444e-05
to O 0 9.081340976990759e-07
TWIST O 0 5.112252620165236e-05
and O 0 7.357926278928062e-06
FGFR O 0 0.00173734943382442
mutations O 0 1.5907437045825645e-05
. O 0 3.901552190654911e-06

Thirty O 0 0.0015882907900959253
- O 0 6.663837848464027e-05
two O 0 3.421469330078253e-07
unrelated O 0 8.970970384325483e-07
patients O 0 5.252762136365163e-08
with O 0 1.4860919161918673e-09
features O 0 1.357834520376855e-07
of O 0 1.2223212252138183e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.41317479776626e-07
a O 0 4.3847933284268947e-07
common O 0 8.68465667736018e-06
autosomal B-Disease 1 0.9999493360519409
dominant I-Disease 1 0.9999914169311523
condition I-Disease 1 0.9999984502792358
of O 1 0.9999923706054688
craniosynostosis B-Disease 1 1.0
and O 1 0.999980092048645
limb B-Disease 1 1.0
anomalies I-Disease 1 0.998907208442688
, O 0 4.6813318022032036e-07
were O 0 8.540413176660877e-08
screened O 0 1.5573499467791407e-07
for O 0 7.112112143659033e-08
mutations O 0 1.4774549583762564e-07
in O 0 2.0987943116779206e-06
TWIST O 0 1.3653318092110567e-05
, O 0 1.4885174550727243e-06
FGFR2 O 0 6.394776573870331e-05
, O 0 7.838481792532548e-07
and O 0 1.2936598068336025e-06
FGFR3 O 0 0.00041581704863347113
. O 0 6.121446858742274e-06

Nine O 0 0.00011578379780985415
novel O 0 2.221938302682247e-05
and O 0 4.011048986285459e-06
three O 0 5.80694586460595e-06
recurrent O 0 0.0005925057921558619
TWIST O 0 0.00010459811892360449
mutations O 0 1.328783696408209e-06
were O 0 9.51718163832993e-07
found O 0 9.638171150072594e-08
in O 0 1.1580639380781577e-07
12 O 0 1.8696821371122496e-06
families O 0 7.253520095673593e-08
. O 0 6.243033681130328e-07

Seven O 0 0.00012628705007955432
families O 0 1.0304656825610436e-06
were O 0 1.2792542065653834e-06
found O 0 2.212895680031579e-07
to O 0 4.392322239255009e-08
have O 0 4.284151202682551e-07
the O 0 7.636029295099434e-06
FGFR3 O 0 0.00037502325722016394
P250R O 0 0.00012093874829588458
mutation O 0 3.6885655845253495e-06
, O 0 1.7828847376222257e-06
and O 0 1.29747263599711e-06
one O 0 6.659709015366388e-07
individual O 0 2.4176483748306055e-07
was O 0 1.1953258763242047e-05
found O 0 5.162771685718326e-07
to O 0 1.271165359639781e-07
have O 0 5.043282271799399e-07
an O 0 1.2773876960636699e-06
FGFR2 O 0 0.00031450032838620245
VV269 O 0 0.00014745820953976363
- O 0 2.8077696697437204e-05
270 O 0 2.5763243684195913e-05
deletion O 0 2.9215985705377534e-05
. O 0 2.0655329535657074e-06

To O 0 2.738332113949582e-06
date O 0 5.403624527389184e-06
, O 0 2.1355133128508896e-07
our O 0 1.1072328476302573e-07
detection O 0 6.903912890265929e-07
rate O 0 1.3597540373666561e-06
for O 0 2.517279256153415e-07
TWIST O 0 5.439314918476157e-06
or O 0 1.5962790484991274e-06
FGFR O 0 2.148334897356108e-05
mutations O 0 1.381638270459007e-07
is O 0 1.377757996579021e-07
68 O 0 1.7471905948696076e-06
% O 0 3.6758882515641744e-07
in O 0 9.540963219478726e-07
our O 0 1.3585844499175437e-05
Saethre B-Disease 1 0.9995124340057373
- I-Disease 1 0.9999998807907104
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 8.463356607535388e-06
, O 0 6.898701343516223e-08
including O 0 4.358357230671572e-08
our O 0 9.21290705946376e-08
five O 0 2.1607333167139586e-07
patients O 0 2.6938940322907e-07
elsewhere O 0 1.5309758794046502e-07
reported O 0 2.591191901046841e-07
with O 0 3.879080523461198e-08
TWIST O 0 9.171639248961583e-06
mutations O 0 2.6729608180176e-06
. O 0 1.6738146086936467e-06

More O 0 8.933806384447962e-06
than O 0 2.3322836568695493e-06
35 O 0 1.411300490872236e-05
different O 0 4.0203718754128204e-07
TWIST O 0 1.0442143320688047e-05
mutations O 0 6.473280222962785e-07
are O 0 7.759185649547362e-08
now O 0 1.7105865168787204e-08
known O 0 4.408294174140792e-08
in O 0 2.971557577780004e-08
the O 0 1.117373784609299e-07
literature O 0 1.3019957805227023e-06
. O 0 9.289483386965003e-07

The O 0 0.00012850374332629144
most O 0 4.541754151432542e-06
common O 0 1.4937589867258794e-06
phenotypic O 0 2.2412321413867176e-05
features O 0 9.475844308326486e-06
, O 0 4.5790991975991346e-07
present O 0 1.5454619983756857e-07
in O 0 3.1142579359766387e-07
more O 0 2.4198113734996696e-08
than O 0 3.2966319452043535e-08
a O 0 2.492198234449461e-07
third O 0 8.921469998313114e-07
of O 0 1.0685462257242762e-06
our O 0 7.768935006424726e-07
patients O 0 4.141099338994536e-07
with O 0 9.967247649456112e-08
TWIST O 0 9.147330274572596e-06
mutations O 0 9.787529506866122e-07
, O 0 2.5228911226804485e-07
are O 0 1.9325054267937958e-07
coronal B-Disease 0 0.00016284956654999405
synostosis I-Disease 0 7.547141285613179e-05
, O 0 1.2810108955818578e-06
brachycephaly B-Disease 0 5.5988191888900474e-05
, O 0 4.0914828787208535e-06
low B-Disease 0 0.003207931062206626
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 1 0.9874950051307678
facial B-Disease 1 1.0
asymmetry I-Disease 1 1.0
, O 0 0.0003933837288059294
ptosis B-Disease 1 0.9999200105667114
, O 0 3.0078590498305857e-05
hypertelorism B-Disease 0 0.08461809158325195
, O 0 7.104747510311427e-06
broad B-Disease 0 0.00013545334513764828
great I-Disease 0 0.27950385212898254
toes I-Disease 1 0.9997797608375549
, O 0 3.0563821837858995e-06
and O 0 2.5315921448054723e-06
clinodactyly B-Disease 0 0.0002621323219500482
. O 0 3.706287998284097e-06

Significant O 0 0.0015861584106460214
intra O 1 0.8998160362243652
- O 0 0.0014667370123788714
and O 0 3.606190375649021e-06
interfamilial O 0 8.590827201260254e-05
phenotypic O 0 5.9200126997893676e-05
variability O 0 2.6194111342192627e-05
is O 0 7.815478397787956e-08
present O 0 1.5736405956090493e-08
for O 0 3.627754807666861e-08
either O 0 2.140625099400495e-07
TWIST O 0 4.259185061528115e-06
mutations O 0 2.577582108642673e-06
or O 0 7.843036655685864e-06
FGFR O 0 0.0002576919796410948
mutations O 0 5.9303724810888525e-06
. O 0 2.2627937141805887e-06

The O 0 1.9892124328180216e-05
overlap O 0 4.329695457272464e-06
in O 0 4.988985438103555e-06
clinical O 0 3.096069485764019e-05
features O 0 3.3669832646410214e-06
and O 0 1.2321713711571647e-06
the O 0 1.6340027286787517e-06
presence O 0 8.009678822418209e-07
, O 0 1.5981359524630534e-07
in O 0 1.5915168205538066e-07
the O 0 1.9553262120552972e-07
same O 0 1.2791781500709476e-07
genes O 0 8.796871497906977e-08
, O 0 7.136326019008266e-08
of O 0 3.642450963070587e-07
mutations O 0 3.157778678541945e-07
for O 0 6.222705337677326e-07
more O 0 1.2762001233568299e-07
than O 0 4.533837625331216e-07
one O 0 2.2274043658399023e-06
craniosynostotic B-Disease 0 0.0001349232770735398
condition I-Disease 0 9.868147753877565e-05
- O 0 1.3575961929745972e-05
such O 0 7.819562028998917e-07
as O 0 3.376623681106139e-06
Saethre B-Disease 0 5.143799353390932e-05
- I-Disease 0 1.3501296962203924e-05
Chotzen I-Disease 0 4.752630047732964e-05
, I-Disease 0 1.7430664911444183e-06
Crouzon I-Disease 0 9.929361112881452e-05
, I-Disease 0 6.343987934087636e-06
and I-Disease 0 5.011203029425815e-05
Pfeiffer I-Disease 1 0.9992539286613464
syndromes I-Disease 1 0.9994847774505615
- O 0 9.108285303227603e-05
support O 0 7.556278887932422e-06
the O 0 6.9592629188264254e-06
hypothesis O 0 2.036249725279049e-06
that O 0 1.2796809301107714e-07
TWIST O 0 2.9284019547048956e-06
and O 0 4.59930163287936e-07
FGFRs O 0 1.3396766007645056e-05
are O 0 4.491323579713935e-08
components O 0 1.6886006903860107e-07
of O 0 4.7238106759550647e-08
the O 0 4.9108805910691444e-08
same O 0 8.049124744502478e-08
molecular O 0 7.682101568207145e-07
pathway O 0 1.8798593259816698e-07
involved O 0 8.139078744306971e-09
in O 0 2.562312317877513e-08
the O 0 6.91263650764995e-08
modulation O 0 7.278629709617235e-06
of O 0 3.1805098842596635e-05
craniofacial O 1 1.0
and O 0 0.034786343574523926
limb O 1 0.999998927116394
development O 0 6.477380520664155e-05
in O 0 7.075896064634435e-06
humans O 0 1.7579021687197383e-06
. O 0 1.0630175495407457e-07
. O 0 3.173686309310142e-07

Mutation O 0 2.5524186639813706e-06
analysis O 0 2.2694555923408188e-07
of O 0 2.390930148976622e-06
UBE3A O 1 0.9997988343238831
in O 1 0.9469000101089478
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9986617565155029
. O 0 7.850692782085389e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999167919158936
AS B-Disease 1 1.0
) O 0 1.3767004020337481e-05
is O 0 1.4603397175960708e-06
caused O 0 1.6461635823361576e-05
by O 0 9.599823442840716e-07
chromosome O 0 0.00046533968998119235
15q11 O 0 0.0007488667033612728
- O 0 0.0001263353624381125
q13 O 0 3.146882590954192e-05
deletions O 0 1.179977630272333e-06
of O 0 1.7979034510062775e-06
maternal O 0 3.355567969265394e-05
origin O 0 1.146614522440359e-06
, O 0 1.8749446439869644e-07
by O 0 1.4946311921448796e-07
paternal O 0 0.0004080203943885863
uniparental B-Disease 0 0.10798420757055283
disomy I-Disease 0 0.01151752658188343
( O 0 0.00010832541738636792
UPD B-Disease 1 0.9999927282333374
) O 0 2.6470627290109405e-06
15 O 0 4.3341287891962565e-06
, O 0 1.2616844458079868e-07
by O 0 1.4606139586703648e-07
imprinting O 0 0.0003063665935769677
defects O 0 0.0035664786119014025
, O 0 8.668487083696164e-08
and O 0 1.59614295114352e-08
by O 0 1.1147932355015655e-08
mutations O 0 8.593551825697432e-08
in O 0 9.285958526561444e-07
the O 0 4.587015610013623e-06
UBE3A O 0 0.0015740891685709357
gene O 0 1.0805371857713908e-05
. O 0 1.9610738490882795e-06

UBE3A O 0 0.03899382799863815
encodes O 0 0.00047056845505721867
a O 0 0.0001692384685156867
ubiquitin O 0 0.00014883790572639555
- O 0 3.1259842216968536e-05
protein O 0 7.539909347542562e-06
ligase O 0 2.278682131873211e-06
and O 0 8.215504863073875e-07
shows O 0 1.158229679276701e-05
brain O 0 0.24908286333084106
- O 0 1.7049445887096226e-05
specific O 0 8.782761256043159e-07
imprinting O 0 0.00015820660337340087
. O 0 6.518412192235701e-06

Here O 0 0.00011130441271234304
we O 0 4.870433713222155e-06
describe O 0 1.2474636605475098e-05
UBE3A O 0 0.0009533027769066393
coding O 0 0.00011750938574550673
- O 0 1.7179036149173044e-05
region O 0 1.262688783754129e-06
mutations O 0 4.983713211004215e-07
detected O 0 1.6144792880368186e-06
by O 0 6.902768490135713e-08
SSCP O 0 1.950797923200298e-05
analysis O 0 1.4809094750489749e-07
in O 0 6.724729928464512e-07
13 O 0 3.3873337088152766e-05
AS B-Disease 1 0.9715961813926697
individuals O 0 1.2886897593489266e-07
or O 0 5.466228572004184e-07
families O 0 4.490997795869589e-08
. O 0 2.7906716582037916e-07

Two O 0 4.057925252709538e-05
identical O 0 3.39585603796877e-05
de O 0 0.0007331874221563339
novo O 0 0.000226181247853674
5 O 0 9.416447574039921e-05
- O 0 1.5442830772371963e-05
bp O 0 1.3102756383887026e-05
duplications O 0 5.653133484884165e-06
in O 0 4.227951194479829e-06
exon O 0 5.531519491341896e-06
16 O 0 1.3141224371793214e-05
were O 0 1.7597437818039907e-06
found O 0 7.428365051964647e-07
. O 0 4.5738397602690384e-07

Among O 0 1.3771441444987431e-05
the O 0 7.394463409582386e-06
other O 0 6.446986162700341e-07
11 O 0 1.0486332030268386e-05
unique O 0 9.655150279286318e-07
mutations O 0 9.353150289825862e-07
, O 0 1.0105233059221064e-06
8 O 0 1.0675393241399433e-05
were O 0 1.8141121245207614e-06
small O 0 9.152828397418489e-07
deletions O 0 3.5480375117913354e-06
or O 0 6.2601543504570145e-06
insertions O 0 1.4251172615331598e-05
predicted O 0 3.8590671465499327e-05
to O 0 1.313797724833421e-06
cause O 0 2.613687320263125e-05
frameshifts O 0 0.00019105910905636847
, O 0 1.8321543393540196e-06
1 O 0 1.3837253391102422e-05
was O 0 6.8082058533036616e-06
a O 0 7.241119988066202e-07
mutation O 0 1.790417769598207e-07
to O 0 1.4263977732298372e-07
a O 0 9.680201173978276e-07
stop O 0 9.214521128342312e-07
codon O 0 2.865248461603187e-06
, O 0 1.7407295160865033e-07
1 O 0 1.666777279751841e-06
was O 0 1.3200358353060437e-06
a O 0 4.4450305836107873e-07
missense O 0 1.9737287857424235e-06
mutation O 0 1.229900448151966e-07
, O 0 8.283148389409689e-08
and O 0 9.85785533202943e-08
1 O 0 8.90679621079471e-06
was O 0 1.0841334187716711e-05
predicted O 0 3.1205208870233037e-06
to O 0 9.357256658404367e-08
cause O 0 1.7824563656176906e-06
insertion O 0 3.6659530451288447e-06
of O 0 9.476403647568077e-06
an O 0 5.654945653077448e-06
isoleucine O 0 8.01804635557346e-05
in O 0 4.177168193564285e-06
the O 0 4.163316134508932e-06
hect O 0 6.705289706587791e-05
domain O 0 7.72187649999978e-06
of O 0 2.229333040304482e-05
the O 0 3.19017271976918e-05
UBE3A O 0 0.0004914238816127181
protein O 0 7.47989906813018e-06
, O 0 1.2331547338817472e-07
which O 0 3.691038941155966e-08
functions O 0 9.449955200580007e-07
in O 0 2.427465688015218e-06
E2 O 0 6.64154504192993e-05
binding O 0 9.245760566045647e-07
and O 0 1.1341512617946137e-06
ubiquitin O 0 6.8295425990072545e-06
transfer O 0 5.481323114508996e-06
. O 0 2.2818353500042576e-06

Eight O 0 0.00011397426715120673
of O 0 1.5095064554770943e-05
the O 0 3.424296892262646e-06
cases O 0 8.314035540024634e-07
were O 0 2.3310649339691736e-06
familial O 0 2.3813588995835744e-05
, O 0 1.0993327350661275e-06
and O 0 2.2030663160421682e-07
five O 0 2.1759676371857495e-07
were O 0 3.370798822288634e-07
sporadic O 0 1.8156775695388205e-05
. O 0 2.3685281576035777e-06

In O 0 3.2000789360608906e-05
two O 0 2.174290330003714e-06
familial O 0 9.370085172122344e-05
cases O 0 4.396229996928014e-06
and O 0 7.86013742981595e-07
one O 0 3.300634148217796e-07
sporadic O 0 1.4025241398485377e-05
case O 0 7.4655749813246075e-06
, O 0 6.986333573877346e-07
mosaicism O 0 9.304542618338019e-05
for O 0 2.5660497158241924e-06
UBE3A O 0 0.00044526485726237297
mutations O 0 7.673176583011809e-07
was O 0 7.653168722754344e-06
detected O 0 7.72079374655732e-07
in O 0 3.3439962976444804e-07
the O 0 6.304660473688273e-07
mother O 0 1.4733618627360556e-06
of O 0 8.325021553901024e-06
three O 0 1.5761053873575293e-05
AS B-Disease 1 0.9999445676803589
sons O 0 2.4955732442322187e-05
, O 0 2.2043315084374626e-07
in O 0 4.770195118908305e-07
the O 0 1.7042790432242327e-06
maternal O 0 4.950595030095428e-05
grandfather O 0 0.00014521296543534845
of O 0 0.00018389360047876835
two O 0 3.360807022545487e-05
AS B-Disease 1 0.9999994039535522
first O 0 3.933853440685198e-05
cousins O 0 1.0407982699689455e-05
, O 0 2.6585129830891674e-07
and O 0 9.111045784493399e-08
in O 0 2.3574334306886158e-07
the O 0 8.935945174926019e-07
mother O 0 2.7907803996640723e-06
of O 0 9.525720997771714e-06
an O 0 1.1828184142359532e-05
AS B-Disease 1 0.9999997615814209
daughter O 0 0.00043354349327273667
. O 0 9.382039024785627e-06

The O 0 7.009106775512919e-05
frequencies O 0 5.626279744319618e-06
with O 0 2.0077368390047923e-07
which O 0 2.8261294460207864e-07
we O 0 1.0964726016027271e-07
detected O 0 4.648783260563505e-07
mutations O 0 7.425943238104082e-08
were O 0 6.945080599507492e-07
5 O 0 6.357375923471409e-07
( O 0 6.079019954086107e-08
14 O 0 8.306688528136874e-07
% O 0 8.134504270174148e-08
) O 0 2.8227828963167667e-08
of O 0 6.938361138963955e-07
35 O 0 2.971299409182393e-06
in O 0 3.8811978697594895e-07
sporadic O 0 7.043814093776746e-06
cases O 0 1.2889408935734536e-06
and O 0 8.226795102928008e-07
8 O 0 6.092246167099802e-06
( O 0 1.352037770629977e-07
80 O 0 5.403761065281287e-07
% O 0 6.755313819439834e-08
) O 0 1.5160479094333823e-08
of O 0 1.8010956637226627e-07
10 O 0 9.367432767248829e-07
in O 0 5.52383653484867e-07
familial O 0 1.9881503249052912e-05
cases O 0 2.9330080906220246e-06
. O 0 4.782001497005695e-07
. O 0 7.529258141403261e-07

The O 0 0.006888182833790779
hemochromatosis B-Disease 1 1.0
845 O 0 0.09254632145166397
G O 0 0.0017714654095470905
- O 0 3.305500285932794e-05
- O 0 1.456920199416345e-05
> O 0 4.271722445992054e-06
A O 0 1.3294668406160781e-06
and O 0 2.0048858573318284e-07
187 O 0 3.560097184163169e-06
C O 0 9.548195521347225e-06
- O 0 1.1763371503548115e-06
- O 0 2.82084556602058e-06
> O 0 8.266288205049932e-06
G O 0 2.505789598217234e-05
mutations O 0 3.608291478940373e-07
: O 0 1.1306355673923463e-07
prevalence O 0 3.2733482839830685e-06
in O 0 1.7499352225058828e-06
non O 0 4.125242412555963e-05
- O 0 9.137285815086216e-06
Caucasian O 0 3.937488600058714e-06
populations O 0 4.1642351789050736e-07
. O 0 2.652124067026307e-07

Hemochromatosis B-Disease 1 0.9999561309814453
, O 0 3.0157170840539038e-05
the O 0 0.00018002749129664153
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999986886978149
, O 0 2.567900310168625e-06
leads O 0 2.577306531748036e-06
, O 0 2.0135564682277618e-07
if O 0 1.5522049068295019e-07
untreated O 0 5.151472214492969e-05
, O 0 1.3529910347642726e-07
to O 0 4.6138558218444814e-07
progressive O 0 0.004824107512831688
iron B-Disease 1 0.9997749924659729
overload I-Disease 1 0.6833289861679077
and O 0 1.5814923244761303e-05
premature B-Disease 0 0.00038379436591640115
death I-Disease 0 9.418378613190725e-05
. O 0 2.7992807645205176e-06

The O 0 0.010422173887491226
hemochromatosis B-Disease 1 1.0
gene O 0 0.0026616354007273912
, O 0 9.125411452259868e-05
HFE O 0 0.003628305858001113
, O 0 4.200068360660225e-06
recently O 0 2.709295813474455e-06
has O 0 2.7695170956576476e-07
been O 0 3.5303844470035983e-07
identified O 0 3.018272707322467e-07
, O 0 1.0316549037270306e-07
and O 0 1.7022455267579062e-07
characterization O 0 3.3638766581134405e-06
of O 0 1.0141822713194415e-05
this O 0 1.789401949281455e-06
gene O 0 1.5425024457726977e-06
has O 0 2.6725146540229616e-07
shown O 0 2.6654868179321056e-07
that O 0 1.1873795280337163e-08
it O 0 4.1977097353651516e-09
contains O 0 2.9233961029717648e-08
two O 0 2.2175894898168735e-08
mutations O 0 2.6030550159816812e-08
that O 0 2.3139996585541667e-08
result O 0 5.753458935942035e-07
in O 0 2.4966448108898476e-06
amino O 0 1.2636980954994215e-06
acid O 0 3.759784590329218e-07
substitutions O 0 4.2730647464850335e-07
- O 0 1.0719911642809166e-06
cDNA O 0 8.657232797304459e-07
nucleotides O 0 3.641384580532758e-07
845 O 0 1.3216470506449696e-05
G O 0 2.0047948055434972e-05
- O 0 3.2657339943398256e-06
- O 0 4.535149400908267e-06
> O 0 4.814839940081583e-06
A O 0 3.742723720279173e-06
( O 0 1.7121314499490836e-07
C282Y O 0 1.3605582580566988e-06
) O 0 3.516013435955756e-08
and O 0 1.306191563799075e-07
187 O 0 1.3241474334790837e-06
C O 0 4.453076599020278e-06
- O 0 6.293018941505579e-07
- O 0 2.268177695441409e-06
> O 0 6.2197009356168564e-06
G O 0 3.241790909669362e-05
( O 0 1.8690635670282063e-06
H63D O 0 9.302893158746883e-05
) O 0 1.5461549764950178e-06
. O 0 1.1557925745364628e-06

Although O 0 0.002325985813513398
hemochromatosis B-Disease 1 1.0
is O 0 9.234454410034232e-06
common O 0 1.6344422419933835e-06
in O 0 1.1286484777883743e-06
Caucasians O 0 1.6927892829698976e-06
, O 0 1.557859548029228e-07
affecting O 0 1.0610339131744695e-06
> O 0 3.213380523447995e-06
= O 0 7.881967576395255e-06
1 O 0 1.566574974276591e-05
/ O 0 1.0334079888707493e-05
300 O 0 1.7217508911926416e-06
individuals O 0 6.698589771758634e-08
of O 0 1.202963903779164e-05
northern O 0 3.5222183214500546e-05
European O 0 3.595851740101352e-05
origin O 0 5.245681222731946e-06
, O 0 4.918070430903754e-07
it O 0 1.8222650055577105e-08
has O 0 2.9571793902505306e-08
not O 0 9.070918238762715e-09
been O 0 3.028311468256106e-08
recognized O 0 4.885021809286627e-08
in O 0 5.881490849901638e-08
other O 0 2.8960798204025195e-08
populations O 0 1.43076022141031e-07
. O 0 1.9893104763468727e-07

The O 0 3.564333383110352e-05
present O 0 4.9369091357220896e-06
study O 0 3.0506657822115812e-06
used O 0 2.5933622964657843e-06
PCR O 0 4.319323124946095e-06
and O 0 1.0894157185248332e-06
restriction O 0 4.144487320445478e-06
- O 0 1.1518917517605587e-06
enzyme O 0 1.0498136759906629e-07
digestion O 0 2.327248012079508e-07
to O 0 2.274069821339708e-08
analyze O 0 7.168330284912372e-08
the O 0 4.438147129803838e-07
frequency O 0 2.2473291210189927e-06
of O 0 1.330084432993317e-05
the O 0 1.9993722162325867e-05
845 O 0 9.244863031199202e-05
G O 0 5.461755063151941e-05
- O 0 4.585978786053602e-06
- O 0 2.7116896035295213e-06
> O 0 1.9229141798859928e-06
A O 0 1.2387246215439518e-06
and O 0 4.0954466840048553e-07
187 O 0 2.6825648546946468e-06
C O 0 4.240565885993419e-06
- O 0 6.047616238902265e-07
- O 0 1.431674945706618e-06
> O 0 4.930307568429271e-06
G O 0 1.2299018635530956e-05
mutations O 0 4.0537443624089065e-07
in O 0 6.42578106635483e-06
HLA O 0 3.13641139655374e-05
- O 0 5.501710802491289e-06
typed O 0 2.3588577278133016e-06
samples O 0 5.453799190036079e-07
from O 0 1.6792715769042843e-06
non O 0 1.2963933841092512e-05
- O 0 1.9959741166530875e-06
Caucasian O 0 9.294765277445549e-07
populations O 0 7.901061849224789e-08
, O 0 2.91347674874487e-08
comprising O 0 1.665936792960565e-07
Australian O 0 3.1156089335127035e-06
Aboriginal O 0 3.4712659271463053e-06
, O 0 8.109173563752847e-07
Chinese O 0 1.157670226348273e-06
, O 0 1.9776184956299403e-07
and O 0 1.8299351722816937e-07
Pacific O 0 3.263292910560267e-06
Islanders O 0 2.6544923912297236e-06
. O 0 7.176141139098036e-07

Results O 0 0.0007778599392622709
showed O 0 8.214187255362049e-05
that O 0 1.3785338524030522e-06
the O 0 1.0085553185490426e-05
845 O 0 0.00016295534442178905
G O 0 0.00025611702585592866
- O 0 3.132047277176753e-05
- O 0 2.654232957866043e-05
> O 0 1.1900528079422656e-05
A O 0 1.2769223758368753e-06
mutation O 0 6.432787102994553e-08
was O 0 8.319587436744769e-07
present O 0 7.894825415633022e-08
in O 0 1.6059829022196936e-07
these O 0 2.0499259179018736e-08
populations O 0 3.837238793380493e-08
( O 0 2.5933667657795922e-08
allele O 0 4.6638458428560625e-08
frequency O 0 4.432745868143684e-07
0 O 0 5.09164237882942e-07
. O 0 2.1560664364983495e-08
32 O 0 6.080644538997149e-07
% O 0 2.2862171533688525e-07
) O 0 1.4084842803185893e-07
, O 0 2.6144951448259235e-07
and O 0 5.461408818518976e-07
, O 0 5.66113840250182e-07
furthermore O 0 1.3747697948929272e-06
, O 0 1.0720825827092995e-07
it O 0 2.2920891851185843e-08
was O 0 1.5072015457917587e-06
always O 0 7.943083346617641e-08
seen O 0 2.3891334421932697e-07
in O 0 5.820335857720238e-08
conjunction O 0 2.4653391506035405e-07
with O 0 1.7668271823367832e-07
HLA O 0 4.3962718336842954e-05
haplotypes O 0 1.4399742212845013e-05
common O 0 4.243697276251623e-06
in O 0 7.084213848429499e-06
Caucasians O 0 1.385526320518693e-05
, O 0 7.529358185820456e-07
suggesting O 0 1.2139686305090436e-06
that O 0 2.7235284960624995e-07
845 O 0 5.479701212607324e-05
G O 0 0.0003641096700448543
- O 0 0.00015308434376493096
- O 0 0.000389539054594934
> O 0 0.00022564793471246958
A O 0 3.179785198881291e-05
may O 0 5.254653842712287e-06
have O 0 2.258573630342653e-07
been O 0 1.6211043885050458e-07
introduced O 0 2.9161341785766126e-08
into O 0 4.440858791809887e-09
these O 0 9.39645361519581e-10
populations O 0 7.710203142607952e-09
by O 0 1.2049721220819265e-08
Caucasian O 0 2.475975634297356e-06
admixture O 0 1.697682455414906e-05
. O 0 5.6494473028578795e-06

187 O 0 0.0007250896305777133
C O 0 0.00031964335357770324
- O 0 1.4636966625403147e-05
- O 0 1.456885365769267e-05
> O 0 1.624249307496939e-05
G O 0 1.9765693650697358e-05
was O 0 1.530256213300163e-06
present O 0 1.8209104268862575e-07
at O 0 7.306457519007381e-07
an O 0 7.668200296961913e-09
allele O 0 1.8731443063302322e-08
frequency O 0 1.5835500732919172e-07
of O 0 2.2225156044441974e-06
2 O 0 1.7814396414905787e-05
. O 0 1.5664900274714455e-06

68 O 0 0.0004413338901940733
% O 0 5.473654709930997e-06
in O 0 1.5385913911813986e-06
the O 0 1.2035385452691116e-06
two O 0 1.557826863063383e-07
populations O 0 2.0344842255326512e-07
analyzed O 0 3.667194334866508e-07
( O 0 6.745701739419019e-07
Australian O 0 6.4016021497081965e-06
Aboriginal O 0 2.190652139688609e-06
and O 0 1.3846499768987997e-06
Chinese O 0 6.9641291702282615e-06
) O 0 6.17677699210617e-07
. O 0 3.230937295484182e-07

In O 0 0.0001253246155101806
the O 0 2.171642154280562e-05
Australian O 0 3.0000239348737523e-05
Aboriginal O 0 6.931556072231615e-06
samples O 0 1.3433204912871588e-06
, O 0 5.77669368340139e-07
187 O 0 3.5582979762693867e-06
C O 0 1.3445274817058817e-05
- O 0 1.8971992403749027e-06
- O 0 4.969402652932331e-06
> O 0 1.1088259270763956e-05
G O 0 2.1562944311881438e-05
was O 0 2.666875161594362e-06
found O 0 7.107826860419664e-08
to O 0 1.6961969606654748e-08
be O 0 1.0154185048349973e-07
associated O 0 4.456337876490579e-07
with O 0 5.12869462454546e-07
HLA O 0 0.00018320998060517013
haplotypes O 0 3.862793528242037e-05
common O 0 4.81480765301967e-06
in O 0 7.981344424479175e-06
Caucasians O 0 6.503980785055319e-06
, O 0 2.5644985157669e-07
suggesting O 0 1.4410167636924598e-07
that O 0 4.499912886757329e-09
it O 0 2.0733215144730366e-09
was O 0 8.963840514297772e-08
introduced O 0 1.9620840063794276e-08
by O 0 3.817307803188896e-09
recent O 0 4.3637886193437225e-08
admixture O 0 2.387291488048504e-06
. O 0 1.4040895166544942e-06

In O 0 0.00010532746819080785
the O 0 1.772762516338844e-05
Chinese O 0 1.0602221664157696e-05
samples O 0 1.2926016097480897e-06
analyzed O 0 8.217691060963261e-07
, O 0 4.06534297781036e-07
187 O 0 3.0351291115948698e-06
C O 0 1.1581204489630181e-05
- O 0 1.6528949799976544e-06
- O 0 3.34430069415248e-06
> O 0 1.1047199222957715e-05
G O 0 2.0641602532123215e-05
was O 0 5.691269507224206e-06
present O 0 6.043592293281108e-07
in O 0 1.3499908391167992e-06
association O 0 5.613152893602091e-07
with O 0 1.3804142717788181e-08
a O 0 2.2725505743892427e-07
wide O 0 1.4343630709845456e-06
variety O 0 8.676110496708134e-07
of O 0 2.0211387891322374e-05
HLA O 0 0.00016048949328251183
haplotypes O 0 1.472208350605797e-05
, O 0 7.586775723211758e-07
showing O 0 1.3435075061352109e-06
this O 0 1.2265410020972922e-07
mutation O 0 6.957756681913452e-08
to O 0 5.2900336555694594e-08
be O 0 2.318088831998466e-07
widespread O 0 7.507496775360778e-07
and O 0 6.141053745523095e-07
likely O 0 9.017950333145563e-07
to O 0 2.9918354016444937e-07
predate O 0 8.670024726598058e-06
the O 0 1.8975267721543787e-06
more O 0 9.20839227092074e-08
genetically O 0 4.329640148625913e-07
restricted O 0 2.474445864208974e-06
845 O 0 2.874371421057731e-05
G O 0 7.466643728548661e-05
- O 0 8.56674523674883e-06
- O 0 6.010111064824741e-06
> O 0 4.848494427278638e-06
A O 0 1.0538316246311297e-06
mutation O 0 8.921758762880927e-07
. O 0 5.390275532590749e-07

Genotype O 0 0.0028501900378614664
- O 0 0.0001817160373320803
phenotype O 0 4.0067399822873995e-05
correlations O 0 2.099018092849292e-05
in O 0 2.2989290300756693e-05
attenuated B-Disease 1 0.9998652935028076
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.00018712658493313938

Germ O 0 0.2760670781135559
- O 0 0.00048091981443576515
line O 0 1.584402889420744e-05
mutations O 0 5.193264200897829e-07
of O 0 3.161396080031409e-06
the O 0 1.2114705896237865e-05
tumor B-Disease 0 0.05777953937649727
suppressor O 0 0.0010652387281879783
APC O 0 1.4776982425246388e-05
are O 0 2.619191263875109e-08
implicated O 0 8.05571119144588e-07
in O 0 2.1608643692161422e-06
attenuated B-Disease 1 0.999504566192627
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9998971223831177
AAPC B-Disease 1 1.0
) O 0 9.68301719694864e-07
, O 0 2.0829741487204956e-08
a O 0 6.231399396483539e-08
variant O 0 2.209728700108826e-05
of O 0 0.0009179329499602318
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9930503368377686
FAP B-Disease 0 0.029707806184887886
) O 0 4.7523685680062044e-06
. O 0 1.0934095371339936e-06

AAPC B-Disease 1 0.9999992847442627
is O 0 2.8265599212318193e-06
recognized O 0 1.803993825433281e-07
by O 0 1.8529325629401683e-08
the O 0 6.109625871886237e-08
occurrence O 0 5.555476718654973e-07
of O 0 3.71097075912985e-06
< O 0 0.00018398514657747
100 O 0 3.507810833980329e-05
colonic B-Disease 0 0.003656242275610566
adenomas I-Disease 0 0.0004334471595939249
and O 0 4.6910209050565754e-08
a O 0 7.24975848243048e-08
later O 0 3.020452652435779e-07
onset O 0 0.24273869395256042
of O 1 0.7742884159088135
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.0651466456911294e-06
age O 0 1.5352378568422864e-06
> O 0 1.8594984112496604e-06
40 O 0 9.636715958549757e-07
years O 0 6.230674216567422e-07
) O 0 4.3008535044464224e-07
. O 0 5.385101644606038e-07

The O 0 1.985469316423405e-05
aim O 0 6.161119927128311e-06
of O 0 1.7235612403965206e-06
this O 0 8.299279130596915e-08
study O 0 2.3495799439388065e-07
was O 0 1.3409039638645481e-06
to O 0 1.0670071048934915e-07
assess O 0 4.529245416051708e-06
genotype O 0 7.13535919203423e-05
- O 0 7.878527685534209e-05
phenotype O 0 2.4026119717746042e-05
correlations O 0 4.206385347060859e-05
in O 0 7.324331818381324e-05
AAPC B-Disease 1 0.9999998807907104
families O 0 9.12227676508337e-07
. O 0 1.2727049352179165e-06

By O 0 3.343506250530481e-05
protein O 0 2.506217424524948e-05
- O 0 8.39709446154302e-06
truncation O 0 5.9108013374498114e-05
test O 0 7.419921530527063e-06
( O 0 1.5440625702467514e-06
PTT O 0 2.890347059292253e-05
) O 0 2.6896736926573794e-07
assay O 0 2.086331505779526e-06
, O 0 8.271339169141356e-08
the O 0 9.8601496745232e-08
entire O 0 6.947677775315242e-07
coding O 0 2.6102550236828392e-06
region O 0 1.2061399274898577e-06
of O 0 8.762842298892792e-06
the O 0 1.4459713383985218e-05
APC B-Disease 0 1.225184132636059e-05
gene O 0 3.49877097960416e-07
was O 0 1.359636030429101e-06
screened O 0 3.6509956657937437e-07
in O 0 2.2385195563856541e-07
affected O 0 1.859826710415291e-07
individuals O 0 5.3044011849578965e-08
from O 0 3.408238171687117e-06
11 O 0 0.0004078496422152966
AAPC B-Disease 1 0.9999943971633911
kindreds O 0 0.0003364257572684437
, O 0 1.510796437287354e-06
and O 0 1.5664181773900054e-07
their O 0 3.7627323479227925e-08
phenotypic O 0 1.2598857210832648e-05
differences O 0 2.608617478472297e-06
were O 0 7.087390258675441e-06
examined O 0 1.6260519259958528e-05
. O 0 2.096607659041183e-06

Five O 0 0.00018088039360009134
novel O 0 0.00013532245066016912
germ O 0 0.006954282056540251
- O 0 0.00032770924735814333
line O 0 6.0859510995214805e-05
APC B-Disease 0 8.195118425646797e-06
mutations O 0 1.7385329442731745e-07
were O 0 2.186962433370354e-07
identified O 0 1.2590125209044345e-07
in O 0 4.1122677885141456e-07
seven O 0 2.062774910882581e-06
kindreds O 0 7.729979552095756e-05
. O 0 3.994154212705325e-06

Mutations O 0 5.177930506761186e-05
were O 0 2.9189581255195662e-05
located O 0 8.227005309890956e-06
in O 0 5.339146582628018e-07
three O 0 1.0467325495255864e-07
different O 0 2.0711327763933696e-08
regions O 0 4.2900018115688e-07
of O 0 9.857948498392943e-06
the O 0 9.045901606441475e-06
APC B-Disease 0 6.490665782621363e-06
gene O 0 3.879924861394102e-07
( O 0 1.4571884321412654e-07
1 O 0 1.1158706456626533e-06
) O 0 5.719213902466436e-08
at O 0 1.202655084853177e-06
the O 0 2.440908417611354e-07
5 O 0 9.379885455018666e-07
end O 0 1.2481531257435563e-06
spanning O 0 3.6699270822282415e-06
exons O 0 4.73285217594821e-06
4 O 0 7.533189545938512e-06
and O 0 6.332801945063693e-07
5 O 0 4.340875420894008e-06
, O 0 3.8276522218438913e-07
( O 0 1.8414648650377785e-07
2 O 0 1.0236670959784533e-06
) O 0 4.9014854397455565e-08
within O 0 1.9784920368692838e-07
exon O 0 5.059410455032776e-07
9 O 0 7.71242685004836e-06
, O 0 2.0222395846758445e-07
and O 0 1.6493915211412968e-07
( O 0 1.4688302485410532e-07
3 O 0 1.4694315950691816e-06
) O 0 8.632468961877748e-08
at O 0 1.2062630503351102e-06
the O 0 3.2917913017627143e-07
3 O 0 3.1723836855235277e-06
distal O 0 2.679862518562004e-06
end O 0 1.7486939896116382e-06
of O 0 2.279638465552125e-06
the O 0 4.676307980844285e-06
gene O 0 3.8613975448242854e-06
. O 0 1.6308329122693976e-06

Variability O 0 7.750166696496308e-05
in O 0 4.262053607817506e-06
the O 0 1.7020228142428095e-06
number O 0 1.070689904736355e-05
of O 1 0.5769153237342834
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.02644994482398033
most O 0 2.054386811778386e-07
apparent O 0 8.438545364697347e-07
in O 0 1.0892561874698004e-07
individuals O 0 2.4270949694482624e-09
with O 0 4.596207414664377e-09
mutations O 0 5.0784368710310446e-08
in O 0 9.507963909527462e-07
region O 0 4.5922715798951685e-06
1 O 0 0.00048765764222480357
, O 0 5.649927061313065e-06
and O 0 3.55890515493229e-05
upper O 1 0.9999957084655762
- O 1 0.9999548196792603
gastrointestinal O 1 0.9999997615814209
manifestations O 1 0.9999982118606567
were O 0 2.5707826353027485e-05
more O 0 1.470076114173935e-07
severe O 0 5.3702307923231274e-05
in O 0 1.5324527566917823e-06
them O 0 1.5011407583642722e-07
. O 0 6.466814284067368e-07

In O 0 3.527979788486846e-05
individuals O 0 5.724609764001798e-07
with O 0 2.517065809115593e-07
mutations O 0 1.3599667454400333e-06
in O 0 4.447219907888211e-06
either O 0 1.6382608691856149e-06
region O 0 4.298648946132744e-06
2 O 0 2.1812998966197483e-05
or O 0 1.608783463780128e-06
region O 0 1.2292792916923645e-06
3 O 0 4.8473661991010886e-06
, O 0 1.069564206090945e-07
the O 0 3.709523639372492e-07
average O 0 6.7484947976481635e-06
number O 0 4.143724709138041e-06
of O 0 7.452936551999301e-05
adenomas B-Disease 0 0.004511188715696335
tended O 0 2.891209805966355e-05
to O 0 1.0785119002321153e-06
be O 0 1.4724643051522435e-06
lower O 0 2.922623934864532e-06
than O 0 2.0568034386769796e-08
those O 0 8.618727953546568e-09
in O 0 6.559974963238346e-08
individuals O 0 3.795592284916438e-09
with O 0 1.2935282178716534e-08
mutations O 0 6.823233178465671e-08
in O 0 2.5531730329930724e-07
region O 0 5.477913305185211e-07
1 O 0 2.679898443602724e-06
, O 0 2.1630151891827154e-08
although O 0 1.4550243676580976e-08
age O 0 4.993870561520453e-07
at O 0 3.6698218082165113e-06
diagnosis O 0 5.404547209764132e-06
was O 0 2.7548758225748315e-06
similar O 0 5.010328436583222e-07
. O 0 7.526536478508206e-07

In O 0 0.00034452456748113036
all O 0 9.467851486988366e-05
AAPC B-Disease 1 0.999998927116394
kindreds O 0 0.00026836947654373944
, O 0 5.910605977987871e-07
a O 0 4.874755177297629e-07
predominance O 0 4.5466975279850885e-05
of O 0 0.00023526095901615918
right O 1 0.9999642372131348
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999839067459106
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999998807907104
sparing O 0 8.399163198191673e-05
was O 0 3.031339292647317e-05
observed O 0 7.732643098279368e-06
. O 0 5.919101226936618e-07

No O 0 0.01217330526560545
desmoid B-Disease 1 0.999930739402771
tumors I-Disease 1 1.0
were O 0 1.5970153981470503e-05
found O 0 2.9599229378618475e-07
in O 0 1.6897911336855032e-07
these O 0 1.0020124818765908e-07
kindreds O 0 3.2134546927409247e-05
. O 0 2.309975116077112e-06

Our O 0 9.722696267999709e-05
data O 0 1.802077349566389e-05
suggest O 0 2.008408273468376e-06
that O 0 4.804308559869241e-07
, O 0 1.23043116673216e-06
in O 0 9.279565347242169e-06
AAPC B-Disease 1 0.9999686479568481
families O 0 1.6513871514689527e-07
, O 0 4.130898290100049e-08
the O 0 5.622443666197796e-08
location O 0 5.187151259633538e-07
of O 0 2.9073344194330275e-06
the O 0 1.3613924238597974e-05
APC B-Disease 0 0.0001756726996973157
mutation O 0 2.891846406782861e-06
may O 0 1.8665199377210229e-06
partially O 0 3.1807023788132938e-06
predict O 0 2.0163889757895959e-07
specific O 0 6.9311461459165e-08
phenotypic O 0 0.00011829626600956544
expression O 0 0.0001548365835333243
. O 0 5.245681222731946e-06

This O 0 3.265319719503168e-06
should O 0 4.099878196939244e-07
help O 0 3.0707600018331505e-08
in O 0 1.498733439575517e-07
the O 0 2.738363491516793e-07
design O 0 2.081141474263859e-06
of O 0 2.095720219585928e-06
tailored O 0 8.106150744424667e-06
clinical O 0 0.0006581195630133152
- O 0 6.089434464229271e-05
management O 0 1.9368278572073905e-06
protocols O 0 1.7497617363915197e-06
in O 0 7.432078774627371e-08
this O 0 1.564521667773988e-08
subset O 0 8.613314435024222e-07
of O 0 8.302531000481395e-07
FAP B-Disease 0 4.3243588152108714e-05
patients O 0 1.2677636505031842e-06
. O 0 1.4662927583231067e-07
. O 0 3.9936759321790305e-07

Wilms B-Disease 1 0.999823272228241
' I-Disease 0 0.008017444983124733
tumor I-Disease 0 0.003182654734700918
1 O 0 7.310961518669501e-05
and O 0 3.7865379454160575e-06
Dax O 1 0.7083224654197693
- O 0 1.3804788977722637e-05
1 O 0 1.1792906661867164e-05
modulate O 0 6.859063887532102e-06
the O 0 4.690582954935962e-06
orphan O 0 2.145010330423247e-05
nuclear O 0 2.91947308141971e-05
receptor O 0 2.948510882561095e-05
SF O 0 0.0006456049159169197
- O 0 1.7542228079037159e-06
1 O 0 7.033812607915024e-07
in O 0 3.9815972741052974e-08
sex O 0 9.221609076348614e-08
- O 0 1.0347548595746048e-07
specific O 0 8.298657760974493e-09
gene O 0 5.222980803409882e-07
expression O 0 3.905676749127451e-06
. O 0 9.170652788270672e-07

Products O 0 0.00010767465573735535
of O 0 9.17505967663601e-05
steroidogenic O 0 0.0005915386718697846
factor O 0 3.047943209821824e-05
1 O 0 3.592020584619604e-05
( O 0 2.1189321159909014e-06
SF O 0 0.00019419575983192772
- O 0 3.3027420158759924e-06
1 O 0 4.926416295347735e-06
) O 0 8.384193250776661e-08
and O 0 3.5464810821395076e-07
Wilms B-Disease 0 0.004556572064757347
tumor I-Disease 0 0.0035812377464026213
1 O 0 8.186956983990967e-05
( O 0 2.3558652628707932e-06
WT1 O 0 3.284271588199772e-05
) O 0 5.466073460524967e-08
genes O 0 2.1709013253712328e-08
are O 0 3.7180496459399137e-09
essential O 0 4.5966920936280076e-08
for O 0 1.0738712319380284e-07
mammalian O 0 1.1114250810351223e-05
gonadogenesis O 0 1.0825888239196502e-05
prior O 0 5.648799401569704e-07
to O 0 4.199441150376515e-08
sexual O 0 9.082016276806826e-07
differentiation O 0 1.6028712707338855e-05
. O 0 2.473249651302467e-06

In O 0 0.00019736409012693912
males O 0 2.36631585721625e-05
, O 0 7.458729214704363e-06
SF O 0 0.0006544277421198785
- O 0 3.0849428185319994e-06
1 O 0 7.954178613545082e-07
participates O 0 1.9061946687770615e-08
in O 0 1.5218946103345843e-08
sexual O 0 3.2909778013845425e-08
development O 0 3.549935101432311e-08
by O 0 3.491012590117748e-09
regulating O 0 2.1829180241184076e-07
expression O 0 4.746561899082735e-07
of O 0 2.314559651495074e-06
the O 0 9.841050086834002e-06
polypeptide O 0 0.00023867159325163811
hormone O 0 8.0774916568771e-05
Mullerian O 0 0.0003737829683814198
inhibiting O 0 6.255383777897805e-05
substance O 0 5.0001428462564945e-05
( O 0 1.1336115676385816e-05
MIS O 0 0.0013786157360300422
) O 0 1.5723180695204064e-06
. O 0 5.861924705641286e-07

Here O 0 0.0002505170996300876
, O 0 3.307293127363664e-06
we O 0 2.8296946652517363e-07
show O 0 8.491228982165921e-07
that O 0 5.564421599046909e-07
WT1 O 0 0.00021603693312499672
- O 0 3.53972427546978e-05
KTS O 0 0.0007159853703342378
isoforms O 0 4.932668616675073e-06
associate O 0 1.0496957656869199e-05
and O 0 7.252613158925669e-07
synergize O 0 1.3966221558803227e-05
with O 0 1.148279920926143e-06
SF O 0 0.005473415832966566
- O 0 2.0477651560213417e-05
1 O 0 8.717424861970358e-06
to O 0 2.6896483973359864e-07
promote O 0 9.90974331216421e-06
MIS O 0 0.04379761591553688
expression O 0 4.206004450679757e-05
. O 0 2.959848416139721e-06

In O 0 2.5432425900362432e-05
contrast O 0 2.1507374185603112e-05
, O 0 6.260339432628825e-06
WT1 O 0 0.000752753228880465
missense O 0 2.6220404834020883e-05
mutations O 0 2.7239645987719996e-06
, O 0 1.9400356165988342e-07
associated O 0 2.37418348092433e-07
with O 0 1.2613236322067678e-07
male B-Disease 0 0.00020698118896689266
pseudohermaphroditism I-Disease 1 1.0
in O 0 0.006603939924389124
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.5478245990816504e-05
fail O 0 1.1140896276629064e-05
to O 0 5.89816693263856e-07
synergize O 0 3.597752220230177e-05
with O 0 6.211515028553549e-06
SF O 1 0.9991224408149719
- O 0 0.00022962533694226295
1 O 0 0.00011134188389405608
. O 0 1.7212927332366235e-06

Additionally O 0 0.00011480128159746528
, O 0 5.756758582720067e-06
the O 0 1.0027262760559097e-05
X O 0 0.0016975888283923268
- O 0 0.000163340984727256
linked O 0 0.00010130366717930883
, O 0 9.721193237055559e-07
candidate O 0 2.474752591297147e-06
dosage O 0 2.4942622985690832e-05
- O 0 1.3037107237323653e-05
sensitive O 0 1.3217364539741538e-05
sex O 0 1.4130696399661247e-06
- O 0 1.4842308928564307e-06
reversal O 0 7.433988230332034e-06
gene O 0 7.047913186397636e-07
, O 0 5.106663820697577e-07
Dax O 0 0.0005781110376119614
- O 0 3.928220849047648e-06
1 O 0 5.354910626920173e-06
, O 0 1.6969032401448203e-07
antagonizes O 0 1.011744075185561e-06
synergy O 0 1.293083755626867e-06
between O 0 1.5567617083434016e-05
SF O 0 0.0009841987630352378
- O 0 1.2772762602253351e-05
1 O 0 1.660921952861827e-05
and O 0 1.1978681868640706e-06
WT1 O 0 7.038214971544221e-05
, O 0 2.6434074129610963e-07
most O 0 3.4837039919466406e-08
likely O 0 2.0259198763028508e-08
through O 0 1.9971071907320948e-08
a O 0 9.706948134180493e-08
direct O 0 4.076469792835269e-07
interaction O 0 1.4937447758711642e-06
with O 0 2.1347752863221103e-06
SF O 0 0.007493284065276384
- O 0 4.0705370338400826e-05
1 O 0 2.311036405444611e-05
. O 0 4.0560178149462445e-07

We O 0 3.894013207172975e-05
propose O 0 1.5467932826140895e-05
that O 0 5.3237267820804846e-06
WT1 O 0 0.0007659484981559217
and O 0 4.368002191768028e-05
Dax O 1 0.9456093907356262
- O 0 2.561986548244022e-05
1 O 0 9.14408519747667e-06
functionally O 0 1.3419146398518933e-06
oppose O 0 5.3269197053396056e-08
each O 0 1.461856236062431e-08
other O 0 2.8447487920857384e-08
in O 0 1.2862982430306147e-06
testis O 0 0.0001255116512766108
development O 0 4.650611117540393e-06
by O 0 1.0195778941124445e-06
modulating O 0 5.94850025663618e-05
SF O 0 0.002289630239829421
- O 0 1.8477783669368364e-05
1 O 0 1.6708336261217482e-05
- O 0 1.5452085335709853e-06
mediated O 0 5.850916750205215e-06
transactivation O 0 3.469776129350066e-05
. O 0 1.6322942997248902e-07
. O 0 3.30337684317783e-07

A O 0 6.098145240684971e-05
mouse O 0 1.4356152860273141e-05
model O 0 2.86443696495553e-06
for O 0 1.4415666555578355e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999579191207886
centre O 1 0.995514452457428
mutations O 0 6.1010714489384554e-06
. O 0 1.417749558640935e-06

Imprinting O 0 0.002415133873000741
in O 0 0.0002665950160007924
the O 0 9.430853242520243e-05
15q11 O 0 0.00029838201589882374
- O 0 3.313535489724018e-05
q13 O 0 4.356815406936221e-05
region O 0 1.9742633412533905e-06
involves O 0 1.799728693185898e-06
an O 0 1.422028617525939e-06
imprinting O 0 5.2444513130467385e-05
centre O 0 0.004475587047636509
( O 0 3.7171694202697836e-06
IC O 0 4.316859849495813e-05
) O 0 1.9977554188699287e-07
, O 0 4.9960807047000344e-08
mapping O 0 1.853816939956232e-07
in O 0 2.863336874270317e-07
part O 0 4.0429725345347833e-07
to O 0 3.4443763752278755e-07
the O 0 2.1872870092920493e-06
promoter O 0 1.6278063412755728e-05
and O 0 8.537202234037977e-07
first O 0 1.9254757717135362e-06
exon O 0 3.4050185604428407e-06
of O 0 8.870702913554851e-06
SNRPN O 0 0.001140930107794702
. O 0 6.625773949053837e-06

Deletion O 0 0.00027321820380166173
of O 0 2.458587914588861e-05
this O 0 3.327537797304103e-06
IC O 0 0.00024196576850954443
abolishes O 0 1.683804475760553e-05
local O 0 4.776969149133947e-07
paternally O 0 1.952806314875488e-06
derived O 0 1.0029781094544887e-07
gene O 0 5.087880339260664e-08
expression O 0 9.819610369277143e-08
and O 0 1.0562323460305834e-08
results O 0 2.7720935236175137e-07
in O 0 5.390170827013208e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999914169311523
PWS B-Disease 1 1.0
) O 0 3.2556177757214755e-05
. O 0 2.240359208371956e-06

We O 0 7.467348495993065e-06
have O 0 2.314327076646805e-07
created O 0 2.9683550906156597e-07
two O 0 2.1412968465028825e-07
deletion O 0 4.735132279165555e-06
mutations O 0 9.313824875789578e-07
in O 0 6.806771125411615e-06
mice O 0 1.1127835023216903e-05
to O 0 1.1224977924939594e-06
understand O 0 6.377326826623175e-06
PWS B-Disease 1 0.9999998807907104
and O 0 6.751925525350089e-07
the O 0 6.044831479812274e-07
mechanism O 0 8.033294420783932e-07
of O 0 1.2374517837088206e-06
this O 0 9.068799613487499e-07
IC O 0 0.00041096366476267576
. O 0 2.243012431790703e-06

Mice O 0 0.005988169927150011
harbouring O 0 0.002507457509636879
an O 0 1.094648087018868e-05
intragenic O 0 0.0004709058557637036
deletion O 0 8.912306657293811e-05
in O 0 7.666816236451268e-05
Snrpn O 0 0.03067953698337078
are O 0 1.1489895769045688e-05
phenotypically O 0 0.0005384893738664687
normal O 0 9.435440006200224e-05
, O 0 3.929862941731699e-07
suggesting O 0 3.4557209005470213e-07
that O 0 2.470448379199297e-08
mutations O 0 1.3441157875604404e-07
of O 0 1.8484090560377808e-06
SNRPN O 0 5.731217606808059e-05
are O 0 3.6418217774780715e-08
not O 0 6.24265039661509e-09
sufficient O 0 2.5093765998462914e-07
to O 0 6.836311285951524e-07
induce O 0 0.0003097511362284422
PWS B-Disease 1 1.0
. O 0 3.8206369936233386e-05

Mice O 0 0.000245816248934716
with O 0 4.79338893910608e-07
a O 0 9.910924063660786e-07
larger O 0 3.49890768802652e-07
deletion O 0 3.490386916382704e-06
involving O 0 1.0442036000313237e-06
both O 0 1.6360297649953282e-06
Snrpn O 0 0.000134169909870252
and O 0 2.161307520509581e-06
the O 0 1.3963292076368816e-05
putative O 0 0.0015540046151727438
PWS O 1 1.0
- O 0 0.00034422482713125646
IC O 0 0.00010169226879952475
lack O 0 2.309662249899702e-06
expression O 0 1.747377041283471e-06
of O 0 2.908884880525875e-06
the O 0 3.933510470233159e-06
imprinted O 0 1.4236991773941554e-05
genes O 0 5.208489255892346e-06
Zfp127 O 0 0.00010949248826364055
( O 0 6.8264102992543485e-06
mouse O 0 1.1005990018020384e-05
homologue O 0 3.7022982724010944e-05
of O 0 2.3971420887392014e-05
ZNF127 O 0 0.0006179146002978086
) O 0 6.914383448020089e-06
, O 0 3.949463007302256e-06
Ndn O 0 0.00020110483455937356
and O 0 1.8730820556811523e-06
Ipw O 0 0.00015573417476844043
, O 0 3.1798666100257833e-07
and O 0 7.954104574992016e-08
manifest O 0 1.2027583125018282e-06
several O 0 1.2354854561635875e-07
phenotypes O 0 1.4108805771684274e-05
common O 0 3.6050282687938306e-06
to O 0 7.027770607237471e-06
PWS B-Disease 1 1.0
infants O 1 0.8828009963035583
. O 0 3.943704541597981e-06

These O 0 3.2874006592464866e-06
data O 0 5.4499387260875665e-06
demonstrate O 0 1.911384742925293e-06
that O 0 1.616120215430783e-07
both O 0 5.19426009759627e-07
the O 0 2.4040700736804865e-06
position O 0 4.022249868285144e-06
of O 0 7.448458291037241e-06
the O 0 6.7684372879739385e-06
IC O 0 4.614763383870013e-05
and O 0 1.339974176062242e-07
its O 0 4.4345465965989206e-08
role O 0 3.1351805773738306e-07
in O 0 3.0524302019330207e-07
the O 0 2.3679311311752826e-07
coordinate O 0 5.047169224781101e-07
expression O 0 5.398160283220932e-06
of O 0 9.47409171203617e-06
genes O 0 1.5779165778440074e-06
is O 0 6.597530273211305e-07
conserved O 0 1.5298272728614393e-06
between O 0 4.81214510728023e-06
mouse O 0 1.1176130101375747e-05
and O 0 1.3166022654331755e-06
human O 0 5.603451882052468e-06
, O 0 2.995384136283974e-07
and O 0 2.7142925773659954e-07
indicate O 0 8.640307669338654e-07
that O 0 2.438330568566016e-07
the O 0 1.886007453322236e-06
mouse O 0 4.4939292820345145e-06
is O 0 2.0918572829486948e-07
a O 0 3.062448854507238e-07
suitable O 0 1.1987445986960665e-06
model O 0 1.8624214135343209e-06
system O 0 5.477589297697705e-07
in O 0 6.833001009454165e-08
which O 0 2.0592448635170513e-08
to O 0 1.628331958158924e-08
investigate O 0 9.359774111317165e-08
the O 0 1.2443605328371632e-06
molecular O 0 1.1772623111028224e-05
mechanisms O 0 3.952190581912873e-06
of O 0 3.4905333450296894e-06
imprinting O 0 1.451701064070221e-05
in O 0 1.1008497722286847e-06
this O 0 5.807627445619801e-08
region O 0 1.2600648346960952e-07
of O 0 4.4818244759881054e-07
the O 0 7.328321203203814e-07
genome O 0 5.223583912083996e-07
. O 0 1.5105038642104773e-07
. O 0 7.001354447311314e-07

Mutations O 0 4.054883447679458e-06
of O 0 3.559828883226146e-06
the O 0 1.7932474065673887e-06
ATM O 0 4.4315496779745445e-05
gene O 0 1.3358317119127605e-06
detected O 0 3.5163802749593742e-06
in O 0 6.935649253136944e-06
Japanese O 1 0.9985918402671814
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999512434005737
: O 0 1.478051103731559e-07
possible O 0 6.257697293676756e-08
preponderance O 0 9.265045264328364e-06
of O 0 4.8995316319633275e-06
the O 0 3.5375264815229457e-06
two O 0 1.7551145674588042e-06
founder O 0 3.5424254747340456e-05
mutations O 0 1.2200468972878298e-06
4612del165 O 0 1.7822603695094585e-05
and O 0 2.6334284939366626e-06
7883del5 O 0 8.934583456721157e-05
. O 0 5.094287644169526e-06

The O 0 0.0002287006500409916
ATM O 0 0.0016304835444316268
( O 0 0.00010583065886748955
A O 1 0.9999997615814209
- O 1 0.999997615814209
T O 1 0.9999998807907104
, O 0 6.572122401848901e-07
mutated O 0 2.403088501523598e-07
) O 0 6.126008855744658e-08
gene O 0 8.438870224836137e-08
on O 0 1.0563198884483427e-06
human O 0 5.380767561291577e-06
chromosome O 0 5.287613385007717e-05
11q22 O 0 9.00461818673648e-05
. O 0 4.263964456185931e-06

3 O 0 0.000487109471578151
has O 0 1.321261265729845e-06
recently O 0 8.374937578992103e-07
been O 0 5.45749934133255e-08
identified O 0 8.76675176897379e-09
as O 0 3.199002618359259e-09
the O 0 2.851864300268403e-09
gene O 0 1.123858162088709e-08
responsible O 0 1.389119663741667e-08
for O 0 9.17868359096019e-09
the O 0 3.4475348797968763e-07
human O 0 0.00037225952837616205
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.02284808337572e-06
. O 0 8.365070698346244e-07

In O 0 3.70036195818102e-06
order O 0 3.097824219366885e-07
to O 0 4.7893124133224774e-08
define O 0 2.761707378340361e-07
the O 0 2.685792992451752e-07
types O 0 7.901978733571013e-07
of O 0 1.755183438945096e-05
disease O 1 0.9226096868515015
- O 0 3.673785613500513e-05
causing O 0 7.040852324280422e-06
ATM O 0 2.3907405193313025e-05
mutations O 0 2.6847865797208215e-07
in O 0 1.6513099581061397e-06
Japanese O 0 0.0002285415248479694
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 1.8019700291915797e-06
as O 0 1.836154837064896e-07
well O 0 6.90932822067225e-08
as O 0 6.39186339412845e-08
to O 0 1.6844037276086965e-08
look O 0 8.194129463845456e-08
for O 0 1.1787308551447495e-07
possible O 0 2.0284544461901532e-06
mutational O 0 0.00019275720114819705
hotspots O 0 0.00011426023411331698
, O 0 1.5711924561401247e-06
reverse O 0 3.4287345442862716e-06
- O 0 1.7824222595663741e-06
transcribed O 0 1.3896042219130322e-06
RNA O 0 4.64414398493318e-07
derived O 0 1.9662597594560793e-07
from O 0 2.1403330663360975e-07
ten O 0 5.232658395470935e-07
patients O 0 1.6310541184338945e-07
belonging O 0 6.512830168503569e-07
to O 0 8.943653995174827e-08
eight O 0 1.9833294118143385e-06
unrelated O 0 1.1375329449947458e-05
Japanese O 0 0.0016638298984616995
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 0.9999994039535522
families O 0 6.091160287269304e-08
was O 0 3.6954349980078405e-07
analyzed O 0 6.670438779110555e-08
for O 0 1.7258749096527026e-08
mutations O 0 2.459385761710564e-08
by O 0 4.856701707467437e-09
the O 0 2.549476363356007e-08
restriction O 0 1.1194750726417624e-07
endonuclease O 0 3.3001099382090615e-06
fingerprinting O 0 1.3946330454928102e-06
method O 0 2.891223175538471e-06
. O 0 1.4260117495723534e-06

As O 0 0.00012125388457207009
has O 0 4.06194294555462e-06
been O 0 2.105263320117956e-06
reported O 0 6.992613066358899e-07
by O 0 6.412598452243401e-08
others O 0 9.55536307856164e-08
, O 0 1.8161337322908366e-08
mutations O 0 2.3491045553214462e-08
that O 0 2.5921700341768883e-08
lead O 0 3.065391354084568e-07
to O 0 2.0764693431374326e-07
exon O 0 9.776132174010854e-06
skipping O 0 1.2426525245246012e-05
or O 0 8.872911166690756e-06
premature O 0 1.8148761228076182e-05
protein O 0 5.214463271840941e-06
truncation O 0 2.1294263206073083e-05
were O 0 1.6625592706986936e-06
also O 0 4.155356805313204e-07
predominant O 0 1.8177263427787693e-06
in O 0 8.571074090468755e-07
our O 0 5.070249358141155e-07
mutants O 0 4.6961336011008825e-06
. O 0 8.405759217566811e-07

Six O 0 2.8330199711490422e-05
different O 0 3.22749741599182e-07
mutations O 0 4.206014523333579e-07
were O 0 7.046031669233344e-07
identified O 0 1.8115986222255742e-07
on O 0 9.167452503788809e-07
12 O 0 1.1830616131192073e-06
of O 0 7.151293743845599e-07
the O 0 1.7138872863142751e-06
16 O 0 2.0041276002302766e-05
alleles O 0 5.054740540799685e-06
examined O 0 1.3264857443573419e-05
. O 0 3.7883728509768844e-06

Four O 0 5.704700743081048e-05
were O 0 5.938918548054062e-06
deletions O 0 6.66524510961608e-06
involving O 0 3.1941442557581468e-06
a O 0 4.165190603089286e-06
loss O 0 3.8070200389483944e-05
of O 0 3.298660521977581e-05
a O 0 1.542427526146639e-05
single O 0 5.624788627756061e-06
exon O 0 8.5953552115825e-06
exon O 0 4.875108970736619e-06
7 O 0 3.0067461921134964e-05
, O 0 9.105631875172548e-07
exon O 0 3.221490260330029e-06
16 O 0 1.3259596016723663e-05
, O 0 5.678565457856166e-07
exon O 0 3.3839703519333852e-06
33 O 0 1.6786274500191212e-05
or O 0 1.8735054254648276e-06
exon O 0 9.319598575530108e-06
35 O 0 2.235890679003205e-05
. O 0 2.9931618428236106e-06

The O 0 0.00018432229990139604
others O 0 7.258997811732115e-06
were O 0 1.8141520286008017e-06
minute O 0 2.0309903447923716e-06
deletions O 0 1.4325845540952287e-06
, O 0 3.22426103593898e-07
4649delA O 0 1.0862609087780584e-06
in O 0 6.124350306890847e-07
exon O 0 3.5360053516342305e-06
33 O 0 1.715516555123031e-05
and O 0 1.3263287428344483e-06
7883del5 O 0 2.908821261371486e-05
in O 0 7.452435966115445e-06
exon O 0 3.340701732668094e-05
55 O 0 4.7744753828737885e-05
. O 0 4.079144218849251e-06

The O 0 0.00030234147561714053
mutations O 0 6.260789814405143e-05
4612del165 O 0 0.00030067426268942654
and O 0 3.241261947550811e-05
7883del5 O 0 8.325077214976773e-05
were O 0 9.164820767182391e-06
found O 0 9.380395908920036e-07
in O 0 4.471330896649306e-07
more O 0 2.402391174882723e-08
than O 0 2.685044719896723e-08
two O 0 5.1075016216373115e-08
unrelated O 0 2.3557905137749913e-07
families O 0 1.4731531550182808e-08
; O 0 2.5873093889572374e-08
44 O 0 4.4728832904183946e-07
% O 0 1.6551680914744793e-07
( O 0 1.307361827684872e-07
7 O 0 4.384226031106664e-06
of O 0 5.363373929867521e-06
16 O 0 3.2793173886602744e-05
) O 0 4.692613515544508e-07
of O 0 2.5094464035646524e-06
the O 0 2.5801102765399264e-06
mutant O 0 3.900562660419382e-06
alleles O 0 2.8754345748893684e-07
had O 0 7.478698194063327e-07
one O 0 7.823860670441718e-08
of O 0 1.7528370221953082e-07
the O 0 4.2799615584954154e-07
two O 0 3.0308228815556504e-07
mutations O 0 1.9092822185484692e-06
. O 0 1.7287151194977923e-06

The O 0 0.00029815564630553126
4612del165 O 0 0.0004287034389562905
mutations O 0 8.127406545099802e-06
in O 0 4.825632913707523e-06
three O 0 4.922086986880458e-07
different O 0 2.7460041351901054e-08
families O 0 6.704559041281755e-08
were O 0 4.2166979596913734e-07
all O 0 1.7260633455862262e-07
ascribed O 0 4.206081484880997e-06
to O 0 7.702929565311933e-07
the O 0 6.822499017289374e-06
same O 0 7.408742931147572e-06
T O 0 3.0570085073122755e-05
- O 0 2.6982415874954313e-06
- O 0 1.6745602806622628e-06
> O 0 1.208351591230894e-06
A O 0 8.170608225555043e-07
substitution O 0 5.844659654030693e-07
at O 0 4.0620516301714815e-06
the O 0 4.834357127947442e-07
splice O 0 1.3879711104891612e-06
donor O 0 5.337720381248801e-07
site O 0 7.859950414967898e-07
in O 0 7.227859555314353e-07
intron O 0 0.00010831642430275679
33 O 0 0.0002235288411611691
. O 0 7.109939815563848e-06

Microsatellite O 0 0.0040834578685462475
genotyping O 0 0.00045819958904758096
around O 0 3.247019776608795e-05
the O 0 1.2328824595897458e-05
ATM O 0 0.00014897067740093917
locus O 0 2.378864519414492e-05
also O 0 1.187343173114641e-06
indicated O 0 5.297414986671356e-07
that O 0 1.67639093717753e-08
a O 0 2.410171191513655e-07
common O 0 2.6981365408573765e-07
haplotype O 0 2.760630195552949e-06
was O 0 1.1259005532338051e-06
shared O 0 1.0949761986012163e-07
by O 0 1.7444278910261346e-08
the O 0 9.498305786337369e-08
mutant O 0 7.438580382768123e-07
alleles O 0 2.7668903612720896e-07
in O 0 3.4711891316874244e-07
both O 0 5.220182401899365e-07
mutations O 0 2.520154794183327e-06
. O 0 1.4705248077007127e-06

This O 0 5.979005891276756e-06
suggests O 0 2.686994548639632e-06
that O 0 1.3329946568774176e-07
these O 0 2.2633885521372576e-07
two O 0 2.155570655304473e-06
founder O 0 3.200271021341905e-05
mutations O 0 5.819408670504345e-07
may O 0 4.557007287075976e-07
be O 0 3.9336121915312106e-08
predominant O 0 3.5547668630897533e-07
among O 0 2.8586949696318698e-08
Japanese O 0 1.9015411680811667e-06
ATM O 0 5.8353944041300565e-05
mutant O 0 1.1597892807913013e-05
alleles O 0 6.884497906867182e-06
. O 0 1.5900253629297367e-06

W474C O 0 0.003256310475990176
amino O 0 0.00010121406376129016
acid O 0 7.027160336292582e-06
substitution O 0 4.895892743661534e-06
affects O 0 7.722140935584321e-07
early O 0 1.6322115925504477e-06
processing O 0 2.9065915896353545e-06
of O 0 5.0786534302460495e-06
the O 0 3.224333340767771e-06
alpha O 0 3.3998592243733583e-06
- O 0 2.0892674967853964e-07
subunit O 0 1.8762611375677807e-07
of O 0 3.0057367439439986e-06
beta O 0 1.3864397260476835e-05
- O 0 4.500654540606774e-06
hexosaminidase O 0 7.397693934763083e-06
A O 0 7.520101235058974e-07
and O 0 9.827797953221307e-08
is O 0 7.374579524821456e-08
associated O 0 1.4150087679354328e-07
with O 0 3.9094081216717314e-07
subacute O 1 0.8324535489082336
G B-Disease 0 0.04129338636994362
( I-Disease 0 1.8171986084780656e-05
M2 I-Disease 0 0.0020547877065837383
) I-Disease 0 4.767107384395786e-06
gangliosidosis I-Disease 0 0.00013385710190050304
. O 0 2.950288944703061e-06

Mutations O 0 2.8909122192999348e-05
in O 0 2.2518755940836854e-05
the O 0 1.6917832908802666e-05
HEXA O 0 0.00032998467213474214
gene O 0 1.2974319361092057e-06
, O 0 3.4714670960056537e-07
encoding O 0 2.759756512205058e-07
the O 0 2.2940871531318408e-06
alpha O 0 2.6366224119556136e-06
- O 0 2.540259345096274e-07
subunit O 0 2.497120306088618e-07
of O 0 5.352010248316219e-06
beta O 0 2.0655723346862942e-05
- O 0 1.3430818398774136e-05
hexosaminidase O 0 7.446576637448743e-05
A O 0 3.35799741151277e-05
( O 0 1.8766257880997728e-06
Hex O 0 2.555159699113574e-05
A O 0 3.826918145932723e-06
) O 0 5.876612974020645e-08
, O 0 4.588980750952487e-09
that O 0 1.8428654158242352e-09
abolish O 0 9.349139418191044e-08
Hex O 0 1.5362543308583554e-06
A O 0 1.7611579039567005e-07
enzyme O 0 2.8007926289319585e-07
activity O 0 3.0197920750651974e-06
cause O 0 0.0003390835190657526
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
( O 0 8.66256141307531e-06
TSD B-Disease 0 0.0022237400989979506
) O 0 7.060884286147484e-07
, O 0 2.256728492966431e-07
the O 0 4.3940963223576546e-06
fatal O 0 0.03363903984427452
infantile B-Disease 0 0.005618075840175152
form I-Disease 0 6.013946858729469e-06
of I-Disease 0 0.00044853086001239717
G I-Disease 0 0.00045068617328070104
( I-Disease 0 2.777494273686898e-06
M2 I-Disease 0 8.74440956977196e-05
) I-Disease 0 3.493093174711248e-07
gangliosidosis I-Disease 0 4.653486030292697e-06
, I-Disease 0 1.2143166827627283e-07
Type I-Disease 0 2.606792122605839e-06
1 I-Disease 0 2.921158193203155e-05
. O 0 2.5396493583684787e-06

Less O 0 0.00021382617705967277
severe O 1 0.9994470477104187
, O 0 3.736565849976614e-05
subacute O 1 0.9999923706054688
( O 0 8.142423030221835e-05
juvenile O 1 0.999920129776001
- O 0 0.0009399940026924014
onset O 1 0.9999773502349854
) O 0 3.616003232309595e-05
and O 0 0.00012021691509289667
chronic O 1 1.0
( O 0 0.0009200800559483469
adult O 0 0.03224809095263481
- O 0 0.050619132816791534
onset O 1 0.9212040901184082
) O 0 4.770304258272517e-07
variants O 0 2.6893607696365507e-07
are O 0 1.2457927134335023e-08
characterized O 0 2.9601475048934844e-08
by O 0 3.6952141346802136e-09
a O 0 4.548696708184252e-08
broad O 0 2.3535899629223422e-07
spectrum O 0 3.224094768938812e-07
of O 0 3.3847891245386563e-07
clinical O 0 2.0867297280346975e-05
manifestations O 0 1.178413731395267e-05
and O 0 2.0680150214502646e-07
are O 0 1.7915958494540973e-08
associated O 0 1.8636187704146323e-08
with O 0 8.564944309341627e-09
residual O 0 5.035586582380347e-06
levels O 0 7.215309324237751e-06
of O 0 9.47038824961055e-06
Hex O 0 6.268395372899249e-05
A O 0 9.389665137859993e-06
enzyme O 0 3.24616826219426e-06
activity O 0 6.2448543758364394e-06
. O 0 1.1409945273044286e-06

We O 0 7.349315274041146e-05
identified O 0 2.8765625756932423e-05
a O 0 2.225734351668507e-05
1422 O 0 0.001029888866469264
G O 0 0.0002970380592159927
- O 0 1.8089234799845144e-05
- O 0 1.8546739738667384e-05
> O 0 1.6618774679955095e-05
C O 0 1.959258588613011e-05
( O 0 5.562851015383785e-07
amino O 0 7.515297966165235e-07
acid O 0 3.0477877999146585e-07
W474C O 0 1.7349334484606516e-06
) O 0 4.75278518763389e-08
substitution O 0 1.9678843443671212e-07
in O 0 3.1973212344382773e-07
the O 0 5.164062031326466e-07
first O 0 7.492698159694555e-07
position O 0 2.3681848233536584e-06
of O 0 3.2529271720704855e-06
exon O 0 3.5067889712081524e-06
13 O 0 1.086106840375578e-05
of O 0 2.2350870494847186e-05
HEXA O 0 0.0018041398143395782
of O 0 6.040942753315903e-05
a O 0 4.309534051571973e-05
non O 0 0.0002883289416786283
- O 0 1.9586719645303674e-05
Jewish O 0 9.595315532351378e-06
proband O 0 9.651798609411344e-05
who O 0 7.65923402923363e-07
manifested O 0 8.203312972909771e-06
a O 0 3.4282604701729724e-06
subacute O 0 0.00047589128371328115
variant O 0 4.980075027560815e-05
of O 0 0.0010012986604124308
G B-Disease 0 0.13046026229858398
( I-Disease 0 2.888561721192673e-05
M2 I-Disease 0 0.002005606424063444
) I-Disease 0 5.572075679083355e-06
gangliosidosis I-Disease 0 0.00010344758629798889
. O 0 4.504055596044054e-06

On O 0 0.00023013669124338776
the O 0 1.824547325668391e-05
second O 0 3.6472760257311165e-05
maternally O 0 5.796676123281941e-05
inherited O 0 6.111289985710755e-05
allele O 0 2.6744958177005174e-06
, O 0 9.62571533591472e-08
we O 0 1.8398562673382912e-08
identified O 0 1.70932835885651e-07
the O 0 6.076296017454297e-07
common O 0 5.047668673796579e-05
infantile O 1 0.9999992847442627
disease O 1 0.9999967813491821
- O 0 0.00018587008526083082
causing O 0 0.00035417272010818124
4 O 0 0.00019062259525526315
- O 0 1.434754449292086e-05
bp O 0 7.181479759310605e-06
insertion O 0 2.8165929961687652e-06
, O 0 1.495757715019863e-06
+ O 0 1.0066181857837364e-05
TATC O 0 8.336277824128047e-05
1278 O 0 0.00010762445162981749
, O 0 8.250113978647278e-07
in O 0 1.4737187257196638e-06
exon O 0 8.255676220869645e-06
11 O 0 1.8180808183387853e-05
. O 0 2.1783896499982802e-06

Pulse O 0 0.003426513634622097
- O 0 0.0001208935645991005
chase O 0 1.490522572566988e-05
analysis O 0 1.71285614669614e-06
using O 0 2.79298501482117e-06
proband O 0 0.0001826033985707909
fibroblasts O 0 9.887522901408374e-05
revealed O 0 3.250886220484972e-05
that O 0 1.2807569191863877e-06
the O 0 9.142097042058595e-06
W474C O 0 1.964553666766733e-05
- O 0 4.056004854646744e-06
containing O 0 1.6507005966559518e-06
alpha O 0 6.088168447604403e-06
- O 0 8.434788583144837e-07
subunit O 0 1.074219085239747e-06
precursor O 0 4.725694452645257e-06
was O 0 8.211414751713164e-06
normally O 0 5.713565656151331e-07
synthesized O 0 1.885825668068719e-06
, O 0 1.1017765189080819e-07
but O 0 1.7713311706302193e-08
not O 0 3.3046081426846285e-08
phosphorylated O 0 4.970693225914147e-07
or O 0 5.059139880358998e-07
secreted O 0 4.284155465938966e-07
, O 0 8.317883271047322e-08
and O 0 1.2918299319153448e-07
the O 0 1.4972076769481646e-06
mature O 0 6.186325663293246e-06
lysosomal O 0 9.3095499323681e-05
alpha O 0 2.2996569896349683e-05
- O 0 1.3716085049964022e-06
subunit O 0 1.9235983472754015e-06
was O 0 3.6363355775392847e-06
not O 0 1.8338694474095973e-07
detected O 0 6.560652309417492e-06
. O 0 1.1749458508347743e-06

When O 0 0.00013056509487796575
the O 0 6.0796577599830925e-05
W474C O 0 8.676631841808558e-05
- O 0 1.0693785043258686e-05
containing O 0 5.766027697973186e-06
alpha O 0 8.37901643535588e-06
- O 0 5.887747533961374e-07
subunit O 0 1.9630349470389774e-06
was O 0 2.6220855943392962e-05
transiently O 0 2.2027559680282138e-05
co O 0 5.682727078237804e-06
- O 0 6.341565494949464e-07
expressed O 0 2.226061326382478e-07
with O 0 5.573605577069429e-08
the O 0 1.0932061513813096e-06
beta O 0 8.868485679158766e-07
- O 0 1.7661635354215832e-07
subunit O 0 2.0441987658159633e-07
to O 0 9.63732560421704e-08
produce O 0 4.989167337043909e-07
Hex O 0 3.553493297658861e-05
A O 0 2.5502542484900914e-05
( O 0 1.4261572687246371e-06
alphabeta O 0 1.6830292224767618e-05
) O 0 5.80106188863283e-07
in O 0 4.858840384258656e-06
COS O 0 0.00011350929707987234
- O 0 1.307823731622193e-05
7 O 0 4.165521386312321e-05
cells O 0 1.1855056527565466e-06
, O 0 1.78857789023823e-07
the O 0 9.911717597788083e-07
mature O 0 1.2789114407496527e-06
alpha O 0 3.6551102766679833e-06
- O 0 1.6506551503425726e-07
subunit O 0 1.9551173124909837e-07
was O 0 1.9086194242845522e-06
present O 0 2.092320272595316e-07
, O 0 1.0704173547537721e-07
but O 0 2.5846262019513233e-08
its O 0 1.3065404402823333e-07
level O 0 9.755233804753516e-06
was O 0 1.0559297152212821e-05
much O 0 6.570969048880215e-07
lower O 0 4.796489065483911e-06
than O 0 1.2195182819141337e-07
that O 0 5.1186972882533155e-08
from O 0 1.1340019909766852e-06
normal O 0 1.094226445275126e-05
alpha O 0 9.342789780930616e-06
- O 0 9.847844921750948e-07
subunit O 0 1.0701055543904658e-06
transfections O 0 6.774346275051357e-06
, O 0 1.8145260582969058e-07
although O 0 4.5940623749629594e-08
higher O 0 9.621362551115453e-07
than O 0 4.014693644194267e-08
in O 0 2.582732179234881e-07
those O 0 2.0979666714993073e-07
cells O 0 7.028568802525115e-07
transfected O 0 1.669015205152391e-06
with O 0 3.309073903778881e-08
an O 0 1.8280269387105363e-07
alpha O 0 2.2953715870244196e-06
- O 0 2.896232444982161e-07
subunit O 0 6.181803655636031e-07
associated O 0 2.551296347519383e-07
with O 0 3.072570962103782e-07
infantile O 1 0.8586187958717346
TSD B-Disease 0 0.010801693424582481
. O 0 5.119603429193376e-06

Furthermore O 0 0.00016305061581078917
, O 0 5.363895979826339e-06
the O 0 2.6350762709625997e-06
precursor O 0 1.2433970368874725e-05
level O 0 5.508564572664909e-05
of O 0 1.963587237696629e-05
the O 0 2.5821093004196882e-05
W474C O 0 5.4126889153849334e-05
alpha O 0 2.234407111245673e-05
- O 0 1.1306080978101818e-06
subunit O 0 9.05208025869797e-07
was O 0 1.6839222780618002e-06
found O 0 5.02554620140927e-08
to O 0 9.072786966157764e-09
accumulate O 0 2.9288990788245428e-08
in O 0 8.844888554904173e-08
comparison O 0 1.244033711600423e-07
to O 0 6.460810197950195e-08
the O 0 7.828232924111944e-07
normal O 0 1.0084966561407782e-05
alpha O 0 9.220567335432861e-06
- O 0 7.86430689458939e-07
subunit O 0 1.1809751185865025e-06
precursor O 0 6.057011432858417e-06
levels O 0 5.187420811125776e-06
. O 0 7.339330068134586e-07

We O 0 2.646569555508904e-05
conclude O 0 1.270032225875184e-05
that O 0 1.2840026784033398e-06
the O 0 7.129263394745067e-06
1422 O 0 0.0005321252974681556
G O 0 0.00019970969879068434
- O 0 8.078629434749018e-06
- O 0 3.6915887449140428e-06
> O 0 2.4086232315312373e-06
C O 0 3.355946091687656e-06
mutation O 0 1.4880441767672892e-08
is O 0 7.155337211628421e-09
the O 0 4.379331031145739e-08
cause O 0 3.5385923524700047e-07
of O 0 4.03215881306096e-06
Hex B-Disease 0 0.0004505409742705524
A I-Disease 0 0.0005838213255628943
enzyme I-Disease 1 0.9999984502792358
deficiency I-Disease 1 1.0
in O 0 1.2109161616535857e-05
the O 0 1.3646786101162434e-05
proband O 0 0.000271620083367452
. O 0 4.785486908076564e-06

The O 0 4.7176796215353534e-05
resulting O 0 3.585302329156548e-05
W474C O 0 0.0001577704824740067
substitution O 0 2.7751544621423818e-05
clearly O 0 9.543244232190773e-06
interferes O 0 3.680266217997996e-06
with O 0 3.455223520631989e-07
alpha O 0 6.133385340945097e-06
- O 0 3.839047337805823e-07
subunit O 0 1.2351301847957075e-06
processing O 0 4.439275016920874e-06
, O 0 1.2592707321346097e-07
but O 0 2.8046862610153767e-08
because O 0 3.0286756214081834e-08
the O 0 1.6676438008289551e-07
base O 0 1.5375236444015172e-06
substitution O 0 1.9198264453734737e-06
falls O 0 3.520555765135214e-05
at O 0 5.973215138510568e-06
the O 0 6.35246692581859e-07
first O 0 7.78577941673575e-07
position O 0 1.216495093103731e-06
of O 0 3.8016301004972775e-06
exon O 0 3.825933163170703e-06
13 O 0 1.6865687939571217e-05
, O 0 7.031599693618773e-07
aberrant O 0 4.199495833745459e-06
splicing O 0 5.995708534101141e-07
may O 0 1.1454997093096608e-06
also O 0 1.7273114849558624e-07
contribute O 0 1.3307463575529255e-07
to O 0 4.93910363275063e-07
Hex B-Disease 0 0.0003236866323277354
A I-Disease 0 0.00018533987167757004
deficiency I-Disease 0 0.3028896749019623
in O 0 7.695573003729805e-06
this O 0 7.41650865165866e-07
proband O 0 6.155204027891159e-05
. O 0 3.3536156252012006e-07
. O 0 5.420659476840228e-07

Two O 0 3.781670159241912e-07
frequent O 0 2.380318846917362e-06
missense O 0 6.859174754936248e-05
mutations O 0 3.746317088371143e-05
in O 0 0.00480606546625495
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00011825724504888058

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.000410535343689844
an O 0 0.00613626791164279
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 1.0
by O 0 1.3618044931718032e-06
early O 1 0.904825747013092
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999998807907104
goiter B-Disease 1 1.0
. O 0 0.00014308185200206935

A O 0 1.3597963516076561e-05
century O 0 1.709181560727302e-06
after O 0 1.3025456269133429e-07
its O 0 9.965381408960639e-09
recognition O 0 2.3548808769646712e-07
as O 0 1.0809667401190381e-06
a O 0 5.297472853271756e-06
syndrome O 1 0.9987428784370422
by O 0 1.4594903063880338e-07
Vaughan O 0 2.428147490718402e-05
Pendred O 0 0.00017632095841690898
, O 0 9.7878000815399e-07
the O 0 5.525872438738588e-06
disease O 0 0.0169875156134367
gene O 0 1.6739531929488294e-05
( O 0 2.2329842977342196e-05
PDS O 0 0.00029747706139460206
) O 0 6.868123136882787e-07
was O 0 6.2743374655838124e-06
mapped O 0 1.7182240981128416e-06
to O 0 2.731847416725941e-06
chromosome O 0 0.0005356692126952112
7q22 O 0 0.0013952809385955334
- O 0 0.0008031256147660315
q31 O 0 0.0006083961925469339
. O 0 6.6208976932102814e-06

1 O 0 0.0006091376999393106
and O 0 6.9314901338657364e-06
, O 0 7.372202048827603e-07
recently O 0 1.0629723874444608e-06
, O 0 6.027986643175609e-08
found O 0 3.547024718386638e-08
to O 0 1.1510189246166647e-08
encode O 0 4.448571360171627e-07
a O 0 2.4553464754717425e-06
putative O 0 7.116631604731083e-05
sulfate O 0 0.00016284490993712097
transporter O 0 0.0007320680888369679
. O 0 6.16099623584887e-06

We O 0 1.4840441053820541e-06
performed O 0 1.2052591955580283e-06
mutation O 0 2.3300285079130845e-07
analysis O 0 6.372422944878053e-08
of O 0 8.625751775070967e-07
the O 0 6.448273779824376e-06
PDS B-Disease 0 0.00015283128595910966
gene O 0 1.3231388038548175e-06
in O 0 1.6390031305490993e-06
patients O 0 1.050058472173987e-06
from O 0 1.5896251852609566e-06
14 O 0 1.3985214536660351e-05
Pendred B-Disease 0 3.22212690662127e-05
families O 0 1.1035642444312543e-07
originating O 0 5.670064524565532e-07
from O 0 1.6673273250944476e-07
seven O 0 7.64230065897209e-08
countries O 0 1.8639529031361235e-08
and O 0 2.992802450307863e-08
identified O 0 1.9778768489686627e-07
all O 0 1.367767907822781e-07
mutations O 0 2.0214097276038956e-06
. O 0 1.8867395965571632e-06

The O 0 3.282985198893584e-05
mutations O 0 3.973286311520496e-06
include O 0 3.3178066587424837e-06
three O 0 2.878907935155439e-06
single O 0 2.8607348667719634e-06
base O 0 1.2237920600455254e-05
deletions O 0 4.31152830060455e-06
, O 0 6.775824772375927e-07
one O 0 1.4436564299558086e-07
splice O 0 2.156347818527138e-06
site O 0 2.682463104974886e-07
mutation O 0 6.241831584929969e-08
and O 0 8.150469454903941e-08
10 O 0 1.3197665111874812e-06
missense O 0 1.2698407772404607e-05
mutations O 0 3.4532970403233776e-06
. O 0 3.48026878782548e-06

One O 0 9.821358980843797e-05
missense O 0 0.0002965389285236597
mutation O 0 3.791411654674448e-05
( O 0 7.658345566596836e-06
L236P O 0 5.3123789257369936e-05
) O 0 8.584423767388216e-07
was O 0 3.965473297284916e-06
found O 0 1.9589471378367307e-07
in O 0 2.2015248646312102e-07
a O 0 3.3547158295732515e-07
homozygous O 0 2.867564319330995e-07
state O 0 1.281866133240328e-07
in O 0 4.805453954759287e-07
two O 0 2.9679080171263195e-07
consanguineous O 0 1.1656394235615153e-05
families O 0 1.1177361614045367e-07
and O 0 1.484250589101066e-07
in O 0 4.881771360487619e-07
a O 0 5.256054578239855e-07
heterozygous O 0 9.091984765063899e-08
state O 0 5.332601915597479e-08
in O 0 2.5083360810640443e-07
five O 0 2.6660970320335764e-07
additional O 0 5.408288075159362e-07
non O 0 0.00011150392674608156
- O 0 6.231847510207444e-05
consanguineous O 0 0.0001688223419478163
families O 0 6.82488632719469e-07
. O 0 6.761493978046929e-07

Another O 0 0.00013583684631157666
missense O 0 0.0003841900615952909
mutation O 0 1.879238334367983e-05
( O 0 6.648116595897591e-06
T416P O 0 5.021421020501293e-05
) O 0 1.105358592212724e-06
was O 0 8.607948075223248e-06
found O 0 2.8075399427507364e-07
in O 0 3.2995262699841987e-07
a O 0 4.902453270005935e-07
homozygous O 0 6.461937118729111e-07
state O 0 3.2352014045500255e-07
in O 0 1.5481704167541466e-06
one O 0 4.907051334157586e-07
family O 0 1.562652300890477e-07
and O 0 9.606714002075023e-08
in O 0 2.6928307761409087e-07
a O 0 3.9521202666037425e-07
heterozygous O 0 9.640395859378259e-08
state O 0 5.423039084462289e-08
in O 0 1.876819482049541e-07
four O 0 3.496939768865559e-07
families O 0 9.547238022378224e-08
. O 0 6.164054866530932e-07

Pendred B-Disease 1 0.8966869711875916
patients O 0 0.0008724011713638902
in O 0 0.00015169171092566103
three O 0 0.00011355595052009448
non O 0 0.0008888790616765618
- O 0 5.549151683226228e-05
consanguineous O 0 9.666527330409735e-05
families O 0 8.590552624809789e-08
were O 0 2.118583353194481e-07
shown O 0 2.4730701397857047e-07
to O 0 9.486682017723069e-08
be O 0 5.438519110612106e-07
compound O 0 5.119271918374579e-06
heterozygotes O 0 4.912210442853393e-06
for O 0 9.705075854071765e-07
L236P O 0 3.689039658638649e-05
and O 0 4.330327101342846e-06
T416P O 0 0.0001726232294458896
. O 0 7.3162655098713e-06

In O 0 0.0001242129219463095
total O 0 0.00021300085063558072
, O 0 7.990818630787544e-06
one O 0 3.0544676974386675e-06
or O 0 1.7761743720257073e-06
both O 0 3.993386599177029e-07
of O 0 3.2389230000262614e-06
these O 0 2.019259994767708e-07
mutations O 0 1.7042303568359785e-07
were O 0 8.143132390614483e-07
found O 0 5.6036114415292104e-08
in O 0 1.1275957234602174e-07
nine O 0 3.153288901103224e-07
of O 0 2.9100289111738675e-07
the O 0 6.57031762330007e-07
14 O 0 6.9685670496255625e-06
families O 0 1.2401791593674716e-07
analyzed O 0 2.094413503073156e-06
. O 0 2.1203368305577897e-06

The O 0 1.9273020370746963e-06
identification O 0 5.122902280163544e-07
of O 0 9.079071787709836e-07
two O 0 4.470593353289587e-07
frequent O 0 3.5354994452063693e-06
PDS B-Disease 0 8.262469782494009e-05
mutations O 0 5.414718984297906e-08
will O 0 3.2265350391469383e-09
facilitate O 0 2.531455933763027e-08
the O 0 6.990399725737007e-08
molecular O 0 3.9461850974475965e-05
diagnosis O 0 0.11848373711109161
of O 0 0.32972848415374756
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0002816052292473614

Insertional O 0 0.003846959676593542
mutation O 0 3.700989964272594e-06
by O 0 2.1320416010439658e-07
transposable O 0 2.698221396713052e-05
element O 0 5.081206381873926e-06
, O 0 6.844923063908936e-07
L1 O 0 1.5152988453337457e-05
, O 0 5.85972301792026e-08
in O 0 1.5693460397869785e-07
the O 0 9.505444040769362e-07
DMD B-Disease 1 0.9999990463256836
gene O 0 2.095184527206584e-06
results O 0 2.8655108508246485e-06
in O 0 7.1462950472778175e-06
X B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999282360076904
linked I-Disease 1 0.9955911636352539
dilated I-Disease 1 0.9999988079071045
cardiomyopathy I-Disease 1 1.0
. O 0 3.302047116449103e-05

X B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999969005584717
linked I-Disease 1 0.999975323677063
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 0.0007052818546071649
XLDCM B-Disease 1 0.9991850256919861
) O 0 8.164665246113145e-07
is O 0 1.017547219817061e-07
a O 0 3.806833035469026e-07
clinical O 0 5.305018203216605e-05
phenotype O 0 2.4848701286828145e-05
of O 0 1.7270760508836247e-05
dystrophinopathy B-Disease 0 0.00039606986683793366
which O 0 2.4214418203882815e-07
is O 0 4.1925744653781294e-08
characterized O 0 6.427683985066324e-08
by O 0 1.0150598583891224e-08
preferential O 0 1.8988699821420596e-06
myocardial B-Disease 1 0.9993429780006409
involvement I-Disease 0 1.7699467207421549e-06
without O 0 2.3470711596473848e-08
any O 0 9.695269476139856e-09
overt O 0 1.6470477248731186e-06
clinical O 0 8.422550308750942e-05
signs O 0 7.817660662112758e-05
of O 0 0.0013193261111155152
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0001499907812103629

To O 0 5.235917797108414e-07
date O 0 2.023394245043164e-06
, O 0 3.2594556387266493e-08
several O 0 1.0831111119102843e-08
mutations O 0 2.933674920768681e-07
in O 0 1.627911615287303e-06
the O 0 3.9809889130992815e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.0012895811814814806
, O 0 4.6406727051362395e-05
DMD O 1 1.0
, O 0 7.259457674990699e-07
have O 0 4.716401491577926e-08
been O 0 9.649722443327846e-08
identified O 0 7.675328816958427e-08
in O 0 1.809816581044288e-07
patients O 0 4.2914092546197935e-07
with O 0 1.3044586921751034e-07
XLDCM B-Disease 0 0.0004076949553564191
, O 0 1.516181526994842e-07
but O 0 1.562404250421423e-08
a O 0 3.390467995245672e-08
pathogenic O 0 1.1753790118973484e-07
correlation O 0 3.9803299500817957e-07
of O 0 8.078067708083836e-07
these O 0 1.886704126263794e-07
cardiospecific O 0 2.169826620956883e-05
mutations O 0 2.1752173324784962e-06
in O 0 1.2678588973358274e-05
DMD O 1 1.0
with O 0 3.3139328934339574e-06
the O 0 3.5307770303916186e-05
XLDCM B-Disease 0 0.0030710615683346987
phenotype O 0 6.894086982356384e-05
has O 0 4.325597274146276e-06
remained O 0 1.3021959603065625e-05
to O 0 7.968302639937974e-08
be O 0 6.264779699449718e-07
elucidated O 0 4.625588553608395e-05
. O 0 2.087099801428849e-06

We O 0 3.572844434529543e-05
report O 0 3.2170844406209653e-06
here O 0 3.238868941934925e-07
the O 0 6.71196715984479e-08
identification O 0 5.3873268512916184e-08
of O 0 5.963329385849647e-07
a O 0 8.211431463678309e-07
unique O 0 1.4894347941663e-06
de O 0 0.00021217465109657496
novo O 0 7.604494749102741e-05
L1 O 0 3.9453345380024984e-05
insertion O 0 1.8492764866095968e-06
in O 0 1.5265014781107311e-06
the O 0 1.7374469507558388e-06
muscle O 0 2.4569628749304684e-06
exon O 0 3.465847612460493e-06
1 O 0 1.9587821952882223e-05
in O 0 1.0034264960268047e-05
DMD O 1 0.9999998807907104
in O 0 1.2159001016698312e-05
three O 0 5.346684702089988e-06
XLDCM B-Disease 0 0.000370371388271451
patients O 0 7.228438789752545e-07
from O 0 1.6426869819952117e-07
two O 0 1.201220811708481e-07
unrelated O 0 1.2988036814931547e-06
Japanese O 0 2.119510099873878e-06
families O 0 4.133066511258221e-07
. O 0 8.921818448470731e-07

The O 0 0.00017129186016973108
insertion O 0 5.772306030848995e-05
was O 0 6.945663335500285e-05
a O 0 3.9870801629149355e-06
5 O 0 5.824128038511844e-06
- O 0 6.73747251767054e-07
truncated O 0 9.871258725979715e-07
form O 0 1.1720903358991563e-07
of O 0 2.129256927219103e-06
human O 0 6.969045443838695e-06
L1 O 0 3.1733296054881066e-05
inversely O 0 1.1255474419158418e-05
integrated O 0 1.0327074960514437e-05
in O 0 1.5501146890528616e-06
the O 0 1.8611943914947915e-06
5 O 0 7.126952368707862e-06
- O 0 2.423887053737417e-06
untranslated O 0 2.0238776414771564e-05
region O 0 2.3177426555776037e-06
in O 0 6.900937933096429e-06
the O 0 8.79826347954804e-06
muscle O 0 5.327967755874852e-06
exon O 0 2.225586740678409e-06
1 O 0 2.7975647753919475e-06
, O 0 2.3609899812981894e-08
which O 0 8.385996785875705e-09
affected O 0 1.7440818567138194e-08
the O 0 9.430449665615015e-08
transcription O 0 1.0511195114304428e-06
or O 0 4.776431410391524e-07
the O 0 4.97644180086354e-07
stability O 0 2.883031811506953e-06
of O 0 5.69122039451031e-06
the O 0 8.998047633212991e-06
muscle O 0 7.163858754211105e-06
form O 0 1.2509785847214516e-06
of O 0 9.284876796300523e-06
dystrophin O 0 4.403539605846163e-06
transcripts O 0 1.1084632660640636e-06
but O 0 1.2801198323586505e-08
not O 0 3.217427657631333e-09
that O 0 3.4844003238276855e-09
of O 0 7.238855346258788e-07
the O 0 1.673400947765913e-05
brain O 1 0.8290852308273315
or O 0 0.00011242165055591613
Purkinje O 0 0.0015057004056870937
cell O 0 0.00027338287327438593
form O 0 5.838175184180727e-06
, O 0 5.975261387902719e-07
probably O 0 8.405021958424186e-07
due O 0 8.055004059315252e-07
to O 0 2.3641712587618713e-08
its O 0 2.6533378161275323e-08
unique O 0 5.1978968684807114e-08
site O 0 3.484512376417115e-07
of O 0 6.957138793950435e-07
integration O 0 5.5028708629834e-06
. O 0 2.575277221694705e-06

We O 0 3.050531267945189e-05
speculate O 0 3.0301082460937323e-06
that O 0 3.131731318717357e-08
this O 0 3.09791552410843e-08
insertion O 0 3.887591617512953e-07
of O 0 8.959290767052153e-07
an O 0 4.2854790649471397e-07
L1 O 0 3.739620296983048e-05
sequence O 0 6.4628034124325495e-06
in O 0 4.7987177822506055e-05
DMD O 1 1.0
is O 0 7.620082669745898e-06
responsible O 0 1.6148458144016331e-06
for O 0 1.1485686712831011e-07
some O 0 5.739635433599233e-09
of O 0 1.1152956602700215e-07
the O 0 8.216384372872199e-08
population O 0 1.2021737383349773e-08
of O 0 1.0358863988813027e-07
Japanese O 0 2.4621795091661625e-06
patients O 0 1.064066736944369e-06
with O 0 2.37436012184844e-07
XLDCM B-Disease 0 0.00019778964633587748
. O 0 3.9392287476403e-07
. O 0 8.615746764917276e-07

Severe O 1 0.9995118379592896
early O 0 0.002966467756778002
- O 1 0.9999868869781494
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0025966414250433445
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.259663462638855
red O 1 0.999974250793457
hair O 1 0.9999966621398926
pigmentation O 1 0.999991774559021
caused O 1 0.8381599187850952
by O 0 5.591164153884165e-06
POMC O 0 0.0037435898557305336
mutations O 0 1.0099876135427621e-06
in O 0 1.1692250154737849e-06
humans O 0 1.9777762645389885e-06
. O 0 2.903337019688479e-07

Sequential O 0 0.0003924770571757108
cleavage O 0 0.0002828599826898426
of O 0 0.0002226550568593666
the O 0 4.886826718575321e-05
precursor O 0 7.28535742382519e-05
protein O 0 1.9094670278718695e-05
pre O 0 0.0001983488618861884
- O 0 0.00012249678547959775
pro O 0 0.0004827404336538166
- O 0 1.7824013411882333e-05
opiomelanocortin O 0 4.993818947696127e-05
( O 0 1.8246563513457659e-06
POMC O 0 9.163360664388165e-05
) O 0 2.3358086309599457e-07
generates O 0 2.8731264478665253e-07
the O 0 1.4650686352979392e-06
melanocortin O 0 0.00022872028057463467
peptides O 0 6.788878181396285e-06
adrenocorticotrophin O 0 7.547451241407543e-05
( O 0 7.700748938077595e-06
ACTH O 0 0.00016760335711296648
) O 0 2.96755570161622e-06
, O 0 2.25869302994397e-06
melanocyte O 0 0.00016704745939932764
- O 0 0.00010821453179232776
stimulating O 0 5.459781823446974e-05
hormones O 0 1.343965959677007e-05
( O 0 9.030273986354587e-07
MSH O 0 1.5449417333002202e-05
) O 0 1.9504410886383994e-07
alpha O 0 2.0001832581328927e-06
, O 0 5.203104791462465e-08
beta O 0 2.2328352144995733e-07
and O 0 1.9789636951372813e-07
gamma O 0 1.5497687400056748e-06
as O 0 1.658203103716005e-07
well O 0 5.7509474515882175e-08
as O 0 9.002511802691515e-08
the O 0 2.0002757139536698e-07
opioid O 0 2.1602647848339984e-06
- O 0 7.668143098271685e-07
receptor O 0 1.8428613657306414e-06
ligand O 0 6.190338353917468e-06
beta O 0 1.882912329165265e-05
- O 0 8.3463492046576e-06
endorphin O 0 3.912185275112279e-05
. O 0 4.5964554828969995e-07

While O 0 9.15095915843267e-06
a O 0 1.229094095833716e-06
few O 0 2.4659834707563277e-07
cases O 0 1.2178695669717854e-06
of O 0 8.936637459555641e-05
isolated O 1 0.5796030759811401
ACTH B-Disease 1 0.9999910593032837
deficiency I-Disease 1 0.9999798536300659
have O 0 3.7341956158343237e-06
been O 0 4.793494099430973e-06
reported O 0 4.140375040151412e-06
( O 0 3.133320205961354e-06
OMIM O 0 0.0004125262494198978
201400 O 0 9.126873919740319e-05
) O 0 3.220396592951147e-06
, O 0 2.3844152110541472e-06
an O 0 1.8550419554230757e-05
inherited O 1 0.9999916553497314
POMC O 1 1.0
defect O 1 0.9957737326622009
has O 0 1.8195049051428214e-05
not O 0 7.652349154341209e-07
been O 0 2.0558579763019225e-06
described O 0 1.1730783171515213e-06
so O 0 7.371232868536026e-08
far O 0 2.558327878432465e-07
. O 0 4.480205006984761e-07

Recent O 0 2.1447278413688764e-05
studies O 0 8.809396604192443e-06
in O 0 3.276965117038344e-06
animal O 0 2.0718500763905467e-06
models O 0 4.5479245613933017e-07
elucidated O 0 5.6222511375381146e-06
a O 0 1.3555227269534953e-06
central O 0 5.069357939646579e-06
role O 0 2.7253886401013006e-06
of O 0 6.497554568341002e-05
alpha O 0 0.00012102896289434284
- O 0 2.018261147895828e-05
MSH O 0 6.925180787220597e-05
in O 0 1.2202762036395143e-06
the O 0 6.116669055700186e-07
regulation O 0 4.3183987941119995e-07
of O 0 1.6891641507754684e-06
food O 0 1.3642130625157733e-06
intake O 0 5.157909299668972e-07
by O 0 2.791099440457856e-08
activation O 0 1.1398798278605682e-06
of O 0 1.5920380974421278e-05
the O 0 5.3736432164441794e-05
brain O 0 0.0015129275852814317
melanocortin O 0 0.0002537479158490896
- O 0 1.2073381185473409e-05
4 O 0 2.0832974769291468e-05
- O 0 2.0594216039171442e-06
receptor O 0 4.0778409129416104e-06
( O 0 1.0354078767704777e-06
MC4 O 0 5.213336044107564e-05
- O 0 4.583827376336558e-06
R O 0 5.980248715786729e-06
; O 0 1.5681953868806886e-07
refs O 0 2.718836412896053e-06
3 O 0 1.3518022115022177e-06
- O 0 2.1576508402176842e-07
5 O 0 3.0328121169986844e-07
) O 0 1.4101718015524511e-08
and O 0 1.6462665897165607e-08
the O 0 1.8833908654869447e-07
linkage O 0 2.9995342174515827e-06
of O 0 8.133687515510246e-06
human O 0 0.00019031166448257864
obesity B-Disease 1 0.9999885559082031
to O 0 5.356568522074667e-07
chromosome O 0 8.130359674396459e-06
2 O 0 1.0303988347004633e-05
in O 0 2.1156890852580545e-06
close O 0 3.070460934395669e-06
proximity O 0 2.321932925042347e-06
to O 0 3.126545493614685e-07
the O 0 6.207440947036957e-06
POMC O 0 0.0001885689707705751
locus O 0 2.04506595764542e-05
, O 0 3.683092586470593e-07
led O 0 3.542874082995695e-07
to O 0 7.837000381982762e-09
the O 0 4.085591953639778e-08
proposal O 0 3.342203669376431e-08
of O 0 2.467110107318149e-07
an O 0 3.846996889933507e-07
association O 0 1.224100401486794e-06
of O 0 2.0317650069046067e-06
POMC O 0 0.001747796661220491
with O 0 1.7659541526882094e-06
human O 0 0.0028483448550105095
obesity B-Disease 1 1.0
. O 0 7.60652028475306e-06

The O 0 1.694943603069987e-05
dual O 0 4.092263043276034e-05
role O 0 3.346427911310457e-05
of O 0 0.00042823332478292286
alpha O 0 0.00046590736019425094
- O 0 3.8845144445076585e-05
MSH O 0 8.243707270594314e-05
in O 0 6.487866244242468e-07
regulating O 0 5.829568181070499e-06
food O 0 4.396749773150077e-06
intake O 0 3.291499160695821e-05
and O 0 2.4481378204654902e-06
influencing O 0 7.327754428843036e-05
hair O 0 0.0017935315845534205
pigmentation O 0 0.0007585456478409469
predicts O 0 8.285252988571301e-06
that O 0 4.3141422878534286e-08
the O 0 3.937478254556481e-07
phenotype O 0 4.204741799185285e-06
associated O 0 3.8624915532636805e-07
with O 0 7.110050148639857e-08
a O 0 4.73172849524417e-06
defect O 0 1.257072563021211e-05
in O 0 3.273341917520156e-06
POMC O 0 0.0003795010270550847
function O 0 3.213864829376689e-06
would O 0 1.1139903222101566e-07
include O 0 2.816216920109582e-06
obesity B-Disease 1 1.0
, O 0 4.305461800413468e-07
alteration O 0 2.2439227905124426e-05
in O 0 2.469114406267181e-05
pigmentation O 1 0.9990608096122742
and O 0 0.009861954487860203
ACTH B-Disease 1 0.9999983310699463
deficiency I-Disease 1 0.9999995231628418
. O 0 1.4543131328537129e-05

The O 0 3.8154521462274715e-05
observation O 0 0.00019375333795323968
of O 0 2.1735131667810492e-05
these O 0 2.449424755468499e-06
symptoms O 0 0.0008394895121455193
in O 0 2.1893150915275328e-05
two O 0 2.569830712673138e-06
probands O 0 5.432152465800755e-05
prompted O 0 5.007939876122691e-07
us O 0 7.296689119584698e-08
to O 0 6.341345226701378e-09
search O 0 6.135445573818288e-08
for O 0 5.3677876366009514e-08
mutations O 0 4.029038791486528e-07
within O 0 4.429474529388244e-07
their O 0 1.0752172556749429e-06
POMC O 0 0.0006120007601566613
genes O 0 7.387062396446709e-06
. O 0 2.8497559014795115e-06

Patient O 0 0.003741758642718196
1 O 0 0.0004258056287653744
was O 0 0.00010648887109709904
found O 0 1.2691863275904325e-06
to O 0 9.382778642930134e-08
be O 0 1.9821879959636135e-07
a O 0 7.895696967352706e-07
compound O 0 9.751996913109906e-06
heterozygote O 0 5.108547156851273e-06
for O 0 4.1104408410319593e-07
two O 0 1.8966497350447753e-07
mutations O 0 3.487291735382314e-07
in O 0 3.611004785852856e-06
exon O 0 8.061189873842523e-06
3 O 0 3.608073529903777e-05
( O 0 3.728576530193095e-06
G7013T O 0 4.3759820982813835e-05
, O 0 1.7697221892376547e-06
C7133delta O 0 1.8998602172359824e-05
) O 0 7.876055718725183e-08
which O 0 1.4881207377470673e-08
interfere O 0 2.774951823880656e-08
with O 0 4.4010248778647565e-09
appropriate O 0 2.2256071474657801e-07
synthesis O 0 8.471996807202231e-06
of O 0 2.1126681531313807e-05
ACTH O 0 0.00019668854656629264
and O 0 2.33511564147193e-05
alpha O 0 0.0004610818577930331
- O 0 0.00010030160046881065
MSH O 0 0.0005334804300218821
. O 0 1.2597322438523406e-06

Patient O 0 0.00046829303028061986
2 O 0 7.037034083623439e-05
was O 0 1.0857982488232665e-05
homozygous O 0 7.168439424276585e-07
for O 0 1.171026724477997e-07
a O 0 3.964286179325427e-07
mutation O 0 1.0163097385884612e-07
in O 0 7.611836849719111e-07
exon O 0 2.8719016427203314e-06
2 O 0 9.465151379117742e-06
( O 0 7.323318982344063e-07
C3804A O 0 4.063283540745033e-06
) O 0 1.6419352277807775e-07
which O 0 3.907686050297343e-07
abolishes O 0 6.832481449237093e-05
POMC O 0 0.000978427822701633
translation O 0 0.0001062898154486902
. O 0 3.886096692440333e-06

These O 0 4.017168180325825e-07
findings O 0 1.886418061758377e-07
represent O 0 2.8227184145634965e-08
the O 0 1.4021472871661445e-08
first O 0 1.8855290662145308e-08
examples O 0 6.158260390520809e-08
of O 0 4.132483297780709e-07
a O 0 2.416122515569441e-05
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.999975323677063
within O 0 1.549972807879385e-06
the O 0 2.6183952286373824e-06
POMC O 0 0.00028196576749905944
gene O 0 2.1244264303277305e-07
and O 0 1.367776381044905e-08
define O 0 1.1928460708077182e-07
a O 0 1.38587296305559e-07
new O 0 6.223856416909257e-07
monogenic B-Disease 1 0.9999998807907104
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9721161723136902
resulting O 0 2.8519534112092515e-07
in O 0 2.1426532725854486e-07
early O 0 8.828917088976596e-06
- O 0 0.003706161165609956
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0010603363625705242
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.09479624778032303
red O 1 0.9881518483161926
hair O 1 0.9577487111091614
pigmentation O 0 0.07209861278533936
. O 0 1.398140739183873e-06
. O 0 1.1514447351146373e-06

A O 0 3.847539574053371e-06
European O 0 2.567988531154697e-06
multicenter O 0 0.0001236703246831894
study O 0 5.0551066124171484e-06
of O 0 0.0006369204493239522
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 6.122053946455708e-06
classification O 0 3.8300877349684015e-06
of O 0 6.975979886192363e-06
105 O 0 4.556894054985605e-05
mutations O 0 4.5649153435078915e-07
and O 0 2.7057222951043514e-07
a O 0 7.001333983680524e-07
general O 0 1.8161981643061154e-06
system O 0 9.624592394175124e-07
for O 0 1.0095824620748317e-07
genotype O 0 1.8364927427683142e-06
- O 0 8.123105885715631e-07
based O 0 1.692321518476092e-07
prediction O 0 4.088296009285841e-06
of O 0 4.398779765324434e-06
metabolic O 0 0.015671811997890472
phenotype O 0 0.0002029464958468452
. O 0 5.437313120637555e-06

Phenylketonuria B-Disease 1 0.9985106587409973
( O 0 0.0002769312122836709
PKU B-Disease 0 0.17905829846858978
) O 0 8.297335625684354e-06
and O 0 7.4654185482359026e-06
mild B-Disease 1 1.0
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9999996423721313
MHP B-Disease 1 1.0
) O 0 7.298140189959668e-06
are O 0 4.610609778410435e-07
allelic B-Disease 1 0.7414116263389587
disorders I-Disease 1 0.9999997615814209
caused O 0 3.7364397940109484e-06
by O 0 1.441813424207794e-08
mutations O 0 2.4648848295782955e-08
in O 0 8.124983708057698e-08
the O 0 3.2952371498140565e-07
gene O 0 9.068245958587795e-07
encoding O 0 6.364804448821815e-06
phenylalanine O 0 0.0001643619907554239
hydroxylase O 0 0.0002527981996536255
( O 0 1.9540935682016425e-05
PAH O 1 0.9717273116111755
) O 0 3.7316040106816217e-06
. O 0 7.130468588911754e-07

Previous O 0 1.7105339793488383e-05
studies O 0 7.327818138946895e-07
have O 0 2.1134491490215623e-08
suggested O 0 8.567166531747716e-09
that O 0 2.864750658915227e-10
the O 0 6.138205499439664e-09
highly O 0 7.719653183357877e-08
variable O 0 8.47401770442957e-06
metabolic O 0 0.017649168148636818
phenotypes O 0 0.0004765218182001263
of O 1 0.5306107401847839
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.002683296799659729
with O 0 0.0001781036116881296
PAH O 1 1.0
genotypes O 1 0.9492997527122498
. O 0 1.7203874449478462e-05

We O 0 8.179611540981568e-06
identified O 0 2.648777353897458e-06
both O 0 7.004092026363651e-07
causative O 0 2.364155079703778e-05
mutations O 0 1.7005188510665903e-06
in O 0 4.419130618771305e-06
686 O 0 0.00013081755605526268
patients O 0 2.1182006548770005e-06
from O 0 5.597094627773913e-07
seven O 0 1.7199062085637706e-06
European O 0 6.537244189530611e-06
centers O 0 1.640441951167304e-05
. O 0 2.407576175755821e-06

On O 0 6.0515612858580425e-06
the O 0 1.3240737928299495e-07
basis O 0 1.4336298193029506e-07
of O 0 2.2642541352979606e-07
the O 0 2.708092381453753e-07
phenotypic O 0 1.2808795872842893e-05
characteristics O 0 7.807857400621288e-06
of O 0 2.802058770612348e-05
297 O 0 0.00020645475888159126
functionally O 0 0.00011082812852691859
hemizygous O 0 0.00012988410890102386
patients O 0 2.983711283377488e-06
, O 0 4.5295462314243196e-07
105 O 0 6.501134976133471e-06
of O 0 3.207746885891538e-06
the O 0 1.3715377917833393e-06
mutations O 0 2.757141714937461e-07
were O 0 1.7090138726416626e-07
assigned O 0 5.020860882609668e-08
to O 0 6.0915996691335295e-09
one O 0 7.199733698115551e-09
of O 0 6.16846449474906e-08
four O 0 1.3051580083356384e-07
arbitrary O 0 3.955373358621728e-06
phenotype O 0 2.4748427676968277e-05
categories O 0 2.0418039639480412e-05
. O 0 2.400793846391025e-06

We O 0 1.728707502479665e-05
proposed O 0 3.3260498639720026e-06
and O 0 7.127259209482872e-07
tested O 0 1.2871142871517804e-06
a O 0 1.6742188790885848e-07
simple O 0 9.108404697144579e-08
model O 0 3.1814494150239625e-08
for O 0 4.988060631205826e-09
correlation O 0 1.497957526908067e-07
between O 0 2.357901109917293e-07
genotype O 0 1.086788302018249e-06
and O 0 1.936852385142629e-07
phenotypic O 0 2.8766202376573347e-05
outcome O 0 1.1921509212697856e-05
. O 0 3.0885046271578176e-06

The O 0 2.350043178012129e-05
observed O 0 2.6805122615769506e-05
phenotype O 0 2.8353579182294197e-05
matched O 0 7.455599643435562e-06
the O 0 3.8059506550780497e-06
predicted O 0 6.060195119061973e-06
phenotype O 0 1.4015183751325822e-06
in O 0 2.0519109966699034e-06
79 O 0 1.4657459360023495e-05
% O 0 6.443796110033873e-07
of O 0 2.7633514037006535e-06
the O 0 6.508994829346193e-06
cases O 0 1.4561259149559191e-06
, O 0 3.203627159109601e-07
and O 0 6.8810784625839e-08
in O 0 1.6918649237140926e-07
only O 0 4.0214988672460095e-08
5 O 0 6.388590918504633e-07
of O 0 4.97068356253294e-07
184 O 0 6.91313698553131e-06
patients O 0 2.3213062831928255e-06
was O 0 1.591311229276471e-05
the O 0 2.947375605799607e-06
observed O 0 1.1012194590875879e-05
phenotype O 0 5.019634500058601e-06
more O 0 7.107934862915499e-08
than O 0 9.659224531333166e-08
one O 0 1.1604618777028008e-07
category O 0 1.3986661997478222e-06
away O 0 2.049093978939709e-07
from O 0 6.170724020648777e-08
that O 0 1.806198390852387e-08
expected O 0 7.977546374604572e-07
. O 0 1.376861177959654e-06

Among O 0 9.571097507432569e-06
the O 0 2.188760163335246e-06
seven O 0 9.393895084031101e-07
contributing O 0 8.70002281772031e-07
centers O 0 5.918163878959604e-07
, O 0 1.5041667467130537e-08
the O 0 1.188902487569976e-08
proportion O 0 7.364599952097706e-08
of O 0 5.455776204144058e-07
patients O 0 8.157597903846181e-07
for O 0 5.904109912080457e-07
whom O 0 2.05554624699289e-06
the O 0 3.3489859561086632e-06
observed O 0 1.1465497664175928e-05
phenotype O 0 8.87856640474638e-06
did O 0 5.746462079514458e-07
not O 0 8.999130329812033e-08
match O 0 1.758618168423709e-06
the O 0 1.7753411611920455e-06
predicted O 0 2.664798103069188e-06
phenotype O 0 9.347907052870141e-07
was O 0 3.6266594634071225e-06
4 O 0 2.2775698198529426e-06
% O 0 3.112268984750699e-07
- O 0 4.034590972423757e-07
23 O 0 5.46859291716828e-06
% O 0 1.1958431969105732e-06
( O 0 1.5170696769928327e-06
P O 0 0.0004108818247914314
< O 0 5.5344815336866304e-05
. O 0 1.719679858069867e-06
0001 O 0 0.0002899954852182418
) O 0 1.5637017725111946e-07
, O 0 9.38068112077417e-09
suggesting O 0 9.77472147667413e-09
that O 0 3.4569397344696995e-10
differences O 0 1.38710676278464e-09
in O 0 1.627568124717982e-08
methods O 0 3.8765140430996325e-08
used O 0 6.695217535934717e-08
for O 0 1.2156537820828817e-07
mutation O 0 3.0492722089547897e-06
detection O 0 2.5521641873638146e-05
or O 0 9.239095561497379e-06
phenotype O 0 3.740430111065507e-05
classification O 0 5.181295819056686e-06
may O 0 2.4387654207203013e-07
account O 0 6.469229596461901e-09
for O 0 7.014785641246135e-09
a O 0 1.6456356277672057e-08
considerable O 0 9.112609689054807e-08
proportion O 0 2.4404760097240796e-06
of O 0 2.7164180210093036e-05
genotype O 0 0.000658856239169836
- O 0 0.0007609769236296415
phenotype O 0 8.071194315562025e-05
inconsistencies O 0 2.0624227545340545e-05
. O 0 2.9071513836242957e-06

Our O 0 3.536636722856201e-05
data O 0 6.022325578669552e-06
indicate O 0 6.638980721618282e-06
that O 0 1.1399351933505386e-06
the O 0 5.878473530174233e-05
PAH O 1 0.9999991655349731
- O 0 4.1559185774531215e-05
mutation O 0 3.259580694248143e-07
genotype O 0 2.328395822814855e-07
is O 0 3.909726320472373e-09
the O 0 1.0933646876765124e-08
main O 0 5.574109422923357e-07
determinant O 0 4.435774826561101e-06
of O 0 1.6997615830405266e-06
metabolic O 0 0.004970855545252562
phenotype O 0 4.533436822384829e-06
in O 0 4.0121830124917324e-07
most O 0 3.0502303616231075e-07
patients O 0 4.784127213497413e-06
with O 0 1.0457010830577929e-05
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 4.124093902646564e-05

In O 0 1.4387113878910895e-05
the O 0 1.3598084933619248e-06
present O 0 3.2904165436775656e-07
study O 0 4.2717326209640305e-07
, O 0 7.989776662498116e-08
the O 0 1.678159264884016e-07
classification O 0 3.827644832199439e-06
of O 0 3.4431592212058604e-05
105 O 0 0.0019043047213926911
PAH O 1 0.9997990727424622
mutations O 0 2.1773719254269963e-06
may O 0 1.4754344874745584e-06
allow O 0 6.586240175465718e-08
the O 0 4.6443034307230846e-07
prediction O 0 5.735152171837399e-06
of O 0 1.4976417332945857e-06
the O 0 3.997256044385722e-06
biochemical O 0 3.4821732697309926e-05
phenotype O 0 1.6047632016125135e-05
in O 0 1.6992195014609024e-05
> O 0 2.6391222490929067e-05
10 O 0 1.0352230674470775e-05
, O 0 1.84452653684275e-06
000 O 0 2.3601882276125252e-05
genotypes O 0 2.119741475326009e-05
, O 0 2.712269235871645e-07
which O 0 4.416558496700418e-08
may O 0 7.212808128542747e-08
be O 0 6.212456327148175e-09
useful O 0 1.02273816082743e-08
for O 0 1.503025437443739e-08
the O 0 1.6684202819305938e-07
management O 0 1.426079734301311e-06
of O 0 5.050365416536806e-06
hyperphenylalaninemia B-Disease 1 0.9999990463256836
in O 0 3.815895979641937e-05
newborns O 0 0.00022165843984112144
. O 0 6.1810533225070685e-06

Somatic O 0 0.0005549053312279284
instability O 0 0.0002682272170204669
of O 0 7.602058030897751e-05
the O 0 4.217652531224303e-05
CTG O 0 0.0007858055178076029
repeat O 0 1.2437587429303676e-05
in O 0 6.170792858029017e-06
mice O 0 1.9677618183777668e-05
transgenic O 0 9.896303708956111e-06
for O 0 3.2372061014029896e-06
the O 0 0.00018308739527128637
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.00012626768148038536
is O 0 2.5075062239920953e-06
age O 0 1.8184841792390216e-06
dependent O 0 3.047642564979469e-07
but O 0 7.066998986005046e-09
not O 0 2.770529361484364e-09
correlated O 0 4.513436380193525e-08
to O 0 3.692402827937258e-09
the O 0 6.47756621674489e-08
relative O 0 3.6056196677236585e-06
intertissue O 0 2.207197030656971e-05
transcription O 0 3.5979719541501254e-05
levels O 0 1.3346701962291263e-05
and O 0 1.8064899904857157e-06
proliferative O 0 0.028147069737315178
capacities O 0 0.0007764461333863437
. O 0 1.055662869475782e-05

A O 0 0.0021322607062757015
( O 0 5.5650285503361374e-05
CTG O 0 0.0007874862640164793
) O 0 5.705970124836313e-06
nexpansion O 0 7.375467976089567e-05
in O 0 5.083950327389175e-06
the O 0 7.404441021208186e-06
3 O 0 1.8770784663502127e-05
- O 0 5.4403058129537385e-06
untranslated O 0 5.6438915635226294e-05
region O 0 2.7393871278036386e-06
( O 0 8.202469530260714e-07
UTR O 0 3.3012820495059714e-05
) O 0 1.8316950445296243e-07
of O 0 2.8234533147042384e-06
the O 0 2.541853245929815e-05
DM O 1 0.9999991655349731
protein O 0 5.453552876133472e-05
kinase O 0 2.231136750197038e-05
gene O 0 2.3950767626956804e-06
( O 0 7.298163495761401e-07
DMPK O 0 1.0357463906984776e-05
) O 0 2.5209038412299378e-08
is O 0 7.918680822172064e-09
responsible O 0 9.154227598173748e-08
for O 0 8.822645440886845e-07
causing O 1 0.9391650557518005
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0004015433951281011
DM B-Disease 1 1.0
) O 0 1.985156995942816e-05
. O 0 3.597976956370985e-06

Major O 1 0.5886885523796082
instability O 0 0.0143533730879426
, O 0 4.10207439927035e-06
with O 0 1.7478275537996524e-07
very O 0 7.686082881264156e-08
large O 0 1.1955280854181183e-07
expansions O 0 5.145096793057746e-07
between O 0 2.309723186044721e-07
generations O 0 1.7069143609660387e-07
and O 0 9.087269603469394e-08
high O 0 2.247813426947687e-06
levels O 0 1.33205844576878e-06
of O 0 1.1746903965104138e-06
somatic O 0 1.6024172509787604e-05
mosaicism O 0 6.078561636968516e-05
, O 0 1.2205444477331184e-07
is O 0 3.1199267169768063e-08
observed O 0 2.4872144877008395e-07
in O 0 5.156955467100488e-07
patients O 0 1.4737215678906068e-06
. O 0 6.002447889841278e-07

There O 0 3.408597331144847e-05
is O 0 3.565656015780405e-06
a O 0 1.8261082459503086e-06
good O 0 1.0554820164543344e-06
correlation O 0 1.8659948182175867e-06
between O 0 2.396093350398587e-06
repeat O 0 3.508280997266411e-06
size O 0 1.234693399965181e-06
( O 0 2.9175370741540974e-07
at O 0 7.774382879688346e-07
least O 0 1.796012760735266e-08
in O 0 1.017046642459718e-07
leucocytes O 0 6.4076980379468296e-06
) O 0 7.87221026143925e-08
, O 0 1.2067937760207315e-08
clinical O 0 1.5717859014330315e-06
severity O 0 2.4837470391503302e-06
and O 0 2.679397255178628e-07
age O 0 3.854653641610639e-06
of O 0 1.2500038792495616e-05
onset O 0 0.23825524747371674
. O 0 2.043654785666149e-05

The O 0 4.195572546450421e-05
trinucleotide O 0 0.0012387835886329412
repeat O 0 3.787754394579679e-05
instability O 0 1.4269940947997384e-05
mechanisms O 0 4.628408987628063e-06
involved O 0 6.847482723060239e-07
in O 0 4.859132332057925e-06
DM B-Disease 1 1.0
and O 0 6.850970635241538e-07
other O 0 1.0346793715143576e-06
human O 0 0.04036807641386986
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 3.0154473051879904e-07
unknown O 0 2.597387037894805e-06
. O 0 2.160111165494527e-07

We O 0 1.3043500075582415e-05
studied O 0 8.047185110626742e-05
somatic O 0 0.00011583734158193693
instability O 0 4.511896622716449e-05
by O 0 1.508271338934719e-06
measuring O 0 0.00023453486210200936
the O 0 2.995458635268733e-05
CTG O 0 0.00018323810945730656
repeat O 0 3.296847580713802e-06
length O 0 1.4306090179161401e-06
at O 0 3.7607346712320577e-06
several O 0 4.1777827419764435e-08
ages O 0 4.910187954010325e-07
in O 0 1.6815828018934553e-07
various O 0 5.147879846845171e-07
tissues O 0 1.2273767424630933e-05
of O 0 2.3311993572860956e-05
transgenic O 0 3.336505324114114e-05
mice O 0 7.5922284850094e-06
carrying O 0 4.759911462315358e-06
a O 0 4.548550805338891e-06
( O 0 2.054072638202342e-06
CTG O 0 6.352164200507104e-05
) O 0 5.643011036227108e-07
55expansion O 0 1.1033133887394797e-05
surrounded O 0 3.475207677183789e-06
by O 0 9.710577586474756e-08
45 O 0 1.743468828863115e-06
kb O 0 1.483375581301516e-05
of O 0 1.244764916918939e-05
the O 0 4.2560357542242855e-05
human O 0 0.00045594372204504907
DM B-Disease 1 1.0
region O 0 5.637602953356691e-05
, O 0 1.6999205172396614e-06
using O 0 6.897384992043953e-07
small O 0 1.3748916671829647e-06
- O 0 3.3405551675969036e-06
pool O 0 9.574438990966883e-06
PCR O 0 8.22581205284223e-06
. O 0 1.2223412113598897e-06

These O 0 2.5012153855641373e-05
mice O 0 2.0861823941231705e-05
have O 0 1.3702511125757155e-07
been O 0 4.736260805771053e-08
shown O 0 4.469761805125927e-08
to O 0 5.731430441358043e-09
reproduce O 0 4.349579185713992e-08
the O 0 5.565988203670713e-08
intergenerational O 0 1.2409699365889537e-06
and O 0 2.3313398855862033e-07
somatic O 0 7.832632036297582e-06
instability O 0 1.0577458851912525e-05
of O 0 2.1255533283692785e-05
the O 0 3.557005766197108e-05
55 O 0 0.00019878544844686985
CTG O 0 0.0006639199564233422
repeat O 0 1.2108595001336653e-05
suggesting O 0 2.432399242024985e-06
that O 0 4.738926762115625e-08
surrounding O 0 4.915247586723126e-07
sequences O 0 3.4277985605513095e-07
and O 0 2.7039089900426916e-07
the O 0 7.997252851055237e-07
chromatin O 0 2.4334710815310245e-06
environment O 0 3.2096147606353043e-07
are O 0 1.0639278791302331e-08
involved O 0 2.383731967370295e-08
in O 0 4.96598318022734e-07
instability O 0 1.3647735613631085e-05
mechanisms O 0 1.63420700118877e-05
. O 0 5.038021754444344e-06

As O 0 1.3715241948375478e-05
observed O 0 2.9330808501981664e-06
in O 0 5.814010819449322e-07
some O 0 4.7341657705146645e-08
of O 0 1.7170528963106335e-06
the O 0 5.954968401056249e-06
tissues O 0 1.853549838415347e-05
of O 0 0.00012708180292975157
DM B-Disease 1 1.0
patients O 0 8.561614959035069e-05
, O 0 3.39049478270681e-07
there O 0 9.848721305161234e-08
is O 0 1.1998845650396106e-07
a O 0 2.0148030444033793e-07
tendency O 0 3.463167388417787e-07
for O 0 1.9705416320903169e-07
repeat O 0 7.872267815400846e-07
length O 0 2.4050493721006205e-06
and O 0 4.014734713564394e-06
somatic O 0 3.0204000722733326e-05
mosaicism O 0 3.8291796954581514e-05
to O 0 5.274869963045603e-08
increase O 0 6.513184303003072e-08
with O 0 1.5670153175051382e-08
the O 0 3.86405389463107e-07
age O 0 1.217850922330399e-06
of O 0 3.757708782359259e-06
the O 0 8.050464202824514e-06
mouse O 0 1.965010778803844e-05
. O 0 1.5947026668072795e-06

Furthermore O 0 7.763451139908284e-05
, O 0 5.249687546893256e-07
we O 0 2.4745132165548966e-08
observed O 0 5.172953621013221e-08
no O 0 1.1622301343550134e-08
correlation O 0 1.0919750081939128e-07
between O 0 1.0963471908098654e-07
the O 0 3.9202726043185976e-07
somatic O 0 2.3874167709436733e-06
mutation O 0 4.593234734784346e-07
rate O 0 4.763721790368436e-06
and O 0 1.5788602922839345e-06
tissue O 0 0.00012735671771224588
proliferation O 0 0.0001698183041298762
capacity O 0 6.628852133871987e-05
. O 0 2.896535761465202e-06

The O 0 0.0003303305711597204
somatic O 0 0.0003344207361806184
mutation O 0 1.4930718862160575e-05
rates O 0 8.820282346277963e-06
in O 0 2.0000632048322586e-06
different O 0 2.1130144034486875e-07
tissues O 0 3.3756093671399867e-06
were O 0 6.472712925642554e-07
also O 0 6.474651570442802e-08
not O 0 1.1228169505272945e-08
correlated O 0 1.8442065652379824e-07
to O 0 4.2231850017060424e-08
the O 0 5.563535410146869e-07
relative O 0 1.8858740077121183e-05
inter O 0 5.9218593378318474e-05
- O 0 8.232938853325322e-06
tissue O 0 1.1795983709816937e-06
difference O 0 2.6585561840875016e-07
in O 0 2.609087630389695e-07
transcriptional O 0 3.3947890187846497e-06
levels O 0 2.283773028466385e-06
of O 0 2.757517449936131e-06
the O 0 3.6845226532022934e-06
three O 0 1.8836365143215517e-06
genes O 0 2.3527422854385804e-06
( O 0 3.1192328151519177e-06
DMAHP O 0 4.990810339222662e-05
, O 0 1.8200786371380673e-06
DMPK O 0 4.167639053775929e-05
and O 0 1.596842366780038e-06
59 O 0 1.4153652955428697e-05
) O 0 1.381036298653271e-07
surrounding O 0 4.3076178712908586e-07
the O 0 8.925767360778991e-07
repeat O 0 2.907057250922662e-06
. O 0 3.8297483229143836e-07
. O 0 6.292166858656856e-07

A O 0 3.802669743890874e-05
novel O 0 1.3047207175986841e-05
missense O 0 5.441018220153637e-05
mutation O 0 2.038526872638613e-06
in O 0 8.001578066796355e-07
patients O 0 1.2305730479056365e-06
from O 0 4.759026523970533e-07
a O 0 1.3918241847932222e-06
retinoblastoma B-Disease 0 0.0003635602770373225
pedigree O 0 6.490455689345254e-06
showing O 0 2.149475903934217e-06
only O 0 1.3221722383605083e-07
mild O 0 2.0695311832241714e-05
expression O 0 6.060963642084971e-06
of O 0 6.062085049052257e-06
the O 0 1.8345202988712117e-05
tumor B-Disease 0 0.054693374782800674
phenotype O 0 4.5555814722320065e-05
. O 0 1.115853592636995e-06

We O 0 1.4011004168423824e-05
have O 0 6.669547474302817e-07
used O 0 3.969817612414772e-07
single O 0 2.805998065014137e-07
strand O 0 1.2123107353545493e-06
conformation O 0 5.469529469337431e-07
polymorphism O 0 3.6144737691756745e-07
analysis O 0 3.739223330967434e-08
to O 0 1.9287782038190926e-08
study O 0 8.651853988794755e-08
the O 0 8.03229056600685e-07
27 O 0 1.277590672543738e-05
exons O 0 7.6204169090487994e-06
of O 0 4.499152510106796e-06
the O 0 8.177989002433605e-06
RB1 O 0 7.692998042330146e-05
gene O 0 1.6785160994459147e-07
in O 0 5.407349945585338e-08
individuals O 0 5.25656806971142e-09
from O 0 3.414199767348691e-08
a O 0 1.2390891868108156e-07
family O 0 1.8645330612798716e-07
showing O 0 4.998224540031515e-06
mild O 0 5.625364065053873e-05
expression O 0 6.0130064412078355e-06
of O 0 7.869170076446608e-06
the O 0 1.3644625141751021e-05
retinoblastoma B-Disease 0 0.0025516755413264036
phenotype O 0 0.00021764794655609876
. O 0 4.059333150507882e-06

In O 0 2.2348249331116676e-05
this O 0 1.0035250852524769e-06
family O 0 1.4510260371025652e-06
affected O 0 1.113574398914352e-06
individuals O 0 2.656842923443037e-07
developed O 0 9.659114766691346e-06
unilateral B-Disease 1 0.8477324843406677
tumors I-Disease 1 1.0
and O 0 9.57038537308108e-06
, O 0 1.4831795169811812e-07
as O 0 4.186932400784826e-08
a O 0 5.487843424134553e-08
result O 0 1.1737257210597818e-07
of O 0 6.854512548670755e-07
linkage O 0 1.0727759217843413e-05
analysis O 0 1.2143021876909188e-06
, O 0 7.68916038396128e-07
unaffected O 0 6.24389531367342e-06
mutation O 0 2.151794262772455e-07
carriers O 0 1.6873674724138255e-07
were O 0 2.047175797770251e-07
also O 0 5.1434874137612496e-08
identified O 0 7.366144672005248e-08
within O 0 1.5154371624248597e-07
the O 0 8.813512408778479e-07
pedigree O 0 1.6391673852922395e-05
. O 0 1.4274485238274792e-06

A O 0 0.0002490550687070936
single O 0 1.7314363503828645e-05
band O 0 1.0290416867064778e-05
shift O 0 3.3886724395415513e-06
using O 0 2.00829731511476e-06
SSCP O 0 0.00017441174713894725
was O 0 1.5671545043005608e-05
identified O 0 3.456825368175487e-07
in O 0 3.0837728104415874e-07
exon O 0 6.038832793819893e-07
21 O 0 1.7858013734439737e-06
which O 0 1.5105925399439002e-08
resulted O 0 1.7060941104318772e-07
in O 0 4.949303047396825e-07
a O 0 1.147356101682817e-06
missense O 0 8.396446901315358e-06
mutation O 0 1.439847892470425e-06
converting O 0 1.1196239029231947e-05
a O 0 9.344001227873378e-06
cys O 0 6.337981903925538e-05
- O 0 5.998292635922553e-06
- O 0 3.5821760775434086e-06
> O 0 2.462989868945442e-06
arg O 0 2.6227489797747694e-06
at O 0 4.869003532803617e-06
nucleotide O 0 7.203513519016269e-07
position O 0 9.179681001114659e-06
28 O 0 3.607990947784856e-05
in O 0 4.357403213361977e-06
the O 0 7.513451691920636e-06
exon O 0 1.8529170120018534e-05
. O 0 2.0968516309949337e-06

The O 0 0.00010780112643260509
mutation O 0 2.096829302900005e-05
destroyed O 0 0.0002052543277386576
an O 0 2.327836909898906e-06
NdeI O 0 0.0001295884430874139
restriction O 0 9.75981220108224e-06
enzyme O 0 4.127467036596499e-06
site O 0 3.56121086042549e-06
. O 0 7.06483092471899e-07

Analysis O 0 6.619047780986875e-06
of O 0 8.707960660103709e-06
all O 0 7.711587386438623e-07
family O 0 3.148727216739644e-07
members O 0 6.725782242256173e-08
demonstrated O 0 1.3538741541196941e-06
that O 0 6.04179888341605e-08
the O 0 8.553876114092418e-07
missense O 0 1.5066214473336004e-05
mutation O 0 7.613807156303665e-06
co O 0 3.0384966521523893e-05
- O 0 7.718415872659534e-06
segregated O 0 2.185649918828858e-06
with O 0 2.0158601898856432e-07
patients O 0 1.2755210264003836e-05
with O 0 3.677108543342911e-05
tumors B-Disease 1 1.0
or O 0 0.2272813469171524
who O 0 4.244769570505014e-06
, O 0 1.0020526275411612e-07
as O 0 7.082466169094914e-08
a O 0 1.2178841757304326e-07
result O 0 3.3401619248252246e-07
of O 0 2.074428039122722e-06
linkage O 0 7.900405762484297e-06
analysis O 0 5.181011601962382e-07
had O 0 1.1608996146605932e-06
been O 0 1.026117502078705e-06
predicted O 0 5.884463689653785e-07
to O 0 1.1052321724491776e-08
carry O 0 8.14888423406046e-08
the O 0 7.012907872194774e-07
predisposing O 0 5.809759022668004e-05
mutation O 0 5.806480658065993e-06
. O 0 4.762190656038001e-06

These O 0 4.498002908803755e-06
observations O 0 1.7166310499305837e-05
point O 0 1.1947799976042006e-05
to O 0 1.4418951366224064e-07
another O 0 1.9544573603980098e-07
region O 0 5.261019282443158e-07
of O 0 3.6433161767490674e-06
the O 0 2.2337297195917927e-05
RB1 O 0 0.00030515508842654526
gene O 0 1.5232004670906463e-06
where O 0 6.190441013131931e-07
mutations O 0 9.981859250274283e-08
only O 0 3.391716418832402e-08
modify O 0 2.69467967939363e-08
the O 0 1.1339052718994935e-07
function O 0 1.2214567277624155e-06
of O 0 8.981037353805732e-07
the O 0 1.0650037438608706e-06
gene O 0 3.705457345404284e-07
and O 0 7.701064674847657e-08
raise O 0 3.897710953992828e-08
important O 0 5.893753396435386e-08
questions O 0 6.286480669359662e-08
for O 0 4.4405474852737825e-08
genetic O 0 5.654404731103568e-07
counseling O 0 3.402051049761212e-07
in O 0 1.2032937490857876e-07
families O 0 2.5113104484830728e-08
with O 0 1.4007465409804354e-08
these O 0 4.7309342221524275e-08
distinctive O 0 1.6461996210637153e-06
phenotypes O 0 3.6157466638542246e-06
. O 0 2.2907545371708693e-07
. O 0 4.2784554921126983e-07

Maternal B-Disease 0 0.019116748124361038
disomy I-Disease 1 0.9975103139877319
and O 0 0.1965615302324295
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9999027252197266
with O 0 1.4100528460403439e-06
gamete O 0 0.08857736736536026
complementation O 0 0.007956995628774166
in O 0 1.709530351945432e-06
a O 0 8.862144795784843e-07
case O 0 7.593405939587683e-07
of O 0 4.1004709601111244e-06
familial O 0 5.497481834026985e-05
translocation O 0 4.2845462303375825e-05
( O 0 3.705694098243839e-06
3 O 0 6.5176723182958085e-06
; O 0 1.95621026932713e-07
15 O 0 1.9835258626699215e-06
) O 0 1.4808219361839292e-07
( O 0 1.6187561868719058e-07
p25 O 0 3.996661234850762e-06
; O 0 1.251147523362306e-07
q11 O 0 2.9766060833935626e-06
. O 0 1.2814432182040036e-07
2 O 0 5.497080110217212e-06
) O 0 3.986499166330759e-07
. O 0 5.358785983844427e-07

Maternal B-Disease 1 0.999450147151947
uniparental I-Disease 1 0.9999788999557495
disomy I-Disease 1 0.9999279975891113
( I-Disease 0 0.0047113923355937
UPD I-Disease 1 1.0
) I-Disease 0 2.1587698938674293e-05
for I-Disease 0 5.489279374160105e-06
chromosome I-Disease 0 0.00014058491797186434
15 I-Disease 0 3.904436016455293e-05
is O 0 4.3318124198776786e-07
responsible O 0 8.810506813006214e-08
for O 0 1.0399144656503267e-08
an O 0 4.414206777880736e-09
estimated O 0 7.545514435491896e-09
30 O 0 1.72001239917563e-08
% O 0 4.032057354663721e-09
of O 0 5.922169865613114e-09
cases O 0 5.011675696664497e-08
of O 0 2.406450585112907e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999344348907471
PWS B-Disease 1 1.0
) O 0 1.575771784700919e-05
. O 0 1.7659879176790128e-06

We O 0 2.2238842575461604e-05
report O 0 2.812180582623114e-06
on O 0 1.5967053741405834e-06
an O 0 1.1093975160747505e-07
unusual O 0 4.434318441326468e-07
case O 0 9.096648341255786e-07
of O 0 5.168355983187212e-06
maternal B-Disease 0 0.0011201126035302877
disomy I-Disease 0 0.02287697046995163
15 I-Disease 0 0.0032881812658160925
in O 0 0.0008080147090367973
PWS B-Disease 1 1.0
that O 0 2.1216740151430713e-06
is O 0 5.29283965988725e-07
most O 0 7.01576468031817e-08
consistent O 0 2.0230092445672199e-07
with O 0 2.189856651568789e-08
adjacent O 0 2.305868065377581e-06
- O 0 5.666767037837417e-07
1 O 0 5.110071924718795e-06
segregation O 0 1.980966317205457e-06
of O 0 1.6809331100375857e-06
a O 0 3.985027888120385e-06
paternal O 0 7.607266161357984e-05
t O 0 2.0732115444843657e-05
( O 0 6.221221724445058e-07
3 O 0 1.7991486629398423e-06
; O 0 7.038429572503446e-08
15 O 0 1.0780747743410757e-06
) O 0 1.0488169266409386e-07
( O 0 1.7467210966515268e-07
p25 O 0 4.941025963489665e-06
; O 0 7.668583634767856e-08
q11 O 0 9.923927564159385e-07
. O 0 1.9727108835354557e-08
2 O 0 2.645203096562909e-07
) O 0 3.163078243773043e-09
with O 0 1.4361586364586287e-09
simultaneous O 0 3.1004183256300166e-06
maternal O 0 0.00020334629516582936
meiotic O 0 0.000509920995682478
nondisjunction O 0 0.0003114327846560627
for O 0 4.901769898424391e-06
chromosome O 0 0.00013553151802625507
15 O 0 5.454109123093076e-05
. O 0 3.1882702842267463e-06

The O 0 0.0001612224878044799
patient O 0 0.000148500083014369
( O 0 1.0511353139008861e-05
J O 0 0.00025041395565494895
. O 0 1.3214653336035553e-06
B O 0 1.4255535461416002e-05
. O 0 1.1805680344423308e-07
) O 0 1.1587753334652007e-07
, O 0 1.2471103616462642e-07
a O 0 1.1680525631163619e-06
17 O 0 1.5620187696185894e-05
- O 0 3.96216137232841e-06
year O 0 7.942088814161252e-06
- O 0 8.576800610171631e-06
old O 0 2.3788006728864275e-05
white O 0 1.966555828403216e-06
male O 0 5.3670887609769125e-06
with O 0 2.385099833190907e-06
PWS B-Disease 1 1.0
, O 0 1.0437483069836162e-05
was O 0 1.7249756638193503e-05
found O 0 2.2177549396928953e-07
to O 0 5.523263268969458e-08
have O 0 2.6199563762929756e-07
47 O 0 6.693112482025754e-06
chromosomes O 0 1.6724775377952028e-06
with O 0 4.397981570036791e-07
a O 0 1.2804497600882314e-05
supernumerary O 0 0.0009948351653292775
, O 0 3.428829131735256e-06
paternal O 0 4.7258388804038987e-05
der O 0 0.0006866204785183072
( O 0 5.936507250225986e-07
15 O 0 1.1759221933971276e-06
) O 0 3.397543579808371e-08
consisting O 0 1.8297239989806258e-07
of O 0 4.762063781527104e-06
the O 0 2.0513421986834146e-05
short O 0 4.542618989944458e-05
arm O 0 0.0001343464682577178
and O 0 6.518754616990918e-06
the O 0 2.5680996259325184e-05
proximal O 0 0.00044522565440274775
long O 0 1.2774358765454963e-05
arm O 0 7.4894423960358836e-06
of O 0 2.3358541056950344e-06
chromosome O 0 1.8748993170447648e-05
15 O 0 1.8329026715946384e-05
, O 0 8.810260965219641e-07
and O 0 2.5460806227783905e-06
distal O 0 0.0005547225009649992
chromosome O 0 0.03371690958738327
arm O 0 0.002003546804189682
3p O 0 0.010469489730894566
. O 0 1.2681297448580153e-05

The O 0 0.0007912494475021958
t O 0 0.00014410506992135197
( O 0 2.884489276766544e-06
3 O 0 1.1309260116831865e-05
; O 0 1.7914989314249397e-07
15 O 0 1.9357494238647632e-06
) O 0 1.5003064390839427e-07
was O 0 1.240419692294381e-06
present O 0 1.0843434239404814e-07
in O 0 1.401931086775221e-07
the O 0 9.900629294179453e-08
balanced O 0 7.5107415398179e-08
state O 0 3.021209593612184e-08
in O 0 1.7724606493629835e-07
the O 0 7.405687938444316e-07
patients O 0 1.1045535757148173e-06
father O 0 4.717787305708043e-06
and O 0 1.1201600500498898e-06
a O 0 6.371247764036525e-06
sister O 0 4.817278386326507e-05
. O 0 3.916127752745524e-06

Fluorescent O 0 0.00012095108831999823
in O 0 5.326113750925288e-06
situ O 0 2.153329478460364e-05
hybridization O 0 4.745611192902288e-07
analysis O 0 1.1569456859206184e-07
demonstrated O 0 8.269436762020632e-07
that O 0 1.613308313608286e-07
the O 0 1.3506860341294669e-05
PWS B-Disease 1 0.9999997615814209
critical O 0 6.03688858973328e-05
region O 0 1.165956291515613e-05
resided O 0 4.67066747660283e-05
on O 0 2.4962137104012072e-05
the O 0 7.742213711026125e-06
derivative O 0 2.6725818315753713e-05
chromosome O 0 8.541603165213019e-06
3 O 0 1.0892352293012664e-05
and O 0 1.95308615502654e-07
that O 0 6.294183663158037e-08
there O 0 1.598983487838268e-07
was O 0 2.3522843548562378e-06
no O 0 2.2007564837167592e-07
deletion O 0 2.942151922979974e-06
of O 0 1.705715294519905e-05
the O 0 5.448910451377742e-05
PWS B-Disease 1 0.9999994039535522
region O 0 2.358228448429145e-05
on O 0 3.826354441116564e-05
the O 0 7.340383490372915e-06
normal O 0 1.683631126070395e-05
pair O 0 1.631892473596963e-06
of O 0 2.008871888392605e-06
15s O 0 2.097197102557402e-05
present O 0 1.6941186231633765e-06
in O 0 1.804410931072198e-05
J O 0 0.0020949754398316145
. O 0 6.1782775446772575e-06

B O 0 0.011940007098019123
. O 0 3.7706286093452945e-05

Methylation O 0 0.00011169748904649168
analysis O 0 8.737358257349115e-06
at O 0 3.961406400776468e-05
exon O 0 6.014107384544332e-06
alpha O 0 1.0221530828857794e-05
of O 0 2.4197875063691754e-06
the O 0 2.9003642794123152e-06
small O 0 2.51300525633269e-06
nuclear O 0 3.425774411880411e-05
ribonucleoprotein O 0 0.0002452506741974503
- O 0 1.3951697837910615e-05
associated O 0 4.823047675017733e-06
polypeptide O 0 3.4278655220987275e-05
N O 0 8.17617546999827e-05
( O 0 1.8594575976749184e-06
SNRPN O 0 3.78249169443734e-05
) O 0 3.3751896921785374e-07
gene O 0 3.3249068565055495e-07
showed O 0 8.035163432396075e-07
a O 0 3.0543287721229717e-07
pattern O 0 9.90141984402726e-07
characteristic O 0 4.461410867406812e-07
of O 0 4.0785110400065605e-07
only O 0 6.728271273459541e-08
the O 0 1.7777372818272852e-07
maternal O 0 1.0528498023631983e-05
chromosome O 0 1.0720703357947059e-05
15 O 0 1.8800306861521676e-05
in O 0 1.2973135198990349e-05
J O 0 0.0016296453541144729
. O 0 4.585742317431141e-06

B O 0 0.008586520329117775
. O 0 3.842033402179368e-05

Maternal B-Disease 0 0.01213170774281025
disomy I-Disease 0 0.001914139138534665
was O 0 1.8236252799397334e-05
confirmed O 0 4.684056023052108e-07
by O 0 1.9860872058075074e-08
polymerase O 0 1.3763072956862743e-06
chain O 0 4.256933436863619e-07
reaction O 0 5.219883547624704e-08
analysis O 0 1.1387402132356783e-08
of O 0 4.0843966075954086e-07
microsatellite O 0 6.7207179199613165e-06
repeats O 0 1.1063942110922653e-05
at O 0 5.381171649787575e-05
the O 0 5.032634362578392e-06
gamma O 0 2.2971429643803276e-05
- O 0 9.947011676558759e-06
aminobutyric O 0 3.0402763513848186e-05
acid O 0 1.1858357993332902e-06
receptor O 0 2.4982734885270474e-06
beta3 O 0 2.1879541236557998e-05
subunit O 0 5.038776180299465e-06
( O 0 3.358516778462217e-06
GABRB3 O 0 8.977114339359105e-05
) O 0 1.6499733419550466e-06
locus O 0 3.366822420503013e-05
. O 0 2.6436850930622313e-06

A O 0 0.0018178003374487162
niece O 0 0.0019465364748612046
( O 0 2.514006700948812e-05
B O 0 7.875282608438283e-05
. O 0 3.4212342825412634e-07
B O 0 4.188001639704453e-06
. O 0 2.8701133913955346e-08
) O 0 1.2547927141781656e-08
with O 0 1.2451798703239092e-08
45 O 0 9.75144530457328e-07
chromosomes O 0 4.335635424013162e-07
and O 0 3.8471543462037516e-07
the O 0 2.1753005512437085e-06
derivative O 0 1.03420861705672e-05
3 O 0 5.505862645804882e-06
but O 0 1.4415913085485954e-07
without O 0 2.1033297059602774e-07
the O 0 1.5309919945138972e-06
der O 0 0.00013593702169600874
( O 0 3.6523957192002854e-07
15 O 0 1.0389201179350493e-06
) O 0 1.0864509647490195e-07
demonstrated O 0 9.043262139130093e-07
a O 0 5.662742523782072e-07
phenotype O 0 1.6619377447568695e-06
consistent O 0 2.9165190085223003e-07
with O 0 1.2234365520669144e-08
that O 0 1.9403866957645732e-08
reported O 0 3.6878583387078834e-07
for O 0 2.390997906331904e-07
haploinsufficiency O 0 2.7988378860754892e-05
of O 0 1.5083781363500748e-05
distal O 0 0.00040887386421673
3 O 0 0.0006837861146777868
p O 0 0.0011470862664282322
. O 0 4.492472726269625e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999998807907104
associated O 0 0.00037016949499957263
with O 0 4.936688128509559e-06
unbalanced O 0 0.003267646534368396
segregation O 0 0.00024740429944358766
of O 0 0.000237334577832371
non O 0 0.002132226014509797
- O 0 0.0003305057471152395
Robertsonian O 0 0.0007052422151900828
translocations O 0 0.00011641072342172265
has O 0 2.0102968846913427e-05
been O 0 1.764713306329213e-05
reported O 0 1.359070392936701e-05
previously O 0 1.0143679901375435e-05
but O 0 5.163992682355456e-07
has O 0 7.280561931111151e-07
not O 0 1.1556918622090961e-07
, O 0 8.14944414173624e-08
to O 0 3.885404353809463e-08
our O 0 2.0832094094203057e-07
knowledge O 0 6.54151449452911e-07
, O 0 9.921726018546906e-08
been O 0 7.874808716223924e-08
observed O 0 1.1513839837107298e-07
in O 0 1.0188406918132387e-07
a O 0 2.6698830879468005e-07
case O 0 8.265951123576087e-07
of O 0 2.9686245397897437e-05
PWS B-Disease 1 1.0
. O 0 2.8251071853446774e-05

Furthermore O 0 0.0004853983991779387
, O 0 4.239574991515838e-06
our O 0 3.272921844654775e-07
findings O 0 1.329689638396303e-07
are O 0 1.719307007874704e-08
best O 0 2.021064737789402e-08
interpreted O 0 4.8861402035527135e-08
as O 0 2.995018277829331e-08
true O 0 2.0479902218539792e-07
gamete O 0 1.0858168025151826e-05
complementation O 0 3.85578277928289e-05
resulting O 0 2.3720906483504223e-06
in O 0 5.755683105235221e-06
maternal B-Disease 1 0.7887651920318604
UPD I-Disease 1 1.0
15 I-Disease 0 0.020018447190523148
and O 0 0.0006662398809567094
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9959661960601807
- I-Disease 1 0.9999721050262451
Jampel I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
type I-Disease 1 0.8871985077857971
2 I-Disease 1 0.9874147772789001
and O 0 0.00017682737961877137
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 7.819055554136867e-07
a O 0 2.6469541580809164e-07
case O 0 1.4962455452405266e-07
for O 0 1.1931896892747318e-07
" O 0 1.3663197933055926e-06
lumping O 0 3.771369165406213e-06
" O 0 6.999938250373816e-06
. O 0 1.2264362112546223e-06

Recent O 0 1.2257310118002351e-05
studies O 0 3.988821845268831e-06
demonstrated O 0 1.1515213373058941e-05
the O 0 1.3076937648293097e-06
existence O 0 1.973600774363149e-06
of O 0 1.693335093477799e-06
a O 0 1.8032196749118157e-06
genetically O 0 4.5244345869832614e-07
distinct O 0 7.476509722437186e-08
, O 0 3.8062154317231034e-08
usually O 0 1.770351687468974e-08
lethal O 0 7.27800824051883e-08
form O 0 2.1183687692882813e-08
of O 0 8.758279363973998e-07
the O 0 5.443975169328041e-06
Schwartz B-Disease 0 0.002364853397011757
- I-Disease 1 0.9917786717414856
Jampel I-Disease 1 0.999955415725708
syndrome I-Disease 1 1.0
( O 0 4.989544322597794e-05
SJS B-Disease 1 0.9976486563682556
) O 0 2.839756007233518e-06
of O 0 0.00012523213808890432
myotonia B-Disease 1 1.0
and O 1 0.9999730587005615
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 2.638223668327555e-05
which O 0 3.466350335656898e-06
we O 0 8.426394515481661e-07
called O 0 6.614316134800902e-06
SJS B-Disease 0 0.0014217698480933905
type I-Disease 0 1.3632866284751799e-05
2 I-Disease 0 3.6330020520836115e-05
. O 0 1.9789495127042755e-06

This O 0 2.651364411576651e-05
disorder O 1 0.9960097074508667
is O 0 1.0925193691946333e-06
reminiscent O 0 2.6863181119551882e-06
of O 0 6.280152433646435e-07
another O 0 4.2957131540788396e-07
rare O 0 2.1077864857943496e-06
condition O 0 0.0001428981777280569
, O 0 1.178143634206208e-06
the O 0 1.0844343705684878e-05
Stuve B-Disease 1 0.9989110231399536
- I-Disease 1 0.9999996423721313
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0028441818431019783
SWS B-Disease 1 0.9999207258224487
) O 0 1.1814099707407877e-06
, O 0 8.251610950082977e-08
which O 0 6.950620701218213e-08
comprises O 0 3.0293513191281818e-06
campomelia B-Disease 0 0.0008768087718635798
at O 0 0.0013577200006693602
birth O 0 0.0012269392609596252
with O 0 1.791047179722227e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 3.6533579987008125e-05
contractures B-Disease 0 0.0150349922478199
, O 0 2.261668754499624e-07
and O 0 9.223121821833047e-08
early B-Disease 0 1.1175053487022524e-06
death I-Disease 0 1.811637412174605e-05
. O 0 1.3020478490943788e-06

To O 0 1.984894197448739e-06
test O 0 1.7234362985618645e-06
for O 0 4.7253246293621487e-07
possible O 0 3.0371850243682275e-06
nosologic O 0 0.0003500652383081615
identity O 0 2.537402679081424e-06
between O 0 6.282145022851182e-06
these O 0 4.3007444219256286e-06
disorders O 0 0.4463004171848297
, O 0 2.8347724878585723e-07
we O 0 2.5923329260990613e-08
reviewed O 0 1.266889597673071e-07
the O 0 1.8650308675205451e-07
literature O 0 8.660610433253169e-07
and O 0 1.9043200438773056e-07
obtained O 0 1.8718534420258948e-06
a O 0 2.075773636533995e-06
follow O 0 3.526242267071211e-07
- O 0 7.661689096494229e-07
up O 0 2.459194092807593e-07
of O 0 3.8516955669365416e-07
the O 0 2.355091908157192e-07
only O 0 1.2795588588687679e-07
two O 0 3.145248683722457e-07
surviving O 0 6.220222985575674e-06
patients O 0 1.2174328958280967e-06
, O 0 2.565442684954178e-07
one O 0 1.9482567381601257e-07
with O 0 1.417199229081234e-07
SJS B-Disease 0 0.0002914653450716287
type I-Disease 0 2.18752848013537e-05
2 I-Disease 0 8.038916712393984e-05
at O 0 2.196270361309871e-05
age O 0 1.3222444295024616e-06
10 O 0 8.125105068756966e-07
years O 0 2.3596511766754702e-07
and O 0 8.453384481299508e-08
another O 0 1.5849190049266326e-07
with O 0 1.6805633151761867e-07
SWS B-Disease 0 0.00020763724751304835
at O 0 4.915556473861216e-06
age O 0 1.4728125279361848e-06
7 O 0 1.249400793312816e-05
years O 0 1.1618852795436396e-06
. O 0 5.980267019367602e-07

Patients O 0 9.805824811337516e-05
reported O 0 6.8092513174633496e-06
as O 0 9.292745062339236e-07
having O 0 7.974162144819275e-06
either O 0 0.00011255315621383488
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.00019158305076416582
SWS B-Disease 0 0.35504528880119324
presented O 0 1.46029634606748e-07
a O 0 5.5977999124934286e-08
combination O 0 3.744118970416821e-08
of O 0 7.973517313075718e-08
a O 0 7.428868116221565e-07
severe O 0 0.10819447040557861
, O 0 9.462824550610094e-07
prenatal O 1 0.9999982118606567
- O 1 0.999971866607666
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 3.568135070963763e-05
with O 0 1.2979929124412593e-05
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999990463256836
respiratory O 1 1.0
and O 0 0.023533008992671967
feeding O 0 0.4639858603477478
difficulties O 0 0.00024018235853873193
, O 0 1.7234330016435706e-06
tendency O 0 4.103244464204181e-06
to O 0 1.0122884077645722e-06
hyperthermia B-Disease 0 0.00035228830529376864
, O 0 3.029374795460171e-08
and O 0 1.5877624548465974e-08
frequent O 0 9.267064626783394e-08
death O 0 3.2594796266494086e-06
in O 0 9.501845852355473e-07
infancy O 0 6.42747909296304e-06
) O 0 2.8009333519207757e-08
with O 0 5.463787200454817e-09
a O 0 3.5955579846813635e-07
distinct O 0 8.95746416063048e-06
campomelic B-Disease 1 0.9550446271896362
- I-Disease 1 0.9999831914901733
metaphyseal I-Disease 1 0.9999971389770508
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 6.648134149145335e-05

The O 0 3.6387430100148777e-06
similarity O 0 4.898531642538728e-06
of O 0 1.1015850759577006e-05
the O 0 7.566871772723971e-06
clinical O 0 0.00013451259292196482
and O 0 3.504408596199937e-06
radiographic O 0 0.00045925844460725784
findings O 0 1.5349012755905278e-05
is O 0 1.6450744624307845e-06
so O 0 1.0896967950202452e-07
extensive O 0 2.7858902740263147e-06
that O 0 1.6339745343429968e-06
these O 0 4.771896783495322e-06
disorders O 1 0.9999420642852783
appear O 0 3.9122005546232685e-06
to O 0 9.908298892469247e-08
be O 0 1.3342422278128652e-07
a O 0 3.2308724939866806e-07
single O 0 5.110605343361385e-07
entity O 0 3.3638957575021777e-06
. O 0 2.3348472950601717e-06

The O 0 0.00032311162794940174
follow O 0 9.723448783915956e-06
- O 0 3.8366606531781144e-06
up O 0 1.7487379011527082e-07
observation O 0 1.721652324704337e-06
of O 0 1.0623202939541443e-07
an O 0 2.0584595361583524e-08
identical O 0 6.883375647248613e-08
and O 0 1.7913087901888503e-08
unique O 0 2.3508418678375165e-07
pattern O 0 2.6125435397261754e-05
of O 0 0.0011613871902227402
progressive O 1 0.9999998807907104
bone B-Disease 1 0.9999998807907104
dysplasia I-Disease 1 0.9999175071716309
in O 0 4.725739563582465e-05
the O 0 1.5357183656306006e-05
two O 0 1.5672596873628208e-06
patients O 0 1.323232140748587e-06
( O 0 2.2148002187805105e-07
one O 0 1.6457147467008326e-07
with O 0 1.264763795916224e-07
SJS B-Disease 0 0.0012258148053660989
type I-Disease 0 3.915701017831452e-05
2 I-Disease 0 8.997871918836609e-05
, O 0 3.6505326761471224e-07
one O 0 1.807906784279112e-07
with O 0 2.6527817453825264e-07
SWS B-Disease 0 0.0008983701700344682
) O 0 1.1349129636073485e-06
surviving O 0 5.6500562095607165e-06
beyond O 0 1.5552437616861425e-05
infancy O 0 1.6786321793915704e-05
adds O 0 1.533149998067529e-07
to O 0 1.0248490944775313e-08
the O 0 2.1991573007085208e-08
evidence O 0 2.08803783152689e-08
in O 0 6.640151184456045e-08
favor O 0 1.9263450212747557e-07
of O 0 5.643059921567328e-07
identity O 0 1.4171588418321335e-06
. O 0 1.913733740366297e-06

The O 0 0.00011780771455960348
hypothesis O 0 5.818407953483984e-05
that O 0 4.7105490921239834e-06
SWS B-Disease 0 0.01915336214005947
and O 0 4.385427382658236e-05
SJS B-Disease 1 0.9991475343704224
type I-Disease 0 0.0004219653201289475
2 I-Disease 0 0.00026786382659338415
are O 0 2.385292532380845e-07
the O 0 5.897520622966113e-07
same O 0 2.3075267563399393e-06
disorder O 0 0.0003156574093736708
should O 0 8.773179160925793e-08
be O 0 1.5883864890042787e-08
testable O 0 1.002257121740513e-07
by O 0 5.819988935229503e-09
molecular O 0 4.261409856098908e-07
methods O 0 1.7789464834550017e-07
. O 0 1.1678014999461084e-07
. O 0 6.399414473889919e-07

A O 0 9.108192898565903e-06
mouse O 0 1.3049144627075293e-06
model O 0 8.636454396082627e-08
of O 0 3.3331517101942154e-07
severe O 1 0.9999762773513794
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9990322589874268
defects O 1 0.9999872446060181
in O 0 6.380364357028157e-05
hemostasis O 1 0.9995693564414978
and O 0 6.012368612573482e-05
thrombosis B-Disease 1 0.9999992847442627
. O 0 1.4361000467033591e-05

von B-Disease 0 0.035811711102724075
Willebrand I-Disease 1 0.999983549118042
factor I-Disease 0 0.00039816717617213726
( I-Disease 0 7.238020043587312e-05
vWf I-Disease 1 0.7868906259536743
) I-Disease 0 0.0023566540330648422
deficiency I-Disease 1 1.0
causes O 1 0.999990701675415
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.9999988079071045
humans O 0 0.00025869611999951303
. O 0 1.3247902188595617e-06

We O 0 8.800177056400571e-06
generated O 0 3.667691316877608e-06
a O 0 1.8760622424451867e-06
mouse O 0 1.3810285963700153e-06
model O 0 1.3669541942817887e-07
for O 0 1.2398783333367192e-08
this O 0 1.4639992329534834e-08
disease O 0 3.206940846212092e-07
by O 0 1.8067248808151248e-09
using O 0 3.133726877990739e-08
gene O 0 2.4204098281188635e-07
targeting O 0 1.1016385315087973e-06
. O 0 6.506194267785759e-07

vWf B-Disease 0 0.11231710016727448
- I-Disease 1 0.9992620348930359
deficient I-Disease 1 0.9972832202911377
mice O 0 0.00023450756270904094
appeared O 0 2.900854087783955e-05
normal O 0 5.39713328180369e-05
at O 0 2.074283293040935e-05
birth O 0 2.649242105690064e-06
; O 0 2.4444345214647e-08
they O 0 8.020722752632992e-09
were O 0 1.1928619869649992e-07
viable O 0 2.2833583557257953e-07
and O 0 3.081224235756963e-07
fertile O 0 1.0644113899616059e-05
. O 0 1.7276589687753585e-06

Neither O 0 0.0006902802851982415
vWf O 0 0.00897059217095375
nor O 0 0.001054886495694518
vWf O 0 0.004408166743814945
propolypeptide O 0 0.005211344920098782
( O 0 0.00010336278501199558
von B-Disease 1 0.6821865439414978
Willebrand I-Disease 1 0.9994713664054871
antigen O 0 0.0025135669857263565
II O 1 0.9999493360519409
) O 0 2.9808500130457105e-06
were O 0 8.365956318812096e-07
detectable O 0 2.7117359877593117e-06
in O 0 5.517745194083545e-07
plasma O 0 5.906182195758447e-06
, O 0 1.6820463599742652e-07
platelets O 0 2.0060747374373022e-06
, O 0 2.1261736549149646e-07
or O 0 5.940839855611557e-07
endothelial O 0 3.807896518992493e-06
cells O 0 1.874687285408072e-07
of O 0 2.2699946100601665e-07
the O 0 9.313434929936193e-07
homozygous O 0 1.1355104106769431e-05
mutant O 0 4.704314051195979e-05
mice O 0 2.3488892111345194e-05
. O 0 6.402747771971917e-07

The O 0 0.00010857133020181209
mutant O 0 0.0005654351552948356
mice O 0 0.00037143603549338877
exhibited O 0 0.0035360963083803654
defects O 0 0.20836417376995087
in O 0 4.361660558060976e-06
hemostasis O 0 0.00028290069894865155
with O 0 2.7946106229137513e-07
a O 0 7.515236120525515e-06
highly O 0 8.665353379910812e-05
prolonged O 1 0.9999468326568604
bleeding O 1 0.9999995231628418
time O 0 8.159946446539834e-06
and O 0 1.478568606216868e-06
spontaneous O 0 2.6627720217220485e-05
bleeding O 0 5.9571571910055354e-05
events O 0 1.111165772726963e-07
in O 0 4.773808370828192e-08
approximately O 0 2.536017973397975e-08
10 O 0 1.2388528602969018e-07
% O 0 1.1335311000948423e-07
of O 0 1.0844287317013368e-06
neonates O 0 8.860615344019607e-05
. O 0 4.918173090118216e-06

As O 0 6.515720997413155e-06
in O 0 1.2198363492643693e-06
the O 0 3.70693851436954e-06
human O 0 3.9216312870848924e-05
disease O 0 4.762216121889651e-05
, O 0 1.964711486834858e-07
the O 0 5.526919153453491e-07
factor O 0 1.5843960454731132e-06
VIII O 0 0.0009210040443576872
level O 0 0.0006359353428706527
in O 0 9.601320016372483e-06
these O 0 4.771214321408479e-07
mice O 0 4.708528649643995e-06
was O 0 2.989364929817384e-06
reduced O 0 7.384981017821701e-07
strongly O 0 1.3861770753464953e-07
as O 0 1.1100409835762548e-07
a O 0 7.147237823801333e-08
result O 0 6.622645543075123e-08
of O 0 1.8810322899298626e-07
the O 0 2.2344777050875564e-07
lack O 0 5.842146606482856e-07
of O 0 4.2483355855438276e-07
protection O 0 1.5157810366872582e-06
provided O 0 5.466786774377397e-07
by O 0 5.63309072276752e-07
vWf O 0 0.00012849958147853613
. O 0 6.386522727552801e-06

Defective O 1 0.9998892545700073
thrombosis B-Disease 1 0.9999958276748657
in O 0 0.0004406419466249645
mutant O 0 0.0002688514650799334
mice O 0 1.990597775147762e-05
was O 0 2.347298277527443e-06
also O 0 4.4046295499811094e-08
evident O 0 6.015776676804307e-08
in O 0 2.3611612220975076e-08
an O 0 8.27292900851262e-09
in O 0 1.0289293328469284e-07
vivo O 0 9.74503291217843e-06
model O 0 1.8794036122926627e-06
of O 0 3.3366963180014864e-05
vascular B-Disease 1 1.0
injury I-Disease 1 0.9999991655349731
. O 0 3.925571218132973e-05

In O 0 3.46280139638111e-05
this O 0 7.396878913823457e-07
model O 0 2.6310585781175178e-06
, O 0 4.461449236714543e-07
the O 0 1.8956059193442343e-06
exteriorized O 0 9.235108154825866e-05
mesentery O 0 0.00014133789227344096
was O 0 6.942651089048013e-05
superfused O 0 8.236776920966804e-05
with O 0 1.450941567782138e-06
ferric O 0 0.0002423864498268813
chloride O 0 4.4452634028857574e-05
and O 0 4.672996055887779e-06
the O 0 1.1923714737349655e-05
accumulation O 0 7.022968929959461e-05
of O 0 5.034679270465858e-05
fluorescently O 0 0.00026317007723264396
labeled O 0 8.418439392698929e-06
platelets O 0 5.741845143347746e-06
was O 0 1.5960812334014918e-06
observed O 0 6.132883640930231e-07
by O 0 1.1442578085052446e-07
intravital O 0 2.581981425464619e-05
microscopy O 0 2.4181163098546676e-05
. O 0 2.30648834076419e-06

We O 0 4.633160642697476e-06
conclude O 0 1.581603214617644e-06
that O 0 2.3369041812770774e-08
these O 0 2.5153898519647555e-08
mice O 0 1.6503558981639799e-06
very O 0 3.055138364516097e-08
closely O 0 3.1537277322968293e-07
mimic O 0 6.722379475831985e-05
severe O 1 0.9995313882827759
human O 1 0.9999567270278931
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.001176284160465002
will O 0 1.5258233361237217e-06
be O 0 7.857359918261864e-08
very O 0 6.206830160948584e-09
useful O 0 7.167616722369985e-09
for O 0 4.131211372992993e-09
investigating O 0 5.496818111794255e-09
the O 0 1.9087231351022638e-08
role O 0 1.393543982430856e-07
of O 0 1.3456950682666502e-06
vWf O 0 1.8364720745012164e-05
in O 0 4.183359578746604e-06
normal O 0 3.836650648736395e-05
physiology O 0 0.0001292685337830335
and O 0 8.86832481228339e-07
in O 0 2.7894020604435354e-06
disease O 0 5.318051262293011e-05
models O 0 1.0853030971702537e-06
. O 0 9.767288844386712e-08
. O 0 6.683517312922049e-07

Oral O 0 0.0005043017445132136
contraceptives O 0 7.612316403537989e-05
and O 0 1.0331140742891876e-07
the O 0 2.375612666583038e-07
risk O 0 5.1542738219723105e-06
of O 0 0.00029770657420158386
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5985513527994044e-05

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9976897239685059
Study O 0 1.6684738511685282e-05
Group O 0 2.5921829092112603e-06
. O 0 7.338490490838012e-07

BACKGROUND O 0 0.00039945257594808936
Women O 0 7.542023467976833e-06
with O 0 1.2192647602660145e-07
mutations O 0 5.868424182153831e-07
in O 0 1.2118633776481147e-06
either O 0 5.915777023801638e-07
the O 0 1.051792423822917e-06
BRCA1 O 0 3.855322574963793e-06
or O 0 7.159837309700379e-07
the O 0 4.263433766027447e-07
BRCA2 O 0 3.273479251220124e-06
gene O 0 9.298828729242814e-08
have O 0 6.393958695838364e-09
a O 0 1.6104975131270294e-08
high O 0 4.224756366966176e-07
lifetime O 0 3.1631755064154277e-06
risk O 0 7.718717824900523e-06
of O 0 0.0021221069619059563
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5364024875452742e-05

Oral O 0 0.009305750951170921
contraceptives O 0 0.3072197437286377
protect O 0 0.00020670391677413136
against O 1 0.999998927116394
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 0.02872481383383274
general O 0 0.0003382205031812191
, O 0 2.0993848011130467e-06
but O 0 1.2994139808597538e-07
it O 0 4.9861228035297245e-08
is O 0 1.0388365012659051e-07
not O 0 3.6589494101235687e-08
known O 0 1.7876062941013515e-07
whether O 0 1.1474241112807704e-08
they O 0 3.6944034498276324e-09
also O 0 1.2080442424178273e-08
protect O 0 2.033193524653143e-08
against O 0 1.1148298995067307e-07
hereditary B-Disease 0 0.000777845794800669
forms I-Disease 0 6.486380152637139e-05
of I-Disease 1 0.9999840259552002
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.4564047887688503e-05

METHODS O 0 2.3827105906093493e-05
We O 0 5.679573291672568e-07
enrolled O 0 4.387045009934809e-06
207 O 0 1.0381336323916912e-05
women O 0 8.913289093470667e-07
with O 0 2.523440116419806e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.378740752348676e-06
161 O 0 4.83494250147487e-06
of O 0 5.0645066949073225e-06
their O 0 1.0068985147881904e-06
sisters O 0 3.096373620792292e-05
as O 0 3.956040927732829e-06
controls O 0 4.178869403403951e-06
in O 0 2.155562469852157e-06
a O 0 2.9613559036079096e-06
case O 0 2.3370437247649534e-06
- O 0 2.1255784758977825e-06
control O 0 1.7632195294936537e-06
study O 0 5.534440674637153e-07
. O 0 7.32256467017578e-07

All O 0 4.189579613012029e-06
the O 0 3.2440887025586562e-06
patients O 0 9.213590033141372e-07
carried O 0 6.712646154483082e-07
a O 0 5.056425038674206e-07
pathogenic O 0 1.9493397758196807e-06
mutation O 0 5.390882620304183e-07
in O 0 1.808460297070269e-06
either O 0 1.0841527000593487e-06
BRCA1 O 0 2.0581885564752156e-06
( O 0 8.195323175641533e-07
179 O 0 2.3296781819226453e-06
women O 0 8.695610063114145e-07
) O 0 2.993056682498718e-07
or O 0 1.0204134923696984e-06
BRCA2 O 0 3.0821695418126183e-06
( O 0 1.015638872559066e-06
28 O 0 4.632492709788494e-05
women O 0 2.3630411760677816e-06
) O 0 7.89446175986086e-07
. O 0 8.007578458091302e-07

The O 0 0.0003592926077544689
control O 0 0.00017151853535324335
women O 0 4.474757588468492e-06
were O 0 1.1624749731709016e-06
enrolled O 0 2.08627193387656e-06
regardless O 0 3.982623297815735e-07
of O 0 9.251520509678812e-07
whether O 0 2.0681964940649777e-07
or O 0 7.135604391805828e-07
not O 0 3.107953006065145e-08
they O 0 1.299758078943114e-08
had O 0 2.7846766670336365e-07
either O 0 2.5586257379472954e-07
mutation O 0 1.6785910474936827e-06
. O 0 1.0709682101150975e-06

Lifetime O 0 0.0009152788552455604
histories O 0 0.00012831382628064603
of O 0 0.00023149652406573296
oral O 0 0.0011201832676306367
- O 0 0.0001048368721967563
contraceptive O 0 2.2288822947302833e-05
use O 0 3.2193295851357107e-07
were O 0 1.041780592458963e-06
obtained O 0 1.3186858041080995e-06
by O 0 2.512465755444282e-07
interview O 0 1.243288238583773e-06
or O 0 1.9561805686407752e-07
by O 0 1.4463222619554017e-08
written O 0 2.239941210291363e-08
questionnaire O 0 2.8741233393247967e-08
and O 0 5.198809560624795e-08
were O 0 2.0400524647357088e-07
compared O 0 8.235602990680491e-07
between O 0 9.68985318650084e-07
patients O 0 1.7782489294404513e-06
and O 0 4.6088248950582056e-07
control O 0 8.591495316068176e-06
women O 0 7.446409426847822e-07
, O 0 6.339679003986021e-08
after O 0 1.1577933634043802e-07
adjustment O 0 2.0889865481876768e-07
for O 0 1.828842322026958e-08
year O 0 1.045778716957102e-07
of O 0 4.4176374558446696e-07
birth O 0 1.0462476893735584e-05
and O 0 2.0437282728380524e-06
parity O 0 6.0885693528689444e-05
. O 0 2.5342058052046923e-06

RESULTS O 0 5.415301347966306e-05
The O 0 1.6984977264655754e-06
adjusted O 0 1.3640214092447422e-05
odds O 0 1.7765605662134476e-05
ratio O 0 0.0001408640091540292
for O 0 0.0014070970937609673
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.2404897208616603e-06
with O 0 3.1453325277652766e-08
any O 0 4.934842934289918e-08
past O 0 1.8442750615577097e-07
use O 0 3.5018778987705446e-08
of O 0 5.635326374431315e-07
oral O 0 2.765342651400715e-05
contraceptives O 0 7.099705544533208e-05
was O 0 4.1561088437447324e-05
0 O 0 2.490064980520401e-05
. O 0 7.42145402909955e-07

5 O 0 0.00011157582048326731
( O 0 6.265386218728963e-06
95 O 0 4.957392593496479e-05
percent O 0 3.0072022127569653e-05
confidence O 0 4.070820068591274e-05
interval O 0 1.4953533536754549e-05
, O 0 7.549066367573687e-07
0 O 0 8.23021650830924e-07
. O 0 1.5072712855612735e-08
3 O 0 1.594632834667209e-07
to O 0 1.6760328236387068e-08
0 O 0 2.3263649495675054e-07
. O 0 1.4891173627518128e-08
8 O 0 1.8652066273716628e-06
) O 0 2.4598014647381206e-07
. O 0 2.871871913612267e-07

The O 0 3.982086491305381e-05
risk O 0 6.025088623573538e-06
decreased O 0 9.76918909145752e-06
with O 0 9.717874505099644e-09
increasing O 0 1.4653771529538062e-07
duration O 0 1.9828657968901098e-06
of O 0 2.7118421712657437e-06
use O 0 1.0083485904033296e-06
( O 0 2.441351398374536e-06
P O 0 5.804962711408734e-05
for O 0 4.916569764645828e-07
trend O 0 2.8073868634237442e-06
, O 0 1.2968810381153162e-07
< O 0 9.102965918827977e-07
0 O 0 5.498718564922456e-07
. O 0 2.4945110865814968e-08
001 O 0 2.37129438573902e-06
) O 0 5.7158768385079384e-08
; O 0 2.4953866528676372e-08
use O 0 8.470493639833876e-08
for O 0 9.439318660042773e-07
six O 0 3.3900817015819484e-06
or O 0 1.2262069049029378e-06
more O 0 2.864677206559918e-08
years O 0 2.1063829080958385e-07
was O 0 1.1378932640582207e-06
associated O 0 2.891051842368597e-08
with O 0 3.836080342267678e-09
a O 0 9.256430644200009e-08
60 O 0 4.913176212539838e-07
percent O 0 5.455167411128059e-07
reduction O 0 5.03668218243547e-07
in O 0 1.434463001714903e-06
risk O 0 1.1151504622830544e-05
. O 0 2.5315316634078044e-06

Oral O 0 0.004584856331348419
- O 0 0.00023564169532619417
contraceptive O 0 0.0001228821638505906
use O 0 9.953870403478504e-07
protected O 0 0.00015606656961608678
against O 1 0.725200891494751
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 2.9361098086155835e-07
for O 0 1.085158629621219e-07
carriers O 0 1.3340209648049495e-07
of O 0 1.7093004771595588e-06
the O 0 5.1707961574720684e-06
BRCA1 O 0 1.0360140549892094e-05
mutation O 0 7.656254297216947e-07
( O 0 2.5687330662549357e-07
odds O 0 1.7445582898290013e-06
ratio O 0 9.787771659830469e-07
, O 0 7.842027827109632e-08
0 O 0 1.967084983789391e-07
. O 0 4.246607510083322e-09
5 O 0 1.6268673164177017e-07
; O 0 4.8515016004557765e-08
95 O 0 1.90151206425071e-06
percent O 0 3.4931272239191458e-06
confidence O 0 7.0505079747817945e-06
interval O 0 4.2042283894261345e-06
, O 0 4.501975752191356e-07
0 O 0 7.346864663304586e-07
. O 0 2.074101779214743e-08
3 O 0 1.7781103167635592e-07
to O 0 3.730205122565167e-08
0 O 0 2.3660913939238526e-07
. O 0 8.93383056421726e-09
9 O 0 5.02405100633041e-07
) O 0 9.499606434815178e-09
and O 0 7.970305304638714e-09
for O 0 2.4227531980614003e-08
carriers O 0 8.933255202236978e-08
of O 0 1.324958361692552e-06
the O 0 7.632475899299607e-06
BRCA2 O 0 1.7240283341379836e-05
mutation O 0 1.3341268640942872e-06
( O 0 4.0884964391807443e-07
odds O 0 1.4547101727657719e-06
ratio O 0 8.36499907563848e-07
, O 0 8.91208387088227e-08
0 O 0 1.9860347322264715e-07
. O 0 7.359008069585116e-09
4 O 0 4.105312427782337e-07
; O 0 3.6089485178081304e-08
95 O 0 1.8601900819703587e-06
percent O 0 2.325598188690492e-06
confidence O 0 6.396982371370541e-06
interval O 0 4.375346634333255e-06
, O 0 2.880083798117994e-07
0 O 0 2.727703076743637e-07
. O 0 8.889008640267093e-09
2 O 0 9.040281412353579e-08
to O 0 9.699208547431226e-09
1 O 0 4.5646103785657033e-07
. O 0 3.4332551024363056e-08
1 O 0 3.5430025491223205e-06
) O 0 4.0477178231412836e-07
. O 0 5.58675992579083e-07

CONCLUSIONS O 0 0.00016894118743948638
Oral O 0 0.0007021620403975248
- O 0 2.91034175461391e-05
contraceptive O 0 1.2557497029774822e-05
use O 0 6.171382693764826e-08
may O 0 7.618577768653267e-08
reduce O 0 3.950611926484271e-08
the O 0 1.783818817102656e-07
risk O 0 6.773441782570444e-06
of O 0 0.00386044685728848
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.735283487709239e-06
women O 0 9.660404742817263e-08
with O 0 2.760601747198166e-09
pathogenic O 0 1.836034044799817e-07
mutations O 0 7.416516467628753e-08
in O 0 2.687258700007078e-07
the O 0 1.5020516457298072e-06
BRCA1 O 0 1.7347185348626226e-05
or O 0 1.1614506547630299e-05
BRCA2 O 0 0.00017429621948394924
gene O 0 0.00014528456085827202

A O 0 0.0002549802011344582
Japanese O 0 8.542758587282151e-05
family O 0 3.876155005855253e-06
with O 0 2.7935336675000144e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 4.6613914150839264e-07
a O 0 1.52657139551593e-06
codon O 0 4.9167988436238375e-06
291 O 0 2.0957281776645686e-06
deletion O 0 2.277335170219885e-06
: O 0 7.552861802651023e-08
a O 0 1.187489928611285e-07
clinical O 0 6.719602879456943e-06
, O 0 4.723071924672695e-07
biochemical O 0 4.2907693568849936e-05
, O 0 1.0743891607489786e-06
pathological O 0 0.0006069291848689318
, O 0 3.591914889966574e-07
and O 0 2.694991394491808e-07
genetic O 0 3.0649255222670035e-06
report O 0 2.313396635145182e-06
. O 0 1.7053764622687595e-06

We O 0 8.612594683654606e-06
report O 0 1.4416988278753706e-06
a O 0 1.1811789590865374e-06
Japanese O 0 1.229193640028825e-05
family O 0 4.25264215664356e-06
with O 0 1.2858902664447669e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.36910420656204224
ALD B-Disease 1 1.0
) O 0 1.7085213812606526e-06
with O 0 1.8638094445577735e-07
a O 0 4.753184384753695e-06
three O 0 3.5384914554015268e-06
base O 0 4.510219150688499e-05
pair O 0 7.72452858655015e-06
deletion O 0 1.4066847143112682e-05
( O 0 1.9370531845197547e-06
delGAG O 0 7.571793958049966e-06
291 O 0 2.397586058577872e-06
) O 0 1.0158505148183394e-07
in O 0 5.215315468376502e-07
the O 0 1.239118955709273e-05
ALD B-Disease 1 1.0
gene O 0 2.866206159524154e-05
. O 0 3.699575017890311e-06

A O 0 7.504203676944599e-05
variety O 0 4.233990694046952e-06
of O 0 8.182920282706618e-06
phenotypes O 0 1.2232088010932785e-05
were O 0 5.230268129707838e-07
observed O 0 2.584727951671084e-07
within O 0 1.0205560840859107e-07
this O 0 3.009539994991428e-08
family O 0 4.6518613316948176e-07
. O 0 5.482125402522797e-07

While O 0 0.00015784964489284903
the O 0 4.898252882412635e-05
proband O 0 0.0006724621052853763
( O 0 1.5238138985296246e-05
patient O 0 2.6395751774543896e-05
1 O 0 4.842140697292052e-05
) O 0 1.0788265853989287e-06
was O 0 3.197832256773836e-06
classified O 0 5.412209134192381e-07
as O 0 1.3118429365022166e-07
having O 0 1.0556426133234709e-07
a O 0 6.676815900164002e-08
rare O 0 2.5275221560150385e-07
intermediate O 0 1.675987050475669e-06
type O 0 7.833206154828076e-07
of O 0 2.41898442254751e-06
adult O 0 7.503418601118028e-05
cerebral O 1 0.9625674486160278
and O 0 5.91062635066919e-05
cerebello O 1 0.9703260064125061
- O 1 0.9881969094276428
brain O 1 0.5643137097358704
stem O 0 7.485836704290705e-06
forms O 0 5.918480496802658e-07
, O 0 2.3295862661143474e-07
his O 0 1.6927700698943227e-06
younger O 0 6.123572347860318e-06
brother O 0 1.8219043340650387e-05
( O 0 1.0739281606220175e-06
patient O 0 2.8262013529456453e-06
2 O 0 1.190630609926302e-05
) O 0 8.440880492344149e-07
and O 0 1.2838459042541217e-06
nephew O 0 0.00012927765783388168
( O 0 2.8715810458379565e-06
patient O 0 4.541290763881989e-06
3 O 0 6.491123713203706e-06
) O 0 1.8181063410338538e-07
had O 0 1.5593013813486323e-06
a O 0 1.0996243872796185e-05
childhood O 0 0.038690607994794846
ALD B-Disease 1 1.0
type O 0 0.0009417138062417507
. O 0 1.0419909813208506e-05

Another O 0 0.0007010567933320999
nephew O 0 0.0022857305593788624
( O 0 1.0486571227374952e-05
patient O 0 1.9050670744036324e-05
4 O 0 2.664052226464264e-05
) O 0 3.230216520933027e-07
of O 0 2.187118070651195e-06
patient O 0 4.0146682295016944e-05
1 O 0 0.00010667780588846654
was O 0 3.169990668538958e-05
classified O 0 1.1531095651662326e-06
as O 0 2.5246964696634677e-07
having O 0 3.1776960440765833e-07
an O 0 2.1717507081575604e-07
adolescent O 0 6.719385055475868e-06
form O 0 2.159237055820995e-06
. O 0 1.715988901196397e-06

The O 0 0.00011845542030641809
tau O 0 0.00013384688645601273
level O 0 0.0001031321007758379
in O 0 1.7732631022226997e-05
the O 0 4.90422171424143e-05
cerebrospinal O 0 0.001154181081801653
fluid O 0 0.0011901025427505374
( O 0 7.807274960214272e-05
CSF O 0 0.002053764881566167
) O 0 1.6356615333279478e-06
in O 0 2.353143827349413e-06
patient O 0 1.4235403796192259e-05
1 O 0 1.8703509340411983e-05
was O 0 5.164680260349996e-06
as O 0 1.7583134592769056e-07
high O 0 2.553151148276811e-07
as O 0 2.72589106842247e-09
that O 0 1.2588859121809293e-10
of O 0 1.0477588574531183e-08
patients O 0 2.8322432399363606e-07
with O 0 4.4762504103346146e-07
Alzheimers B-Disease 1 0.9999995231628418
disease I-Disease 0 0.10500722378492355
( O 0 1.7084139471990056e-06
AD B-Disease 0 7.510607247240841e-06
) O 0 7.912944397503452e-07
. O 0 7.192598445726617e-07

His O 0 0.0007549579022452235
brain O 1 0.9990076422691345
magnetic O 0 0.0004258774861227721
resonance O 0 0.00013419910101220012
image O 0 4.470153362490237e-05
( O 0 3.5420196127233794e-06
MRI O 0 0.00010294777894159779
) O 0 7.138606292755867e-07
showed O 0 5.0404150897520594e-06
abnormalities B-Disease 0 9.584432700648904e-05
in I-Disease 0 2.554710363256163e-06
the I-Disease 0 4.628020633390406e-06
bilateral I-Disease 0 0.0017938388045877218
cerebellar I-Disease 1 0.9999983310699463
hemispheres I-Disease 1 0.9889336824417114
and O 0 0.00027163251070305705
brain O 1 0.9974049925804138
stem O 0 2.6551799237495288e-05
, O 0 1.1899397378556387e-07
but O 0 1.6487584630908714e-08
not O 0 2.4137129628343246e-08
in O 0 4.930910222356033e-07
the O 0 4.088011792191537e-06
cerebral O 0 0.001350610051304102
white O 0 3.287921117589576e-06
matter O 0 2.4823825128805765e-07
, O 0 1.1626802631781175e-08
where O 0 8.932672379557971e-09
marked O 0 1.7516605055334367e-07
reductions O 0 2.1936195082616905e-07
of O 0 1.3242105296740192e-06
the O 0 4.513738986133831e-06
cerebral O 0 0.0006586192175745964
blood O 0 1.6713132936274633e-05
flow O 0 1.8552313122199848e-05
and O 0 2.7310190944263013e-06
oxygen O 0 1.8505312255001627e-05
metabolism O 0 1.6018626411096193e-05
were O 0 3.729351760739519e-07
clearly O 0 1.6206114139549754e-07
demonstrated O 0 4.123696157876111e-07
by O 0 5.817172521460634e-08
positron O 0 2.9395209821814205e-06
emission O 0 1.9000184465767234e-06
tomography O 0 7.6230921877140645e-06
( O 0 1.460657358620665e-06
PET O 0 7.103764801286161e-06
) O 0 3.1887643103800656e-07
. O 0 3.168133844155818e-07

In O 0 6.25580723863095e-05
patients O 0 1.621307455934584e-05
2 O 0 1.608443562872708e-05
and O 0 6.259542146835884e-07
3 O 0 7.180911325121997e-06
, O 0 7.07147833622912e-08
the O 0 9.517710708450977e-08
autopsy O 0 2.53735447586223e-06
findings O 0 3.22448556744348e-07
showed O 0 1.1853286196128465e-05
massive O 0 0.00041940511437132955
demyelination B-Disease 1 1.0
of I-Disease 1 0.9880126714706421
the I-Disease 0 0.056955594569444656
cerebral I-Disease 1 0.9999953508377075
white I-Disease 0 1.1664112207654398e-05
matter I-Disease 0 5.730612997467688e-07
with O 0 4.9335536544958813e-08
sparing O 0 7.54840357330977e-07
of O 0 1.7835322069004178e-05
the O 0 0.00011183955939486623
U O 1 0.9929485321044922
- O 0 0.0005103172734379768
fibers O 0 1.8521766833146103e-05
, O 0 5.056245910850521e-08
compatible O 0 1.1422930157323208e-07
with O 0 2.2566470914142656e-09
the O 0 4.108879991804315e-08
findings O 0 1.3909814811086108e-07
of O 0 4.250185156706721e-06
childhood O 0 0.35444819927215576
ALD B-Disease 1 1.0
. O 0 2.925476655946113e-05

Oleic O 0 0.014796358533203602
and O 0 0.0010184587445110083
erucic O 1 0.521791398525238
acids O 0 0.0005141245783306658
( O 0 6.168154504848644e-05
Lorenzos O 0 0.0012658776249736547
Oil O 0 0.00021689035929739475
) O 0 4.326041107560741e-07
were O 0 3.041333229703014e-07
administered O 0 1.997865979319613e-07
to O 0 8.524318673153175e-08
patients O 0 7.21531137060083e-07
1 O 0 5.503259217221057e-06
and O 0 5.043267492510495e-07
4 O 0 9.542661246086936e-06
, O 0 3.3877078919886117e-08
but O 0 1.978286645609728e-09
sufficient O 0 4.112564866431967e-08
effectiveness O 0 7.735806661912648e-07
was O 0 3.503182369968272e-06
not O 0 8.513821114775055e-08
obtained O 0 1.7739923805493163e-06
. O 0 1.3464086805470288e-06

The O 0 0.00010340713924961165
findings O 0 1.5376102965092286e-05
in O 0 4.63139804196544e-06
this O 0 3.8470662389045174e-07
family O 0 4.5485842292691814e-07
suggest O 0 9.617383511795197e-08
that O 0 1.8697676296142163e-08
delGAG291 O 0 1.104144871533208e-06
is O 0 2.1363886659742093e-08
part O 0 2.0944517231669124e-08
of O 0 2.0353380136839405e-07
the O 0 5.993878744448011e-07
cause O 0 2.6302407150069484e-06
of O 0 5.367774519982049e-06
Japanese O 0 0.0008901189430616796
ALD B-Disease 1 1.0
with O 0 5.77386799704982e-07
phenotypic O 0 0.0001087483178707771
variations O 0 0.0001520810037618503
. O 0 8.92000571184326e-06

Moreover O 0 0.00015538587467744946
, O 0 2.175935378545546e-06
although O 0 1.0500379232780688e-07
the O 0 3.575291884772014e-07
scale O 0 3.833175469480921e-06
of O 0 4.782558335136855e-06
the O 0 1.5686352980992524e-06
study O 0 5.128934503773053e-07
is O 0 2.1101789116073633e-07
limited O 0 2.448985298997286e-07
, O 0 7.368294774323658e-08
there O 0 4.962063115954152e-08
is O 0 8.014930585886759e-08
a O 0 1.9817777285879856e-07
possibility O 0 3.835197617263475e-07
that O 0 6.83378914345667e-07
PET O 0 4.620064646587707e-05
can O 0 7.371077686002536e-07
detect O 0 5.931583018536912e-06
an O 0 2.8635138278332306e-06
insidious B-Disease 0 0.00010263274452881888
lesion I-Disease 0 0.000753504631575197
which O 0 8.508576456733863e-07
is O 0 3.745340677596687e-07
undetectable O 0 2.417118821540498e-06
by O 0 4.698596356433882e-08
computed O 0 1.4864378954371205e-06
tomogram O 0 1.4692725926579442e-05
( O 0 3.5072237096756e-06
CT O 0 0.0005492634372785687
) O 0 2.5749482119863387e-06
or O 0 2.9869397621951066e-06
MRI O 0 0.00011431265738792717
analysis O 0 1.8019321146311995e-07
, O 0 2.4066702408731544e-08
and O 0 8.429037023915953e-09
that O 0 2.404535459632484e-09
the O 0 2.428263101705852e-08
higher O 0 1.6507259203990543e-07
level O 0 1.9812259210993943e-07
of O 0 1.224536561039713e-07
tau O 0 5.846627573191654e-07
reflects O 0 7.581363981046252e-09
the O 0 1.0432918529090784e-08
process O 0 3.196711162445354e-08
of O 0 1.8879527488024905e-06
neuronal B-Disease 0 0.0017144089797511697
degeneration I-Disease 1 0.9999128580093384
in O 0 0.0007270606583915651
ALD B-Disease 1 1.0
. O 0 3.1594998290529475e-05

Lorenzos O 0 0.03872206434607506
Oil O 0 0.0010723818559199572
should O 0 9.947133321475121e-07
be O 0 8.745111301777797e-08
given O 0 3.601631703986641e-08
in O 0 1.4264195158375514e-07
the O 0 2.3728388498511777e-07
early O 0 6.670400125585729e-07
stage O 0 3.344096512591932e-06
. O 0 2.1696970975426666e-07
. O 0 3.487255071377149e-07

Nonsense O 0 0.0006227440317161381
mutation O 0 4.722855919681024e-06
in O 0 2.7097814836452017e-06
exon O 0 4.087497018190334e-06
4 O 0 5.847558895766269e-06
of O 0 1.7246331935893977e-06
human O 0 2.8339500204310752e-06
complement O 0 2.779542228381615e-06
C9 O 0 0.000209772857488133
gene O 0 2.376607426413102e-07
is O 0 2.1633947966392952e-08
the O 0 2.544065047516142e-08
major O 0 2.7914728661926347e-07
cause O 0 1.413065575661676e-07
of O 0 8.160811830748571e-07
Japanese O 0 2.3893504476291128e-05
complement B-Disease 0 0.0003290485474281013
C9 I-Disease 1 0.9999847412109375
deficiency I-Disease 1 0.9999840259552002
. O 0 1.0630194992700126e-05

Deficiency B-Disease 1 0.9999364614486694
of I-Disease 0 0.0005024729180149734
the I-Disease 0 0.00012026059994241223
ninth I-Disease 0 0.0007596130017191172
component I-Disease 0 3.6997749703004956e-05
of I-Disease 0 1.833107126003597e-05
human I-Disease 0 3.062096584471874e-05
complement I-Disease 0 9.453675374970771e-06
( O 0 6.76115359965479e-06
C9 O 0 0.00023059728846419603
) O 0 2.1914785008902982e-07
is O 0 4.423488775273654e-08
the O 0 7.963759429685524e-08
most O 0 1.80189616116877e-07
common O 0 1.7191343431477435e-05
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 0.00012507593783084303
Japan O 0 1.2218354640936013e-05
but O 0 1.9811126605873142e-07
is O 0 6.030975896464952e-08
rare O 0 8.426083297763398e-08
in O 0 7.373229493623512e-08
other O 0 2.422416045533282e-08
countries O 0 8.618435742846486e-08
. O 0 6.817944608883408e-07

We O 0 2.9100954179739347e-07
studied O 0 7.497064871131442e-07
the O 0 1.3035372603553697e-07
molecular O 0 8.984172268355906e-07
basis O 0 1.8327799580220017e-06
of O 0 2.7014551960746758e-05
C9 B-Disease 1 0.9986085295677185
deficiency I-Disease 1 0.9996975660324097
in O 0 5.597564813797362e-05
four O 0 3.812120485235937e-05
Japanese O 0 0.0007800447638146579
C9 B-Disease 1 0.9999958276748657
- I-Disease 1 0.9816568493843079
deficient I-Disease 0 0.002074873074889183
patients O 0 1.5213654478429817e-06
who O 0 1.9390536465380137e-07
had O 0 6.69404425934772e-06
suffered O 1 0.9999980926513672
from O 0 0.0030343225225806236
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.073719613486901e-05

Direct O 0 1.9761340809054673e-05
sequencing O 0 1.4119143088464625e-05
of O 0 2.019986459345091e-05
amplified O 0 4.7875011659925804e-05
C9 O 0 0.00021622776694130152
cDNA O 0 7.195122179837199e-06
and O 0 9.65390768215002e-07
DNA O 0 2.272735628139344e-06
revealed O 0 1.0104979992320295e-05
a O 0 9.657595001044683e-06
nonsense O 0 5.683187919203192e-05
substitution O 0 1.7381384168402292e-05
( O 0 4.750515017803991e-06
CGA O 0 3.128488970105536e-05
- O 0 4.5952638174640015e-06
- O 0 3.892558197549079e-06
> O 0 3.210721615687362e-06
TGA O 0 2.2314227408060106e-06
) O 0 9.067548489838373e-08
at O 0 1.7937622942554299e-06
codon O 0 1.0212020242761355e-06
95 O 0 1.128911208070349e-06
in O 0 4.143824980928912e-07
exon O 0 1.0097642189066391e-06
4 O 0 7.83941777626751e-06
in O 0 2.2096658085501986e-06
the O 0 5.022833647672087e-06
four O 0 1.6063939256127924e-05
C9 B-Disease 0 0.009953837841749191
- I-Disease 0 0.0009907876374199986
deficient I-Disease 0 0.0001692791556706652
individuals O 0 2.1932869742613548e-07
. O 0 6.277015245359507e-07

An O 0 3.3025764423655346e-05
allele O 0 2.0045958081027493e-05
- O 0 1.3590250091510825e-05
specific O 0 1.1070592336182017e-06
polymerase O 0 0.0004253046354278922
chain O 0 9.809182665776461e-05
reaction O 0 6.657252924924251e-06
system O 0 3.4392862744425656e-06
designed O 0 7.08006780314463e-07
to O 0 8.829145770050673e-08
detect O 0 2.836092107827426e-07
exclusively O 0 1.3547250432566216e-07
only O 0 3.9646526062142584e-08
one O 0 3.012721805362162e-08
of O 0 7.15367434622749e-07
the O 0 1.4258035889724852e-06
normal O 0 4.780884410138242e-06
and O 0 5.363382342693512e-07
mutant O 0 3.383212060725782e-06
alleles O 0 4.66541649757346e-07
indicated O 0 5.19118941610941e-07
that O 0 1.8864570350274334e-08
all O 0 3.0200862255469474e-08
the O 0 1.1286231682561265e-07
four O 0 1.6230860921950807e-07
patients O 0 6.020724185873405e-08
were O 0 1.2357212142433127e-07
homozygous O 0 2.427582899144909e-07
for O 0 1.3926538144914957e-07
the O 0 5.078078970655042e-07
mutation O 0 2.401562824161374e-07
in O 0 1.3754647625319194e-06
exon O 0 3.110612169621163e-06
4 O 0 1.171586336567998e-05
and O 0 2.1943769468180108e-07
that O 0 2.8462032730658393e-08
the O 0 1.485163778625065e-07
parents O 0 5.899005728338125e-08
of O 0 6.742935738657252e-07
patient O 0 7.305612143682083e-06
2 O 0 1.2945512025908101e-05
were O 0 3.0909357064956566e-06
heterozygous O 0 6.99275824445067e-06
. O 0 1.303251679019013e-06

The O 0 6.302722613327205e-05
common O 0 1.347983652522089e-05
mutation O 0 2.5685419586807257e-06
at O 0 2.631336246849969e-05
codon O 0 8.06212756288005e-06
95 O 0 3.496933686619741e-06
in O 0 5.99586826410814e-07
exon O 0 1.6353262708435068e-06
4 O 0 4.440295469976263e-06
might O 0 3.4889971800566855e-08
be O 0 1.5336611980387715e-08
responsible O 0 2.433242407562375e-08
for O 0 4.912360651587733e-08
most O 0 4.0978764559440606e-07
Japanese O 0 8.816013723844662e-05
C9 B-Disease 1 0.9995959401130676
deficiency I-Disease 1 0.9984341263771057
. O 0 1.1531161590028205e-06
. O 0 1.4779961929889396e-06

BRCA1 O 0 2.2108268240117468e-05
required O 0 1.1704254347932874e-06
for O 0 9.056009275809629e-07
transcription O 0 8.772473665885627e-05
- O 0 2.10148973565083e-05
coupled O 0 2.3925447749206796e-05
repair O 0 1.3344652870728169e-05
of O 0 5.598804818873759e-06
oxidative O 0 0.00015437691763509065
DNA O 0 4.0190050640376285e-05
damage O 0 0.0007362393080256879
. O 0 1.1209112926735543e-05

The O 0 3.536657095537521e-05
breast B-Disease 1 0.9999983310699463
and I-Disease 1 0.9995129108428955
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0016409741947427392
gene O 0 8.528303624188993e-06
BRCA1 O 0 9.041347766469698e-06
encodes O 0 6.633772500208579e-06
a O 0 8.984207852336112e-06
zinc O 0 9.779399260878563e-05
finger O 0 2.6037212592200376e-05
protein O 0 1.8465277662471635e-06
of O 0 2.629603841342032e-06
unknown O 0 9.044469152286183e-06
function O 0 1.9904326109099202e-05
. O 0 1.3784720067633316e-06

Association O 0 0.00012760199024342
of O 0 2.2432464902522042e-05
the O 0 8.782436452747788e-06
BRCA1 O 0 4.3205632209719624e-06
protein O 0 9.228468798028189e-07
with O 0 6.389767293057957e-08
the O 0 1.0454650691826828e-06
DNA O 0 1.4433441037908779e-06
repair O 0 2.248525561299175e-05
protein O 0 2.6898844225797802e-05
Rad51 O 0 6.74656403134577e-05
and O 0 5.107150968797214e-07
changes O 0 1.1832291590962996e-07
in O 0 3.3715159020175633e-07
the O 0 1.7259793594348594e-07
phosphorylation O 0 1.153816455712331e-07
and O 0 1.747164333210094e-07
cellular O 0 6.6336583586235065e-06
localization O 0 1.196154971694341e-05
of O 0 3.3489634461147944e-06
the O 0 4.221721610520035e-06
protein O 0 6.584019502042793e-06
after O 0 9.938913535734173e-06
exposure O 0 2.7483902158564888e-05
to O 0 2.367550450799172e-06
DNA O 0 2.2728378098690882e-05
- O 0 5.029980093240738e-05
damaging O 0 1.3276753634272609e-05
agents O 0 3.794632164044742e-07
are O 0 1.601583399235551e-08
consistent O 0 5.4998938736616765e-08
with O 0 5.244500389522955e-09
a O 0 7.524994316554512e-08
role O 0 3.1520170296062133e-07
for O 0 2.2759188311738399e-07
BRCA1 O 0 1.5590159136991133e-06
in O 0 1.2515155276560108e-06
DNA O 0 3.4142631193390116e-06
repair O 0 6.349245813908055e-05
. O 0 4.6805648707959335e-06

Here O 0 4.4606269511859864e-05
, O 0 3.9620525171812915e-07
it O 0 1.0234484371096642e-08
is O 0 2.230978601858169e-08
shown O 0 1.8978494153998327e-07
that O 0 2.6787637352754246e-07
mouse O 0 3.0755880288779736e-05
embryonic O 0 4.678174445871264e-05
stem O 0 8.615619299234822e-05
cells O 0 3.0173339837347157e-05
deficient B-Disease 0 6.72105816192925e-05
in I-Disease 0 7.3624182732601184e-06
BRCA1 I-Disease 0 2.750398743955884e-05
are O 0 1.3321485994310933e-06
defective O 0 4.921706477034604e-06
in O 0 6.771941798433545e-07
the O 0 2.733515600539249e-07
ability O 0 3.2507887937072155e-08
to O 0 1.9148124863477278e-08
carry O 0 6.918638462138915e-08
out O 0 1.335989168183005e-07
transcription O 0 1.0442849998071324e-05
- O 0 1.2565871656988747e-05
coupled O 0 2.448034138069488e-05
repair O 0 1.6230291294050403e-05
of O 0 1.5895608157734387e-05
oxidative O 0 0.00012367208546493202
DNA O 0 2.9123324566171505e-05
damage O 0 0.0003144679358229041
, O 0 1.1773315691243624e-06
and O 0 3.1676808021074976e-07
are O 0 1.8239485655158205e-07
hypersensitive O 0 6.8852205004077405e-06
to O 0 3.542340323292592e-07
ionizing O 0 0.0002010390453506261
radiation O 0 0.00017971482884604484
and O 0 9.63747083915223e-07
hydrogen O 0 1.3775625120615587e-06
peroxide O 0 1.0326849405828398e-05
. O 0 1.4869482356516528e-06

These O 0 1.4217303942132276e-05
results O 0 4.3690972233889624e-05
suggest O 0 2.7355026759323664e-06
that O 0 6.356539188345778e-07
BRCA1 O 0 4.361410901765339e-06
participates O 0 3.1610404676030157e-06
, O 0 6.634269880123611e-07
directly O 0 5.782248990726657e-07
or O 0 4.429973330388748e-07
indirectly O 0 5.252156825008569e-07
, O 0 1.1127416144063318e-07
in O 0 6.973286872380413e-07
transcription O 0 3.1851694075157866e-05
- O 0 2.2410054953070357e-05
coupled O 0 3.473457763902843e-05
repair O 0 1.5949985026963986e-05
of O 0 6.010930519551039e-06
oxidative O 0 4.077561243320815e-05
DNA O 0 7.484915386157809e-06
damage O 0 6.913304241606966e-05
. O 0 4.6010342202862375e-07
. O 0 6.314980396382452e-07

Truncation O 0 0.003875155234709382
mutations O 0 4.706059189629741e-05
in O 0 9.174726983474102e-06
the O 0 3.130082632196718e-06
transactivation O 0 9.917921124724671e-05
region O 0 4.275626906746766e-06
of O 0 3.189132621628232e-05
PAX6 O 0 0.008496829308569431
result O 0 5.610245716525242e-05
in O 0 3.437345731072128e-05
dominant O 0 0.00029959206585772336
- O 0 1.066876848199172e-05
negative O 0 1.0665181662261602e-06
mutants O 0 3.718307425515377e-06
. O 0 4.554344172902347e-07

PAX6 O 0 0.019446738064289093
is O 0 3.2353054848499596e-05
a O 0 8.738124051888008e-06
transcription O 0 2.13646035263082e-05
factor O 0 3.072083472943632e-06
with O 0 3.8858345874359657e-07
two O 0 1.3739230553255766e-06
DNA O 0 1.9391677597013768e-06
- O 0 3.12483325615176e-06
binding O 0 2.883444267354207e-06
domains O 0 1.670849451329559e-05
( O 0 1.4582687981601339e-06
paired O 0 1.7338484212814365e-06
box O 0 1.1247029760852456e-05
and O 0 7.770483989588683e-07
homeobox O 0 8.121145583572797e-06
) O 0 2.3782828861840244e-07
and O 0 6.219335091373068e-07
a O 0 7.142139111238066e-06
proline O 0 2.163458520954009e-05
- O 0 1.0034303159045521e-05
serine O 0 1.0050574019260239e-05
- O 0 5.006525498174597e-06
threonine O 0 8.112522664305288e-06
( O 0 1.2699346143563162e-06
PST O 0 6.167036917759106e-05
) O 0 6.792380418119137e-07
- O 0 1.921797547765891e-06
rich O 0 5.878541173842677e-07
transactivation O 0 5.982371294521727e-05
domain O 0 1.5293404430849478e-05
. O 0 1.747907163007767e-06

PAX6 O 1 0.9968218803405762
regulates O 0 0.02741396799683571
eye O 1 0.997215747833252
development O 0 5.904390127398074e-05
in O 0 4.621695552486926e-06
animals O 0 1.267761263079592e-06
ranging O 0 1.022116975946119e-05
from O 0 1.32927164031571e-06
jellyfish O 0 2.159279119950952e-07
to O 0 3.3068211280351534e-08
Drosophila O 0 2.5499978164589265e-06
to O 0 7.676544555579312e-08
humans O 0 6.448461817853968e-07
. O 0 4.0198315787165484e-07

Heterozygous O 0 1.6649531971779652e-05
mutations O 0 1.08886001726205e-06
in O 0 2.1991095877638145e-07
the O 0 2.546255188917712e-07
human O 0 1.940225729413214e-06
PAX6 O 0 0.00010470011329744011
gene O 0 1.5892871374489914e-07
result O 0 3.3848142066972287e-08
in O 0 2.6337438896462118e-08
various O 0 2.5277939741386035e-08
phenotypes O 0 1.0157676797462045e-06
, O 0 5.1075307538894776e-08
including O 0 3.62561820566043e-07
aniridia B-Disease 1 1.0
, O 0 6.80842049405328e-06
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 1.0
, O 0 2.9678303690161556e-06
autosomal B-Disease 1 0.998668909072876
dominant I-Disease 1 0.9983072280883789
keratitis I-Disease 1 0.9999998807907104
, O 0 4.1513862925057765e-06
and O 0 8.178036296158098e-06
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.8093610405921936

It O 0 3.113713773927884e-06
is O 0 4.2501835650909925e-07
believed O 0 1.9514197902026353e-07
that O 0 1.5482509496678176e-08
the O 0 1.6301474659030646e-07
mutated O 0 8.807412541500526e-07
allele O 0 1.5455652828677557e-06
of O 0 7.135609394026687e-06
PAX6 O 0 0.00025691871996968985
produces O 0 9.85102929007553e-07
an O 0 4.537124880243937e-07
inactive O 0 9.946954378392547e-06
protein O 0 7.776631719025318e-06
and O 0 2.5382353214808973e-06
aniridia B-Disease 1 0.9999998807907104
is O 0 1.4296324479801115e-06
caused O 0 1.459184318264306e-06
due O 0 2.0121506167924963e-06
to O 0 2.171928912275689e-07
genetic O 0 1.0170724635827355e-05
haploinsufficiency O 0 0.0003020876320078969
. O 0 5.579536264121998e-06

However O 0 6.504243356175721e-05
, O 0 5.5770833569113165e-06
several O 0 1.0706822877182276e-06
truncation O 0 8.54944228194654e-05
mutations O 0 3.581872078939341e-06
have O 0 7.252267550938996e-07
been O 0 5.057895577920135e-07
found O 0 3.8361410048537437e-08
to O 0 9.22065623853996e-09
occur O 0 1.1254782350533787e-07
in O 0 1.030950329550251e-06
the O 0 8.128561603371054e-06
C O 0 0.0001897400215966627
- O 0 1.02096837508725e-05
terminal O 0 1.0965371984639205e-05
half O 0 8.473644186324236e-08
of O 0 2.9487091524060816e-07
PAX6 O 0 3.593257497414015e-05
in O 0 5.525127448890998e-07
patients O 0 6.870206448184035e-07
with O 0 2.8582485356309917e-07
Aniridia B-Disease 1 0.9999926090240479
resulting O 0 1.6126379705383442e-05
in O 0 1.071734914148692e-05
mutant O 0 1.2607078133441973e-05
proteins O 0 5.676567980117397e-07
that O 0 1.8400288581688073e-07
retain O 0 1.8771538634609897e-06
the O 0 5.115221028972883e-06
DNA O 0 1.5289054999811924e-06
- O 0 3.5305870369484182e-06
binding O 0 2.377762029937003e-06
domains O 0 8.22258061816683e-06
but O 0 1.6874930963695078e-07
have O 0 1.278582999475475e-07
lost O 0 2.722541694311076e-06
most O 0 3.6519214319241655e-08
of O 0 3.8445247696472507e-07
the O 0 1.8334879996473319e-06
transactivation O 0 0.00014738352911081165
domain O 0 3.6341592931421474e-05
. O 0 3.95371762351715e-06

It O 0 6.4139585447264835e-06
is O 0 9.137339702647296e-07
not O 0 7.818027825123863e-08
clear O 0 2.1422323470687843e-07
whether O 0 8.364625614376564e-08
such O 0 1.1860382755912724e-06
mutants O 0 2.9291195460245945e-05
really O 0 4.766643996845232e-06
behave O 0 3.861029199470067e-06
as O 0 1.7828693898991332e-06
loss O 0 8.415846423304174e-06
- O 0 1.693370677458006e-06
of O 0 4.211901341477642e-06
- O 0 6.313267931545852e-06
function O 0 5.9847729971806984e-06
mutants O 0 1.0958658549498068e-06
as O 0 2.988114431445865e-07
predicted O 0 1.5250450360326795e-06
by O 0 2.2582678127491818e-07
haploinsufficiency O 0 5.876259820070118e-05
. O 0 2.9497036848624703e-06

Contrary O 0 9.97956667561084e-05
to O 0 9.952010486813379e-07
this O 0 4.822789492209267e-07
theory O 0 9.762959052750375e-06
, O 0 3.4709145779743267e-07
our O 0 2.0998663785576355e-07
data O 0 7.363081522271386e-07
showed O 0 1.3521464552468387e-06
that O 0 5.760124821563295e-08
these O 0 7.450415751009132e-08
mutants O 0 3.0889052595739486e-06
are O 0 2.124118481106052e-07
dominant O 0 3.302470986454864e-06
- O 0 4.3437140107016603e-07
negative O 0 2.1008878547945642e-07
in O 0 5.422097046903218e-07
transient O 0 4.609568713931367e-05
transfection O 0 7.076244219206274e-05
assays O 0 5.113416591484565e-06
when O 0 8.503075719090702e-07
they O 0 7.888458242177876e-08
are O 0 5.480155351733629e-08
coexpressed O 0 2.684353830773034e-06
with O 0 1.0906844494229517e-07
wild O 0 5.600230906566139e-06
- O 0 1.8744236513157375e-05
type O 0 3.290347376605496e-05
PAX6 O 0 0.003595221322029829
. O 0 4.878973868471803e-06

We O 0 2.0740459149237722e-05
found O 0 2.123593048963812e-06
that O 0 1.674463163681139e-07
the O 0 4.05701848649187e-06
dominant O 0 7.791455573169515e-05
- O 0 1.254080325452378e-05
negative O 0 8.865060863172403e-07
effects O 0 7.515959623560775e-06
result O 0 1.0867178161788615e-06
from O 0 2.2606381833156775e-07
the O 0 7.551277292350278e-08
enhanced O 0 4.0025292946666013e-07
DNA O 0 1.0451086751572802e-07
binding O 0 1.5587885116019606e-07
ability O 0 1.3050522795765573e-07
of O 0 9.693420679468545e-07
these O 0 2.913744481247704e-07
mutants O 0 7.80964364821557e-06
. O 0 9.767677511263173e-07

Kinetic O 0 0.00032268805080093443
studies O 0 1.7674739865469746e-05
of O 0 9.524304914521053e-06
binding O 0 4.478347818803741e-06
and O 0 1.8368887140240986e-06
dissociation O 0 9.530755050946027e-06
revealed O 0 2.7755665996664902e-06
that O 0 6.79054252827882e-08
various O 0 4.7275875658669975e-07
truncation O 0 6.735276838298887e-05
mutants O 0 7.614975856995443e-06
have O 0 6.603435167562566e-07
3 O 0 2.9361956421780633e-06
- O 0 7.967655051288602e-07
5 O 0 3.820722668024246e-06
- O 0 1.383497760798491e-06
fold O 0 1.5590068187520956e-06
higher O 0 3.212357114534825e-06
affinity O 0 4.290284323360538e-07
to O 0 3.1041673764775624e-07
various O 0 5.044888098382216e-07
DNA O 0 4.84030806546798e-07
- O 0 3.212937826901907e-07
binding O 0 9.804190170825677e-08
sites O 0 1.484690841380143e-07
when O 0 3.8344655450828213e-08
compared O 0 1.7498872750820738e-07
with O 0 9.834301373246035e-09
the O 0 4.5599637132909265e-07
wild O 0 3.104782535956474e-06
- O 0 8.98972666618647e-06
type O 0 2.2776242985855788e-05
PAX6 O 0 0.001033529988490045
. O 0 6.056630354578374e-06

These O 0 2.569076059444342e-06
results O 0 3.487092953946558e-06
provide O 0 9.110576115745062e-08
a O 0 2.1751543499703985e-07
new O 0 6.821880305096784e-08
insight O 0 1.1817699885341426e-07
into O 0 1.108705394159415e-08
the O 0 3.2792730308983664e-08
role O 0 1.8503303067518573e-07
of O 0 1.295735387429886e-06
mutant O 0 2.7694544769474305e-05
PAX6 O 0 0.0006931163952685893
in O 0 2.1590582036878914e-05
causing O 0 0.00016625993885099888
aniridia B-Disease 1 0.999981164932251
. O 0 1.2770028661179822e-06
. O 0 1.3028403600401361e-06

Reversal O 0 0.00045839374070055783
of O 0 0.00018523138714954257
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 0.7498039603233337
excellent O 1 0.9528699517250061
neuropsychologic O 1 0.979548454284668
outcome O 0 0.0008656641584821045
in O 0 6.341373227769509e-05
very B-Disease 0 4.762299795402214e-06
- I-Disease 0 1.0261262104904745e-05
long I-Disease 0 5.76932825424592e-06
- I-Disease 0 6.433366252167616e-06
chain I-Disease 0 5.720970875700004e-06
acyl I-Disease 0 1.953746959770797e-06
- I-Disease 0 3.489012215140974e-06
coenzyme I-Disease 0 5.64238871447742e-06
A I-Disease 0 0.00011248684313613921
dehydrogenase I-Disease 0 0.002936015138402581
deficiency I-Disease 1 0.9997854828834534
. O 0 1.0860136171686463e-05

Very B-Disease 0 0.0005508355679921806
- I-Disease 0 0.00029400535277090967
long I-Disease 0 4.626373993232846e-05
- I-Disease 0 2.359861900913529e-05
chain I-Disease 0 1.2763412087224424e-05
acyl I-Disease 0 1.2421575092957937e-06
- I-Disease 0 6.601968038921768e-07
coenzyme I-Disease 0 3.312121066301188e-07
A I-Disease 0 1.918909447340411e-06
dehydrogenase I-Disease 0 7.706405995122623e-06
( I-Disease 0 3.4544598292995943e-06
VLCAD I-Disease 0 0.0032249544747173786
) I-Disease 0 1.0622605259413831e-05
deficiency I-Disease 1 0.9808763861656189
is O 0 6.258604798858869e-07
a O 0 8.606896699347999e-06
disorder O 1 0.9999945163726807
of O 0 0.2941652536392212
fatty O 0 0.0002285744558321312
acid O 0 9.787327144294977e-06
beta O 0 3.3171231734741013e-06
oxidation O 0 5.296591325532063e-07
that O 0 6.926666173967533e-08
reportedly O 0 1.2132602478232002e-06
has O 0 8.231584303075579e-08
high O 0 7.072698053889326e-07
rates O 0 8.011171104271853e-08
of O 0 1.1096260976728445e-07
morbidity O 0 1.7482239854871295e-05
and O 0 1.0632967359924805e-06
mortality O 0 0.00010674800432752818
. O 0 2.3707698346697725e-06

We O 0 1.3039967598160729e-05
describe O 0 3.3677220017125364e-06
the O 0 3.2405298497906188e-06
outcome O 0 4.778286438522628e-06
of O 0 8.885629540600348e-06
a O 0 6.942650543351192e-06
5 O 0 1.0210696018475574e-05
- O 0 2.667231228770106e-06
year O 0 2.542884885770036e-06
- O 0 7.3454675657558255e-06
old O 0 1.7005373592837714e-05
girl O 0 2.021585896727629e-05
with O 0 1.4767035281693097e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 5.4138246923685074e-05
was O 0 4.650818300433457e-05
first O 0 1.421461774953059e-06
seen O 0 4.383430507459707e-07
at O 0 1.2623236500530766e-07
5 O 0 2.8780018368479432e-08
months O 0 3.74591735408103e-09
of O 0 5.765166566362723e-09
age O 0 1.7177148947666865e-07
with O 0 1.1108204489573836e-07
severe O 1 0.9999620914459229
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999815225601196
hepatomegaly B-Disease 1 1.0
, O 1 0.9999475479125977
encephalopathy B-Disease 1 1.0
, O 0 5.954293101240182e-06
and O 0 5.214696557231946e-06
hypotonia B-Disease 1 0.7077092528343201
. O 0 1.7887972717289813e-05

Biochemical O 0 0.001863639336079359
studies O 0 0.0004199906252324581
indicated O 1 0.9980199337005615
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 1 0.9257960319519043
by O 0 8.420891504101746e-07
a O 0 2.8455356186896097e-06
stable O 0 1.568371408211533e-05
yet O 0 7.097543743839196e-07
inactive O 0 9.764689821167849e-06
enzyme O 0 4.073744094057474e-06
. O 0 8.72719624567253e-07

Molecular O 0 0.00014617656415794045
genetic O 0 1.0065721653518267e-05
analysis O 0 2.0953484636265785e-06
of O 0 7.728492164460476e-06
her O 0 2.916540324804373e-05
VLCAD O 1 0.7475366592407227
gene O 0 4.438541145646013e-05
revealed O 0 2.36567975662183e-05
a O 0 7.213575372588821e-06
T1372C O 0 5.7523033319739625e-05
( O 0 3.7034262732049683e-06
F458L O 0 2.449470412102528e-05
) O 0 8.194197675948089e-07
missense O 0 5.426336429081857e-06
mutation O 0 1.0709825346566504e-06
and O 0 1.311575715590152e-06
a O 0 1.1929515494557563e-05
1668 O 0 0.01582922600209713
ACAG O 0 0.007149501703679562
1669 O 0 0.002300909021869302
splice O 0 0.00013432545529212803
site O 0 1.2133657037338708e-05
mutation O 0 6.536770797538338e-06
. O 0 1.3568420627052546e-06

After O 0 1.2144238098699134e-05
initial O 0 6.181825483508874e-06
treatment O 0 7.076793281157734e-06
with O 0 4.363202492640994e-07
intravenous O 0 3.194772943970747e-05
glucose O 0 0.000276083912467584
and O 0 1.16939181680209e-05
carnitine O 0 0.00023614933888893574
, O 0 1.6767671695561148e-06
the O 0 2.8525075776997255e-06
patient O 0 1.3848354683432262e-05
has O 0 3.644198841357138e-06
thrived O 0 1.3119298273522872e-05
on O 0 1.4696117432322353e-05
a O 0 1.1610309229581617e-05
low O 0 6.125188519945368e-05
- O 0 8.6029986050562e-06
fat O 0 8.191273991542403e-06
diet O 0 4.1450661569797376e-07
supplemented O 0 8.981947274833146e-08
with O 0 3.572867868228968e-08
medium O 0 3.7402082853077445e-06
- O 0 4.7009998525027186e-06
chain O 0 5.421071364253294e-06
triglyceride O 0 1.7859267245512456e-05
oil O 0 1.2921512279717717e-05
and O 0 3.0823380825495406e-07
carnitine O 0 1.2993762538826559e-05
and O 0 2.276795925126862e-07
avoidance O 0 4.3515683501027524e-06
of O 0 8.897984116629232e-06
fasting O 0 0.00014666674542240798
. O 0 3.6577430364559405e-06

Her O 0 0.00833197869360447
ventricular O 1 0.9999995231628418
hypertrophy O 1 0.9983054399490356
resolved O 0 5.75839621888008e-05
significantly O 0 5.43466376257129e-06
over O 0 2.4284545361297205e-06
1 O 0 3.0208639145712368e-05
year O 0 4.658454599848483e-06
, O 0 8.673686693327909e-07
and O 0 2.4146904706867645e-06
cognitively O 0 8.897396037355065e-05
, O 0 4.321084929870267e-07
she O 0 2.0758515972829628e-07
is O 0 6.512140515724241e-08
in O 0 6.942141084209652e-08
the O 0 1.3466717518895166e-07
superior O 0 2.5228698632417945e-06
range O 0 1.5598725440213457e-06
for O 0 4.894245080322435e-07
age O 0 1.1113285836472642e-05
. O 0 2.345465873077046e-06

Clinical O 0 0.0026361632626503706
recognition O 0 0.019586194306612015
of O 1 1.0
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 0.00024295516777783632
important O 0 2.2808128505857894e-06
because O 0 5.197678731860833e-08
it O 0 3.9742960034061525e-09
is O 0 4.9707566951440185e-09
one O 0 1.2544451033491555e-09
of O 0 8.742005341844106e-09
the O 0 5.364154276321642e-08
few O 0 1.0568877684136169e-07
directly O 0 1.4912595815985696e-06
treatable O 0 0.0015985439531505108
causes O 0 1.1678147529892158e-05
of O 0 0.00030869984766468406
cardiomyopathy B-Disease 1 1.0
in O 0 0.00010668950562831014
children O 0 3.2927378015301656e-06
. O 0 2.2986657199908223e-07
. O 0 4.162797893059178e-07

Cloning O 0 5.145447721588425e-05
of O 0 7.439825822075363e-06
a O 0 2.070706159429392e-06
novel O 0 1.742667564030853e-06
member O 0 2.8978427053516498e-06
of O 0 4.880607320956187e-06
the O 0 1.1218193321838044e-05
low O 0 9.651089931139722e-05
- O 0 9.180942470266018e-06
density O 0 7.690797247050796e-06
lipoprotein O 0 0.00023009609139990062
receptor O 0 4.842048292630352e-05
family O 0 5.71636201129877e-06
. O 0 1.9491985767672304e-06

A O 0 4.461784192244522e-05
gene O 0 4.169657586317044e-06
encoding O 0 2.270922095704009e-06
a O 0 5.280497816784191e-07
novel O 0 1.1898958973688423e-06
transmembrane O 0 2.7556641271075932e-06
protein O 0 3.832638242329267e-07
was O 0 5.638520050865736e-08
identified O 0 9.357998820291868e-10
by O 0 1.0975465675189255e-10
DNA O 0 1.518118963872439e-09
sequence O 0 2.5460393793252933e-09
analysis O 0 4.160786826190588e-09
within O 0 2.3381570457559064e-08
the O 0 3.6953821336283e-07
insulin B-Disease 0 0.0005184803740121424
- I-Disease 0 0.1672331541776657
dependent I-Disease 0 0.2892204821109772
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.824215334840119e-05
IDDM B-Disease 0 0.0007689452613703907
) O 0 1.6833008658068138e-06
locus O 0 3.159035986755043e-05
IDDM4 O 0 0.0001277305418625474
on O 0 1.2185689229227137e-05
chromosome O 0 0.00011579715646803379
11q13 O 0 0.00019449260435067117
. O 0 4.5913825488241855e-06

Based O 0 4.853559221373871e-05
on O 0 2.9653649107785895e-05
its O 0 2.5252120394725353e-06
chromosomal O 0 0.00013764965115115047
position O 0 1.8217202523374e-05
, O 0 1.4579474338916043e-07
this O 0 2.3147766370357203e-08
gene O 0 1.1505004238188121e-07
is O 0 2.435392332245101e-08
a O 0 5.643792277965076e-08
candidate O 0 1.228974042533082e-07
for O 0 2.003130816774501e-08
conferring O 0 4.579881533572916e-06
susceptibility O 0 0.00017153752560261637
to O 0 1.1305809493933339e-05
diabetes B-Disease 1 0.9999443292617798
. O 0 1.0110070434166119e-05

The O 0 0.00015486139454878867
gene O 0 3.614603338064626e-05
, O 0 4.935130164085422e-06
termed O 0 4.023517976747826e-05
low O 0 7.193472993094474e-05
- O 0 5.6707199291849975e-06
density O 0 4.233268100506393e-06
lipoprotein O 0 5.407761636888608e-05
receptor O 0 1.7793105143937282e-05
related O 0 8.912897101254202e-06
protein O 0 7.32135413272772e-06
5 O 0 1.137394065153785e-05
( O 0 9.827776921156328e-07
LRP5 O 0 2.3559063265565783e-05
) O 0 1.276643359915397e-07
, O 0 3.7267344765723465e-08
encodes O 0 1.7187635137361212e-07
a O 0 8.77367824614339e-07
protein O 0 1.520479145256104e-06
of O 0 2.7119815058540553e-05
1615 O 0 0.0011166948825120926
amino O 0 7.79290530772414e-06
acids O 0 5.32999422375724e-07
that O 0 2.808647714402923e-08
contains O 0 1.8091365916461655e-07
conserved O 0 5.481304583554447e-07
modules O 0 8.419189043706865e-07
which O 0 3.231316014762342e-08
are O 0 1.9537560902449513e-08
characteristic O 0 3.2071181976789376e-07
of O 0 1.431676196261833e-06
the O 0 2.64990694631706e-06
low O 0 2.698818570934236e-05
- O 0 4.053963039041264e-06
density O 0 5.158645308256382e-06
lipoprotein O 0 7.962121162563562e-05
( O 0 3.7926240565866465e-06
LDL O 0 0.00014493422349914908
) O 0 1.0809985724336002e-06
receptor O 0 8.246799552580342e-06
family O 0 1.5223872651404236e-06
. O 0 6.358727659971919e-07

These O 0 1.1598051514738472e-06
modules O 0 1.0369591109338216e-05
include O 0 3.858210391172179e-07
a O 0 1.3279146742206649e-06
putative O 0 8.111655915854499e-06
signal O 0 1.2066798262821976e-05
peptide O 0 1.9500205326039577e-06
for O 0 5.968740310891008e-07
protein O 0 2.4619400846859207e-06
export O 0 7.183253728726413e-06
, O 0 4.12837465546545e-07
four O 0 1.2131873745602206e-06
epidermal O 0 1.189423073810758e-05
growth O 0 6.435108844016213e-06
factor O 0 2.600368588900892e-06
( O 0 1.4141576230031205e-06
EGF O 0 1.420415810571285e-05
) O 0 2.5864540020847926e-07
repeats O 0 7.032095368231239e-07
with O 0 2.584917808690079e-07
associated O 0 4.017599621874979e-06
spacer O 0 1.9002769477083348e-05
domains O 0 1.5165247532422654e-05
, O 0 1.7227017679033452e-06
three O 0 1.879061301224283e-06
LDL O 0 7.099874346749857e-05
- O 0 1.0750618457677774e-05
receptor O 0 8.239197995862924e-06
( O 0 1.08774429463665e-06
LDLR O 0 2.2246924345381558e-05
) O 0 2.583488480922824e-07
repeats O 0 8.890722824617114e-07
, O 0 2.1585894671716233e-07
a O 0 8.174131380656036e-07
single O 0 2.4006151306821266e-06
transmembrane O 0 1.869967491074931e-05
spanning O 0 5.913062341278419e-05
domain O 0 2.3920178136904724e-05
, O 0 6.671214123343816e-07
and O 0 2.6319770540794707e-07
a O 0 1.3465962638292694e-06
cytoplasmic O 0 7.84999610914383e-06
domain O 0 1.557660107209813e-05
. O 0 2.956564230771619e-06

The O 0 3.716571518452838e-05
encoded O 0 7.284324055945035e-06
protein O 0 5.553582013817504e-06
has O 0 3.4606549093041394e-07
a O 0 2.1564659391515306e-07
unique O 0 2.4143213295246824e-07
organization O 0 1.1723043371603126e-06
of O 0 9.682061318017077e-06
EGF O 0 0.00020139513071626425
and O 0 7.794667908456177e-06
LDLR O 0 0.0007300770375877619
repeats O 0 2.1275915059959516e-05
; O 0 9.343147553408926e-07
therefore O 0 1.6782869352027774e-06
, O 0 1.042857093125349e-06
LRP5 O 0 6.294206104939803e-05
likely O 0 6.151405500531837e-07
represents O 0 2.438335116039525e-07
a O 0 1.0317317133967663e-07
new O 0 5.22985885709204e-08
category O 0 1.5589072290822514e-06
of O 0 2.3818925001251046e-06
the O 0 1.5549117961199954e-05
LDLR O 0 0.0009852956281974912
family O 0 8.835874723445158e-06
. O 0 3.8585853872064035e-06

Both O 0 0.0003631937725003809
human O 0 0.0006646278197877109
and O 0 0.000138153787702322
mouse O 0 0.0005787197151221335
LRP5 O 0 0.001700457651168108
cDNAs O 0 0.0001328940998064354
have O 0 1.1737362228814163e-06
been O 0 2.1113876300660195e-06
isolated O 0 1.8516731188356061e-06
and O 0 2.3340250265846407e-07
the O 0 6.252901130210375e-07
encoded O 0 6.166795287754212e-07
mature O 0 3.593782196276152e-07
proteins O 0 2.531426979146545e-08
are O 0 9.840306347541627e-09
95 O 0 1.917845224852499e-07
% O 0 3.026891093327322e-08
identical O 0 5.959941162814175e-08
, O 0 2.4218431704525756e-08
indicating O 0 2.5238631451429683e-07
a O 0 1.2533628535038588e-07
high O 0 2.1408404791145585e-06
degree O 0 9.3991075118538e-06
of O 0 3.463078883214621e-06
evolutionary O 0 9.176879757433198e-06
conservation O 0 1.1424393733250326e-06
. O 0 1.0686507323498518e-07
. O 0 3.7017204590483743e-07

The O 0 0.00017486735305283219
APC B-Disease 0 0.0001758354192133993
variants O 0 1.4434787772188429e-05
I1307K O 0 0.00010000781912822276
and O 0 2.5877591269818367e-06
E1317Q O 0 8.468594023725018e-05
are O 0 1.334879129899491e-06
associated O 0 0.00014081285917200148
with O 1 0.9995984435081482
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0001914953754749149
but O 0 7.202290674968026e-08
not O 0 1.5635757577570075e-08
always O 0 1.9955002983351733e-08
with O 0 4.757535254640288e-09
a O 0 1.3891852290726092e-07
family O 0 2.130972376335194e-07
history O 0 1.7241004570678342e-06
. O 0 1.5670487982788472e-06

Classical O 1 0.9896355271339417
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9959630370140076
FAP B-Disease 1 0.9799273014068604
) O 0 2.8421429760783212e-06
is O 0 6.970826689212117e-07
a O 0 7.01255976309767e-06
high O 1 0.9999871253967285
- O 1 0.9999998807907104
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999861717224121
that O 0 7.747679831027199e-08
predisposes O 0 1.748779027366254e-06
to O 0 1.4756954769268305e-08
hundreds O 0 1.015207402588203e-07
or O 0 9.00447005847127e-08
thousands O 0 2.99341934351105e-07
of O 0 6.901039159856737e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999465942382812
carcinoma I-Disease 1 1.0
and O 0 1.955663492481108e-06
that O 0 6.120566808931471e-08
results O 0 5.534124056794099e-07
from O 0 1.0916814119354967e-07
truncating O 0 5.724397169615258e-07
mutations O 0 8.709788090754955e-08
in O 0 5.575863610829401e-07
the O 0 3.1328479508374585e-06
APC B-Disease 0 4.898388579022139e-05
gene O 0 4.3349223233235534e-06
. O 0 2.029694769589696e-06

A O 0 2.4618511815788224e-05
variant O 0 2.3999900804483332e-05
of O 0 1.4104770343692508e-05
FAP B-Disease 0 0.0011451320024207234
is O 0 2.0391575162648223e-05
attenuated B-Disease 0 0.19894982874393463
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 5.059934119344689e-05
which O 0 5.956553650321439e-06
results O 0 9.945082274498418e-05
from O 0 2.831788151524961e-05
germ O 0 0.001952259917743504
- O 0 2.4834296709741466e-05
line O 0 8.628174327895977e-06
mutations O 0 7.278521962916784e-08
in O 0 2.837360852936399e-07
the O 0 2.1743785794114956e-07
5 O 0 4.004499487564317e-07
and O 0 2.323233694312421e-08
3 O 0 6.960118525967118e-07
regions O 0 9.058335592726507e-08
of O 0 1.6643659819237655e-06
the O 0 1.0999945516232401e-05
APC B-Disease 0 6.996885349508375e-05
gene O 0 6.240180937311379e-06
. O 0 2.411873310848023e-06

Attenuated B-Disease 1 0.9999986886978149
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9989826083183289
have O 0 5.602795226877788e-06
" O 0 2.850956479960587e-05
multiple O 0 0.0023799706250429153
" O 1 0.9999990463256836
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 4.745258138427744e-06
typically O 0 1.2687286243817653e-07
fewer O 0 3.160794292966784e-08
than O 0 2.296298617920911e-08
100 O 0 2.4063038495114597e-07
) O 0 1.324261500457169e-08
without O 0 8.611432456007151e-09
the O 0 1.2433505958142632e-07
florid O 0 7.757497769489419e-06
phenotype O 0 1.8870113080993178e-06
of O 0 2.8675744943029713e-06
classical O 0 9.516195132164285e-05
FAP B-Disease 0 0.00011694141721818596
. O 0 2.3557213353342377e-06

Another O 0 2.7444748411653563e-05
group O 0 9.308417929787538e-07
of O 0 9.73876922216732e-07
patients O 0 1.4581075902242446e-06
with O 0 2.923112845110154e-07
multiple O 0 0.00014034865307621658
adenomas B-Disease 1 0.9999973773956299
has O 0 5.712416623282479e-06
no O 0 5.768898176938819e-07
mutations O 0 3.3010431366164994e-07
in O 0 3.5690850381797645e-06
the O 0 7.256284789036727e-06
APC B-Disease 0 2.0710456738015637e-05
gene O 0 1.0020561376222759e-06
, O 0 1.7653299266839895e-07
and O 0 9.482231888569004e-08
their O 0 1.2557413242575421e-07
phenotype O 0 4.304018602852011e-06
probably O 0 2.146433871530462e-06
results O 0 6.517733481814503e-07
from O 0 1.7956980968847347e-07
variation O 0 8.400862725466141e-07
at O 0 1.0039864719146863e-05
a O 0 1.2518794392235577e-06
locus O 0 7.853560418880079e-06
, O 0 4.1188226873600797e-07
or O 0 5.123850428390142e-07
loci O 0 1.1742345122911502e-06
, O 0 7.784029065760478e-08
elsewhere O 0 5.909501510359405e-08
in O 0 1.271717025019825e-07
the O 0 5.384505925576377e-07
genome O 0 2.8089480110793374e-06
. O 0 1.5704583802289562e-06

Recently O 0 0.00015761199756525457
, O 0 1.96577570932277e-06
however O 0 3.4353519140495337e-07
, O 0 7.929504874937265e-08
a O 0 3.912168153874518e-07
missense O 0 9.57410975388484e-06
variant O 0 0.00011975605593761429
of O 0 0.0024138521403074265
APC B-Disease 0 0.0007073025335557759
( O 0 1.8605858713272028e-05
I1307K O 0 6.686268898192793e-05
) O 0 5.663050046678109e-07
was O 0 8.875863386492711e-07
described O 0 6.412586373016893e-08
that O 0 1.0598502075964689e-09
confers O 0 9.481834695179714e-08
an O 0 1.1645690634054517e-08
increased O 0 1.1834645192720927e-06
risk O 0 9.420680726179853e-06
of O 0 0.1195247545838356
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.5517267456743866e-05
including O 0 1.5571019957860699e-06
multiple O 0 1.2897540727863088e-05
adenomas B-Disease 1 0.6194255352020264
, O 0 1.3047053926129593e-06
in O 0 5.579237949859817e-06
Ashkenazim O 0 0.0003006246406584978
. O 0 1.9586946109484416e-06

We O 0 4.054392320540501e-06
have O 0 6.05459220537341e-08
studied O 0 3.9483529690187424e-07
a O 0 4.223289806759567e-08
set O 0 2.3876042476445036e-08
of O 0 3.688688110514704e-08
164 O 0 3.1755678264744347e-06
patients O 0 4.64385607301665e-07
with O 0 3.259089567109186e-07
multiple O 1 0.9999679327011108
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999914169311523
/ I-Disease 1 1.0
or I-Disease 1 0.9971379041671753
carcinoma I-Disease 1 1.0
and O 0 3.1674640922574326e-05
analyzed O 0 1.472021631343523e-05
codons O 0 1.821761907194741e-05
1263 O 0 7.230541086755693e-05
- O 0 8.762909601500724e-06
1377 O 0 3.6651214031735435e-05
( O 0 7.363446457020473e-07
exon O 0 1.5707580587331904e-06
15G O 0 6.2834214986651205e-06
) O 0 1.1002602917642434e-07
of O 0 1.5259790870914003e-06
the O 0 6.401144673873205e-06
APC B-Disease 0 2.9627641197293997e-05
gene O 0 2.5521387669869e-06
for O 0 4.705278570327209e-06
germ O 0 0.0005734734004363418
- O 0 1.8225977328256704e-05
line O 0 5.327322924131295e-06
variants O 0 1.6780981013653218e-06
. O 0 1.1668022352750995e-06

Three O 0 0.00012453942326828837
patients O 0 1.3554008546634577e-05
with O 0 6.652573460996791e-07
the O 0 6.338569619401824e-06
I1307K O 0 3.227926936233416e-05
allele O 0 1.5297806612579734e-06
were O 0 5.488183205670794e-07
detected O 0 5.986109954392305e-07
, O 0 8.247909022429667e-09
each O 0 4.228381644821866e-09
of O 0 6.132837029326765e-07
Ashkenazi O 0 3.692295285873115e-05
descent O 0 0.00013604074774775654
. O 0 4.206326138955774e-06

Four O 0 0.00024414618383161724
patients O 0 6.096889774198644e-05
had O 0 4.9318499804940075e-05
a O 0 4.4035943574272096e-05
germ O 0 0.0041694738902151585
- O 0 0.00012754385534208268
line O 0 6.187818507896736e-05
E1317Q O 0 6.329947791527957e-05
missense O 0 3.463055327301845e-05
variant O 0 2.6871488444157876e-05
of O 0 0.0001624148862902075
APC O 0 4.571918907458894e-05
that O 0 7.41661494885193e-07
was O 0 1.1917052688659169e-05
not O 0 1.9223351443997672e-07
present O 0 3.44287570896995e-07
in O 0 2.681542127902503e-06
controls O 0 8.513465218129568e-06
; O 0 6.056775987417495e-07
one O 0 2.5584549234736187e-07
of O 0 6.111637276262627e-07
these O 0 1.0072935197058541e-07
individuals O 0 9.488419294712003e-08
had O 0 8.652858127788932e-07
an O 0 8.155243591545513e-08
unusually O 0 7.036858278297586e-07
large O 0 1.3702013745842123e-07
number O 0 5.636352398141753e-07
of O 0 1.305248497374123e-05
metaplastic B-Disease 0 0.0007460197084583342
polyps I-Disease 0 0.0003239678917452693
of I-Disease 0 2.5199118681484833e-05
the I-Disease 0 2.0584557205438614e-05
colorectum I-Disease 0 0.0003929847152903676
. O 0 8.110348971968051e-06

There O 0 1.706623334030155e-05
is O 0 1.1617113386819256e-06
increasing O 0 5.326975269781542e-07
evidence O 0 4.931803800900525e-07
that O 0 7.929263290407107e-08
there O 0 5.261947535473155e-07
exist O 0 2.349652277189307e-06
germ O 0 9.687723650131375e-05
- O 0 3.2685318274161546e-06
line O 0 1.5221839930745773e-06
variants O 0 2.7555276460589084e-07
of O 0 1.148091655522876e-06
the O 0 3.7328782127588056e-06
APC B-Disease 0 1.1317277312627994e-05
gene O 0 1.0737115019310295e-07
that O 0 5.71269165305921e-09
predispose O 0 2.2914623798442335e-07
to O 0 4.332462832934425e-09
the O 0 2.161885070961489e-08
development O 0 3.507400379021419e-07
of O 0 5.306988441589056e-06
multiple O 1 0.9999994039535522
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 1.034965316648595e-05
but O 0 5.057808749597825e-08
without O 0 3.994589548028671e-08
the O 0 2.644925416461774e-07
florid O 0 2.176201087422669e-05
phenotype O 0 2.9009061108808964e-06
of O 0 2.630649760249071e-06
classical O 0 4.586036448017694e-05
FAP B-Disease 0 9.624633094063029e-06
, O 0 1.762464307830669e-08
and O 0 1.3413666843931082e-09
possibly O 0 1.5792324115082579e-09
with O 0 8.14923406533552e-10
importance O 0 1.4505790204566438e-06
for O 0 0.0007316923001781106
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 7.472256584151182e-06
in O 0 4.808699713976239e-07
the O 0 2.3237262780639867e-07
general O 0 5.939383527220343e-07
population O 0 7.757764564075842e-08
. O 0 6.261936391638301e-08
. O 0 5.376008971325064e-07

Genomic O 0 1.6072213838924654e-05
structure O 0 2.561253040767042e-06
of O 0 1.8461190620655543e-06
the O 0 1.9131108274450526e-05
human O 1 0.9999251365661621
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9831601977348328
CLD B-Disease 1 0.9999884366989136
) O 0 3.1886049782769987e-06
gene O 0 4.014661953988252e-06
. O 0 1.163954834737524e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999979734420776
CLD B-Disease 1 1.0
) O 0 5.861097633896861e-06
is O 0 3.138788429168926e-07
caused O 0 1.2910937812193879e-06
by O 0 2.5017680371774986e-08
mutations O 0 8.907665716151314e-08
in O 0 2.1289837093263486e-07
a O 0 1.911507183649519e-07
gene O 0 1.462598788748437e-07
which O 0 6.510936145787127e-08
encodes O 0 1.1471109928606893e-06
an O 0 8.810899316813448e-07
intestinal O 0 0.023020755499601364
anion O 0 0.00020430538279470056
transporter O 0 0.0007446474628522992
. O 0 3.2259204090223648e-06

We O 0 7.539527814515168e-06
report O 0 4.817931085199234e-07
here O 0 4.5925816039016354e-08
the O 0 2.1265257998948073e-08
complete O 0 2.627104436214722e-07
genomic O 0 1.6105639133456862e-06
organization O 0 1.0429894246044569e-06
of O 0 7.002075108175632e-06
the O 0 1.973619691852946e-05
human O 0 9.534505807096139e-05
CLD B-Disease 0 0.0005520193953998387
gene O 0 1.6120760619742214e-06
which O 0 3.0539385420524923e-07
spans O 0 2.8337121875665616e-06
approximately O 0 1.2749086408803123e-06
39kb O 0 2.1228366676950827e-05
, O 0 1.908252329485549e-07
and O 0 1.7020701648107206e-07
comprises O 0 2.4547284738218877e-06
21 O 0 2.7569902158575132e-05
exons O 0 5.55672449991107e-05
. O 0 3.2714538065192755e-06

All O 0 5.396418055170216e-05
exon O 0 0.00011330803681630641
/ O 0 5.4439973609987646e-05
intron O 0 1.6017726011341438e-05
boundaries O 0 9.081080634132377e-07
conform O 0 6.873240749882825e-07
to O 0 2.474044435984979e-07
the O 0 4.067187546752393e-06
GT O 0 0.00018990275566466153
/ O 0 0.00017757521709427238
AG O 0 0.0005579874850809574
rule O 0 2.5958170226658694e-05
. O 0 3.7429306303238263e-06

An O 0 3.7480313039850444e-06
analysis O 0 1.424094193680503e-06
of O 0 5.3748026402899995e-06
the O 0 9.2507507361006e-06
putative O 0 9.386254532728344e-05
promoter O 0 6.454320100601763e-05
region O 0 1.306832359659893e-06
sequence O 0 1.4394937579709222e-06
shows O 0 5.34320770384511e-06
a O 0 2.197856520069763e-05
putative O 0 0.00019887700909748673
TATA O 0 0.00034899194724857807
box O 0 2.2422027541324496e-05
and O 0 7.432517463712429e-07
predicts O 0 3.544763330864953e-06
multiple O 0 7.331858569159522e-07
transcription O 0 2.060749648080673e-05
factor O 0 2.1002419998694677e-06
binding O 0 9.841911605690257e-07
sites O 0 2.6161862933804514e-06
. O 0 1.073467274181894e-06

The O 0 8.90243609319441e-05
genomic O 0 5.9458801842993125e-05
structure O 0 3.992996789747849e-05
was O 0 2.0099556422792375e-05
determined O 0 7.218456516966398e-07
using O 0 1.1585996873009208e-07
DNA O 0 1.850206672315835e-07
from O 0 1.0032784558688945e-07
several O 0 3.841999074438718e-08
sources O 0 7.168986826400214e-08
including O 0 8.415290153607202e-08
multiple O 0 6.990919132476847e-07
large O 0 5.747247087128926e-06
- O 0 1.3929495253250934e-05
insert O 0 1.9609149148891447e-06
libaries O 0 7.155139428505208e-06
and O 0 8.803585416217174e-08
genomic O 0 7.524348006882065e-07
DNA O 0 4.151696941789851e-07
from O 0 1.5993662145774579e-06
Finnish O 0 0.0006946794455870986
CLD B-Disease 1 0.8462960124015808
patients O 0 4.05126265832223e-05
and O 0 2.960573738164385e-06
controls O 0 3.657718843896873e-05
. O 0 3.850729171972489e-06

Exon O 0 0.0026837128680199385
- O 0 7.928722334327176e-05
specific O 0 2.3336312438004825e-07
primers O 0 1.9149267245666124e-05
developed O 0 3.4316846608817286e-07
in O 0 3.099404821682583e-08
this O 0 2.6479973769255594e-09
study O 0 2.8320572553752754e-09
will O 0 8.041566856853422e-10
facilitate O 0 6.647041583818236e-09
mutation O 0 7.85178322360025e-09
screening O 0 2.1560129681574836e-08
studies O 0 2.59516781397906e-08
of O 0 9.172526915790513e-08
patients O 0 2.0986290394375828e-07
with O 0 4.837401235135985e-08
the O 0 6.394579031621106e-06
disease O 0 0.0015266139525920153
. O 0 2.1259941149764927e-06

Genomic O 0 0.00010460639896336943
sequencing O 0 3.160054257023148e-05
of O 0 6.542457413161173e-05
a O 0 0.00017571273201610893
BAC O 0 0.02725330926477909
clone O 0 0.0014967843890190125
H O 1 1.0
_ O 0 8.535072083759587e-06
RG364P16 O 0 1.0939593266812153e-05
revealed O 0 2.2827930479252245e-06
the O 0 4.375624200747552e-07
presence O 0 4.339486565640982e-07
of O 0 1.7472871149948332e-06
another O 0 3.3756467132661783e-07
, O 0 5.6369284351376336e-08
highly O 0 5.0014769215067645e-08
homologous O 0 1.7842543797996768e-07
gene O 0 2.939452201644599e-07
3 O 0 3.896465841535246e-06
of O 0 4.23113760916749e-06
the O 0 1.2972986041859258e-05
CLD B-Disease 0 0.0012840182753279805
gene O 0 1.7096004967243061e-06
, O 0 3.358114852858307e-08
with O 0 2.6385496010306042e-09
a O 0 3.749378763018285e-08
similar O 0 2.3823275796530652e-08
genomic O 0 6.662478426733287e-07
structure O 0 1.0833734904736048e-06
, O 0 3.6103667611087076e-08
recently O 0 1.2049875408592925e-07
identified O 0 9.720510263377946e-08
as O 0 2.6436393341100484e-07
the O 0 1.0506251783226617e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.00024187949020415545
( O 0 2.146729275409598e-05
PDS B-Disease 0 0.0001593774650245905
) O 0 2.5364130351590575e-07
. O 0 5.4815249228568064e-08
. O 0 4.1210697077076475e-07

The O 0 0.00020645337644964457
APCI1307K O 0 0.011921299621462822
allele O 0 0.0002827421703841537
and O 0 3.816027310676873e-05
cancer B-Disease 1 0.9776538014411926
risk O 0 5.884081929252716e-06
in O 0 1.9050952460020198e-06
a O 0 1.543679672977305e-06
community O 0 1.9194112610421143e-07
- O 0 1.058521874597318e-07
based O 0 8.248711935721076e-09
study O 0 7.917109634547614e-09
of O 0 1.5187633550795e-07
Ashkenazi O 0 7.746490155113861e-06
Jews O 0 6.11803852734738e-06
. O 0 1.6673735672156909e-06

Mutations O 0 7.890858250902966e-05
in O 0 1.5175533917499706e-05
APC O 0 7.049486157484353e-05
are O 0 9.179738214015742e-08
classically O 0 9.277636308979709e-06
associated O 0 4.295995665870578e-07
with O 0 9.146214665634034e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.999839186668396
FAP B-Disease 1 0.994755744934082
) O 0 2.600797870400129e-07
, O 0 1.4963976724402528e-08
a O 0 4.146485821365786e-07
highly O 0 0.07446383684873581
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999998807907104
by O 0 4.212676503811963e-05
multiple O 0 0.4973967969417572
intestinal O 1 1.0
polyps B-Disease 1 0.9996175765991211
and O 0 2.840620538790972e-07
, O 0 1.6751892317756756e-08
without O 0 8.553842967273795e-09
surgical O 0 4.70980330646853e-06
intervention O 0 6.450958949244523e-07
, O 0 9.819849822179094e-09
the O 0 1.5390940077963933e-08
development O 0 8.692385335962172e-07
of O 0 0.00014711482799611986
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00036698428448289633
CRC B-Disease 0 0.002900727791711688
) O 0 2.275487759106909e-06
. O 0 1.097676545214199e-06

APC B-Disease 0 0.004225953482091427
is O 0 4.243302464601584e-05
a O 0 9.69696557149291e-05
tumour O 1 1.0
- O 0 0.0002453142951708287
suppressor O 0 0.00014468554581981152
gene O 0 1.5908885586668475e-07
, O 0 1.849927322439271e-08
and O 0 4.2901572072651106e-08
somatic O 0 5.256392796582077e-06
loss O 0 5.4713935242034495e-05
occurs O 0 9.963795491785277e-06
in O 0 5.5859560234239325e-05
tumours B-Disease 1 1.0
. O 0 1.3270335330162197e-05

The O 0 0.0038229268975555897
germline O 0 0.003425345988944173
T O 0 0.0006370600895024836
- O 0 6.084366759750992e-06
to O 0 5.277139507597894e-07
- O 0 1.4303443549579242e-06
A O 0 2.2801145860285033e-06
transversion O 0 1.6181995306396857e-05
responsible O 0 2.1297787498042453e-06
for O 0 1.123307356465375e-06
the O 0 1.6313420928781852e-05
APC O 0 7.5410476711113e-05
I1307K O 0 5.602547389571555e-05
allele O 0 5.8028272178489715e-06
converts O 0 2.4060013856797013e-06
the O 0 1.1299440529910498e-06
wild O 0 1.3074405842417036e-06
- O 0 3.008616431543487e-07
type O 0 2.818485143052385e-07
sequence O 0 1.8358852571509487e-07
to O 0 4.323182736243325e-07
a O 0 2.3703541955910623e-05
homopolymer O 0 0.0012734623160213232
tract O 0 0.35463762283325195
( O 0 3.163738801958971e-05
A8 O 0 0.0004507385892793536
) O 0 4.628319629773614e-07
that O 0 9.9440057965694e-08
is O 0 1.3945226555733825e-06
genetically O 0 8.363512279174756e-06
unstable O 0 7.633331551915035e-05
and O 0 2.3233085357787786e-06
prone O 0 1.3355538612813689e-05
to O 0 4.837137907998112e-07
somatic O 0 2.7198891984880902e-05
mutation O 0 3.83485757993185e-06
. O 0 1.318233103120292e-06

The O 0 0.0001600459945620969
I1307K O 0 0.00040595594327896833
allele O 0 2.4756100174272433e-05
was O 0 1.9045566659769975e-05
found O 0 4.134087419060961e-07
in O 0 1.0029835948444088e-06
6 O 0 4.7617075324524194e-05
. O 0 2.2411818463297095e-06

1 O 0 9.450648940401152e-05
% O 0 4.3409995669208e-06
of O 0 7.5999937507731374e-06
unselected O 0 0.0011798138730227947
Ashkenazi O 0 9.183480142382905e-05
Jews O 0 1.3727176337852143e-05
and O 0 2.162484861401026e-06
higher O 0 1.4535810805682559e-05
proportions O 0 8.27244821266504e-06
of O 0 8.261236871476285e-06
Ashkenazim O 0 8.355936006410047e-05
with O 0 4.903397439193213e-07
family O 0 1.1510329613884096e-06
or O 0 1.2140380931668915e-06
personal O 0 2.3551128833787516e-06
histories O 0 3.0441617582255276e-06
of O 0 0.0001693950907792896
CRC B-Disease 0 0.0036009931936860085
( O 0 7.746461051283404e-06
ref O 0 5.297798998071812e-05
. O 0 3.029198865078797e-07
2 O 0 5.112319286126876e-06
) O 0 3.2147431738849264e-07
. O 0 3.9602392121196317e-07

To O 0 1.6169771015484002e-06
evaluate O 0 1.4764211755391443e-06
the O 0 1.9937444903916912e-06
role O 0 5.314433565217769e-06
of O 0 2.473733911756426e-05
I1307K O 0 0.00024103460600599647
in O 0 3.9718961488688365e-05
cancer B-Disease 0 0.0006122761988081038
, O 0 1.2984320392206428e-06
we O 0 3.7319026091608976e-07
genotyped O 0 1.959144719876349e-05
5 O 0 1.277953833778156e-05
, O 0 1.8661746707948623e-06
081 O 0 0.00010037995525635779
Ashkenazi O 0 2.0175108147668652e-05
volunteers O 0 9.68929839473276e-07
in O 0 5.45708246590948e-07
a O 0 1.1068988214901765e-06
community O 0 4.1768987557588844e-07
survey O 0 1.0877205340875662e-06
. O 0 6.395815148607653e-07

Risk O 0 0.0002510134654585272
of O 0 0.0001413055433658883
developing O 0 0.3612467348575592
colorectal B-Disease 1 1.0
, I-Disease 0 0.002990114036947489
breast I-Disease 1 0.9988679885864258
and I-Disease 0 1.652371429372579e-05
other I-Disease 0 1.2907477184853633e-06
cancers I-Disease 1 0.7901332974433899
were O 0 1.5654562957934104e-05
compared O 0 3.3802789403125644e-05
between O 0 9.842532563197892e-06
genotyped O 0 0.00036996061680838466
I1307K O 0 0.00016117207997012883
carriers O 0 6.96734468874638e-06
and O 0 4.1749576666916255e-06
non O 0 2.3835402316763066e-05
- O 0 1.2939386806465336e-06
carriers O 0 1.0783498538557978e-07
and O 0 5.117760082384848e-08
their O 0 2.5494180988516746e-08
first O 0 6.15568410466949e-07
- O 0 8.504446782353625e-07
degree O 0 1.2891810911241919e-05
relatives O 0 3.032230324606644e-06
. O 0 8.973896683528437e-07

Sperm O 0 8.937973689171486e-06
DNA O 0 1.5508037449762924e-06
analysis O 0 2.637686122852756e-07
in O 0 9.18381601877627e-07
a O 0 2.1758916773251258e-05
Friedreich B-Disease 1 0.9999454021453857
ataxia I-Disease 1 1.0
premutation O 1 0.9999974966049194
carrier O 0 0.00022691026970278472
suggests O 0 4.585712304105982e-06
both O 0 7.312488037314324e-07
meiotic O 0 2.2376396373147145e-05
and O 0 4.215025342091394e-07
mitotic O 0 1.7904021660797298e-06
expansion O 0 2.114575636369409e-06
in O 0 1.0608538332235184e-06
the O 0 2.6515297122386983e-06
FRDA B-Disease 0 0.00027863201103173196
gene O 0 1.0521001058805268e-05
. O 0 3.453639465078595e-06

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 0.2936183512210846
usually O 0 9.994518768507987e-05
caused O 0 6.191408465383574e-05
by O 0 1.2751563360779983e-07
an O 0 8.605147883145037e-08
expansion O 0 2.0260763449186925e-06
of O 0 6.049708645150531e-06
a O 0 1.4476283467956819e-05
GAA O 0 0.0001883176009869203
trinucleotide O 0 5.537775359698571e-05
repeat O 0 2.1860041670151986e-06
in O 0 6.51853497402044e-07
intron O 0 1.242797134182183e-05
1 O 0 8.08553522801958e-06
of O 0 2.358511210331926e-06
the O 0 8.502674063493032e-06
FRDA B-Disease 0 0.0010219111572951078
gene O 0 2.865561327780597e-05
. O 0 7.498340437450679e-06

Occasionally O 0 0.000532580423168838
, O 0 1.584602432558313e-05
a O 0 7.805430868756957e-06
fully O 0 3.198378180968575e-06
expanded O 0 5.552904440264683e-06
allele O 0 5.008426342101302e-06
has O 0 8.789155003796623e-07
been O 0 7.121653879949008e-07
found O 0 2.1215433321231103e-07
to O 0 5.3956672019239704e-08
arise O 0 3.4462198073015315e-07
from O 0 5.593668674919172e-07
a O 0 8.416187142756826e-07
premutation O 0 1.2751378562825266e-05
of O 0 7.688158802920952e-06
100 O 0 1.645945303607732e-05
or O 0 1.8262162484461442e-06
less O 0 1.2009072634100448e-06
triplet O 0 0.00013701582793146372
repeats O 0 1.9847633666358888e-05
. O 0 2.493396777936141e-06

We O 0 1.1047515727113932e-05
have O 0 3.5257917829767393e-07
examined O 0 4.782922928825428e-07
the O 0 1.5634215344562108e-07
sperm O 0 1.6600463936811138e-07
DNA O 0 1.8312165650513634e-07
of O 0 1.6877503412615624e-06
a O 0 1.2439425518095959e-05
premutation O 0 0.0003299273957964033
carrier O 0 6.400663551175967e-05
. O 0 1.1030208952433895e-05

This O 0 2.3928503651404753e-05
mans O 0 0.00046738819219172
leucocyte O 0 0.0003708222066052258
DNA O 0 1.2091507414879743e-05
showed O 0 1.5389377949759364e-05
one O 0 1.846784812187252e-06
normal O 0 7.036267561488785e-06
allele O 0 9.975575494536315e-07
and O 0 1.8396973189283017e-07
one O 0 7.811335933638475e-08
allele O 0 5.0747381408200454e-08
of O 0 2.4263886189146433e-07
approximately O 0 4.089401102191914e-07
100 O 0 3.2261757496598875e-06
repeats O 0 3.1739875794301042e-06
. O 0 1.9752390016947174e-06

His O 0 0.0003470196097623557
sperm O 0 3.71742935385555e-05
showed O 0 1.6088300981209613e-05
an O 0 6.866577564323961e-07
expanded O 0 3.093046871072147e-06
allele O 0 5.9003164096793626e-06
in O 0 1.5741346942377277e-05
a O 0 3.0251532734837383e-05
tight O 0 4.123351027374156e-05
range O 0 9.343323654320557e-06
centering O 0 6.189317446114728e-06
on O 0 1.3521580513042863e-06
a O 0 1.083012364233582e-07
size O 0 4.911582962563443e-08
of O 0 6.305003239504003e-07
approximately O 0 1.0420210401207441e-06
320 O 0 9.977316949516535e-06
trinucleotide O 0 0.00010417517478344962
repeats O 0 2.264149770780932e-05
. O 0 4.5117249101167545e-06

His O 0 0.0011104505974799395
affected O 0 0.0004808877420146018
son O 0 0.00028993189334869385
has O 0 2.201935330958804e-06
repeat O 0 1.6781638123575249e-06
sizes O 0 9.059644980879966e-07
of O 0 4.235214419168187e-06
1040 O 0 2.5993942472268827e-05
and O 0 1.524903950667067e-06
540 O 0 3.525342617649585e-05
. O 0 2.495766239007935e-06

These O 0 7.844323590688873e-06
data O 0 8.90946375875501e-06
suggest O 0 9.169393138108717e-07
that O 0 7.763775045077637e-08
expansion O 0 2.1412447495094966e-06
occurs O 0 4.5801954229318653e-07
in O 0 4.270441138487513e-07
two O 0 2.532212590722338e-07
stages O 0 3.1606878110324033e-06
, O 0 1.6213549258736748e-07
the O 0 1.8681319602364965e-07
first O 0 2.1645861636443442e-07
during O 0 4.818357979274879e-07
meiosis O 0 4.953632810611452e-07
followed O 0 4.782754103871412e-07
by O 0 3.69025734414663e-08
a O 0 3.8509645605699916e-07
second O 0 1.911464778459049e-06
mitotic O 0 9.77198487817077e-06
expansion O 0 1.8496930351830088e-05
. O 0 3.2589202874078183e-06

We O 0 7.263485895236954e-05
also O 0 4.924866061628563e-06
show O 0 2.2232256924326066e-06
that O 0 9.403615308656299e-08
in O 0 5.384562768995238e-07
all O 0 2.187421301869108e-07
informative O 0 1.821287128223048e-06
carrier O 0 4.418077423906652e-06
father O 0 3.579126996555715e-06
to O 0 2.9939647561150196e-07
affected O 0 1.359155021418701e-06
child O 0 3.6679464301414555e-06
transmissions O 0 4.771979092765832e-06
, O 0 1.0241851100545318e-07
with O 0 8.993291444880924e-09
the O 0 1.406284440008676e-07
notable O 0 5.295697746987571e-07
exception O 0 9.27944256545743e-07
of O 0 5.359253009373788e-06
the O 0 8.263766176241916e-06
premutation O 0 4.729219654109329e-05
carrier O 0 3.5464981920085847e-06
, O 0 2.942697676644457e-07
the O 0 2.308188413735479e-07
expansion O 0 4.267274107405683e-07
size O 0 3.0271857553998416e-07
decreases O 0 3.750674068214721e-06
. O 0 3.1446219850295165e-07
. O 0 1.0506485068617621e-06

The O 0 1.9441045878920704e-05
R496H O 0 0.00012271029117982835
mutation O 0 1.515483404546103e-06
of O 0 5.8624341363611165e-06
arylsulfatase O 0 0.0004960551159456372
A O 0 2.2737265680916607e-05
does O 0 3.896514897405723e-07
not O 0 6.484563073172467e-07
cause O 0 0.0005972906947135925
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 9.658681847213302e-06

Deficiency B-Disease 1 0.9999951124191284
of I-Disease 0 0.0010437190067023039
arylsulfatase I-Disease 1 0.5255131721496582
A I-Disease 0 0.0002301116765011102
( O 0 5.9049825722468086e-06
ARSA O 0 0.00018041892326436937
) O 0 3.163038115872041e-07
enzyme O 0 1.7629974990995834e-06
activity O 0 2.283600770169869e-05
causes O 0 0.0004483876109588891
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00018704043759498745
MLD B-Disease 1 1.0
) O 0 7.912628461781424e-06
. O 0 1.0656947324605426e-06

A O 0 1.2409033843141515e-05
number O 0 1.9071712813456543e-06
of O 0 1.882341348391492e-05
ARSA O 0 0.010715517215430737
gene O 0 2.2080266717239283e-05
mutations O 0 8.173622518370394e-06
responsible O 0 1.3661850061907899e-05
for O 0 1.9934188458137214e-05
MLD B-Disease 1 1.0
have O 0 5.201009116717614e-06
been O 0 4.5360488911683206e-06
identified O 0 2.767003707049298e-06
. O 0 1.1159334007970756e-06

Recently O 0 0.00010976325575029477
, O 0 2.8788419967895607e-06
the O 0 2.50964512815699e-06
R496H O 0 3.787631430895999e-05
mutation O 0 1.917135023177252e-06
of O 0 5.160819637239911e-05
ARSA O 0 0.0008411983144469559
was O 0 2.0720059183076955e-05
proposed O 0 5.066904122941196e-07
to O 0 4.652367024959858e-08
be O 0 1.7786987882573158e-07
a O 0 1.018945113173686e-06
cause O 0 5.041837539465632e-06
of O 0 5.6450211559422314e-05
MLD B-Disease 1 1.0
( O 0 3.663464667624794e-05
Draghia O 0 0.00037313002394512296
et O 0 0.001064608688466251
al O 0 8.397320925723761e-05
. O 0 1.1402968880247499e-07
, O 0 1.69005076600115e-07
1997 O 0 1.5551430578852887e-06
) O 0 3.881501129399112e-07
. O 0 4.0325869576918194e-07

We O 0 1.529457040305715e-05
have O 0 1.0037232414106256e-06
investigated O 0 2.186131496273447e-06
the O 0 1.8476866898708977e-06
R496H O 0 1.7058715457096696e-05
mutation O 0 3.5985493695989135e-07
and O 0 2.0583128446105547e-07
found O 0 8.997344735917068e-08
this O 0 3.1398418087746904e-08
mutation O 0 1.7676023844614974e-07
at O 0 3.395488420210313e-06
a O 0 3.587857690945384e-07
relatively O 0 1.2847532104842685e-07
high O 0 8.638643862468598e-07
frequency O 0 2.6866973712458275e-07
in O 0 2.011389739209335e-07
an O 0 1.5047729107209307e-07
African O 0 2.2585371084460348e-07
American O 0 1.355655570023373e-07
population O 0 3.700399986428238e-08
( O 0 5.956781734539618e-08
f O 0 2.552328624005895e-06
= O 0 1.0240107712888857e-06
0 O 0 3.7908597505520447e-07
. O 0 1.889316081360448e-08
09 O 0 1.978930868062889e-06
, O 0 1.2592694531576853e-07
n O 0 2.8544179713207996e-06
= O 0 5.628490725939628e-06
61 O 0 5.570901066676015e-06
subjects O 0 3.484439957901486e-06
) O 0 1.0484504855412524e-06
. O 0 6.355459731821611e-07

The O 0 0.0013144535478204489
ARSA O 0 0.007262099534273148
enzyme O 0 2.4696986656636e-05
activity O 0 6.820449470978929e-06
in O 0 9.844727628660621e-07
subjects O 0 1.391272121509246e-06
with O 0 8.149785202249404e-08
and O 0 3.605856306876376e-07
without O 0 2.3242805013978796e-07
the O 0 1.6153355772985378e-06
R496H O 0 1.4671612007077783e-05
mutation O 0 1.09107099888206e-06
was O 0 7.090993221936515e-06
determined O 0 8.55483904160792e-07
and O 0 2.1473049116593756e-07
found O 0 1.1308156189215879e-07
to O 0 3.567066286791487e-08
be O 0 2.173056117271699e-07
normal O 0 8.370997420570347e-06
. O 0 1.1622211104622693e-06

It O 0 2.7617995783657534e-06
is O 0 5.474732915899949e-07
therefore O 0 2.150875246798023e-07
concluded O 0 5.259028057480464e-07
that O 0 4.4405560117866116e-08
the O 0 8.741556598579336e-07
R496H O 0 2.6530738978181034e-05
mutation O 0 3.5753503198066028e-06
of O 0 5.940201663179323e-05
ARSA O 0 0.0019590239971876144
does O 0 1.0867281616810942e-06
not O 0 2.860793131276296e-07
negatively O 0 6.399060907824605e-07
influence O 0 1.1000123549820273e-06
the O 0 1.5979941281329957e-06
activity O 0 2.633184976730263e-06
of O 0 5.466758011607453e-06
ARSA O 0 0.00017578646657057106
and O 0 2.7243260092291166e-07
is O 0 5.6773696854861555e-08
not O 0 1.6824834858653048e-08
a O 0 4.472491070828255e-07
cause O 0 7.447541975125205e-06
of O 0 0.00024878146359696984
MLD B-Disease 1 1.0

Down O 0 0.0012947199866175652
- O 0 1.0231898158963304e-05
regulation O 0 8.007104952412192e-07
of O 0 6.859888230792421e-07
transmembrane O 0 3.3812269975896925e-05
carbonic O 0 0.00014287748490460217
anhydrases O 0 0.0004886530223302543
in O 0 0.001126631861552596
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999992847442627
lines O 0 0.00013166427379474044
by O 0 7.514237267969293e-07
wild O 0 8.128181434585713e-06
- O 0 9.758843589224853e-06
type O 0 2.728667459450662e-05
von B-Disease 1 0.9996166229248047
Hippel I-Disease 1 0.9999847412109375
- I-Disease 0 0.45257583260536194
Lindau I-Disease 0 0.1592414826154709
transgenes O 0 0.0015467494959011674
. O 0 5.459880412672646e-06

To O 0 4.845305284106871e-06
discover O 0 1.5410290643558255e-06
genes O 0 5.405678393799462e-07
involved O 0 5.485817382577807e-07
in O 0 5.358087491913466e-06
von B-Disease 1 0.9471316933631897
Hippel I-Disease 1 0.9999881982803345
- I-Disease 1 0.999923825263977
Lindau I-Disease 1 0.9999500513076782
( O 0 0.00030266621615737677
VHL B-Disease 0 0.10287564992904663
) O 0 2.404636688879691e-06
- O 0 4.157737294008257e-06
mediated O 0 2.0694305931101553e-05
carcinogenesis O 0 0.0023586752358824015
, O 0 1.8693866365993017e-07
we O 0 1.0247810422470138e-07
used O 0 1.296079335588729e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999994039535522
lines O 0 0.0004215997760184109
stably O 0 0.0007877263706177473
transfected O 0 5.252353730611503e-05
with O 0 8.394463861804979e-07
wild O 0 1.7890703020384535e-05
- O 0 4.6191220462787896e-05
type O 0 0.00013781093002762645
VHL O 0 0.006537885870784521
- O 0 2.4801449399092235e-05
expressing O 0 2.540695959396544e-06
transgenes O 0 0.00011259544407948852
. O 0 3.035351937796804e-06

Large O 0 4.519562207860872e-05
- O 0 5.37022197022452e-06
scale O 0 1.0278038644173648e-05
RNA O 0 6.03005537413992e-06
differential O 0 2.2381818780559115e-05
display O 0 4.73627878818661e-05
technology O 0 7.961866685946006e-06
applied O 0 1.1404854376451112e-06
to O 0 6.157133469741893e-08
these O 0 4.5483758981390565e-08
cell O 0 1.6839127283674316e-06
lines O 0 1.5734926250843273e-07
identified O 0 1.6390291790457923e-08
several O 0 1.1061896287856143e-08
differentially O 0 5.956292739028868e-07
expressed O 0 6.908405225658498e-08
genes O 0 6.93806398999186e-08
, O 0 1.9051659805313648e-08
including O 0 1.7930178231040372e-08
an O 0 7.881931196607184e-08
alpha O 0 7.863183782319538e-06
carbonic O 0 3.1684186978964135e-05
anhydrase O 0 0.00014836039918009192
gene O 0 6.2656254158355296e-06
, O 0 1.5036296190373832e-06
termed O 0 6.0693753766827285e-05
CA12 O 0 0.000974557246081531
. O 0 1.0644418580341153e-05

The O 0 8.434985647909343e-05
deduced O 0 2.817541462718509e-05
protein O 0 6.818017482146388e-06
sequence O 0 1.9860681277350523e-06
was O 0 1.8526519852457568e-05
classified O 0 2.471505013090791e-06
as O 0 2.100256097037345e-06
a O 0 5.255049927654909e-06
one O 0 3.2563011700403877e-06
- O 0 1.8694949176278897e-05
pass O 0 2.200568087573629e-05
transmembrane O 0 0.00018521706806495786
CA O 0 6.378977559506893e-05
possessing O 0 1.6450838302262127e-05
an O 0 3.194521923433058e-06
apparently O 0 5.378012247092556e-06
intact O 0 3.1537538234260865e-06
catalytic O 0 6.567285595338035e-07
domain O 0 1.2313067827562918e-06
in O 0 2.136449438694399e-06
the O 0 8.715304829820525e-06
extracellular O 0 0.00026659859577193856
CA O 0 0.00032353639835491776
module O 0 0.0003080700698774308
. O 0 6.918281542311888e-06

Reintroduced O 0 0.0014126368332654238
wild O 0 0.00042495690286159515
- O 0 0.0007185969152487814
type O 0 0.00019517866894602776
VHL B-Disease 0 0.002969789318740368
strongly O 0 1.5717633914391627e-06
inhibited O 0 4.813242071577406e-07
the O 0 3.604222342801222e-08
overexpression O 0 5.36745915269421e-07
of O 0 2.1172846231820586e-07
the O 0 2.174115252273623e-07
CA12 O 0 7.871113666624296e-06
gene O 0 3.53060940483374e-08
in O 0 3.086543998165325e-08
the O 0 2.9665807232959196e-07
parental O 0 0.00015283114043995738
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.002687569707632065
. O 0 8.219053597713355e-06

Similar O 0 1.200964834424667e-05
results O 0 7.492764325434109e-06
were O 0 1.1427194976931787e-06
obtained O 0 7.900886771494697e-07
with O 0 4.166026883467566e-07
CA9 O 0 0.0008015018538571894
, O 0 1.4595781294701737e-06
encoding O 0 5.195070116315037e-06
another O 0 9.322675396106206e-06
transmembrane O 0 0.0001356279681203887
CA O 0 3.298830415587872e-05
with O 0 2.3590708053689013e-07
an O 0 1.5541304492217023e-06
intact O 0 1.6353344108210877e-05
catalytic O 0 1.218337729369523e-05
domain O 0 3.412301521166228e-05
. O 0 3.3164239994221134e-06

Although O 0 1.063356194208609e-05
both O 0 1.9183478343620664e-06
domains O 0 1.4026431927049998e-05
of O 0 1.655227788432967e-05
the O 0 2.7021429559681565e-05
VHL B-Disease 0 0.0005134673556312919
protein O 0 4.691764388553565e-06
contribute O 0 2.1002368555400608e-07
to O 0 2.583840625902667e-07
regulation O 0 3.0731030165043194e-06
of O 0 2.081992533931043e-05
CA12 O 0 0.0013085509417578578
expression O 0 8.308659016620368e-05
, O 0 2.1939010821370175e-06
the O 0 2.230695145044592e-06
elongin O 0 4.5252207200974226e-05
binding O 0 4.773990895046154e-06
domain O 0 8.329445336130448e-06
alone O 0 1.4824513527855743e-06
could O 0 1.665287072682986e-07
effectively O 0 1.7898149735628976e-06
regulate O 0 9.887379746942315e-06
CA9 O 0 0.001565312733873725
expression O 0 2.2890037143952213e-05
. O 0 1.8809796529239975e-06

We O 0 3.273009497206658e-05
mapped O 0 0.00010251587082166225
CA12 O 0 0.003014423418790102
and O 0 7.281793659785762e-05
CA9 O 0 0.010062623769044876
loci O 0 3.363474752404727e-05
to O 0 9.885757208394352e-07
chromosome O 0 2.5294340957771055e-05
bands O 0 1.1923066267627291e-05
15q22 O 0 7.276137330336496e-05
and O 0 4.105961124878377e-06
17q21 O 0 0.00019296389655210078
. O 0 4.768021426571067e-06

2 O 0 0.0009298308868892491
respectively O 0 0.0002662947808858007
, O 0 2.182144726248225e-06
regions O 0 2.757930360530736e-06
prone O 0 7.02271199770621e-06
to O 0 9.237769660330741e-08
amplification O 0 2.874370466088294e-06
in O 0 6.940750267858675e-07
some O 0 5.091909542898065e-07
human O 0 0.00011565325257834047
cancers B-Disease 1 0.860037088394165
. O 0 5.7655215641716495e-06

Additional O 0 1.4736788216396235e-05
experiments O 0 2.2967093173065223e-05
are O 0 5.480713980432483e-07
needed O 0 3.5151120414411707e-07
to O 0 5.8267229263719855e-08
define O 0 5.961765623396786e-07
the O 0 1.8796383756125579e-06
role O 0 5.883414814888965e-06
of O 0 6.499903975054622e-05
CA O 0 6.681749800918624e-05
IX O 0 0.0006027833442203701
and O 0 1.8110500604962e-05
CA O 0 1.9547944248188287e-05
XII O 0 0.0002314788434887305
enzymes O 0 1.4938487993276794e-06
in O 0 1.411912535331794e-06
the O 0 9.89635964288027e-07
regulation O 0 6.84797214489663e-07
of O 0 2.4415328425675398e-06
pH O 0 3.709136217366904e-05
in O 0 5.901987151446519e-06
the O 0 6.00868406763766e-06
extracellular O 0 1.9338054698891938e-05
microenvironment O 0 2.4734463295317255e-05
and O 0 1.3850103641743772e-07
its O 0 2.028889767302644e-08
potential O 0 1.1107737662996442e-07
impact O 0 1.8023463326244382e-06
on O 0 2.1974961782689206e-05
cancer B-Disease 0 0.11586311459541321
cell O 0 0.00014412292512133718
growth O 0 1.1424075637478381e-05
. O 0 9.035193215822801e-07

A O 0 2.3854137907619588e-05
gene O 0 2.758096115940134e-06
encoding O 0 1.4524298421747517e-06
a O 0 6.05525087848946e-07
transmembrane O 0 3.440926548137213e-06
protein O 0 6.25806137577456e-07
is O 0 7.607016350164031e-09
mutated O 0 2.465712434229772e-08
in O 0 1.2361214274392296e-08
patients O 0 1.3827403222421708e-07
with O 0 1.6896267140964483e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999741315841675
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.999998927116394
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 8.9049954112852e-06
. O 0 1.4382696917891735e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.5937069654464722
WFS B-Disease 1 0.9999948740005493
; O 0 1.791542672435753e-05
OMIM O 1 0.9913864135742188
222300 O 0 0.00016443754429928958
) O 0 3.0693286134919617e-07
is O 0 6.067332236625589e-08
an O 0 4.475238597478892e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 0.0013377269497141242
by O 0 5.540582037610875e-07
young O 0 2.327040192540153e-06
- O 0 3.449387077125721e-05
onset O 1 0.9998072981834412
non O 1 0.9994539618492126
- O 1 0.6441400051116943
immune O 1 0.5235764980316162
insulin B-Disease 1 0.8530649542808533
- I-Disease 0 0.0011529315961524844
dependent I-Disease 0 0.14901672303676605
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.3844834864139557
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999992847442627
. O 0 1.1500134860398248e-05

Linkage O 0 0.0008514641667716205
to O 0 1.0682287211238872e-05
markers O 0 4.3933090637438e-05
on O 0 3.848941923934035e-05
chromosome O 0 0.00021267635747790337
4p O 0 0.002160102827474475
was O 0 2.174493965867441e-05
confirmed O 0 9.583934570400743e-07
in O 0 4.3234712165940437e-07
five O 0 5.193566607886169e-07
families O 0 7.469796514669724e-08
. O 0 3.840647764263849e-07

On O 0 4.7180305955407675e-06
the O 0 1.5588359758567094e-07
basis O 0 4.968143230144051e-07
of O 0 5.166936716705095e-06
meiotic O 0 0.0015572410775348544
recombinants O 0 0.07287192344665527
and O 0 0.00016382327885366976
disease O 1 0.9999368190765381
- O 0 7.781142630847171e-05
associated O 0 2.7358730676496634e-06
haplotypes O 0 1.0281803952238988e-05
, O 0 4.1428887698202743e-07
the O 0 2.0658383164118277e-06
WFS B-Disease 0 0.0002133626549039036
gene O 0 2.925652552221436e-06
was O 0 1.0297651897417381e-05
localized O 0 6.3711017901368905e-06
to O 0 5.473249871101871e-07
a O 0 1.0621095498208888e-05
BAC O 0 0.0007972756866365671
/ O 0 0.0001290842774324119
P1 O 0 0.00036194288986735046
contig O 0 0.00014988625480327755
of O 0 1.2904529285151511e-05
less O 0 1.8346197521168506e-06
than O 0 6.016987867951684e-07
250 O 0 6.6826396505348384e-06
kb O 0 0.00015561882173642516
. O 0 5.593590685748495e-06

Mutations O 0 1.4087279851082712e-05
in O 0 3.937082965421723e-06
a O 0 2.848522399290232e-06
novel O 0 4.108342182007618e-06
gene O 0 2.451703494443791e-06
( O 0 1.814726488191809e-06
WFS1 O 0 6.084854976506904e-05
) O 0 7.44817043596413e-07
encoding O 0 3.54512872036139e-06
a O 0 1.2360703294689301e-05
putative O 0 5.7394001487409696e-05
transmembrane O 0 3.332117194077e-05
protein O 0 1.074252122634789e-05
were O 0 1.9724529920495115e-06
found O 0 1.2535564053450798e-07
in O 0 1.8013395219895756e-07
all O 0 8.707047527423128e-08
affected O 0 4.739848691315274e-07
individuals O 0 7.813942914935978e-08
in O 0 3.187796210113447e-06
six O 0 3.561682751751505e-05
WFS B-Disease 0 0.0013179754605516791
families O 0 1.1047520587226245e-07
, O 0 3.458822916968529e-08
and O 0 4.444129508840433e-09
these O 0 1.2184802056225408e-09
mutations O 0 1.4302112383290932e-08
were O 0 2.5588835939061028e-08
associated O 0 1.8742666085813653e-08
with O 0 1.2661789838830373e-08
the O 0 1.91047524822352e-06
disease O 0 0.0004895917372778058
phenotype O 0 7.241478306241333e-05
. O 0 2.8829631446569692e-06

WFS1 O 0 0.006038262974470854
appears O 0 9.584624422132038e-06
to O 0 2.39516509736859e-07
function O 0 3.2149987418961246e-06
in O 0 1.0183874792346614e-06
survival O 0 7.588855623907875e-06
of O 0 1.5254918253049254e-05
islet O 0 0.0002836493367794901
beta O 0 8.299363980768248e-05
- O 0 2.732034590735566e-05
cells O 0 1.1440257594586e-06
and O 0 2.745193228292919e-07
neurons O 0 1.6086746654764283e-06
. O 0 5.283942883238524e-08
. O 0 1.7007737085350527e-07

Stable O 0 0.0006330254836939275
interaction O 0 3.134910457447404e-06
between O 0 1.512033009021252e-06
the O 0 1.0871739277718007e-06
products O 0 2.313391433972356e-07
of O 0 3.4794817338479334e-07
the O 0 5.403117029345594e-07
BRCA1 O 0 4.280608663975727e-06
and O 0 1.5959747088345466e-06
BRCA2 O 0 3.156063758069649e-05
tumor B-Disease 0 0.00014288946113083512
suppressor O 0 3.0180131943779998e-05
genes O 0 2.127981133526191e-07
in O 0 5.931509576839744e-07
mitotic O 0 4.415343482833123e-06
and O 0 1.7765945585779264e-06
meiotic O 0 0.00021835736697539687
cells O 0 6.434407987399027e-05
. O 0 3.0422199870372424e-06

BRCA1 O 0 0.0012032807571813464
and O 0 7.589173492306145e-06
BRCA2 O 0 5.041606982558733e-06
account O 0 2.3545052130202748e-08
for O 0 4.634438610651159e-09
most O 0 2.182949598861228e-09
cases O 0 4.393543751035622e-09
of O 0 3.329459374867838e-08
familial O 0 8.348690244019963e-06
, O 0 1.3224899930719403e-07
early O 0 1.8769158032228006e-06
onset O 1 0.9994977712631226
breast B-Disease 1 0.9997535347938538
and I-Disease 0 0.0005817683413624763
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.764285222336184e-06
encode O 0 1.6478960560561973e-06
products O 0 2.040293111349456e-06
that O 0 3.8960681791877505e-08
each O 0 2.80823009290998e-08
interact O 0 1.0711096365412232e-07
with O 0 3.3824004930238516e-08
hRAD51 O 0 1.4742860912519973e-05
. O 0 1.6392439192713937e-06

Results O 0 7.044633821351454e-05
presented O 0 6.496710284409346e-06
here O 0 1.4118601256996044e-06
show O 0 3.125931300473894e-07
that O 0 5.694103322184674e-08
BRCA1 O 0 1.6514485423613223e-06
and O 0 5.930932616138307e-07
BRCA2 O 0 4.808562607649947e-06
coexist O 0 7.689453127568413e-07
in O 0 4.979247023584321e-07
a O 0 1.5133674651224283e-06
biochemical O 0 3.949234451283701e-05
complex O 0 7.157685467973351e-05
and O 0 4.153936515649548e-06
colocalize O 0 0.00015449797501787543
in O 0 3.4185064578196034e-05
subnuclear O 0 0.0007705134339630604
foci O 0 0.0003652576415333897
in O 0 1.672721373324748e-05
somatic O 0 7.376502708211774e-06
cells O 0 7.925616500870092e-07
and O 0 4.535762343493843e-08
on O 0 1.587672358027703e-07
the O 0 7.683678404646344e-08
axial O 0 5.061891101831861e-07
elements O 0 5.021282731831889e-07
of O 0 2.540095238146023e-06
developing O 0 8.501717275066767e-06
synaptonemal O 0 0.00015555947902612388
complexes O 0 8.530784543836489e-05
. O 0 3.861552158923587e-06

Like O 0 0.00012103750486858189
BRCA1 O 0 0.00017112941714003682
and O 0 2.8124701202614233e-05
RAD51 O 0 0.0020288031082600355
, O 0 5.229418093222193e-06
BRCA2 O 0 7.556458513136022e-06
relocates O 0 2.5183528578054393e-06
to O 0 1.6558973925384635e-07
PCNA O 0 1.7222306269104593e-05
+ O 0 1.0166796755584073e-06
replication O 0 5.921935297692471e-08
sites O 0 6.529192120297012e-08
following O 0 1.653763774811523e-07
exposure O 0 2.5811684736254392e-06
of O 0 1.6050509657361545e-05
S O 0 0.0004957277560606599
phase O 0 4.570110104396008e-05
cells O 0 4.566240022541024e-06
to O 0 1.0570122412900673e-06
hydroxyurea O 0 0.00017468933947384357
or O 0 1.8727405404206365e-05
UV O 0 0.0005634196568280458
irradiation O 0 5.769872950622812e-05
. O 0 1.6011213119782042e-06

Thus O 0 0.000118837138870731
, O 0 7.5637694862962235e-06
BRCA1 O 0 1.117216561397072e-05
and O 0 1.4323072718980256e-06
BRCA2 O 0 2.723268607951468e-06
participate O 0 2.102056271269248e-07
, O 0 9.186253890902663e-08
together O 0 2.4886704252935488e-08
, O 0 6.608348712688894e-08
in O 0 5.352172252059972e-07
a O 0 2.8220563308423152e-06
pathway O 0 5.6770240917103365e-06
( O 0 1.3467541748468648e-06
s O 0 1.0174644557991996e-05
) O 0 9.629204811290037e-08
associated O 0 1.7731606760662544e-07
with O 0 7.627374287721977e-08
the O 0 2.0159786799922585e-06
activation O 0 4.7111334424698725e-06
of O 0 2.155459878849797e-05
double O 0 1.983395304705482e-05
- O 0 7.279650162672624e-06
strand O 0 4.51789901489974e-06
break O 0 2.785722699627513e-06
repair O 0 9.171018064080272e-06
and O 0 1.791288696040283e-06
/ O 0 2.2575350158149377e-05
or O 0 6.168971253828204e-07
homologous O 0 1.0960320651065558e-06
recombination O 0 1.348954810964642e-06
. O 0 8.78585240116081e-07

Dysfunction O 1 0.999998927116394
of O 0 0.005263502709567547
this O 0 2.7672973374137655e-05
pathway O 0 0.0001189198883366771
may O 0 1.1566415878405678e-06
be O 0 4.209594095527791e-08
a O 0 3.404601400802676e-08
general O 0 7.747295427407153e-08
phenomenon O 0 7.317510863913412e-08
in O 0 4.4732137993719334e-09
the O 0 2.1295041285895877e-09
majority O 0 6.65629995566519e-10
of O 0 6.4151648437871245e-09
cases O 0 3.508342771851858e-08
of O 0 1.3406481684796745e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9916810393333435
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.736399882356636e-07
. O 0 6.621899615311122e-07

A O 0 0.00011522175191203132
novel O 0 2.7436532036517747e-05
Arg362Ser O 0 0.00026682260795496404
mutation O 0 2.0321836018410977e-06
in O 0 3.4863346627389546e-06
the O 0 4.344582066551084e-06
sterol O 0 3.301253673271276e-05
27 O 0 0.00018853983783628792
- O 0 4.684326268034056e-05
hydroxylase O 0 0.00010642927372828126
gene O 0 3.226273975087679e-06
( O 0 2.4810149170662044e-06
CYP27 O 0 0.00012480156146921217
) O 0 9.722343747853301e-07
: O 0 1.199226744574844e-07
its O 0 1.508820872686556e-07
effects O 0 2.8084873520128895e-06
on O 0 4.47550019089249e-06
pre O 0 1.3205659342929721e-05
- O 0 7.285868832695996e-07
mRNA O 0 3.070511525038455e-07
splicing O 0 6.748693692770757e-08
and O 0 8.863194977948297e-08
enzyme O 0 4.5549393234978197e-07
activity O 0 3.5586442663770868e-06
. O 0 1.0142063047169358e-06

A O 0 5.850082015967928e-05
novel O 0 7.794064913468901e-06
C O 0 5.7979479606729e-05
to O 0 1.7485061221123033e-07
A O 0 1.3634002016260638e-06
mutation O 0 1.4540165693688323e-07
in O 0 6.243635652936064e-07
the O 0 1.7215177194884745e-06
sterol O 0 1.4547514183504973e-05
27 O 0 0.00011489917960716411
- O 0 3.33357929775957e-05
hydroxylase O 0 4.593123230733909e-05
gene O 0 1.5430143776029581e-06
( O 0 7.287536618605372e-07
CYP27 O 0 2.46564613917144e-05
) O 0 8.78369377232957e-08
was O 0 4.808644575859944e-07
identified O 0 2.2644004005201168e-08
by O 0 9.476009310560585e-09
sequencing O 0 1.2029188383166911e-06
amplified O 0 1.0889777513511945e-05
CYP27 O 0 0.00013673235662281513
gene O 0 9.469035830989014e-07
products O 0 3.658894343061547e-07
from O 0 1.5427157507019729e-07
a O 0 4.4693871359413606e-07
patient O 0 2.439200898152194e-06
with O 0 1.7312279396719532e-06
cerebrotendinous B-Disease 1 0.9999990463256836
xanthomatosis I-Disease 1 0.9999991655349731
( O 0 7.806017674738541e-05
CTX B-Disease 0 0.0033861687406897545
) O 0 2.433067493257113e-06
. O 0 9.717449529489386e-07

The O 0 4.53814172942657e-05
mutation O 0 1.0690328963391948e-05
changed O 0 1.793594128685072e-05
the O 0 7.457974788849242e-06
adrenodoxin O 0 9.217126353178173e-05
cofactor O 0 2.2308600819087587e-05
binding O 0 3.851306246360764e-06
residue O 0 2.3027912902762182e-05
362Arg O 0 1.391953628626652e-05
to O 0 1.8731498130364344e-06
362Ser O 0 8.047775918385014e-05
( O 0 1.875330417533405e-05
CGT O 0 0.0009718977962620556
362Arg O 0 2.873573794204276e-05
to O 0 3.1373838282888755e-06
AGT O 0 0.0005921467090956867
362Ser O 0 4.0006194467423484e-05
) O 0 5.971359655632114e-07
, O 0 9.109551513120095e-08
and O 0 8.265362083648142e-08
was O 0 4.068758698849706e-06
responsible O 0 2.6210411760985153e-06
for O 0 4.777188223670237e-06
deficiency O 1 0.9809930324554443
in O 0 0.00013440297334454954
the O 0 9.019080607686192e-05
sterol O 0 0.0001830866967793554
27 O 0 0.0007058702758513391
- O 0 4.701408397522755e-05
hydroxylase O 0 3.332488995511085e-05
activity O 0 1.683333039181889e-06
, O 0 2.5468567699249434e-08
as O 0 1.4732655984062148e-08
confirmed O 0 2.0194848460164394e-08
by O 0 4.945148290858015e-09
expression O 0 1.680173795648443e-07
of O 0 8.029448963497998e-07
mutant O 0 1.9078022432950092e-06
cDNA O 0 4.131866262468975e-06
into O 0 3.379058853170136e-06
COS O 0 0.00013584343832917511
- O 0 7.443310551025206e-06
1 O 0 8.48856052471092e-06
cells O 0 2.5176327653753106e-06
. O 0 5.956792961114843e-07

Quantitative O 0 0.00012588081881403923
analysis O 0 5.056833288108464e-06
showed O 0 1.7144757293863222e-06
that O 0 3.1390033683464935e-08
the O 0 2.4132322096193093e-07
expression O 0 8.259702894974907e-07
of O 0 1.6852171711434494e-06
CYP27 O 0 2.230921745649539e-05
gene O 0 1.0043851261798409e-07
mRNA O 0 2.7941200642089825e-07
in O 0 1.5340597769863962e-07
the O 0 3.590572248413082e-07
patient O 0 1.846638610913942e-06
represented O 0 4.562874892144464e-06
52 O 0 6.840199785074219e-05
. O 0 3.328048705952824e-06

5 O 0 2.0327734091551974e-05
% O 0 1.4350540595842176e-06
of O 0 1.7137335817096755e-06
the O 0 5.375274213292869e-06
normal O 0 0.00010468423715792596
level O 0 0.0003154095320496708
. O 0 5.119725756230764e-06

As O 0 1.286817769141635e-05
the O 0 1.521671606496966e-06
mutation O 0 4.7162305349957023e-07
occurred O 0 1.2055272236466408e-05
at O 0 7.983308023540303e-06
the O 0 8.555328463444312e-07
penultimate O 0 1.1858951438625809e-05
nucleotide O 0 2.8715319331240607e-06
of O 0 2.3330876501859166e-05
exon O 0 9.537675396131817e-06
6 O 0 5.092337232781574e-05
( O 0 1.2967168458999367e-06
- O 0 1.7915363059728406e-06
2 O 0 1.1057602932851296e-05
position O 0 3.468545855866978e-06
of O 0 9.603260878066067e-06
exon O 0 6.484578079835046e-06
6 O 0 2.471395055181347e-05
- O 0 3.6176918456476415e-06
intron O 0 7.25254176359158e-06
6 O 0 1.311286905547604e-05
splice O 0 2.62797925643099e-06
site O 0 1.2454646594051155e-06
) O 0 5.876512076952167e-08
of O 0 6.954996365493571e-07
the O 0 1.7311882629655884e-06
gene O 0 2.075083102681674e-06
, O 0 4.771559929395153e-07
we O 0 1.0399308081332492e-07
hypothesized O 0 4.59048465017986e-07
that O 0 3.08509022772796e-08
the O 0 3.6329558383840777e-07
mutation O 0 2.336200566332991e-07
may O 0 7.74506361267413e-07
partially O 0 1.265177843379206e-06
affect O 0 1.1166004298956977e-07
the O 0 2.704386190544028e-07
normal O 0 1.257341409655055e-06
splicing O 0 1.2970666318778967e-07
efficiency O 0 7.148682357183134e-07
in O 0 3.928348917270341e-07
exon O 0 1.1556713843674515e-06
6 O 0 6.445820417866344e-06
and O 0 3.362239624493668e-07
cause O 0 2.912832314905245e-06
alternative O 0 5.263157163426513e-07
splicing O 0 4.470742851481191e-07
elsewhere O 0 7.864856854666868e-08
, O 0 4.25792956448845e-09
which O 0 9.057532501799415e-10
resulted O 0 2.626850736930919e-08
in O 0 1.0328697896966332e-07
decreased O 0 1.0924236448772717e-05
transcript O 0 3.9999372347665485e-06
in O 0 5.439696337816713e-07
the O 0 1.8189698494097684e-06
patient O 0 1.112942845793441e-05
. O 0 2.509436853870284e-06

Transfection O 0 0.003553005401045084
of O 0 0.0007057556067593396
constructed O 0 0.0005043080309405923
minigenes O 0 0.00040534246363677084
, O 0 1.665757167756965e-06
with O 0 1.343416187182811e-07
or O 0 9.824132121138973e-07
without O 0 1.6185231288545765e-07
the O 0 1.8043411955659394e-06
mutation O 0 4.6540270659534144e-07
, O 0 6.772678489141981e-07
into O 0 2.572471657913411e-06
COS O 0 0.00011674577399389818
- O 0 8.747730134928133e-06
1 O 0 8.648553375678603e-06
cells O 0 3.477338736956881e-07
confirmed O 0 1.046520949898877e-07
that O 0 1.5611441028795525e-08
the O 0 2.3478374089336285e-07
mutant O 0 5.0581543291627895e-06
minigene O 0 2.0628378479159437e-05
was O 0 4.797720066562761e-06
responsible O 0 4.861042270931648e-07
for O 0 1.6134899283315463e-07
a O 0 4.269936368928029e-07
mRNA O 0 8.421919801548938e-07
species O 0 4.4496108131397705e-08
alternatively O 0 3.6979130868530774e-07
spliced O 0 2.2060401079215808e-06
at O 0 1.4336547792481724e-05
an O 0 7.964607675603474e-07
activated O 0 2.1684758394258097e-05
cryptic O 0 1.8701226508710533e-05
5 O 0 1.76138746610377e-05
splice O 0 2.0669969671871513e-05
site O 0 2.7924103051191196e-05
88 O 0 5.103557850816287e-05
bp O 0 1.022303149511572e-05
upstream O 0 6.0394531828933395e-06
from O 0 1.0555485232544015e-06
the O 0 1.108477022171428e-06
3 O 0 6.46918533675489e-06
end O 0 2.6721043013822054e-06
of O 0 3.907920017809374e-06
exon O 0 1.0027750249719247e-05
6 O 0 6.384556763805449e-05
. O 0 3.36040079673694e-06

Our O 0 7.830911636119708e-05
data O 0 1.0125064363819547e-05
suggest O 0 8.084495561888616e-07
that O 0 9.475451889784381e-08
the O 0 1.718007865747495e-06
C O 0 1.8949131117551588e-05
to O 0 1.1327639271030421e-07
A O 0 3.2753530376794515e-06
mutation O 0 3.833299899724807e-07
at O 0 4.142720626987284e-06
the O 0 4.458169939880463e-07
penultimate O 0 4.257353339198744e-06
nucleotide O 0 3.7013850828770956e-07
of O 0 1.1710081935234484e-06
exon O 0 1.0015087354986463e-06
6 O 0 3.668320687211235e-06
of O 0 8.635018957647844e-07
the O 0 1.3003094636587775e-06
CYP27 O 0 4.9013931857189164e-05
gene O 0 3.374002233158535e-07
not O 0 5.510089451377098e-08
only O 0 1.5653340312837827e-07
causes O 0 2.9311149774002843e-06
the O 0 4.077028279425576e-06
deficiency B-Disease 0 0.00021194273722358048
in I-Disease 0 1.102776968764374e-05
the I-Disease 0 1.4689055205963086e-05
sterol I-Disease 0 4.784407065017149e-05
27 I-Disease 0 0.00033958686981350183
- I-Disease 0 5.199568477110006e-05
hydroxylase I-Disease 0 0.00010609185846988112
activity I-Disease 0 1.6225525541813113e-05
, O 0 2.45068861204345e-07
but O 0 3.9754507241696047e-08
also O 0 2.236541405409298e-07
partially O 0 2.683386355784023e-06
leads O 0 4.817990770789038e-07
to O 0 4.875713344176802e-08
alternative O 0 8.858175704062887e-08
pre O 0 2.1782066141895484e-06
- O 0 2.0409652279340662e-07
mRNA O 0 8.975953136314274e-08
splicing O 0 4.412458309843714e-08
of O 0 3.131361552277667e-07
the O 0 7.43911243716866e-07
gene O 0 1.8411153632769128e-06
. O 0 9.527043403068092e-07

To O 0 1.2573987078212667e-05
our O 0 5.757780400017509e-06
knowledge O 0 7.205627753137378e-06
, O 0 3.9161773202067707e-07
this O 0 6.685978348741628e-08
is O 0 1.338418655905116e-07
the O 0 2.521962585433357e-07
first O 0 7.777645691930957e-07
report O 0 3.372332741946593e-07
regarding O 0 7.477378289877379e-07
effects O 0 5.016945124225458e-06
on O 0 9.918999239744153e-06
pre O 0 1.1910554349015001e-05
- O 0 6.371426479745423e-07
mRNA O 0 2.0526947253074468e-07
splicing O 0 9.15770286269435e-08
of O 0 1.2967268503416562e-06
a O 0 1.4793471336815855e-06
mutation O 0 3.3074840644076176e-07
at O 0 1.1609778084675781e-05
the O 0 2.22843686970009e-06
- O 0 1.7209727047884371e-06
2 O 0 5.858823442395078e-06
position O 0 1.2440294767657178e-06
of O 0 2.4987309643620392e-06
a O 0 4.1239259189751465e-06
5 O 0 1.1372086191840935e-05
splice O 0 1.499671816418413e-05
site O 0 6.711251899105264e-06
. O 0 1.247238060386735e-06

ATM O 0 0.004422955214977264
germline O 0 0.00040101652848534286
mutations O 0 1.4852000276732724e-05
in O 0 2.0212060917401686e-05
classical O 1 0.9999996423721313
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9981096982955933
in O 0 1.5187797544058412e-05
the O 0 5.9593430705717765e-06
Dutch O 0 6.14978198427707e-05
population O 0 6.673104167020938e-07
. O 0 3.4722154396149563e-07

Germline O 0 0.0010164909763261676
mutations O 0 2.762400072242599e-06
in O 0 5.208590891925269e-07
the O 0 3.7430555721584824e-07
ATM O 0 9.393265827384312e-06
gene O 0 3.8775713306904436e-08
are O 0 1.8049165495526154e-09
responsible O 0 1.3091504769136009e-08
for O 0 4.361242744721494e-08
the O 0 3.903412653016858e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.1193452994339168e-05
. O 0 1.9631304439826636e-06

In O 0 0.00016502295329701155
our O 0 8.436908501607832e-06
study O 0 8.413803698203992e-07
, O 0 1.4498057510081708e-07
we O 0 1.3297336565187834e-08
have O 0 7.395168921675577e-09
determined O 0 3.5860441727209036e-08
the O 0 1.6981108785785182e-07
ATM O 0 4.731890840048436e-06
mutation O 0 6.859117007707027e-08
spectrum O 0 4.68535176878504e-07
in O 0 5.782497964901268e-07
19 O 0 2.1549809389398433e-05
classical O 0 0.0010077577317133546
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.263512998179067e-06
, O 0 1.4952227900266735e-07
including O 0 4.9261721812854375e-08
some O 0 1.856091103036306e-08
immigrant O 0 4.6577474677178543e-07
populations O 0 6.406730079788758e-08
, O 0 2.8876627311547054e-08
as O 0 3.964017381008489e-08
well O 0 3.3885349637330364e-08
as O 0 7.408019797594534e-08
12 O 0 2.636720353166311e-07
of O 0 1.6855453566222423e-07
Dutch O 0 3.119319217148586e-06
ethnic O 0 2.0136677392201818e-07
origin O 0 8.460899607598549e-07
. O 0 9.219223784384667e-07

Both O 0 2.37294880207628e-05
the O 0 2.0191719158901833e-05
protein O 0 1.1966615602432285e-05
truncation O 0 7.505570829380304e-05
test O 0 1.615687506273389e-05
( O 0 4.28804878538358e-06
PTT O 0 5.2439911087276414e-05
) O 0 3.5603582659859967e-07
and O 0 2.0400524647357088e-07
the O 0 4.3896258716813463e-07
restriction O 0 1.2493022722992464e-06
endonuclease O 0 1.2464016435842495e-05
fingerprinting O 0 6.077111720514949e-06
( O 0 2.66698702944268e-06
REF O 0 3.589356492739171e-05
) O 0 1.3080165217616013e-07
method O 0 2.8491425041465845e-07
were O 0 3.6871023212370346e-07
used O 0 1.3033557877406565e-07
and O 0 7.338994834071855e-08
compared O 0 4.687242096679256e-07
for O 0 4.328219560534308e-08
their O 0 3.9549320263176924e-08
detection O 0 6.214177119545639e-07
efficiency O 0 7.927725960144016e-07
, O 0 4.450731339034064e-08
identifying O 0 6.339823954704116e-08
76 O 0 1.5504148223044467e-06
% O 0 1.0373851466738415e-07
and O 0 3.9938733209510247e-08
60 O 0 3.1250490906131745e-07
% O 0 9.301525238925024e-08
of O 0 3.861055404286162e-07
the O 0 1.5524270793321193e-06
mutations O 0 1.091647618522984e-06
, O 0 1.2303888752285275e-06
respectively O 0 1.1965634257649072e-05
. O 0 1.1734351801351295e-06

Most O 0 2.7006204618373886e-05
patients O 0 6.682792900392087e-06
were O 0 1.8144028217648156e-06
found O 0 2.865153305720014e-07
to O 0 5.229779631577003e-08
be O 0 6.814486255279917e-07
compound O 0 3.5951110476162285e-05
heterozygote O 0 5.9481430071173236e-05
. O 0 1.7633406059758272e-06

Seventeen O 0 0.000617663434240967
mutations O 0 2.4370117898797616e-05
were O 0 1.2545109711936675e-05
distinct O 0 1.4657002793683205e-06
, O 0 5.168175789549423e-07
of O 0 1.4991107946116244e-06
which O 0 3.227201830213744e-07
10 O 0 8.572275191909284e-07
were O 0 2.85299535107697e-07
not O 0 5.411765968688087e-08
reported O 0 8.68881272708677e-07
previously O 0 3.51113271790382e-06
. O 0 1.1778021189456922e-06

Mutations O 0 0.0002907160669565201
are O 0 5.179230811336311e-06
small O 0 1.7510036514067906e-06
deletions O 0 6.5971175899903756e-06
or O 0 6.911917353136232e-06
point O 0 7.811416253389325e-06
mutations O 0 5.994090201966173e-07
frequently O 0 1.0505733598620282e-06
affecting O 0 2.4667178877280094e-06
splice O 0 7.803198059264105e-06
sites O 0 3.348541667946847e-06
. O 0 1.0918006410065573e-06

Moreover O 0 0.00020066827710252255
, O 0 4.725820417661453e-06
a O 0 5.401182988862274e-06
16 O 0 4.1632614738773555e-05
. O 0 3.5600496630650014e-06

7 O 0 0.0010445237858220935
- O 0 8.204034384107217e-05
kb O 0 0.0001350154198007658
genomic O 0 6.8580043262045365e-06
deletion O 0 5.943667019892018e-06
of O 0 3.514507261570543e-05
the O 0 2.737116847129073e-05
3 O 0 4.915032332064584e-05
end O 0 7.593510417791549e-06
of O 0 6.140460300230188e-06
the O 0 5.6992375903064385e-06
gene O 0 2.1994358121446567e-06
, O 0 2.7642926170301507e-07
most O 0 5.869152630566532e-08
likely O 0 1.148455908150936e-07
a O 0 1.9404188833505032e-07
result O 0 2.1252714077490964e-07
of O 0 6.484921755145479e-07
recombination O 0 3.638204404410317e-08
between O 0 9.611275118004414e-07
two O 0 1.165299977401446e-06
LINE O 0 7.232959433167707e-06
elements O 0 4.291184438898199e-07
, O 0 1.7592743972727476e-07
was O 0 2.925683247667621e-06
identified O 0 1.1519412055349676e-06
. O 0 8.747486504034896e-07

The O 0 8.792556764092296e-05
most O 0 1.53473570208007e-06
frequently O 0 5.966537628410151e-07
found O 0 8.299468845507363e-08
mutation O 0 4.3596543264357024e-08
, O 0 3.158624650723141e-08
identified O 0 2.9206484342125805e-08
in O 0 1.8939836365916562e-07
three O 0 5.863183218934864e-07
unrelated O 0 7.87888711784035e-06
Turkish O 0 0.0160902701318264
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.591963041391864e-06
, O 0 5.304219143908995e-07
was O 0 1.7599921875444124e-06
previously O 0 3.0680675422445347e-07
described O 0 6.361129578635882e-08
to O 0 8.04009836485875e-09
be O 0 2.2268549670911852e-08
a O 0 3.4255569403285335e-07
Turkish O 0 4.627988892025314e-05
A B-Disease 1 0.9999973773956299
- I-Disease 1 0.9999979734420776
T I-Disease 1 1.0
founder O 0 0.00020009797299280763
mutation O 0 2.023811248363927e-06
. O 0 8.791477057457087e-07

The O 0 2.9171216738177463e-05
presence O 0 1.4042506336409133e-05
of O 0 3.497025682008825e-05
a O 0 7.467883551726118e-05
founder O 0 0.0002477912057656795
mutation O 0 1.6934836821747012e-06
among O 0 8.191473455099185e-08
relatively O 0 9.921669175128045e-08
small O 0 1.9296614084396424e-08
ethnic O 0 2.7685443271252552e-08
population O 0 3.954758653890167e-08
groups O 0 9.745457774101851e-09
in O 0 3.0942277362555615e-07
Western O 0 3.1247200240613893e-06
Europe O 0 2.6781046926771523e-06
could O 0 2.1266076544179668e-07
indicate O 0 2.5959778326978267e-07
a O 0 2.038360662481864e-07
high O 0 8.731541925044439e-07
carrier O 0 4.3086000545145e-08
frequency O 0 1.234404294336855e-07
in O 0 5.309138373377209e-08
such O 0 2.515154839954903e-08
communities O 0 1.396646638340826e-07
. O 0 5.531712758966023e-07

In O 0 4.527378405327909e-05
patients O 0 6.334098088700557e-06
of O 0 5.995461378915934e-06
Dutch O 0 4.75439774163533e-05
ethnic O 0 1.0968277592837694e-06
origin O 0 2.1286457467795117e-06
, O 0 2.635744635881565e-07
however O 0 1.2495758028308046e-07
, O 0 5.344739761881101e-08
no O 0 1.2091662426882976e-07
significant O 0 9.462039542995626e-07
founder O 0 2.405941268079914e-05
effect O 0 2.8438021217880305e-06
could O 0 4.490484286634455e-07
be O 0 3.026989645604772e-07
identified O 0 7.537045689787192e-07
. O 0 7.338000500567432e-07

The O 0 4.1779967432376e-06
observed O 0 3.378575684109819e-06
genetic O 0 1.2843871672885143e-06
heterogeneity O 0 7.4406416388228536e-06
including O 0 2.0031975509482436e-06
the O 0 3.967731572629418e-06
relative O 0 7.027510582702234e-05
high O 0 0.0004649464099202305
percentage O 0 4.276092295185663e-05
of O 0 5.109567428007722e-05
splice O 0 9.614787995815277e-05
- O 0 2.1248337361612357e-05
site O 0 1.5736112572994898e-06
mutations O 0 2.474122311468818e-07
had O 0 6.534481258313463e-07
no O 0 3.0541920637006115e-07
reflection O 0 2.0182542357360944e-06
on O 0 3.5641905924421735e-06
the O 0 2.1682628812413896e-06
phenotype O 0 2.297543869644869e-05
. O 0 2.2852020720165456e-06

All O 0 3.1880820188234793e-06
patients O 0 2.9045991141174454e-06
manifested O 0 8.698764759174082e-06
classical O 0 0.0005317049799486995
A B-Disease 1 0.9999974966049194
- I-Disease 0 0.280705988407135
T I-Disease 1 0.685016393661499
and O 0 3.735295450724152e-08
increased O 0 5.830758027514094e-07
cellular O 0 6.511683295684634e-06
radioresistant O 0 1.2338420674495865e-05
DNA O 0 1.249719389306847e-06
synthesis O 0 1.7500255125924014e-05
. O 0 1.8066072016154067e-06

Determination O 0 8.771730790613219e-06
of O 0 2.809832267303136e-06
the O 0 9.288323212786054e-07
genomic O 0 1.64813343417336e-06
structure O 0 3.2342944678021013e-07
of O 0 1.8817016211869486e-07
the O 0 2.939499950116442e-07
COL4A4 O 0 1.611346669960767e-05
gene O 0 1.9729180067429297e-08
and O 0 1.0840778275067464e-09
of O 0 1.303054553147831e-08
novel O 0 1.2037061196679133e-06
mutations O 0 0.00011269126844126731
causing O 0 0.000678824435453862
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00011473397171357647

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00013270264025777578
a O 0 2.380659498157911e-05
progressive O 1 0.9999282360076904
hematuric B-Disease 1 0.9999996423721313
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9997193217277527
by O 0 7.618517702212557e-05
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999170303344727
abnormalities I-Disease 1 0.9999998807907104
and O 0 6.640950232394971e-06
associated O 0 3.5430600746622076e-06
with O 0 2.441825586174673e-07
mutations O 0 8.591680398239987e-07
in O 0 5.331897227733862e-06
either O 0 2.544236167523195e-06
the O 0 7.680742783122696e-06
COL4A3 O 0 0.00014933617785573006
or O 0 5.343054908735212e-06
the O 0 3.6592296055459883e-06
COL4A4 O 0 4.0120274206856266e-05
gene O 0 3.833409323306114e-07
, O 0 5.186300455761739e-08
which O 0 1.98405398776913e-08
encode O 0 8.084512614914274e-08
the O 0 1.2976954621990444e-06
alpha3 O 0 4.7279794671339914e-05
and O 0 4.104492745682364e-06
alpha4 O 0 0.00023567922471556813
type O 0 0.0005290703265927732
IV O 1 0.9999960660934448
collagen O 1 0.7571616768836975
chains O 0 0.00023631959629710764
, O 0 1.3992492995384964e-06
respectively O 0 9.244163265975658e-06
. O 0 7.785957905070973e-07

To O 0 1.2678806342591997e-05
date O 0 3.194906821590848e-05
, O 0 1.4055968904358451e-06
mutation O 0 2.0615208029539644e-07
screening O 0 6.376788519446563e-07
in O 0 2.0563304587994935e-06
the O 0 1.3974142802908318e-06
two O 0 3.229375522550981e-07
genes O 0 5.470416226671659e-07
has O 0 1.586689961641241e-07
been O 0 1.1129453980629478e-07
hampered O 0 2.2585585668366548e-07
by O 0 3.3905633856079476e-09
the O 0 1.1340432592987781e-08
lack O 0 8.851031907397555e-08
of O 0 4.378437665764068e-07
genomic O 0 5.7256647778558545e-06
structure O 0 2.1594185454887338e-05
information O 0 1.7870331703306874e-06
. O 0 2.2112933493190212e-06

We O 0 5.260956459096633e-05
report O 0 3.020725444002892e-06
here O 0 4.2490245277804206e-07
the O 0 1.868538106464257e-07
complete O 0 1.102470946534595e-06
characterization O 0 1.4929557892173762e-06
of O 0 3.488536549411947e-06
the O 0 3.6938779430784052e-06
48 O 0 1.3666541235579643e-05
exons O 0 8.997772056318354e-06
of O 0 2.0227738787070848e-05
the O 0 6.674522592220455e-05
COL4A4 O 0 0.00206882250495255
gene O 0 8.55252528708661e-06
, O 0 5.908148636990518e-07
a O 0 3.1948917467161664e-07
comprehensive O 0 1.16405033168121e-06
gene O 0 6.602931534871459e-07
screen O 0 2.0058701011294033e-06
, O 0 2.8325125356332137e-08
and O 0 5.162010374704096e-09
the O 0 6.333753521658991e-09
subsequent O 0 1.3782095464875965e-08
detection O 0 3.1510726472561146e-08
of O 0 2.061123183239033e-08
10 O 0 7.987689087940453e-08
novel O 0 2.8244954819456325e-08
mutations O 0 3.1506701247963065e-08
in O 0 1.581970643371733e-08
eight O 0 5.812159997731214e-07
patients O 0 1.9915358279831707e-05
diagnosed O 1 0.989959180355072
with O 0 3.8520847738254815e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00025602595997042954

Furthermore O 0 0.0002033540658885613
, O 0 5.495297955349088e-06
we O 0 7.792449991939066e-07
identified O 0 8.672917033436534e-07
a O 0 1.7253438500119955e-06
glycine O 0 3.0770386274525663e-06
to O 0 5.854137157257355e-07
alanine O 0 7.720286703261081e-06
substitution O 0 1.1300376172584947e-05
in O 0 1.0887181815633085e-05
the O 0 1.4330725207400974e-05
collagenous O 0 0.00015666789840906858
domain O 0 9.865782885754015e-06
that O 0 2.4515321683793445e-07
is O 0 9.751873903951491e-07
apparently O 0 9.465117614126939e-07
silent O 0 6.4175196712312754e-06
in O 0 4.496792200825439e-07
the O 0 3.971252624523913e-07
heterozygous O 0 2.2844103853003617e-07
carriers O 0 9.095904829337087e-08
, O 0 5.365648192423578e-08
in O 0 2.3575773866468808e-07
11 O 0 7.725021532678511e-06
. O 0 1.383745711791562e-06

5 O 0 9.18747391551733e-05
% O 0 7.593981081299717e-06
of O 0 1.2636821338674054e-05
all O 0 2.1485618617589353e-06
control O 0 1.8947723219753243e-05
individuals O 0 1.9152423647028627e-07
, O 0 2.258481117678457e-07
and O 0 9.377517784514566e-08
in O 0 3.0405880124817486e-07
one O 0 9.208286400053112e-08
control O 0 3.035514453131327e-07
individual O 0 1.1737633975883455e-08
homozygous O 0 2.841436241851625e-07
for O 0 5.930220581262802e-08
this O 0 4.016370880322029e-08
glycine O 0 2.404345195827773e-06
substitution O 0 3.5607149584393483e-06
. O 0 7.665394718969765e-07

There O 0 4.236089807818644e-05
has O 0 4.963273568137083e-06
been O 0 1.5884733102211612e-06
no O 0 3.493163092116447e-07
previous O 0 6.318498435575748e-07
finding O 0 3.160345727337699e-07
of O 0 1.8987161638506223e-06
a O 0 3.282889110778342e-06
glycine O 0 5.373921339923982e-06
substitution O 0 1.6503621509400546e-06
that O 0 3.9282962660536214e-08
is O 0 3.9374178584239417e-08
not O 0 8.626523495536276e-09
associated O 0 1.2727890741359715e-08
with O 0 4.770820627442163e-09
any O 0 4.4895244855069905e-08
obvious O 0 8.774305229053425e-07
phenotype O 0 4.010074007965159e-06
in O 0 3.902271430433757e-07
homozygous O 0 2.209668082286953e-06
individuals O 0 1.8297640735909226e-07
. O 0 7.67331528095383e-07

Founder O 0 0.0009921635501086712
BRCA1 O 0 2.930935806944035e-05
and O 0 4.526307577634725e-07
BRCA2 O 0 1.320397132076323e-06
mutations O 0 3.347601307268633e-08
in O 0 4.4500520601786775e-08
French O 0 1.9055140001000836e-05
Canadian O 0 0.0005487443413585424
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9999581575393677
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.2968777127753128e-06
. O 0 9.00446707419178e-07

We O 0 5.914569101150846e-06
have O 0 2.221298416316131e-07
identified O 0 5.67726168299032e-08
four O 0 1.2132397309017051e-08
mutations O 0 2.854846581357151e-09
in O 0 6.146219089231408e-09
each O 0 5.1664033051679326e-09
of O 0 4.6020699073778815e-07
the O 0 4.0149057895177975e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
- O 0 0.0006394823431037366
susceptibility O 0 4.691469803219661e-05
genes O 0 1.1584609183046268e-06
, O 0 9.461853522907404e-08
BRCA1 O 0 5.585214921666193e-07
and O 0 4.480542514784247e-08
BRCA2 O 0 1.9434429532338982e-07
, O 0 1.3228294015732445e-09
in O 0 3.0412006246649526e-09
French O 0 1.5145643601499614e-06
Canadian O 0 3.6153207474853843e-05
breast B-Disease 1 0.9996067881584167
cancer I-Disease 0 0.04990813508629799
and O 0 1.163793513114797e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.787101026224263e-07
from O 0 3.1045278774399776e-06
Quebec O 0 8.116475510178134e-05
. O 0 4.670932867156807e-06

To O 0 2.788788333418779e-05
identify O 0 4.155070928391069e-05
founder O 0 0.0002947232569567859
effects O 0 7.713639206485823e-05
, O 0 2.5910756562552706e-07
we O 0 2.668716447828956e-08
examined O 0 1.5854405432946805e-07
independently O 0 4.313780266329559e-08
ascertained O 0 1.3114492958266055e-06
French O 0 1.850852459028829e-05
Canadian O 0 2.588909956102725e-05
cancer B-Disease 0 2.9434508178383112e-05
families O 0 1.438407437603928e-08
for O 0 3.847416163438311e-09
the O 0 1.4637143941342856e-08
distribution O 0 4.0088551145345264e-08
of O 0 1.1034505575935327e-07
these O 0 3.754115951437598e-08
eight O 0 1.4275765352067538e-06
mutations O 0 1.7274348920182092e-06
. O 0 1.2375603546388447e-06

Mutations O 0 2.1418029064079747e-05
were O 0 2.5671706680441275e-06
found O 0 1.2159020457147562e-07
in O 0 1.4023309802269068e-07
41 O 0 1.6515634797542589e-06
of O 0 6.643722940680163e-07
97 O 0 1.6591726307524368e-05
families O 0 2.2937013000046136e-07
. O 0 1.7305196706729475e-06

Six O 0 3.945055868825875e-05
of O 0 2.083987055812031e-05
eight O 0 8.849174264469184e-06
mutations O 0 1.1691034842442605e-06
were O 0 1.1421922181398259e-06
observed O 0 1.5284798564607627e-06
at O 0 3.7576298836938804e-06
least O 0 1.7179834799208038e-07
twice O 0 2.402018935754313e-06
. O 0 5.933603119956388e-07

The O 0 0.0002807637501973659
BRCA1 O 0 0.0004619436804205179
C4446T O 0 0.0004702034348156303
mutation O 0 8.518331014784053e-06
was O 0 1.3773043974651955e-05
the O 0 8.47005480864027e-07
most O 0 1.1140136990661631e-07
common O 0 1.1397511201494126e-07
mutation O 0 7.500820231598482e-08
found O 0 4.7768690336624786e-08
, O 0 6.247188988339758e-09
followed O 0 4.874039660762719e-08
by O 0 2.0045222370868032e-08
the O 0 8.095481689451844e-07
BRCA2 O 0 2.9564476790255867e-05
8765delAG O 0 4.5330212742555887e-05
mutation O 0 5.946989404037595e-06
. O 0 2.942701712527196e-06

Together O 0 2.421427780063823e-05
, O 0 2.160242047466454e-06
these O 0 7.243773580967172e-08
mutations O 0 1.5463584190911206e-07
were O 0 2.4218897465289047e-07
found O 0 5.41206546245121e-08
in O 0 8.074896129528497e-08
28 O 0 3.791651124629425e-06
of O 0 1.423173671355471e-06
41 O 0 1.2935750419273973e-05
families O 0 8.344007085270277e-08
identified O 0 1.8319099126529181e-07
to O 0 7.033491300489914e-08
have O 0 1.6461009977319918e-07
a O 0 1.234692149409966e-06
mutation O 0 3.0707535643159645e-06
. O 0 2.245561518066097e-06

The O 0 2.175304871343542e-05
odds O 0 1.3522094377549365e-05
of O 0 3.22726191370748e-06
detection O 0 2.19259163714014e-06
of O 0 1.8623414916874026e-06
any O 0 2.460934922510205e-07
of O 0 1.1436644854256883e-05
the O 0 5.725102255382808e-06
four O 0 2.4020123419177253e-06
BRCA1 O 0 5.06394644617103e-06
mutations O 0 7.800852017680882e-07
was O 0 6.982948889344698e-06
18 O 0 9.380123628943693e-06
. O 0 1.2039220109727466e-06

7x O 0 0.026626942679286003
greater O 0 2.974626659124624e-05
if O 0 1.473749648539524e-06
one O 0 1.374587270674965e-07
or O 0 6.446875033816468e-08
more O 0 4.4574064439473204e-09
cases O 0 3.583768091175443e-07
of O 0 0.0005572620430029929
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 4.788221758644795e-06
also O 0 1.3531406750644237e-07
present O 0 7.2093001790563e-08
in O 0 3.3391970077900623e-07
the O 0 1.2359208767520613e-06
family O 0 1.3648858612214099e-06
. O 0 1.680407422099961e-06

The O 0 1.6412323020631447e-05
odds O 0 1.4838396964478306e-05
of O 0 3.1357326406578068e-06
detection O 0 2.524711135265534e-06
of O 0 1.7878053313324926e-06
any O 0 1.793752204548582e-07
of O 0 4.442353656486375e-06
the O 0 8.58183284435654e-06
four O 0 4.717481260740897e-06
BRCA2 O 0 9.646531907492317e-06
mutations O 0 9.917523584590526e-07
was O 0 9.015911928145215e-06
5 O 0 9.382316420669667e-06
. O 0 1.2754693443639553e-06

3x O 0 0.009739699773490429
greater O 0 4.5064272853778675e-05
if O 0 8.266400755019276e-07
there O 0 1.536820093406277e-07
were O 0 7.065600016176177e-08
at O 0 7.207018626331774e-08
least O 0 1.5357738414323308e-09
five O 0 2.4437432077917265e-09
cases O 0 1.2303585705808473e-08
of O 0 1.3998325130160083e-06
breast B-Disease 1 0.8880354166030884
cancer I-Disease 0 0.020518280565738678
in O 0 1.2046641131746583e-05
the O 0 1.0132570423593279e-05
family O 0 4.996556072001113e-06
. O 0 1.99597798200557e-06

Interestingly O 0 6.091961404308677e-05
, O 0 6.86018267970212e-07
the O 0 1.2405813265559118e-07
presence O 0 2.2523079223901732e-07
of O 0 2.163569661206566e-06
a O 0 2.7738629796658643e-05
breast B-Disease 1 0.995374858379364
cancer I-Disease 0 0.05595709756016731
case O 0 3.3494743547635153e-06
< O 0 1.9926890672650188e-05
36 O 0 7.644962352060247e-06
years O 0 7.291304200407467e-07
of O 0 2.457190021232236e-06
age O 0 5.885199243493844e-06
was O 0 8.789475032244809e-06
strongly O 0 3.074581513828889e-07
predictive O 0 6.159130521155021e-07
of O 0 5.064281367594958e-07
the O 0 1.8873898000038025e-07
presence O 0 6.431154986330512e-08
of O 0 2.7648803779811715e-07
any O 0 3.6687119120415446e-08
of O 0 7.137298894122068e-07
the O 0 4.3515132119864575e-07
eight O 0 6.026693881722167e-07
mutations O 0 3.079288433127658e-07
screened O 0 4.7519238250970375e-06
. O 0 1.2136780469518271e-06

Carriers O 0 2.9001708753639832e-05
of O 0 3.1708190363133326e-05
the O 0 6.976199529162841e-06
same O 0 1.6588610378676094e-06
mutation O 0 4.262336403826339e-07
, O 0 8.379444693673577e-08
from O 0 2.7176589867394796e-08
different O 0 3.500354006646944e-09
families O 0 9.95109861179344e-09
, O 0 2.7745498343278996e-08
shared O 0 7.945431690359328e-08
similar O 0 1.4428842121105845e-07
haplotypes O 0 1.0545772056502756e-05
, O 0 8.295992870444024e-07
indicating O 0 3.6831452234764583e-06
that O 0 1.6190341511901352e-07
the O 0 1.7959670230993652e-06
mutant O 0 1.1191563316970132e-05
alleles O 0 4.079264726897236e-06
were O 0 1.2051971225446323e-06
likely O 0 1.2343572564077476e-07
to O 0 6.882965752907921e-09
be O 0 9.080161511576534e-09
identical O 0 3.136914727974727e-08
by O 0 6.879264713433031e-09
descent O 0 8.739356189835235e-07
for O 0 3.4954119598751276e-08
a O 0 1.419378179434716e-07
mutation O 0 1.4634024125825817e-07
in O 0 5.887815177629818e-07
the O 0 1.5912178241705988e-06
founder O 0 1.9160977899446152e-05
population O 0 2.8431250598259794e-07
. O 0 4.799797466148448e-07

The O 0 2.032034444710007e-06
identification O 0 9.924165169650223e-07
of O 0 6.365787612594431e-06
common O 0 6.191644206410274e-05
BRCA1 O 0 0.00012188553955638781
and O 0 2.9124323646101402e-06
BRCA2 O 0 1.0608046977722552e-05
mutations O 0 4.6298648470610715e-08
will O 0 1.4984989915589608e-09
facilitate O 0 3.662662173553599e-09
carrier O 0 1.1106334518729e-08
detection O 0 1.8449519245677948e-08
in O 0 9.469631301328718e-09
French O 0 3.478152166280779e-06
Canadian O 0 6.612802826566622e-05
breast B-Disease 1 0.9999805688858032
cancer I-Disease 1 0.9219469428062439
and O 0 1.945955773408059e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.610693061593338e-06
. O 0 1.1650687383735203e-06

Are O 0 7.022892532404512e-06
Dp71 O 0 0.000516982632689178
and O 0 4.165087375440635e-06
Dp140 O 0 0.0008523075375705957
brain O 0 0.0035502242390066385
dystrophin O 0 5.6969485740410164e-05
isoforms O 0 1.328570874647994e-06
related O 0 3.701332218497555e-07
to O 0 8.556082065069859e-08
cognitive B-Disease 0 0.005626953672617674
impairment I-Disease 1 0.9999998807907104
in O 1 0.9971427321434021
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.00016904914809856564

Molecular O 0 0.0004359089070931077
study O 0 2.407353349553887e-06
and O 0 2.954062949811487e-07
neuropsychological O 0 4.234164862282341e-06
analysis O 0 3.993309860561567e-08
were O 0 2.9834779979864834e-08
performed O 0 6.633492688479237e-08
concurrently O 0 1.0932566851806769e-07
on O 0 4.2599589278324856e-07
49 O 0 8.584517672716174e-06
patients O 0 2.505034899513703e-06
with O 0 4.160569915256929e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0011283934582024813
DMD B-Disease 1 1.0
) O 0 2.1311674913704337e-07
in O 0 4.4398785092880644e-08
order O 0 2.0414356427522762e-08
to O 0 5.6928510794307385e-09
find O 0 4.643463835662942e-09
a O 0 3.135371073881288e-08
molecular O 0 2.866077011276502e-07
explanation O 0 2.6750560877530916e-08
for O 0 1.690551165722809e-08
the O 0 3.630084677297418e-07
cognitive B-Disease 0 0.00012159949983470142
impairment I-Disease 0 0.0004638259706553072
observed O 0 2.5134390853054356e-06
in O 0 1.0654954394340166e-06
most O 0 3.7070162761665415e-06
DMD B-Disease 1 1.0
patients O 0 1.719203282846138e-05
. O 0 1.5547961993434e-06

Complete O 0 2.823870636348147e-05
analysis O 0 1.74655576756777e-06
of O 0 9.985503311327193e-06
the O 0 1.1245849236729555e-05
dystrophin O 0 5.715739098377526e-05
gene O 0 3.3121539217972895e-06
was O 0 6.099872734921519e-06
performed O 0 1.621843466637074e-06
to O 0 8.338581380940013e-08
define O 0 3.8660886048091925e-07
the O 0 1.1021880936823436e-06
localization O 0 1.2053513273713179e-05
of O 0 1.996015953409369e-06
deletions O 0 2.0557129118969897e-06
and O 0 5.179301751923049e-07
duplications O 0 2.254004357382655e-06
in O 0 4.2632063923520036e-07
relation O 0 1.2558243724924978e-06
to O 0 1.0692643570564542e-07
the O 0 6.244034125302278e-07
different O 0 1.6140420484589413e-06
DMD B-Disease 1 0.9999998807907104
promoters O 0 0.0002524542505852878
. O 0 5.946978035353823e-06

Qualitative O 0 9.729003068059683e-05
analysis O 0 1.0499239579075947e-05
of O 0 2.180237243010197e-05
the O 0 1.2052869351464324e-05
Dp71 O 0 0.00023057682847138494
transcript O 0 2.0666106138378382e-05
and O 0 6.313620133369113e-07
testing O 0 4.078565609688667e-07
for O 0 1.7548005359913077e-07
the O 0 4.383459497603326e-07
specific O 0 1.231797170930804e-07
first O 0 5.998664164508227e-06
exon O 0 6.733336704201065e-06
of O 0 1.6502362996106967e-05
Dp140 O 0 1.6004441931727342e-05
were O 0 2.2455785710917553e-06
also O 0 2.8803529517063e-07
carried O 0 4.6666133357575745e-07
out O 0 2.5461750396971183e-07
. O 0 3.767048895042535e-07

Neuropsychological O 0 0.0011796436738222837
analysis O 0 6.51396931061754e-06
assessed O 0 2.1847330572200008e-05
verbal O 0 8.268097008112818e-05
and O 0 1.8200029444415122e-05
visuospatial O 0 0.006925297901034355
intelligence O 0 2.5973426090786234e-05
, O 0 1.0593313390927506e-06
verbal O 0 6.86404891894199e-05
memory O 1 0.6183881163597107
, O 0 1.3147101753929746e-06
and O 0 9.671306315794936e-07
reading O 0 6.025294351275079e-05
skills O 0 7.088874554028735e-05
. O 0 4.611120402842062e-06

Comparison O 0 6.887299241498113e-05
of O 0 5.8325684221927077e-05
molecular O 0 0.0001659461995586753
and O 0 1.1036942851205822e-05
psychometric O 0 0.0006053647957742214
findings O 0 6.521627256006468e-06
demonstrated O 0 1.5404855730594136e-05
that O 0 4.89917226786929e-07
deletions O 0 1.6172439245565329e-06
and O 0 1.1098458116975962e-06
duplications O 0 3.952982297050767e-06
that O 0 8.122674444166478e-08
were O 0 5.042521706855041e-07
localized O 0 2.827772959790309e-06
in O 0 1.4922982245479943e-06
the O 0 2.165223122574389e-06
distal O 0 9.515761121292599e-06
part O 0 1.3381395547185093e-06
of O 0 1.189395879919175e-05
the O 0 8.216913556680083e-06
gene O 0 1.8427066379445023e-06
seemed O 0 5.0747678415064e-07
to O 0 5.541135106312822e-09
be O 0 1.198931265378178e-08
preferentially O 0 1.265096756242201e-07
associated O 0 2.3518578018411063e-07
with O 0 2.1373183756168146e-07
cognitive B-Disease 0 0.009267662651836872
impairment I-Disease 1 0.9994109869003296
. O 0 1.3869118447473738e-05

Two O 0 9.877750562736765e-05
altered O 0 9.094459528569132e-05
Dp71 O 0 0.00048286994569934905
transcripts O 0 7.651485066162422e-05
and O 0 1.732863211145741e-06
two O 0 7.554978083135211e-07
deleted O 0 1.1844954315165523e-06
Dp140 O 0 1.4771901533094933e-06
DNA O 0 1.5988364410191025e-08
sequences O 0 8.294116504714566e-09
were O 0 1.5991322044328626e-08
found O 0 2.7147097902968653e-09
in O 0 5.86146375880503e-09
four O 0 4.7954369364333616e-08
patients O 0 5.373312887968495e-07
with O 0 6.68736788611568e-07
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 4.7475659812334925e-05

These O 0 1.325608081970131e-05
findings O 0 3.370356580489897e-06
suggest O 0 7.021548071861616e-07
that O 0 3.221236255512849e-08
some O 0 1.387223846904817e-08
sequences O 0 1.5854601542741875e-07
located O 0 2.816319010889856e-06
in O 0 9.235503739546402e-07
the O 0 1.2021837392239831e-06
distal O 0 4.803318915946875e-06
part O 0 1.1552581327123335e-06
of O 0 1.4573968655895442e-05
the O 0 4.3388349695305806e-06
gene O 0 8.36760023048555e-07
and O 0 3.0243523951867246e-07
, O 0 4.5462076769808846e-08
in O 0 3.6570305894656485e-08
particular O 0 4.9577870697703474e-08
, O 0 5.367214228613193e-08
some O 0 4.9243684685507105e-08
DMD B-Disease 1 0.9904762506484985
isoforms O 0 2.8268241294426844e-06
expressed O 0 7.601680636071251e-07
in O 0 3.4718452752713347e-06
the O 0 1.034451270243153e-05
brain O 0 0.0004242643772158772
may O 0 5.337043376130168e-07
be O 0 1.702673380066244e-08
related O 0 4.173999101908521e-08
to O 0 9.719765436955186e-09
the O 0 4.2961019630638475e-07
cognitive B-Disease 0 0.0003776746743824333
impairment I-Disease 1 0.9977315068244934
associated O 0 1.4706114598084241e-05
with O 0 6.4976138673955575e-06
DMD B-Disease 1 1.0
. O 0 1.624758510843094e-06
. O 0 1.4836479067525943e-06

I1307K O 0 0.015300283208489418
APC O 0 0.0022011129185557365
and O 0 1.5886516848695464e-05
hMLH1 O 0 0.00011001201346516609
mutations O 0 3.3544708912813803e-06
in O 0 2.170898824260803e-06
a O 0 2.988355845445767e-06
non O 0 2.0062425392097794e-05
- O 0 1.2775643654094893e-06
Jewish O 0 3.0175186793712783e-07
family O 0 6.972635446800268e-08
with O 0 6.726590129346732e-08
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.475866105873138e-05

We O 0 1.1711199476849288e-06
describe O 0 3.529448520112055e-07
a O 0 1.997873511072612e-07
French O 0 1.7511240002932027e-05
Canadian O 0 0.00012167906970717013
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.5120722055435181
HNPCC B-Disease 1 0.9999850988388062
) O 0 1.998652123802458e-06
kindred O 0 8.250976861745585e-06
which O 0 4.6639527795377944e-08
carries O 0 2.7769488042395096e-07
a O 0 1.7367382554311916e-07
novel O 0 4.2357297047601605e-07
truncating O 0 7.2056418503052555e-06
mutation O 0 1.1115087090729503e-06
in O 0 3.5556724924390437e-06
hMLH1 O 0 6.224666867638007e-05
. O 0 5.593830792349763e-06

Interestingly O 0 0.0004251838254276663
, O 0 1.2542333934106864e-05
the O 0 9.25506537896581e-06
I1307K O 0 0.0001429499825462699
APC O 0 1.8587466911412776e-05
polymorphism O 0 9.685834356787382e-07
, O 0 4.1368114267470446e-08
associated O 0 9.553099644676877e-09
with O 0 7.573685567585642e-10
an O 0 7.850015748545047e-09
increased O 0 1.2152497674833285e-06
risk O 0 1.616433473827783e-05
of O 1 0.9992126226425171
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.4983713703695685e-06
is O 0 9.467142092489667e-08
also O 0 2.182455283161744e-08
present O 0 1.7088485293470512e-08
in O 0 1.7144630248822068e-07
this O 0 7.782722377669415e-08
family O 0 5.069843496130488e-07
. O 0 8.054389581957366e-07

The O 0 0.0005552785005420446
I1307K O 0 0.0006705798441544175
polymorphism O 0 5.978298941045068e-05
has O 0 5.046744718129048e-06
previously O 0 3.4015845358226215e-06
only O 0 1.9849119325954234e-07
been O 0 4.848101866627985e-07
identified O 0 1.6962350457561115e-07
in O 0 1.537413680807731e-07
individuals O 0 3.096910816680065e-08
of O 0 2.5275103325839154e-06
self O 0 2.0493573174462654e-05
- O 0 1.6891972336452454e-05
reported O 0 1.6060854477473185e-06
Ashkenazi O 0 4.018388608528767e-06
Jewish O 0 2.629709115353762e-06
origins O 0 4.519502454058966e-06
. O 0 1.3089178310110583e-06

In O 0 0.0001258073898497969
addition O 0 1.1297154742351267e-05
, O 0 2.3568786673422437e-06
in O 0 3.3516314488224452e-06
this O 0 1.0187100087932777e-06
family O 0 1.444440158593352e-06
, O 0 5.631168278341647e-07
there O 0 4.2496563423810585e-07
appears O 0 7.902891070443729e-07
to O 0 6.376568961741214e-08
be O 0 1.577126766960646e-07
no O 0 1.801334263973331e-07
relationship O 0 1.256251636050365e-07
between O 0 1.7908563449964277e-06
the O 0 2.8779224976460682e-06
I1307K O 0 6.111938546382589e-06
polymorphism O 0 5.660253350470157e-07
and O 0 1.1877628480760904e-07
the O 0 1.494341859142878e-07
presence O 0 5.282416282170743e-07
or O 0 9.083679515242693e-07
absence O 0 2.6039992917503696e-06
of O 0 4.853759492107201e-06
cancer B-Disease 0 7.629634637851268e-05
. O 0 3.244346942210541e-07
. O 0 8.584538591094315e-07

Identification O 0 5.320523996488191e-06
of O 0 2.339938419027021e-06
a O 0 1.0336575542169157e-06
novel O 0 5.120855917084555e-07
mutation O 0 1.571327317151372e-07
of O 0 2.5451947749388637e-06
the O 0 5.651042101817438e-06
CPO O 0 0.00020505829888861626
gene O 0 2.819737972004077e-07
in O 0 4.920115657114366e-07
a O 0 2.1835726329300087e-06
Japanese O 0 8.36725885164924e-05
hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9983951449394226
family O 0 2.502797360648401e-05
. O 0 3.3100320706580533e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999988079071045
( O 0 0.006100024562329054
HCP B-Disease 1 0.9999996423721313
) O 0 3.3148337479360634e-06
is O 0 2.368003464425783e-07
an O 0 4.208815482797945e-07
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 0.0001364178315270692
by O 0 4.6488278826473106e-07
a O 0 3.252461465308443e-05
deficiency B-Disease 1 0.9999996423721313
of I-Disease 1 0.996488094329834
coproporphyrinogen I-Disease 1 0.9999557733535767
oxidase I-Disease 0 0.002385094529017806
( O 0 8.423996405326761e-06
CPO O 0 0.0003062089381273836
) O 0 9.77200329543848e-08
caused O 0 8.851554866851075e-08
by O 0 6.10548811508238e-09
a O 0 5.881939557639271e-08
mutation O 0 4.761414018616961e-08
in O 0 4.5866906361879956e-07
the O 0 4.383122359286062e-06
CPO O 0 0.00045231435797177255
gene O 0 5.7993865993921645e-06
. O 0 2.2162059849506477e-06

Only O 0 9.97774532152107e-06
11 O 0 4.442118734004907e-05
mutations O 0 9.2681221985913e-07
of O 0 3.613288527049008e-06
the O 0 2.692360567380092e-06
gene O 0 6.921732733644603e-07
have O 0 1.2616399658327282e-07
been O 0 3.1539894962406834e-07
reported O 0 5.175243131816387e-07
in O 0 2.661823828020715e-06
HCP B-Disease 1 0.9937852621078491
patients O 0 1.131087810790632e-05
. O 0 3.722071824086015e-06

We O 0 1.516257270850474e-05
report O 0 1.3148091966286302e-06
another O 0 1.8419005698433466e-07
mutation O 0 8.724602906795553e-08
in O 0 3.638975272224343e-07
a O 0 1.9967242224083748e-06
Japanese O 0 1.3378101357375272e-05
family O 0 3.8115006191219436e-06
. O 0 2.3837424123485107e-06

Polymerase O 0 0.04721478000283241
chain O 0 0.001082312548533082
reaction O 0 5.7324366935063154e-05
- O 0 1.3736879736825358e-05
single O 0 6.928092943780939e-07
strand O 0 4.842311795982823e-07
conformational O 0 1.2014808703497692e-07
polymorphism O 0 9.353848895443662e-08
and O 0 2.1474148681477345e-08
direct O 0 6.678433095430591e-08
sequence O 0 1.4592230002108408e-07
analyses O 0 1.2171062735433225e-07
demonstrated O 0 3.982907401223201e-06
a O 0 5.137465450388845e-06
C O 0 2.3362737920251675e-05
to O 0 3.5552923804971215e-07
T O 0 4.134668870392488e-06
substitution O 0 1.3204773097186262e-07
in O 0 2.1387721460541798e-07
exon O 0 1.7305283961377427e-07
1 O 0 1.5566773754471797e-06
of O 0 1.5710755860709469e-06
the O 0 3.4014517495961627e-06
CPO O 0 5.8989928220398724e-05
gene O 0 9.393537538926466e-07
at O 0 1.088350654754322e-05
nucleotide O 0 1.2607129065145273e-06
position O 0 7.185624781413935e-06
85 O 0 9.245838555216324e-06
, O 0 2.1795980842398421e-07
which O 0 1.25061191624809e-07
lies O 0 1.3933567970525473e-06
in O 0 6.543273798342852e-07
the O 0 2.507472800061805e-06
putative O 0 1.793645424186252e-05
presequence O 0 1.5769564924994484e-05
for O 0 3.762051221656293e-07
targeting O 0 1.068694132300152e-06
to O 0 4.4711435975841596e-07
mitochondria O 0 1.17330591820064e-05
. O 0 1.467476522520883e-06

This O 0 4.860731223743642e-06
mutation O 0 1.9472106487228302e-06
changes O 0 6.004153760841291e-07
the O 0 2.567226829341962e-06
codon O 0 4.763853212352842e-06
for O 0 2.998825436861807e-07
glutamine O 0 2.6957340537592245e-07
to O 0 4.6642906426086483e-08
a O 0 5.423700599749282e-07
termination O 0 2.759872131719021e-06
codon O 0 1.7174907043226995e-05
at O 0 5.4827178246341646e-05
amino O 0 2.6317663923691725e-06
acid O 0 1.5930731933622155e-06
position O 0 8.599094144301489e-06
29 O 0 0.0001239266130141914
. O 0 2.1503308289538836e-06

MaeI O 0 0.0059862397611141205
restriction O 0 0.00014620358706451952
analysis O 0 9.194856829708442e-06
showed O 0 1.1767684554797597e-05
two O 0 5.588603357864486e-07
other O 0 6.348064118810726e-08
carriers O 0 8.916334337527587e-08
in O 0 4.2452654724911554e-07
the O 0 9.102792546400451e-07
family O 0 9.549038395562093e-07
. O 0 8.173920491572062e-07

The O 0 0.002331268973648548
C O 1 0.9936869740486145
- O 0 0.42927980422973633
T O 0 0.0004465764213819057
mutation O 0 1.7511678152004606e-07
is O 0 8.514259519643019e-08
located O 0 1.9379129412300244e-07
within O 0 3.9164753218301485e-08
a O 0 1.07230135881764e-07
recently O 0 2.482131549186306e-07
proposed O 0 2.6671449404602754e-07
putative O 0 2.407722831776482e-06
alternative O 0 6.684269351353578e-07
translation O 0 6.7552236941992305e-06
initiation O 0 6.200884854479227e-06
codon O 0 1.4572160580428317e-05
( O 0 1.168335529655451e-06
TIC O 0 8.835023436404299e-06
- O 0 3.085237040068023e-06
1 O 0 7.203786481113639e-06
) O 0 1.1188069493073272e-07
, O 0 5.470286623676657e-08
supporting O 0 2.3757849021421862e-07
that O 0 1.965015172800122e-07
TIC O 0 1.4161647413857281e-05
- O 0 6.009406206430867e-06
1 O 0 2.417908763163723e-05
is O 0 1.4837951312074438e-06
the O 0 4.399215868033934e-06
real O 0 7.821583130862564e-05
TIC O 0 9.812242205953225e-05
rather O 0 1.371803364236257e-06
than O 0 5.665816047439876e-07
TIC O 0 1.2560072718770243e-05
- O 0 1.966683157661464e-06
2 O 0 1.576761405885918e-06
. O 0 4.224619232218174e-08
. O 0 2.1992794074776612e-07

Human B-Disease 0 4.0732388697506394e-06
complement I-Disease 0 7.788574293954298e-06
factor I-Disease 0 0.0006949152448214591
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 2.6223031454719603e-05
with O 0 0.00011330327834002674
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0008236352005042136

This O 0 7.284409662133839e-07
study O 0 5.234609261606238e-07
reports O 0 8.8795239605588e-08
on O 0 1.5384330254164524e-07
six O 0 6.034727562109765e-08
cases O 0 8.706681597914212e-08
of O 0 2.566820512583945e-06
deficiency B-Disease 1 0.9976407289505005
in I-Disease 0 5.534232059289934e-06
the I-Disease 0 2.3150344077293994e-06
human I-Disease 0 1.3110741292621242e-06
complement I-Disease 0 4.886102829004813e-07
regulatory I-Disease 0 2.031703161264886e-06
protein I-Disease 0 1.172561042039888e-05
Factor I-Disease 0 3.403912705834955e-05
H I-Disease 1 0.999790608882904
( O 0 8.237487918449915e-07
FH O 0 2.1027992715971777e-06
) O 0 1.6758657794824217e-09
in O 0 5.893668886258752e-10
the O 0 1.0022581653501561e-09
context O 0 7.117700207004418e-09
of O 0 4.3021781692687e-08
an O 0 3.0411206353164744e-06
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.3974334403174e-05

Five O 0 7.954824468470179e-06
of O 0 6.859554559923708e-07
the O 0 1.671200635655623e-07
cases O 0 4.111655371730194e-08
were O 0 2.5528192892920742e-08
observed O 0 1.9737724343826812e-08
in O 0 4.586565349740113e-09
children O 0 6.056334544979336e-09
presenting O 0 6.454688161738886e-08
with O 0 1.123190600083035e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.001460139756090939
. O 0 1.476940178690711e-05

Two O 0 2.684768787730718e-06
of O 0 1.2588327535922872e-06
the O 0 5.451880724649527e-07
children O 0 4.3900362811655214e-07
exhibited O 0 3.495344935799949e-05
a O 0 1.6364716429961845e-05
homozygous O 0 0.00039604571065865457
deficiency O 1 0.9992918968200684
characterized O 0 8.164235623553395e-06
by O 0 4.4427039824768144e-07
the O 0 2.484720653228578e-06
absence O 0 1.0802415090438444e-05
of O 0 1.688834890956059e-05
the O 0 6.688314442726551e-06
150 O 0 3.848823780572275e-06
- O 0 1.082173525901453e-06
kD O 0 2.468242882969207e-06
form O 0 6.212944754224736e-07
of O 0 1.7713717170408927e-05
Factor O 0 7.370181265287101e-05
H O 1 0.9999834299087524
and O 0 1.497298967478855e-06
the O 0 1.1874835763592273e-06
presence O 0 6.625924129366467e-07
, O 0 1.1566864799306131e-07
upon O 0 7.250213798215555e-07
immunoblotting O 0 5.2716695790877566e-06
, O 0 2.5646232870712993e-07
of O 0 1.0114363249158487e-06
the O 0 1.5116669374037883e-06
42 O 0 1.006503043754492e-05
- O 0 2.3522081846749643e-06
kD O 0 2.543388109188527e-05
Factor O 0 4.445704325917177e-05
H O 1 0.916320264339447
- O 0 7.1420026870328e-06
like O 0 5.59972193059366e-07
protein O 0 1.4684285360999638e-06
1 O 0 5.60114949621493e-06
( O 0 4.6769139316893416e-07
FHL O 0 1.3961081094748806e-05
- O 0 1.293985519623675e-06
1 O 0 4.290380275051575e-06
) O 0 8.95106069265239e-08
and O 0 1.4927864810942992e-07
other O 0 1.84115393153661e-07
FH O 0 5.278021490084939e-05
- O 0 5.87420890951762e-06
related O 0 3.678420398500748e-06
protein O 0 5.861818863195367e-06
( O 0 1.5234794545904151e-06
FHR O 0 6.0791011492256075e-05
) O 0 5.926952439949673e-07
bands O 0 4.325415829953272e-06
. O 0 1.386681105941534e-06

Southern O 0 6.819123518653214e-05
blot O 0 5.5377488024532795e-05
and O 0 3.907529730895476e-07
PCR O 0 1.5469559002667665e-06
analysis O 0 3.8834482296579154e-08
of O 0 1.0423872254250455e-07
DNA O 0 1.8523289213590033e-07
of O 0 1.5265014781107311e-06
one O 0 1.7084205410355935e-06
patient O 0 1.4305913282441907e-05
with O 0 4.280849680071697e-06
homozygous O 0 0.0005191103555262089
deficiency O 1 0.9857666492462158
ruled O 0 1.7829928765422665e-05
out O 0 1.948776855442702e-07
the O 0 4.751588988938238e-08
presence O 0 3.723523178678079e-08
of O 0 9.489270524909443e-08
a O 0 6.108099626089825e-08
large O 0 3.7764220195413145e-08
deletion O 0 2.0890404073270474e-07
of O 0 7.597766966682684e-07
the O 0 1.7833217498264275e-06
FH O 0 4.092052040505223e-05
gene O 0 3.642947490334336e-07
as O 0 2.3402078852541308e-07
the O 0 4.259053412170033e-07
underlying O 0 3.4298958780709654e-05
defect O 0 1.1795775208156556e-05
for O 0 2.182835714847897e-06
the O 0 7.304800965357572e-05
deficiency O 1 0.9999918937683105
. O 0 2.0068608137080446e-05

The O 0 1.265625178348273e-05
other O 0 1.7969608734347275e-07
four O 0 1.1773894925681816e-07
children O 0 5.11944904246775e-08
presented O 0 3.4980871532752644e-07
with O 0 3.550017027009744e-07
heterozygous O 0 4.372536204755306e-05
deficiency O 0 0.31574878096580505
and O 0 1.0780531738419086e-06
exhibited O 0 0.00018737584468908608
a O 0 5.776611487817718e-06
normal O 0 1.848820102168247e-05
immunoblotting O 0 1.876811802503653e-05
pattern O 0 1.0621627097862074e-06
of O 0 1.0345087275709375e-06
proteins O 0 1.9085599944901332e-07
of O 0 3.072804247494787e-06
the O 0 7.015683422650909e-06
FH O 0 0.00036414890200830996
family O 0 4.453161636774894e-06
. O 0 1.7442986290916451e-06

Factor B-Disease 1 0.999859094619751
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999971389770508
is O 0 8.334835115419992e-07
the O 0 2.510635681574058e-07
only O 0 8.259907531282806e-07
complement B-Disease 1 0.9999979734420776
deficiency I-Disease 1 1.0
associated O 0 4.261794674675912e-05
with O 0 7.166072464315221e-06
HUS B-Disease 1 1.0
. O 0 1.3623522136185784e-05

These O 0 1.7724482859193813e-06
observations O 0 7.56742019802914e-06
suggest O 0 1.3598162240668898e-06
a O 0 6.005419663779321e-07
role O 0 1.304894567510928e-06
for O 0 1.1518521887410316e-06
FH O 0 8.515497029293329e-05
and O 0 2.5683018520794576e-06
/ O 0 4.856976374867372e-05
or O 0 1.0025197525465046e-06
FH O 0 2.8781154469470493e-05
receptors O 0 3.578934979486803e-07
in O 0 1.4033598461082875e-07
the O 0 6.126406333351042e-07
pathogenesis O 0 0.0003300878743175417
of O 0 5.387116834754124e-05
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 5.7687939261086285e-06
. O 0 2.504399390090839e-06

Further O 0 3.2208373568209936e-07
evidence O 0 1.327517935578726e-07
for O 0 1.8734482409854536e-08
a O 0 9.940895751014978e-08
major O 0 1.059514147527807e-06
ancient O 0 2.550847602833528e-05
mutation O 0 0.0032038188073784113
underlying O 1 0.9999169111251831
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 5.795720880996669e-06
linkage O 0 1.4044529052625876e-05
disequilibrium O 0 1.6493962903041393e-05
studies O 0 2.7487533316161716e-07
in O 0 1.1147256628873947e-07
the O 0 1.9550373053789372e-07
Japanese O 0 1.3337656810108456e-06
population O 0 2.408801833553298e-07
. O 0 3.9730824141770427e-07

The O 0 0.0058808960020542145
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0033442797139286995
DM B-Disease 1 1.0
) O 0 3.987896707258187e-05
mutation O 0 7.129664481908549e-06
is O 0 3.6115764032729203e-06
an O 0 4.582148903864436e-06
unstable O 0 0.00011583468585740775
( O 0 6.017561190674314e-06
CTG O 0 0.00013240723637863994
) O 0 8.714064279047307e-07
n O 0 7.198271759989439e-06
repeat O 0 2.815137577272253e-06
, O 0 2.786637196550146e-07
present O 0 2.14130295717041e-07
at O 0 2.6626462386047933e-06
a O 0 1.8396656287222868e-07
copy O 0 2.6599434477247996e-07
number O 0 2.1090461643780145e-07
of O 0 1.6460395499962033e-06
5 O 0 5.171763405087404e-06
- O 0 2.081716957036406e-06
37 O 0 8.630906449980102e-06
repeats O 0 2.061231270999997e-06
on O 0 1.2529231753433123e-05
normal O 0 1.903586962725967e-05
chromosomes O 0 3.231456730645732e-06
but O 0 2.834550798525015e-07
amplified O 0 6.076510317143402e-07
to O 0 1.4444675855429523e-07
50 O 0 1.325797597928613e-06
- O 0 6.936078875696694e-07
3000 O 0 1.2442466186257661e-06
copies O 0 6.267947014748643e-07
on O 0 1.7350164853269234e-05
DM B-Disease 1 0.9999696016311646
chromosomes O 0 4.125344639760442e-05
. O 0 3.877944436680991e-06

Previous O 0 6.113691779319197e-05
findings O 0 4.990969955542823e-06
in O 0 1.6548381154279923e-06
Caucasian O 0 7.014814400463365e-06
populations O 0 8.583327257838391e-07
of O 0 1.544219776405953e-05
a O 0 0.0009509895462542772
DM B-Disease 1 1.0
founder O 1 0.9969570636749268
chromosome O 0 0.00015273556346073747
raise O 0 1.2319763982304721e-06
a O 0 5.082429765934648e-07
question O 0 4.9760615183913615e-08
about O 0 5.2945532402759454e-09
the O 0 4.6389338592689455e-08
molecular O 0 3.0829437491775025e-07
events O 0 7.743395258330565e-08
involved O 0 3.392596070739273e-08
in O 0 1.4589406305276498e-07
the O 0 1.9863264810737746e-07
expansion O 0 3.507197106955573e-06
mutation O 0 1.5087747442521504e-06
. O 0 1.3601768387161428e-06

To O 0 5.019528998673195e-06
investigate O 0 3.1980150652088923e-06
whether O 0 8.573371133024921e-07
a O 0 6.615779511776054e-06
founder O 0 3.464941619313322e-05
chromosome O 0 9.924941878125537e-06
for O 0 1.8709307596509461e-06
the O 0 2.9087712391628884e-05
DM B-Disease 1 1.0
mutation O 0 2.6373265882284613e-06
exists O 0 4.177165635610436e-07
in O 0 5.507167770701926e-07
the O 0 6.932996257091872e-07
Japanese O 0 2.4936607587733306e-06
population O 0 1.6273298797386815e-07
, O 0 9.692832492191883e-08
we O 0 1.1716321068888647e-07
genotyped O 0 4.224649728712393e-06
families O 0 3.793676484065145e-08
using O 0 8.525602623876694e-08
polymorphic O 0 1.7904380911204498e-06
markers O 0 8.63661989569664e-06
near O 0 0.0001039150301949121
the O 0 6.939559170859866e-06
( O 0 2.781406465146574e-06
CTG O 0 9.811756171984598e-05
) O 0 1.5414317431350355e-06
n O 0 1.3157337889424525e-05
repeat O 0 2.9697162062802818e-06
region O 0 1.2044158665958093e-06
and O 0 4.268633517767739e-07
constructed O 0 5.216608042246662e-05
haplotypes O 0 6.48123532300815e-05
. O 0 2.7833170861413237e-06

Six O 0 5.006464562029578e-05
different O 0 8.243145543929131e-07
haplotypes O 0 3.6715158785227686e-05
were O 0 5.784731911262497e-06
found O 0 1.3888992498323205e-06
and O 0 2.0941577076882822e-06
DM B-Disease 1 0.9999991655349731
alleles O 0 4.4764860831492115e-06
were O 0 2.236917680420447e-06
always O 0 5.959435043223493e-07
haplotype O 0 1.8890383216785267e-05
A O 0 1.071501992555568e-05
. O 0 1.170327209365496e-06

To O 0 3.7473450902325567e-06
find O 0 5.387942110246513e-07
an O 0 2.605641213904164e-07
origin O 0 4.58110832823877e-07
of O 0 4.703542344941525e-06
the O 0 8.047900337260216e-06
( O 0 2.9287593861226924e-06
CTG O 0 6.179245974635705e-05
) O 0 1.2519714118752745e-06
n O 0 1.5194837942544837e-05
repeat O 0 3.1308350116887596e-06
mutation O 0 2.107612573354345e-07
and O 0 1.660562674032917e-07
to O 0 6.699535504139931e-08
investigate O 0 7.788395350871724e-08
the O 0 3.2352724588236015e-07
mechanism O 0 6.559286589435942e-07
of O 0 2.114829612764879e-06
the O 0 1.3514656984625617e-06
expansion O 0 3.931582796212751e-06
mutation O 0 1.9343954704709176e-07
in O 0 6.233099156816024e-07
the O 0 3.4596220643834386e-07
Japanese O 0 4.14634740764086e-07
population O 0 1.2730853704567835e-08
we O 0 5.1628967767669565e-09
have O 0 4.43131442651179e-09
studied O 0 8.505809319103719e-07
90 O 0 6.011687673890265e-06
Japanese O 0 1.4745771295565646e-05
DM B-Disease 1 0.9998555183410645
families O 0 2.9727149808422837e-07
comprising O 0 7.0992899736666e-07
190 O 0 2.6840314149012556e-06
affected O 0 5.310141091285914e-07
and O 0 6.525021944980836e-07
130 O 0 1.521859121567104e-05
unaffected O 0 3.7308611354092136e-05
members O 0 1.150827756646322e-06
. O 0 1.1498086678329855e-06

The O 0 0.0002081679122056812
results O 0 4.758398426929489e-05
suggest O 0 1.5007186675575213e-06
that O 0 8.000786522188719e-08
a O 0 1.168520498140424e-06
few O 0 6.510539378723479e-07
common O 0 1.8946370801131707e-06
ancestral O 0 1.91461258509662e-05
mutations O 0 1.4008207926963223e-06
in O 0 4.526602424448356e-06
both O 0 1.9301896827528253e-06
Caucasian O 0 1.2190233974251896e-05
and O 0 1.8201307057097438e-06
Japanese O 0 3.9087362893042155e-06
populations O 0 8.12191487398195e-08
have O 0 1.518160352986797e-08
originated O 0 5.537777880704198e-08
by O 0 1.2835892349016831e-08
expansion O 0 3.8879846897543757e-07
of O 0 5.746560987063276e-07
an O 0 3.4435453244441305e-07
ancestral O 0 4.321597316447878e-06
n O 0 1.2500300726969726e-05
= O 0 7.60427838031319e-06
5 O 0 2.8786773782485398e-06
repeat O 0 9.393788218403643e-07
to O 0 7.992578616722312e-07
n O 0 1.9143917597830296e-05
= O 0 1.585334030096419e-05
19 O 0 1.4893246770952828e-05
- O 0 3.196012130501913e-06
37 O 0 3.084763193328399e-06
copies O 0 8.418242600782833e-07
. O 0 1.0911802519331104e-06

These O 0 1.0260234830639092e-06
data O 0 2.425760158075718e-06
support O 0 1.7538681049700244e-06
multistep O 0 4.404098217491992e-05
models O 0 2.1481670046341605e-05
of O 0 8.070439071161672e-05
triplet O 0 0.001397086656652391
repeat O 0 6.996925367275253e-05
expansion O 0 6.69550627208082e-06
that O 0 4.741837855704034e-08
have O 0 2.1904833502617294e-08
been O 0 3.384413815865628e-08
proposed O 0 3.013411387087217e-08
for O 0 9.405964362940722e-08
both O 0 1.9901501673302846e-06
DM B-Disease 1 1.0
and O 0 3.194511009496637e-05
Friedreichs B-Disease 0 0.024634867906570435
ataxia I-Disease 1 0.9999710321426392
. O 0 6.998790013312828e-06
. O 0 4.425933639140567e-06

The O 0 3.927029865735676e-06
molecular O 0 1.6784977560746484e-05
basis O 0 3.3940461435122415e-05
of O 0 0.02670283243060112
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 0.0004991450114175677
the O 0 2.3173593945102766e-05
western O 0 5.475951638800325e-06
Cape O 0 6.7586524892249145e-06
, O 0 1.4657391034234024e-07
South O 0 4.4313591729405744e-07
Africa O 0 8.382608598367369e-07
. O 0 5.999116865496035e-07

Deficiency B-Disease 1 0.9999239444732666
of I-Disease 0 0.0011020960519090295
the I-Disease 0 0.0002786008990369737
sixth I-Disease 0 0.0045828670263290405
component I-Disease 0 0.0001358005974907428
of I-Disease 0 8.58021667227149e-05
human I-Disease 0 0.00011962320422753692
complement I-Disease 0 4.438964242581278e-05
( O 0 2.1609470422845334e-05
C6 O 0 0.0005552610964514315
) O 0 7.283228455889912e-07
has O 0 2.882251521896251e-07
been O 0 3.3196820936609583e-07
reported O 0 2.7740424002331565e-07
in O 0 1.3277345090045856e-07
a O 0 1.6592392171332904e-07
number O 0 1.7380655492615915e-07
of O 0 1.209434230986517e-06
families O 0 1.7952444864022254e-07
from O 0 6.726269248247263e-07
the O 0 5.865464913767937e-07
western O 0 1.8440831581756356e-06
Cape O 0 4.366463144833688e-06
, O 0 2.411753143860551e-07
South O 0 3.50745722244028e-07
Africa O 0 3.214148307506548e-07
. O 0 5.156473434908548e-07

Meningococcal B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999966621398926
is O 0 6.649835086136591e-06
endemic O 0 1.8450137986292248e-06
in O 0 8.649195137877541e-07
the O 0 1.198503468913259e-06
Cape O 0 3.516521246638149e-06
and O 0 3.6457134200418295e-08
almost O 0 3.662670877702112e-08
all O 0 3.892003608285677e-09
pedigrees O 0 5.405576075645513e-08
of O 0 1.0549920261837542e-06
total O 0 0.010707921348512173
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.00010806923819473013
C6Q0 O 0 0.0006015184917487204
) O 0 1.5549755971733248e-07
have O 0 1.552195350029706e-08
been O 0 3.987296892660197e-08
ascertained O 0 3.383653108812723e-07
because O 0 1.8641449273104627e-08
of O 0 9.901797284328495e-07
recurrent O 1 0.9490697383880615
disease O 1 0.9988823533058167
. O 0 9.473097634327132e-06

We O 0 4.539484962151619e-06
have O 0 1.9144316354413604e-07
sequenced O 0 4.407558833463554e-07
the O 0 1.8270317525548307e-07
expressed O 0 2.1100822777953e-07
exons O 0 5.268252152745845e-06
of O 0 1.4905977877788246e-05
the O 0 2.6800647901836783e-05
C6 O 0 0.0005547383916564286
gene O 0 1.7072738955903333e-06
from O 0 4.4147188305032614e-07
selected O 0 1.6312112904870446e-07
cases O 0 3.3209101246711725e-08
and O 0 3.478021071146031e-08
have O 0 3.226844569326204e-08
found O 0 1.4338691300963546e-07
three O 0 1.396248649143672e-06
molecular O 0 0.0004353793920017779
defects O 0 0.0017793687293305993
leading O 0 9.598665201338008e-05
to O 0 1.1430267932155402e-06
total O 0 0.0005435596103779972
deficiency O 1 0.9999920129776001
879delG O 0 0.00037924732896499336
, O 0 1.6668471971570398e-06
which O 0 4.272298781415884e-07
is O 0 5.959150826129189e-07
the O 0 2.700715640457929e-06
common O 0 1.340686412731884e-05
defect O 0 1.833397436712403e-05
in O 0 1.019148294290062e-05
the O 0 1.034129672916606e-05
Cape O 0 1.4704250133945607e-05
and O 0 1.2119788834752399e-06
hitherto O 0 1.569670348544605e-05
unreported O 0 1.4611778169637546e-05
, O 0 5.905940270167775e-07
and O 0 7.61638261792541e-07
1195delC O 0 1.388801774737658e-05
and O 0 8.364301720575895e-06
1936delG O 0 1.8497848941478878e-05
, O 0 7.864651365707687e-07
which O 0 9.556219282558231e-08
have O 0 7.991239669991046e-08
been O 0 3.273752327004331e-07
previously O 0 1.093564947041159e-06
reported O 0 1.427644633622549e-06
in O 0 1.9271512883278774e-06
African O 0 6.880670753162121e-06
- O 0 5.602976671070792e-06
Americans O 0 3.762474705126806e-07
. O 0 3.43205783792655e-07

We O 0 1.8569553503766656e-05
also O 0 1.3368894542509224e-06
show O 0 3.979403686571459e-07
that O 0 3.5858665370369636e-08
the O 0 4.574349929953314e-07
879delG O 0 1.51888689288171e-05
and O 0 2.409519311186159e-06
1195delC O 0 0.00016058287292253226
defects O 0 0.0010478222975507379
are O 0 2.0084472396320052e-07
associated O 0 4.897415806226491e-07
with O 0 4.853732207266148e-07
characteristic O 1 0.9819207787513733
C6 O 1 1.0
/ O 1 0.9998812675476074
C7 O 1 0.7911432981491089
region O 0 2.3096285076462664e-05
DNA O 0 5.480434538185364e-06
marker O 0 2.2321346477838233e-05
haplotypes O 0 8.065741894824896e-06
, O 0 1.54366645688242e-07
although O 0 2.354859951481103e-08
small O 0 4.0814015278556326e-08
variations O 0 1.9476510715321638e-07
were O 0 6.207158094184706e-07
observed O 0 2.731235326791648e-06
. O 0 5.972515850771742e-07

The O 0 0.0011866054264828563
1936delG O 0 0.0026647874619811773
defect O 0 0.0004893586738035083
was O 0 8.136631367960945e-05
observed O 0 4.728020485345041e-06
only O 0 6.420878548851761e-07
once O 0 1.6656189245622954e-06
in O 0 1.6078494127214071e-06
the O 0 2.195016577388742e-06
Cape O 0 8.800613613857422e-06
, O 0 2.86849967778835e-07
but O 0 3.4873739451768415e-08
its O 0 4.449330504030513e-08
associated O 0 7.854337695789582e-07
haplotype O 0 1.754127697495278e-05
could O 0 8.415793786298309e-07
be O 0 7.15877888524119e-07
deduced O 0 7.825537977623753e-06
. O 0 1.2422262898326153e-06

The O 0 5.770736970589496e-05
data O 0 1.0129478141607251e-05
from O 0 8.580192343288218e-07
the O 0 3.993386599177029e-07
haplotypes O 0 2.6068767056131037e-06
indicate O 0 4.043828596422827e-07
that O 0 2.4428405964727062e-08
these O 0 7.365133569692262e-08
three O 0 4.113422619411722e-06
molecular O 0 0.0006699500372633338
defects O 0 0.000662053469568491
account O 0 1.782245476533717e-06
for O 0 9.733487786434125e-06
the O 0 8.864231494953856e-05
defects O 0 0.00149832374881953
in O 0 1.0520911018829793e-05
all O 0 2.2668759811494965e-06
the O 0 1.3865930668544024e-05
38 O 0 0.0001084680698113516
unrelated O 0 1.471659470553277e-05
C6Q0 O 0 0.00017834694881457835
individuals O 0 1.8853138783470058e-07
we O 0 1.181613242806634e-07
have O 0 6.785311512658154e-08
studied O 0 1.6245755887211999e-06
from O 0 6.14110092556075e-07
the O 0 8.28276711217768e-07
Cape O 0 7.325907972699497e-06
. O 0 9.530078841635259e-07

We O 0 1.9788818462984636e-05
have O 0 6.055135486349172e-07
also O 0 2.7091101628684555e-07
observed O 0 9.210224902744812e-07
the O 0 1.3381267081058468e-06
879delG O 0 1.3041832971794065e-05
defect O 0 5.478286766447127e-06
in O 0 2.4774542453087633e-06
two O 0 6.712697995681083e-06
Dutch O 1 0.9997504353523254
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.0011508369352668524
, O 0 1.4214374459697865e-06
but O 0 1.6102018207675428e-07
the O 0 2.235420652141329e-06
879delG O 0 7.725624163867906e-05
defect O 0 3.926372664864175e-05
in O 0 3.1395655241794884e-05
the O 0 6.494067201856524e-05
Cape O 0 0.00011231064854655415
probably O 0 1.1150696082040668e-05
did O 0 4.1266542893936276e-07
not O 0 6.639947969233617e-08
come O 0 5.563461868973718e-08
from O 0 1.0287899954164459e-07
The O 0 1.4393849312455131e-07
Netherlands O 0 2.0836732801399194e-06
. O 0 2.0965107694337348e-07
. O 0 8.014820878088358e-07

Complement B-Disease 1 0.9999340772628784
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.1250655916228425e-05
seven O 0 6.680422302451916e-06
further O 0 9.510117706668098e-06
molecular O 1 0.9707072973251343
defects O 0 0.16144046187400818
and O 0 8.328327112394618e-07
their O 0 3.0032614972697047e-07
associated O 0 4.593231096805539e-06
marker O 0 2.773090818664059e-05
haplotypes O 0 2.4208737158915028e-05
. O 0 1.1393397016945528e-06

Seven O 0 7.829883543308824e-06
further O 0 1.8999858184542973e-06
molecular O 0 7.562176324427128e-05
bases O 0 9.197099279845133e-05
of O 1 0.9943645000457764
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.9818089640466496e-05
described O 0 1.0302356713509653e-05
. O 0 5.994753564664279e-07

All O 0 2.1729906620748807e-06
these O 0 4.1432244302086474e-07
new O 0 3.975651452492457e-06
molecular O 0 0.0005363704403862357
defects O 0 0.00037922890624031425
involve O 0 6.291642421274446e-06
single O 0 1.9203598640160635e-05
- O 0 3.06089932564646e-05
nucleotide O 0 9.151744961855002e-06
events O 0 5.321919616108062e-06
, O 0 6.174439022288425e-07
deletions O 0 7.037194222903054e-07
and O 0 1.0366666174377315e-06
substitutions O 0 1.7008027271003812e-06
, O 0 2.3171384100351133e-07
some O 0 2.7032404759097517e-08
of O 0 7.91292904978036e-07
which O 0 3.807704445080162e-07
alter O 0 1.5346538475569105e-06
splice O 0 3.064726797674666e-06
sites O 0 5.695079607903608e-07
, O 0 1.1723754056447433e-07
and O 0 1.8212908514669834e-07
others O 0 3.9070451407496876e-07
codons O 0 1.1028946573787834e-05
. O 0 2.8954116260138107e-06

They O 0 3.5783521070698043e-06
are O 0 2.1102835034980671e-07
distributed O 0 1.165191605423388e-07
along O 0 6.365912099681736e-07
the O 0 4.1635744310042355e-06
C7 O 0 0.0004342631727922708
gene O 0 1.6421666941823787e-06
, O 0 1.0247908477367673e-07
but O 0 6.772431060397821e-09
predominantly O 0 1.2719737263466868e-08
towards O 0 2.0802036715394934e-07
the O 0 2.877355029795581e-07
3 O 0 4.47344336862443e-06
end O 0 4.36792106484063e-06
. O 0 1.1300335245323367e-06

All O 0 5.400085683504585e-06
were O 0 2.4348175884369994e-06
found O 0 2.2800072940754035e-07
in O 0 3.9733021139909397e-07
compound O 0 5.432384114101296e-06
heterozygous O 0 2.789298889638303e-07
individuals O 0 5.418521098476958e-08
. O 0 4.4946872890250233e-07

The O 0 0.0006027290946803987
C6 O 1 0.9958382844924927
/ O 0 0.1118062436580658
C7 O 0 0.016181154176592827
marker O 0 0.00010311293590348214
haplotypes O 0 4.556837666314095e-05
associated O 0 1.0794917216117028e-05
with O 0 5.1869656090275384e-06
most O 0 0.003509251633659005
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999912977218628
are O 0 1.3773943692285684e-06
tabulated O 0 3.1981537176761776e-05
. O 0 8.159521769357525e-08
. O 0 1.9874974555023073e-07

A O 0 0.0003130213881377131
genome O 0 1.4957069652155042e-05
- O 0 1.680450736785133e-06
wide O 0 5.709131869480188e-07
search O 0 9.58155155217355e-08
for O 0 1.455609321965312e-07
chromosomal O 0 0.0017230386147275567
loci O 0 0.0001888712722575292
linked O 0 2.3802986106602475e-05
to O 0 2.0432339908893482e-07
mental O 1 0.9428914189338684
health O 0 1.2112580407119822e-05
wellness O 0 1.6379581211367622e-05
in O 0 1.5543201925538597e-07
relatives O 0 3.248978828196414e-07
at O 0 1.6873029835551279e-06
high O 0 8.631005584902596e-06
risk O 0 2.238592969661113e-06
for O 0 8.146790605678689e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 2.1217913399596e-06
the O 0 1.2428922673279885e-06
Old O 0 3.5309842587594176e-06
Order O 0 4.926449719278025e-07
Amish O 0 5.399019755714107e-06
. O 0 7.568485784759105e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999998807907104
BPAD B-Disease 1 1.0
; O 1 1.0
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 3.739477051567519e-06
is O 0 5.1099572573320984e-08
characterized O 0 2.5551576854354607e-08
by O 0 2.5831512484586483e-09
episodes O 0 4.6283903998300957e-07
of O 0 8.736291420063935e-06
mania B-Disease 0 0.20359084010124207
and O 0 2.3070750103215687e-05
/ O 0 0.012502402998507023
or O 0 5.195263383939164e-06
hypomania B-Disease 0 0.00024802403640933335
interspersed O 0 5.269339453661814e-07
with O 0 1.87527131600973e-08
periods O 0 2.2517267552757403e-06
of O 0 6.929784831299912e-06
depression B-Disease 0 0.03148898109793663
. O 0 9.303330443799496e-06

Compelling O 0 8.378232450922951e-06
evidence O 0 9.216129228661885e-07
supports O 0 2.2630648288668453e-07
a O 0 4.453669433246432e-08
significant O 0 9.54913232931176e-08
genetic O 0 7.792353358127002e-07
component O 0 3.0626786156062735e-06
in O 0 5.092647370474879e-07
the O 0 7.708441103204677e-07
susceptibility O 0 1.8646020180312917e-05
to O 0 1.1913936077689868e-06
develop O 0 3.801697675953619e-05
BPAD B-Disease 1 1.0
. O 0 2.0050718376296572e-05

To O 0 1.2881462680525146e-05
date O 0 5.797975609311834e-05
, O 0 1.548860041111766e-06
however O 0 4.638960433567263e-07
, O 0 1.792420079027579e-07
linkage O 0 1.2018043662465061e-06
studies O 0 8.143010887806668e-08
have O 0 1.4127347292003378e-08
attempted O 0 6.305791089289414e-08
only O 0 1.5643783157770486e-08
to O 0 2.981236946197896e-08
identify O 0 2.896776720717753e-07
chromosomal O 0 0.00016051136481110007
loci O 0 1.3975561159895733e-05
that O 0 1.2494828638409672e-07
cause O 0 9.127828093369317e-07
or O 0 6.646968131462927e-08
increase O 0 4.1821600405000936e-08
the O 0 2.96483278816595e-07
risk O 0 7.400378763122717e-07
of O 0 7.107011242624139e-06
developing O 0 0.0001526115374872461
BPAD B-Disease 1 1.0
. O 0 1.6054274965426885e-05

To O 0 2.9132352210581303e-05
determine O 0 8.577144399168901e-06
whether O 0 2.65790708908753e-06
there O 0 5.030085958424024e-06
could O 0 1.4974018540669931e-06
be O 0 4.904173920294852e-07
protective O 0 1.6151184354384895e-06
alleles O 0 1.4760381361611508e-07
that O 0 3.430060857567696e-08
prevent O 0 2.5021836336236447e-07
or O 0 2.5874186349028605e-07
reduce O 0 1.4629321754000557e-07
the O 0 8.752184044169553e-07
risk O 0 2.779280066533829e-06
of O 0 1.4993314835010096e-05
developing O 0 0.0001627579767955467
BPAD B-Disease 1 1.0
, O 0 1.474403319434714e-07
similar O 0 3.515139734844297e-09
to O 0 1.2613092792435054e-09
what O 0 5.388441914888631e-10
is O 0 1.4453978014472568e-09
observed O 0 1.1674335276268266e-08
in O 0 3.1685207346754396e-08
other O 0 5.808989840261347e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.6146670961679774e-07
we O 0 5.350951681748484e-08
used O 0 1.0252889524053899e-06
mental O 0 0.04582250863313675
health O 0 3.8033293094486e-05
wellness O 0 0.00012568938836921006
( O 0 6.254738309507957e-07
absence O 0 6.197186053213954e-07
of O 0 9.506205174147908e-07
any O 0 2.7688829504768364e-06
psychiatric B-Disease 1 0.9999973773956299
disorder I-Disease 1 0.999981164932251
) O 0 1.329138513028738e-06
as O 0 8.155342356985784e-07
the O 0 9.100188549382437e-07
phenotype O 0 6.948963346076198e-06
in O 0 3.783556621783646e-06
our O 0 4.6912273319321685e-06
genome O 0 9.832288924371824e-06
- O 0 1.1450886631791946e-05
wide O 0 1.234328101418214e-05
linkage O 0 2.1477633708855137e-05
scan O 0 1.5532488760072738e-05
of O 0 7.623906185472151e-06
several O 0 1.6812795138321235e-06
large O 0 9.720770322019234e-06
multigeneration O 0 0.00017800834029912949
Old O 0 2.029203824349679e-05
Order O 0 1.2809193776774919e-06
Amish O 0 5.582133326242911e-06
pedigrees O 0 2.3549062007077737e-06
exhibiting O 0 2.3258332930709003e-06
an O 0 1.8654115763183654e-07
extremely O 0 1.096545361178869e-06
high O 0 1.5123968296393286e-05
incidence O 0 0.0013646756997331977
of O 0 0.0016098713967949152
BPAD B-Disease 1 1.0
. O 0 4.1876264731399715e-05

We O 0 3.717684739967808e-05
have O 0 1.3170870261092205e-06
found O 0 2.3699826101619692e-07
strong O 0 1.6833976701491338e-07
evidence O 0 1.0270469630313528e-07
for O 0 1.2620684231023915e-07
a O 0 1.0379308150731958e-06
locus O 0 1.3307657354744151e-05
on O 0 2.0802024664590135e-05
chromosome O 0 0.00013141706585884094
4p O 0 0.003218807280063629
at O 0 0.00028499984182417393
D4S2949 O 0 5.128297925693914e-05
( O 0 1.8307536038264516e-06
maximum O 0 2.4253451556432992e-05
GENEHUNTER O 0 0.00012747700384352356
- O 0 5.276407591736643e-06
PLUS O 0 3.0641540433862247e-06
nonparametric O 0 1.1768997865146957e-05
linkage O 0 2.8736355943692615e-06
score O 0 2.5008193915709853e-06
= O 0 2.381485955993412e-06
4 O 0 2.119974851666484e-06
. O 0 8.927258932089899e-08
05 O 0 2.2948768673813902e-05
, O 0 8.655532610646333e-07
P O 0 2.124432648997754e-05
= O 0 1.8628761608852074e-06
5 O 0 8.257426316049532e-07
. O 0 3.807667425803629e-08
22 O 0 3.426972625675262e-06
x O 0 8.402935236517806e-06
10 O 0 1.3690183777725906e-06
( O 0 1.7221550763224514e-07
- O 0 4.185766897535359e-07
4 O 0 1.5615514712408185e-06
) O 0 4.6086491067853785e-08
; O 0 5.997572571914134e-08
SIBPAL O 0 8.988441550172865e-06
Pempirical O 0 9.276008313463535e-06
value O 0 4.918571903544944e-06
< O 0 8.991836693894584e-06
3 O 0 8.402766979997978e-06
x O 0 1.3119198229105677e-05
10 O 0 3.2021871447796e-06
( O 0 2.4534944031984196e-07
- O 0 6.693123282275337e-07
5 O 0 1.449676005904621e-06
) O 0 6.408135533320092e-08
) O 0 2.701580648079016e-08
and O 0 2.759108497230045e-08
suggestive O 0 5.438378707367519e-07
evidence O 0 5.663785174192526e-08
for O 0 1.0192002264375333e-07
a O 0 7.783611977174587e-07
locus O 0 1.2915338629682083e-05
on O 0 3.362185452715494e-05
chromosome O 0 0.0006384763401001692
4q O 0 0.06551728397607803
at O 0 0.0002659709716681391
D4S397 O 0 4.0180770156439394e-05
( O 0 2.0658146695495816e-06
maximum O 0 2.934706208179705e-05
GENEHUNTER O 0 0.0001691391080385074
- O 0 7.4162853707093745e-06
PLUS O 0 3.856363491649972e-06
nonparametric O 0 7.5382918112154584e-06
linkage O 0 2.913732259912649e-06
score O 0 2.9052141599095194e-06
= O 0 2.244266170237097e-06
3 O 0 7.776399684189528e-07
. O 0 3.2120453852257924e-08
29 O 0 3.756791556952521e-06
, O 0 4.796031589648919e-07
P O 0 1.8180720871896483e-05
= O 0 1.4587084251616034e-06
2 O 0 1.2069961030647391e-06
. O 0 5.5029477863399734e-08
57 O 0 1.908137164718937e-06
x O 0 4.803704086953076e-06
10 O 0 1.8518567230785266e-06
( O 0 2.7900304644390417e-07
- O 0 4.6001170517229184e-07
3 O 0 2.2192411961441394e-06
) O 0 9.35515132027831e-08
; O 0 1.3037784185598866e-07
SIBPAL O 0 1.2867563782492653e-05
Pempirical O 0 7.2854077188821975e-06
value O 0 4.925293524138397e-06
< O 0 9.662016964284703e-06
1 O 0 1.0558502253843471e-05
x O 0 2.462283373461105e-05
10 O 0 5.53434801986441e-06
( O 0 6.294771992543247e-07
- O 0 1.9867140963469865e-06
3 O 0 3.3265828278672416e-06
) O 0 4.086612648279697e-08
) O 0 6.186537060415276e-09
that O 0 2.387070319187501e-09
are O 0 2.1820765638835837e-08
linked O 0 7.16861677574343e-07
to O 0 1.3865128778434155e-07
mental O 0 0.1049821525812149
health O 0 0.0001509289286332205
wellness O 0 0.0005429358570836484
. O 0 4.1829962356132455e-06

These O 0 3.986494903074345e-06
findings O 0 3.1896938708086964e-06
are O 0 1.7276096286877873e-07
consistent O 0 1.8738631979431375e-07
with O 0 1.2420487749409403e-08
the O 0 2.2957561895964318e-07
hypothesis O 0 1.9143841711866116e-07
that O 0 6.953561726419366e-09
certain O 0 1.109128788812086e-07
alleles O 0 5.680391268469975e-07
could O 0 1.5985779100446962e-07
prevent O 0 1.481094642485914e-07
or O 0 1.1461778370858156e-07
modify O 0 3.3953085676330375e-08
the O 0 5.758773724551247e-08
clinical O 0 3.961522907047765e-06
manifestations O 0 2.5681560146040283e-05
of O 0 1.4634830222348683e-05
BPAD B-Disease 1 1.0
and O 0 3.6289873150963103e-07
perhaps O 0 9.713597393101736e-08
other O 0 5.325588858795527e-08
related O 0 4.7796642320463434e-05
affective B-Disease 1 0.9999995231628418
disorders I-Disease 1 1.0
. O 0 2.030411815212574e-05

Segregation O 0 0.021405745297670364
distortion O 1 0.9969567060470581
in O 0 0.06751973927021027
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 5.2587893151212484e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9981824159622192
DM B-Disease 1 1.0
) O 0 0.00010166850552195683
is O 0 4.687801720137941e-06
an O 0 6.8007043410034385e-06
autosomal B-Disease 1 0.9999996423721313
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999998807907104
which O 0 3.730778189492412e-06
, O 0 1.9422570574079145e-07
in O 0 4.017171875148051e-07
the O 0 1.0412433084638906e-06
typical O 0 2.1824860141350655e-06
pedigree O 0 1.8715124951995676e-06
, O 0 3.743505061493124e-08
shows O 0 5.369630784457513e-08
a O 0 1.8166487336657156e-07
three O 0 3.131773667064408e-07
generation O 0 3.3224325761693763e-06
anticipation O 0 7.786048627167474e-06
cascade O 0 0.0001715736580081284
. O 0 6.4429568737978116e-06

This O 0 1.6946148662100313e-07
results O 0 2.663469331309898e-06
in O 0 9.57283191382885e-06
infertility B-Disease 1 0.9999997615814209
and O 1 0.9999654293060303
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0016380534507334232
CDM B-Disease 0 0.04561376944184303
) O 0 1.1076447492541774e-07
with O 0 2.725112757673287e-08
the O 0 2.432946530461777e-06
disappearance O 0 5.6191238400060683e-05
of O 0 0.00014391446893569082
DM B-Disease 1 1.0
in O 0 2.616490382933989e-05
that O 0 1.7323244492217782e-06
pedigree O 0 4.866810195380822e-05
. O 0 3.3944138522201683e-06

The O 0 8.212126886064652e-06
concept O 0 7.91391903476324e-06
of O 0 2.376619704591576e-05
segregation O 0 0.00011297789751552045
distortion O 0 9.701395902084187e-05
, O 0 1.5939274078391463e-07
where O 0 6.430357757380989e-08
there O 0 1.910005131833259e-08
is O 0 1.8051791172979392e-08
preferential O 0 2.0814557899484498e-07
transmission O 0 1.5052852404551231e-06
of O 0 1.3370067790674511e-06
the O 0 9.330708508059615e-07
larger O 0 7.253450462485489e-07
allele O 0 2.766773832263425e-06
at O 0 5.304396108840592e-05
the O 0 1.541514393466059e-05
DM B-Disease 1 0.9999440908432007
locus O 0 0.00017830579599831253
, O 0 2.5843728508334607e-06
has O 0 5.929530288995011e-07
been O 0 7.926478247100022e-07
put O 0 1.8315833472115628e-07
forward O 0 2.581119247224706e-07
to O 0 5.7630586525192484e-08
explain O 0 2.2840117708256003e-07
partially O 0 3.8104465147625888e-06
the O 0 1.140672566180001e-06
maintenance O 0 2.0765397493960336e-05
of O 0 4.963992614648305e-05
DM B-Disease 1 1.0
in O 0 1.1219476618862245e-05
the O 0 2.074348913083668e-06
population O 0 5.983895334793488e-07
. O 0 4.775324669026304e-07

In O 0 6.154851871542633e-05
a O 0 1.6424470231868327e-05
survey O 0 1.0335055776522495e-05
of O 0 3.875415859511122e-05
DM B-Disease 1 1.0
in O 0 4.159654054092243e-05
Northern O 0 1.550816887174733e-05
Ireland O 0 6.597973424504744e-06
, O 0 9.898398047880619e-07
59 O 0 6.030739314155653e-06
pedigrees O 0 2.3050763502396876e-06
were O 0 1.9952051388827385e-06
ascertained O 0 1.5824383808649145e-05
. O 0 1.8649861885933205e-06

Sibships O 0 0.007976546883583069
where O 0 8.520874689565971e-05
the O 0 1.7940525140147656e-05
status O 0 8.365051144210156e-06
of O 0 3.182497312081978e-05
all O 0 4.400911166158039e-06
the O 0 7.191856639110483e-06
members O 0 5.368094093682885e-07
had O 0 1.4771324003959307e-06
been O 0 6.506950853690796e-07
identified O 0 1.2944173022333416e-07
were O 0 6.794169848944875e-08
examined O 0 7.265511214882281e-08
to O 0 1.1892812068481362e-08
determine O 0 1.110070613208336e-07
the O 0 2.0590150597854517e-06
transmission O 0 2.5622161047067493e-05
of O 0 5.1623796025523916e-05
the O 0 0.00020322611089795828
DM B-Disease 1 1.0
expansion O 0 0.0002909275935962796
from O 0 5.34727587364614e-06
affected O 0 9.070417377188278e-07
parents O 0 8.739642254340652e-08
to O 0 3.6589494101235687e-08
their O 0 1.569982259752578e-07
offspring O 0 2.357063067393028e-06
. O 0 1.0418441434012493e-06

Where O 0 4.719182470580563e-05
the O 0 8.83360826264834e-06
transmitting O 0 0.00016437657177448273
parent O 0 6.49254161544377e-06
was O 0 1.666319258220028e-05
male O 0 4.596964572556317e-06
, O 0 5.885311225029e-07
58 O 0 1.502704071754124e-05
. O 0 1.2110662055420107e-06

3 O 0 0.0002673515409696847
% O 0 1.4703744454891421e-05
of O 0 2.315020356036257e-05
the O 0 2.0119425244047306e-05
offspring O 0 3.59026148544217e-06
were O 0 6.267609478527447e-06
affected O 0 9.854805966824642e-07
, O 0 6.39146122694001e-08
and O 0 2.7976339467272737e-08
in O 0 1.382831271712348e-07
the O 0 1.6363856047973968e-07
case O 0 1.7453839973313734e-07
of O 0 5.003457204111328e-07
a O 0 1.0944600035145413e-06
female O 0 7.476390692318091e-06
transmitting O 0 9.535715071251616e-05
parent O 0 4.978486686013639e-06
, O 0 1.2938202189616277e-06
68 O 0 3.7809772038599476e-05
. O 0 2.2388107936421875e-06

7 O 0 0.0001894220768008381
% O 0 1.05386643554084e-05
were O 0 4.3715467654692475e-06
affected O 0 5.744469035562361e-06
. O 0 2.2206129415280884e-06

Studies O 0 0.00012626238458324224
on O 0 9.443506132811308e-05
meiotic O 0 0.000569970638025552
drive O 0 3.8742997276131064e-05
in O 0 7.49914124753559e-06
DM B-Disease 1 0.9999862909317017
have O 0 2.921507586961525e-07
shown O 0 1.6190665519388858e-07
increased O 0 3.6492969002210884e-07
transmission O 0 5.841611709911376e-07
of O 0 3.156727927944303e-07
the O 0 1.843649073407505e-07
larger O 0 1.1895607343603842e-07
allele O 0 4.45327060560885e-07
at O 0 6.556811513291905e-06
the O 0 4.068549515068298e-06
DM B-Disease 1 0.9925252199172974
locus O 0 5.9594698541332036e-05
in O 0 1.6135194528033026e-05
non O 0 0.0002695344155654311
- O 0 0.0004937833291478455
DM O 1 0.9999991655349731
heterozygotes O 0 0.00012082647299394011
for O 0 6.108506113378098e-06
CTGn O 0 0.0005410729208961129
. O 0 3.933851530746324e-06

This O 0 8.343026252077834e-07
study O 0 4.3713450281757105e-07
provides O 0 1.5578342527078348e-07
further O 0 1.4794416358654416e-07
evidence O 0 1.4997370954006328e-06
that O 0 1.3827049087922205e-06
the O 0 5.277492891764268e-05
DM B-Disease 1 0.9999998807907104
expansion O 0 0.00018636340973898768
tends O 0 4.046600679430412e-06
to O 0 1.114666119406138e-07
be O 0 1.5734882197193656e-07
transmitted O 0 1.4552819038726739e-06
preferentially O 0 7.167605531321897e-07
. O 0 3.0569106002076296e-07

Diagnosis O 1 0.9999955892562866
of O 1 0.9837784767150879
hemochromatosis B-Disease 1 1.0
. O 0 0.00047791647375561297

If O 0 0.0005070777260698378
untreated O 1 0.9999939203262329
, O 0 0.00010114516771864146
hemochromatosis B-Disease 1 1.0
can O 0 9.392960055265576e-05
cause O 0 0.0059454417787492275
serious O 1 0.8948129415512085
illness O 1 0.9999814033508301
and O 0 1.4057536645850632e-06
early B-Disease 0 5.655802851833869e-06
death I-Disease 0 1.1217241080885287e-05
, O 0 1.2108290547985234e-07
but O 0 3.463906494971525e-08
the O 0 3.070397553983639e-07
disease O 0 3.830054538411787e-06
is O 0 1.3912945462379867e-07
still O 0 1.0034354147592239e-07
substantially O 0 1.9014360077562742e-06
under O 0 2.3301994588109665e-05
- O 0 0.0028941675554960966
diagnosed O 0 0.09136641770601273
. O 0 4.345190973253921e-06

The O 0 4.979581353836693e-05
cornerstone O 0 0.00010073032899526879
of O 0 2.4761432086961577e-06
screening O 0 1.6563001281610923e-06
and O 0 2.2764224638649466e-07
case O 0 2.903038023305271e-07
detection O 0 5.974036412226269e-07
is O 0 4.0271174839290325e-08
the O 0 6.82926142303586e-08
measurement O 0 2.033500095421914e-06
of O 0 2.932135657829349e-06
serum O 0 2.368094828852918e-05
transferrin O 0 8.31484139780514e-05
saturation O 0 3.126291267108172e-05
and O 0 7.579413932035095e-07
the O 0 2.2738238385500154e-06
serum O 0 4.534118852461688e-05
ferritin O 0 0.00047144663403742015
level O 0 0.0001492953160777688
. O 0 5.5384398365276866e-06

Once O 0 9.571134432917461e-05
the O 0 8.361884283658583e-06
diagnosis O 0 0.0005351415602490306
is O 0 2.3986883661564207e-06
suspected O 0 6.010850484017283e-06
, O 0 1.0674589390191613e-07
physicians O 0 1.7073635660835862e-07
must O 0 8.127990014372699e-08
use O 0 2.3164203355463542e-07
serum O 0 3.3270942367380485e-05
ferritin O 0 0.0006032937671989202
levels O 0 0.0001503642270108685
and O 0 2.284326183144003e-05
hepatic O 1 0.9999997615814209
iron O 1 0.9999480247497559
stores O 0 7.393989653792232e-05
on O 0 8.745944796828553e-05
liver O 1 0.9973375201225281
biopsy O 0 0.00015252933371812105
specimens O 0 3.035482620816765e-07
to O 0 3.155469485704998e-08
assess O 0 3.298437718513014e-07
patients O 0 3.9255590422726527e-07
for O 0 1.139636935931776e-07
the O 0 6.526801712425367e-07
presence O 0 3.166241867802455e-06
of O 0 7.341351738432422e-05
iron B-Disease 1 0.8759228587150574
overload I-Disease 0 0.0015940662706270814
. O 0 5.6791191127558704e-06

Liver O 1 1.0
biopsy O 1 0.9999878406524658
is O 0 3.1517865863861516e-05
also O 0 1.0738584705904941e-06
used O 0 1.0967089281166409e-07
to O 0 1.741535804455907e-08
establish O 0 1.3168467205559864e-07
the O 0 5.140456664776138e-07
presence O 0 9.8845123375213e-07
or O 0 2.222676585006411e-06
absence O 0 7.470083801308647e-06
of O 0 1.3322844097274356e-05
cirrhosis B-Disease 1 0.9999912977218628
, O 0 4.235455151047063e-07
which O 0 5.757873111633671e-08
can O 0 6.034497346263379e-08
affect O 0 1.0882631613640115e-06
prognosis O 0 0.0001422144559910521
and O 0 2.478962187524303e-06
management O 0 2.4414988729404286e-05
. O 0 2.711896286200499e-06

A O 0 0.0003495227138046175
DNA O 0 9.179330845654476e-06
- O 0 4.657721547118854e-06
based O 0 6.540840331581421e-07
test O 0 7.21664662250987e-07
for O 0 9.244024568033637e-07
the O 0 1.1040943718398921e-05
HFE O 0 0.0010469865519553423
gene O 0 3.3642102152953157e-06
is O 0 1.7274713570714084e-07
commercially O 0 8.586882671579588e-08
available O 0 1.396598214853384e-08
, O 0 2.4844148960312396e-09
but O 0 4.3243536529402604e-10
its O 0 1.7221910564302334e-09
place O 0 4.646956952569781e-08
in O 0 1.256762089951735e-07
the O 0 7.088871143423603e-07
diagnosis O 0 0.00043092379928566515
of O 0 0.0004354628035798669
hemochromatosis B-Disease 1 1.0
is O 0 3.2325511710951105e-05
still O 0 1.5969750393196591e-06
being O 0 9.208793585457897e-07
evaluated O 0 3.72611680177215e-06
. O 0 6.054489176676725e-07

Currently O 0 0.00013429022510536015
, O 0 2.3924560537125217e-06
the O 0 7.313631726901804e-07
most O 0 6.790697426595216e-08
useful O 0 1.266024867163651e-07
role O 0 2.6646810624697537e-07
for O 0 3.8888298803385624e-08
this O 0 1.168335650447716e-08
test O 0 3.6729058905393686e-08
is O 0 2.7794225587740584e-08
in O 0 4.3892157464142656e-08
the O 0 2.7562950322135293e-07
detection O 0 4.580423137667822e-06
of O 0 5.590549699263647e-05
hemochromatosis B-Disease 1 1.0
in O 0 0.00021200334595050663
the O 0 1.533354770799633e-05
family O 0 4.6178175239219854e-07
members O 0 1.8236452348219245e-08
of O 0 8.333032042173727e-08
patients O 0 1.2165806140274071e-07
with O 0 7.879748409322929e-09
a O 0 2.291069165494264e-07
proven O 0 1.9716819679160835e-06
case O 0 8.392400729917426e-08
of O 0 9.047790854310733e-07
the O 0 1.3222596862760838e-05
disease O 0 0.003495604731142521
. O 0 4.480432380660204e-06

It O 0 3.2284671647175855e-07
is O 0 1.431543665830759e-07
crucial O 0 1.010103233056725e-06
to O 0 8.809672635834431e-07
diagnose O 1 0.9996999502182007
hemochromatosis B-Disease 1 1.0
before O 1 0.9978530406951904
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.0001540116936666891
because O 0 4.154439466219628e-06
phlebotomy O 1 0.9999923706054688
therapy O 0 0.22020983695983887
can O 0 8.123632824208471e-07
avert O 0 0.00013575423508882523
serious O 1 0.9999603033065796
chronic O 1 1.0
disease O 1 1.0
and O 0 2.58661430052598e-06
can O 0 1.0000096750673038e-07
even O 0 4.4062765880426014e-08
lead O 0 5.511224543397475e-08
to O 0 2.2396164922611206e-08
normal O 0 2.5601443667255808e-06
life O 0 6.175481530590332e-07
expectancy O 0 2.997789806613582e-06
. O 0 1.2118131564875512e-07
. O 0 4.859160185333167e-07

Prevalence O 0 0.0025497793685644865
of O 0 0.00020023880642838776
the O 0 8.129047637339681e-05
I1307K O 0 0.0014896931825205684
APC B-Disease 0 0.00020613844390027225
gene O 0 1.3316837339516496e-06
variant O 0 5.738619393014233e-07
in O 0 4.158019706324012e-08
Israeli O 0 1.1324960524916605e-07
Jews O 0 2.5984020268765562e-08
of O 0 1.0790859761300453e-08
differing O 0 4.382546325842895e-09
ethnic O 0 5.24244025967846e-09
origin O 0 2.275267263485148e-08
and O 0 5.901549116060778e-08
risk O 0 2.2387764602171956e-06
for O 0 2.6496303689782508e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.421831236977596e-06

BACKGROUND O 0 0.00077251618495211
& O 0 0.00016711822536308318
AIMS O 0 1.056994642567588e-05
Israeli O 0 6.797384685341967e-06
Jews O 0 6.26624114374863e-06
of O 0 1.3393010704021435e-05
European O 0 1.957329732249491e-05
birth O 0 4.5040469558443874e-05
, O 0 1.592886405887839e-06
i O 0 1.049612933456956e-06
. O 0 7.502708854190132e-08
e O 0 4.4887627836942556e-07
. O 0 1.3718365110548802e-08
, O 0 2.7863123364113562e-08
Ashkenazim O 0 8.700570788278128e-07
, O 0 8.16200884656837e-09
have O 0 5.8661950852467726e-09
the O 0 1.6264112900898908e-07
highest O 1 0.999536395072937
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9980853796005249
of O 0 1.0534503417147789e-05
any O 0 5.674381213793822e-07
Israeli O 0 2.7579420930123888e-05
ethnic O 0 3.434851578276721e-06
group O 0 2.6228012757201213e-06
. O 0 9.944866405930952e-07

The O 0 0.000314962409902364
I1307K O 0 0.0015932550886645913
APC B-Disease 0 0.00027333543403074145
gene O 0 4.24768131779274e-06
variant O 0 6.997755463089561e-06
was O 0 1.6732477888581343e-05
found O 0 3.320923269711784e-07
in O 0 9.350528102913813e-07
6 O 0 3.628612103057094e-05
. O 0 2.1375988126237644e-06

1 O 0 3.5666216717800125e-05
% O 0 5.580550350714475e-07
of O 0 3.248099176289543e-07
American O 0 2.6345159653828887e-07
Jews O 0 1.3701465206850116e-07
, O 0 1.2371640600861156e-08
28 O 0 2.619771635181678e-07
% O 0 3.3927257447885495e-08
of O 0 9.1293458126529e-08
their O 0 2.8468548407545313e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.0013561679515987635
, O 0 8.24735252535902e-07
but O 0 8.447114652199161e-08
not O 0 8.762509651205619e-08
in O 0 1.044781356540625e-06
non O 0 1.3475801097229123e-05
- O 0 2.9071984499751125e-06
Jews O 0 1.6387624555136426e-06
. O 0 5.883936182726757e-07

We O 0 3.0040177080081776e-05
assessed O 0 2.524616320442874e-05
the O 0 2.6810128019860713e-06
I1307K O 0 2.949230656668078e-05
prevalence O 0 2.796967464746558e-06
in O 0 3.545658699977139e-08
Israeli O 0 7.090549303256921e-08
Jews O 0 3.158064387775994e-08
of O 0 8.07812838843347e-09
differing O 0 4.666540043274381e-09
ethnic O 0 6.379242911691563e-09
origin O 0 2.5429054417713814e-08
and O 0 4.368327566339758e-08
risk O 0 2.0481770661717746e-06
for O 0 2.2995101971901022e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6002426491468213e-05

METHODS O 0 6.883050809847191e-05
DNA O 0 3.1352271889772965e-06
samples O 0 2.5980609734688187e-06
from O 0 3.93659911424038e-06
500 O 0 1.9024173525394872e-06
unrelated O 0 7.498188097088132e-07
Jews O 0 2.5919332529156236e-06
of O 0 1.2878883353550918e-05
European O 0 3.709900556714274e-05
or O 0 1.4666309652966447e-05
non O 0 1.7726239093462937e-05
- O 0 1.2020152553304797e-06
European O 0 9.391476964992762e-07
origin O 0 1.3953300026514626e-07
, O 0 3.901146783391596e-08
with O 0 1.549852335358537e-08
or O 0 1.9412848928368476e-07
without O 0 6.498839155710812e-08
a O 0 6.43993814719579e-07
personal O 0 4.527370947471354e-06
and O 0 5.174935722607188e-06
/ O 0 7.979146903380752e-05
or O 0 1.318285853812995e-06
family O 0 2.677795691852225e-07
history O 0 2.5213425942638423e-06
of O 0 3.0150442398735322e-05
neoplasia B-Disease 0 0.0017854653997346759
, O 0 8.404524578509154e-07
were O 0 3.8981127659099e-07
examined O 0 4.3424756768217776e-07
for O 0 1.627121832825651e-07
the O 0 7.481901320716133e-07
I1307K O 0 7.684699085075408e-06
variant O 0 3.5431446576694725e-06
by O 0 4.0976811988002737e-07
the O 0 1.2106712574677658e-06
allele O 0 8.290433015645249e-07
- O 0 1.0408103889858467e-06
specific O 0 5.7325163282939684e-08
oligonucleotide O 0 2.0408422642503865e-05
( O 0 9.539639904687647e-06
ASO O 0 0.000492523075081408
) O 0 6.3480155176876e-07
method O 0 2.438749561406439e-06
. O 0 1.370009726997523e-06

RESULTS O 0 9.0978801381425e-06
In O 0 4.280381631360797e-07
persons O 0 3.014412186530535e-07
at O 0 7.501091090489354e-07
average O 0 1.4110698884906014e-06
risk O 0 2.690053179321694e-06
for O 0 0.00013823865447193384
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 9.068912731891032e-06
I1307K O 0 2.78123752650572e-05
was O 0 8.276409062091261e-06
found O 0 3.2958121209958335e-07
in O 0 5.504820705937163e-07
5 O 0 9.144609066424891e-06
. O 0 1.4414774796023266e-06

0 O 0 5.704684735974297e-05
% O 0 1.4556566156898043e-06
of O 0 2.5945448669517646e-06
120 O 0 4.080871349287918e-06
European O 0 3.0751612030144315e-06
and O 0 1.4824597656115657e-06
1 O 0 5.131688158144243e-05
. O 0 2.104111217704485e-06

6 O 0 0.0004993734182789922
% O 0 1.1055567483708728e-05
of O 0 2.051085903076455e-05
188 O 0 3.4627155400812626e-05
non O 0 5.693450657417998e-05
- O 0 4.0737554627412464e-06
European O 0 2.41057659877697e-06
Jews O 0 1.5641388699805248e-06
( O 0 5.988073894513946e-07
P O 0 1.974146653083153e-05
= O 0 1.5642492598999524e-06
0 O 0 7.89441685355996e-07
. O 0 5.468002228781188e-08
08 O 0 3.5901211958844215e-06
) O 0 2.0143248491422128e-07
. O 0 2.823370550686377e-07

It O 0 2.846765482900082e-06
occurred O 0 3.055361594306305e-05
in O 0 3.1509698601439595e-06
15 O 0 1.7142931028502062e-05
. O 0 1.8532559806772042e-06

4 O 0 2.1459554773173295e-05
% O 0 3.8894680187695485e-07
of O 0 3.7050756418466335e-07
52 O 0 5.235805474512745e-06
Ashkenazi O 0 1.9986046027042903e-06
Israelis O 0 4.5725488462267094e-07
with O 0 1.914358449539577e-07
familial O 0 0.011153003200888634
cancer B-Disease 1 0.9997836947441101
( O 0 9.328598025604151e-06
P O 0 0.0006837212713435292
= O 0 1.5443509255419485e-05
0 O 0 4.3612612898868974e-06
. O 0 1.6870087904408138e-07
02 O 0 2.188025064242538e-05
) O 0 1.9054026267895097e-07
and O 0 2.1962569007882848e-07
was O 0 4.6469845074170735e-06
not O 0 1.3345541560738639e-07
detected O 0 1.849378918450384e-06
in O 0 1.485021016378596e-06
51 O 0 1.5346817235695198e-05
non O 0 8.093018550425768e-06
- O 0 4.687532566549635e-07
European O 0 7.052930328654838e-08
Jews O 0 1.1683740552825839e-07
at O 0 7.134536303965433e-07
increased O 0 3.4314070944674313e-06
cancer B-Disease 0 0.00010605735587887466
risk O 0 3.6953153994545573e-06
. O 0 7.023517127890955e-07

Colorectal B-Disease 1 0.9999997615814209
neoplasia I-Disease 1 0.9999972581863403
occurred O 1 0.9884029030799866
personally O 0 8.74186007422395e-05
or O 0 5.013520421925932e-06
in O 0 8.491430776302877e-07
the O 0 4.417115064825339e-07
families O 0 3.8577425698349543e-08
of O 0 1.964722514458117e-06
13 O 0 2.585460606496781e-05
of O 0 3.858434138237499e-05
20 O 0 0.00013743940507993102
Ashkenazi O 0 7.746869960101321e-05
I1307K O 0 5.5016502301441506e-05
carriers O 0 1.7654811017564498e-06
, O 0 5.864060881322075e-07
8 O 0 5.038877588958712e-06
of O 0 1.057754388966714e-06
whom O 0 6.71020075060369e-07
also O 0 5.287749331728264e-07
had O 0 7.037691034383897e-07
a O 0 5.550456307901186e-07
personal O 0 2.6231366518914e-06
or O 0 5.85482951009908e-07
family O 0 1.5025386801426066e-07
history O 0 7.14012401203945e-07
of O 0 1.3061671779723838e-05
noncolonic O 0 0.0035141974221915007
neoplasia B-Disease 1 0.9947545528411865
. O 0 4.2913463403237984e-05

CONCLUSIONS O 0 0.00027553303516469896
The O 0 5.768349001300521e-05
I1307K O 0 0.0006899185827933252
APC O 0 0.00013245927402749658
variant O 0 1.0052309335151222e-05
may O 0 7.045386496429273e-07
represent O 0 1.3493212236426189e-07
a O 0 3.065072746721853e-07
susceptibility O 0 2.140502147085499e-05
gene O 0 1.2259531104064081e-05
for O 0 2.9158421966712922e-05
colorectal B-Disease 1 1.0
, I-Disease 0 0.00014681884204037488
or I-Disease 0 2.2992338926997036e-05
other I-Disease 0 5.642639848701947e-07
, I-Disease 0 1.8494034748073318e-06
cancers I-Disease 0 0.00012182652426417917
in O 0 5.225103336670145e-07
Ashkenazi O 0 1.3118520882926532e-06
Jews O 0 1.396433475520098e-07
, O 0 7.097107790343671e-09
and O 0 6.2083223006936805e-09
partially O 0 1.4960529881591356e-07
explains O 0 1.9926325478536455e-08
the O 0 1.9969890630022746e-08
higher O 0 1.622867671358108e-06
incidence O 0 0.00027570119709707797
of O 0 0.09969692677259445
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.3440534278051928e-05
European O 0 7.881697456468828e-06
Israelis O 0 3.0283056275948184e-06
. O 0 8.045622053032275e-07

Systematic O 0 5.645768851536559e-06
analysis O 0 7.982409329088114e-07
of O 0 1.0493033187231049e-05
coproporphyrinogen O 0 0.00427170330658555
oxidase O 0 0.15313594043254852
gene O 0 0.03155077248811722
defects O 1 0.9727353453636169
in O 0 6.461549492087215e-05
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9949835538864136
and O 0 4.359331796877086e-06
mutation O 0 6.854879302409245e-06
update O 0 5.264314495434519e-06
. O 0 1.2205414350319188e-06

Hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9999076128005981
( O 0 0.00012812567001674324
HC B-Disease 1 0.9999996423721313
) O 0 5.410323410615092e-06
is O 0 4.262385289166559e-07
an O 0 1.9212679944757838e-06
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.999862790107727
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 1 0.9992427825927734
caused O 1 0.6985586881637573
by O 0 4.808832727576373e-07
deficient B-Disease 0 3.285487400717102e-05
activity I-Disease 0 4.135544713790296e-06
of I-Disease 0 1.219460682477802e-05
coproporphyrinogen I-Disease 0 0.00022059772163629532
III I-Disease 0 0.018562840297818184
oxidase I-Disease 0 0.00014889356680214405
( O 0 8.454127964796498e-06
CPO O 0 0.00043696395005099475
) O 0 1.0797725735756103e-06
. O 0 5.554163067245099e-07

Clinical O 0 0.0022286144085228443
manifestations O 0 0.0028020620811730623
of O 0 1.3244530236988794e-05
the O 0 1.721721673675347e-05
disease O 0 0.22585560381412506
are O 0 1.3772267770661983e-08
characterized O 0 5.219913390419606e-08
by O 0 1.2881068656156458e-08
acute O 0 0.3605324923992157
attacks O 0 2.0605904865078628e-05
of O 0 0.48325711488723755
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 3.430827746342402e-06
precipitated O 0 5.937689820711967e-06
by O 0 1.3379433561055976e-08
drugs O 0 1.5717739643150708e-07
, O 0 1.6216063158935867e-08
fasting O 0 7.880914267843764e-07
, O 0 1.8235085974538379e-07
cyclical O 0 5.768657138105482e-05
hormonal O 0 9.365770529257134e-05
changes O 0 6.649325996477273e-07
, O 0 1.1539137858562754e-06
or O 0 3.050094710488338e-05
infectious B-Disease 1 0.997364342212677
diseases I-Disease 1 0.9984118938446045
. O 0 3.394527084310539e-06

Skin O 1 1.0
photosensitivity O 1 0.9999997615814209
may O 0 0.05379406362771988
also O 0 8.031080142245628e-06
be O 0 5.373005933506647e-07
present O 0 7.314203571695543e-07
. O 0 8.793614938440442e-07

The O 0 0.00014465683489106596
seven O 0 7.027343235677108e-05
exons O 0 0.00011039052333217114
, O 0 4.659334081225097e-06
the O 0 8.325823728227988e-06
exon O 0 1.851784691098146e-05
/ O 0 1.9167940990882926e-05
intron O 0 8.90671981323976e-06
boundaries O 0 6.863683665869758e-07
and O 0 2.179820484116135e-07
part O 0 1.8285271607965115e-07
of O 0 3.310341298856656e-06
3 O 0 6.955374374228995e-06
noncoding O 0 3.4803520065906923e-06
sequence O 0 1.4508474350805045e-06
of O 0 1.9604063709266484e-05
the O 0 3.029573599633295e-05
CPO O 0 0.0002275162114528939
gene O 0 6.132684688964218e-07
were O 0 7.226839215945802e-07
systematically O 0 3.1667869393459114e-07
analyzed O 0 5.453399012367299e-07
by O 0 1.1862142201835013e-07
an O 0 3.1157523494584893e-07
exon O 0 9.632306046114536e-07
- O 0 1.3626540749100968e-06
by O 0 5.583030997513561e-07
- O 0 9.094982488022652e-06
exon O 0 2.2211566829355434e-05
denaturing O 0 0.00038056523771956563
gradient O 0 0.0009323259582743049
gel O 0 0.00033751543378457427
electrophoresis O 0 0.00018388852186035365
( O 0 9.618145668355282e-06
DGGE O 0 0.0001078031855286099
) O 0 1.3326234693522565e-07
strategy O 0 4.114738416660657e-08
followed O 0 2.1858379994910138e-08
by O 0 8.635705484039136e-10
direct O 0 2.7151617842946507e-08
sequencing O 0 2.443162543386279e-07
in O 0 4.925439611724869e-07
seven O 0 2.3924378638184862e-06
unrelated O 0 7.681159331696108e-06
heterozygous O 0 1.1950990483455826e-05
HC B-Disease 0 0.12458844482898712
patients O 0 1.442809934815159e-05
from O 0 3.4795984902302735e-06
France O 0 1.4308914614957757e-05
, O 0 7.056993354126462e-07
Holland O 0 2.0273830614314647e-06
, O 0 1.02063395956975e-07
and O 0 6.800107144044887e-08
Czech O 0 6.692365332128247e-06
Republic O 0 1.7440277588320896e-05
. O 0 6.057975951989647e-06

Seven O 0 5.639888331643306e-05
novel O 0 7.6128626460558735e-06
mutations O 0 1.8598707356431987e-06
and O 0 4.931173407385359e-07
two O 0 1.7038696853433066e-07
new O 0 2.5371170409016486e-07
polymorphisms O 0 2.5494921374047408e-06
were O 0 3.2252773962682113e-06
detected O 0 2.376896190980915e-05
. O 0 1.563604996590584e-06

Among O 0 7.741408808215056e-06
these O 0 3.987731247434567e-07
mutations O 0 9.824234439292923e-07
two O 0 5.168091661289509e-07
are O 0 3.1176668358057213e-07
missense O 0 8.013079423108138e-06
( O 0 2.398965079919435e-06
G197W O 0 2.7181749828741886e-05
, O 0 1.9018078774024616e-06
W427R O 0 1.79699927684851e-05
) O 0 1.1215025779165444e-06
, O 0 5.104005253997457e-07
two O 0 4.425100428306905e-07
are O 0 4.665251935875858e-07
nonsense O 0 1.7246729839826003e-05
( O 0 1.9918136331398273e-06
Q306X O 0 3.440411819610745e-05
, O 0 2.8131837552791694e-06
Q385X O 0 1.0933252269751392e-05
) O 0 6.631202040807693e-07
, O 0 1.3549511379551404e-07
two O 0 1.2399497961723682e-07
are O 0 9.902782238668806e-08
small O 0 1.7867506585389492e-07
deletions O 0 1.0236992693535285e-06
( O 0 2.217997007392114e-06
662de14bp O 0 1.6210260582738556e-05
; O 0 1.1310600029901252e-06
1168del3bp O 0 4.121314486837946e-05
removing O 0 9.424401469004806e-06
a O 0 1.5193794752121903e-05
glycine O 0 1.3515442333300598e-05
at O 0 7.61042902013287e-05
position O 0 6.621699412789894e-06
390 O 0 5.230216174822999e-06
) O 0 1.0651993420651706e-07
, O 0 5.1400252942812585e-08
and O 0 1.083347029862125e-07
one O 0 1.23623280501306e-07
is O 0 3.0180481758179667e-07
a O 0 1.3069682154309703e-06
splicing O 0 1.7896101098813233e-06
mutation O 0 3.0126816454867367e-06
( O 0 4.77627690997906e-06
IVS1 O 0 0.00012305876589380205
- O 0 8.875907042238396e-06
15c O 0 3.202798689017072e-05
- O 0 3.234651103412034e-06
- O 0 2.4220985324063804e-06
> O 0 2.3101799797586864e-06
g O 0 1.5505612509514322e-06
) O 0 3.634459133650125e-08
which O 0 1.2365224399957242e-08
creates O 0 8.6024726897449e-08
a O 0 1.876968127589862e-07
new O 0 2.1289613982844457e-07
acceptor O 0 8.670147053635446e-07
splice O 0 9.945399142452516e-06
site O 0 6.466113518399652e-06
. O 0 8.704537890480424e-07

The O 0 1.6356758351321332e-05
pathological O 0 0.0002043747517745942
significance O 0 9.887219675874803e-06
of O 0 4.2028448660857975e-05
the O 0 1.2095762940589339e-05
point O 0 2.0156683604000136e-05
mutations O 0 1.1620494433373096e-06
G197W O 0 2.7053843950852752e-05
, O 0 2.192968167946674e-06
W427R O 0 1.8346252545597963e-05
, O 0 1.7631791706662625e-06
and O 0 1.2833392020183965e-06
the O 0 7.1880986070027575e-06
in O 0 1.8814762370311655e-05
- O 0 3.950636164518073e-05
frame O 0 8.226204226957634e-05
deletion O 0 2.61946606769925e-05
390delGly O 0 3.2128358725458384e-05
were O 0 2.3556585801998153e-06
assessed O 0 1.5387645362352487e-06
by O 0 4.4032940849092483e-08
their O 0 5.109528089519699e-08
respective O 0 1.428890982424491e-06
expression O 0 5.3483877309190575e-06
in O 0 1.7075376490538474e-06
a O 0 1.3377069763009786e-06
prokaryotic O 0 1.1632902214842034e-06
system O 0 2.4474377369188005e-06
using O 0 1.3926910469308496e-07
site O 0 6.452116281252529e-07
- O 0 3.2535928085053456e-07
directed O 0 1.4134454318082135e-07
mutagenesis O 0 7.092488431226229e-06
. O 0 1.0028534234152175e-06

These O 0 8.687420631758869e-07
mutations O 0 1.8033384776572348e-06
resulted O 0 3.0967037218943005e-06
in O 0 1.3880121514375787e-06
the O 0 9.989561249312828e-07
absence O 0 3.4557547223812435e-06
or O 0 3.182730665685085e-07
a O 0 1.2049541453507118e-07
dramatic O 0 2.7089856757811503e-06
decrease O 0 3.0085791877354495e-05
of O 0 0.00010903842485276982
CPO O 0 0.009733268991112709
activity O 0 7.315654511330649e-05
. O 0 3.6755031942448113e-06

The O 0 7.809785165591165e-05
two O 0 1.9011059748663683e-06
polymorphisms O 0 8.406757842749357e-06
were O 0 1.3736414530285401e-06
localized O 0 3.1498252610617783e-06
in O 0 1.2183633089080104e-06
noncoding O 0 2.3113193492463324e-06
part O 0 5.436533001557109e-07
of O 0 4.565290964819724e-06
the O 0 1.4860183910059277e-06
gene O 0 2.0190829275179567e-07
1 O 0 1.6335196733052726e-06
) O 0 6.18180919786937e-08
a O 0 5.673970235875458e-07
C O 0 2.6156996682402678e-05
/ O 0 1.2641389730561059e-05
G O 0 2.203087933594361e-05
polymorphism O 0 1.5949796079439693e-06
in O 0 3.823507540801074e-06
the O 0 9.55060932028573e-06
promotor O 0 0.0001204140207846649
region O 0 1.0260978342557792e-05
, O 0 1.8325737300983747e-06
142 O 0 8.517818969266955e-06
bp O 0 5.659742328134598e-06
upstream O 0 3.089724259552895e-06
from O 0 8.778867481851194e-07
the O 0 9.92721311376954e-07
transcriptional O 0 6.206405032571638e-06
initiation O 0 4.854277904087212e-06
site O 0 3.725452415892505e-06
( O 0 3.533810399858339e-07
- O 0 2.0796849184989696e-06
142C O 0 1.750995397742372e-05
/ O 0 2.6646186597645283e-05
G O 0 3.4251534088980407e-05
) O 0 5.19083812378085e-07
, O 0 2.2291631296411651e-07
and O 0 5.115711019243463e-07
2 O 0 9.36625110625755e-06
) O 0 3.430954791383556e-07
a O 0 2.1605119400192052e-06
6 O 0 2.7372787371859886e-05
bp O 0 3.2231496334134135e-06
deletion O 0 6.502795031337882e-07
polymorphism O 0 2.201130087087222e-07
in O 0 5.116330612509046e-07
the O 0 6.324310106720077e-07
3 O 0 1.3349707614906947e-06
noncoding O 0 1.043098791342345e-06
part O 0 6.926995865796926e-07
of O 0 1.3357653187995311e-05
the O 0 4.353443000582047e-05
CPO O 0 0.0004918277845717967
gene O 0 4.197033376840409e-06
, O 0 2.117251369782025e-06
574 O 0 2.4016730094444938e-05
bp O 0 7.192473731265636e-06
downstream O 0 7.234387339849491e-06
of O 0 2.8508650302683236e-06
the O 0 2.004181624215562e-06
last O 0 1.2062848782079527e-06
base O 0 1.6800580624476424e-06
of O 0 8.243601996582584e-07
the O 0 1.1662538099699304e-06
normal O 0 7.81910875957692e-06
termination O 0 1.4830715372227132e-05
codon O 0 1.8612105122883804e-05
( O 0 2.2576421088160714e-06
+ O 0 1.0496406503079925e-05
574 O 0 4.184237332083285e-05
delATTCTT O 0 5.863463593414053e-05
) O 0 2.353693616896635e-06
. O 0 1.095100060410914e-06

Five O 0 0.0013990012230351567
intragenic O 0 0.005954599007964134
dimorphisms O 0 0.002496530767530203
are O 0 2.5405747692275327e-06
now O 0 2.458092183132976e-07
well O 0 5.4598316978626826e-08
characterized O 0 6.329022284035091e-08
and O 0 2.0302369563296452e-08
the O 0 8.923905880919847e-08
high O 0 9.729114935908e-07
degree O 0 5.418502496468136e-06
of O 0 3.2800976441649254e-06
allelic O 0 4.328459908720106e-05
heterogeneity O 0 4.106007327209227e-05
in O 0 2.025916546699591e-05
HC B-Disease 1 0.996613085269928
is O 0 5.188152954360703e-06
demonstrated O 0 2.1954688236291986e-06
with O 0 2.0428688074503043e-08
seven O 0 5.9439230426505674e-08
new O 0 3.542148574453563e-09
different O 0 7.483136887920239e-10
mutations O 0 9.631442310364946e-09
making O 0 8.93607943197594e-09
a O 0 2.0419651747261014e-08
total O 0 5.625714152301953e-07
of O 0 7.410608304780908e-06
nineteen O 0 0.001208791509270668
CPO O 1 0.9995039701461792
gene B-Disease 0 0.011454036459326744
defects I-Disease 0 0.035247281193733215
reported O 0 8.4746479842579e-06
so O 0 1.5813286324828368e-07
far O 0 1.8179451899413834e-07
. O 0 4.11914378162237e-08
. O 0 1.6950998826814612e-07

Coincidence O 0 7.563842518720776e-05
of O 0 6.72808619128773e-06
two O 0 6.719229759255541e-07
novel O 0 2.813232185872039e-06
arylsulfatase O 0 3.23579297401011e-05
A O 0 2.311160642420873e-06
alleles O 0 3.8271886637630814e-07
and O 0 1.498711981184897e-07
mutation O 0 4.583061468110827e-07
459 O 0 2.1342080799513496e-05
+ O 0 4.606229413184337e-05
1G O 0 0.0006500416784547269
> O 0 1.2089892152289394e-05
A O 0 5.579789785770117e-07
within O 0 1.0568454200665656e-07
a O 0 2.8889829195577477e-07
family O 0 3.247287736485305e-07
with O 0 6.190210797285545e-07
metachromatic B-Disease 1 0.9999982118606567
leukodystrophy I-Disease 1 0.9999990463256836
: O 0 1.2256897718998516e-07
molecular O 0 1.7705009724977572e-07
basis O 0 1.4707953255310713e-07
of O 0 7.080884643073659e-07
phenotypic O 0 0.00014330167323350906
heterogeneity O 0 0.00031884139752946794
. O 0 1.74581837200094e-05

In O 0 8.164753671735525e-05
a O 0 9.932497960107867e-06
family O 0 6.090313036111183e-07
with O 0 7.66459109513562e-08
three O 0 3.669531167815876e-07
siblings O 0 6.833658972027479e-07
, O 0 1.4231905431927316e-08
one O 0 5.984075013287793e-09
developed O 0 1.4538736081703973e-07
classical O 0 4.025033922516741e-05
late O 0 0.00411985395476222
infantile O 1 0.9999997615814209
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 4.880335109191947e-05
MLD B-Disease 1 1.0
) O 0 2.3441507437382825e-06
, O 0 6.356229960147175e-07
fatal O 0 1.946033808053471e-05
at O 0 9.08464971871581e-06
age O 0 1.6494526562382816e-06
5 O 0 3.3022413390426664e-06
years O 0 5.099831241750508e-07
, O 0 1.226982107027652e-07
with O 0 2.0496939612257847e-07
deficient O 0 0.0003873409586958587
arylsulfatase O 0 0.00024915457470342517
A O 0 0.00010350472439313307
( O 0 4.257613454683451e-06
ARSA O 0 8.545089804101735e-05
) O 0 1.3526542375075223e-07
activity O 0 1.981619135449364e-07
and O 0 8.18511622924234e-08
increased O 0 4.506052846409148e-06
galactosylsulfatide O 0 0.00013219492393545806
( O 0 1.6273392247967422e-05
GS O 1 0.9999035596847534
) O 0 2.452718263157294e-06
excretion O 0 1.1366360922693275e-05
. O 0 8.283936381303647e-07

The O 0 0.00015576000441797078
two O 0 1.733691715344321e-05
other O 0 2.9140546757844277e-06
siblings O 0 1.5948615327943116e-05
, O 0 2.394784587522736e-06
apparently O 0 7.470674972864799e-06
healthy O 0 3.9452088458347134e-06
at O 0 6.737967851222493e-06
12 O 0 1.818354121496668e-06
( O 0 1.765553889754301e-07
1 O 0 4.426866325957235e-06
/ O 0 2.6380132567283e-06
2 O 0 2.699212018342223e-06
) O 0 8.602866330420511e-08
and O 0 3.136735529096768e-07
15 O 0 3.149065378238447e-06
years O 0 1.2421883184288163e-06
, O 0 3.326213402488065e-07
respectively O 0 4.285105660528643e-06
, O 0 2.4098380890791304e-07
and O 0 1.5201196390535188e-07
their O 0 3.2300161478815426e-07
father O 0 1.4078738786338363e-05
, O 0 1.0272424333379604e-06
apparently O 0 2.14066926673695e-06
healthy O 0 3.1853056725594797e-07
as O 0 5.8839926708742496e-08
well O 0 4.8969067023563184e-08
, O 0 4.7668024194535974e-08
presented O 0 1.2428329227986978e-06
ARSA O 0 0.0006085742497816682
and O 0 8.931915544962976e-06
GS O 1 0.999996542930603
values O 0 5.575555519499176e-07
within O 0 7.934649204344169e-08
the O 0 5.77951517755082e-08
range O 0 1.0284461495757569e-06
of O 0 1.5256315236911178e-05
MLD B-Disease 1 1.0
patients O 0 4.790730235981755e-05
. O 0 4.573753813019721e-06

Mutation O 0 4.849336164625129e-06
screening O 0 9.177337005894515e-07
and O 0 1.4208612242327945e-07
sequence O 0 3.739398266588978e-07
analysis O 0 1.9961593977768644e-07
disclosed O 0 6.063832529434876e-07
the O 0 2.911250192028092e-07
involvement O 0 1.6688672985765152e-06
of O 0 1.2612830460057012e-06
three O 0 6.423787226594868e-07
different O 0 1.7141589125913015e-07
ARSA O 0 0.0002420287491986528
mutations O 0 3.155415697619901e-07
being O 0 1.0021270924198689e-07
the O 0 2.1130702521077183e-08
molecular O 0 1.7724066481150658e-07
basis O 0 1.1085260354093407e-07
of O 0 2.165683781640837e-06
intrafamilial O 0 0.00016997268539853394
phenotypic O 0 0.0003357893438078463
heterogeneity O 0 0.0007000173209235072
. O 0 1.9102266378467903e-05

The O 0 6.668542482657358e-05
late O 0 0.002047956455498934
infantile O 1 0.9999958276748657
patient O 0 0.0017005620757117867
inherited O 0 0.0012076142011210322
from O 0 1.9398616132093593e-05
his O 0 8.267139492090791e-06
mother O 0 1.5536192222498357e-05
the O 0 3.399570687179221e-06
frequent O 0 2.7077408049080987e-06
0 O 0 1.6169868104043417e-05
- O 0 1.261793158846558e-06
type O 0 1.5825854688955587e-06
mutation O 0 1.2908980124848313e-06
459 O 0 2.925557600974571e-05
+ O 0 2.197506546508521e-05
1G O 0 0.0003264843253418803
> O 0 1.7286893125856295e-05
A O 0 7.400587037409423e-06
, O 0 2.0713586934562045e-07
and O 0 1.6201525454562216e-07
from O 0 4.614401518665545e-07
his O 0 1.0216209602731396e-06
father O 0 2.945610958704492e-06
a O 0 6.194752018018335e-07
novel O 0 6.392253339981835e-07
, O 0 1.5421582588714955e-07
single O 0 4.1975357589763007e-07
basepair O 0 1.632188468647655e-05
microdeletion O 0 2.783874879241921e-05
of O 0 1.5196243111859076e-05
guanine O 0 1.363269711873727e-05
at O 0 4.0672348404768854e-05
nucleotide O 0 2.6535053621046245e-06
7 O 0 9.37446384341456e-06
in O 0 1.4224951883079484e-06
exon O 0 2.3959494228620315e-06
1 O 0 8.68579991220031e-06
( O 0 1.3020852520639892e-06
7delG O 0 7.3488517955411226e-06
) O 0 1.3073970421828562e-06
. O 0 1.2583010402522632e-06

The O 0 5.705669173039496e-05
two O 0 1.3571767340181395e-05
clinically O 0 0.006513753905892372
unaffected O 0 6.529423990286887e-05
siblings O 0 1.1940461490667076e-06
carried O 0 2.6793870233632333e-07
the O 0 2.2974580815571244e-07
maternal O 0 1.362055991194211e-05
mutation O 0 3.319442839710973e-06
459 O 0 0.00010415650467621163
+ O 0 0.00011499245738377795
1G O 0 0.0015502630267292261
> O 0 4.856707892031409e-05
A O 0 1.2868569683632813e-05
and O 0 8.969293503469089e-07
, O 0 2.0153527202637633e-07
on O 0 1.0744967084974633e-06
their O 0 9.764476516238574e-08
paternal O 0 1.443049495719606e-05
allele O 0 1.8839563153960626e-06
, O 0 4.299438316479609e-08
a O 0 8.319153010916125e-08
novel O 0 1.9616692270574276e-07
cytosine O 0 3.272903370543645e-07
to O 0 3.834121997670081e-08
thymidine O 0 6.52066910333815e-06
transition O 0 1.2465538020478562e-05
at O 0 3.684500916278921e-05
nucleotide O 0 5.214651991991559e-06
2435 O 0 5.040284668211825e-05
in O 0 1.1738392231563921e-06
exon O 0 8.658636829750321e-07
8 O 0 1.8495993572287261e-06
, O 0 2.389157671700559e-08
resulting O 0 4.2396820276735525e-08
in O 0 8.801772111155515e-08
substitution O 0 5.580912443292618e-07
of O 0 2.7258463433099678e-06
alanine O 0 6.39086692899582e-06
464 O 0 3.093852865276858e-05
by O 0 1.8780814343699603e-06
valine O 0 8.901808905648068e-05
( O 0 2.1457688035297906e-06
A464V O 0 4.38859460700769e-05
) O 0 1.7040840702975402e-06
. O 0 1.2237326245667646e-06

The O 0 8.044268906814978e-05
fathers O 0 4.7160508984234184e-05
genotype O 0 2.085167943732813e-05
thus O 0 3.8103739825601224e-06
was O 0 3.256781928939745e-05
7delG O 0 0.0002116579853463918
/ O 0 0.00018835962691809982
A464V O 0 0.00024870934430509806
. O 0 6.544405550812371e-06

Mutation O 0 0.00034059101017192006
A464V O 0 0.0004065959947183728
was O 0 1.2329318451520521e-05
not O 0 5.072473641121178e-08
found O 0 2.6010747333771178e-08
in O 0 4.07141058644811e-08
18 O 0 5.966326170891989e-06
unrelated O 0 1.4777588148717768e-05
MLD B-Disease 1 1.0
patients O 0 6.338448656606488e-06
and O 0 1.370285417578998e-06
50 O 0 1.4933154488971923e-05
controls O 0 3.684795956360176e-05
. O 0 5.27386691828724e-06

A464V O 0 0.0015538492007181048
, O 0 6.00046087129158e-06
although O 0 8.747578021939262e-07
clearly O 0 4.168226496403804e-06
modifying O 0 1.4774219380342402e-05
ARSA O 0 0.00440552830696106
and O 0 0.0002793629828374833
GS O 1 1.0
levels O 0 0.00023717645672149956
, O 0 5.43718613243982e-07
apparently O 0 4.822863388653786e-07
bears O 0 1.611899591580368e-07
little O 0 1.2437224583550233e-08
significance O 0 3.6534821390432626e-08
for O 0 4.519750973486225e-08
clinical O 0 9.244532520824578e-06
manifestation O 0 9.6537871286273e-05
of O 0 0.00019981047080364078
MLD B-Disease 1 1.0
, O 0 1.530104964331258e-05
mimicking O 0 2.5072216885746457e-05
the O 0 2.1467571968969423e-06
frequent O 0 1.853690810094122e-05
ARSA O 0 0.022732997313141823
pseudodeficiency O 0 0.0026993874926120043
allele O 0 0.00015300493396352977
. O 0 1.2628702279471327e-05

Our O 0 4.034578068967676e-06
results O 0 9.114728527492844e-07
demonstrate O 0 1.2713751118553773e-07
that O 0 3.299335027406869e-09
in O 0 3.5627824246375894e-08
certain O 0 2.378605046260418e-07
genetic O 0 1.4025321434019133e-05
conditions O 0 0.0013848982052877545
MLD B-Disease 1 1.0
- O 0 0.05990007147192955
like O 0 3.772160562220961e-05
ARSA O 0 0.005235430784523487
and O 0 5.640867675538175e-05
GS O 1 1.0
values O 0 1.0830366363734356e-06
need O 0 2.6294975086216255e-08
not O 0 3.6440848116825464e-09
be O 0 4.928838670537061e-09
paralleled O 0 1.0339459777242155e-07
by O 0 2.2207554906117366e-08
clinical O 0 2.9817640097462572e-05
disease O 0 3.2845535315573215e-05
, O 0 4.07345339681342e-08
a O 0 4.619085913759591e-08
finding O 0 2.6191512958462226e-08
with O 0 1.8860395911701744e-08
serious O 0 4.747548246086808e-06
diagnostic O 0 8.431616151938215e-05
and O 0 3.832122729363618e-06
prognostic O 0 0.013005583547055721
implications O 0 5.560318459174596e-05
. O 0 6.504173597932095e-06

Moreover O 0 0.0002532961661927402
, O 0 1.4609394384024199e-05
further O 0 1.6867119484231807e-05
ARSA O 0 0.007745650596916676
alleles O 0 5.5360225815093145e-05
functionally O 0 4.2833653424168006e-05
similar O 0 1.0541170922806486e-06
to O 0 8.616691502538742e-07
A464V O 0 2.0176992620690726e-05
might O 0 1.7916953254371037e-07
exist O 0 8.849579558045662e-08
which O 0 5.610948505818669e-08
, O 0 7.006762281491774e-09
together O 0 2.592751791041792e-09
with O 0 1.5797454011590162e-08
0 O 0 4.35481933891424e-06
- O 0 6.94506070431089e-07
type O 0 6.240343282115646e-07
mutations O 0 3.364613121448201e-07
, O 0 1.7523606743452547e-07
may O 0 3.251655698477407e-06
cause O 0 1.648067518544849e-05
pathological O 0 0.11250424385070801
ARSA O 0 0.014686007983982563
and O 0 9.28973822738044e-05
GS O 1 1.0
levels O 0 4.327557235228596e-06
, O 0 1.1778158004460693e-08
but O 0 7.739815455209964e-10
not O 0 1.9481807278509677e-09
clinical O 0 3.192613462488225e-07
outbreak O 0 8.710899237485137e-07
of O 0 1.2887146567663876e-06
the O 0 9.005642823467497e-06
disease O 0 0.0001491745060775429
. O 0 4.6669384801134584e-07
. O 0 1.6702874745533336e-06

Human O 1 0.9993094205856323
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.002694816095754504
to O 0 1.168433027487481e-05
hematological B-Disease 1 0.9999983310699463
malignancy I-Disease 1 0.9999887943267822
and O 0 4.3429481593193486e-05
neurofibromatosis B-Disease 1 0.9999998807907104
type I-Disease 1 0.9091637134552002
1 I-Disease 1 0.8375691175460815
. O 0 7.907128747319803e-06

Heterozygous O 0 0.0014011547900736332
germ O 0 0.0063450997695326805
- O 0 2.9858161724405363e-05
line O 0 1.536896093057294e-06
mutations O 0 3.3718237091306946e-08
in O 0 2.7257158308202634e-08
the O 0 4.0937823797548845e-08
DNA O 0 4.065501855166076e-07
mismatch O 0 3.754005956579931e-05
repair O 0 2.1151457985979505e-05
genes O 0 2.3182822133094305e-06
lead O 0 4.3788322727777995e-06
to O 0 4.328370323491981e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.908618625951931e-05

The O 0 0.00015434203669428825
disease O 1 0.6745867133140564
susceptibility O 0 0.00032140559051185846
of O 0 0.00013175760977901518
individuals O 0 3.320104497106513e-06
who O 0 9.221006621373817e-06
constitutionally O 0 0.00012820083065889776
lack O 0 2.2575111870537512e-05
both O 0 3.1765312087372877e-06
wild O 0 4.6898453547328245e-06
- O 0 2.3630927898921072e-06
type O 0 6.256868232412671e-07
alleles O 0 4.157909643254243e-07
is O 0 1.2572175478453573e-07
unknown O 0 1.0112521522387397e-06
. O 0 4.15174838508392e-07

We O 0 1.581840024300618e-06
have O 0 7.34221501375032e-08
identified O 0 3.42278028142573e-08
three O 0 1.1944644384698222e-08
offspring O 0 2.3649697311611817e-08
in O 0 5.897340926708239e-08
a O 0 4.822118626179872e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.001009662402793765
who O 0 9.297742508351803e-06
developed O 0 0.0001182284759124741
hematological B-Disease 1 0.9999790191650391
malignancy I-Disease 1 0.999995231628418
at O 0 0.001283470424823463
a O 0 4.625408109859563e-06
very O 0 4.375390574296034e-07
early O 0 2.222555849584751e-06
age O 0 3.1251788641384337e-06
, O 0 1.550629065150133e-07
and O 0 1.2002931271126727e-07
at O 0 1.7958060425371514e-06
least O 0 1.681514660845096e-08
two O 0 1.3554146249816768e-08
of O 0 5.430729999034156e-08
them O 0 6.584152778543739e-09
displayed O 0 2.7081644020654494e-06
signs O 0 5.4313377404469065e-06
of O 0 4.070998329552822e-06
neurofibromatosis B-Disease 0 0.003495297161862254
type I-Disease 0 0.00010707741603255272
1 I-Disease 0 0.00023338272876571864
( O 0 7.062526947265724e-06
NF1 B-Disease 0 0.00025862979236990213
) O 0 2.3451614197256276e-06
. O 0 7.099615118022484e-07

DNA O 0 3.653981138995732e-06
sequence O 0 3.445773700150312e-06
analysis O 0 1.4743359315616544e-06
and O 0 8.452237807432539e-07
allele O 0 2.1066491626697825e-06
- O 0 9.726684311317513e-07
specific O 0 4.8085436077371924e-08
amplification O 0 1.660165139583114e-06
in O 0 1.0097960512212012e-06
two O 0 8.684281169735186e-07
siblings O 0 4.756703219754854e-06
revealed O 0 8.003937182365917e-06
a O 0 5.545786279981257e-06
homozygous O 0 4.356951831141487e-05
MLH1 O 0 0.0007988102734088898
mutation O 0 3.606455038607237e-06
( O 0 1.8855777170756483e-06
C676T O 0 1.721677472232841e-05
- O 0 1.1946706763410475e-05
- O 0 1.774809425114654e-05
> O 0 1.781331047823187e-05
Arg226Stop O 0 5.087172758067027e-05
) O 0 1.435476974620542e-06
. O 0 8.816496688268671e-07

Thus O 0 2.0640145521610975e-05
, O 0 1.6206266764129396e-06
a O 0 1.358052372779639e-06
homozygous O 0 1.2966901522304397e-05
germ O 0 0.0021456407848745584
- O 0 3.788224057643674e-05
line O 0 5.505663466465194e-06
MLH1 O 0 9.375465742778033e-05
mutation O 0 1.2280004568765435e-07
and O 0 6.237035421463588e-08
consequent O 0 0.0016588231083005667
mismatch O 1 0.9999992847442627
repair O 1 0.9999990463256836
deficiency O 1 1.0
results O 0 6.869052594993263e-05
in O 0 1.9227159100410063e-06
a O 0 2.7591140678850934e-06
mutator O 0 0.02366788685321808
phenotype O 0 1.2805107871827204e-05
characterized O 0 5.996108143335732e-07
by O 0 7.762501041952419e-08
leukemia B-Disease 1 0.9998440742492676
and O 0 1.9702572899404913e-05
/ O 1 0.9999998807907104
or O 1 0.9999632835388184
lymphoma B-Disease 1 1.0
associated O 0 0.00039353244937956333
with O 0 1.7325360204267781e-06
neurofibromatosis B-Disease 1 0.9999994039535522
type I-Disease 0 0.02542898617684841
1 I-Disease 0 0.0014611940132454038
. O 0 7.740810019640776e-07
. O 0 1.0686359246392385e-06

Missense O 0 0.0013855008874088526
mutations O 0 2.5175671908073127e-05
in O 0 7.4862505243800115e-06
the O 0 1.3668710607817047e-06
most O 0 1.0000783134955782e-07
ancient O 0 7.086086384333612e-07
residues O 0 4.285928980607423e-07
of O 0 4.1842062614705355e-07
the O 0 1.8993409867107403e-06
PAX6 O 0 0.0005212701507844031
paired O 0 4.695004918175982e-06
domain O 0 6.010139713907847e-06
underlie O 0 1.1347754480084404e-05
a O 0 5.532984346245939e-07
spectrum O 0 6.093680894991849e-06
of O 0 3.6896515666740015e-05
human O 1 0.9999998807907104
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.00015891509247012436

Mutations O 0 2.248306600449723e-06
of O 0 5.945736916146416e-07
the O 0 5.22633456512267e-07
human O 0 9.998539098887704e-06
PAX6 O 0 0.006023062393069267
gene O 0 0.00013266023597680032
underlie O 1 0.9948329925537109
aniridia B-Disease 1 1.0
( O 1 0.9998390674591064
congenital B-Disease 1 1.0
absence I-Disease 1 0.9995429515838623
of I-Disease 1 0.8788106441497803
the I-Disease 0 0.00024342794495169073
iris I-Disease 0 0.0009194305748678744
) O 0 3.2813946404530725e-07
, O 0 2.4354154248840132e-08
a O 0 1.7787819217573997e-07
rare O 0 1.3224665963207372e-05
dominant O 1 0.9996814727783203
malformation B-Disease 1 1.0
of I-Disease 1 0.9999960660934448
the I-Disease 1 0.9997746348381042
eye I-Disease 1 0.9999995231628418
. O 0 2.2098087356425822e-05

The O 0 1.5143366908887401e-05
spectrum O 0 2.6674839318729937e-05
of O 0 1.981525383598637e-05
PAX6 O 0 0.005735862534493208
mutations O 0 5.148387572262436e-05
in O 0 0.00016907555982470512
aniridia B-Disease 1 1.0
patients O 0 3.5370379919186234e-05
is O 0 5.817011583530984e-07
highly O 0 4.558859245662461e-07
biased O 0 1.7128009233147168e-07
, O 0 6.824635967461745e-09
with O 0 3.012030846960556e-09
92 O 0 1.592400394656579e-06
% O 0 7.917309119420679e-08
of O 0 2.982812929985812e-07
all O 0 3.6959528415536624e-07
reported O 0 4.145348611928057e-06
mutations O 0 1.3861205161447288e-06
leading O 0 1.851731758506503e-05
to O 0 3.231686207527673e-07
premature O 0 3.961232323490549e-06
truncation O 0 7.149983048293507e-06
of O 0 8.509342478646431e-06
the O 0 9.039502401719801e-06
protein O 0 5.121107733430108e-06
( O 0 1.758128519213642e-06
nonsense O 0 1.2249130122654606e-05
, O 0 5.244132808002178e-07
splicing O 0 4.091612879619788e-07
, O 0 3.019320615749166e-07
insertions O 0 9.45675367347576e-07
and O 0 7.567749094050669e-07
deletions O 0 1.1902614005521173e-06
) O 0 2.0631867414522276e-07
and O 0 1.6983797479497298e-07
just O 0 3.8345064012901275e-07
2 O 0 1.1825608225990436e-06
% O 0 1.871182604418209e-07
leading O 0 4.327411033955286e-07
to O 0 1.5652110718633594e-08
substitution O 0 3.903909089331137e-07
of O 0 2.8095000743633136e-06
one O 0 1.825840172386961e-06
amino O 0 9.782779670786113e-07
acid O 0 2.0539735601232678e-07
by O 0 5.032231698010037e-08
another O 0 4.395054702399648e-07
( O 0 2.8476159741330775e-07
missense O 0 3.7015477118984563e-06
) O 0 6.291032832450583e-07
. O 0 4.860416424889991e-07

The O 0 4.3476907194417436e-06
extraordinary O 0 3.6622036532207858e-06
conservation O 0 1.0245353223581333e-06
of O 0 1.227334792019974e-06
the O 0 1.1679422868837719e-06
PAX6 O 0 9.646130638429895e-05
protein O 0 2.867577450160752e-06
at O 0 5.443352165457327e-06
the O 0 1.0403747410236974e-06
amino O 0 2.64520804194035e-06
acid O 0 2.0004370071546873e-06
level O 0 2.9978418751852587e-05
amongst O 0 1.0380197636550292e-05
vertebrates O 0 7.900518539827317e-05
predicts O 0 6.653952368651517e-06
that O 0 2.2378385722277017e-07
pathological O 0 0.00041072280146181583
missense O 0 7.718746201135218e-05
mutations O 0 3.5768066481978167e-06
should O 0 1.7798640783439623e-06
in O 0 1.8596597328723874e-06
fact O 0 7.214554216261604e-07
be O 0 1.182176333713869e-06
common O 0 8.397866508857987e-07
even O 0 1.6196456442685303e-07
though O 0 7.168193860707106e-08
they O 0 1.0145972950681426e-08
are O 0 1.30225199512779e-08
hardly O 0 1.9934161343826418e-07
ever O 0 3.054934722968028e-07
seen O 0 1.6611280670986162e-06
in O 0 3.4701308777584927e-06
aniridia B-Disease 1 0.9999973773956299
patients O 0 1.8653097868082114e-05
. O 0 2.261095914946054e-06

This O 0 8.626643648312893e-06
indicates O 0 8.933592653193045e-06
that O 0 1.5468201297608175e-07
there O 0 2.7173072680852783e-07
is O 0 2.482659624547523e-07
a O 0 3.398672276944126e-07
heavy O 0 1.1811624062829651e-05
ascertainment O 0 0.00020762874919455498
bias O 0 2.9832019663444953e-06
in O 0 3.078222619024018e-07
the O 0 8.470105683500151e-08
selection O 0 6.966534016328296e-08
of O 0 2.6969709665536357e-07
patients O 0 4.077959090409422e-07
for O 0 2.0574728409883392e-07
PAX6 O 0 0.0001903960801428184
mutation O 0 2.328633428305693e-07
analysis O 0 3.956825977979861e-08
and O 0 2.236227381047229e-08
that O 0 1.7464721224769164e-08
the O 0 5.916267582506407e-07
missing O 0 7.381576324405614e-06
PAX6 O 0 0.0010898462496697903
missense O 0 0.00011976907262578607
mutations O 0 1.1676834219542798e-05
frequently O 0 3.2290658964484464e-06
may O 0 6.662022769887699e-06
underlie O 0 4.704246748588048e-05
phenotypes O 0 1.2255183719389606e-05
distinct O 0 1.4560258705387241e-06
from O 0 8.259251444542315e-06
textbook O 0 0.0010126767447218299
aniridia B-Disease 1 0.9999992847442627
. O 0 1.173144846688956e-05

Here O 0 2.3159256670624018e-05
we O 0 2.7930252599617233e-07
present O 0 1.9893255398528709e-07
four O 0 3.465149802650558e-07
novel O 0 2.761183168331627e-06
PAX6 O 0 0.0004542492388281971
missense O 0 2.8683005439233966e-05
mutations O 0 1.3928945463703712e-06
, O 0 1.1398402222084769e-07
two O 0 6.049224765547478e-08
in O 0 4.952551080350531e-07
association O 0 1.6819914208099362e-06
with O 0 5.2554778307012384e-08
atypical O 0 0.0004345948691479862
phenotypes O 0 0.0008742960053496063
ectopia B-Disease 0 0.019218280911445618
pupillae I-Disease 0 0.0017287014052271843
( O 0 2.2770311716158176e-06
displaced B-Disease 0 1.813902827052516e-06
pupils I-Disease 0 1.6438982129329816e-05
) O 0 6.269301138672745e-06
and O 0 0.0005708782118745148
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999998807907104
( O 0 7.889662083471194e-05
searching B-Disease 0 1.3983867575007025e-05
gaze I-Disease 0 0.0002286736125824973
) O 0 4.573896319470805e-07
, O 0 8.935265327636444e-08
and O 0 9.736561423778767e-08
two O 0 1.2100140622806066e-07
in O 0 1.493377340011648e-06
association O 0 1.9998267362097977e-06
with O 0 2.7509004851822283e-08
more O 0 2.0464847239054507e-07
recognizable O 0 7.897165778558701e-05
aniridia B-Disease 1 0.9999990463256836
phenotypes O 0 0.00022497872123494744
. O 0 5.326519840309629e-06

Strikingly O 0 0.0009219900239259005
, O 0 7.976322194735985e-06
all O 0 3.471308218649938e-07
four O 0 4.417115064825339e-07
mutations O 0 9.66250510714417e-08
are O 0 3.1629351582296295e-08
located O 0 4.5118056846149557e-07
within O 0 3.0409242413043103e-07
the O 0 2.321273086636211e-06
PAX6 O 0 0.00019630201859399676
paired O 0 8.57016220834339e-06
domain O 0 2.039879109361209e-05
and O 0 6.976838449190836e-06
affect O 0 2.249913632113021e-05
amino O 0 1.3098944691591896e-05
acids O 0 1.2253021850483492e-06
which O 0 2.509304977138527e-07
are O 0 4.0135756051995486e-08
highly O 0 7.949645919325121e-08
conserved O 0 2.5074939458136214e-07
in O 0 1.5074358827860124e-07
all O 0 8.154388098091658e-08
known O 0 6.025699121892103e-07
paired O 0 4.571667773234367e-07
domain O 0 8.008166787476512e-07
proteins O 0 5.750836749029986e-07
. O 0 4.733199716611125e-07

Our O 0 0.00017935277719516307
results O 0 3.173253935528919e-05
support O 0 3.1905333344184328e-06
the O 0 2.29920124183991e-06
hypothesis O 0 5.516987471310131e-07
that O 0 2.3380410496542936e-08
the O 0 9.719657612095034e-08
under O 0 1.9019822161681077e-07
- O 0 1.3152728683962778e-07
representation O 0 1.260122530766239e-07
of O 0 5.689032605005195e-07
missense O 0 1.5232341866067145e-05
mutations O 0 3.469171133474447e-06
is O 0 1.096054006666236e-06
caused O 0 1.398486233483709e-06
by O 0 6.871962909826834e-08
ascertainment O 0 5.014558701077476e-05
bias O 0 1.6248252450168366e-06
and O 0 4.8184773504544864e-08
suggest O 0 9.67070512558621e-09
that O 0 1.5368756267619688e-09
a O 0 1.6844680317262828e-08
substantial O 0 1.7202575008923304e-07
burden O 0 2.888202743633883e-06
of O 0 0.00014845153782516718
PAX6 B-Disease 1 0.9999966621398926
- I-Disease 1 0.9994869232177734
related I-Disease 0 0.03138308227062225
disease I-Disease 0 0.3668604791164398
remains O 0 2.7735582079913e-06
to O 0 5.10712148127368e-08
be O 0 3.5628988825919805e-07
uncovered O 0 6.352512627927354e-06
. O 0 1.667135052230151e-07
. O 0 5.969474159428501e-07

The O 0 5.390304522734368e-06
chromosomal O 0 3.4108405088773e-05
order O 0 8.704437846063229e-07
of O 0 4.840188466914697e-06
genes O 0 1.3326861107998411e-06
controlling O 0 1.10385217340081e-05
the O 0 1.7844831745605916e-05
major O 0 8.893527410691604e-05
histocompatibility O 0 0.007009813096374273
complex O 0 0.0002060647530015558
, O 0 4.1544376472302247e-07
properdin O 0 6.4908208514680155e-06
factor O 0 1.658022824813088e-06
B O 0 8.36291383166099e-06
, O 0 5.897115684661003e-08
and O 0 2.3488719591568952e-07
deficiency B-Disease 0 2.824422699632123e-05
of I-Disease 0 4.249350695317844e-06
the I-Disease 0 2.3915617930470034e-06
second I-Disease 0 6.431955171137815e-06
component I-Disease 0 4.7812950469960924e-06
of I-Disease 0 2.511833599783131e-06
complement I-Disease 0 6.609781848965213e-06
. O 0 7.121801900211722e-06

The O 0 1.2332858204899821e-05
relationship O 0 1.1469523997220676e-06
of O 0 8.434647497779224e-06
the O 0 2.843672064045677e-06
genes O 0 6.092345756769646e-07
coding O 0 2.553136937422096e-06
for O 0 5.293546223583689e-07
HLA O 0 3.3526766856084578e-06
to O 0 2.15991491359091e-08
those O 0 2.3535354998216462e-08
coding O 0 6.159518193271651e-07
for O 0 2.0659808797063306e-07
properdin O 0 1.5920881196507253e-05
Factor O 0 6.0682914408971556e-06
B O 0 1.8748673028312624e-05
allotypes O 0 7.233304131659679e-06
and O 0 2.2136261179639405e-07
for O 0 7.923984526314598e-07
deficiency B-Disease 0 0.0001014895096886903
of I-Disease 0 1.9221301045035943e-05
the I-Disease 0 8.153335329552647e-06
second I-Disease 0 2.591007068986073e-05
component I-Disease 0 1.9374156181584112e-05
of I-Disease 0 1.3148081961844582e-05
complement I-Disease 0 1.3601090358861256e-05
( O 0 3.642590172603377e-06
C2 O 0 5.226047960604774e-06
) O 0 7.512371169582366e-09
was O 0 7.377376043393724e-09
studied O 0 1.966924934038161e-08
in O 0 3.325846487101103e-09
families O 0 6.645339278854578e-10
of O 0 1.874631294640494e-08
patients O 0 1.4048905541130807e-06
with O 0 6.855421815998852e-06
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 6.114012649049982e-05

Patients O 0 0.0002561729634180665
were O 0 5.338440132618416e-06
selected O 0 3.5790782249023323e-07
because O 0 1.4591568842092784e-08
they O 0 2.029484802434922e-09
were O 0 3.818081495410297e-08
heterozygous O 0 1.5437754541380855e-07
or O 0 3.3894633588715806e-07
homozygous O 0 5.439486358227441e-06
for O 0 4.188049570075236e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.5911920602084137e-05

12 O 0 9.149573452305049e-05
families O 0 1.5218689952689601e-07
with O 0 8.477960733443979e-08
15 O 0 9.215134923579171e-06
matings O 0 5.3775285778101534e-05
informative O 0 5.133684680913575e-05
for O 0 0.0002717716561164707
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 3.677452332340181e-05
found O 0 1.874883537311689e-06
. O 0 4.343722252997395e-07

Of O 0 0.000775219639763236
57 O 0 0.0006456735427491367
informative O 0 3.251682937843725e-05
meioses O 0 0.00016347730706911534
, O 0 8.140647764776077e-07
two O 0 6.562089538419968e-08
crossovers O 0 8.521635663782945e-08
were O 0 7.191624717961531e-08
noted O 0 1.5004252418293618e-07
between O 0 1.5229826431095717e-06
the O 0 0.00015581528714392334
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 5.857974429090973e-06
and O 0 2.201345296271029e-06
the O 0 8.482385965180583e-06
HLA O 0 4.546593481791206e-05
- O 0 2.7957832571701147e-05
B O 0 2.9990684197400697e-05
gene O 0 1.8807075718996202e-07
, O 0 9.670244160986385e-09
with O 0 1.7446101230333966e-09
a O 0 6.160704657531824e-08
recombinant O 0 4.6256457153504016e-07
fraction O 0 4.047254549277568e-07
of O 0 3.1739209589431994e-06
0 O 0 2.1185329387662932e-05
. O 0 1.5236944364005467e-06

035 O 0 0.07072238624095917
. O 0 8.398577483603731e-05

A O 0 0.00014223100151866674
lod O 0 0.0004454036825336516
score O 0 6.806011697335634e-06
of O 0 6.6444404183130246e-06
13 O 0 5.796621735498775e-06
was O 0 7.147659175643639e-07
calculated O 0 2.921178747783415e-07
for O 0 5.453591143123049e-07
linkage O 0 5.022565892431885e-05
between O 0 0.002722854493185878
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 7.197349623311311e-05
HLA O 0 0.0002524607698433101
- O 0 1.9088571207248606e-05
B O 0 7.997909051482566e-06
at O 0 3.866531130825024e-07
a O 0 1.7420672904222556e-08
maximum O 0 6.773002070303846e-08
likelihood O 0 1.042238153559083e-07
value O 0 1.8266082690843177e-07
of O 0 4.2985448089893907e-07
the O 0 3.153556349388964e-07
recombinant O 0 3.707638427385973e-07
fraction O 0 3.025044463811355e-07
of O 0 2.2687295313517097e-06
0 O 0 1.5147787053138018e-05
. O 0 9.18005071071093e-07

04 O 0 0.04235900938510895
. O 0 0.000124978760140948

18 O 0 0.00020825011597480625
families O 0 4.839108100895828e-07
with O 0 9.033851711137686e-08
21 O 0 5.152362064109184e-06
informative O 0 6.245636541279964e-07
matings O 0 1.5081130868566106e-06
for O 0 2.652969044447673e-07
both O 0 8.0376770483781e-07
properdin O 0 7.019045733613893e-05
Factor O 0 4.418139360495843e-05
B O 0 0.0001471998548367992
allotype O 0 5.569329368881881e-05
and O 0 4.530187197815394e-06
HLA O 0 4.6177301555871964e-05
- O 0 2.1360141545301303e-05
B O 0 2.4688177290954627e-05
were O 0 4.915955855722132e-07
found O 0 3.455078569913894e-07
. O 0 2.397153195943247e-07

Of O 0 0.0012356183724477887
72 O 0 0.001541667734272778
informative O 0 5.736910316045396e-05
meioses O 0 0.00036645011277869344
, O 0 5.000847068004077e-06
three O 0 3.678701432363596e-06
recombinants O 0 6.0782778746215627e-05
were O 0 1.8812972939485917e-06
found O 0 1.5474928716230352e-07
, O 0 1.507811830947503e-08
giving O 0 1.043962694069478e-08
a O 0 7.088060982596289e-08
recombinant O 0 3.841545037630567e-07
fraction O 0 6.130018732619646e-07
of O 0 6.4861424107220955e-06
0 O 0 4.418215394252911e-05
. O 0 3.3539718060637824e-06

042 O 0 0.02619505487382412
. O 0 0.0001351225801045075

A O 0 0.00021537221618928015
lod O 0 0.0008761774515733123
score O 0 4.1423827497055754e-05
of O 0 5.346756006474607e-05
16 O 0 6.361572013702244e-05
between O 0 2.535473686293699e-05
HLA O 0 0.0001254785165656358
- O 0 2.513347499188967e-05
B O 0 1.5057624295877758e-05
and O 0 1.3866728920675087e-07
Factor O 0 2.2282479221757967e-06
B O 0 1.242750931851333e-05
allotypes O 0 4.0279423956235405e-06
was O 0 1.8111061308445642e-06
calculated O 0 2.5948222059923864e-07
at O 0 4.517919762747624e-07
a O 0 1.5344335579925428e-08
maximum O 0 1.0369321046255209e-07
likelihood O 0 1.1907468433491886e-07
value O 0 2.3307775620651228e-07
of O 0 3.2057329235612997e-07
the O 0 3.7221246884655557e-07
recombinant O 0 4.716716546226962e-07
fraction O 0 3.8961320569796953e-07
of O 0 3.643872105385526e-06
0 O 0 1.9276258171885274e-05
. O 0 1.4949717979106936e-06

04 O 0 0.04535210505127907
. O 0 8.171919034793973e-05

A O 0 0.00019504898227751255
crossover O 0 1.219221121573355e-05
was O 0 1.5937106581986882e-05
shown O 0 4.309541168368014e-07
to O 0 4.1537713713069024e-08
have O 0 3.6790197555092163e-08
occurred O 0 4.268576390131784e-07
between O 0 6.491703175015573e-08
genes O 0 5.3994348547803384e-08
for O 0 2.2612245231812267e-07
Factor O 0 1.314124801865546e-06
B O 0 7.717253538430668e-06
and O 0 1.032198724715272e-06
HLA O 0 7.912839464552235e-06
- O 0 6.106089131208137e-06
D O 0 1.1121554962301161e-05
, O 0 1.2473434196635935e-07
in O 0 3.138872273211746e-07
which O 0 1.137268327511265e-06
HLA O 0 2.1762840333394706e-05
- O 0 3.00412666547345e-05
D O 0 5.7609118812251836e-05
segregared O 0 2.5427867512917146e-05
with O 0 1.3224663462096942e-06
HLA O 0 5.088686884846538e-05
- O 0 7.650841325812507e-06
A O 0 6.51949403618346e-06
and O 0 1.134800413638004e-06
B O 0 5.490403054864146e-05
. O 0 7.17904299563088e-07

These O 0 5.645406417897902e-07
studies O 0 4.0852808069757884e-07
suggest O 0 4.726324931425552e-08
that O 0 2.4580573132482186e-09
the O 0 2.627061057580704e-08
genes O 0 4.321010393937286e-08
for O 0 2.8973653343200567e-07
Factor O 0 2.77759027085267e-05
B O 0 0.0017288256203755736
and O 0 0.00039791595190763474
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.1493941656226525e-06
located O 0 1.961622047019773e-06
outside O 0 3.2395237781202013e-07
those O 0 3.135042447865999e-08
for O 0 2.795106581743312e-07
HLA O 0 6.916078291396843e-06
, O 0 1.5297470667974267e-07
that O 0 2.0972059644464025e-08
the O 0 4.411111831359449e-07
order O 0 1.2552424095702008e-06
of O 0 3.1658029911341146e-05
genese O 0 0.0003260127850808203
is O 0 3.102942355326377e-05
HLA O 0 3.6253466532798484e-05
- O 0 7.324881153181195e-06
A O 0 1.4056749932933599e-05
, O 0 1.924725268054317e-07
- O 0 3.5434280221124936e-07
B O 0 3.4381155273877084e-06
, O 0 1.1104560115882123e-07
- O 0 5.032519538872293e-07
D O 0 1.4329657460621092e-06
, O 0 4.295569411283395e-08
Factor O 0 2.1541936803259887e-06
B O 0 0.00012439592683222145
allotype O 0 0.0006885647308081388
, O 0 0.0002269926917506382
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
, O 0 3.405192572358828e-08
that O 0 1.5742642744953628e-09
the O 0 3.1961317148443413e-08
genes O 0 3.811606177350768e-07
coding O 0 1.9871875338139944e-05
for O 0 9.260611841455102e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.8327073929831386e-05
Factor O 0 3.9549740904476494e-05
B O 0 3.3499793062219396e-05
allotypes O 0 8.171089575625956e-06
are O 0 1.0476713185880726e-07
approximately O 0 2.3172201224497257e-07
3 O 0 1.08825474853802e-06
- O 0 3.494052975838713e-07
- O 0 5.63422986488149e-07
5 O 0 2.738830744419829e-06
centimorgans O 0 5.1741803872573655e-06
from O 0 2.062670773739228e-06
the O 0 5.137617790751392e-06
HLA O 0 2.0209919966873713e-05
- O 0 6.55023768558749e-06
A O 0 2.1316349375410937e-05
and O 0 4.829149929719279e-06
HLA O 0 9.005793981486931e-05
- O 0 5.067896927357651e-05
B O 0 5.019036689191125e-05
loci O 0 1.0318896102035069e-06
, O 0 1.8396740131265688e-08
and O 0 2.9267253065512477e-09
that O 0 1.9538708428967766e-09
the O 0 3.632532497022112e-08
apparent O 0 4.923861638417293e-07
lack O 0 3.813555338183505e-07
of O 0 4.88353123273555e-07
recombinants O 0 1.664331080064585e-06
between O 0 8.659662853460759e-08
the O 0 2.1259445759369555e-07
Factor O 0 2.902170990637387e-06
B O 0 5.5398304539266974e-05
gene O 0 1.3279388440423645e-05
and O 0 0.0001062579030985944
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.0531401130720042e-05
suggests O 0 4.04201614401245e-07
that O 0 1.025388751685341e-08
these O 0 2.1302687613911075e-08
two O 0 2.2848310265999316e-07
genes O 0 6.873358415759867e-07
lie O 0 5.107066044729436e-06
in O 0 9.4922540938569e-07
close O 0 3.6412807276064996e-06
proximity O 0 2.712499053814099e-06
to O 0 2.0741596529205708e-07
one O 0 6.242385097721126e-07
another O 0 1.2847314110331354e-06
. O 0 1.6763898429417168e-06

Distribution O 0 6.465864862548187e-05
of O 0 4.368176814750768e-05
emerin O 0 0.00040151452412828803
and O 0 5.062295258539962e-06
lamins O 0 0.00020589564519468695
in O 0 2.5381482373632025e-06
the O 0 3.8045643577788724e-06
heart O 0 0.00013209324970375746
and O 0 3.715156253747409e-07
implications O 0 3.838135398837039e-06
for O 0 1.5611390153935645e-06
Emery B-Disease 1 0.5575828552246094
- I-Disease 1 0.9999878406524658
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.7892101823235862e-05

Emerin O 0 0.012443751096725464
is O 0 4.2044724978040904e-05
a O 0 1.360184160148492e-05
nuclear O 0 1.704063470242545e-05
membrane O 0 1.3316607692104299e-05
protein O 0 3.529533159962739e-06
which O 0 2.3135127946716239e-07
is O 0 6.759153734492429e-07
missing O 0 2.1856644707440864e-06
or O 0 1.4930327552065137e-06
defective O 0 1.4025910786585882e-05
in O 0 1.6334435713361017e-05
Emery B-Disease 1 0.9995263814926147
- I-Disease 1 0.9999996423721313
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00030133227119222283
EDMD B-Disease 1 1.0
) O 0 8.19751039671246e-06
. O 0 2.05916035156406e-06

It O 0 8.046803486649878e-06
is O 0 2.1959042442176724e-06
one O 0 3.754023225610581e-07
member O 0 9.048178526427364e-07
of O 0 3.6910043945681537e-06
a O 0 1.002702356345253e-05
family O 0 3.4735344343062025e-06
of O 0 0.00012178679025964811
lamina O 0 0.003909123130142689
- O 0 0.0001260137651115656
associated O 0 3.136064606223954e-06
proteins O 0 2.8837226295763685e-07
which O 0 1.8302807802683674e-07
includes O 0 4.773116302203562e-07
LAP1 O 0 6.415524694602937e-05
, O 0 1.5543542986051762e-06
LAP2 O 0 7.334417750826105e-05
and O 0 7.067094884405378e-06
lamin O 0 0.000263378897216171
B O 0 0.00015461041766684502
receptor O 0 6.44553656456992e-05
( O 0 8.61477201397065e-06
LBR O 0 0.00026796935708262026
) O 0 1.1168021956109442e-06
. O 0 1.001662440103246e-06

A O 0 0.00041133526246994734
panel O 0 6.865207978989929e-05
of O 0 5.4141346481628716e-05
16 O 0 0.00010264263983117417
monoclonal O 0 3.4200547815999016e-05
antibodies O 0 9.568378118274268e-06
( O 0 1.0227898201264907e-05
mAbs O 0 2.2286803869064897e-05
) O 0 4.4348976757646597e-07
has O 0 1.2297338969347038e-07
been O 0 9.351493446274617e-08
mapped O 0 5.382694823197198e-08
to O 0 2.3168263751927043e-08
six O 0 6.585762690747288e-08
specific O 0 9.439930614973946e-09
sites O 0 4.3951553152510314e-07
throughout O 0 7.970580782057368e-07
the O 0 3.393885890545789e-06
emerin O 0 4.227759563946165e-05
molecule O 0 2.3044960926199565e-06
using O 0 1.3698437442144495e-06
phage O 0 1.0083917914016638e-05
- O 0 2.4181058506655972e-06
displayed O 0 2.930877371909446e-06
peptide O 0 1.4809252206759993e-06
libraries O 0 7.172562277446559e-07
and O 0 8.665925577133748e-08
has O 0 3.9313167832233376e-08
been O 0 5.782095513495733e-08
used O 0 4.261458030896392e-08
to O 0 3.783285151826021e-08
localize O 0 3.066565795961651e-06
emerin O 0 3.744670175365172e-05
in O 0 2.592966666270513e-06
human O 0 9.725758900458459e-06
and O 0 3.1649196898797527e-06
rabbit O 0 6.714069604640827e-05
heart O 0 0.0011713241692632437
. O 0 4.866208655585069e-06

Several O 0 6.021956505719572e-05
mAbs O 0 0.0003766645968426019
against O 0 2.8218086299602874e-05
different O 0 3.09664187625458e-06
emerin O 0 0.0002530135097913444
epitopes O 0 7.029453990980983e-05
did O 0 1.3534546496885014e-06
not O 0 1.4027992278897727e-07
recognize O 0 4.24646430019493e-07
intercalated O 0 2.3663700631004758e-05
discs O 0 3.3986845664912835e-05
in O 0 1.0305904652341269e-05
the O 0 2.8050291803083383e-05
heart O 0 0.0004925204557366669
, O 0 5.427021960713319e-07
though O 0 6.590475010170849e-08
they O 0 2.6836518784989494e-08
recognized O 0 9.250452421838418e-07
cardiomyocyte O 0 2.2453417841461487e-05
nuclei O 0 7.455848390236497e-06
strongly O 0 4.734838512376882e-06
, O 0 9.298702252635849e-07
both O 0 1.6734826431274996e-06
at O 0 6.18456833763048e-05
the O 0 4.908707524009515e-06
rim O 0 7.83282575866906e-06
and O 0 3.0095637271188025e-07
in O 0 2.5719589302752865e-06
intranuclear O 0 3.795890370383859e-05
spots O 0 4.849507149629062e-06
or O 0 1.1183144579263171e-06
channels O 0 3.0065396003919886e-06
. O 0 1.7670391798674245e-06

A O 0 0.0009063713951036334
polyclonal O 0 0.0013307222397997975
rabbit O 0 0.00026827125111594796
antiserum O 0 0.0003831277717836201
against O 0 0.00013636882067658007
emerin O 0 0.0005949711194261909
did O 0 3.0675923881062772e-06
recognize O 0 3.211260718671838e-06
both O 0 4.584522685036063e-06
nuclear O 0 2.6211755539407022e-05
membrane O 0 8.527474165020976e-06
and O 0 1.0919703754552756e-06
intercalated O 0 1.717266241030302e-05
discs O 0 3.791011067733052e-06
but O 0 4.772187978119291e-08
, O 0 2.1459696242231985e-08
after O 0 7.396484846822204e-08
affinity O 0 2.3191546461021062e-07
purification O 0 7.1074514380597975e-06
against O 0 3.739919293366256e-06
a O 0 8.481674740323797e-06
pure O 0 6.76807394484058e-05
- O 0 1.507131673861295e-05
emerin O 0 6.760810356354341e-05
band O 0 5.081284143670928e-06
on O 0 5.919410341448383e-06
a O 0 3.1582987958245212e-06
western O 0 2.8030929115629988e-06
blot O 0 1.7727150407154113e-05
, O 0 4.2223800278407e-07
it O 0 4.464453695618431e-08
stained O 0 1.61503139679553e-05
only O 0 4.0925340272224275e-07
the O 0 2.647383553266991e-06
nuclear O 0 1.7048307199729607e-05
membrane O 0 1.618276655790396e-05
. O 0 1.310919060415472e-06

These O 0 6.057637801859528e-05
results O 0 5.909544779569842e-05
would O 0 1.86176430361229e-06
not O 0 3.3407769706172985e-07
be O 0 4.350052620338829e-07
expected O 0 1.2497456509663607e-06
if O 0 5.147275601302681e-07
immunostaining O 0 3.5520562960300595e-05
at O 0 3.148641553707421e-05
intercalated O 0 4.586696741171181e-05
discs O 0 1.612908636161592e-05
were O 0 1.645185761844914e-06
due O 0 3.3963046917051543e-06
to O 0 2.0575532744260272e-07
a O 0 1.5269587265720475e-06
product O 0 1.7783573866836377e-06
of O 0 1.3133306310919579e-05
the O 0 2.1365458451327868e-05
emerin O 0 0.0003380148846190423
gene O 0 7.787704817019403e-06
and O 0 1.3739597761741607e-06
, O 0 1.7865444590370316e-07
therefore O 0 9.141926682332269e-08
, O 0 8.525501193901164e-09
cast O 0 1.5121203844614683e-08
some O 0 1.1635870045267893e-09
doubt O 0 7.482683805903889e-09
upon O 0 2.5517872259683827e-08
the O 0 7.999535256431045e-08
hypothesis O 0 4.877103947364958e-07
that O 0 7.88424415532063e-07
cardiac B-Disease 1 0.9999996423721313
defects I-Disease 1 0.8634079098701477
in O 0 0.00023485349083784968
EDMD B-Disease 1 1.0
are O 0 2.750271505647106e-06
caused O 0 7.3953938226622995e-06
by O 0 2.284656659412576e-07
absence O 0 9.296315511164721e-06
of O 0 2.5527873731334694e-05
emerin O 0 0.0004116498166695237
from O 0 2.5452562113059685e-05
intercalated O 0 0.00044179183896631
discs O 0 0.00023757752205710858
. O 0 3.988019670941867e-06

Although O 0 0.00012391396739985794
emerin O 0 0.0012301167007535696
was O 0 8.590188372181728e-05
abundant O 0 1.1535502380866092e-05
in O 0 8.39590938994661e-06
the O 0 1.0830844075826462e-05
membranes O 0 1.9969140339526348e-05
of O 0 0.00011374799214536324
cardiomyocyte O 0 0.00035658085835166276
nuclei O 0 5.396330379880965e-05
, O 0 1.357937208013027e-06
it O 0 9.802675293713037e-08
was O 0 1.0944048881356139e-05
absent O 0 5.873066129424842e-06
from O 0 3.4415495520079276e-07
many O 0 5.5389719477716426e-08
non O 0 4.801413979294011e-06
- O 0 5.850135494256392e-06
myocyte O 0 4.346104833530262e-05
cells O 0 4.2095459207303065e-07
in O 0 3.3866973581098136e-07
the O 0 2.830452331181732e-06
heart O 0 0.00039157341234385967
. O 0 4.002871264674468e-06

This O 0 6.2192616496759e-06
distribution O 0 1.9514603991410695e-05
of O 0 6.436802505049855e-05
emerin O 0 0.00044052014709450305
was O 0 1.8516362615628168e-05
similar O 0 9.339373008288021e-08
to O 0 4.6411642529164965e-08
that O 0 3.6564031802299723e-08
of O 0 2.8098108941776445e-06
lamin O 0 9.724884876050055e-05
A O 0 6.219956048880704e-06
, O 0 1.592055696164607e-07
a O 0 1.4655000768470927e-07
candidate O 0 2.261759419752707e-07
gene O 0 1.39247845254431e-07
for O 0 5.5769550755258024e-08
an O 0 9.853663129888446e-08
autosomal O 0 7.485679361707298e-06
form O 0 1.2992883057449944e-05
of O 0 0.165668323636055
EDMD B-Disease 1 1.0
. O 0 8.945557055994868e-05

In O 0 0.000132456625578925
contrast O 0 0.0001076205589924939
, O 0 4.091630762559362e-05
lamin O 0 0.0012507929932326078
B1 O 0 0.008083496242761612
was O 0 0.0005041396361775696
absent O 0 8.979503036243841e-05
from O 0 9.445474461244885e-06
cardiomyocyte O 0 6.804695294704288e-05
nuclei O 0 3.197363912477158e-05
, O 0 1.8340003862249432e-06
showing O 0 1.651478305575438e-05
that O 0 2.2090127913543256e-06
lamin O 0 0.0006163570797070861
B1 O 0 0.001531266956590116
is O 0 3.527365777244995e-07
not O 0 2.7502814248236973e-08
essential O 0 4.327807232584746e-07
for O 0 4.1625477820161905e-07
localization O 0 1.862290082499385e-05
of O 0 8.766553946770728e-06
emerin O 0 5.9105699619976804e-05
to O 0 1.2637800637094188e-06
the O 0 1.1295743206574116e-05
nuclear O 0 0.0001237077231053263
lamina O 0 0.0014497898519039154
. O 0 8.102702850010246e-06

Lamin O 1 0.9571540355682373
B1 O 1 0.9876603484153748
is O 0 7.80995651439298e-06
also O 0 1.1097631613665726e-06
almost O 0 1.5235898445098428e-06
completely O 0 4.942119176121196e-06
absent O 0 1.0507323167985305e-05
from O 0 3.6779995298275026e-06
skeletal O 0 0.00083844707114622
muscle O 0 3.2963020203169435e-05
nuclei O 0 2.448008490318898e-05
. O 0 1.821540763558005e-06

In O 0 0.0006437720730900764
EDMD B-Disease 1 0.9999991655349731
, O 0 1.0812997288667248e-06
the O 0 1.0811321260462137e-07
additional O 0 7.670660551184483e-08
absence O 0 6.3346415117848665e-06
of O 0 4.3375381210353225e-05
lamin O 0 0.002417674520984292
B1 O 1 0.9715472459793091
from O 0 0.0001725300680845976
heart O 1 0.9999977350234985
and O 0 0.0007820436148904264
skeletal O 1 0.9999998807907104
muscle O 0 0.48280471563339233
nuclei O 0 0.00026420486392453313
which O 0 3.15291185870592e-06
already O 0 2.7503579076437745e-06
lack O 0 1.7596950783627108e-05
emerin O 0 0.00011908647138625383
may O 0 1.086427687368996e-06
offer O 0 6.658489581923277e-08
an O 0 5.636659849983516e-08
alternative O 0 1.85626703341768e-07
explanation O 0 2.4065951720331213e-07
of O 0 1.8464431832398986e-06
why O 0 6.59882687159552e-07
these O 0 3.28756215139947e-07
tissues O 0 7.141402875276981e-06
are O 0 1.65921079542386e-07
particularly O 0 1.9124061623188027e-07
affected O 0 3.3096864626713796e-07
. O 0 9.501440700887542e-08
. O 0 3.8815679204162734e-07

Genetic O 0 2.3383960069622844e-05
mapping O 0 2.163726821891032e-05
of O 0 8.244029595516622e-05
the O 0 0.000284753245068714
copper B-Disease 0 0.4468201696872711
toxicosis I-Disease 1 0.5129652619361877
locus O 0 0.00038194801891222596
in O 0 7.230423943838105e-05
Bedlington O 0 0.000596849073190242
terriers O 0 0.00015049793000798672
to O 0 2.8028978249494685e-06
dog O 0 1.2991829862585291e-05
chromosome O 0 1.1987664947810117e-05
10 O 0 4.9871159717440605e-06
, O 0 8.823607089425423e-08
in O 0 2.8742064728248806e-07
a O 0 1.4638368384112255e-06
region O 0 5.121825779497158e-06
syntenic O 0 6.465469778049737e-05
to O 0 1.3536921414925018e-06
human O 0 3.897364149452187e-05
chromosome O 0 0.000110684493847657
region O 0 3.0099077775957994e-05
2p13 O 0 0.000315667042741552
- O 0 7.598500815220177e-05
p16 O 0 6.141413177829236e-05
. O 0 1.3630426565214293e-06

Abnormal O 1 0.9999998807907104
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999738931655884
accumulation I-Disease 0 0.00023944406711962074
is O 0 3.530758192482608e-07
recognized O 0 3.875842082834424e-07
as O 0 7.626936167071108e-07
an O 0 2.3928485006763367e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 1 0.9958661794662476
man O 0 0.002418930409476161
, O 0 3.258737024225411e-06
mouse O 0 1.9645780412247404e-05
, O 0 2.18135210161563e-06
rat O 0 2.3598528059665114e-05
and O 0 3.0498599699058104e-06
dog O 0 3.789380571106449e-05
. O 0 2.0277871044527274e-06

The O 0 1.9222528862883337e-05
major O 0 5.729900294682011e-05
cause O 0 8.753621659707278e-05
of O 0 0.0021621943451464176
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999995231628418
accumulation I-Disease 0 0.21180281043052673
in O 0 5.434572449303232e-05
man O 0 2.3292750483960845e-05
is O 0 1.6757043397319649e-07
a O 0 3.491151687740057e-07
dysfunctional O 0 5.196675374463666e-06
ATP7B O 0 9.681526717031375e-05
gene O 0 3.4101369692507433e-06
, O 0 7.807989277353045e-07
causing O 0 1.7284337445744313e-05
Wilson B-Disease 0 6.709736044285819e-05
disease I-Disease 0 0.0004348435322754085
( O 0 3.714295417012181e-06
WD B-Disease 0 0.0002800310030579567
) O 0 6.089480848459061e-06
. O 0 2.310422360096709e-06

Mutations O 0 0.00014030862075742334
in O 0 5.696437801816501e-05
the O 0 3.342996205901727e-05
ATP7B O 0 0.0002934584626927972
genes O 0 1.8401464103590115e-06
have O 0 3.1411241252499167e-07
also O 0 2.2056269699533004e-07
been O 0 2.8810782737309637e-07
demonstrated O 0 2.402145128144184e-06
in O 0 3.7791751310578547e-06
mouse O 0 1.606556361366529e-05
and O 0 4.737883045891067e-06
rat O 0 5.756814789492637e-05
. O 0 8.138676435009984e-07

The O 0 0.0005999945569783449
ATP7B O 0 0.0050493027083575726
gene O 0 8.407735549553763e-06
has O 0 2.7041284056394943e-07
been O 0 1.1284133449862566e-07
excluded O 0 1.069419397481397e-07
in O 0 1.4703740447430391e-08
the O 0 2.4995642888825387e-08
much O 0 7.535536639124985e-08
rarer O 0 2.2268151951720938e-05
human O 0 0.00041918648639693856
copper B-Disease 1 0.9999840259552002
overload I-Disease 1 0.9999868869781494
disease O 1 0.9834343194961548
non B-Disease 0 9.579334437148646e-05
- I-Disease 0 5.614037945633754e-06
Indian I-Disease 0 5.734560204473382e-07
childhood I-Disease 0 9.687178680906072e-05
cirrhosis I-Disease 1 0.9999997615814209
, O 0 1.794872872551423e-07
indicating O 0 1.9047719206355396e-06
genetic O 0 2.997272531501949e-06
heterogeneity O 0 4.234554580762051e-05
. O 0 3.612286263887654e-06

By O 0 2.7508013999977265e-07
investigating O 0 9.250920243175642e-07
the O 0 1.8197315512225032e-06
common O 0 0.00011641559831332415
autosomal O 1 0.9999982118606567
recessive O 1 1.0
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 0.0012438566191121936
CT B-Disease 1 0.9999275207519531
) O 0 7.736869520158507e-06
in O 0 3.802368519245647e-05
Bedlington O 0 0.013265570625662804
terriers O 0 0.0003699595690704882
, O 0 1.0700437513833094e-07
we O 0 3.5357561323223763e-09
have O 0 7.644392896466456e-10
identified O 0 7.249240097095822e-10
a O 0 5.953470494368673e-10
new O 0 5.169900063606292e-10
locus O 0 7.48539932260428e-08
involved O 0 2.674989829642982e-08
in O 0 3.0817109291092493e-06
progressive O 1 0.9999995231628418
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.1720590009645093e-05

We O 0 1.3675457921635825e-05
examined O 0 4.640121005650144e-06
whether O 0 3.620942834459129e-07
the O 0 2.919167400250444e-06
WD B-Disease 0 0.00037919945316389203
gene O 0 2.2569645807379857e-05
ATP7B O 0 0.0003690444282256067
was O 0 2.4443295842502266e-05
also O 0 6.324044647953997e-07
causative O 0 7.585707407997688e-06
for O 0 1.197090455207217e-06
CT B-Disease 0 0.00016976019833236933
by O 0 1.8184358907546994e-07
investigating O 0 1.1841758578157169e-06
the O 0 8.002715730981436e-06
chromosomal O 0 0.0016421275213360786
co O 0 0.0012287910794839263
- O 0 0.0002325657260371372
localization O 0 0.00057285773800686
of O 0 5.9926314861513674e-05
ATP7B O 0 0.0003972341073676944
and O 0 1.8176017420046264e-06
C04107 O 0 1.2940785381942987e-05
, O 0 1.3494010886461183e-07
using O 0 5.5587523917211e-08
fluorescence O 0 1.4562564274456236e-06
in O 0 3.1281069823307917e-06
situ O 0 3.506332359393127e-05
hybridization O 0 1.3848283515471849e-06
( O 0 1.7926370219356613e-06
FISH O 0 6.333711553452304e-06
) O 0 3.7572394262497255e-07
. O 0 3.8244161260081455e-07

C04107 O 0 0.002920869505032897
is O 0 3.9094929888960905e-06
an O 0 3.694159431688604e-07
anonymous O 0 1.107029675040394e-06
microsatellite O 0 1.4678958905278705e-05
marker O 0 2.0614435925381258e-05
closely O 0 7.595260171910923e-07
linked O 0 1.2118693121010438e-05
to O 0 1.6709708461348782e-06
CT B-Disease 0 0.18743997812271118
. O 0 1.0945207577606197e-05

However O 0 0.0003005882608704269
, O 0 5.605689875665121e-05
BAC O 0 0.00139371317345649
clones O 0 3.744959394680336e-05
containing O 0 1.9758042981266044e-05
ATP7B O 0 0.0003152063291054219
and O 0 3.2962977911665803e-06
C04107 O 0 2.9899103537900373e-05
mapped O 0 2.566842567830463e-06
to O 0 7.953678391459107e-07
the O 0 5.96465952185099e-06
canine O 0 0.00029716239077970386
chromosome O 0 0.0001276792900171131
regions O 0 3.2345738873118535e-05
CFA22q11 O 0 0.0012124711647629738
and O 0 3.1567651603836566e-05
CFA10q26 O 0 0.00047337080468423665
, O 0 2.1597702470899094e-06
respectively O 0 5.007246272725752e-06
, O 0 1.0309744169489932e-07
demonstrating O 0 4.4549696553985996e-07
that O 0 1.5087431393112638e-07
WD B-Disease 0 5.530281487153843e-05
cannot O 0 6.489908059847949e-07
be O 0 2.3619116973350174e-07
homologous O 0 1.1959299399677548e-06
to O 0 1.0331017392672948e-06
CT B-Disease 0 0.0009485792252235115
. O 0 3.8944331208767835e-06

The O 0 0.0013981794472783804
copper O 0 0.003635805333033204
transport O 0 0.00023230288934428245
genes O 0 5.850444358657114e-05
CTR1 O 0 0.0018471612129360437
and O 0 2.630164635775145e-05
CTR2 O 0 0.0006030520307831466
were O 0 9.705413503979798e-06
also O 0 6.407121304619068e-07
excluded O 0 1.404530280524341e-06
as O 0 7.962087238411186e-07
candidate O 0 8.799772217571444e-07
genes O 0 7.900848686404061e-07
for O 0 1.253536538570188e-06
CT B-Disease 0 0.00036985272890888155
since O 0 1.2279565453354735e-06
they O 0 1.7606264890446255e-08
both O 0 4.625186988960195e-08
mapped O 0 2.6003215225500753e-07
to O 0 2.691608358418307e-07
canine O 0 0.000158245355123654
chromosome O 0 0.0002807709970511496
region O 0 8.785214595263824e-05
CFA11q22 O 0 0.00989475566893816
. O 0 2.1552337784669362e-05

2 O 0 0.0011250398820266128
- O 0 0.00014952213678043336
22 O 0 0.0001501278456998989
. O 0 3.5891762308892794e-06

5 O 0 0.0008685779757797718
. O 0 2.9939219530206174e-05

A O 0 0.00011370504944352433
transcribed O 0 2.9499648007913493e-05
sequence O 0 7.212392119981814e-06
identified O 0 4.327990609453991e-06
from O 0 5.642355972668156e-06
the O 0 1.0608987395244185e-05
C04107 O 0 6.525198114104569e-05
- O 0 3.998559986939654e-05
containing O 0 1.6017282177926973e-05
BAC O 0 0.00015208942932076752
was O 0 1.5659954442526214e-05
found O 0 1.157527265149838e-07
to O 0 1.328686494161957e-08
be O 0 3.8679541347619306e-08
homologous O 0 8.963122155591918e-08
to O 0 3.509527601863738e-08
a O 0 2.442063191665511e-07
gene O 0 6.39552240500052e-07
expressed O 0 1.1981549050688045e-06
from O 0 5.670033260685159e-06
human O 0 3.383588409633376e-05
chromosome O 0 0.00010809468949446455
2p13 O 0 0.0001924842654261738
- O 0 2.2546153559233062e-05
p16 O 0 1.1720153452188242e-05
, O 0 1.4157430427985673e-07
a O 0 1.0679579531824857e-07
region O 0 1.539505802838903e-07
devoid O 0 2.23344113692292e-06
of O 0 4.4315200398159504e-07
any O 0 1.7869398050152085e-07
positional O 0 1.7831340301199816e-05
candidate O 0 1.2794903341273312e-05
genes O 0 3.4633167160791345e-06
. O 0 1.0599234201436047e-06

Molecular O 0 0.00015431627980433404
analysis O 0 4.553898179437965e-06
of O 0 1.1933383575524203e-05
the O 0 8.892767255019862e-06
APC B-Disease 0 1.2246514415892307e-05
gene O 0 3.0256967420427827e-07
in O 0 3.1797787869436434e-07
205 O 0 1.786666643965873e-06
families O 0 1.2963852213943028e-07
: O 0 2.0547101087231567e-07
extended O 0 9.48255092225736e-06
genotype O 0 5.056253576185554e-05
- O 0 5.3580570238409564e-05
phenotype O 0 1.0706276043492835e-05
correlations O 0 8.853360668581445e-06
in O 0 1.4136734307612642e-06
FAP B-Disease 0 2.0999855223635677e-06
and O 0 5.269708225341674e-09
evidence O 0 4.891881566493339e-09
for O 0 2.929718911914847e-09
the O 0 6.509406791366246e-09
role O 0 4.888134697011992e-08
of O 0 4.612373061263497e-07
APC B-Disease 0 3.926089902961394e-06
amino O 0 2.4872855419744155e-07
acid O 0 1.2643259594824485e-07
changes O 0 2.630248161494819e-07
in O 0 0.002028291579335928
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9885187745094299
. O 0 7.198004368547117e-06

BACKGROUND O 0 0.00042644236236810684
/ O 0 0.00013848088565282524
AIMS O 0 2.745109213719843e-06
The O 0 5.757844974141335e-07
development O 0 7.932286280265544e-06
of O 0 0.0012307660654187202
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.306374741716354e-07
a O 0 3.300507600556557e-08
variable O 0 5.7003951781098294e-08
range O 0 2.8771070859079373e-08
of O 0 2.0993796567836398e-07
extracolonic O 0 0.0001261191937373951
manifestations O 0 0.001459438935853541
in O 0 6.265054253162816e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.01816600002348423
FAP B-Disease 0 0.0005104077863506973
) O 0 9.024499547649611e-08
is O 0 8.697366382648397e-09
the O 0 1.0205557288145428e-08
result O 0 4.550284771198676e-08
of O 0 2.4056060965449433e-07
the O 0 1.1257137657594285e-06
dominant O 0 1.8398604879621416e-05
inheritance O 0 2.1208477846812457e-05
of O 0 6.407582259271294e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.00020855749608017504
APC B-Disease 0 0.00030385624268092215
) O 0 2.1083133106003515e-06
gene O 0 2.7827543362946017e-06
mutations O 0 2.7156129362992942e-06
. O 0 1.3766380106972065e-06

In O 0 3.854197984765051e-06
this O 0 7.059538376097407e-08
study O 0 2.5720563456843593e-08
, O 0 4.949687326671892e-09
direct O 0 2.8743647462192712e-08
mutation O 0 8.457222833158085e-08
analysis O 0 1.0475774558926787e-07
of O 0 1.7837520545072039e-06
the O 0 7.772094249958172e-06
APC B-Disease 0 1.7654505427344702e-05
gene O 0 1.1041680636481033e-06
was O 0 5.3786998250870965e-06
performed O 0 3.0237345072237076e-06
to O 0 2.579878923825163e-07
determine O 0 3.7168219932937063e-06
genotype O 0 3.774146534851752e-05
- O 0 2.538616899983026e-05
phenotype O 0 4.743751560454257e-06
correlations O 0 3.2367058793170145e-06
for O 0 1.3051223959337221e-06
nine O 0 8.458014235657174e-06
extracolonic O 0 2.8029593522660434e-05
manifestations O 0 5.49753076484194e-06
and O 0 2.3697694473412412e-08
to O 0 2.6695092802953013e-09
investigate O 0 1.0017005891427289e-08
the O 0 4.162662037288101e-08
incidence O 0 4.873848865827313e-06
of O 0 4.2885767470579594e-06
APC B-Disease 0 1.663894363446161e-05
mutations O 0 6.79683864746039e-07
in O 0 3.1121462598093785e-06
non O 1 0.9282746315002441
- O 1 0.9999912977218628
FAP O 1 0.9999995231628418
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0219843716186006e-05

METHODS O 0 0.0003078061272390187
The O 0 4.507398989517242e-05
APC B-Disease 0 4.0959792386274785e-05
gene O 0 3.971669286784163e-07
was O 0 1.4055325436856947e-06
analysed O 0 2.284419053921738e-07
in O 0 1.6244040068613685e-07
190 O 0 1.2533333801911795e-06
unrelated O 0 8.405101539210591e-07
FAP B-Disease 0 3.252793931096676e-06
and O 0 1.3571509782650537e-07
15 O 0 2.1051844669273123e-05
non O 0 0.014320033602416515
- O 1 0.9999426603317261
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.021888111717999e-05
using O 0 2.03107924789947e-06
denaturing O 0 0.00022298519616015255
gradient O 0 0.00019420907483436167
gel O 0 2.9719556550844572e-05
electrophoresis O 0 9.056847375177313e-06
, O 0 4.3032616758864606e-07
the O 0 3.715599063980335e-07
protein O 0 3.5572256251725776e-07
truncation O 0 2.2543094928551e-06
test O 0 1.120412775890145e-07
, O 0 1.4898701827803507e-08
and O 0 8.86555806545175e-09
direct O 0 1.6731080165754975e-07
sequencing O 0 3.833489699900383e-06
. O 0 1.2286627679714002e-06

RESULTS O 0 0.011643694713711739
Chain O 0 0.00029358299798332155
terminating O 0 1.585142126714345e-05
signals O 0 7.238024409161881e-06
were O 0 2.9149589408916654e-07
only O 0 4.679385767758504e-08
identified O 0 9.3220918984116e-08
in O 0 2.2144644162835903e-07
patients O 0 5.100901034893468e-07
belonging O 0 1.4932448948457022e-06
to O 0 1.4755201505067816e-07
the O 0 2.736337592068594e-06
FAP B-Disease 0 2.2121468646219e-05
group O 0 9.190641776513075e-07
( O 0 4.874086130257638e-07
105 O 0 2.1020792701165192e-05
patients O 0 1.4461313639912987e-06
) O 0 8.54520123994007e-07
. O 0 1.2882157989224652e-06

Amino O 0 0.0004859259643126279
acid O 0 1.6597106878180057e-05
changes O 0 1.6292350437652203e-06
were O 0 3.805006826951285e-06
identified O 0 4.1169687392539345e-07
in O 0 4.3367768398638873e-07
four O 0 7.25993515970913e-07
patients O 0 3.546572315826779e-07
, O 0 6.103930161316384e-08
three O 0 1.3012419231017702e-07
of O 0 1.1417423593229614e-06
whom O 0 1.2344390825091978e-06
belonged O 0 4.127593001612695e-06
to O 0 1.0505687697559551e-07
the O 0 1.1476712415969814e-06
non O 0 2.657510594872292e-05
- O 0 8.81606865732465e-06
FAP O 0 6.659862719970988e-06
group O 0 1.4392368541393807e-07
of O 0 2.097805372613948e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0004551000311039388
. O 0 2.0708030206151307e-06

Genotype O 0 0.4228678345680237
- O 0 0.003736824030056596
phenotype O 0 6.26067048870027e-05
correlations O 0 9.770801625563763e-06
identified O 0 2.537603336350003e-07
significant O 0 5.082836551650871e-08
differences O 0 5.9339203772879046e-08
in O 0 1.2981098507225397e-07
the O 0 5.994221652372289e-08
nature O 0 8.764481407297353e-08
of O 0 1.5865643376855587e-07
certain O 0 4.6968000333436066e-07
extracolonic O 0 6.523785850731656e-05
manifestations O 0 8.166380575858057e-05
in O 0 4.200108833174454e-06
FAP B-Disease 0 5.4972144425846636e-05
patients O 0 5.356823749025352e-07
belonging O 0 6.555084723913751e-07
to O 0 3.3402535848381376e-08
three O 0 5.448096658255963e-07
mutation O 0 5.098516339785419e-06
subgroups O 0 0.00017077324446290731
. O 0 6.87183137415559e-06

CONCLUSIONS O 0 0.0004173925262875855
Extended O 0 0.0009004235034808517
genotype O 0 0.0007871234556660056
- O 0 0.0003138512256555259
phenotype O 0 3.122316411463544e-05
correlations O 0 1.210884965985315e-05
made O 0 2.360171720283688e-06
in O 0 1.5274029010470258e-06
this O 0 2.225276034550916e-07
study O 0 7.841853744139371e-07
may O 0 1.6041230992414057e-06
have O 0 1.5163551836394618e-07
the O 0 1.9204441059628152e-07
potential O 0 1.0985219489612064e-07
to O 0 1.943068106413648e-08
determine O 0 9.481219365170546e-08
the O 0 1.5293356625534216e-07
most O 0 2.2935017440772754e-08
appropriate O 0 6.098949256738706e-08
surveillance O 0 1.7830546994446195e-06
and O 0 4.839108100895828e-07
prophylactic O 0 0.001035069115459919
treatment O 0 3.7412075471365824e-05
regimens O 0 6.9911852733639535e-06
for O 0 5.1629289288257496e-08
those O 0 1.15836620295795e-08
patients O 0 5.057480478853904e-08
with O 0 4.368008621469244e-09
mutations O 0 3.307276017494587e-07
associated O 0 1.8759516251520836e-07
with O 0 1.0803446315321708e-07
life O 0 2.2106039523350773e-06
threatening O 0 1.8828406609827653e-05
conditions O 0 3.335095971124247e-05
. O 0 3.173935738232103e-06

This O 0 5.014200610276021e-07
study O 0 1.678449024211659e-07
also O 0 3.2855464127123923e-08
provided O 0 8.768657799862467e-09
evidence O 0 1.3733837178619979e-08
for O 0 1.9650725491260346e-08
the O 0 2.048968781309668e-07
pathological O 0 7.365754572674632e-05
nature O 0 4.3849245230376255e-06
of O 0 2.5138555429293774e-05
amino O 0 4.305898983147927e-06
acid O 0 4.1471975009699236e-07
changes O 0 1.4520639979309635e-07
in O 0 1.510949118710414e-06
APC O 0 6.9668326432292815e-06
associated O 0 6.678942554572131e-08
with O 0 1.4630864519915576e-08
both O 0 2.0293624913847452e-07
FAP B-Disease 0 1.158244049292989e-05
and O 0 8.215426419155847e-07
non O 0 0.04791237786412239
- O 1 0.9999545812606812
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.2848511434858665e-05
. O 0 1.435567185126274e-07
. O 0 2.5288457550232124e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.9322718381881714
cancer B-Disease 1 0.9999998807907104
risk O 0 2.2526768589159474e-05
of O 0 5.564487219089642e-05
the O 0 0.00011947183520533144
APC O 0 0.0003219287609681487
I1307K O 0 0.00015971962420735508
polymorphism O 0 3.0809667805442587e-05
. O 0 6.658021447947249e-06

Germ O 1 0.6502936482429504
- O 0 0.00037845168844796717
line O 0 1.1330991583236028e-05
and O 0 4.272730507182132e-07
somatic O 0 4.456730493984651e-06
truncating O 0 1.0237597962259315e-05
mutations O 0 5.029381782151177e-07
of O 0 3.0176215659594163e-06
the O 0 4.112097485631239e-06
APC B-Disease 0 1.5466472177649848e-05
gene O 0 1.3274976140564831e-07
are O 0 4.51883508389983e-09
thought O 0 3.9448879718406715e-09
to O 0 3.6143334991578513e-09
initiate O 0 5.131002126290696e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9816208481788635
formation O 0 1.946750307979528e-05
in O 0 5.148991840542294e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9997865557670593
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 4.44024772150442e-05
respectively O 0 8.354660531040281e-05
. O 0 1.2721092161882552e-06

Recently O 0 0.0005588601343333721
, O 0 1.3833123375661671e-05
an O 0 7.121964699763339e-06
isoleucine O 0 0.00015085494669619948
- O 0 2.8999884307268076e-05
- O 0 5.375755063141696e-05
> O 0 3.795155862462707e-05
lysine O 0 1.126002553064609e-05
polymorphism O 0 1.8090519233737723e-06
at O 0 4.93410334456712e-05
codon O 0 1.4830927284492645e-05
1307 O 0 3.1013652915135026e-05
( O 0 8.381760494557966e-07
I1307K O 0 3.448847564868629e-06
) O 0 1.6757795151534083e-07
of O 0 4.52691756436252e-06
the O 0 1.5031712791824248e-05
APC B-Disease 0 2.333695192646701e-05
gene O 0 7.047261192383303e-07
has O 0 5.331747843229095e-07
been O 0 6.678445743091288e-07
identified O 0 9.558279856491936e-08
in O 0 3.8906404142835527e-07
6 O 0 3.7574366160697537e-06
% O 0 2.3051262587614474e-07
- O 0 2.10899997910019e-07
7 O 0 1.5093318097569863e-06
% O 0 8.882334867621466e-08
of O 0 2.0602769268407428e-07
the O 0 7.137012971725198e-07
Ashkenazi O 0 6.487930477305781e-06
Jewish O 0 2.8715483040286927e-06
population O 0 1.910809004357361e-07
. O 0 3.003316066951811e-07

To O 0 1.0058696489068097e-06
assess O 0 1.2790137589036021e-06
the O 0 5.969429253127601e-07
risk O 0 5.134890557201288e-07
of O 0 5.470541850627342e-07
this O 0 1.920817709333278e-07
common O 0 4.54804740002146e-06
APC B-Disease 0 5.0389244279358536e-05
allelic O 0 3.417273910599761e-05
variant O 0 0.0008317254832945764
in O 0 0.003344788448885083
colorectal O 1 1.0
carcinogenesis O 1 0.9999998807907104
, O 0 2.452500666549895e-06
we O 0 5.1189903871318165e-08
have O 0 1.578727193418672e-08
analyzed O 0 5.188625351593146e-08
a O 0 3.544252180631702e-08
large O 0 7.810724866885721e-08
cohort O 0 1.0103566410180065e-06
of O 0 4.113656473236915e-07
unselected O 0 0.00019459554459899664
Ashkenazi O 0 2.1842164642293938e-05
Jewish O 0 5.732838872063439e-06
subjects O 0 7.81919061410008e-06
with O 0 1.104697844311886e-06
adenomatous B-Disease 0 0.014474723488092422
polyps I-Disease 0 0.0006763332639820874
and O 0 4.4356761463859584e-07
. O 0 6.005969339639705e-07
or O 1 0.7092863917350769
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.1432034625613596e-06
for O 0 4.936485424877901e-07
the O 0 5.561685611610301e-06
APC O 0 6.814163498347625e-05
I1307K O 0 7.324681064346805e-05
polymorphism O 0 2.4980256057460792e-05
. O 0 6.848332759545883e-06

The O 0 0.0010832279222086072
APC O 0 0.0006136700976639986
I1307K O 0 0.00019715250527951866
allele O 0 1.5546893337159418e-05
was O 0 4.486077887122519e-05
identified O 0 1.2707607766060391e-06
in O 0 1.673701376603276e-06
48 O 0 4.5390088416752405e-06
( O 0 2.838576165231643e-07
10 O 0 1.8549734193129552e-07
. O 0 9.732620931401925e-09
1 O 0 6.134820296210819e-07
% O 0 8.603030465792472e-08
) O 0 1.7210886937846226e-08
of O 0 2.9029550319137343e-07
476 O 0 4.4726730266120285e-05
patients O 0 6.106944965722505e-06
. O 0 2.118184511346044e-06

Compared O 0 7.153140904847533e-05
with O 0 3.90121442706004e-07
the O 0 7.348728559009032e-07
frequency O 0 9.132452305493644e-07
in O 0 2.4468701553814753e-07
two O 0 3.5477690119023464e-08
separate O 0 1.9215480762113657e-08
population O 0 5.861612351054646e-08
control O 0 7.26098051018198e-07
groups O 0 1.3273850640871387e-07
, O 0 4.2800553501365357e-07
the O 0 2.7697519726643804e-06
APC O 0 6.94047921570018e-05
I1307K O 0 4.018027175334282e-05
allele O 0 3.458517539911554e-06
is O 0 1.602056158844789e-07
associated O 0 2.2387409259749802e-08
with O 0 1.3404842791331362e-09
an O 0 5.6333036013711535e-09
estimated O 0 5.101893307823957e-08
relative O 0 9.923483048623893e-07
risk O 0 5.743694941884314e-07
of O 0 6.0666657191177364e-06
1 O 0 0.00012346377479843795
. O 0 3.4606225653988076e-06

5 O 0 0.0005320576019585133
- O 0 0.0001073506791726686
1 O 0 9.597685857443139e-05
. O 0 4.1248067645938136e-06

7 O 0 0.0005131053039804101
for O 0 6.689369183732197e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9997207522392273
( O 0 1.249481829290744e-05
both O 0 7.853291208448354e-06
P O 0 0.0017603751039132476
= O 0 1.8666371033759788e-05
. O 0 3.535023722633923e-07
01 O 0 3.8657457480439916e-05
) O 0 5.001134013582487e-07
. O 0 3.6162666106065444e-07

Furthermore O 0 0.00018816502415575087
, O 0 6.597174433409236e-06
compared O 0 1.5600864571752027e-05
with O 0 1.9690794488269603e-06
noncarriers O 0 0.0009272612514905632
, O 0 1.6212979971896857e-05
APC O 0 6.19252969045192e-05
I1307K O 0 1.0027598364104051e-05
carriers O 0 1.292315374712416e-07
had O 0 6.040508537807909e-08
increased O 0 1.6717618223083264e-07
numbers O 0 1.8594934658722195e-07
of O 0 2.9106720376148587e-06
adenomas B-Disease 1 0.9993661046028137
and O 0 0.00021876892424188554
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999985694885254
per O 0 6.495138222817332e-05
patient O 0 1.3099483112455346e-05
( O 0 2.174719611502951e-06
P O 0 0.0002312917640665546
= O 0 1.0185887731495313e-05
. O 0 3.192403710272629e-07
03 O 0 3.170359559589997e-05
) O 0 1.8456633199548378e-07
, O 0 2.656487474439473e-08
as O 0 4.073002912718948e-08
well O 0 3.047863117444649e-08
as O 0 5.924274404378593e-08
a O 0 1.0644824754990623e-07
younger O 0 2.8049976208421867e-07
age O 0 1.6647661595925456e-06
at O 0 1.2791633707820438e-05
diagnosis O 0 5.245031206868589e-05
. O 0 1.748797444633965e-06

We O 0 9.083671102416702e-06
conclude O 0 4.55218741990393e-06
that O 0 4.092299832336721e-07
the O 0 4.5710758058703505e-06
APC O 0 6.38066849205643e-05
I1307K O 0 0.00010961702355416492
variant O 0 9.097365546040237e-05
leads O 0 3.5496246709953994e-05
to O 0 4.108256234758301e-06
increased O 0 0.0015075511764734983
adenoma B-Disease 1 1.0
formation O 0 0.0004504735697992146
and O 0 1.2034756764478516e-05
directly O 0 2.0731920358230127e-06
contributes O 0 6.500172275991645e-07
to O 0 5.105903966295955e-08
3 O 0 9.058919658855302e-07
% O 0 5.579657269549898e-08
- O 0 3.0053985966560504e-08
4 O 0 5.4528690895949694e-08
% O 0 4.203157377702382e-09
of O 0 3.707703255528827e-09
all O 0 4.4264847787189865e-08
Ashkenazi O 0 0.0001141308675869368
Jewish O 0 0.29109349846839905
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.484125828545075e-06

The O 0 1.0443278370075859e-05
estimated O 0 9.683519238024019e-06
relative O 0 4.390813410282135e-05
risk O 0 3.85960447601974e-06
for O 0 6.137986474641366e-07
carriers O 0 9.267379823540978e-07
may O 0 4.4281483724262216e-07
justify O 0 2.297372674320286e-07
specific O 0 4.46384049723747e-08
clinical O 0 2.404152837698348e-06
screening O 0 5.253043013908609e-07
for O 0 7.15778242010856e-07
the O 0 2.4108708203129936e-06
360 O 0 9.265080734621733e-06
, O 0 2.8430625320652325e-07
000 O 0 2.9135933345969534e-06
Americans O 0 1.5253083063271333e-07
expected O 0 2.796812736960419e-07
to O 0 7.982906424786052e-08
harbor O 0 5.835269803355914e-06
this O 0 5.7141765097412645e-08
allele O 0 2.1379361214712844e-07
, O 0 3.410307769513565e-08
and O 0 3.0754961244383594e-08
genetic O 0 1.928170121345829e-07
testing O 0 2.1760817503491126e-07
in O 0 4.3103921143483603e-07
the O 0 9.470733175476198e-07
setting O 0 4.530394562607398e-06
of O 0 5.986012183711864e-06
long O 0 8.588964192313142e-06
- O 0 6.899174422869692e-06
term O 0 2.055752020169166e-06
- O 0 2.115066735086657e-07
outcome O 0 3.96957098303119e-08
studies O 0 5.1450278704123775e-08
may O 0 6.215635295347965e-08
impact O 0 1.2529373805136856e-07
significantly O 0 1.7837656969277305e-06
on O 0 0.0008389836293645203
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 2.4599576136097312e-05
in O 0 8.182119870525639e-08
this O 0 1.8606707286039637e-08
population O 0 9.483027696433055e-08
. O 0 2.0396770139541331e-07

Localization O 0 0.0021464191377162933
of O 0 0.00022030262334737927
human O 0 0.00010649313480826095
BRCA1 O 0 1.1888550034200307e-05
and O 0 1.2550664223454078e-06
its O 0 1.0168192829951295e-06
loss O 0 1.3117572052578907e-05
in O 0 4.138069471082417e-06
high O 0 0.0001496633340138942
- O 0 3.697189094964415e-05
grade O 0 0.00036681711208075285
, O 0 3.014874437212711e-06
non B-Disease 1 0.9304459095001221
- I-Disease 1 0.9999122619628906
inherited I-Disease 1 0.9999996423721313
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 5.4086845921119675e-05

Although O 0 1.4927223901395337e-06
the O 0 2.5267098635595175e-07
link O 0 1.0200369615631644e-06
between O 0 8.702653531145188e-07
the O 0 5.588605290540727e-06
BRCA1 O 0 0.000460414303233847
tumour B-Disease 1 1.0
- O 0 8.625838381703943e-05
suppressor O 0 6.439933349611238e-05
gene O 0 7.811244699951203e-07
and O 0 8.571351486352796e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 4.754317615152104e-06
established O 0 1.254149879059696e-06
, O 0 1.0094188240827862e-07
the O 0 1.789122165973822e-07
role O 0 6.401734253813629e-07
, O 0 1.0385274151758495e-07
if O 0 7.732499973656104e-09
any O 0 7.4199513200312595e-09
, O 0 1.5917041906732265e-08
of O 0 1.705412415731189e-07
BRCA1 O 0 8.387299203604925e-06
in O 0 1.138334846473299e-05
non B-Disease 0 0.2733425498008728
- I-Disease 0 0.46859633922576904
familial I-Disease 1 0.6800572276115417
cancers I-Disease 1 0.9999991655349731
is O 0 3.588649178709602e-06
unclear O 0 1.1400743460399099e-06
. O 0 7.968042154971045e-07

BRCA1 O 0 0.0026294232811778784
mutations O 0 1.8085300325765274e-05
are O 0 3.641592911662883e-07
rare O 0 7.558098786830669e-07
in O 0 9.955151654139627e-07
sporadic B-Disease 0 0.00014715309953317046
cancers I-Disease 1 0.9998359680175781
, O 0 2.88234787149122e-07
but O 0 1.3504574347678044e-08
loss O 0 1.4515879911414231e-06
of O 0 1.061578473127156e-06
BRCA1 O 0 2.776170276774792e-06
resulting O 0 1.274739702239458e-06
from O 0 1.4729403119417839e-06
reduced O 0 1.0953477612929419e-05
expression O 0 3.617362381191924e-05
or O 0 8.8698561739875e-06
incorrect O 0 1.3038188626524061e-05
subcellular O 0 0.0005406111013144255
localization O 0 0.00010839889728231356
is O 0 4.544473597434262e-07
postulated O 0 9.011425277094531e-07
to O 0 8.699241327292384e-09
be O 0 1.5965905930670488e-08
important O 0 3.30382690094666e-08
in O 0 1.7099888793836726e-07
non B-Disease 0 4.5461296394933015e-05
- I-Disease 0 0.00013618350203614682
familial I-Disease 1 0.986070454120636
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 6.342770211631432e-05

Epigenetic O 0 0.30986446142196655
loss O 1 0.9967004656791687
, O 0 2.0043778931722045e-05
however O 0 1.0674655186448945e-06
, O 0 9.351654739475634e-08
has O 0 1.900331803028621e-08
not O 0 8.178589361307331e-09
received O 0 6.623744752687344e-08
general O 0 7.358153766290343e-07
acceptance O 0 2.181913714593975e-06
due O 0 4.254139184922678e-06
to O 0 1.1780341679923367e-07
controversy O 0 3.4516565960984735e-07
regarding O 0 6.438710329348396e-07
the O 0 3.468185241217725e-06
subcellular O 0 0.00025446992367506027
localization O 0 0.00020144449081271887
of O 0 8.901095134206116e-05
BRCA1 O 0 2.0248118744348176e-05
proteins O 0 3.347437086631544e-06
, O 0 1.1822259011751157e-06
reports O 0 3.2001949534787855e-07
of O 0 5.788947987639403e-07
which O 0 2.253070476854191e-07
have O 0 1.8125750500530557e-07
ranged O 0 1.39805206345045e-05
from O 0 9.878311857391964e-07
exclusively O 0 6.350026069412706e-07
nuclear O 0 3.896606813214021e-06
, O 0 1.3295209555508336e-07
to O 0 9.418297963748046e-08
conditionally O 0 3.149630174448248e-06
nuclear O 0 5.401780526881339e-06
, O 0 1.7996069345826982e-07
to O 0 9.434064907054562e-08
the O 0 1.923585386975901e-06
ER O 0 0.00029788431129418314
/ O 0 8.732460992177948e-05
golgi O 0 0.00014308089157566428
, O 0 9.936856031345087e-07
to O 0 3.9721314237795013e-07
cytoplasmic O 0 1.3235036021796986e-05
invaginations O 0 8.254004933405668e-05
into O 0 3.878994903061539e-06
the O 0 6.167645551613532e-06
nucleus O 0 1.07265723272576e-05
. O 0 2.0821062207687646e-06

In O 0 0.00019397976575419307
an O 0 1.2536521353467833e-05
attempt O 0 6.936449608474504e-06
to O 0 1.276454895560164e-06
resolve O 0 4.743258159578545e-06
this O 0 1.0854272431970458e-06
issue O 0 1.2618833125088713e-06
, O 0 6.213821848177759e-07
we O 0 1.9350245850091596e-07
have O 0 2.3145079808273294e-07
comprehensively O 0 5.01706426803139e-06
characterized O 0 1.1073474524891935e-05
19 O 0 0.00010345212649554014
anti O 0 7.288283086381853e-05
- O 0 2.2916185116628185e-05
BRCA1 O 0 3.962263690482359e-06
antibodies O 0 1.3220251275924966e-06
. O 0 1.487954023104976e-06

These O 0 2.5527726393193007e-05
reagents O 0 0.0001343809417448938
detect O 0 3.801436832873151e-05
a O 0 8.442960279353429e-06
220 O 0 5.4464057939185295e-06
- O 0 1.0080485708385822e-06
kD O 0 3.2900195492402418e-06
protein O 0 9.1538407787084e-07
localized O 0 9.274647823076521e-07
in O 0 7.610602779095643e-07
discrete O 0 1.044192413246492e-05
nuclear O 0 1.994713966269046e-05
foci O 0 4.9058537115342915e-05
in O 0 2.8349529657134553e-06
all O 0 9.225635722032166e-07
epithelial O 0 5.847264765179716e-05
cell O 0 2.0041332390974276e-05
lines O 0 6.149340947558812e-07
, O 0 1.518148629031657e-08
including O 0 1.1540393529685389e-08
those O 0 8.530787631855219e-09
derived O 0 5.28056773418939e-07
from O 0 1.9129090560454642e-06
breast B-Disease 0 0.0002812475722748786
malignancies I-Disease 0 0.00029158455436117947
. O 0 3.6293479297455633e-06

Immunohistochemical O 0 0.006287547759711742
staining O 0 0.0006631048745475709
of O 0 8.753796282690018e-05
human O 0 0.00012099077139282599
breast O 0 0.00018660718342289329
specimens O 0 1.6347929658877547e-06
also O 0 6.240462084861065e-07
revealed O 0 4.5701344788540155e-06
BRCA1 O 0 1.4747936802450567e-05
nuclear O 0 9.058989235199988e-06
foci O 0 8.721941412659362e-05
in O 0 8.703112143848557e-06
benign O 1 0.9999486207962036
breast O 1 0.9999547004699707
, O 0 2.5607603674870916e-05
invasive B-Disease 1 0.9994794726371765
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 1 0.5082781314849854
low B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 9.359823889099061e-05

Conversely O 0 0.000499817484524101
, O 0 9.010685971588828e-06
BRCA1 O 0 7.147610176616581e-06
expression O 0 8.412315764871892e-06
was O 0 5.170717940927716e-06
reduced O 0 2.0941738512192387e-06
or O 0 5.408359697867127e-07
undetectable O 0 1.6037911336752586e-06
in O 0 8.50140722263859e-08
the O 0 4.9995698248039844e-08
majority O 0 1.873201505020461e-08
of O 0 1.0395335721113952e-06
high O 0 0.0002442064869683236
- O 0 0.0002457909577060491
grade O 1 0.5233011841773987
, O 0 3.757777449209243e-05
ductal B-Disease 1 0.9999998807907104
carcinomas I-Disease 1 1.0
, O 0 4.1929774852178525e-06
suggesting O 0 1.1270136610619375e-06
that O 0 5.384307044664638e-08
absence O 0 6.1466998886317015e-06
of O 0 5.5030491239449475e-06
BRCA1 O 0 1.3828902410750743e-05
may O 0 4.5821875005458423e-07
contribute O 0 1.7188316547844806e-08
to O 0 1.0383367943234134e-08
the O 0 7.81656694925914e-08
pathogenesis O 0 2.240034518763423e-06
of O 0 3.144570470681174e-08
a O 0 1.7812578079201558e-08
significant O 0 3.4419688432762996e-08
percentage O 0 5.25456584909989e-07
of O 0 1.5491673366341274e-06
sporadic B-Disease 1 0.5718750953674316
breast I-Disease 1 1.0
cancers I-Disease 1 0.9999997615814209
. O 0 2.158948746000533e-06
. O 0 1.146719455391576e-06

